S8168418B2	NNP	O
-	:	O
Expression	NN	O
of	IN	O
HIV	NNP	O
polypeptides	NNS	O
and	CC	O
production	NN	O
of	IN	O
virus-like	JJ	O
particles	NNS	O
-	:	O
Google	NNP	O
Patents	NNP	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
division	NN	O
of	IN	O
Ser.	.	O
No.	.	O
12/026,619,	,	O
filed	VBD	O
Feb.	NNP	O
6,	,	O
2008,	,	O
now	RB	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
7,718,401,	,	O
issued	VBN	O
May	NNP	O
18,	,	O
2010,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
division	NN	O
of	IN	O
Ser.	.	O
No.	.	O
10/387,336	CD	O
filed	VBD	O
Mar.	.	O
11,	,	O
2003,	,	O
now	RB	O
issued	VBN	O
as	IN	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
7,348,177,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
Ser.	.	O
No.	.	O
09/475,515,	,	O
filed	VBN	O
Dec.	NNP	O
30,	,	O
1999,	,	O
now	RB	O
U.S.	NNP	O
Pat.	.	O
No.	.	O
6,602,705,	,	O
and	CC	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
Ser.	.	O
No.	.	O
60/114,495	CD	O
filed	VBN	O
Dec.	NNP	O
31,	,	O
1998	CD	O
and	CC	O
Ser.	.	O
No.	.	O
60/168,471	CD	O
filed	VBN	O
Dec.	NNP	O
1,	,	O
1999.	.	O
Each	DT	O
of	IN	O
these	DT	O
applications	NNS	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety.	.	O
INCORPORATION	NNP	O
OF	NNP	O
SEQUENCE	NNP	O
LISTING	NNP	O
BY	NNP	O
REFERENCE	NNP	O
This	DT	O
application	NN	O
incorporates	VBZ	O
by	IN	O
reference	NN	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
190	CD	O
kb	NN	O
text	NN	O
file	NN	O
created	VBD	O
on	IN	O
Nov.	NNP	O
24,	,	O
2010	CD	O
and	CC	O
named	VBD	O
“51381.txt,”	NNP	O
which	WDT	O
is	VBZ	O
the	DT	O
sequence	NN	O
listing	NN	O
for	IN	O
this	DT	O
application.	.	O
TECHNICAL	NNP	O
FIELD	NNP	O
Synthetic	NNP	O
expression	NN	O
cassettes	VBZ	O
encoding	VBG	O
the	DT	O
HIV	NNP	O
polypeptides	NNS	O
(e.g.,	,	O
Gag-,	,	O
pol-,	,	O
prot-,	,	O
reverse	JJ	O
transcriptase,	,	O
Env-	NNP	O
or	CC	O
tat-containing	JJ	O
polypeptides)	)	O
are	VBP	O
described,	,	O
as	IN	O
are	VBP	O
uses	NNS	O
of	IN	O
the	DT	O
expression	NN	O
cassettes.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
efficient	JJ	O
expression	NN	O
of	IN	O
HIV	NNP	O
polypeptides	NNS	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types.	.	O
Further,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
producing	VBG	O
Virus-Like	JJ	O
Particles	NNP	O
(VLPs),	,	O
as	RB	O
well	RB	O
as,	,	O
uses	VBZ	O
of	IN	O
the	DT	O
VLPs	NNP	O
and	CC	O
high	JJ	O
level	NN	O
expression	NN	O
of	IN	O
oligomeric	JJ	O
envelope	NN	O
proteins.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Acquired	NNP	O
immune	JJ	O
deficiency	NN	O
syndrome	NN	O
(AIDS)	)	O
is	VBZ	O
recognized	VBN	O
as	IN	O
one	CD	O
of	IN	O
the	DT	O
greatest	JJS	O
health	NN	O
threats	NNS	O
facing	VBG	O
modern	JJ	O
medicine.	.	O
There	EX	O
is,	,	O
as	IN	O
yet,	,	O
no	DT	O
cure	NN	O
for	IN	O
this	DT	O
disease.	.	O
In	IN	O
1983-1984,	,	O
three	CD	O
groups	NNS	O
independently	RB	O
identified	VBD	O
the	DT	O
suspected	JJ	O
etiological	JJ	O
agent	NN	O
of	IN	O
AIDS.	.	O
See,	,	O
e.g.,	,	O
Barre-Sinoussi	NNP	B
et	FW	I
al.	.	I
(1983)	)	I
Science	NNP	I
220:868-871;	:	I
Montagnier	NNP	B
et	FW	I
al.,	,	I
in	IN	I
Human	NNP	I
T-Cell	NNP	I
Leukemia	NNP	I
Viruses	NNP	I
(Gallo,	,	I
Essex	NNP	I
&	CC	I
Gross,	,	I
eds.,	,	I
1984);	:	I
Vilmer	NNP	B
et	FW	I
al.	.	I
(1984)	)	I
The	DT	I
Lancet	NNP	I
1:753;	:	I
Popovic	NNP	B
et	FW	I
al.	.	I
(1984)	)	I
Science	NNP	I
224:497-500;	:	I
Levy	NNP	B
et	FW	I
al.	.	I
(1984)	)	I
Science	NNP	I
225:840-842.	.	I
These	DT	O
isolates	NNS	O
were	VBD	O
variously	RB	O
called	VBN	O
lymphadenopathy-associated	JJ	O
virus	NN	O
(LAV),	,	O
human	JJ	O
T-cell	NNP	O
lymphotropic	NN	O
virus	NN	O
type	NN	O
III	NNP	O
(HTLV-III),	,	O
or	CC	O
AIDS-associated	JJ	O
retrovirus	NN	O
(ARV).	.	O
All	DT	O
of	IN	O
these	DT	O
isolates	NNS	O
are	VBP	O
strains	NNS	O
of	IN	O
the	DT	O
same	JJ	O
virus,	,	O
and	CC	O
were	VBD	O
later	RB	O
collectively	RB	O
named	VBN	O
Human	NNP	O
Immunodeficiency	NNP	O
Virus	NNP	O
(HIV).	.	O
With	IN	O
the	DT	O
isolation	NN	O
of	IN	O
a	DT	O
related	JJ	O
AIDS-causing	JJ	O
virus,	,	O
the	DT	O
strains	NNS	O
originally	RB	O
called	VBN	O
HIV	NNP	O
are	VBP	O
now	RB	O
termed	VBN	O
HIV-1	NNP	O
and	CC	O
the	DT	O
related	JJ	O
virus	NN	O
is	VBZ	O
called	VBN	O
HIV-2	NNP	O
See,	,	O
e.g.,	,	O
Guyader	NNP	B
et	CC	I
al.	.	I
(1987)	)	I
Nature	NNP	I
326:662-669;	:	I
Brun-Vezinet	NNP	B
et	FW	I
al.	.	I
(1986)	)	I
233:343-346;	:	I
Clavel	NNP	B
et	FW	I
al.	.	I
(1986)	)	I
Nature	NN	I
324:691-695.
A	.	O
great	DT	O
deal	JJ	O
of	NN	O
information	IN	O
has	NN	O
been	VBZ	O
gathered	VBN	O
about	VBN	O
the	IN	O
HIV	DT	O
virus,	NNP	O
however,	,	O
to	,	O
date	TO	O
an	NN	O
effective	DT	O
vaccine	JJ	O
has	NN	O
not	VBZ	O
been	RB	O
identified.	VBN	O
Several	.	O
targets	JJ	O
for	NNS	O
vaccine	IN	O
development	NN	O
have	NN	O
been	VBP	O
examined	VBN	O
including	VBN	O
the	VBG	O
env,	DT	O
Gag,	,	O
poi	,	O
and	NN	O
tat	CC	O
gene	JJ	O
products	NN	O
encoded	NNS	O
by	VBN	O
HIV.	IN	O
Haas,	.	B
et	,	I
al.,	FW	I
(Current	,	I
Biology	NNP	I
6(3):315-324,	NNP	I
1996)	,	I
suggested	)	O
that	VBD	O
selective	IN	O
codon	JJ	O
usage	NN	O
by	NN	O
HIV-1	IN	O
appeared	NNP	O
to	VBD	O
account	TO	O
for	VB	O
a	IN	O
substantial	DT	O
fraction	JJ	O
of	NN	O
the	IN	O
inefficiency	DT	O
of	NN	O
viral	IN	O
protein	JJ	O
synthesis.	NN	O
Andre,	.	B
et	,	I
al.,	FW	I
(J.	,	I
Virol.	NNP	I
72(2):1497-1503,	.	I
1998)	,	I
described	)	O
an	VBD	O
increased	DT	O
immune	VBN	O
response	NN	O
elicited	NN	O
by	VBN	O
DNA	IN	O
vaccination	NNP	O
employing	NN	O
a	VBG	O
synthetic	DT	O
gp120	JJ	O
sequence	NN	O
with	NN	O
optimized	IN	O
codon	JJ	O
usage.	NN	O
Schneider,	.	B
et	,	I
al.,	FW	I
(J.	,	I
Virol.	NNP	I
71(7):4892-4903,	.	I
1997)	,	I
discuss	)	O
inactivation	NN	O
of	NN	O
inhibitory	IN	O
(or	NN	O
instability)	CC	O
elements	)	O
(INS)	NNS	O
located	)	O
within	VBD	O
the	IN	O
coding	DT	O
sequences	VBG	O
of	NNS	O
the	IN	O
Gag	DT	O
and	NNP	O
Gag-protease	CC	O
coding	NNP	O
sequences.	NN	O
The	.	O
Gag	DT	O
proteins	NNP	O
of	NNS	O
HIV-1	IN	O
are	NNP	O
necessary	VBP	O
for	JJ	O
the	IN	O
assembly	DT	O
of	NN	O
virus-like	IN	O
particles.	JJ	O
HIV-1	.	O
Gag	NNP	O
proteins	NNP	O
are	NNS	O
involved	VBP	O
in	VBN	O
many	IN	O
stages	JJ	O
of	NNS	O
the	IN	O
life	DT	O
cycle	NN	O
of	NN	O
the	IN	O
virus	DT	O
including,	NN	O
assembly,	,	O
virion	,	O
maturation	NN	O
after	NN	O
particle	IN	O
release,	NN	O
and	,	O
early	CC	O
post-entry	RB	O
steps	NN	O
in	NNS	O
virus	IN	O
replication.	NN	O
The	.	O
roles	DT	O
of	NNS	O
HIV-1	IN	O
Gag	NNP	O
proteins	NNP	O
are	NNS	O
numerous	VBP	O
and	JJ	O
complex	CC	O
Freed,	JJ	B
E.	,	I
O.,	NNP	I
Virology	,	I
251:1-15,	NNP	I
1998).(	,	O
Wolf,	.	O
et	,	O
al.,	FW	O
(PCT	,	O
International	NNP	O
Application,	NNP	O
WO	,	O
96/30523,	NNP	O
published	,	O
3	VBD	O
Oct.	CD	O
1996;	NNP	O
European	:	O
Patent	JJ	O
Application,	NNP	O
Publication	,	O
No.	NNP	O
0	.	O
449	CD	O
116	CD	O
A1,	CD	O
published	,	O
2	VBD	O
Oct.	CD	O
1991)	NNP	O
have	)	O
described	VBP	O
the	VBN	O
use	DT	O
of	NN	O
altered	IN	O
pr55	JJ	O
Gag	NN	O
of	NNP	O
HIV-1	IN	O
to	NNP	O
act	TO	O
as	VB	O
a	IN	O
non-infectious	DT	O
retroviral-like	JJ	O
particulate	JJ	O
carrier,	NN	O
in	,	O
particular,	IN	O
for	,	O
the	IN	O
presentation	DT	O
of	NN	O
immunologically	IN	O
important	RB	O
epitopes.	JJ	O
Wang,	.	B
et	,	I
al.,	FW	I
(Virology	,	I
200:524-534,	NNP	I
1994)	,	I
describe	)	O
a	VB	O
system	DT	O
to	NN	O
study	TO	O
assembly	VB	O
of	NN	O
HIV	IN	O
Gag-β-galactosidase	NNP	O
fusion	NNP	O
proteins	NN	O
into	VBZ	O
virions.	IN	O
They	.	O
describe	PRP	O
the	VBP	O
construction	DT	O
of	NN	O
sequences	IN	O
encoding	NNS	O
HIV	VBG	O
Gag-β-galactosidase	NNP	O
fusion	NNP	O
proteins,	NN	O
the	,	O
expression	DT	O
of	NN	O
such	IN	O
sequences	JJ	O
in	NNS	O
the	IN	O
presence	DT	O
of	NN	O
HIV	IN	O
Gag	NNP	O
proteins,	NNP	O
and	,	O
assembly	CC	O
of	RB	O
these	IN	O
proteins	DT	O
into	NNS	O
virus	IN	O
particles.	NN	O
Recently,	.	O
Shiver,	,	O
et	,	O
al.,	FW	O
(PCT	,	O
International	NNP	O
Application,	NNP	O
WO	,	O
98/34640,	NNP	O
published	,	O
13	VBN	O
Aug.	CD	O
1998)	NNP	O
described	)	O
altering	VBD	O
HIV-1	VBG	O
(CAM1)	NNP	O
Gag	)	O
coding	NNP	O
sequences	VBG	O
to	NNS	O
produce	TO	O
synthetic	VB	O
DNA	JJ	O
molecules	NNP	O
encoding	NNS	O
HIV	VBG	O
Gag	NNP	O
and	NNP	O
modifications	CC	O
of	NNS	O
HIV	IN	O
Gag.	NNP	O
The	.	O
codons	DT	O
of	NNS	O
the	IN	O
synthetic	DT	O
molecules	JJ	O
were	NNS	O
codons	VBD	O
preferred	NNS	O
by	VBN	O
a	IN	O
projected	DT	O
host	VBN	O
cell.	NN	O
The	.	O
envelope	DT	O
protein	NN	O
of	NN	O
HIV-1	IN	O
is	NNP	O
a	VBZ	O
glycoprotein	DT	O
of	NN	O
about	IN	O
160	IN	O
kD	CD	O
(gp160).	NNS	O
During	.	O
virus	IN	O
infection	JJ	O
of	NN	O
the	IN	O
host	DT	O
cell,	NN	O
gp160	,	O
is	NN	O
cleaved	VBZ	O
by	VBN	O
host	IN	O
cell	NN	O
proteases	NN	O
to	VBZ	O
form	TO	O
gp120	VB	O
and	NN	O
the	CC	O
integral	DT	O
membrane	JJ	O
protein,	NN	O
gp41.	,	O
The	.	O
gp41	DT	O
portion	JJ	O
is	NN	O
anchored	VBZ	O
in	VBN	O
(and	IN	O
spans)	CC	O
the	)	O
membrane	DT	O
bilayer	NN	O
of	NN	O
virion,	IN	O
while	,	O
the	IN	O
gp120	DT	O
segment	NN	O
protrudes	NN	O
into	VBZ	O
the	IN	O
surrounding	DT	O
environment.	VBG	O
As	.	O
there	IN	O
is	EX	O
no	VBZ	O
covalent	DT	O
attachment	JJ	O
between	NN	O
gp120	IN	O
and	NN	O
gp41,	CC	O
free	,	O
gp120	JJ	O
is	NN	O
released	VBZ	O
from	VBN	O
the	IN	O
surface	DT	O
of	NN	O
virions	IN	O
and	NNS	O
infected	CC	O
cells.	JJ	O
Haas,	.	B
et	,	I
al.,	FW	I
(Current	,	I
Biology	NNP	I
6(3):315-324,	NNP	I
1996)	,	I
suggested	)	O
that	VBD	O
selective	IN	O
codon	JJ	O
usage	NN	O
by	NN	O
HIV-1	IN	O
appeared	NNP	O
to	VBD	O
account	TO	O
for	VB	O
a	IN	O
substantial	DT	O
fraction	JJ	O
of	NN	O
the	IN	O
inefficiency	DT	O
of	NN	O
viral	IN	O
protein	JJ	O
synthesis.	NN	O
Andre,	.	B
et	,	I
al.,	FW	I
(J.	,	I
Virol.	NNP	I
72(2):1497-1503,	.	I
1998)	,	I
described	)	O
an	VBD	O
increased	DT	O
immune	VBN	O
response	NN	O
elicited	NN	O
by	VBN	O
DNA	IN	O
vaccination	NNP	O
employing	NN	O
a	VBG	O
synthetic	DT	O
gp120	JJ	O
sequence	NN	O
with	NN	O
optimized	IN	O
codon	JJ	O
usage.	NN	O
SUMMARY	.	O
OF	NN	O
THE	IN	O
INVENTION	NNP	O
The	NNP	O
present	DT	O
invention	JJ	O
relates	NN	O
to	VBZ	O
improved	TO	O
expression	JJ	O
of	NN	O
HIV	IN	O
Env-,	NNP	O
tat-,	,	O
pol-,	,	O
prot-,	,	O
reverse	,	O
transcriptase,	JJ	O
or	,	O
Gag-containing	CC	O
polypeptides	NNP	O
and	NNS	O
production	CC	O
of	NN	O
virus-like	IN	O
particles.	JJ	O
In	.	O
one	IN	O
embodiment	CD	O
the	NN	O
present	DT	O
invention	JJ	O
includes	NN	O
an	VBZ	O
expression	DT	O
cassette,	NN	O
comprising	,	O
a	VBG	O
polynucleotide	DT	O
encoding	NN	O
an	VBG	O
HIV	DT	O
Gag	NNP	O
polypeptide	NNP	O
comprising	IN	O
a	VBG	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:20.	NNP	O
In	.	O
certain	IN	O
embodiments,	JJ	O
the	,	O
polynucleotide	DT	O
sequence	NN	O
encoding	NN	O
said	VBG	O
Gag	VBD	O
polypeptide	NNP	O
comprises	NN	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:9	NNP	O
or	NNP	O
SEQ	CC	O
ID	NNP	O
NO:4.	NNP	O
The	.	O
expression	DT	O
cassettes	NN	O
may	NNS	O
further	MD	O
include	RB	O
a	VB	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
protease	NNP	O
polypeptide,	NN	O
for	,	O
example	IN	O
a	NN	O
nucleotide	DT	O
sequence	JJ	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
a	TO	O
sequence	DT	O
selected	NN	O
from	VBN	O
the	IN	O
group	DT	O
consisting	NN	O
of:	VBG	O
SEQ	:	O
ID	NNP	O
NO:5,	NNP	O
SEQ	,	O
ID	NNP	O
NO:78,	NNP	O
and	,	O
SEQ	CC	O
ID	NNP	O
NO:79.	NNP	O
The	.	O
expression	DT	O
cassettes	NN	O
may	NNS	O
further	MD	O
include	RB	O
a	VB	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
reverse	NNP	O
transcriptase	NN	O
polypeptide,	NN	O
for	,	O
example	IN	O
a	NN	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
a	TO	O
sequence	DT	O
selected	NN	O
from	VBN	O
the	IN	O
group	DT	O
consisting	NN	O
of:	VBG	O
SEQ	:	O
ID	NNP	O
NO:80,	NNP	O
SEQ	,	O
ID	NNP	O
NO:81,	NNP	O
SEQ	,	O
ID	NNP	O
NO:82,	NNP	O
SEQ	,	O
ID	NNP	O
NO:83,	NNP	O
and	,	O
SEQ	CC	O
ID	NNP	O
NO:84.	NNP	O
The	.	O
expression	DT	O
cassettes	NN	O
may	NNS	O
further	MD	O
include	RB	O
a	VB	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
tat	NNP	O
polypeptide,	NN	O
for	,	O
example	IN	O
a	NN	O
sequence	DT	O
selected	NN	O
from	VBN	O
the	IN	O
group	DT	O
consisting	NN	O
of:	VBG	O
SEQ	:	O
ID	NNP	O
NO:87,	NNP	O
SEQ	,	O
ID	NNP	O
NO:88,	NNP	O
and	,	O
SEQ	CC	O
ID	NNP	O
NO:89.	NNP	O
The	.	O
expression	DT	O
cassettes	NN	O
may	NNS	O
further	MD	O
include	RB	O
a	VB	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
polymerase	NNP	O
polypeptide,	NN	O
for	,	O
example	IN	O
a	NN	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:6.	NNP	O
The	.	O
expression	DT	O
cassettes	NN	O
may	VBZ	O
include	MD	O
a	VB	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
polymerase	NNP	O
polypeptide,	NN	O
wherein	,	O
(i)	NN	O
the	)	O
nucleotide	DT	O
sequence	JJ	O
encoding	NN	O
said	NN	O
polypeptide	VBD	O
comprises	JJ	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:4,	NNP	O
and	,	O
(ii)	CC	O
wherein	)	O
the	VBZ	O
sequence	DT	O
is	NN	O
modified	VBZ	O
by	VBN	O
deletions	IN	O
of	NNS	O
coding	IN	O
regions	VBG	O
corresponding	NNS	O
to	VBG	O
reverse	TO	O
transcriptase	VB	O
and	NN	O
integrase.	CC	O
The	.	O
expression	DT	O
cassettes	NN	O
described	VBZ	O
above	VBN	O
may	IN	O
preserves	MD	O
T-helper	VB	O
cell	NNP	O
and	NN	O
CTL	CC	O
epitopes.	NNP	O
The	.	O
expression	DT	O
cassettes	NN	O
may	NNS	O
further	MD	O
include	RB	O
a	VB	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HCV	DT	O
core	NNP	O
polypeptide,	NN	O
for	,	O
example	IN	O
a	NN	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:7.	NNP	O
In	.	O
another	IN	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
an	VBZ	O
expression	DT	O
cassette,	NN	O
comprising	,	O
a	VBG	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
a	VBG	O
polypeptide	DT	O
including	NN	O
an	VBG	O
HIV	DT	O
Env	NNP	O
polypeptide,	NNP	O
wherein	,	O
the	VBP	O
polynucleotide	DT	O
sequence	NN	O
encoding	NN	O
said	VBG	O
Env	VBD	O
polypeptide	NNP	O
comprises	NN	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
SEQ	TO	O
ID	NNP	O
NO:71	NNP	O
(FIG.	NNP	O
58)	.	O
or	)	O
SEQ	CC	O
ID	NNP	O
NO:72	NNP	O
(FIG.	NNP	O
59).	.	O
In	.	O
certain	IN	O
embodiments,	JJ	O
the	,	O
Env	DT	O
expression	NNP	O
cassettes	NN	O
includes	VBZ	O
sequences	VBZ	O
flanking	NNS	O
a	VBG	O
V1	DT	O
region	JJ	O
but	NN	O
have	CC	O
a	VBP	O
deletion	DT	O
in	NN	O
the	IN	O
V1	DT	O
region	NNP	O
itself,	NN	O
for	,	O
example	IN	O
the	NN	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:65	NNP	O
(FIG.	NNP	O
52,	.	O
gp160.modUS4.delV1).	,	O
In	.	O
certain	IN	O
embodiments,	JJ	O
the	,	O
Env	DT	O
expression	NNP	O
cassettes,	NN	O
include	,	O
sequences	VBP	O
flanking	NNS	O
a	VBG	O
V2	DT	O
region	JJ	O
but	NN	O
have	CC	O
a	VBP	O
deletion	DT	O
in	NN	O
the	IN	O
V2	DT	O
region	NNP	O
itself,	NN	O
for	,	O
example	IN	O
the	NN	O
sequences	DT	O
shown	NNS	O
in	VBN	O
SEQ	IN	O
ID	NNP	O
NO:60	NNP	O
(FIG.	NNP	O
47);	.	O
SEQ	:	O
ID	NNP	O
NO:66	NNP	O
(FIG.	NNP	O
53);	.	O
SEQ	:	O
ID	NNP	O
NO:34	NNP	O
(FIG.	NNP	O
20);	.	O
SEQ	:	O
ID	NNP	O
NO:37	NNP	O
(FIG.	NNP	O
24);	.	O
SEQ	:	O
ID	NNP	O
NO:40	NNP	O
(FIG.	NNP	O
27);	.	O
SEQ	:	O
ID	NNP	O
NO:43	NNP	O
(FIG.	NNP	O
30);	.	O
SEQ	:	O
ID	NNP	O
NO:46	NNP	O
(FIG.	NNP	O
33);	.	O
SEQ	:	O
ID	NNP	O
NO:76	NNP	O
(FIG.	NNP	O
64)	.	O
and	)	O
SEQ	CC	O
ID	NNP	O
NO:49	NNP	O
(FIG.	NNP	O
36).	.	O
In	.	O
certain	IN	O
embodiments,	JJ	O
the	,	O
Env	DT	O
expression	NNP	O
cassettes	NN	O
include	NNS	O
sequences	VBP	O
flanking	NNS	O
a	VBG	O
V1/V2	DT	O
region	JJ	O
but	NN	O
have	CC	O
a	VBP	O
deletion	DT	O
in	NN	O
the	IN	O
V1/V2	DT	O
region	NNP	O
itself,	NN	O
for	,	O
example,	IN	O
SEQ	,	O
ID	NNP	O
NO:59	NNP	O
(FIG.	NNP	O
46);	.	O
SEQ	:	O
ID	NNP	O
NO:61	NNP	O
(FIG.	NNP	O
48);	.	O
SEQ	:	O
ID	NNP	O
NO:67	NNP	O
(FIG.	NNP	O
54);	.	O
SEQ	:	O
ID	NNP	O
NO:75	NNP	O
(FIG.	NNP	O
63);	.	O
SEQ	:	O
ID	NNP	O
NO:35	NNP	O
(FIG.	NNP	O
21);	.	O
SEQ	:	O
ID	NNP	O
NO:38	NNP	O
(FIG.	NNP	O
25);	.	O
SEQ	:	O
ID	NNP	O
NO:41	NNP	O
(FIG.	NNP	O
28);	.	O
SEQ	:	O
ID	NNP	O
NO:44	NNP	O
(FIG.	NNP	O
31);	.	O
SEQ	:	O
ID	NNP	O
NO:47	NNP	O
(FIG.	NNP	O
34)	.	O
and	)	O
SEQ	CC	O
ID	NNP	O
NO:50	NNP	O
(FIG.	NNP	O
37).	.	O
The	.	O
Env-encoding	DT	O
expression	JJ	O
cassettes	NN	O
may	NNS	O
also	MD	O
include	RB	O
a	VB	O
mutated	DT	O
cleavage	JJ	O
site	NN	O
that	NN	O
prevents	WDT	O
the	VBZ	O
cleavage	DT	O
of	NN	O
a	IN	O
gp140	DT	O
polypeptide	JJ	O
into	NN	O
a	IN	O
gp120	DT	O
polypeptide	JJ	O
and	NN	O
a	CC	O
gp41	DT	O
polypeptide,	NN	O
for	,	O
example,	IN	O
SEQ	,	O
ID	NNP	O
NO:57	NNP	O
(FIG.	NNP	O
44);	.	O
SEQ	:	O
ID	NNP	O
NO:61	NNP	O
(FIG.	NNP	O
48);	.	O
SEQ	:	O
ID	NNP	O
NO:63	NNP	O
(FIG.	NNP	O
50);	.	O
SEQ	:	O
ID	NNP	O
NO:39	NNP	O
(FIG.	NNP	O
26);	.	O
SEQ	:	O
ID	NNP	O
NO:40	NNP	O
(FIG.	NNP	O
27);	.	O
SEQ	:	O
ID	NNP	O
NO:41	NNP	O
(FIG.	NNP	O
28);	.	O
SEQ	:	O
ID	NNP	O
NO:42	NNP	O
(FIG.	NNP	O
29);	.	O
SEQ	:	O
ID	NNP	O
NO:43	NNP	O
(FIG.	NNP	O
30);	.	O
SEQ	:	O
ID	NNP	O
NO:44	NNP	O
(FIG.	NNP	O
31);	.	O
SEQ	:	O
ID	NNP	O
NO:45	NNP	O
(FIG.	NNP	O
32);	.	O
SEQ	:	O
ID	NNP	O
NO:46	NNP	O
(FIG.	NNP	O
33);	.	O
and	:	O
SEQ	CC	O
ID	NNP	O
NO:47	NNP	O
(FIG.	NNP	O
34).	.	O
The	.	O
Env	DT	O
expression	NNP	O
cassettes	NN	O
may	NNS	O
include	MD	O
a	VB	O
gp160	DT	O
Env	JJ	O
polypeptide	NNP	O
or	NN	O
a	CC	O
polypeptide	DT	O
derived	JJ	O
from	VBN	O
a	IN	O
gp160	DT	O
Env	NN	O
polypeptide,	NNP	O
for	,	O
example	IN	O
SEQ	NN	O
ID	NNP	O
NO:64	NNP	O
(FIG.	NNP	O
51);	.	O
SEQ	:	O
ID	NNP	O
NO:65	NNP	O
(FIG.	NNP	O
52);	.	O
SEQ	:	O
ID	NNP	O
NO:66	NNP	O
(FIG.	NNP	O
53);	.	O
SEQ	:	O
ID	NNP	O
NO:67	NNP	O
(FIG.	NNP	O
54);	.	O
SEQ	:	O
ID	NNP	O
NO:68	NNP	O
(FIG.	NNP	O
55);	.	O
SEQ	:	O
ID	NNP	O
NO:75	NNP	O
(FIG.	NNP	O
63);	.	O
SEQ	:	O
ID	NNP	O
NO:73	NNP	O
(FIG.	NNP	O
61);	.	O
SEQ	:	O
ID	NNP	O
NO:48	NNP	O
(FIG.	NNP	O
35);	.	O
SEQ	:	O
ID	NNP	O
NO:49	NNP	O
(FIG.	NNP	O
36);	.	O
SEQ	:	O
ID	NNP	O
NO:50	NNP	O
(FIG.	NNP	O
37);	.	O
SEQ	:	O
ID	NNP	O
NO:76	NNP	O
(FIG.	NNP	O
64);	.	O
and	:	O
SEQ	CC	O
ID	NNP	O
NO:74	NNP	O
(FIG.	NNP	O
62).	.	O
The	.	O
Env	DT	O
expression	NNP	O
cassettes	NN	O
may	NNS	O
include	MD	O
a	VB	O
gp140	DT	O
Env	JJ	O
polypeptide	NNP	O
or	NN	O
a	CC	O
polypeptide	DT	O
derived	JJ	O
from	VBN	O
a	IN	O
gp140	DT	O
Env	NN	O
polypeptide,	NNP	O
for	,	O
example	IN	O
SEQ	NN	O
ID	NNP	O
NO:56	NNP	O
(FIG.	NNP	O
43);	.	O
SEQ	:	O
ID	NNP	O
NO:57	NNP	O
(FIG.	NNP	O
44);	.	O
SEQ	:	O
ID	NNP	O
NO:58	NNP	O
(FIG.	NNP	O
45);	.	O
SEQ	:	O
ID	NNP	O
NO:59	NNP	O
(FIG.	NNP	O
46);	.	O
SEQ	:	O
ID	NNP	O
NO:60	NNP	O
(FIG.	NNP	O
47);	.	O
SEQ	:	O
ID	NNP	O
NO:61	NNP	O
(FIG.	NNP	O
48);	.	O
SEQ	:	O
ID	NNP	O
NO:62	NNP	O
(FIG.	NNP	O
49);	.	O
SEQ	:	O
ID	NNP	O
NO:63	NNP	O
(FIG.	NNP	O
50);	.	O
SEQ	:	O
ID	NNP	O
NO:36	NNP	O
(FIG.	NNP	O
23);	.	O
SEQ	:	O
ID	NNP	O
NO:37	NNP	O
(FIG.	NNP	O
24);	.	O
SEQ	:	O
ID	NNP	O
NO:38	NNP	O
(FIG.	NNP	O
25);	.	O
SEQ	:	O
ID	NNP	O
NO:39	NNP	O
(FIG.	NNP	O
26);	.	O
SEQ	:	O
ID	NNP	O
NO:40	NNP	O
(FIG.	NNP	O
27);	.	O
SEQ	:	O
ID	NNP	O
NO:41	NNP	O
(FIG.	NNP	O
28);	.	O
SEQ	:	O
ID	NNP	O
NO:42	NNP	O
(FIG.	NNP	O
29);	.	O
SEQ	:	O
ID	NNP	O
NO:43	NNP	O
(FIG.	NNP	O
30);	.	O
SEQ	:	O
ID	NNP	O
NO:44	NNP	O
(FIG.	NNP	O
31);	.	O
SEQ	:	O
ID	NNP	O
NO:45	NNP	O
(FIG.	NNP	O
32);	.	O
SEQ	:	O
ID	NNP	O
NO:46	NNP	O
(FIG.	NNP	O
33);	.	O
and	:	O
SEQ	CC	O
ID	NNP	O
NO:47	NNP	O
(FIG.	NNP	O
34).	.	O
The	.	O
Env	DT	O
expression	NNP	O
cassettes	NN	O
may	NNS	O
also	MD	O
include	RB	O
a	VB	O
gp120	DT	O
Env	JJ	O
polypeptide	NNP	O
or	NN	O
a	CC	O
polypeptide	DT	O
derived	JJ	O
from	VBN	O
a	IN	O
gp120	DT	O
Env	NN	O
polypeptide,	NNP	O
for	,	O
example	IN	O
SEQ	NN	O
ID	NNP	O
NO:54	NNP	O
(FIG.	NNP	O
41);	.	O
and	:	O
SEQ	CC	O
ID	NNP	O
NO:55	NNP	O
(FIG.	NNP	O
42);	.	O
SEQ	:	O
ID	NNP	O
NO:33	NNP	O
(FIG.	NNP	O
19);	.	O
SEQ	:	O
ID	NNP	O
NO:34	NNP	O
(FIG.	NNP	O
20);	.	O
and	:	O
SEQ	CC	O
ID	NNP	O
NO:35	NNP	O
(FIG.	NNP	O
21).	.	O
The	.	O
Env	DT	O
expression	NNP	O
cassettes	NN	O
may	NNS	O
include	MD	O
an	VB	O
Env	DT	O
polypeptide	NNP	O
lacking	NN	O
the	VBG	O
amino	DT	O
acids	NN	O
corresponding	NNS	O
to	VBG	O
residues	TO	O
128	VB	O
to	CD	O
about	TO	O
194,	IN	O
relative	,	O
to	JJ	O
strains	TO	O
SF162	VB	O
or	NNP	O
US4,	CC	O
for	,	O
example,	IN	O
SEQ	,	O
ID	NNP	O
NO:55	NNP	O
(FIG.	NNP	O
42);	.	O
SEQ	:	O
ID	NNP	O
NO:62	NNP	O
(FIG.	NNP	O
49);	.	O
SEQ	:	O
ID	NNP	O
NO:63	NNP	O
(FIG.	NNP	O
50);	.	O
and	:	O
SEQ	CC	O
ID	NNP	O
NO:68	NNP	O
(FIG.	NNP	O
55).	.	O
In	.	O
another	IN	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
a	VBZ	O
recombinant	DT	O
expression	JJ	O
system	NN	O
for	NN	O
use	IN	O
in	NN	O
a	IN	O
selected	DT	O
host	VBN	O
cell,	NN	O
comprising,	,	O
one	,	O
or	CD	O
more	CC	O
of	JJR	O
the	IN	O
expression	DT	O
cassettes	NN	O
described	VBZ	O
herein	VBN	O
operably	NN	O
linked	RB	O
to	VBD	O
control	TO	O
elements	VB	O
compatible	NNS	O
with	JJ	O
expression	IN	O
in	NN	O
the	IN	O
selected	DT	O
host	VBN	O
cell.	NN	O
The	.	O
expression	DT	O
cassettes	NN	O
may	NNS	O
be	MD	O
included	VB	O
on	VBN	O
one	IN	O
or	CD	O
on	CC	O
multiple	IN	O
vectors	JJ	O
and	NNS	O
may	CC	O
use	MD	O
the	VB	O
same	DT	O
or	JJ	O
different	CC	O
promoters.	JJ	O
Exemplary	.	O
control	JJ	O
elements	NN	O
include	NNS	O
a	VBP	O
transcription	DT	O
promoter	NN	O
(e.g.,	NN	O
CMV,	,	O
CMV+intron	,	O
A,	NNP	O
SV40,	,	O
RSV,	,	O
HIV-Ltr,	,	O
MMLV-ltr,	,	O
and	,	O
metallothionein),	CC	O
a	,	O
transcription	DT	O
enhancer	NN	O
element,	NN	O
a	,	O
transcription	DT	O
termination	NN	O
signal,	NN	O
polyadenylation	,	O
sequences,	NN	O
sequences	,	O
for	NNS	O
optimization	IN	O
of	NN	O
initiation	IN	O
of	NN	O
translation,	IN	O
and	,	O
translation	CC	O
termination	NN	O
sequences.	NN	O
In	.	O
another	IN	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
a	VBZ	O
recombinant	DT	O
expression	JJ	O
system	NN	O
for	NN	O
use	IN	O
in	NN	O
a	IN	O
selected	DT	O
host	VBN	O
cell,	NN	O
comprising,	,	O
any	,	O
one	DT	O
of	CD	O
the	IN	O
expression	DT	O
cassettes	NN	O
described	VBZ	O
herein	VBN	O
operably	NN	O
linked	RB	O
to	VBD	O
control	TO	O
elements	VB	O
compatible	NNS	O
with	JJ	O
expression	IN	O
in	NN	O
the	IN	O
selected	DT	O
host	VBN	O
cell.	NN	O
Exemplary	.	O
control	JJ	O
elements	NN	O
include,	NNS	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
a	,	O
transcription	DT	O
promoter	NN	O
(e.g.,	NN	O
CMV,	,	O
CMV+intron	,	O
A,	NNP	O
SV40,	,	O
RSV,	,	O
HIV-LTR,	,	O
MMLV-LTR,	,	O
and	,	O
metallothionein),	CC	O
a	,	O
transcription	DT	O
enhancer	NN	O
element,	NN	O
a	,	O
transcription	DT	O
termination	NN	O
signal,	NN	O
polyadenylation	,	O
sequences,	NN	O
sequences	,	O
for	NNS	O
optimization	IN	O
of	NN	O
initiation	IN	O
of	NN	O
translation,	IN	O
and	,	O
translation	CC	O
termination	NN	O
sequences.	NN	O
In	.	O
yet	IN	O
another	RB	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
a	VBZ	O
cell	DT	O
comprising	NN	O
one	VBG	O
or	CD	O
more	CC	O
of	JJR	O
the	IN	O
expression	DT	O
cassettes	NN	O
described	VBZ	O
herein	VBN	O
operably	NN	O
linked	RB	O
to	VBD	O
control	TO	O
elements	VB	O
compatible	NNS	O
with	JJ	O
expression	IN	O
in	NN	O
the	IN	O
cell.	DT	O
The	.	O
cell	DT	O
can	NN	O
be,	MD	O
for	,	O
example,	IN	O
a	,	O
mammalian	DT	O
cell	JJ	O
(e.g.,	NN	O
BHK,	,	O
VERO,	,	O
HT1080,	,	O
293,	,	O
RD,	,	O
COS-7,	,	O
or	,	O
CHO	CC	O
cells),	NNP	O
an	,	O
insect	DT	O
cell	NN	O
(e.g.,	NN	O
Trichoplusia	,	O
ni	NNP	O
(Tn5)	FW	O
or	)	O
Sf9),	CC	O
a	,	O
bacterial	DT	O
cell,	JJ	O
a	,	O
plant	DT	O
cell,	NN	O
a	,	O
yeast	DT	O
cell,	NN	O
an	,	O
antigen	DT	O
presenting	NN	O
cell	NN	O
(e.g.,	NN	O
primary,	,	O
immortalized	,	O
or	JJ	O
tumor-derived	CC	O
lymphoid	JJ	O
cells	JJ	O
such	NNS	O
as	JJ	O
macrophages,	IN	O
monocytes,	,	O
dendritic	,	O
cells,	JJ	O
B-cells,	,	O
T-cells,	,	O
stem	,	O
cells,	NN	O
and	,	O
progenitor	CC	O
cells	NN	O
thereof).	NNS	O
In	.	O
another	IN	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
methods	VBZ	O
for	NNS	O
producing	IN	O
a	VBG	O
polypeptide	DT	O
including	NN	O
HIV	VBG	O
Gag-,	NNP	O
prot-,	,	O
pol-,	,	O
reverse	,	O
transcriptase,	JJ	O
Env-	,	O
or	NNP	O
Tat-containing	CC	O
polypeptide	NNP	O
sequences,	NN	O
said	,	O
method	VBD	O
comprising,	NN	O
incubating	,	O
the	VBG	O
cells	DT	O
comprising	NNS	O
one	VBG	O
or	CD	O
more	CC	O
the	JJR	O
expression	DT	O
cassettes	NN	O
describe	VBZ	O
herein,	JJ	O
under	,	O
conditions	IN	O
for	NNS	O
producing	IN	O
said	VBG	O
polypeptide.	VBD	O
In	.	O
yet	IN	O
another	RB	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
compositions	VBZ	O
for	NNS	O
generating	IN	O
an	VBG	O
immunological	DT	O
response,	JJ	O
comprising	,	O
one	VBG	O
or	CD	O
more	CC	O
of	JJR	O
the	IN	O
expression	DT	O
cassettes	NN	O
described	VBZ	O
herein.	VBN	O
In	.	O
certain	IN	O
embodiments,	JJ	O
the	,	O
compositions	DT	O
also	NNS	O
include	RB	O
an	VBP	O
adjuvant.	DT	O
In	.	O
a	IN	O
still	DT	O
further	RB	O
aspect,	JJ	O
the	,	O
invention	DT	O
includes	NN	O
methods	VBZ	O
of	NNS	O
generating	IN	O
an	VBG	O
immune	DT	O
response	JJ	O
in	NN	O
a	IN	O
subject,	DT	O
comprising	,	O
introducing	VBG	O
a	VBG	O
composition	DT	O
comprising	NN	O
one	VBG	O
or	CD	O
more	CC	O
of	JJR	O
the	IN	O
expression	DT	O
cassettes	NN	O
described	VBZ	O
herein	VBN	O
into	RB	O
the	IN	O
subject	DT	O
under	JJ	O
conditions	IN	O
that	NNS	O
are	WDT	O
compatible	VBP	O
with	JJ	O
expression	IN	O
of	NN	O
said	IN	O
expression	VBD	O
cassette	NN	O
in	NN	O
the	IN	O
subject.	DT	O
In	.	O
certain	IN	O
embodiments,	JJ	O
the	,	O
expression	DT	O
cassette	NN	O
is	NN	O
introduced	VBZ	O
using	VBN	O
a	VBG	O
gene	DT	O
delivery	NN	O
vector.	NN	O
More	.	O
than	JJR	O
one	IN	O
expression	CD	O
cassette	NN	O
may	NN	O
be	MD	O
introduced	VB	O
using	VBN	O
one	VBG	O
or	CD	O
more	CC	O
gene	JJR	O
delivery	NN	O
vectors.	NN	O
In	.	O
yet	IN	O
another	RB	O
aspect,	DT	O
the	,	O
invention	DT	O
includes	NN	O
a	VBZ	O
purified	DT	O
polynucleotide	JJ	O
comprising	NN	O
a	VBG	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
a	VBG	O
polypeptide	DT	O
including	NN	O
an	VBG	O
HIV	DT	O
Env	NNP	O
polypeptide,	NNP	O
wherein	,	O
the	VBP	O
polynucleotide	DT	O
sequence	NN	O
encoding	NN	O
said	VBG	O
Env	VBD	O
polypeptide	NNP	O
comprises	NN	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
SEQ	TO	O
ID	NNP	O
NO:71	NNP	O
(FIG.	NNP	O
58)	.	O
or	)	O
SEQ	CC	O
ID	NNP	O
NO:72	NNP	O
(FIG.	NNP	O
59).	.	O
Further	.	O
exemplary	RB	O
purified	JJ	O
polynucleotide	VBD	O
sequences	JJ	O
were	NNS	O
presented	VBD	O
above.	VBN	O
The	.	O
polynucleotides	DT	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
can	NN	O
be	MD	O
produced	VB	O
by	VBN	O
recombinant	IN	O
techniques,	NN	O
synthetic	,	O
techniques,	JJ	O
or	,	O
combinations	CC	O
thereof.	NNS	O
In	.	O
another	IN	O
embodiment,	DT	O
the	,	O
invention	DT	O
includes	NN	O
a	VBZ	O
method	DT	O
for	NN	O
producing	IN	O
a	VBG	O
polypeptide	DT	O
including	NN	O
HIV	VBG	O
Gag	NNP	O
polypeptide	NNP	O
sequences,	NN	O
where	,	O
the	WRB	O
method	DT	O
comprises	NN	O
incubating	VBZ	O
any	VBG	O
of	DT	O
the	IN	O
above	DT	O
cells	JJ	O
containing	NNS	O
an	VBG	O
expression	DT	O
cassette	NN	O
of	NN	O
interest	IN	O
under	NN	O
conditions	IN	O
for	NNS	O
producing	IN	O
the	VBG	O
polypeptide.	DT	O
The	.	O
invention	DT	O
further	NN	O
includes,	RBR	O
a	,	O
method	DT	O
for	NN	O
producing	IN	O
virus-like	VBG	O
particles	JJ	O
(VLPs)	NNS	O
where	)	O
the	WRB	O
method	DT	O
comprises	NN	O
incubating	VBZ	O
any	VBG	O
of	DT	O
the	IN	O
above-described	DT	O
cells	JJ	O
containing	NNS	O
an	VBG	O
expression	DT	O
cassette	NN	O
of	NN	O
interest	IN	O
under	NN	O
conditions	IN	O
for	NNS	O
producing	IN	O
VLPs.	VBG	O
In	.	O
another	IN	O
aspect	DT	O
the	NN	O
invention	DT	O
includes	NN	O
a	VBZ	O
method	DT	O
for	NN	O
producing	IN	O
a	VBG	O
composition	DT	O
of	NN	O
virus-like	IN	O
particles	JJ	O
(VLPs)	NNS	O
where,	)	O
any	,	O
of	DT	O
the	IN	O
above-described	DT	O
cells	JJ	O
containing	NNS	O
an	VBG	O
expression	DT	O
cassette	NN	O
of	NN	O
interest	IN	O
are	NN	O
incubated	VBP	O
under	VBN	O
conditions	IN	O
for	NNS	O
producing	IN	O
VLPs,	VBG	O
and	,	O
the	CC	O
VLPs	DT	O
are	NNP	O
substantially	VBP	O
purified	RB	O
to	VBN	O
produce	TO	O
a	VB	O
composition	DT	O
of	NN	O
VLPs.	IN	O
In	.	O
a	IN	O
further	DT	O
embodiment	JJ	O
of	NN	O
the	IN	O
present	DT	O
invention,	JJ	O
packaging	,	O
cell	NN	O
lines	NN	O
are	NNS	O
produced	VBP	O
using	VBN	O
the	VBG	O
expression	DT	O
cassettes	NN	O
of	NNS	O
the	IN	O
present	DT	O
invention.	JJ	O
For	.	O
example,	IN	O
a	,	O
cell	DT	O
line	NN	O
useful	NN	O
for	JJ	O
packaging	IN	O
lentivirus	VBG	O
vectors	JJ	O
comprises	NNS	O
suitable	VBZ	O
host	JJ	O
cells	NN	O
that	NNS	O
have	WDT	O
an	VBP	O
expression	DT	O
vector	NN	O
containing	NN	O
an	VBG	O
expression	DT	O
cassette	NN	O
of	NN	O
the	IN	O
present	DT	O
invention	JJ	O
wherein	NN	O
said	NN	O
polynucleotide	VBD	O
sequence	JJ	O
is	NN	O
operably	VBZ	O
linked	RB	O
to	VBN	O
control	TO	O
elements	VB	O
compatible	NNS	O
with	JJ	O
expression	IN	O
in	NN	O
the	IN	O
host	DT	O
cell.	NN	O
In	.	O
a	IN	O
preferred	DT	O
embodiment,	JJ	O
such	,	O
host	JJ	O
cells	NN	O
may	NNS	O
be	MD	O
transfected	VB	O
with	VBN	O
one	IN	O
or	CD	O
more	CC	O
expression	JJR	O
cassettes	NN	O
having	VBZ	O
a	VBG	O
polynucleotide	DT	O
sequence	JJ	O
that	NN	O
encodes	WDT	O
an	VBZ	O
HIV	DT	O
polymerase	NNP	O
polypeptide	NN	O
or	NN	O
polypeptides	CC	O
derived	NNS	O
therefrom,	VBN	O
for	,	O
example,	IN	O
where	,	O
the	WRB	O
nucleotide	DT	O
sequence	JJ	O
encoding	NN	O
said	NN	O
polypeptide	VBD	O
comprises	JJ	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:6.	NNP	O
Further,	.	O
the	,	O
HIV	DT	O
polymerase	NNP	O
polypeptide	NN	O
may	NN	O
be	MD	O
modified	VB	O
by	VBN	O
deletions	IN	O
of	NNS	O
coding	IN	O
regions	VBG	O
corresponding	NNS	O
to	VBG	O
reverse	TO	O
transcriptase	VB	O
and	NN	O
integrase.	CC	O
Such	.	O
a	JJ	O
polynucleotide	DT	O
sequence	JJ	O
may	NN	O
preserve	MD	O
T-helper	VB	O
cell	NNP	O
and	NN	O
CTL	CC	O
epitopes,	NNP	O
for	,	O
example	IN	O
when	NN	O
used	WRB	O
in	VBN	O
a	IN	O
vaccine	DT	O
application.	NN	O
In	.	O
addition,	IN	O
the	,	O
polynucleotide	DT	O
sequence	JJ	O
may	NN	O
also	MD	O
include	RB	O
other	VB	O
polypeptides.	JJ	O
Further,	.	O
polynucleotide	,	O
sequences	JJ	O
encoding	NNS	O
additional	VBG	O
polypeptides	JJ	O
whose	NNS	O
expression	WP$	O
are	NN	O
useful	VBP	O
for	JJ	O
packaging	IN	O
cell	VBG	O
line	NN	O
function	NN	O
may	NN	O
also	MD	O
be	RB	O
utilized.	VB	O
In	.	O
another	IN	O
aspect,	DT	O
the	,	O
present	DT	O
invention	JJ	O
includes	NN	O
a	VBZ	O
gene	DT	O
delivery	NN	O
or	NN	O
vaccine	CC	O
vector	NN	O
for	NN	O
use	IN	O
in	NN	O
a	IN	O
subject,	DT	O
where	,	O
the	WRB	O
vector	DT	O
is	NN	O
a	VBZ	O
suitable	DT	O
gene	JJ	O
delivery	NN	O
vector	NN	O
for	NN	O
use	IN	O
in	NN	O
the	IN	O
subject,	DT	O
and	,	O
the	CC	O
vector	DT	O
comprises	NN	O
one	VBZ	O
or	CD	O
more	CC	O
of	JJR	O
any	IN	O
of	DT	O
the	IN	O
expression	DT	O
cassettes	NN	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
where	NN	O
the	WRB	O
polynucleotide	DT	O
sequences	NN	O
of	NNS	O
interest	IN	O
are	NN	O
operably	VBP	O
linked	RB	O
to	VBN	O
control	TO	O
elements	VB	O
compatible	NNS	O
with	JJ	O
expression	IN	O
in	NN	O
the	IN	O
subject.	DT	O
Such	.	O
gene	JJ	O
delivery	NN	O
vectors	NN	O
can	NNS	O
be	MD	O
used	VB	O
in	VBN	O
a	IN	O
method	DT	O
of	NN	O
DNA	IN	O
immunization	NNP	O
of	NN	O
a	IN	O
subject,	DT	O
for	,	O
example,	IN	O
by	,	O
introducing	IN	O
a	VBG	O
gene	DT	O
delivery	NN	O
vector	NN	O
into	NN	O
the	IN	O
subject	DT	O
under	JJ	O
conditions	IN	O
that	NNS	O
are	WDT	O
compatible	VBP	O
with	JJ	O
expression	IN	O
of	NN	O
the	IN	O
expression	DT	O
cassette	NN	O
in	NN	O
the	IN	O
subject.	DT	O
Gene	.	O
delivery	NNP	O
vectors	NN	O
useful	NNS	O
in	JJ	O
the	IN	O
practice	DT	O
of	NN	O
the	IN	O
present	DT	O
invention	JJ	O
include,	NN	O
but	,	O
are	CC	O
not	VBP	O
limited	RB	O
to,	VBN	O
nonviral	,	O
vectors,	JJ	O
bacterial	,	O
plasmid	JJ	O
vectors,	NN	O
viral	,	O
vectors,	JJ	O
particulate	,	O
carriers	NN	O
(where	NNS	O
the	WRB	O
vector	DT	O
is	NN	O
coated	VBZ	O
on	VBN	O
a	IN	O
polylactide	DT	O
co-glycolide	JJ	O
particles,	JJ	O
gold	,	O
or	NN	O
tungsten	CC	O
particle,	JJ	O
for	,	O
example,	IN	O
the	,	O
coated	DT	O
particle	JJ	O
can	NN	O
be	MD	O
delivered	VB	O
to	VBN	O
a	TO	O
subject	DT	O
cell	NN	O
using	NN	O
a	VBG	O
gene	DT	O
gun),	NN	O
liposome	,	O
preparations,	JJ	O
and	,	O
viral	CC	O
vectors	JJ	O
(e.g.,	NNS	O
vectors	,	O
derived	NNS	O
from	VBD	O
alphaviruses,	IN	O
pox	,	O
viruses,	NN	O
and	,	O
vaccinia	CC	O
viruses,	NN	O
as	,	O
well	RB	O
as,	RB	O
retroviral	,	O
vectors,	JJ	O
including,	,	O
but	,	O
not	CC	O
limited	RB	O
to,	JJ	O
lentiviral	,	O
vectors).	JJ	O
Alphavirus-derived	.	O
vectors	JJ	O
include,	NNS	O
for	,	O
example,	IN	O
an	,	O
alphavirus	DT	O
cDNA	NN	O
construct,	NN	O
a	,	O
recombinant	DT	O
alphavirus	JJ	O
particle	NN	O
preparation	NN	O
and	NN	O
a	CC	O
eukaryotic	DT	O
layered	JJ	O
vector	JJ	O
initiation	NN	O
system.	NN	O
In	.	O
one	IN	O
embodiment,	CD	O
the	,	O
subject	DT	O
is	NN	O
a	VBZ	O
vertebrate,	DT	O
preferably	,	O
a	RB	O
mammal,	DT	O
and	,	O
in	CC	O
a	IN	O
further	DT	O
embodiment	JJ	O
the	NN	O
subject	DT	O
is	NN	O
a	VBZ	O
human.	DT	O
The	.	O
invention	DT	O
further	NN	O
includes	RB	O
a	VBZ	O
method	DT	O
of	NN	O
generating	IN	O
an	VBG	O
immune	DT	O
response	JJ	O
in	NN	O
a	IN	O
subject,	DT	O
where	,	O
cells	WRB	O
of	NNS	O
a	IN	O
subject	DT	O
are	NN	O
transfected	VBP	O
with	VBN	O
any	IN	O
of	DT	O
the	IN	O
above-described	DT	O
gene	JJ	O
delivery	NN	O
vectors	NN	O
(e.g.,	NNS	O
alphavirus	,	O
constructs;	JJ	O
alphavirus	:	O
cDNA	CC	O
constructs;	NN	O
eukaryotic	:	O
layered	JJ	O
vector	VBD	O
initiation	JJ	O
systems	NN	O
(see,	NNS	O
e.g.,	,	O
U.S.	,	O
Pat.	NNP	O
No.	.	O
5,814,482	.	O
for	CD	O
description	IN	O
of	NN	O
suitable	IN	O
eukaryotic	JJ	O
layered	JJ	O
vector	VBD	O
initiation	JJ	O
systems);	NN	O
alphavirus	:	O
particle	JJ	O
preparations;	NN	O
etc.)	:	O
under	)	O
conditions	IN	O
that	NNS	O
permit	WDT	O
the	VBP	O
expression	DT	O
of	NN	O
a	IN	O
selected	DT	O
polynucleotide	VBN	O
and	NN	O
production	CC	O
of	NN	O
a	IN	O
polypeptide	DT	O
of	NN	O
interest	IN	O
(i.e.,	NN	O
encoded	,	O
by	VBN	O
any	IN	O
expression	DT	O
cassette	NN	O
of	NN	O
the	IN	O
present	DT	O
invention),	JJ	O
thereby	,	O
eliciting	RB	O
an	VBG	O
immunological	DT	O
response	JJ	O
to	NN	O
the	TO	O
polypeptide.	DT	O
Transfection	.	O
of	NN	O
the	IN	O
cells	DT	O
may	NNS	O
be	MD	O
performed	VB	O
ex	VBN	O
vivo	JJ	O
and	NN	O
the	CC	O
transfected	DT	O
cells	JJ	O
are	NNS	O
reintroduced	VBP	O
into	VBN	O
the	IN	O
subject.	DT	O
Alternately,	.	O
or	,	O
in	CC	O
addition,	IN	O
the	,	O
cells	DT	O
may	NNS	O
be	MD	O
transfected	VB	O
in	VBN	O
vivo	IN	O
in	NN	O
the	IN	O
subject.	DT	O
The	.	O
immune	DT	O
response	JJ	O
may	NN	O
be	MD	O
humoral	VB	O
and/or	JJ	O
cell-mediated	JJ	O
(cellular).	JJ	O
Further	.	O
embodiments	JJ	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
include	NN	O
purified	VBP	O
polynucleotides.	VBN	O
In	.	O
one	IN	O
embodiment,	CD	O
the	,	O
purified	DT	O
polynucleotide	JJ	O
comprises	NN	O
a	VBZ	O
polynucleotide	DT	O
sequence	NN	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:20,	NNP	O
and	,	O
complements	CC	O
thereof.	NNS	O
In	.	O
another	IN	O
embodiment,	DT	O
the	,	O
purified	DT	O
polynucleotide	JJ	O
comprises	NN	O
a	VBZ	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
Gag	NNP	O
polypeptide,	NNP	O
wherein	,	O
the	VBP	O
polynucleotide	DT	O
sequence	NN	O
comprises	NN	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:20,	NNP	O
and	,	O
complements	CC	O
thereof.	NNS	O
In	.	O
still	IN	O
another	RB	O
embodiment,	DT	O
the	,	O
purified	DT	O
polynucleotide	JJ	O
comprises	NN	O
a	VBZ	O
polynucleotide	DT	O
sequence	JJ	O
encoding	NN	O
an	VBG	O
HIV	DT	O
Gag	NNP	O
polypeptide,	NNP	O
wherein	,	O
the	VBP	O
polynucleotide	DT	O
sequence	NN	O
comprises	NN	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
the	TO	O
sequence	DT	O
presented	NN	O
as	VBD	O
SEQ	IN	O
ID	NNP	O
NO:9,	NNP	O
and	,	O
complements	CC	O
thereof.	NNS	O
In	.	O
further	IN	O
embodiments	JJ	O
the	NNS	O
polynucleotide	DT	O
sequence	NN	O
comprises	NN	O
a	VBZ	O
sequence	DT	O
having	NN	O
at	VBG	O
least	IN	O
90%	JJS	O
sequence	NN	O
identity	NN	O
to	NN	O
one	TO	O
of	CD	O
the	IN	O
following	DT	O
sequences:	JJ	O
SEQ	:	O
ID	NNP	O
NO:4,	NNP	O
SEQ	,	O
ID	NNP	O
NO:5,	NNP	O
SEQ	,	O
ID	NNP	O
NO:6,	NNP	O
SEQ	,	O
ID	NNP	O
NO:7,	NNP	O
and	,	O
complements	CC	O
thereof.	NNS	O
The	.	O
polynucleotides	DT	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
can	NN	O
be	MD	O
produced	VB	O
by	VBN	O
recombinant	IN	O
techniques,	NN	O
synthetic	,	O
techniques,	JJ	O
or	,	O
combinations	CC	O
thereof.	NNS	O
These	.	O
and	DT	O
other	CC	O
embodiments	JJ	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
will	NN	O
readily	MD	O
occur	RB	O
to	VB	O
those	TO	O
of	DT	O
ordinary	IN	O
skill	JJ	O
in	NN	O
the	IN	O
art	DT	O
in	NN	O
view	IN	O
of	NN	O
the	IN	O
disclosure	DT	O
herein.	NN	O
BRIEF	.	O
DESCRIPTION	JJ	O
OF	NNP	O
THE	IN	O
FIGURES	NNP	O
FIG.	NNP	O
1	.	O
shows	CD	O
the	VBZ	O
locations	DT	O
of	NNS	O
the	IN	O
inactivation	DT	O
sites	NN	O
for	VBZ	O
the	IN	O
native	DT	O
HIV-1SF2	JJ	O
Gag	NNP	O
protein	NNP	O
coding	NN	O
sequence	VBG	O
SEQ	NN	O
ID	NNP	O
NO:1.	NNP	O
FIG.	.	O
2	.	O
shows	CD	O
the	VBZ	O
locations	DT	O
of	NNS	O
the	IN	O
inactivation	DT	O
sites	NN	O
for	VBZ	O
the	IN	O
native	DT	O
HIV-1SF2	JJ	O
Gag-protease	NNP	O
protein	NNP	O
coding	NN	O
sequence	VBG	O
SEQ	NN	O
ID	NNP	O
NO:2.	NNP	O
FIGS.	.	O
3A	.	O
and	CD	O
3B	CC	O
show	CD	O
electron	NN	O
micrographs	NN	O
of	NN	O
virus-like	IN	O
particles.	JJ	O
FIG.	.	O
3A	.	O
shows	CD	O
immature	NNS	O
p55Gag	JJ	O
virus-like	JJ	O
particles	JJ	O
in	NNS	O
COS-7	IN	O
cells	NNP	O
transfected	NNS	O
with	VBN	O
a	IN	O
synthetic	DT	O
HIV-1SF2	JJ	O
gag	NNP	O
construct	NN	O
while	NN	O
FIG.	IN	O
3B	.	O
shows	CD	O
mature	NNS	O
(arrows)	VBP	O
and	)	O
immature	CC	O
VLP	JJ	O
in	NNP	O
cells	IN	O
transfected	NNS	O
with	VBN	O
a	IN	O
modified	DT	O
HIV-1SF2	JJ	O
gagprotease	JJ	O
construct	NN	O
(GP2,	NN	O
SEQ	,	O
ID	NNP	O
NO:70).	NNP	O
Transfected	.	O
cells	VBN	O
were	NNS	O
fixed	VBD	O
at	VBN	O
24	IN	O
h	CD	O
(gag)	NN	O
or	)	O
48	CC	O
h	CD	O
(gagprotease)	NN	O
post-transfection	)	O
and	NN	O
subsequently	CC	O
analyzed	RB	O
by	VBN	O
electron	IN	O
microscopy	NN	O
(magnification	NN	O
at	NN	O
100,000×).	IN	O
Cells	.	O
transfected	NNS	O
with	VBN	O
vector	IN	O
alone	NN	O
(pCMVKm2)	RB	O
served	)	O
as	VBD	O
negative	IN	O
control	JJ	O
(data	NN	O
not	NNS	O
shown).	RB	O
FIG.	.	O
4	.	O
presents	CD	O
an	NNS	O
image	DT	O
of	NN	O
samples	IN	O
from	NNS	O
a	IN	O
series	DT	O
of	NN	O
fractions	IN	O
which	NNS	O
were	WDT	O
electrophoresed	VBD	O
on	VBN	O
an	IN	O
8-16%	DT	O
SDS	NN	O
polyacrylamide	NNP	O
gel	NN	O
and	NN	O
the	CC	O
resulting	DT	O
bands	VBG	O
visualized	NNS	O
by	VBN	O
commassie	IN	O
blue	NN	O
staining.	NN	O
The	.	O
results	DT	O
show	NNS	O
that	VBP	O
the	IN	O
native	DT	O
p55	JJ	O
Gag	NN	O
virus-like	NNP	O
particles	NN	O
(VLPs)	NNS	O
banded	)	O
at	VBD	O
a	IN	O
sucrose	DT	O
density	JJ	O
of	NN	O
range	IN	O
of	NN	O
1.15-1.19	IN	O
g/ml	JJ	O
with	NN	O
the	IN	O
peak	DT	O
at	NN	O
approximately	IN	O
1.17	RB	O
g/ml.	CD	O
FIG.	.	O
5	.	O
presents	CD	O
an	NNS	O
image	DT	O
similar	NN	O
to	JJ	O
FIG.	TO	O
4	.	O
where	CD	O
the	WRB	O
analysis	DT	O
was	NN	O
performed	VBD	O
using	VBN	O
Gag	VBG	O
VLPs	NNP	O
produced	NNP	O
by	VBN	O
a	IN	O
synthetic	DT	O
Gag	JJ	O
expression	NNP	O
cassette.	NN	O
FIG.	.	O
6	.	O
presents	CD	O
a	NNS	O
comparison	DT	O
of	NN	O
the	IN	O
total	DT	O
amount	JJ	O
of	NN	O
purified	IN	O
HIV	JJ	O
p55	NNP	O
Gag	NN	O
from	NNP	O
several	IN	O
preparations	JJ	O
obtained	NNS	O
from	VBN	O
two	IN	O
baculovirus	CD	O
expression	NN	O
cassettes	NN	O
encoding	VBZ	O
native	VBG	O
and	JJ	O
modified	CC	O
Gag.	JJ	O
FIG.	.	O
7	.	O
presents	CD	O
an	NNS	O
alignment	DT	O
of	NN	O
modified	IN	O
coding	JJ	O
sequences	VBG	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
including	NN	O
a	VBG	O
synthetic	DT	O
Gag	JJ	O
expression	NNP	O
cassette	NN	O
(SEQ	NN	O
ID	NNP	O
NO:4),	NNP	O
a	,	O
synthetic	DT	O
Gag-protease	JJ	O
expression	NNP	O
cassette	NN	O
(SEQ	NN	O
ID	NNP	O
NO:5),	NNP	O
and	,	O
a	CC	O
synthetic	DT	O
Gag-polymerase	JJ	O
expression	NNP	O
cassette	NN	O
(SEQ	NN	O
ID	NNP	O
NO:6).	NNP	O
A	.	O
common	DT	O
region	JJ	O
(Gag-common;	NN	O
SEQ	:	O
ID	NNP	O
NO:9)	NNP	O
extends	)	O
from	VBZ	O
position	IN	O
1	NN	O
to	CD	O
position	TO	O
1262.	NN	O
FIG.	.	O
8	.	O
presents	CD	O
an	NNS	O
image	DT	O
of	NN	O
wild-type	IN	O
Gag-HCV	JJ	O
core	NNP	O
expression	NN	O
samples	NN	O
from	NNS	O
a	IN	O
series	DT	O
of	NN	O
fractions	IN	O
which	NNS	O
were	WDT	O
electrophoresed	VBD	O
on	VBN	O
an	IN	O
8-16%	DT	O
SDS	NN	O
polyacrylamide	NNP	O
gel	NN	O
and	NN	O
the	CC	O
resulting	DT	O
bands	VBG	O
visualized	NNS	O
by	VBN	O
commassie	IN	O
staining.	NN	O
FIG.	.	O
9	.	O
shows	CD	O
the	VBZ	O
results	DT	O
of	NNS	O
Western	IN	O
blot	JJ	O
analysis	NN	O
of	NN	O
the	IN	O
gel	DT	O
shown	NN	O
presented	VBN	O
in	VBN	O
FIG.	IN	O
8.	.	O
FIG.	.	O
10	.	O
presents	CD	O
results	NNS	O
similar	NNS	O
to	JJ	O
those	TO	O
shown	DT	O
in	VBN	O
FIG.	IN	O
9.	.	O
The	.	O
results	DT	O
in	NNS	O
FIG.	IN	O
10	.	O
indicate	CD	O
that	NN	O
the	IN	O
main	DT	O
HCV	JJ	O
Core-specific	NNP	O
reactivity	NNP	O
migrates	NN	O
at	NNS	O
an	IN	O
approximate	DT	O
molecular	JJ	O
weight	JJ	O
of	NN	O
72,000	IN	O
kD,	CD	O
which	,	O
is	WDT	O
in	VBZ	O
accordance	IN	O
with	NN	O
the	IN	O
predicted	DT	O
molecular	JJ	O
weight	JJ	O
of	NN	O
the	IN	O
Gag-HCV	DT	O
core	NNP	O
chimeric	NN	O
protein.	NN	O
FIGS.	.	O
11A	.	O
to	CD	O
11D	TO	O
present	CD	O
a	NN	O
comparison	DT	O
of	NN	O
AT	IN	O
content,	NNP	O
in	,	O
percent,	IN	O
of	,	O
cDNAs	IN	O
corresponding	NN	O
to	VBG	O
an	TO	O
unstable	DT	O
human	JJ	O
mRNA	JJ	O
(human	NN	O
IFNγ	JJ	O
mRNA;	NNP	O
11A),	:	O
wild-type	,	O
HIV	JJ	O
Gag	NNP	O
native	NNP	O
RNA	JJ	O
(11B),	NNP	O
a	,	O
stable	DT	O
human	JJ	O
mRNA	JJ	O
(human	NN	O
GAPDH	JJ	O
mRNA;	NNP	O
11C),	:	O
and	,	O
synthetic	CC	O
HIV	JJ	O
Gag	NNP	O
RNA	NNP	O
(11D).	NNP	O
FIG.	.	O
12	.	O
shows	CD	O
the	VBZ	O
location	DT	O
of	NN	O
the	IN	O
inactivation	DT	O
sites	NN	O
for	VBZ	O
the	IN	O
native	DT	O
HIV-1SF2	JJ	O
Gag-polymerase	NNP	O
sequence	NNP	O
SEQ	NN	O
ID	NNP	O
NO:3.	NNP	O
FIG.	.	O
13A	.	O
presents	CD	O
a	NNS	O
vector	DT	O
map	NN	O
of	NN	O
pESN2dhfr.	IN	O
FIG.	.	O
13B	.	O
presents	CD	O
a	NNS	O
map	DT	O
of	NN	O
the	IN	O
pCMVIII	DT	O
vector.	NN	O
FIG.	.	O
14	.	O
presents	CD	O
a	NNS	O
vector	DT	O
map	NN	O
of	NN	O
pCMV-LINK.	IN	O
FIG.	.	O
15	.	O
presents	CD	O
a	NNS	O
schematic	DT	O
diagram	JJ	O
showing	NN	O
the	VBG	O
relationships	DT	O
between	NNS	O
the	IN	O
following	DT	O
forms	VBG	O
of	NNS	O
the	IN	O
HIV	DT	O
Env	NNP	O
polypeptide:	NNP	O
gp160,	:	O
gp140,	,	O
gp120,	,	O
and	,	O
gp41.	CC	O
FIG.	.	O
16	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
wild-type	IN	O
gp120	JJ	O
from	NN	O
SF162	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:30).	NNP	O
FIG.	.	O
17	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
wild-type	DT	O
gp140	JJ	O
from	NN	O
SF162	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:31).	NNP	O
FIG.	.	O
18	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
wild-type	DT	O
gp160	JJ	O
from	NN	O
SF162	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:32).	NNP	O
FIG.	.	O
19	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp120.modSF162	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:33).	NNP	O
FIG.	.	O
20	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp120.modSF162.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:34).	NNP	O
FIG.	.	O
21	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp120.modSF162.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:35).	NNP	O
FIGS.	.	O
22A-H	.	O
show	JJ	O
the	NN	O
percent	DT	O
A-T	NN	O
content	NNP	O
over	NN	O
the	IN	O
length	DT	O
of	NN	O
the	IN	O
sequences	DT	O
for	NNS	O
IFNγ	IN	O
(FIGS.	NNP	O
2C	.	O
and	CD	O
2G);	CC	O
native	:	O
gp160	JJ	O
Env	NN	O
US4	NNP	O
and	NNP	O
SF162	CC	O
(FIGS.	NNP	O
2A	.	O
and	CD	O
2E,	CC	O
respectively);	,	O
GAPDH	:	O
(FIGS.	NNP	O
2D	.	O
and	CD	O
2H);	CC	O
and	:	O
the	CC	O
synthetic	DT	O
gp160	JJ	O
Env	NN	O
for	NNP	O
US4	IN	O
and	NNP	O
SF162	CC	O
(FIGS.	NNP	O
2B	.	O
and	CD	O
2F,	CC	O
respectively).	,	O
FIG.	.	O
23	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modSF162	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:36).	NNP	O
FIG.	.	O
24	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modSF162.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:37).	NNP	O
FIG.	.	O
25	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modSF162.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:38).	NNP	O
FIG.	.	O
26	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut.modSF162	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:39).	NNP	O
FIG.	.	O
27	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut.modSF162.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:40).	NNP	O
FIG.	.	O
28	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut.modSF162.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:41).	NNP	O
FIG.	.	O
29	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut7.modSF162	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:42).	NNP	O
FIG.	.	O
30	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut7.modSF162.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:43).	NNP	O
FIG.	.	O
31	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut7.modSF162.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:44).	NNP	O
FIG.	.	O
32	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut8.modSF162	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:45).	NNP	O
FIG.	.	O
33	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut8.modSF162.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:46).	NNP	O
FIG.	.	O
34	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut8.modSF162.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:47).	NNP	O
FIG.	.	O
35	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modSF162	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:48).	NNP	O
FIG.	.	O
36	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modSF162.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:49).	NNP	O
FIG.	.	O
37	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modSF162.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:50).	NNP	O
FIG.	.	O
38	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
wild-type	DT	O
gp120	JJ	O
from	NN	O
US4	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:51).	NNP	O
FIG.	.	O
39	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
wild-type	DT	O
gp140	JJ	O
from	NN	O
US4	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:52).	NNP	O
FIG.	.	O
40	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
wild-type	DT	O
gp160	JJ	O
from	NN	O
US4	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:53).	NNP	O
FIG.	.	O
41	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp120.modUS4	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:54).	NNP	O
FIG.	.	O
42	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp120.modUS4.del	VBN	O
128-194	JJ	O
(SEQ	JJ	O
ID	NNP	O
NO:55).	NNP	O
FIG.	.	O
43	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modUS4	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:56).	NNP	O
FIG.	.	O
44	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut.modUS4	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:57).	NNP	O
FIG.	.	O
45	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.TM.modUS4	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:58).	NNP	O
FIG.	.	O
46	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modUS4.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:59).	NNP	O
FIG.	.	O
47	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modUS4.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:60).	NNP	O
FIG.	.	O
48	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut.modUS4.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:61).	NNP	O
FIG.	.	O
49	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.modUS4.del	VBN	O
128-194	JJ	O
(SEQ	JJ	O
ID	NNP	O
NO:62).	NNP	O
FIG.	.	O
50	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp140.mut.modUS4.del	VBN	O
128-194	JJ	O
(SEQ	JJ	O
ID	NNP	O
NO:63).	NNP	O
FIG.	.	O
51	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modUS4	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:64).	NNP	O
FIG.	.	O
52	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modUS4.delV1	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:65).	NNP	O
FIG.	.	O
53	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modUS4.delV2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:66).	NNP	O
FIG.	.	O
54	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modUS4.delV1/V2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:67).	NNP	O
FIG.	.	O
55	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
gp160.modUS4.del	VBN	O
128-194	JJ	O
(SEQ	JJ	O
ID	NNP	O
NO:68).	NNP	O
FIG.	.	O
56	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
common	DT	O
region	JJ	O
of	NN	O
Env	IN	O
from	NNP	O
wild-type	IN	O
US4	JJ	O
(SEQ	NNP	O
ID	NNP	O
NO:69).	NNP	O
FIG.	.	O
57	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
common	DT	O
region	JJ	O
of	NN	O
Env	IN	O
from	NNP	O
wild-type	IN	O
SF162	JJ	O
(SEQ	NNP	O
ID	NNP	O
NO:70).	NNP	O
FIG.	.	O
58	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
synthetic	IN	O
sequences	JJ	O
corresponding	NNS	O
to	VBG	O
the	TO	O
common	DT	O
region	JJ	O
of	NN	O
Env	IN	O
from	NNP	O
US4	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:71).	NNP	O
FIG.	.	O
59	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
synthetic	IN	O
sequences	JJ	O
corresponding	NNS	O
to	VBG	O
the	TO	O
common	DT	O
region	JJ	O
of	NN	O
Env	IN	O
from	NNP	O
SF162	IN	O
(SEQ	NNP	O
ID	NNP	O
NO:72).	NNP	O
FIG.	.	O
60	.	O
presents	CD	O
a	NNS	O
schematic	DT	O
representation	JJ	O
of	NN	O
an	IN	O
Env	DT	O
polypeptide	NNP	O
purification	NN	O
strategy.	NN	O
FIG.	.	O
61	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
bicistronic	DT	O
construct	JJ	O
designated	NN	O
gp160.modUS4.Gag.modSF2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:73).	NNP	O
FIG.	.	O
62	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
bicistronic	DT	O
construct	JJ	O
designated	NN	O
gp160.modSF162.Gag.modSF2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:74).	NNP	O
FIG.	.	O
63	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
bicistronic	DT	O
construct	JJ	O
designated	NN	O
gp160.modUS4.-delV1/V2.Gag.modSF2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:75).	NNP	O
FIG.	.	O
64	.	O
depicts	CD	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
bicistronic	DT	O
construct	JJ	O
designated	NN	O
gp160.modSF162.delV2.Gag.modSF2	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:76).	NNP	O
FIGS.	.	O
65A-65F	.	O
show	JJ	O
micrographs	NN	O
of	NN	O
293T	IN	O
cells	CD	O
transfected	NNS	O
with	VBN	O
the	IN	O
following	DT	O
polypeptide	JJ	O
encoding	NN	O
sequences:	VBG	O
FIG.	:	O
65A,	.	O
gag.modSF2;	,	O
FIG.	:	O
65B,	.	O
gp160.modUS4;	,	O
FIG.	:	O
65C,	.	O
gp160.modUS4.delV1/V2.gag.modSF2	,	O
(bicistronic	NN	O
Env	JJ	O
and	NNP	O
Gag);	CC	O
FIGS.	:	O
65D	.	O
and	CD	O
65E,	CC	O
gp160.modUS4.delV1/V2	,	O
and	NN	O
gag.modSF2;	CC	O
and	:	O
FIG.	CC	O
65F,	.	O
gp120.modSF162.delV2	,	O
and	NN	O
gag.modSF2.	CC	O
FIGS.	.	O
66A	.	O
and	CD	O
66B	CC	O
present	CD	O
alignments	JJ	O
of	NNS	O
selected	IN	O
modified	VBN	O
coding	JJ	O
sequences	VBG	O
of	NNS	O
the	IN	O
present	DT	O
invention	JJ	O
including	NN	O
a	VBG	O
common	DT	O
region	JJ	O
defined	NN	O
for	VBN	O
each	IN	O
group	DT	O
of	NN	O
synthetic	IN	O
Env	JJ	O
expression	NNP	O
cassettes.	NN	O
FIG.	.	O
66A	.	O
presents	CD	O
alignments	NNS	O
of	NNS	O
modified	IN	O
SF162	JJ	O
sequences.	NNP	O
gp160.modSF162,	.	O
SEQ	,	O
ID	NNP	O
NO:48;	NNP	O
gp160.modSF162.delV2,	:	O
SEQ	,	O
ID	NNP	O
NO:49;	NNP	O
gp160.modSF162.delV1V2,	:	O
SEQ	,	O
ID	NNP	O
NO:50;	NNP	O
gp140.mut.modSF162,	:	O
SEQ	,	O
ID	NNP	O
NO:39;	NNP	O
gp140.mut7.modSF162,	:	O
SEQ	,	O
ID	NNP	O
NO:42;	NNP	O
gp140.mut8.modSF162,	:	O
SEQ	,	O
ID	NNP	O
NO:45;	NNP	O
gp120.modSF162,	:	O
SEQ	,	O
ID	NNP	O
NO:33.	NNP	O
FIG.	.	O
66B	.	O
presents	CD	O
alignments	NNS	O
of	NNS	O
modified	IN	O
US4	JJ	O
sequences.	NNP	O
gp160,	.	O
SEQ	,	O
ID	NNP	O
NO:53;	NNP	O
gp160	:	O
del	JJ	O
V1,	NN	O
SEQ	,	O
ID	NNP	O
NO:65;	NNP	O
gp160	:	O
del	JJ	O
V2,	NN	O
SEQ	,	O
ID	NNP	O
NO:66;	NNP	O
gp160	:	O
del	JJ	O
128-194,	FW	O
SEQ	,	O
ID	NNP	O
NO:63;	NNP	O
gp140™,	:	O
SEQ	,	O
ID	NNP	O
NO:58;	NNP	O
gp140,	:	O
SEQ	,	O
ID	NNP	O
NO:52;	NNP	O
gp140mut,	:	O
SEQ	,	O
ID	NNP	O
NO:57;	NNP	O
gp120,	:	O
SEQ	,	O
ID	NNP	O
NO:51.	NNP	O
The	.	O
SEQ	DT	O
ID	NNP	O
NOs	NNP	O
for	NNP	O
these	IN	O
sequences	DT	O
are	NNS	O
presented	VBP	O
in	VBN	O
Tables	IN	O
1A	NNP	O
and	CD	O
1B.	CC	O
FIG.	.	O
67	.	O
shows	CD	O
the	VBZ	O
ELISA	DT	O
titers	NNP	O
(binding	NNS	O
antibodies)	VBG	O
obtained	)	O
in	VBN	O
two	IN	O
rhesus	CD	O
macaques	NN	O
(H445,	NNS	O
lines	,	O
with	NNS	O
solid	IN	O
black	JJ	O
dots;	JJ	O
and	:	O
J408,	CC	O
lines	,	O
with	NNS	O
open	IN	O
squares).	JJ	O
The	.	O
y-axis	DT	O
is	NN	O
the	VBZ	O
end-point	DT	O
gp140	JJ	O
ELISA	NN	O
titers	NNP	O
and	NNS	O
the	CC	O
x-axis	DT	O
shows	JJ	O
weeks	NNS	O
post-immunization.	NNS	O
The	.	O
dashed	DT	O
lines	JJ	O
at	NNS	O
0,	IN	O
4,	,	O
and	,	O
8	CC	O
weeks	CD	O
represent	NNS	O
DNA	JJ	O
immunizations.	NNP	O
The	.	O
alternating	DT	O
dash/dotted	NN	O
line	VBD	O
at	NN	O
27	IN	O
weeks	CD	O
indicates	NNS	O
a	VBZ	O
DNA	DT	O
plus	NN	O
protein	CC	O
boost	NN	O
immunization.	NN	O
FIG.	.	O
68	.	O
(SEQ	CD	O
ID	NNP	O
NO:77)	NNP	O
depicts	)	O
the	VBZ	O
wild-type	DT	O
nucleotide	JJ	O
sequence	JJ	O
of	NN	O
Gag	IN	O
reverse	NNP	O
transcriptase	NN	O
from	NN	O
SF2.	IN	O
FIG.	.	O
69	.	O
(SEQ	CD	O
ID	NNP	O
NO:78)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
GP1.	VBN	O
FIG.	.	O
70	.	O
(SEQ	CD	O
ID	NNP	O
NO:79)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
GP2.	VBN	O
FIG.	.	O
71	.	O
(SEQ	CD	O
ID	NNP	O
NO:80)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
FS(+).protinact_RTopt.YM.	VBN	O
FS(+)	.	O
indicates	)	O
that	VBZ	O
there	IN	O
is	EX	O
a	VBZ	O
frameshift	DT	O
in	NN	O
the	IN	O
GagPol	DT	O
coding	NNP	O
sequence.	NN	O
FIG.	.	O
72	.	O
(SEQ	CD	O
ID	NNP	O
NO:81)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
FS(+).protinact.RTopt.YMWM.	VBN	O
FIG.	.	O
73	.	O
(SEQ	CD	O
ID	NNP	O
NO:82)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
FS(−).protmod.RTopt.YM.	VBN	O
FS(−)	.	O
indicates	)	O
that	VBZ	O
there	IN	O
is	EX	O
no	VBZ	O
frameshift	DT	O
in	NN	O
the	IN	O
GagPol	DT	O
coding	NNP	O
sequence.	NN	O
FIG.	.	O
74	.	O
(SEQ	CD	O
ID	NNP	O
NO:83)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
FS(−).protmod.RTopt.YMWM.	VBN	O
FIG.	.	O
75	.	O
(SEQ	CD	O
ID	NNP	O
NO:84)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
FS(−).protmod.RTopt(+).	VBN	O
FIG.	.	O
76	.	O
(SEQ	CD	O
ID	NNP	O
NO:85)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
wild	IN	O
type	JJ	O
Tat	JJ	O
from	NN	O
isolate	IN	O
SF162.	JJ	O
FIG.	.	O
77	.	O
(SEQ	CD	O
ID	NNP	O
NO:86)	NNP	O
depicts	)	O
the	VBZ	O
amino	DT	O
acid	NN	O
sequence	JJ	O
of	NN	O
the	IN	O
tat	DT	O
polypeptide.	JJ	O
FIG.	.	O
78	.	O
(SEQ	CD	O
ID	NNP	O
NO:87)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
a	IN	O
synthetic	DT	O
Tat	JJ	O
construct	NNP	O
designated	NN	O
Tat.SF162.opt.	VBN	O
FIG.	.	O
79	.	O
(SEQ	CD	O
ID	NNP	O
NO:88)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
a	IN	O
synthetic	DT	O
Tat	JJ	O
construct	NNP	O
designated	NN	O
tat.cys22.sf162.opt.	VBN	O
The	.	O
construct	DT	O
encodes	NN	O
a	VBZ	O
tat	DT	O
polypeptide	JJ	O
in	NN	O
which	IN	O
the	WDT	O
cystein	DT	O
residue	NN	O
at	NN	O
position	IN	O
22	NN	O
of	CD	O
the	IN	O
wild	DT	O
type	JJ	O
Tat	NN	O
polypeptide	NNP	O
is	NN	O
replaced	VBZ	O
by	VBN	O
a	IN	O
glycine	DT	O
residue.	NN	O
FIGS.	.	O
80A	.	O
to	CD	O
80E	TO	O
are	CD	O
an	VBP	O
alignment	DT	O
of	NN	O
the	IN	O
nucleotide	DT	O
sequences	JJ	O
of	NNS	O
the	IN	O
constructs	DT	O
designated	NNS	O
Gag.mod.SF2,	VBN	O
GP1	,	O
(SEQ	NNP	O
ID	NNP	O
NO:78),	NNP	O
and	,	O
GP2	CC	O
(SEQ	NNP	O
ID	NNP	O
NO:79).	NNP	O
FIG.	.	O
81	.	O
(SEQ	CD	O
ID	NNP	O
NO:89)	NNP	O
depicts	)	O
the	VBZ	O
nucleotide	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
construct	DT	O
designated	NN	O
tataminoSF162.opt,	VBN	O
which	,	O
encodes	WDT	O
the	VBZ	O
amino	DT	O
terminus	NN	O
of	NN	O
that	IN	O
tat	DT	O
protein.	NN	O
The	.	O
codon	DT	O
encoding	NN	O
the	VBG	O
cystein-22	DT	O
residue	JJ	O
is	NN	O
underlined.	VBZ	O
FIG.	.	O
82	.	O
(SEQ	CD	O
ID	NNP	O
NO:90)	NNP	O
depicts	)	O
the	VBZ	O
amino	DT	O
acid	NN	O
sequence	JJ	O
of	NN	O
the	IN	O
polypeptide	DT	O
encoded	NN	O
by	VBN	O
the	IN	O
construct	DT	O
designated	NN	O
tat.cys22.5F162.opt	VBN	O
(SEQ	NN	O
ID	NNP	O
NO:88).	NNP	O
DETAILED	.	O
DESCRIPTION	JJ	O
OF	NNP	O
THE	IN	O
INVENTION	NNP	O
The	NNP	O
practice	DT	O
of	NN	O
the	IN	O
present	DT	O
invention	JJ	O
will	NN	O
employ,	MD	O
unless	,	O
otherwise	IN	O
indicated,	RB	O
conventional	,	O
methods	JJ	O
of	NNS	O
chemistry,	IN	O
biochemistry,	,	O
molecular	,	O
biology,	JJ	O
immunology	,	O
and	NN	O
pharmacology,	CC	O
within	,	O
the	IN	O
skill	DT	O
of	NN	O
the	IN	O
art.	DT	O
Such	.	O
techniques	JJ	O
are	NNS	O
explained	VBP	O
fully	VBN	O
in	RB	O
the	IN	O
literature.	DT	O
See,	.	O
e.g.,	,	O
Remington's	,	B
Pharmaceutical	POS	I
Sciences,	NNP	I
18th	,	I
Edition	CD	I
(Easton,	NNP	I
Pa.:	,	I
Mack	:	I
Publishing	NN	I
Company,	VBG	I
1990);	,	I
Methods	:	B
In	NNS	I
Enzymology	IN	I
(S.	NNP	I
Colowick	NNP	I
and	NNP	I
N.	CC	I
Kaplan,	NNP	I
eds.,	,	I
Academic	,	I
Press,	NNP	I
Inc.);	,	I
and	:	O
Handbook	CC	B
of	NNP	I
Experimental	IN	I
Immunology,	NNP	I
Vols.	,	I
I-IV	.	I
(D.	NNP	I
M.	NNP	I
Weir	NNP	I
and	NNP	I
C.	CC	I
C.	NNP	I
Blackwell,	NNP	I
eds.,	,	I
1986,	,	I
Blackwell	,	I
Scientific	NNP	I
Publications);	NNP	I
Sambrook,	:	B
et	,	I
al.,	FW	I
Molecular	,	I
Cloning:	JJ	I
A	:	I
Laboratory	DT	I
Manual	NNP	I
(2nd	NNP	I
Edition,	CD	I
1989);	,	I
Short	:	B
Protocols	NNP	I
in	NNP	I
Molecular	IN	I
Biology,	NNP	I
4th	,	I
ed.	CD	I
(Ausubel	.	I
et	NNP	I
al.	RB	I
eds.,	.	I
1999,	,	I
John	,	I
Wiley	NNP	I
&	NNP	I
Sons);	CC	I
Molecular	:	B
Biology	NNP	I
Techniques:	NNP	I
An	:	I
Intensive	DT	I
Laboratory	JJ	I
Course,	NNP	I
(Ream	,	I
et	NNP	I
al.,	RB	I
eds.,	,	I
1998,	,	I
Academic	,	I
Press);	NNP	I
PCR	:	B
(Introduction	NNP	I
to	NNP	I
Biotechniques	TO	I
Series),	NNP	I
2nd	,	I
ed.	CD	I
(Newton	.	I
&	NNP	I
Graham	CC	I
eds.,	NNP	I
1997,	,	I
Springer	,	I
Verlag).
All	NNP	O
publications,	.	O
patents	DT	O
and	,	O
patent	NNS	O
applications	CC	O
cited	NN	O
herein,	NNS	O
whether	VBD	O
supra	,	O
or	IN	O
infra,	NN	O
are	CC	O
hereby	,	O
incorporated	VBP	O
by	RB	O
reference	VBN	O
in	IN	O
their	NN	O
entirety.	IN	O
As	PRP$	O
used	.	O
in	IN	O
this	VBN	O
specification	IN	O
and	DT	O
the	NN	O
appended	CC	O
claims,	DT	O
the	JJ	O
singular	,	O
forms	DT	O
“a,”	JJ	O
“an”	NNS	O
and	JJ	O
“the”	NN	O
include	CC	O
plural	NNP	O
references	VBP	O
unless	JJ	O
the	NNS	O
content	IN	O
clearly	DT	O
dictates	NN	O
otherwise.	RB	O
Thus,	VBZ	O
for	.	O
example,	,	O
reference	IN	O
to	,	O
“an	NN	O
antigen”	TO	O
includes	VB	O
a	NN	O
mixture	VBZ	O
of	DT	O
two	NN	O
or	IN	O
more	CD	O
such	CC	O
agents.	JJR	O
1.	JJ	O
Definitions	.	O
In	.	O
describing	NNS	O
the	IN	O
present	VBG	O
invention,	DT	O
the	JJ	O
following	,	O
terms	DT	O
will	JJ	O
be	NNS	O
employed,	MD	O
and	VB	O
are	,	O
intended	CC	O
to	VBP	O
be	VBN	O
defined	TO	O
as	VB	O
indicated	VBN	O
below.	IN	O
“Synthetic”	JJ	O
sequences,	.	O
as	NN	O
used	,	O
herein,	IN	O
refers	VBN	O
to	,	O
Env-,	NNS	O
tat-	TO	O
or	,	O
Gag-encoding	JJ	O
polynucleotides	CC	O
whose	JJ	O
expression	NNS	O
has	WP$	O
been	NN	O
optimized	VBZ	O
as	VBN	O
described	VBN	O
herein,	IN	O
for	JJ	O
example,	,	O
by	IN	O
codon	,	O
substitution,	IN	O
deletions,	JJ	O
replacements	,	O
and/or	,	O
inactivation	NNS	O
of	VBP	O
inhibitory	NN	O
sequences.	IN	O
“Wild-type”	JJ	O
or	.	O
“native”	NN	O
sequences,	CC	O
as	NN	O
used	,	O
herein,	IN	O
refers	VBN	O
to	,	O
polypeptide	NNS	O
encoding	TO	O
sequences	VB	O
that	VBG	O
are	NNS	O
essentially	WDT	O
as	VBP	O
they	RB	O
are	IN	O
found	PRP	O
in	VBP	O
nature,	VBN	O
e.g.,	IN	O
Gag	,	O
encoding	,	O
sequences	NNP	O
as	VBG	O
found	NNS	O
in	IN	O
the	VBN	O
isolate	IN	O
HIV-1SF2	DT	O
or	JJ	O
Env	NNP	O
encoding	CC	O
sequences	NNP	O
as	VBG	O
found	NNS	O
in	IN	O
the	VBN	O
isolates	IN	O
HIV-1SF162	DT	O
or	NNS	O
HIV1US4.	NNP	O
As	CC	O
used	.	O
herein,	IN	O
the	VBN	O
term	,	O
“virus-like	DT	O
particle”	NN	O
or	JJ	O
“VLP”	NN	O
refers	CC	O
to	JJ	O
a	NNS	O
nonreplicating,	TO	O
viral	DT	O
shell,	,	O
derived	JJ	O
from	,	O
any	VBN	O
of	IN	O
several	DT	O
viruses	IN	O
discussed	JJ	O
further	NNS	O
below.	VBD	O
VLPs	RB	O
are	.	O
generally	NN	O
composed	VBP	O
of	RB	O
one	VBN	O
or	IN	O
more	CD	O
viral	CC	O
proteins,	JJR	O
such	JJ	O
as,	,	O
but	JJ	O
not	,	O
limited	CC	O
to	RB	O
those	JJ	O
proteins	TO	O
referred	DT	O
to	NNS	O
as	VBD	O
capsid,	TO	O
coat,	IN	O
shell,	,	O
surface	,	O
and/or	,	O
envelope	NN	O
proteins,	NNS	O
or	VBP	O
particle-forming	,	O
polypeptides	CC	O
derived	JJ	O
from	NNS	O
these	VBN	O
proteins.	IN	O
VLPs	DT	O
can	.	O
forth	NNP	O
spontaneously	MD	O
upon	VB	O
recombinant	RB	O
expression	IN	O
of	JJ	O
the	NN	O
protein	IN	O
in	DT	O
an	NN	O
appropriate	IN	O
expression	DT	O
system.	JJ	O
Methods	NN	O
for	.	O
producing	NNS	O
particular	IN	O
VLPs	VBG	O
are	JJ	O
known	NNP	O
in	VBP	O
the	VBN	O
art	IN	O
and	DT	O
discussed	NN	O
more	CC	O
fully	VBD	O
below.	RBR	O
The	RB	O
presence	.	O
of	DT	O
VLPs	NN	O
following	IN	O
recombinant	NNP	O
expression	VBG	O
of	JJ	O
viral	NN	O
proteins	IN	O
can	JJ	O
be	NNS	O
detected	MD	O
using	VB	O
conventional	VBN	O
techniques	VBG	O
known	JJ	O
in	NNS	O
the	VBN	O
art,	IN	O
such	DT	O
as	,	O
by	JJ	O
electron	IN	O
microscopy,	IN	O
biophysical	NN	O
characterization,	,	O
and	JJ	O
the	,	O
like.	CC	O
See,	DT	O
e.g.,	.	O
Baker	,	B
et	,	I
al.,	NNP	I
Biophys.	FW	I
J.	,	I
(1991)	.	I
60:1445-1456;	.	I
Hagensee	)	B
et	:	I
al.,	NNP	I
J.	FW	I
Virol.	,	I
(1994)	NNP	I
68:4503-4505.	.	I
For	)	O
example,	.	O
VLPs	IN	O
can	,	O
be	NNP	O
isolated	MD	O
by	VB	O
density	VBN	O
gradient	IN	O
centrifugation	NN	O
and/or	NN	O
identified	NN	O
by	NN	O
characteristic	VBN	O
density	IN	O
banding	JJ	O
(e.g.,	NN	O
Example	NN	O
7).	,	O
Alternatively,	NNP	O
cryoelectron	.	O
microscopy	,	O
can	NN	O
be	NN	O
performed	MD	O
on	VB	O
vitrified	VBN	O
aqueous	IN	O
samples	JJ	O
of	JJ	O
the	NNS	O
VLP	IN	O
preparation	DT	O
in	NNP	O
question,	NN	O
and	IN	O
images	,	O
recorded	CC	O
under	NNS	O
appropriate	VBN	O
exposure	IN	O
conditions.	JJ	O
By	NN	O
“particle-forming	.	O
polypeptide”	IN	O
derived	JJ	O
from	NNS	O
a	VBN	O
particular	IN	O
viral	DT	O
protein	JJ	O
is	JJ	O
meant	NN	O
a	VBZ	O
full-length	VBN	O
or	DT	O
near	NN	O
full-length	CC	O
viral	IN	O
protein,	JJ	O
as	JJ	O
well	,	O
as	RB	O
a	RB	O
fragment	IN	O
thereof,	DT	O
or	NN	O
a	,	O
viral	CC	O
protein	DT	O
with	JJ	O
internal	NN	O
deletions,	IN	O
which	JJ	O
has	,	O
the	WDT	O
ability	VBZ	O
to	DT	O
form	NN	O
VLPs	TO	O
under	VB	O
conditions	NNP	O
that	IN	O
favor	NNS	O
VLP	WDT	O
formation.	VBP	O
Accordingly,	NNP	O
the	.	O
polypeptide	,	O
may	DT	O
comprise	NN	O
the	MD	O
full-length	VB	O
sequence,	DT	O
fragments,	JJ	O
truncated	,	O
and	,	O
partial	VBN	O
sequences,	CC	O
as	JJ	O
well	,	O
as	RB	O
analogs	RB	O
and	IN	O
precursor	NNS	O
forms	CC	O
of	NN	O
the	NNS	O
reference	IN	O
molecule.	DT	O
The	NN	O
term	.	O
therefore	DT	O
intends	NN	O
deletions,	RB	O
additions	VBZ	O
and	,	O
substitutions	NNS	O
to	CC	O
the	NNS	O
sequence,	TO	O
so	DT	O
long	,	O
as	RB	O
the	RB	O
polypeptide	IN	O
retains	DT	O
the	NN	O
ability	VBZ	O
to	DT	O
form	NN	O
a	TO	O
VLP.	VB	O
Thus,	DT	O
the	.	O
term	,	O
includes	DT	O
natural	NN	O
variations	VBZ	O
of	JJ	O
the	NNS	O
specified	IN	O
polypeptide	DT	O
since	VBN	O
variations	NN	O
in	IN	O
coat	NNS	O
proteins	IN	O
often	NN	O
occur	NNS	O
between	RB	O
viral	VBP	O
isolates.	IN	O
The	JJ	O
term	.	O
also	DT	O
includes	NN	O
deletions,	RB	O
additions	VBZ	O
and	,	O
substitutions	NNS	O
that	CC	O
do	NNS	O
not	WDT	O
naturally	VBP	O
occur	RB	O
in	RB	O
the	VBP	O
reference	IN	O
protein,	DT	O
so	NN	O
long	,	O
as	RB	O
the	RB	O
protein	IN	O
retains	DT	O
the	NN	O
ability	VBZ	O
to	DT	O
form	NN	O
a	TO	O
VLP.	VB	O
Preferred	DT	O
substitutions	.	O
are	VBN	O
those	NNS	O
which	VBP	O
are	DT	O
conservative	WDT	O
in	VBP	O
nature,	JJ	O
i.e.,	IN	O
those	,	O
substitutions	,	O
that	DT	O
take	NNS	O
place	WDT	O
within	VBP	O
a	NN	O
family	IN	O
of	DT	O
amino	NN	O
acids	IN	O
that	NN	O
are	NNS	O
related	WDT	O
in	VBP	O
their	VBN	O
side	IN	O
chains.	PRP$	O
Specifically,	NN	O
amino	.	O
acids	,	O
are	JJ	O
generally	NNS	O
divided	VBP	O
into	RB	O
four	VBN	O
families:	IN	O
(1)	CD	O
acidic—aspartate	:	O
and	)	O
glutamate;	NN	O
(2)	CC	O
basic—lysine,	:	O
arginine,	)	O
histidine;	,	O
(3)	,	O
non-polar—alanine,	:	O
valine,	)	O
leucine,	,	O
isoleucine,	,	O
proline,	,	O
phenylalanine,	,	O
methionine,	,	O
tryptophan;	,	O
and	,	O
(4)	:	O
uncharged	CC	O
polar—glycine,	)	O
asparagine,	VBD	O
glutamine,	,	O
cystine,	,	O
serine	,	O
threonine,	,	O
tyrosine.	JJ	O
Phenylalanine,	,	O
tryptophan,	.	O
and	,	O
tyrosine	,	O
are	CC	O
sometimes	NN	O
classified	VBP	O
as	RB	O
aromatic	VBN	O
amino	IN	O
acids.	JJ	O
An	NN	O
“antigen”	.	O
refers	DT	O
to	JJ	O
a	NNS	O
molecule	TO	O
containing	DT	O
one	NN	O
or	VBG	O
more	CD	O
epitopes	CC	O
(either	JJR	O
linear,	NNS	O
conformational	DT	O
or	,	O
both)	NN	O
that	CC	O
will	)	O
stimulate	WDT	O
a	MD	O
host's	VB	O
immune	DT	O
system	POS	O
to	JJ	O
make	NN	O
a	TO	O
humoral	VB	O
and/or	DT	O
cellular	JJ	O
antigen-specific	NN	O
response.	JJ	O
The	JJ	O
term	.	O
is	DT	O
used	NN	O
interchangeably	VBZ	O
with	VBN	O
the	RB	O
term	IN	O
“immunogen.”	DT	O
Normally,	NN	O
a	NNP	O
B-cell	,	O
epitope	DT	O
will	NNP	O
include	NN	O
at	MD	O
least	VB	O
about	IN	O
5	JJS	O
amino	IN	O
acids	CD	O
but	JJ	O
can	NNS	O
be	CC	O
as	MD	O
small	VB	O
as	RB	O
3-4	JJ	O
amino	IN	O
acids.	JJ	O
A	NN	O
T-cell	.	O
epitope,	DT	O
such	NNP	O
as	,	O
a	JJ	O
CTL	IN	O
epitope,	DT	O
will	NNP	O
include	,	O
at	MD	O
least	VB	O
about	IN	O
7-9	JJS	O
amino	IN	O
acids,	JJ	O
and	NN	O
a	,	O
helper	CC	O
T-cell	DT	O
epitope	JJ	O
at	NNP	O
least	NN	O
about	IN	O
12-20	JJS	O
amino	IN	O
acids.	JJ	O
Normally,	NN	O
an	.	O
epitope	,	O
will	DT	O
include	NN	O
between	MD	O
about	VB	O
7	IN	O
and	RB	O
15	CD	O
amino	CC	O
acids,	CD	O
such	NN	O
as,	,	O
9,	JJ	O
10,	,	O
12	,	O
or	,	O
15	CD	O
amino	CC	O
acids.	CD	O
The	JJ	O
term	.	O
“antigen”	DT	O
denotes	NN	O
both	NN	O
subunit	VBZ	O
antigens,	DT	O
(i.e.,	NN	O
antigens	,	O
which	,	O
are	NNS	O
separate	WDT	O
and	VBP	O
discrete	JJ	O
from	CC	O
a	JJ	O
whole	IN	O
organism	DT	O
with	JJ	O
which	NN	O
the	IN	O
antigen	WDT	O
is	DT	O
associated	NN	O
in	VBZ	O
nature),	VBN	O
as	IN	O
well	,	O
as,	RB	O
killed,	RB	O
attenuated	,	O
or	,	O
inactivated	VBD	O
bacteria,	CC	O
viruses,	JJ	O
fungi,	,	O
parasites	,	O
or	,	O
other	NNS	O
microbes.	CC	O
Antibodies	JJ	O
such	.	O
as	NNS	O
anti-idiotype	JJ	O
antibodies,	IN	O
or	JJ	O
fragments	,	O
thereof,	CC	O
and	NNS	O
synthetic	,	O
peptide	CC	O
mimotopes,	JJ	O
which	NN	O
can	,	O
mimic	WDT	O
an	MD	O
antigen	VB	O
or	DT	O
antigenic	NN	O
determinant,	CC	O
are	JJ	O
also	,	O
captured	VBP	O
under	RB	O
the	VBN	O
definition	IN	O
of	DT	O
antigen	NN	O
as	IN	O
used	NN	O
herein.	IN	O
Similarly,	VBN	O
an	.	O
oligonucleotide	,	O
or	DT	O
polynucleotide	NN	O
which	CC	O
expresses	NN	O
an	WDT	O
antigen	VBZ	O
or	DT	O
antigenic	NN	O
determinant	CC	O
in	JJ	O
vivo,	NN	O
such	IN	O
as	,	O
in	JJ	O
gene	IN	O
therapy	IN	O
and	NN	O
DNA	NN	O
immunization	CC	O
applications,	NNP	O
is	NN	O
also	,	O
included	VBZ	O
in	RB	O
the	VBN	O
definition	IN	O
of	DT	O
antigen	NN	O
herein.	IN	O
For	NN	O
purposes	.	O
of	IN	O
the	NNS	O
present	IN	O
invention,	DT	O
antigens	JJ	O
can	,	O
be	NNS	O
derived	MD	O
from	VB	O
any	VBN	O
of	IN	O
several	DT	O
known	IN	O
viruses,	JJ	O
bacteria,	VBN	O
parasites	,	O
and	,	O
fungi,	NNS	O
as	CC	O
described	,	O
more	IN	O
fully	VBN	O
below.	RBR	O
The	RB	O
term	.	O
also	DT	O
intends	NN	O
any	RB	O
of	VBZ	O
the	DT	O
various	IN	O
tumor	DT	O
antigens.	JJ	O
Furthermore,	NN	O
for	.	O
purposes	,	O
of	IN	O
the	NNS	O
present	IN	O
invention,	DT	O
an	JJ	O
“antigen”	,	O
refers	DT	O
to	JJ	O
a	NNS	O
protein	TO	O
which	DT	O
includes	NN	O
modifications,	WDT	O
such	VBZ	O
as	,	O
deletions,	JJ	O
additions	IN	O
and	,	O
substitutions	NNS	O
(generally	CC	O
conservative	NNS	O
in	RB	O
nature),	JJ	O
to	IN	O
the	,	O
native	TO	O
sequence,	DT	O
so	JJ	O
long	,	O
as	RB	O
the	RB	O
protein	IN	O
maintains	DT	O
the	NN	O
ability	VBZ	O
to	DT	O
elicit	NN	O
an	TO	O
immunological	VB	O
response,	DT	O
as	JJ	O
defined	,	O
herein.	IN	O
These	VBN	O
modifications	.	O
may	DT	O
be	NNS	O
deliberate,	MD	O
as	VB	O
through	,	O
site-directed	IN	O
mutagenesis,	IN	O
or	JJ	O
may	,	O
be	CC	O
accidental,	MD	O
such	VB	O
as	,	O
through	JJ	O
mutations	IN	O
of	IN	O
hosts	NNS	O
which	IN	O
produce	NNS	O
the	WDT	O
antigens.	VBP	O
An	DT	O
“immunological	.	O
response”	DT	O
to	JJ	O
an	NN	O
antigen	TO	O
or	DT	O
composition	NN	O
is	CC	O
the	NN	O
development	VBZ	O
in	DT	O
a	NN	O
subject	IN	O
of	DT	O
a	NN	O
humoral	IN	O
and/or	DT	O
a	JJ	O
cellular	NN	O
immune	DT	O
response	JJ	O
to	NN	O
an	NN	O
antigen	TO	O
present	DT	O
in	NN	O
the	NN	O
composition	IN	O
of	DT	O
interest.	NN	O
For	IN	O
purposes	.	O
of	IN	O
the	NNS	O
present	IN	O
invention,	DT	O
a	JJ	O
“humoral	,	O
immune	DT	O
response”	JJ	O
refers	NN	O
to	NN	O
an	NNS	O
immune	TO	O
response	DT	O
mediated	JJ	O
by	NN	O
antibody	VBN	O
molecules,	IN	O
while	NN	O
a	,	O
“cellular	IN	O
immune	DT	O
response”	JJ	O
is	NN	O
one	NN	O
mediated	VBZ	O
by	CD	O
T-lymphocytes	VBN	O
and/or	IN	O
other	NNP	O
white	NN	O
blood	JJ	O
cells.	JJ	O
One	NN	O
important	.	O
aspect	CD	O
of	JJ	O
cellular	NN	O
immunity	IN	O
involves	JJ	O
an	NN	O
antigen-specific	VBZ	O
response	DT	O
by	JJ	O
cytolytic	NN	O
T-cells	IN	O
(“CTL”s).	JJ	O
CTLs	NNP	O
have	.	O
specificity	NNP	O
for	VBP	O
peptide	NN	O
antigens	IN	O
that	NN	O
are	NNS	O
presented	WDT	O
in	VBP	O
association	VBN	O
with	IN	O
proteins	NN	O
encoded	IN	O
by	NNS	O
the	VBN	O
major	IN	O
histocompatibility	DT	O
complex	JJ	O
(MHC)	NN	O
and	NN	O
expressed	)	O
on	CC	O
the	VBN	O
surfaces	IN	O
of	DT	O
cells.	NNS	O
CTLs	IN	O
help	.	O
induce	NNP	O
and	NN	O
promote	NN	O
the	CC	O
destruction	VB	O
of	DT	O
intracellular	NN	O
microbes,	IN	O
or	JJ	O
the	,	O
lysis	CC	O
of	DT	O
cells	NN	O
infected	IN	O
with	NNS	O
such	VBN	O
microbes.	IN	O
Another	JJ	O
aspect	.	O
of	DT	O
cellular	NN	O
immunity	IN	O
involves	JJ	O
an	NN	O
antigen-specific	VBZ	O
response	DT	O
by	JJ	O
helper	NN	O
T-cells.	IN	O
Helper	JJR	O
T-cells	.	O
act	NNP	O
to	NNP	O
help	NN	O
stimulate	TO	O
the	VB	O
function,	VB	O
and	DT	O
focus	,	O
the	CC	O
activity	VB	O
of,	DT	O
nonspecific	NN	O
effector	,	O
cells	JJ	O
against	NN	O
cells	NNS	O
displaying	IN	O
peptide	NNS	O
antigens	VBG	O
in	NN	O
association	NNS	O
with	IN	O
MHC	NN	O
molecules	IN	O
on	NNP	O
their	NNS	O
surface.	IN	O
A	PRP$	O
“cellular	.	O
immune	DT	O
response”	JJ	O
also	NN	O
refers	NN	O
to	RB	O
the	VBZ	O
production	TO	O
of	DT	O
cytokines,	NN	O
chemokines	IN	O
and	,	O
other	NNS	O
such	CC	O
molecules	JJ	O
produced	JJ	O
by	NNS	O
activated	VBN	O
T-cells	IN	O
and/or	JJ	O
other	NNP	O
white	NN	O
blood	JJ	O
cells,	JJ	O
including	NN	O
those	,	O
derived	VBG	O
from	DT	O
CD4+	VBN	O
and	IN	O
CD8+	NNP	O
T-cells.	CC	O
A	NNP	O
composition	.	O
or	DT	O
vaccine	NN	O
that	CC	O
elicits	NN	O
a	IN	O
cellular	VBZ	O
immune	DT	O
response	JJ	O
may	JJ	O
serve	NN	O
to	MD	O
sensitize	VB	O
a	TO	O
vertebrate	VB	O
subject	DT	O
by	NN	O
the	NN	O
presentation	IN	O
of	DT	O
antigen	NN	O
in	IN	O
association	NN	O
with	IN	O
MHC	NN	O
molecules	IN	O
at	NNP	O
the	NNS	O
cell	IN	O
surface.	DT	O
The	NN	O
cell-mediated	.	O
immune	DT	O
response	JJ	O
is	JJ	O
directed	NN	O
at,	VBZ	O
or	VBN	O
near,	,	O
cells	CC	O
presenting	,	O
antigen	NNS	O
at	VBG	O
their	NN	O
surface.	IN	O
In	PRP$	O
addition,	.	O
antigen-specific	IN	O
T-lymphocytes	,	O
can	JJ	O
be	NNS	O
generated	MD	O
to	VB	O
allow	VBN	O
for	TO	O
the	VB	O
future	IN	O
protection	DT	O
of	JJ	O
an	NN	O
immunized	IN	O
host.	DT	O
The	JJ	O
ability	.	O
of	DT	O
a	NN	O
particular	IN	O
antigen	DT	O
to	JJ	O
stimulate	NN	O
a	TO	O
cell-mediated	VB	O
immunological	DT	O
response	JJ	O
may	JJ	O
be	NN	O
determined	MD	O
by	VB	O
a	VBN	O
number	IN	O
of	DT	O
assays,	NN	O
such	IN	O
as	,	O
by	JJ	O
lymphoproliferation	IN	O
(lymphocyte	IN	O
activation)	NN	O
assays,	JJ	O
CTL	)	O
cytotoxic	,	O
cell	NNP	O
assays,	NN	O
or	NN	O
by	,	O
assaying	CC	O
for	IN	O
T-lymphocytes	VBG	O
specific	IN	O
for	NNP	O
the	NN	O
antigen	IN	O
in	DT	O
a	NN	O
sensitized	IN	O
subject.	DT	O
Such	JJ	O
assays	.	O
are	JJ	O
well	NNS	O
known	VBP	O
in	RB	O
the	VBN	O
art.	IN	O
See,	DT	O
e.g.,	.	O
Erickson	,	B
et	,	I
al.,	NNP	I
J.	FW	I
Immunol.	,	I
(1993)	NNP	I
151:4189-4199;	.	I
Doe	)	B
et	:	I
al.,	NNP	I
Eur.	FW	I
J.	,	I
Immunol.	.	I
(1994)	NNP	I
24:2369-2376.	.	I
Recent	)	O
methods	.	O
of	JJ	O
measuring	NNS	O
cell-mediated	IN	O
immune	VBG	O
response	JJ	O
include	JJ	O
measurement	NN	O
of	VBP	O
intracellular	NN	O
cytokines	IN	O
or	JJ	O
cytokine	NNS	O
secretion	CC	O
by	JJ	O
T-cell	NN	O
populations,	IN	O
or	NNP	O
by	,	O
measurement	CC	O
of	IN	O
epitope	NN	O
specific	IN	O
T-cells	NN	O
(e.g.,	JJ	O
by	NNP	O
the	,	O
tetramer	IN	O
technique)(reviewed	DT	O
by	NN	O
McMichael,	VBN	B
A.	IN	I
J.,	,	I
and	NNP	I
O'Callaghan,	,	I
C.	CC	I
A.,	,	I
J.	NNP	I
Exp.	,	I
Med.	NNP	I
187(9)1367-1371,	.	I
1998;	.	I
Mcheyzer-Williams,	,	B
M.	:	I
G.,	,	I
et	NNP	I
al,	,	I
Immunol.	FW	I
Rev.	,	I
150:5-21,	.	I
1996;	.	I
Lalvani,	,	B
A.,	:	I
et	,	I
al,	,	I
J.	FW	I
Exp.	,	I
Med.	NNP	I
186:859-865,	.	I
1997).Thus,	.	O
an	,	O
immunological	.	O
response	,	O
as	DT	O
used	JJ	O
herein	NN	O
may	IN	O
be	VBN	O
one	NN	O
which	MD	O
stimulates	VB	O
the	CD	O
production	WDT	O
of	VBZ	O
CTLs,	DT	O
and/or	NN	O
the	IN	O
production	,	O
or	VBZ	O
activation	DT	O
of	NN	O
helper	CC	O
T-cells.	NN	O
The	IN	O
antigen	JJ	O
of	.	O
interest	DT	O
may	NN	O
also	IN	O
elicit	NN	O
an	MD	O
antibody-mediated	RB	O
immune	VB	O
response.	DT	O
Hence,	JJ	O
an	NN	O
immunological	.	O
response	,	O
may	DT	O
include	JJ	O
one	NN	O
or	MD	O
more	VB	O
of	CD	O
the	CC	O
following	JJR	O
effects:	IN	O
the	DT	O
production	JJ	O
of	:	O
antibodies	DT	O
by	NN	O
B-cells;	IN	O
and/or	NNS	O
the	IN	O
activation	:	O
of	VBZ	O
suppressor	DT	O
T-cells	NN	O
and/or	IN	O
γδ	NN	O
T-cells	NNP	O
directed	NN	O
specifically	NNP	O
to	NNP	O
an	VBD	O
antigen	RB	O
or	TO	O
antigens	DT	O
present	NN	O
in	CC	O
the	NNS	O
composition	JJ	O
or	IN	O
vaccine	DT	O
of	NN	O
interest.	CC	O
These	NN	O
responses	IN	O
may	.	O
serve	DT	O
to	NNS	O
neutralize	MD	O
infectivity,	VB	O
and/or	TO	O
mediate	VB	O
antibody-complement,	,	O
or	JJ	O
antibody	NN	O
dependent	,	O
cell	CC	O
cytotoxicity	NN	O
(ADCC)	JJ	O
to	NN	O
provide	NN	O
protection	)	O
to	TO	O
an	VB	O
immunized	NN	O
host.	TO	O
Such	DT	O
responses	JJ	O
can	.	O
be	JJ	O
determined	NNS	O
using	MD	O
standard	VB	O
immunoassays	VBN	O
and	VBG	O
neutralization	JJ	O
assays,	NNS	O
well	CC	O
known	NN	O
in	,	O
the	RB	O
art.	VBN	O
An	IN	O
“immunogenic	DT	O
composition”	.	O
is	DT	O
a	JJ	O
composition	NN	O
that	VBZ	O
comprises	DT	O
an	NN	O
antigenic	WDT	O
molecule	VBZ	O
where	DT	O
administration	JJ	O
of	NN	O
the	WRB	O
composition	NN	O
to	IN	O
a	DT	O
subject	NN	O
results	TO	O
in	DT	O
the	JJ	O
development	NNS	O
in	IN	O
the	DT	O
subject	NN	O
of	IN	O
a	DT	O
humoral	NN	O
and/or	IN	O
a	DT	O
cellular	JJ	O
immune	NN	O
response	DT	O
to	JJ	O
the	NN	O
antigenic	NN	O
molecule	TO	O
of	DT	O
interest.	JJ	O
By	NN	O
“subunit	IN	O
vaccine”	.	O
is	IN	O
meant	NNP	O
a	NN	O
vaccine	VBZ	O
composition	VBN	O
which	DT	O
includes	NN	O
one	NN	O
or	WDT	O
more	VBZ	O
selected	CD	O
antigens	CC	O
but	JJR	O
not	VBN	O
all	NNS	O
antigens,	CC	O
derived	RB	O
from	DT	O
or	,	O
homologous	VBN	O
to,	IN	O
an	CC	O
antigen	JJ	O
from	,	O
a	DT	O
pathogen	NN	O
of	IN	O
interest	DT	O
such	NN	O
as	IN	O
from	NN	O
a	JJ	O
virus,	IN	O
bacterium,	IN	O
parasite	DT	O
or	,	O
fungus.	,	O
Such	NN	O
a	CC	O
composition	.	O
is	JJ	O
substantially	DT	O
free	NN	O
of	VBZ	O
intact	RB	O
pathogen	JJ	O
cells	IN	O
or	JJ	O
pathogenic	NN	O
particles,	NNS	O
or	CC	O
the	JJ	O
lysate	,	O
of	CC	O
such	DT	O
cells	NN	O
or	IN	O
particles.	JJ	O
Thus,	NNS	O
a	CC	O
“subunit	.	O
vaccine”	,	O
can	DT	O
be	JJ	O
prepared	NN	O
from	MD	O
at	VB	O
least	VBN	O
partially	IN	O
purified	IN	O
(preferably	JJS	O
substantially	RB	O
purified)	VBN	O
immunogenic	RB	O
polypeptides	RB	O
from	)	O
the	JJ	O
pathogen,	NNS	O
or	IN	O
analogs	DT	O
thereof.	,	O
The	CC	O
method	NNS	O
of	.	O
obtaining	DT	O
an	NN	O
antigen	IN	O
included	VBG	O
in	DT	O
the	NN	O
subunit	VBD	O
vaccine	IN	O
can	DT	O
thus	NN	O
include	NN	O
standard	MD	O
purification	RB	O
techniques,	VB	O
recombinant	JJ	O
production,	NN	O
or	,	O
synthetic	JJ	O
production.	,	O
“Substantially	CC	O
purified”	JJ	O
general	.	O
refers	RB	O
to	JJ	O
isolation	JJ	O
of	NNS	O
a	TO	O
substance	NN	O
(compound,	IN	O
polynucleotide,	DT	O
protein,	NN	O
polypeptide,	,	O
polypeptide	,	O
composition)	,	O
such	,	O
that	JJ	O
the	)	O
substance	PDT	O
comprises	IN	O
the	DT	O
majority	NN	O
percent	VBZ	O
of	DT	O
the	NN	O
sample	NN	O
in	IN	O
which	DT	O
it	NN	O
resides.	IN	O
Typically	WDT	O
in	PRP	O
a	.	O
sample	RB	O
a	IN	O
substantially	DT	O
purified	NN	O
component	DT	O
comprises	RB	O
50%	VBN	O
,	NN	O
preferably	VBZ	O
80%-85%	NN	O
,	,	O
more	RB	O
preferably	NN	O
90-95%	,	O
of	JJR	O
the	RB	O
sample.	NN	O
Techniques	IN	O
for	DT	O
purifying	.	O
polynucleotides	NNS	O
and	IN	O
polypeptides	VBG	O
of	NNS	O
interest	CC	O
are	NNS	O
well-known	IN	O
in	NN	O
the	VBP	O
art	JJ	O
and	IN	O
include,	DT	O
for	NN	O
example,	CC	O
ion-exchange	,	O
chromatography,	IN	O
affinity	,	O
chromatography	JJ	O
and	,	O
sedimentation	NN	O
according	NN	O
to	CC	O
density.	NN	O
A	VBG	O
“coding	TO	O
sequence”	.	O
or	DT	O
a	VBG	O
sequence	NN	O
which	CC	O
“encodes”	DT	O
a	NN	O
selected	WDT	O
polypeptide,	VBZ	O
is	DT	O
a	VBN	O
nucleic	,	O
acid	VBZ	O
molecule	DT	O
which	JJ	O
is	NN	O
transcribed	NN	O
(in	WDT	O
the	VBZ	O
case	VBN	O
of	IN	O
DNA)	DT	O
and	NN	O
translated	IN	O
(in	)	O
the	CC	O
case	VBN	O
of	IN	O
mRNA)	DT	O
into	NN	O
a	IN	O
polypeptide	)	O
in	IN	O
vivo	DT	O
when	NN	O
placed	IN	O
under	NN	O
the	WRB	O
control	VBN	O
of	IN	O
appropriate	DT	O
regulatory	NN	O
sequences	IN	O
(or	JJ	O
“control	JJ	O
elements”).	NNS	O
The	CC	O
boundaries	VB	O
of	.	O
the	DT	O
coding	NNS	O
sequence	IN	O
are	DT	O
determined	NN	O
by	NN	O
a	VBP	O
start	VBN	O
codon	IN	O
at	DT	O
the	NN	O
5′	NN	O
(amino)	IN	O
terminus	DT	O
and	CD	O
a	)	O
translation	NN	O
stop	CC	O
codon	DT	O
at	NN	O
the	NN	O
3′	NN	O
(carboxy)	IN	O
terminus.	DT	O
A	CD	O
coding	)	O
sequence	.	O
can	DT	O
include,	VBG	O
but	NN	O
is	MD	O
not	,	O
limited	CC	O
to,	VBZ	O
cDNA	RB	O
from	VBN	O
viral,	,	O
procaryotic	NN	O
or	IN	O
eucaryotic	,	O
mRNA,	JJ	O
genomic	CC	O
DNA	JJ	O
sequences	,	O
from	JJ	O
viral	NN	O
or	NNS	O
procaryotic	IN	O
DNA,	JJ	O
and	CC	O
even	JJ	O
synthetic	,	O
DNA	CC	O
sequences.	RB	O
A	JJ	O
transcription	NNP	O
termination	.	O
sequence	DT	O
may	NN	O
be	NN	O
located	NN	O
3′	MD	O
to	VB	O
the	VBN	O
coding	CD	O
sequence.	TO	O
Typical	DT	O
“control	VBG	O
elements”,	.	O
include,	JJ	O
but	NN	O
are	,	O
not	,	O
limited	CC	O
to,	VBP	O
transcription	RB	O
promoters,	VBN	O
transcription	,	O
enhancer	NN	O
elements,	,	O
transcription	NN	O
termination	NN	O
signals,	,	O
polyadenylation	NN	O
sequences	NN	O
(located	,	O
3′	NN	O
to	NNS	O
the	VBN	O
translation	CD	O
stop	TO	O
codon),	DT	O
sequences	NN	O
for	VB	O
optimization	,	O
of	NNS	O
initiation	IN	O
of	NN	O
translation	IN	O
(located	NN	O
5′	IN	O
to	NN	O
the	VBN	O
coding	CD	O
sequence),	TO	O
and	DT	O
translation	VBG	O
termination	,	O
sequences,	CC	O
see	NN	O
e.g.,	NN	O
McCaughan	,	B
et	VBP	I
al.	,	I
(1995)	NNP	I
PNAS	VBZ	I
USA	.	I
92:5431-5435;	)	I
Kochetov	NNP	B
et	NNP	I
al	:	I
(1998)	NNP	I
FEBS	FW	I
Letts.	NN	I
440:351-355.
A	)	O
“nucleic	NNP	O
acid”	.	O
molecule	.	O
can	DT	O
include,	JJ	O
but	NN	O
is	NN	O
not	MD	O
limited	,	O
to,	CC	O
procaryotic	VBZ	O
sequences,	RB	O
eucaryotic	VBN	O
mRNA,	,	O
cDNA	JJ	O
from	,	O
eucaryotic	JJ	O
mRNA,	,	O
genomic	NN	O
DNA	IN	O
sequences	JJ	O
from	,	O
eucaryotic	JJ	O
(e.g.,	NN	O
mammalian)	NNS	O
DNA,	IN	O
and	JJ	O
even	,	O
synthetic	)	O
DNA	,	O
sequences.	CC	O
The	RB	O
term	JJ	O
also	NNP	O
captures	.	O
sequences	DT	O
that	NN	O
include	RB	O
any	VBZ	O
of	NNS	O
the	WDT	O
known	VBP	O
base	DT	O
analogs	IN	O
of	DT	O
DNA	JJ	O
and	NN	O
RNA.	NN	O
“Operably	IN	O
linked”	NNP	O
refers	CC	O
to	.	O
an	RB	O
arrangement	JJ	O
of	NNS	O
elements	TO	O
wherein	DT	O
the	NN	O
components	IN	O
so	NNS	O
described	VBP	O
are	DT	O
configured	NNS	O
so	RB	O
as	VBN	O
to	VBP	O
perform	VBN	O
their	RB	O
usual	IN	O
function.	TO	O
Thus,	VB	O
a	PRP$	O
given	JJ	O
promoter	.	O
operably	,	O
linked	DT	O
to	VBN	O
a	NN	O
coding	RB	O
sequence	VBD	O
is	TO	O
capable	DT	O
of	NN	O
effecting	NN	O
the	VBZ	O
expression	JJ	O
of	IN	O
the	VBG	O
coding	DT	O
sequence	NN	O
when	IN	O
the	DT	O
proper	VBG	O
enzymes	NN	O
are	WRB	O
present.	DT	O
The	JJ	O
promoter	NNS	O
need	VBP	O
not	.	O
be	DT	O
contiguous	NN	O
with	MD	O
the	RB	O
coding	VB	O
sequence,	JJ	O
so	IN	O
long	DT	O
as	VBG	O
it	,	O
functions	RB	O
to	RB	O
direct	IN	O
the	PRP	O
expression	VBZ	O
thereof.	TO	O
Thus,	VB	O
for	DT	O
example,	NN	O
intervening	.	O
untranslated	,	O
yet	IN	O
transcribed	,	O
sequences	VBG	O
can	JJ	O
be	RB	O
present	VBN	O
between	NNS	O
the	MD	O
promoter	VB	O
sequence	JJ	O
and	IN	O
the	DT	O
coding	NN	O
sequence	NN	O
and	CC	O
the	DT	O
promoter	NN	O
sequence	NN	O
can	CC	O
still	DT	O
be	NN	O
considered	NN	O
“operably	MD	O
linked”	RB	O
to	VB	O
the	VBN	O
coding	RB	O
sequence.	RBR	O
“Recombinant”	TO	O
as	DT	O
used	VBG	O
herein	.	O
to	NN	O
describe	IN	O
a	VBN	O
nucleic	NN	O
acid	TO	O
molecule	VB	O
means	DT	O
a	JJ	O
polynucleotide	NN	O
of	NN	O
genomic,	VBZ	O
cDNA,	DT	O
semisynthetic,	NN	O
or	IN	O
synthetic	,	O
origin	,	O
which,	,	O
by	CC	O
virtue	JJ	O
of	NN	O
its	,	O
origin	IN	O
or	NN	O
manipulation:	IN	O
(1)	PRP$	O
is	NN	O
not	CC	O
associated	:	O
with	)	O
all	VBZ	O
or	RB	O
a	VBN	O
portion	IN	O
of	DT	O
the	CC	O
polynucleotide	DT	O
with	NN	O
which	IN	O
it	DT	O
is	NN	O
associated	IN	O
in	WDT	O
nature;	PRP	O
and/or	VBZ	O
(2)	VBN	O
is	IN	O
linked	:	O
to	CC	O
a	)	O
polynucleotide	VBZ	O
other	VBN	O
than	TO	O
that	DT	O
to	NN	O
which	JJ	O
it	IN	O
is	DT	O
linked	TO	O
in	WDT	O
nature.	PRP	O
The	VBZ	O
term	VBN	O
“re-combinant”	IN	O
as	.	O
used	DT	O
with	NN	O
respect	JJ	O
to	IN	O
a	VBN	O
protein	IN	O
or	NN	O
polypeptide	TO	O
means	DT	O
a	NN	O
polypeptide	CC	O
produced	NN	O
by	VBZ	O
expression	DT	O
of	NN	O
a	VBN	O
recombinant	IN	O
polynucleotide.	NN	O
“Recombinant	IN	O
host	DT	O
cells,”	JJ	O
“host	.	O
cells,”	JJ	O
“cells,”	NN	O
“cell	VBZ	O
lines,”	NNP	O
“cell	NNP	O
cultures,”	NNP	O
and	NNP	O
other	NNP	O
such	NNP	O
terms	NNP	O
denoting	CC	O
procaryotic	JJ	O
microorganisms	JJ	O
or	NNS	O
eucaryotic	VBG	O
cell	JJ	O
lines	NNS	O
cultured	CC	O
as	JJ	O
unicellular	NN	O
entities,	NNS	O
are	VBD	O
used	IN	O
interchangeably,	JJ	O
and	,	O
refer	VBP	O
to	VBN	O
cells	,	O
which	CC	O
can	VBP	O
be,	TO	O
or	NNS	O
have	WDT	O
been,	MD	O
used	,	O
as	CC	O
recipients	VBP	O
for	,	O
recombinant	VBN	O
vectors	IN	O
or	NNS	O
other	IN	O
transfer	JJ	O
DNA,	NNS	O
and	CC	O
include	JJ	O
the	NN	O
progeny	,	O
of	CC	O
the	VBP	O
original	DT	O
cell	NN	O
which	IN	O
has	DT	O
been	JJ	O
transfected.	NN	O
It	WDT	O
is	VBZ	O
understood	VBN	O
that	.	O
the	PRP	O
progeny	VBZ	O
of	JJ	O
a	IN	O
single	DT	O
parental	NN	O
cell	IN	O
may	DT	O
not	JJ	O
necessarily	NN	O
be	NN	O
completely	MD	O
identical	RB	O
in	RB	O
morphology	VB	O
or	RB	O
in	JJ	O
genomic	IN	O
or	NN	O
total	CC	O
DNA	IN	O
complement	JJ	O
to	CC	O
the	JJ	O
original	NNP	O
parent,	NN	O
due	TO	O
to	DT	O
accidental	JJ	O
or	,	O
deliberate	JJ	O
mutation.	TO	O
Progeny	JJ	O
of	CC	O
the	JJ	O
parental	.	O
cell	NNP	O
which	IN	O
are	DT	O
sufficiently	NN	O
similar	NN	O
to	WDT	O
the	VBP	O
parent	RB	O
to	JJ	O
be	TO	O
characterized	DT	O
by	NN	O
the	TO	O
relevant	VB	O
property,	VBN	O
such	IN	O
as	DT	O
the	JJ	O
presence	,	O
of	JJ	O
a	IN	O
nucleotide	DT	O
sequence	NN	O
encoding	IN	O
a	DT	O
desired	JJ	O
peptide,	NN	O
are	VBG	O
included	DT	O
in	JJ	O
the	,	O
progeny	VBP	O
intended	VBN	O
by	IN	O
this	DT	O
definition,	NN	O
and	VBN	O
are	IN	O
covered	DT	O
by	,	O
the	CC	O
above	VBP	O
terms.	VBN	O
Techniques	IN	O
for	DT	O
determining	NN	O
amino	.	O
acid	NNS	O
sequence	IN	O
“similarity”	VBG	O
are	NN	O
well	JJ	O
known	NN	O
in	NN	O
the	VBP	O
art.	RB	O
In	VBN	O
general,	IN	O
“similarity”	DT	O
means	.	O
the	IN	O
exact	,	O
amino	JJ	O
acid	VBZ	O
to	DT	O
amino	JJ	O
acid	NN	O
comparison	NN	O
of	TO	O
two	VB	O
or	JJ	O
more	NN	O
polypeptides	IN	O
at	CD	O
the	CC	O
appropriate	JJR	O
place,	NNS	O
where	IN	O
amino	DT	O
acids	JJ	O
are	,	O
identical	WRB	O
or	NN	O
possess	NNS	O
similar	VBP	O
chemical	JJ	O
and/or	CC	O
physical	JJ	O
properties	JJ	O
such	NN	O
as	NN	O
charge	JJ	O
or	NNS	O
hydrophobicity.	JJ	O
A	IN	O
so-termed	NN	O
“percent	CC	O
similarity”	.	O
then	DT	O
can	JJ	O
be	NN	O
determined	NN	O
between	RB	O
the	MD	O
compared	VB	O
polypeptide	VBN	O
sequences.	IN	O
Techniques	DT	O
for	VBN	O
determining	NN	O
nucleic	.	O
acid	NNS	O
and	IN	O
amino	VBG	O
acid	JJ	O
sequence	NN	O
identity	CC	O
also	NN	O
are	VBP	O
well	NN	O
known	NN	O
in	RB	O
the	VBP	O
art	RB	O
and	VBN	O
include	IN	O
determining	DT	O
the	NN	O
nucleotide	CC	O
sequence	VBP	O
of	VBG	O
the	DT	O
mRNA	JJ	O
for	NN	O
that	IN	O
gene	DT	O
(usually	NN	O
via	IN	O
a	DT	O
cDNA	NN	O
intermediate)	RB	O
and	IN	O
determining	DT	O
the	JJ	O
amino	)	O
acid	CC	O
sequence	VBG	O
encoded	DT	O
thereby,	NN	O
and	JJ	O
comparing	NN	O
this	VBD	O
to	,	O
a	CC	O
second	VBG	O
amino	DT	O
acid	TO	O
sequence.	DT	O
In	JJ	O
general,	NN	O
“identity”	NN	O
refers	.	O
to	IN	O
an	,	O
exact	JJ	O
nucleotide	NNS	O
to	TO	O
nucleotide	DT	O
or	JJ	O
amino	NN	O
acid	TO	O
to	VB	O
amino	CC	O
acid	VB	O
correspondence	NN	O
of	TO	O
two	VB	O
polynucleotides	JJ	O
or	NN	O
polypeptide	IN	O
sequences,	CD	O
respectively.	NNS	O
Two	CC	O
or	NN	O
more	,	O
polynucleotide	.	O
sequences	CD	O
can	CC	O
be	JJR	O
compared	JJ	O
by	NNS	O
determining	MD	O
their	VB	O
“percent	VBN	O
identity.”	IN	O
Two	VBG	O
or	PRP$	O
more	JJ	O
amino	NN	O
acid	CD	O
sequences	CC	O
likewise	JJR	O
can	JJ	O
be	NN	O
compared	NNS	O
by	VBP	O
determining	MD	O
their	VB	O
“percent	VBN	O
identity.”	IN	O
The	VBG	O
percent	PRP$	O
identity	NN	O
of	IN	O
two	DT	O
sequences,	NN	O
whether	NN	O
nucleic	IN	O
acid	CD	O
or	,	O
peptide	IN	O
sequences,	JJ	O
is	NN	O
generally	CC	O
described	NN	O
as	,	O
the	VBZ	O
number	RB	O
of	VBN	O
exact	IN	O
matches	DT	O
between	NN	O
two	IN	O
aligned	JJ	O
sequences	NNS	O
divided	IN	O
by	CD	O
the	VBD	O
length	NNS	O
of	VBN	O
the	IN	O
shorter	DT	O
sequence	NN	O
and	IN	O
multiplied	DT	O
by	JJR	O
100.	NN	O
An	CC	O
approximate	VBN	O
alignment	IN	O
for	.	O
nucleic	DT	O
acid	JJ	O
sequences	NN	O
is	IN	O
provided	JJ	O
by	NN	O
the	NNS	O
local	VBZ	O
homology	VBN	O
algorithm	IN	O
of	DT	O
Smith	JJ	B
and	NN	I
Waterman,	NN	I
Advances	IN	I
in	NNP	I
Applied	CC	I
Mathematics	,	I
2:482-489	NNP	I
(1981).	IN	I
This	NNP	O
algorithm	NNP	O
can	CD	O
be	.	O
extended	DT	O
to	NN	O
use	MD	O
with	VB	O
peptide	VBN	O
sequences	TO	O
using	VB	O
the	IN	O
scoring	JJ	O
matrix	NNS	O
developed	VBG	O
by	DT	O
Dayhoff,	VBG	B
Atlas	NN	I
of	VBN	I
Protein	IN	I
Sequences	,	I
and	NNP	I
Structure,	IN	I
M.	NNP	I
O.	NNPS	I
Dayhoff	CC	I
ed.,	,	I
5	NNP	I
suppl.	NNP	I
3:353-358,	NNP	I
National	,	I
Biomedical	CD	I
Research	.	I
Foundation,	,	I
Washington,	NNP	I
D.C.,	NNP	I
USA,	NNP	I
and	,	O
normalized	,	O
by	,	O
Gribskov,	,	B
Nucl.	CC	I
Acids	VBN	I
Res.	IN	I
14(6):6745-6763	,	I
(1986).	.	I
An	NNP	O
implementation	.	O
of	NN	O
this	.	O
algorithm	DT	O
for	NN	O
nucleic	IN	O
acid	DT	O
and	NN	O
peptide	IN	O
sequences	JJ	O
is	NN	O
provided	CC	O
by	NN	O
the	NNS	O
Genetics	VBZ	O
Computer	VBN	O
Group	IN	O
(Madison,	DT	O
Wis.)	NNP	O
in	NNP	O
their	NNP	O
BestFit	,	O
utility	)	O
application.	IN	O
The	PRP$	O
default	NNP	O
parameters	NN	O
for	.	O
this	DT	O
method	NN	O
are	NNS	O
described	IN	O
in	DT	O
the	NN	O
Wisconsin	VBP	O
Sequence	VBN	O
Analysis	IN	O
Package	DT	O
Program	NNP	O
Manual,	NNP	O
Version	NNP	O
8	NNP	O
(1995)	NNP	O
(available	,	O
from	NNP	O
Genetics	CD	O
Computer	)	O
Group,	JJ	O
Madison,	IN	O
Wis.).	NNP	O
Other	NNP	O
equally	,	O
suitable	,	O
programs	.	O
for	JJ	O
calculating	RB	O
the	JJ	O
percent	NNS	O
identity	IN	O
or	VBG	O
similarity	DT	O
between	NN	O
sequences	NN	O
are	CC	O
generally	NN	O
known	IN	O
in	NNS	O
the	VBP	O
art.	RB	O
For	VBN	O
example,	IN	O
percent	DT	O
identity	.	O
of	IN	O
a	,	O
particular	NN	O
nucleotide	NN	O
sequence	IN	O
to	DT	O
a	JJ	O
reference	NN	O
sequence	NN	O
can	TO	O
be	DT	O
determined	NN	O
using	NN	O
the	MD	O
homology	VB	O
algorithm	VBN	O
of	VBG	O
Smith	DT	O
and	NN	O
Waterman	NN	O
with	IN	O
a	NNP	O
default	CC	O
scoring	NNP	O
table	IN	O
and	DT	O
a	NN	O
gap	VBG	O
penalty	NN	O
of	CC	O
six	DT	O
nucleotide	NN	O
positions.	NN	O
Another	IN	O
method	CD	O
of	JJ	O
establishing	.	O
percent	DT	O
identity	NN	O
in	IN	O
the	VBG	O
context	NN	O
of	NN	O
the	IN	O
present	DT	O
invention	NN	O
is	IN	O
to	DT	O
use	JJ	O
the	NN	O
MPSRCH	VBZ	O
package	TO	O
of	VB	O
programs	DT	O
copyrighted	NNP	O
by	NN	O
the	IN	O
University	NNS	O
of	VBN	O
Edinburgh,	IN	O
developed	DT	O
by	NNP	O
John	IN	O
F.	,	O
Collins	VBN	O
and	IN	O
Shane	NNP	O
S.	NNP	O
Sturrok,	NNP	O
and	CC	O
distributed	NNP	O
by	NNP	O
IntelliGenetics,	,	O
Inc.	CC	O
(Mountain	VBN	O
View,	IN	O
Calif.).	,	O
From	NNP	O
this	NNP	O
suite	,	O
of	.	O
packages,	IN	O
the	DT	O
Smith-Waterman	NN	O
algorithm	IN	O
can	,	O
be	DT	O
employed	NNP	O
where	NN	O
default	MD	O
parameters	VB	O
are	VBN	O
used	WRB	O
for	NN	O
the	NNS	O
scoring	VBP	O
table	VBN	O
(for	IN	O
example,	DT	O
gap	NN	O
open	NN	O
penalty	IN	O
of	,	O
12,	NN	O
gap	JJ	O
extension	NN	O
penalty	IN	O
of	,	O
one,	NN	O
and	NN	O
a	NN	O
gap	IN	O
of	,	O
six).	CC	O
From	DT	O
the	NN	O
data	IN	O
generated,	.	O
the	IN	O
“Match”	DT	O
value	NN	O
reflects	,	O
“sequence	DT	O
identity.”	NNP	O
Other	NN	O
suitable	VBZ	O
programs	NNP	O
for	NN	O
calculating	JJ	O
the	JJ	O
percent	NNS	O
identity	IN	O
or	VBG	O
similarity	DT	O
between	NN	O
sequences	NN	O
are	CC	O
generally	NN	O
known	IN	O
in	NNS	O
the	VBP	O
art,	RB	O
such	VBN	O
as	IN	O
the	DT	O
alignment	,	O
program	JJ	O
BLAST,	IN	O
which	DT	O
can	JJ	O
also	NN	O
be	,	O
used	WDT	O
with	MD	O
default	RB	O
parameters.	VB	O
For	VBN	O
example,	IN	O
BLASTN	NN	O
and	.	O
BLASTP	IN	O
can	,	O
be	NNP	O
used	CC	O
with	NNP	O
the	MD	O
following	VB	O
default	VBN	O
parameters:	IN	O
genetic	DT	O
code=standard;	VBG	O
filter=none;	NN	O
strand=both;	:	O
cutoff=60;	JJ	O
expect=10;	:	O
Matrix=BLOSUM62;	:	O
Descriptions=50	:	O
sequences;	:	O
sort	:	O
by=HIGH	:	O
SCORE;	NNP	O
Databases=non-redundant,	:	O
GenBank+EMBL+DDBJ+PDB+GenBank	VB	O
CDS	NN	O
translations+Swiss	:	O
protein+Spupdate+PIR.	,	O
Details	NNP	O
of	NNP	O
these	JJ	O
programs	.	O
can	NNS	O
be	IN	O
found	DT	O
at	NNS	O
the	MD	O
following	VB	O
internet	VBN	O
address:	IN	O
http://www.ncbi.nlm.gov/cgi-bin/BLAST.	DT	O
One	JJ	O
of	NN	O
skill	:	O
in	.	O
the	CD	O
art	IN	O
can	NN	O
readily	IN	O
determine	DT	O
the	NN	O
proper	MD	O
search	RB	O
parameters	VB	O
to	DT	O
use	JJ	O
for	NN	O
a	NNS	O
given	TO	O
sequence	VB	O
in	IN	O
the	DT	O
above	VBN	O
programs.	NN	O
For	IN	O
example,	DT	O
the	JJ	O
search	.	O
parameters	IN	O
may	,	O
vary	DT	O
based	NN	O
on	NNS	O
the	MD	O
size	VB	O
of	VBN	O
the	IN	O
sequence	DT	O
in	NN	O
question.	IN	O
Thus,	DT	O
for	NN	O
example,	IN	O
a	.	O
representative	,	O
embodiment	IN	O
of	,	O
the	DT	O
present	JJ	O
invention	NN	O
would	IN	O
include	DT	O
an	JJ	O
isolated	NN	O
polynucleotide	MD	O
having	VB	O
X	DT	O
contiguous	JJ	O
nucleotides,	NN	O
wherein	VBG	O
(i)	NNP	O
the	JJ	O
X	,	O
contiguous	NN	O
nucleotides	)	O
have	DT	O
at	NNP	O
least	JJ	O
about	NNS	O
50%	VBP	O
identity	IN	O
to	JJS	O
Y	IN	O
contiguous	NN	O
nucleotides	NN	O
derived	TO	O
from	NNP	O
any	JJ	O
of	NNS	O
the	VBN	O
sequences	IN	O
described	DT	O
herein,	IN	O
(ii)	DT	O
X	NNS	O
equals	VBD	O
Y,	,	O
and	)	O
(iii)	NN	O
X	NNS	O
is	,	O
greater	CC	O
than	)	O
or	NN	O
equal	VBZ	O
to	JJR	O
6	IN	O
nucleotides	CC	O
and	JJ	O
up	TO	O
to	CD	O
5000	NNS	O
nucleotides,	CC	O
preferably	RB	O
greater	TO	O
than	CD	O
or	,	O
equal	RB	O
to	JJR	O
8	IN	O
nucleotides	CC	O
and	JJ	O
up	TO	O
to	CD	O
5000	NNS	O
nucleotides,	CC	O
more	RB	O
preferably	TO	O
10-12	CD	O
nucleotides	,	O
and	JJR	O
up	RB	O
to	JJ	O
5000	NNS	O
nucleotides,	CC	O
and	RB	O
even	TO	O
more	CD	O
preferably	,	O
15-20	CC	O
nucleotides,	RB	O
up	JJR	O
to	RB	O
the	JJ	O
number	,	O
of	RB	O
nucleotides	TO	O
present	DT	O
in	NN	O
the	IN	O
full-length	JJ	O
sequences	NN	O
described	IN	O
herein	DT	O
(e.g.,	JJ	O
see	NNS	O
the	VBN	O
Sequence	NN	O
Listing	,	O
and	VB	O
claims),	DT	O
including	NNP	O
all	NNP	O
integer	CC	O
values	,	O
falling	VBG	O
within	DT	O
the	NN	O
above-described	NNS	O
ranges.	VBG	O
The	IN	O
synthetic	DT	O
expression	JJ	O
cassettes	.	O
(and	DT	O
purified	JJ	O
polynucleotides)	NN	O
of	NNS	O
the	CC	O
present	VBN	O
invention	)	O
include	IN	O
related	DT	O
polynucleotide	JJ	O
sequences	NN	O
having	VBP	O
about	VBN	O
80%	JJ	O
to	NNS	O
100%	VBG	O
,	RB	O
greater	NN	O
than	TO	O
80-85%	NN	O
,	,	O
preferably	JJR	O
greater	IN	O
than	NN	O
90-92%	,	O
,	RB	O
more	JJR	O
preferably	IN	O
greater	NN	O
than	,	O
95%	JJR	O
,	RB	O
and	JJR	O
most	IN	O
preferably	NN	O
greater	,	O
than	CC	O
98%	JJS	O
sequence	RB	O
(including	JJR	O
all	IN	O
integer	NN	O
values	NN	O
falling	VBG	O
within	DT	O
these	NN	O
described	NNS	O
ranges)	VBG	O
identity	IN	O
to	DT	O
the	VBN	O
synthetic	)	O
expression	NN	O
cassette	TO	O
sequences	DT	O
disclosed	JJ	O
herein	NN	O
(for	NN	O
example,	NNS	O
to	VBD	O
the	NN	O
sequences	IN	O
presented	,	O
in	TO	O
Tables	DT	O
1A	NNS	O
and	VBN	O
1B)	IN	O
when	NNP	O
the	CD	O
sequences	CC	O
of	)	O
the	WRB	O
present	DT	O
invention	NNS	O
are	IN	O
used	DT	O
as	JJ	O
the	NN	O
query	VBP	O
sequence.	VBN	O
Two	IN	O
nucleic	DT	O
acid	NN	O
fragments	.	O
are	CD	O
considered	JJ	O
to	NN	O
“selectively	NNS	O
hybridize”	VBP	O
as	VBN	O
described	TO	O
herein.	RB	O
The	VB	O
degree	IN	O
of	JJ	O
sequence	.	O
identity	DT	O
between	NN	O
two	IN	O
nucleic	NN	O
acid	NN	O
molecules	IN	O
affects	CD	O
the	JJ	O
efficiency	NN	O
and	NNS	O
strength	VBZ	O
of	DT	O
hybridization	NN	O
events	CC	O
between	NN	O
such	IN	O
molecules.	NN	O
A	NNS	O
partially	IN	O
identical	JJ	O
nucleic	.	O
acid	DT	O
sequence	RB	O
will	JJ	O
at	NN	O
least	NN	O
partially	NN	O
inhibit	MD	O
a	IN	O
completely	JJS	O
identical	RB	O
sequence	VB	O
from	DT	O
hybridizing	RB	O
to	JJ	O
a	NN	O
target	IN	O
molecule.	VBG	O
Inhibition	TO	O
of	DT	O
hybridization	NN	O
of	.	O
the	NN	O
completely	IN	O
identical	NN	O
sequence	IN	O
can	DT	O
be	RB	O
assessed	JJ	O
using	NN	O
hybridization	MD	O
assays	VB	O
that	VBN	O
are	VBG	O
well	NN	O
known	NNS	O
in	WDT	O
the	VBP	O
art	RB	O
(e.g.,	VBN	O
Southern	IN	O
blot,	DT	O
Northern	NN	O
blot,	,	O
solution	JJ	O
hybridization,	,	O
or	NNP	O
the	,	O
like,	NN	O
see	,	O
Sambrook,	CC	B
et	DT	I
al.,	,	I
Molecular	VB	I
Cloning:	,	I
A	FW	I
Laboratory	,	I
Manual,	JJ	I
Second	:	I
Edition,	DT	I
(1989)	NNP	I
Cold	,	I
Spring	NNP	I
Harbor,	,	I
N.	)	I
Y.).Such	NNP	O
assays	NNP	O
can	,	O
be	.	O
conducted	.	O
using	JJ	O
varying	NNS	O
degrees	MD	O
of	VB	O
selectivity,	VBN	O
for	VBG	O
example,	VBG	O
using	NNS	O
conditions	IN	O
varying	,	O
from	IN	O
low	,	O
to	VBG	O
high	NNS	O
stringency.	VBG	O
If	IN	O
conditions	JJ	O
of	TO	O
low	JJ	O
stringency	.	O
are	IN	O
employed,	NNS	O
the	IN	O
absence	JJ	O
of	NN	O
non-specific	VBP	O
binding	,	O
can	DT	O
be	NN	O
assessed	IN	O
using	JJ	O
a	NN	O
secondary	MD	O
probe	VB	O
that	VBN	O
lacks	VBG	O
even	DT	O
a	JJ	O
partial	NN	O
degree	IN	O
of	VBZ	O
sequence	RB	O
identity	DT	O
(for	JJ	O
example,	NN	O
a	IN	O
probe	NN	O
having	NN	O
less	IN	O
than	,	O
about	DT	O
30%	NN	O
sequence	VBG	O
identity	JJR	O
with	IN	O
the	RB	O
target	NN	O
molecule),	NN	O
such	NN	O
that,	IN	O
in	DT	O
the	NN	O
absence	,	O
of	JJ	O
non-specific	,	O
binding	IN	O
events,	DT	O
the	NN	O
secondary	IN	O
probe	JJ	O
will	NN	O
not	,	O
hybridize	DT	O
to	JJ	O
the	NN	O
target.	MD	O
When	RB	O
utilizing	VB	O
a	TO	O
hybridization-based	DT	O
detection	.	O
system,	WRB	O
a	VBG	O
nucleic	DT	O
acid	JJ	O
probe	NN	O
is	,	O
chosen	DT	O
that	JJ	O
is	NN	O
complementary	NN	O
to	VBZ	O
a	VBN	O
target	IN	O
nucleic	VBZ	O
acid	JJ	O
sequence,	TO	O
and	DT	O
then	NN	O
by	JJ	O
selection	JJ	O
of	,	O
appropriate	CC	O
conditions	RB	O
the	IN	O
probe	NN	O
and	IN	O
the	JJ	O
target	NNS	O
sequence	DT	O
“selectively	NN	O
hybridize,”	CC	O
or	DT	O
bind,	NN	O
to	NN	O
each	RB	O
other	FW	O
to	CC	O
form	,	O
a	TO	O
hybrid	DT	O
molecule.	JJ	O
A	TO	O
nucleic	VB	O
acid	DT	O
molecule	JJ	O
that	.	O
is	DT	O
capable	JJ	O
of	NN	O
hybridizing	NN	O
selectively	WDT	O
to	VBZ	O
a	JJ	O
target	IN	O
sequence	VBG	O
under	RB	O
“moderately	TO	O
stringent”	DT	O
typically	NN	O
hybridizes	NN	O
under	IN	O
conditions	RB	O
that	JJ	O
allow	RB	O
detection	VBZ	O
of	IN	O
a	NNS	O
target	WDT	O
nucleic	VBP	O
acid	NN	O
sequence	IN	O
of	DT	O
at	NN	O
least	JJ	O
about	JJ	O
10-14	NN	O
nucleotides	IN	O
in	IN	O
length	JJS	O
having	IN	O
at	JJ	O
least	NNS	O
approximately	IN	O
70%	NN	O
sequence	VBG	O
identity	IN	O
with	JJS	O
the	RB	O
sequence	NN	O
of	NN	O
the	NN	O
selected	IN	O
nucleic	DT	O
acid	NN	O
probe.	IN	O
Stringent	DT	O
hybridization	VBN	O
conditions	NN	O
typically	NN	O
allow	.	O
detection	JJ	O
of	NN	O
target	NNS	O
nucleic	RB	O
acid	VBP	O
sequences	NN	O
of	IN	O
at	NN	O
least	JJ	O
about	JJ	O
10-14	NNS	O
nucleotides	IN	O
in	IN	O
length	JJS	O
having	IN	O
a	JJ	O
sequence	NNS	O
identity	IN	O
of	NN	O
greater	VBG	O
than	DT	O
about	NN	O
90-95%	NN	O
with	IN	O
the	JJR	O
sequence	IN	O
of	RB	O
the	NN	O
selected	IN	O
nucleic	DT	O
acid	NN	O
probe.	IN	O
Hybridization	DT	O
conditions	VBN	O
useful	NN	O
for	NN	O
probe/target	.	O
hybridization	NNP	O
where	NNS	O
the	JJ	O
probe	IN	O
and	NN	O
target	NN	O
have	WRB	O
a	DT	O
specific	NN	O
degree	CC	O
of	NN	O
sequence	VBP	O
identity,	DT	O
can	JJ	O
be	NN	O
determined	IN	O
as	NN	O
is	,	O
known	MD	O
in	VB	O
the	VBN	O
art	IN	O
(see,	VBZ	O
for	VBN	O
example,	IN	O
Nucleic	DT	B
Acid	NN	I
Hybridization:	,	I
A	IN	I
Practical	,	I
Approach,	NNP	I
editors	NNP	I
B.	:	I
D.	DT	I
Hames	NNP	I
and	,	I
S.	NNS	I
J.	NNP	I
Higgins,	NNP	I
(1985)	NNP	I
Oxford;	CC	I
Washington,	NNP	I
D.C.;	NNP	I
IRL	,	I
Press).With	)	O
respect	:	O
to	,	O
stringency	:	O
conditions	NNP	O
for	.	O
hybridization,	IN	O
it	NN	O
is	TO	O
well	VB	O
known	NNS	O
in	IN	O
the	,	O
art	PRP	O
that	VBZ	O
numerous	RB	O
equivalent	VBN	O
conditions	IN	O
can	DT	O
be	NN	O
employed	WDT	O
to	JJ	O
establish	JJ	O
a	NNS	O
particular	MD	O
stringency	VB	O
by	VBN	O
varying,	TO	O
for	VB	O
example,	DT	O
the	JJ	O
following	NN	O
factors:	IN	O
the	,	O
length	IN	O
and	,	O
nature	DT	O
of	JJ	O
probe	:	O
and	DT	O
target	NN	O
sequences,	CC	O
base	NN	O
composition	IN	O
of	NN	O
the	CC	O
various	NN	O
sequences,	,	O
concentrations	NN	O
of	NN	O
salts	IN	O
and	DT	O
other	JJ	O
hybridization	,	O
solution	NNS	O
components,	IN	O
the	NNS	O
presence	CC	O
or	JJ	O
absence	NN	O
of	NN	O
blocking	,	O
agents	DT	O
in	NN	O
the	CC	O
hybridization	NN	O
solutions	IN	O
(e.g.,	VBG	O
formamide,	NNS	O
dextran	IN	O
sulfate,	DT	O
and	NN	O
polyethylene	NNS	O
glycol),	,	O
hybridization	,	O
reaction	JJ	O
temperature	,	O
and	CC	O
time	VB	O
parameters,	,	O
as	NN	O
well	NN	O
as,	NN	O
varying	CC	O
wash	NN	O
conditions.	,	O
The	RB	O
selection	RB	O
of	,	O
a	VBG	O
particular	JJ	O
set	.	O
of	DT	O
hybridization	NN	O
conditions	IN	O
is	DT	O
selected	JJ	O
following	NN	O
standard	IN	O
methods	NN	O
in	NNS	O
the	VBZ	O
art	VBN	O
(see,	VBG	O
for	JJ	O
example,	NNS	O
Sambrook,	IN	B
et	DT	I
al.,	NN	I
Molecular	,	I
Cloning:	IN	I
A	,	I
Laboratory	,	I
Manual,	FW	I
Second	,	I
Edition,	JJ	I
(1989)	:	I
Cold	DT	I
Spring	NNP	I
Harbor,	,	I
N.	NNP	I
Y.).A	,	O
first	)	O
polynucleotide	NNP	O
is	NNP	O
“derived	,	O
from”	.	O
second	.	O
polynucleotide	DT	O
if	JJ	O
it	NN	O
has	VBZ	O
the	VBN	O
same	JJ	O
or	JJ	O
substantially	NN	O
the	IN	O
same	PRP	O
basepair	VBZ	O
sequence	DT	O
as	JJ	O
a	CC	O
region	RB	O
of	DT	O
the	JJ	O
second	NN	O
polynucleotide,	NN	O
its	IN	O
cDNA,	DT	O
complements	NN	O
thereof,	IN	O
or	DT	O
if	JJ	O
it	,	O
displays	PRP$	O
sequence	,	O
identity	NNS	O
as	,	O
described	CC	O
above.	IN	O
A	PRP	O
first	VBZ	O
polypeptide	NN	O
is	NN	O
“derived	IN	O
from”	VBN	O
a	.	O
second	DT	O
polypeptide	JJ	O
if	NN	O
it	VBZ	O
is	VBN	O
(i)	RB	O
encoded	DT	O
by	JJ	O
a	NN	O
first	IN	O
polynucleotide	PRP	O
derived	VBZ	O
from	)	O
a	VBN	O
second	IN	O
polynucleotide,	DT	O
or	JJ	O
(ii)	NN	O
displays	VBN	O
sequence	IN	O
identity	DT	O
to	JJ	O
the	,	O
second	CC	O
polypeptides	)	O
as	VBZ	O
described	NN	O
above.	NN	O
Generally,	TO	O
a	DT	O
viral	JJ	O
polypeptide	NNS	O
is	IN	O
“derived	VBN	O
from”	.	O
a	,	O
particular	DT	O
polypeptide	JJ	O
of	NN	O
a	VBZ	O
virus	VBN	O
(viral	RB	O
polypeptide)	DT	O
if	JJ	O
it	NN	O
is	IN	O
(i)	DT	O
encoded	NN	O
by	JJ	O
an	)	O
open	IN	O
reading	PRP	O
frame	VBZ	O
of	)	O
a	VBN	O
polynucleotide	IN	O
of	DT	O
that	JJ	O
virus	NN	O
(viral	NN	O
polynucleotide),	IN	O
or	DT	O
(ii)	NN	O
displays	IN	O
sequence	DT	O
identity	NN	O
to	JJ	O
polypeptides	,	O
of	CC	O
that	)	O
virus	VBZ	O
as	NN	O
described	NN	O
above.	TO	O
“Encoded	NNS	O
by”	IN	O
refers	DT	O
to	NN	O
a	IN	O
nucleic	VBN	O
acid	.	O
sequence	VBN	O
which	NN	O
codes	NNS	O
for	TO	O
a	DT	O
polypeptide	JJ	O
sequence,	NN	O
wherein	NN	O
the	WDT	O
polypeptide	VBZ	O
sequence	IN	O
or	DT	O
a	JJ	O
portion	,	O
thereof	VBP	O
contains	DT	O
an	NN	O
amino	NN	O
acid	CC	O
sequence	DT	O
of	NN	O
at	NN	O
least	VBZ	O
3	DT	O
to	NN	O
5	JJ	O
amino	NN	O
acids,	IN	O
more	IN	O
preferably	JJS	O
at	CD	O
least	TO	O
8	CD	O
to	NN	O
10	,	O
amino	JJR	O
acids,	RB	O
and	IN	O
even	JJS	O
more	CD	O
preferably	TO	O
at	CD	O
least	NN	O
15	,	O
to	CC	O
20	RB	O
amino	JJR	O
acids	RB	O
from	IN	O
a	JJS	O
polypeptide	CD	O
encoded	TO	O
by	CD	O
the	NN	O
nucleic	NNS	O
acid	IN	O
sequence.	DT	O
Also	NN	O
encompassed	VBN	O
are	IN	O
polypeptide	DT	O
sequences	JJ	O
which	NN	O
are	.	O
immunologically	RB	O
identifiable	VBN	O
with	VBP	O
a	JJ	O
polypeptide	NNS	O
encoded	WDT	O
by	VBP	O
the	RB	O
sequence.	JJ	O
“Purified	IN	O
polynucleotide”	DT	O
refers	NN	O
to	VBN	O
a	IN	O
polynucleotide	DT	O
of	.	O
interest	VBN	O
or	NN	O
fragment	NNS	O
thereof	TO	O
which	DT	O
is	NN	O
essentially	IN	O
free,	NN	O
e.g.,	CC	O
contains	NN	O
less	NN	O
than	WDT	O
about	VBZ	O
50%	RB	O
,	,	O
preferably	,	O
less	VBZ	O
than	JJR	O
about	IN	O
70%	RB	O
,	NN	O
and	,	O
more	RB	O
preferably	JJR	O
less	IN	O
than	RB	O
about	NN	O
90%	,	O
,	CC	O
of	JJR	O
the	RB	O
protein	RBR	O
with	IN	O
which	RB	O
the	NN	O
polynucleotide	,	O
is	IN	O
naturally	DT	O
associated.	NN	O
Techniques	IN	O
for	WDT	O
purifying	DT	O
polynucleotides	NN	O
of	VBZ	O
interest	RB	O
are	.	O
well-known	NNS	O
in	IN	O
the	VBG	O
art	NNS	O
and	IN	O
include,	NN	O
for	VBP	O
example,	JJ	O
disruption	IN	O
of	DT	O
the	NN	O
cell	CC	O
containing	,	O
the	IN	O
polynucleotide	,	O
with	NN	O
a	IN	O
chaotropic	DT	O
agent	NN	O
and	VBG	O
separation	DT	O
of	NN	O
the	IN	O
polynucleotide(s)	DT	O
and	NN	O
proteins	NN	O
by	CC	O
ion-exchange	NN	O
chromatography,	IN	O
affinity	DT	O
chromatography	)	O
and	CC	O
sedimentation	NNS	O
according	IN	O
to	JJ	O
density.	,	O
By	NN	O
“nucleic	NN	O
acid	CC	O
immunization”	NN	O
is	VBG	O
meant	TO	O
the	.	O
introduction	IN	O
of	NNP	O
a	NN	O
nucleic	NN	O
acid	VBZ	O
molecule	VBN	O
encoding	DT	O
one	NN	O
or	IN	O
more	DT	O
selected	JJ	O
antigens	NN	O
into	NN	O
a	VBG	O
host	CD	O
cell,	CC	O
for	JJR	O
the	VBN	O
in	NNS	O
vivo	IN	O
expression	DT	O
of	NN	O
an	,	O
antigen,	IN	O
antigens,	DT	O
an	IN	O
epitope,	JJ	O
or	NN	O
epitopes.	IN	O
The	DT	O
nucleic	,	O
acid	,	O
molecule	DT	O
can	,	O
be	CC	O
introduced	.	O
directly	DT	O
into	JJ	O
a	NN	O
recipient	NN	O
subject,	MD	O
such	VB	O
as	VBN	O
by	RB	O
injection,	IN	O
inhalation,	DT	O
oral,	NN	O
intranasal	,	O
and	JJ	O
mucosal	IN	O
administration,	IN	O
or	,	O
the	,	O
like,	,	O
or	JJ	O
can	CC	O
be	JJ	O
introduced	,	O
ex	CC	O
vivo,	DT	O
into	,	O
cells	CC	O
which	MD	O
have	VB	O
been	VBN	O
removed	JJ	O
from	,	O
the	IN	O
host.	NNS	O
In	WDT	O
the	VBP	O
latter	VBN	O
case,	VBN	O
the	IN	O
transformed	DT	O
cells	.	O
are	IN	O
reintroduced	DT	O
into	JJ	O
the	,	O
subject	DT	O
where	JJ	O
an	NNS	O
immune	VBP	O
response	VBN	O
can	IN	O
be	DT	O
mounted	NN	O
against	WRB	O
the	DT	O
antigen	JJ	O
encoded	NN	O
by	MD	O
the	VB	O
nucleic	VBN	O
acid	IN	O
molecule.	DT	O
“Gene	NN	O
transfer”	VBN	O
or	IN	O
“gene	DT	O
delivery”	JJ	O
refers	NN	O
to	.	O
methods	JJ	O
or	NN	O
systems	CC	O
for	NN	O
reliably	NN	O
inserting	NNS	O
DNA	TO	O
or	NNS	O
RNA	CC	O
of	NNS	O
interest	IN	O
into	RB	O
a	VBG	O
host	NNP	O
cell.	CC	O
Such	NNP	O
methods	IN	O
can	NN	O
result	IN	O
in	DT	O
transient	NN	O
expression	.	O
of	JJ	O
non-integrated	NNS	O
transferred	MD	O
DNA,	VB	O
extrachromosomal	IN	O
replication	JJ	O
and	NN	O
expression	IN	O
of	JJ	O
transferred	JJ	O
replicons	,	O
(e.g.,	JJ	O
episomes),	NN	O
or	CC	O
integration	NN	O
of	IN	O
transferred	JJ	O
genetic	NNS	O
material	,	O
into	,	O
the	CC	O
genomic	NN	O
DNA	IN	O
of	VBN	O
host	JJ	O
cells.	NN	O
Gene	IN	O
delivery	DT	O
expression	JJ	O
vectors	NN	O
include,	IN	O
but	NN	O
are	.	O
not	NNP	O
limited	NN	O
to,	NN	O
vectors	NNS	O
derived	,	O
from	CC	O
bacterial	VBP	O
plasmid	RB	O
vectors,	VBN	O
viral	,	O
vectors,	NNS	O
non-viral	VBD	O
vectors,	IN	O
alphaviruses,	JJ	O
pox	NN	O
viruses	,	O
and	JJ	O
vaccinia	,	O
viruses.	JJ	O
When	,	O
used	,	O
for	NN	O
immunization,	NNS	O
such	CC	O
gene	NN	O
delivery	.	O
expression	WRB	O
vectors	VBN	O
may	IN	O
be	,	O
referred	JJ	O
to	NN	O
as	NN	O
vaccines	NN	O
or	NNS	O
vaccine	MD	O
vectors.	VB	O
“T	VBN	O
lymphocytes”	TO	O
or	IN	O
“T	NNS	O
cells”	CC	O
are	NN	O
non-antibody	.	O
producing	JJ	O
lymphocytes	NN	O
that	CC	O
constitute	NN	O
a	NNS	O
part	VBP	O
of	JJ	O
the	VBG	O
cell-mediated	NNS	O
arm	IN	O
of	VBP	O
the	DT	O
immune	NN	O
system.	IN	O
T	DT	O
cells	JJ	O
arise	NN	O
from	IN	O
immature	DT	O
lymphocytes	NN	O
that	.	O
migrate	NNP	O
from	NNS	O
the	VBP	O
bone	IN	O
marrow	NN	O
to	VBZ	O
the	IN	O
thymus,	NN	O
where	IN	O
they	DT	O
undergo	NN	O
a	NN	O
maturation	TO	O
process	DT	O
under	,	O
the	WRB	O
direction	PRP	O
of	VBP	O
thymic	DT	O
hormones.	NN	O
Here,	NN	O
the	IN	O
mature	DT	O
lymphocytes	NN	O
rapidly	IN	O
divide	JJ	O
increasing	.	O
to	,	O
very	DT	O
large	NN	O
numbers.	VBZ	O
The	RB	O
maturing	JJ	O
T	VBG	O
cells	TO	O
become	RB	O
immunocompetent	JJ	O
based	.	O
on	DT	O
their	VBG	O
ability	NNP	O
to	NNS	O
recognize	VBP	O
and	JJ	O
bind	VBN	O
a	IN	O
specific	PRP$	O
antigen.	NN	O
Activation	TO	O
of	VB	O
immunocompetent	CC	O
T	VB	O
cells	DT	O
is	JJ	O
triggered	.	O
when	NN	O
an	IN	O
antigen	JJ	O
binds	NNP	O
to	NNS	O
the	VBZ	O
lymphocyte's	VBN	O
surface	WRB	O
receptors.	DT	O
The	NN	O
term	VBZ	O
“transfection”	TO	O
is	DT	O
used	POS	O
to	NN	O
refer	.	O
to	DT	O
the	NN	O
uptake	NNP	O
of	VBZ	O
foreign	VBN	O
DNA	TO	O
by	VB	O
a	TO	O
cell.	DT	O
A	NN	O
cell	IN	O
has	JJ	O
been	NNP	O
“transfected”	IN	O
when	DT	O
exogenous	.	O
DNA	DT	O
has	NN	O
been	VBZ	O
introduced	VBN	O
inside	VBN	O
the	WRB	O
cell	JJ	O
membrane.	NN	O
A	VBZ	O
number	VBN	O
of	VBN	O
transfection	IN	O
techniques	DT	O
are	NN	O
generally	.	O
known	DT	O
in	NN	O
the	IN	O
art.	NN	O
See,	NNS	O
e.g.,	VBP	O
Graham	RB	B
et	VBN	I
al.	IN	I
(1973)	DT	I
Virology,	.	I
52:456,	,	I
Sambrook	,	B
et	NNP	I
al.	CC	I
(1989)	.	I
Molecular	)	I
Cloning,	,	I
a	,	I
laboratory	NNP	I
manual,	CC	I
Cold	.	I
Spring	)	I
Harbor	NNP	I
Laboratories,	,	I
New	DT	I
York,	NN	I
Davis	,	B
et	NNP	I
al.	NNP	I
(1986)	NNP	I
Basic	,	I
Methods	NNP	I
in	,	I
Molecular	NNP	I
Biology,	CC	I
Elsevier,	.	I
and	)	I
Chu	NNP	I
et	NNP	I
al.	IN	I
(1981)	NNP	I
Gene	,	I
13:197.	,	I
Such	CC	O
techniques	NNP	O
can	VBP	O
be	.	O
used	)	O
to	NNP	O
introduce	.	O
one	JJ	O
or	NNS	O
more	MD	O
exogenous	VB	O
DNA	VBN	O
moieties	TO	O
into	VB	O
suitable	CD	O
host	CC	O
cells.	JJR	O
The	JJ	O
term	NN	O
refers	NNS	O
to	IN	O
both	JJ	O
stable	NN	O
and	.	O
transient	DT	O
uptake	NN	O
of	NNS	O
the	TO	O
genetic	DT	O
material,	JJ	O
and	CC	O
includes	JJ	O
uptake	NN	O
of	IN	O
peptide-	DT	O
or	JJ	O
antibody-linked	,	O
DNAs.	CC	O
A	VBZ	O
“vector”	NN	O
is	IN	O
capable	JJ	O
of	CC	O
transferring	JJ	O
gene	.	O
sequences	DT	O
to	NN	O
target	VBZ	O
cells	JJ	O
(e.g.,	IN	O
bacterial	VBG	O
plasmid	NN	O
vectors,	NNS	O
viral	TO	O
vectors,	VB	O
non-viral	NNS	O
vectors,	,	O
particulate	JJ	O
carriers,	NN	O
and	,	O
liposomes).	JJ	O
Typically,	,	O
“vector	JJ	O
construct,”	,	O
“expression	NN	O
vector,”	,	O
and	CC	O
“gene	.	O
transfer	,	O
vector,”	NNP	O
mean	JJ	O
any	NN	O
nucleic	NNP	O
acid	CC	O
construct	NNP	O
capable	NN	O
of	JJ	O
directing	VBP	O
the	DT	O
expression	JJ	O
of	NN	O
a	NN	O
gene	JJ	O
of	IN	O
interest	VBG	O
and	DT	O
which	NN	O
can	IN	O
transfer	DT	O
gene	NN	O
sequences	IN	O
to	NN	O
target	CC	O
cells.	WDT	O
Thus,	MD	O
the	VB	O
term	NN	O
includes	NNS	O
cloning	TO	O
and	VB	O
expression	.	O
vehicles,	,	O
as	DT	O
well	NN	O
as	VBZ	O
viral	NN	O
vectors.	CC	O
Transfer	NN	O
of	,	O
a	RB	O
“suicide	RB	O
gene”	IN	O
(e.g.,	JJ	O
a	.	O
drug-susceptibility	NN	O
gene)	IN	O
to	DT	O
a	JJ	O
target	NN	O
cell	,	O
renders	DT	O
the	JJ	O
cell	)	O
sensitive	TO	O
to	DT	O
compounds	NN	O
or	NN	O
compositions	VBZ	O
that	DT	O
are	NN	O
relatively	JJ	O
nontoxic	TO	O
to	NNS	O
normal	CC	O
cells.	NNS	O
Moolten,	WDT	B
F.	VBP	I
L.	RB	I
(1994)	JJ	I
Cancer	TO	I
Gene	JJ	I
Ther.	.	I
1:279-287.	,	I
Examples	NNP	O
of	NNP	O
suicide	)	O
genes	NNP	O
are	NNP	O
thymidine	.	O
kinase	.	O
of	NNS	O
herpes	IN	O
simplex	NN	O
virus	NNS	O
(HSV-tk),	VBP	O
cytochrome	JJ	O
P450	NN	O
Manome	IN	B
et	NNS	I
al.	JJ	I
(1996)	NN	I
Gene	,	I
Therapy	JJ	I
3:513-520),(	NNP	O
human	NNP	O
deoxycytidine	RB	O
kinase	.	O
Manome	)	B
et	NNP	I
al.	NNP	I
(1996)	,	I
Nature	JJ	I
Medicine	NN	I
2(5):567-573)	NN	I
(and	NNP	O
the	RB	O
bacterial	.	O
enzyme	)	O
cytosine	NNP	O
deaminase	NNP	O
Dong	)	B
et	CC	I
al.	DT	I
(1996)	JJ	I
Human	NN	I
Gene	NN	I
Therapy	NN	I
7:713-720).(	NNP	O
Cells	RB	O
which	.	O
express	)	O
these	NNP	O
genes	NNP	O
are	NNP	O
rendered	.	O
sensitive	NNS	O
to	WDT	O
the	VBP	O
effects	DT	O
of	NNS	O
the	VBP	O
relatively	VBN	O
nontoxic	JJ	O
prodrugs	TO	O
ganciclovir	DT	O
(HSV-tk),	NNS	O
cyclophosphamide	IN	O
(cytochrome	DT	O
P450	RB	O
2B1),	JJ	O
cytosine	NNS	O
arabinoside	NN	O
(human	,	O
deoxycytidine	NN	O
kinase)	JJ	O
or	NNP	O
5-fluorocytosine	,	O
(bacterial	JJ	O
cytosine	NN	O
deaminase).	JJ	O
Culver	NN	B
et	)	I
al.	CC	I
(1992)	JJ	I
Science	JJ	I
256:1550-1552,	NN	I
Huber	.	B
et	NNP	I
al.	CC	I
(1994)	.	I
Proc.	)	I
Natl.	NNP	I
Acad.	,	I
Sci.	NNP	I
USA	CC	I
91:8302-8306.
A	.	O
“selectable	)	O
marker”	.	O
or	.	O
“reporter	.	O
marker”	.	O
refers	NNP	O
to	.	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
included	CC	O
in	NN	O
a	NN	O
gene	NNS	O
transfer	TO	O
vector	DT	O
that	JJ	O
has	NN	O
no	VBD	O
therapeutic	IN	O
activity,	DT	O
but	NN	O
rather	NN	O
is	NN	O
included	WDT	O
to	VBZ	O
allow	DT	O
for	JJ	O
simpler	,	O
preparation,	CC	O
manufacturing,	RB	O
characterization	VBZ	O
or	VBN	O
testing	TO	O
of	VB	O
the	IN	O
gene	JJR	O
transfer	,	O
vector.	,	O
A	NN	O
“specific	CC	O
binding	NN	O
agent”	IN	O
refers	DT	O
to	NN	O
a	NN	O
member	.	O
of	DT	O
a	JJ	O
specific	NN	O
binding	NN	O
pair	NNS	O
of	TO	O
molecules	DT	O
wherein	NN	O
one	IN	O
of	DT	O
the	JJ	O
molecules	VBG	O
specifically	NN	O
binds	IN	O
to	NNS	O
the	VBP	O
second	CD	O
molecule	IN	O
through	DT	O
chemical	NNS	O
and/or	RB	O
physical	VBZ	O
means.	TO	O
One	DT	O
example	JJ	O
of	NN	O
a	IN	O
specific	NN	O
binding	NN	O
agent	JJ	O
is	.	O
an	CD	O
antibody	NN	O
directed	IN	O
against	DT	O
a	JJ	O
selected	NN	O
antigen.	NN	O
By	VBZ	O
“subject”	DT	O
is	NN	O
meant	VBN	O
any	IN	O
member	DT	O
of	VBN	O
the	.	O
subphylum	IN	O
chordata,	NNP	O
including,	VBZ	O
without	VBN	O
limitation,	DT	O
humans	NN	O
and	IN	O
other	DT	O
primates,	NN	O
including	,	O
non-human	,	O
primates	IN	O
such	,	O
as	NNS	O
chimpanzees	CC	O
and	JJ	O
other	,	O
apes	VBG	O
and	JJ	O
monkey	NNS	O
species;	JJ	O
farm	IN	O
animals	NNS	O
such	CC	O
as	JJ	O
cattle,	NNS	O
sheep,	CC	O
pigs,	JJ	O
goats	:	O
and	NN	O
horses;	NNS	O
domestic	JJ	O
mammals	IN	O
such	,	O
as	,	O
dogs	,	O
and	NNS	O
cats;	CC	O
laboratory	:	O
animals	JJ	O
including	NNS	O
rodents	JJ	O
such	IN	O
as	NNS	O
mice,	CC	O
rats	:	O
and	NN	O
guinea	NNS	O
pigs;	VBG	O
birds,	NNS	O
including	JJ	O
domestic,	IN	O
wild	,	O
and	NNS	O
game	CC	O
birds	NN	O
such	:	O
as	,	O
chickens,	VBG	O
turkeys	,	O
and	JJ	O
other	CC	O
gallinaceous	NN	O
birds,	NNS	O
ducks,	JJ	O
geese,	IN	O
and	,	O
the	NNS	O
like.	CC	O
The	JJ	O
term	JJ	O
does	,	O
not	,	O
denote	,	O
a	CC	O
particular	DT	O
age.	.	O
Thus,	DT	O
both	NN	O
adult	VBZ	O
and	RB	O
newborn	VB	O
individuals	DT	O
are	JJ	O
intended	.	O
to	,	O
be	DT	O
covered.	NN	O
The	CC	O
system	JJ	O
described	NNS	O
above	VBP	O
is	VBN	O
intended	TO	O
for	VB	O
use	.	O
in	DT	O
any	NN	O
of	VBN	O
the	IN	O
above	VBZ	O
vertebrate	VBN	O
species,	IN	O
since	NN	O
the	IN	O
immune	DT	O
systems	IN	O
of	DT	O
all	JJ	O
of	NN	O
these	,	O
vertebrates	IN	O
operate	DT	O
similarly.	JJ	O
By	NNS	O
“pharmaceutically	IN	O
acceptable”	DT	O
or	IN	O
“pharmacologically	DT	O
acceptable”	NNS	O
is	VBP	O
meant	.	O
a	IN	O
material	RB	O
which	JJ	O
is	CC	O
not	RB	O
biologically	JJ	O
or	VBZ	O
otherwise	VBN	O
undesirable,	DT	O
i.e.,	NN	O
the	WDT	O
material	VBZ	O
may	RB	O
be	RB	O
administered	CC	O
to	RB	O
an	,	O
individual	,	O
in	DT	O
a	NN	O
formulation	MD	O
or	VB	O
composition	VBN	O
without	TO	O
causing	DT	O
any	NN	O
undesirable	IN	O
biological	DT	O
effects	NN	O
or	CC	O
interacting	NN	O
in	IN	O
a	VBG	O
deleterious	DT	O
manner	JJ	O
with	JJ	O
any	NNS	O
of	CC	O
the	VBG	O
components	IN	O
of	DT	O
the	JJ	O
composition	NN	O
in	IN	O
which	DT	O
it	IN	O
is	DT	O
contained.	NNS	O
By	IN	O
“physiological	DT	O
pH”	NN	O
or	IN	O
a	WDT	O
“pH	PRP	O
in	VBZ	O
the	.	O
physiological	IN	O
range”	JJ	O
is	NN	O
meant	CC	O
a	DT	O
pH	NN	O
in	IN	O
the	DT	O
range	JJ	O
of	NN	O
approximately	VBZ	O
7.2	VBN	O
to	DT	O
8.0	NN	O
inclusive,	IN	O
more	DT	O
typically	NN	O
in	IN	O
the	RB	O
range	CD	O
of	TO	O
approximately	CD	O
7.2	,	O
to	RBR	O
7.6	RB	O
inclusive.	IN	O
As	DT	O
used	NN	O
herein,	IN	O
“treatment”	RB	O
refers	CD	O
to	TO	O
any	CD	O
of	.	O
(I)	IN	O
the	VBN	O
prevention	,	O
of	JJ	O
infection	NNS	O
or	TO	O
reinfection,	DT	O
as	IN	O
in	)	O
a	DT	O
traditional	NN	O
vaccine,	IN	O
(ii)	NN	O
the	CC	O
reduction	,	O
or	IN	O
elimination	IN	O
of	DT	O
symptoms,	JJ	O
and	,	O
(iii)	)	O
the	DT	O
substantial	NN	O
or	CC	O
complete	NN	O
elimination	IN	O
of	,	O
the	CC	O
pathogen	)	O
in	DT	O
question.	JJ	O
Treatment	CC	O
may	JJ	O
be	NN	O
effected	IN	O
prophylactically	DT	O
(prior	NN	O
to	IN	O
infection)	.	O
or	NN	O
therapeutically	MD	O
(following	VB	O
infection).	VBN	O
“Lentiviral	RB	O
vector”,	JJ	O
and	TO	O
“recombinant	)	O
lentiviral	CC	O
vector”	RB	O
are	VBG	O
derived	.	O
from	JJ	O
the	,	O
subset	CC	O
of	JJ	O
retroviral	JJ	O
vectors	NN	O
known	VBP	O
as	VBN	O
lentiviruses.	IN	O
Lentiviral	DT	O
vectors	NN	O
refer	IN	O
to	JJ	O
a	NNS	O
nucleic	VBN	O
acid	IN	O
construct	.	O
which	JJ	O
carries,	NNS	O
and	VBP	O
within	TO	O
certain	DT	O
embodiments,	JJ	O
is	NN	O
capable	NN	O
of	WDT	O
directing	,	O
the	CC	O
expression	IN	O
of	JJ	O
a	,	O
nucleic	VBZ	O
acid	JJ	O
molecule	IN	O
of	VBG	O
interest.	DT	O
The	NN	O
lentiviral	IN	O
vector	DT	O
includes	JJ	O
at	NN	O
least	NN	O
one	IN	O
transcriptional	.	O
promoter/enhancer	DT	O
or	JJ	O
locus	NN	O
defining	VBZ	O
element(s),	IN	O
or	JJS	O
other	CD	O
elements	JJ	O
which	NN	O
control	CC	O
gene	NN	O
expression	VBG	O
by	,	O
other	CC	O
means	JJ	O
such	NNS	O
as	WDT	O
alternate	VBP	O
splicing,	NN	O
nuclear	NN	O
RNA	IN	O
export,	JJ	O
post-translational	NNS	O
modification	JJ	O
of	IN	O
messenger,	NN	O
or	,	O
post-transcriptional	JJ	O
modification	NNP	O
of	,	O
protein.	JJ	O
Such	NN	O
vector	IN	O
constructs	,	O
must	CC	O
also	JJ	O
include	NN	O
a	IN	O
packaging	.	O
signal,	JJ	O
long	NN	O
terminal	NNS	O
repeats	MD	O
(LTRS)	RB	O
or	VB	O
portion	DT	O
thereof,	JJ	O
and	,	O
positive	JJ	O
and	JJ	O
negative	NNS	O
strand	)	O
primer	CC	O
binding	NN	O
sites	,	O
appropriate	CC	O
to	JJ	O
the	CC	O
lentiviral	JJ	O
vector	NN	O
used	NN	O
(if	VBG	O
these	NNS	O
are	VBP	O
not	TO	O
already	DT	O
present	JJ	O
in	NN	O
the	VBN	O
retroviral	IN	O
vector).	DT	O
Optionally,	VBP	O
the	RB	O
recombinant	RB	O
lentiviral	JJ	O
vector	IN	O
may	DT	O
also	JJ	O
include	.	O
a	,	O
signal	DT	O
which	JJ	O
directs	JJ	O
polyadenylation,	NN	O
selectable	MD	O
markers	RB	O
such	VB	O
as	DT	O
Neo,	NN	O
TK,	WDT	O
hygromycin,	VBZ	O
phleomycin,	,	O
histidinol,	JJ	O
or	NNS	O
DHFR,	JJ	O
as	IN	O
well	,	O
as	,	O
one	,	O
or	,	O
more	,	O
restriction	CC	O
sites	,	O
and	RB	O
a	RB	O
translation	IN	O
termination	CD	O
sequence.	CC	O
By	JJR	O
way	NN	O
of	NNS	O
example,	CC	O
such	DT	O
vectors	NN	O
typically	NN	O
include	.	O
a	IN	O
5′	NN	O
LTR,	IN	O
a	,	O
tRNA	JJ	O
binding	NNS	O
site,	RB	O
a	VBP	O
packaging	DT	O
signal,	CD	O
an	,	O
origin	DT	O
of	NN	O
second	VBG	O
strand	,	O
DNA	DT	O
synthesis,	NN	O
and	,	O
a	DT	O
3′LTR	NN	O
or	IN	O
a	JJ	O
portion	NN	O
thereof.	NNP	O
“Lentiviral	,	O
vector	CC	O
particle”	DT	O
as	CD	O
utilized	CC	O
within	DT	O
the	NN	O
present	.	O
invention	JJ	O
refers	NN	O
to	NN	O
a	IN	O
lentivirus	JJ	O
which	IN	O
carries	DT	O
at	JJ	O
least	NN	O
one	NNS	O
gene	TO	O
of	DT	O
interest.	NN	O
The	WDT	O
retrovirus	VBZ	O
may	IN	O
also	JJS	O
contain	CD	O
a	NN	O
selectable	IN	O
marker.	.	O
The	DT	O
recombinant	NN	O
lentivirus	MD	O
is	RB	O
capable	VB	O
of	DT	O
reverse	JJ	O
transcribing	.	O
its	DT	O
genetic	JJ	O
material	NN	O
(RNA)	VBZ	O
into	JJ	O
DNA	IN	O
and	NN	O
incorporating	VBG	O
this	PRP$	O
genetic	JJ	O
material	NN	O
into	)	O
a	IN	O
host	NN	O
cell's	CC	O
DNA	VBG	O
upon	DT	O
infection.	JJ	O
Lentiviral	NN	O
vector	IN	O
particles	DT	O
may	NN	O
have	POS	O
a	NNP	O
lentiviral	IN	O
envelope,	.	O
a	JJ	O
non-lentiviral	NN	O
envelope	NNS	O
(e.g.,	MD	O
an	VB	O
ampho	DT	O
or	JJ	O
VSV-G	,	O
envelope),	DT	O
or	JJ	O
a	NN	O
chimeric	,	O
envelope.	DT	O
“Nucleic	NN	O
acid	CC	O
expression	NNP	O
vector”	,	O
or	CC	O
“Expression	DT	O
cassette”	JJ	O
refers	.	O
to	JJ	O
an	JJ	O
assembly	NN	O
which	NN	O
is	CC	O
capable	NN	O
of	NN	O
directing	NNS	O
the	TO	O
expression	DT	O
of	NN	O
a	WDT	O
sequence	VBZ	O
or	JJ	O
gene	IN	O
of	VBG	O
interest.	DT	O
The	NN	O
nucleic	IN	O
acid	DT	O
expression	NN	O
vector	CC	O
includes	NN	O
a	IN	O
promoter	.	O
which	DT	O
is	JJ	O
operably	JJ	O
linked	NN	O
to	NN	O
the	VBZ	O
sequences	DT	O
or	NN	O
gene(s)	WDT	O
of	VBZ	O
interest.	RB	O
Other	VBN	O
control	TO	O
elements	DT	O
may	NNS	O
be	CC	O
present	)	O
as	IN	O
well.	.	O
Expression	JJ	O
cassettes	NN	O
described	NNS	O
herein	MD	O
may	VB	O
be	JJ	O
contained	RB	O
within	.	O
a	NN	O
plasmid	NNS	O
construct.	VBD	O
In	NN	O
addition	MD	O
to	VB	O
the	VBN	O
components	IN	O
of	DT	O
the	JJ	O
expression	.	O
cassette,	IN	O
the	NN	O
plasmid	TO	O
construct	DT	O
may	NNS	O
also	IN	O
include	DT	O
a	NN	O
bacterial	,	O
origin	DT	O
of	JJ	O
replication,	NN	O
one	MD	O
or	RB	O
more	VB	O
selectable	DT	O
markers,	JJ	O
a	NN	O
signal	IN	O
which	,	O
allows	CD	O
the	CC	O
plasmid	JJR	O
construct	JJ	O
to	,	O
exist	DT	O
as	NN	O
single-stranded	WDT	O
DNA	VBZ	O
(e.g.,	DT	O
a	JJ	O
M13	NN	O
origin	TO	O
of	VB	O
replication),	IN	O
a	JJ	O
multiple	NNP	O
cloning	,	O
site,	DT	O
and	NNP	O
a	NN	O
“mammalian”	IN	O
origin	,	O
of	DT	O
replication	JJ	O
(e.g.,	NN	O
a	,	O
SV40	CC	O
or	DT	O
adenovirus	JJ	O
origin	NN	O
of	IN	O
replication).	NN	O
“Packaging	,	O
cell”	DT	O
refers	NNP	O
to	CC	O
a	JJ	O
cell	NN	O
which	IN	O
contains	.	O
those	VBG	O
elements	NN	O
necessary	NNS	O
for	TO	O
production	DT	O
of	NN	O
infectious	WDT	O
recombinant	VBZ	O
retrovirus	DT	O
(e.g.,	NNS	O
lentivirus)	JJ	O
which	IN	O
are	NN	O
lacking	IN	O
in	JJ	O
a	JJ	O
recombinant	NN	O
retroviral	,	O
vector.	)	O
Typically,	WDT	O
such	VBP	O
packaging	VBG	O
cells	IN	O
contain	DT	O
one	JJ	O
or	JJ	O
more	.	O
expression	,	O
cassettes	JJ	O
which	NN	O
are	NNS	O
capable	VBP	O
of	CD	O
expressing	CC	O
proteins	JJR	O
which	NN	O
encode	NNS	O
Gag,	WDT	O
pol	VBP	O
and	JJ	O
env	IN	O
proteins.	VBG	O
“Producer	NNS	O
cell”	WDT	O
or	VBP	O
“vector	,	O
producing	NN	O
cell”	CC	O
refers	JJ	O
to	.	O
a	NN	O
cell	NN	O
which	CC	O
contains	NN	O
all	VBG	O
elements	NN	O
necessary	NNS	O
for	TO	O
production	DT	O
of	NN	O
recombinant	WDT	O
retroviral	VBZ	O
vector	DT	O
particles.	NNS	O
2.	JJ	O
Modes	IN	O
of	NN	O
Carrying	IN	O
Out	JJ	O
the	JJ	O
Invention	NN	O
Before	.	O
describing	.	O
the	NNS	O
present	IN	O
invention	VBG	O
in	RP	O
detail,	DT	O
it	NN	O
is	IN	O
to	VBG	O
be	DT	O
understood	JJ	O
that	NN	O
this	IN	O
invention	,	O
is	PRP	O
not	VBZ	O
limited	TO	O
to	VB	O
particular	JJ	O
formulations	IN	O
or	DT	O
process	NN	O
parameters	VBZ	O
as	RB	O
such	VBN	O
may,	TO	O
of	JJ	O
course,	NNS	O
vary.	CC	O
It	NN	O
is	NNS	O
also	IN	O
to	JJ	O
be	,	O
understood	IN	O
that	,	O
the	.	O
terminology	PRP	O
used	VBZ	O
herein	RB	O
is	TO	O
for	VB	O
the	JJ	O
purpose	IN	O
of	DT	O
describing	NN	O
particular	VBN	O
embodiments	NN	O
of	VBZ	O
the	IN	O
invention	DT	O
only,	NN	O
and	IN	O
is	VBG	O
not	JJ	O
intended	NNS	O
to	IN	O
be	DT	O
limiting.	NN	O
Although	,	O
a	CC	O
number	VBZ	O
of	RB	O
methods	VBN	O
and	TO	O
materials	VB	O
similar	.	O
or	IN	O
equivalent	DT	O
to	NN	O
those	IN	O
described	NNS	O
herein	CC	O
can	NNS	O
be	JJ	O
used	CC	O
in	JJ	O
the	TO	O
practice	DT	O
of	VBN	O
the	NNS	O
present	MD	O
invention,	VB	O
the	VBN	O
preferred	IN	O
materials	DT	O
and	NN	O
methods	IN	O
are	DT	O
described	JJ	O
herein.	,	O
2.1	DT	O
Synthetic	JJ	O
Expression	NNS	O
Cassettes	CC	O
2.1.1	NNS	O
Modification	VBP	O
of	VBN	O
HIV-1	.	O
Gag	CD	O
Nucleic	JJ	O
Acid	NNP	O
Coding	VBZ	O
Sequences	CD	O
One	NN	O
aspect	IN	O
of	NNP	O
the	NNP	O
present	NNP	O
invention	NNP	O
is	NNP	O
the	NNP	O
generation	NNP	O
of	NN	O
HIV-1	IN	O
Gag	DT	O
protein	JJ	O
coding	NN	O
sequences,	VBZ	O
and	DT	O
related	NN	O
sequences,	IN	O
having	NNP	O
improved	NNP	O
expression	NN	O
relative	VBG	O
to	,	O
the	CC	O
corresponding	JJ	O
wild-type	,	O
sequence.	VBG	O
An	VBN	O
exemplary	NN	O
embodiment	NN	O
of	TO	O
the	DT	O
present	JJ	O
invention	JJ	O
is	.	O
illustrated	DT	O
herein	JJ	O
modifying	NN	O
the	IN	O
Gag	DT	O
protein	JJ	O
wild-type	NN	O
sequences	VBZ	O
obtained	VBN	O
from	RB	O
the	VBG	O
HIV-1SF2	DT	O
strain	NNP	O
(SEQ	NN	O
ID	JJ	O
NO:1;	NNS	O
Sanchez-Pescador,	VBN	O
R.,	IN	B
et	DT	I
al.,	NNP	I
Science	NN	I
227(4686):	NNP	I
484-492,	NNP	I
1985;	:	I
Luciw,	,	O
P.	,	O
A.,	FW	O
et	,	O
al.	NNP	O
U.S.	:	O
Pat.	,	O
No.	:	O
5,156,949,	,	O
issued	NNP	O
Oct.	,	O
20,	CC	O
1992,	.	O
herein	NNP	O
incorporated	.	O
by	.	O
reference;	,	O
Luciw,	VBN	O
P.	NNP	O
A.,	,	O
et	,	O
al.,	RB	O
U.S.	VBN	O
Pat.	IN	O
No.	:	O
5,688,688,	,	O
Nov.	NNP	O
18,	,	O
1997,	FW	O
herein	,	O
incorporated	NNP	O
by	.	O
reference).	.	O
Gag	,	O
sequence	NNP	O
obtained	,	O
from	,	O
other	RB	O
HIV	VBN	O
variants	IN	O
may	.	O
be	NNP	O
manipulated	NN	O
in	VBN	O
similar	IN	O
fashion	JJ	O
following	NNP	O
the	NNS	O
teachings	MD	O
of	VB	O
the	VBN	O
present	IN	O
specification.	JJ	O
Such	NN	O
other	VBG	O
variants	DT	O
include,	NNS	O
but	IN	O
are	DT	O
not	JJ	O
limited	.	O
to,	JJ	O
Gag	JJ	O
protein	NNS	O
encoding	,	O
sequences	CC	O
obtained	VBP	O
from	RB	O
the	VBN	O
isolates.	,	O
HIVIIIb,	NNP	O
HIVSF2,	VBZ	O
HIV-1SF162,	VBG	O
HIV-1SF170,	NNS	O
HIVLAV,	VBN	O
HIVLAI,	IN	O
HIVMN,	DT	O
HIV-1CM235,	.	O
HIV-1US4,	,	O
other	,	O
HIV-1	,	O
strains	,	O
from	,	O
diverse	,	O
subtypes	,	O
(e.g.,	,	O
subtypes,	,	O
A	JJ	O
through	JJ	O
G,	NNS	O
and	IN	O
O),	JJ	O
HIV-2	NNS	O
strains	,	O
and	,	O
diverse	NNP	O
subtypes	IN	O
(e.g.,	,	O
HIV-2UC1	CC	O
and	,	O
HIV-2UC2),	NNP	O
and	NNS	O
simian	CC	O
immunodeficiency	JJ	O
virus	NNS	O
(Sly).	,	O
(See,	NNP	O
e.g.,	CC	O
Virology,	,	B
3rd	CC	I
Edition	JJ	I
(W.	NN	I
K.	NN	I
Joklik	.	I
ed.	,	I
1988);	,	I
Fundamental	,	B
Virology,	CD	I
2nd	NNP	I
Edition	NNP	I
(B.	NNP	I
N.	NNP	I
Fields	.	I
and	:	I
D.	NNP	I
M.	,	I
Knipe,	CD	I
eds.	NNP	I
1991);	NNP	I
Virology,	NNP	B
3rd	NNP	I
Edition	CC	I
(Fields,	NNP	I
B	NNP	I
N,	,	I
D	.	I
M	:	I
Knipe,	,	I
P	CD	I
M	NNP	I
Howley,	,	I
Editors,	NNP	I
1996,	,	I
Lippincott-Raven,	NNP	I
Philadelphia,	NNP	I
Pa.;	,	I
for	NNP	O
a	NNP	O
description	,	O
of	,	O
these	,	O
and	,	O
other	,	O
related	:	O
viruses).	IN	O
First,	DT	O
the	NN	O
HIV-1	IN	O
codon	DT	O
usage	CC	O
pattern	JJ	O
was	JJ	O
modified	.	O
so	,	O
that	DT	O
the	NNP	O
resulting	NN	O
nucleic	NN	O
acid	NN	O
coding	VBD	O
sequence	VBN	O
was	RB	O
comparable	IN	O
to	DT	O
codon	VBG	O
usage	JJ	O
found	NN	O
in	VBG	O
highly	NN	O
expressed	VBD	O
human	JJ	O
genes	TO	O
(Example	VB	O
1).	NN	O
The	VBN	O
HIV	IN	O
codon	RB	O
usage	VBN	O
reflects	JJ	O
a	NNS	O
high	NNP	O
content	.	O
of	DT	O
the	NNP	O
nucleotides	NN	O
A	NN	O
or	VBZ	O
T	DT	O
of	JJ	O
the	NN	O
codon-triplet.	IN	O
The	DT	O
effect	NNS	O
of	NNP	O
the	CC	O
HIV-1	NNP	O
codon	IN	O
usage	DT	O
is	.	O
a	DT	O
high	NN	O
AT	IN	O
content	DT	O
in	NNP	O
the	NN	O
DNA	NN	O
sequence	VBZ	O
that	DT	O
results	JJ	O
in	NNP	O
a	NN	O
decreased	IN	O
translation	DT	O
ability	NN	O
and	NN	O
instability	WDT	O
of	NNS	O
the	IN	O
mRNA.	DT	O
In	JJ	O
comparison,	NN	O
highly	NN	O
expressed	CC	O
human	NN	O
codons	IN	O
prefer	DT	O
the	.	O
nucleotides	IN	O
G	,	O
or	RB	O
C.	VBN	O
The	JJ	O
Gag	NNS	O
coding	VBP	O
sequences	DT	O
were	NNS	O
modified	NNP	O
to	CC	O
be	NNP	O
comparable	DT	O
to	NNP	O
codon	NN	O
usage	NNS	O
found	VBD	O
in	VBN	O
highly	TO	O
expressed	VB	O
human	JJ	O
genes.	TO	O
In	VB	O
FIG.	NN	O
11	VBN	O
(Example	IN	O
1),	RB	O
the	VBN	O
percent	JJ	O
A-T	.	O
content	IN	O
of	.	O
cDNA	CD	O
sequences	NNP	O
corresponding	,	O
to	DT	O
the	NN	O
mRNA	NNP	O
for	NN	O
a	IN	O
known	NN	O
unstable	NNS	O
mRNA	VBG	O
and	TO	O
a	DT	O
known	NN	O
stable	IN	O
mRNA	DT	O
are	VBN	O
compared	JJ	O
to	NN	O
the	CC	O
percent	DT	O
A-T	VBN	O
content	JJ	O
of	NN	O
native	VBP	O
HIV-1SF2	VBN	O
Gag	TO	O
cDNA	DT	O
and	NN	O
to	NNP	O
the	NN	O
synthetic	IN	O
Gag	JJ	O
cDNA	NNP	O
sequence	NNP	O
of	NN	O
the	CC	O
present	TO	O
invention.	DT	O
Experiments	JJ	O
performed	NNP	O
in	NN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	.	O
showed	NNS	O
that	VBN	O
the	IN	O
synthetic	NN	O
Gag	IN	O
sequences	DT	O
were	JJ	O
capable	NN	O
of	VBD	O
higher	IN	O
level	DT	O
of	JJ	O
protein	NNP	O
production	NNS	O
(see	VBD	O
the	JJ	O
Examples)	IN	O
relative	JJR	O
to	NN	O
the	IN	O
native	JJ	O
Gag	NN	O
sequences.	VB	O
The	DT	O
data	)	O
in	VBP	O
FIG.	TO	O
11	DT	O
suggest	JJ	O
that	NNP	O
one	.	O
reason	DT	O
for	NN	O
this	IN	O
increased	.	O
production	CD	O
is	JJS	O
increased	IN	O
stability	CD	O
of	NN	O
the	IN	O
mRNA	DT	O
corresponding	VBN	O
to	NN	O
the	VBZ	O
synthetic	VBN	O
Gag	NN	O
coding	IN	O
sequences	DT	O
versus	NN	O
the	VBG	O
mRNA	TO	O
corresponding	DT	O
to	JJ	O
the	NNP	O
native	NN	O
Gag	NNS	O
coding	VBP	O
sequences.	DT	O
Second,	NN	O
there	VBG	O
are	TO	O
inhibitory	DT	O
(or	JJ	O
instability)	NNP	O
elements	NN	O
(INS)	.	O
located	,	O
within	EX	O
the	VBP	O
coding	JJ	O
sequences	CC	O
of	)	O
the	NNS	O
Gag	)	O
coding	VBD	O
sequences	IN	O
(Example	DT	O
1).	VBG	O
The	NNS	O
RRE	IN	O
is	DT	O
a	NNP	O
secondary	NN	O
RNA	NNS	O
structure	NNP	O
that	.	O
interacts	DT	O
with	NNP	O
the	VBZ	O
HIV	DT	O
encoded	JJ	O
Rev-protein	NNP	O
to	NN	O
overcome	WDT	O
the	VBZ	O
expression	IN	O
down-regulating	DT	O
effects	NNP	O
of	VBD	O
the	NNP	O
INS.	TO	O
To	VB	O
overcome	DT	O
the	NN	O
post-transcriptional	JJ	O
activating	NNS	O
mechanisms	IN	O
of	DT	O
RRE	.	O
and	TO	O
Rev,	VB	O
the	DT	O
instability	JJ	O
elements	NN	O
were	NNS	O
inactivated	IN	O
by	NNP	O
introducing	CC	O
multiple	,	O
point	DT	O
mutations	NN	O
that	NNS	O
did	VBD	O
not	VBN	O
alter	IN	O
the	VBG	O
reading	JJ	O
frame	NN	O
of	NNS	O
the	WDT	O
encoded	VBD	O
proteins.	RB	O
FIG.	VB	O
1	DT	O
shows	NN	O
the	NN	O
original	IN	O
SF2	DT	O
Gag	JJ	O
sequence,	.	O
the	.	O
location	CD	O
of	VBZ	O
the	DT	O
INS	JJ	O
sequences,	NNP	O
and	NNP	O
the	,	O
modifications	DT	O
made	NN	O
to	IN	O
the	DT	O
INS	NNP	O
sequences	,	O
to	CC	O
reduce	DT	O
their	NNS	O
effects.	VBN	O
The	TO	O
resulting	DT	O
modified	NNP	O
coding	NNS	O
sequences	TO	O
are	VB	O
presented	PRP$	O
as	.	O
a	DT	O
synthetic	VBG	O
Gag	JJ	O
expression	NN	O
cassette	NNS	O
(SEQ	VBP	O
ID	VBN	O
NO:4).	IN	O
Modification	DT	O
of	JJ	O
the	NNP	O
Gag	NN	O
polypeptide	NN	O
coding	NNP	O
sequences	NNP	O
resulted	.	O
in	NN	O
improved	IN	O
expression	DT	O
relative	NNP	O
to	NN	O
the	VBG	O
wild-type	NNS	O
coding	VBD	O
sequences	IN	O
in	JJ	O
a	NN	O
number	NN	O
of	TO	O
mammalian	DT	O
cell	JJ	O
lines	NN	O
(as	NNS	O
well	IN	O
as	DT	O
other	NN	O
types	IN	O
of	JJ	O
cell	NN	O
lines,	NNS	O
including,	RB	O
but	RB	O
not	IN	O
limited	JJ	O
to,	NNS	O
insect	IN	O
cells).	NN	O
Further,	,	O
expression	,	O
of	CC	O
the	RB	O
sequences	JJ	O
resulted	,	O
in	VB	O
production	.	O
of	,	O
virus-like	NN	O
particles	IN	O
(VLPs)	DT	O
by	NNS	O
these	VBD	O
cell	IN	O
lines	NN	O
(see	IN	O
below).	JJ	O
Similar	NNS	O
Gag	)	O
polypeptide	IN	O
coding	DT	O
sequences	NN	O
can	NNS	O
be	VB	O
obtained	.	O
from	JJ	O
a	NNP	O
variety	NN	O
of	VBG	O
isolates	NNS	O
(families,	MD	O
sub-types,	VB	O
strains,	VBN	O
etc.)	IN	O
including,	DT	O
but	NN	O
not	IN	O
limited	NNS	O
to	,	O
such	,	O
other	,	O
variants	)	O
include,	,	O
but	CC	O
are	RB	O
not	JJ	O
limited	TO	O
to,	JJ	O
Gag	JJ	O
polypeptide	NNS	O
encoding	,	O
sequences	CC	O
obtained	VBP	O
from	RB	O
the	VBN	O
isolates	,	O
HIVIIIb,	NNP	O
HIVSF2,	IN	O
HIV-1SF162,	VBG	O
HIV-1SF170,	NNS	O
HIVLAV,	VBN	O
HIVLAI,	IN	O
HIVMN,	DT	O
HIV-1CM235,	NNS	O
HIV-1US4,	,	O
other	,	O
HIV-1	,	O
strains	,	O
from	,	O
diverse	,	O
subtypes(e.g.,	,	O
subtypes,	,	O
A	,	O
through	JJ	O
G,	JJ	O
and	NNS	O
O),	IN	O
HIV-2	JJ	O
strains	,	O
and	,	O
diverse	NNP	O
subtypes	IN	O
(e.g.,	,	O
HIV-2UC1	CC	O
and	,	O
HIV-2UC2),	NNP	O
and	NNS	O
simian	CC	O
immunodeficiency	JJ	O
virus	NNS	O
(SIV).	,	O
(See,	NNP	O
e.g.,	CC	O
Virology,	,	B
3rd	CC	I
Edition	JJ	I
(W.	NN	I
K.	NN	I
Joklik	.	I
ed.	,	I
1988);	,	I
Fundamental	,	B
Virology,	CD	I
2nd	NNP	I
Edition	NNP	I
(B.	NNP	I
N.	NNP	I
Fields	.	I
and	:	I
D.	NNP	I
M.	,	I
Knipe,	CD	I
eds.	NNP	I
1991;	NNP	I
Virology,	NNP	B
3rd	NNP	I
Edition	CC	I
(Fields,	NNP	I
B	NNP	I
N,	,	I
D	.	I
M	:	I
Knipe,	,	I
P	CD	I
M	NNP	I
Howley,	,	I
Editors,	NNP	I
1996,	,	I
Lippincott-Raven,	NNP	I
Philadelphia,	NNP	I
Pa.).	,	I
Gag	NNP	O
polypeptide	NNP	O
encoding	,	O
sequences	,	O
derived	,	O
from	,	O
these	,	O
variants	.	O
can	NNP	O
be	NN	O
optimized	VBG	O
and	NNS	O
tested	VBN	O
for	IN	O
improved	DT	O
expression	NNS	O
in	MD	O
mammals	VB	O
by	VBN	O
following	CC	O
the	VBN	O
teachings	IN	O
of	JJ	O
the	NN	O
present	IN	O
specification	NNS	O
(see	IN	O
the	VBG	O
Examples,	DT	O
in	NNS	O
particular	IN	O
Example	DT	O
1).	JJ	O
2.1.2	NN	O
Further	VB	O
Modification	DT	O
of	,	O
Sequences	IN	O
Including	JJ	O
HIV-1	NNP	O
Gag	.	O
Nucleic	CD	O
Acid	JJ	O
Coding	NN	O
Sequences	IN	O
Experiments	NNS	O
performed	VBG	O
in	NNP	O
support	NNP	O
of	NNP	O
the	NNP	O
present	NNP	O
invention	NNP	O
have	NNP	O
shown	VBD	O
that	IN	O
similar	NN	O
modifications	IN	O
of	DT	O
HIV-1	JJ	O
Gag-protease,	NN	O
Gag-reverse	VBP	O
transcriptase	VBN	O
and	IN	O
Gag-polymerase	JJ	O
sequences	NNS	O
also	IN	O
result	NNP	O
in	,	O
improved	NNP	O
expression	NN	O
of	CC	O
the	NNP	O
polyproteins,	NNS	O
as	RB	O
well	VBP	O
as,	IN	O
the	JJ	O
production	NN	O
of	IN	O
VLPs	DT	O
formed	,	O
by	RB	O
polypeptides	RB	O
produced	,	O
from	DT	O
such	NN	O
modified	IN	O
coding	NNP	O
sequences.	VBN	O
For	IN	O
the	NNS	O
Gag-protease	VBN	O
sequence	IN	O
(wild	JJ	O
type,	VBN	O
SEQ	NN	O
ID	.	O
NO:2;	IN	O
modified,	DT	O
SEQ	NNP	O
ID	NN	O
NOs:5,	JJ	O
78,	,	O
79),	NNP	O
the	NNP	O
changes	:	O
in	,	O
codon	NNP	O
usage	NNP	O
were	,	O
restricted	,	O
to	,	O
the	DT	O
regions	NNS	O
upstream	IN	O
of	NN	O
the	NN	O
−1	VBD	O
frameshift	VBN	O
(FIG.	TO	O
2).	DT	O
Further,	NNS	O
inhibitory	NN	O
(or	IN	O
instability)	DT	O
elements	NNP	O
(INS)	NN	O
located	.	O
within	.	O
the	,	O
coding	NN	O
sequences	CC	O
of	)	O
the	NNS	O
Gag-protease	)	O
polypeptide	VBD	O
coding	IN	O
sequence	DT	O
were	VBG	O
altered	NNS	O
as	IN	O
well	DT	O
(indicated	NNP	O
in	NN	O
FIG.	VBG	O
2).	NN	O
Exemplary	VBD	O
constructs	VBN	O
(which	RB	O
include	RB	O
the	VBN	O
−1	IN	O
frameshift)	.	O
encoding	.	O
modified	JJ	O
Gag-protease	NNS	O
sequences	WDT	O
include	VBP	O
those	DT	O
shown	NNP	O
in	)	O
SEQ	VBG	O
ID	VBN	O
NOs:78	NNP	O
and	NNS	O
79	VBP	O
(FIGS.	DT	O
69	VBN	O
and	IN	O
70).	NNP	O
These	NNP	O
are:	NNP	O
GP1	CC	O
(SEQ	CD	O
ID	.	O
NO:78)	CD	O
in	CC	O
which	.	O
the	DT	O
protease	:	O
region	NNP	O
was	NNP	O
also	NNP	O
codon	)	O
optimized	IN	O
and	WDT	O
INS	DT	O
inactivated	NN	O
and	NN	O
GP2	VBD	O
(SEQ	RB	O
ID	JJ	O
NO:79),	VBN	O
in	CC	O
which	NNP	O
the	VBD	O
protease	CC	O
region	NNP	O
was	NNP	O
only	NNP	O
subjected	,	O
to	IN	O
INS	WDT	O
inactivation.	DT	O
For	NN	O
other	NN	O
Gag-containing	VBD	O
sequences,	RB	O
for	VBN	O
example	TO	O
the	NNP	O
Gag-polymerase	.	O
sequence	IN	O
(wild	JJ	O
type,	JJ	O
SEQ	,	O
ID	IN	O
NO:3;	NN	O
modified,	DT	O
SEQ	NNP	O
ID	NN	O
NO:6)	JJ	O
or	,	O
Gag-reverse	NNP	O
transcriptase	NNP	O
(wild	:	O
type,	,	O
SEQ	NNP	O
ID	NNP	O
NO:77;	)	O
modified	CC	O
SEQ	JJ	O
ID	NN	O
NOs:80-84),	JJ	O
the	,	O
changes	NNP	O
in	NNP	O
codon	:	O
usage	VBD	O
are	NNP	O
similar	NNP	O
to	,	O
those	DT	O
for	NNS	O
the	IN	O
Gag-protease	NN	O
sequence.	NN	O
Those	VBP	O
expression	JJ	O
cassettes	TO	O
which	DT	O
contain	IN	O
a	DT	O
frameshift	NNP	O
in	.	O
the	DT	O
GagPol	NN	O
coding	NNS	O
sequence	WDT	O
are	VBP	O
designated	DT	O
“FS(+)”	NN	O
(SEQ	IN	O
ID	DT	O
NOs:80	NNP	O
and	NN	O
81,	NN	O
FIGS.	VBP	O
71	VBN	O
and	NN	O
72)	NNP	O
while	NNP	O
the	NNP	O
designation	CC	O
“FS(−)”	,	O
(SEQ	.	O
ID	CD	O
Nos:	CC	O
82,	)	O
83	IN	O
and	DT	O
84,	NN	O
FIGS.	NN	O
73,	NNP	O
74	NNP	O
and	:	O
75)	,	O
indicates	CD	O
that	CC	O
there	,	O
is	.	O
no	,	O
frameshift	CD	O
utilized	CC	O
in	)	O
this	VBZ	O
coding	IN	O
sequence.	EX	O
In	VBZ	O
addition	DT	O
to	NN	O
polyproteins	VBN	O
containing	IN	O
HIV-related	DT	O
sequences,	NN	O
the	.	O
various	IN	O
Gag-,	NN	O
Gag-prot,	TO	O
Gag-pol,	NNS	O
Gag-reverse	VBG	O
transcriptase	JJ	O
encoding	,	O
sequences	DT	O
of	JJ	O
the	,	O
present	,	O
invention	,	O
can	NNP	O
be	NN	O
fused	VBG	O
to	NNS	O
other	IN	O
polypeptides	DT	O
(creating	JJ	O
chimeric	NN	O
polypeptides)	MD	O
for	VB	O
which	VBN	O
an	TO	O
immunogenic	JJ	O
response	NNS	O
is	VBG	O
desired.	RB	O
An	)	O
example	IN	O
of	WDT	O
such	DT	O
a	JJ	O
chimeric	NN	O
protein	VBZ	O
is	.	O
the	DT	O
joining	NN	O
of	IN	O
the	PDT	O
improved	DT	O
expression	JJ	O
Gag	NN	O
encoding	VBZ	O
sequences	DT	O
to	NN	O
the	IN	O
Hepatitis	DT	O
C	JJ	O
Virus	NN	O
(HCV)	NNP	O
core	VBG	O
protein.	NNS	O
In	TO	O
this	DT	O
case,	NNP	O
the	NNP	O
HCV-core	NNP	O
encoding	)	O
sequences	NN	O
were	.	O
placed	IN	O
in-frame	DT	O
with	,	O
the	DT	O
HIV-Gag	NNP	O
encoding	NN	O
sequences,	NNS	O
resulting	VBD	O
in	VBN	O
the	JJ	O
Gag/HCV-core	IN	O
encoding	DT	O
sequence	NNP	O
presented	NN	O
as	,	O
SEQ	VBG	O
ID	IN	O
NO:7	DT	O
(wild	NNP	O
type	NN	O
sequence	NN	O
presented	VBD	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:8).	NNP	O
Further	JJ	O
sequences	NN	O
useful	NN	O
in	VBD	O
the	IN	O
practice	NNP	O
of	NNP	O
the	.	O
present	JJ	O
invention	NNS	O
include,	JJ	O
but	IN	O
are	DT	O
not	NN	O
limited	IN	O
to,	DT	O
sequences	JJ	O
encoding	NN	O
viral	,	O
epitopes/antigens	CC	O
{including	VBP	O
but	RB	O
not	VBN	O
limited	,	O
to,	NNS	O
HCV	VBG	O
antigens	JJ	O
(e.g.,	NNS	O
E1,	VBG	O
E2;	CC	O
Houghton,	RB	O
M.,	JJ	O
et	,	O
al.,	NNP	O
U.S.	VBZ	O
Pat.	,	O
No.	,	O
5,714,596,	:	O
issued	,	O
Feb.	,	O
3,	FW	O
1998;	,	O
Houghton,	NNP	O
M.,	.	O
et	.	O
al.,	,	O
U.S.	VBN	O
Pat.	NNP	O
No.	,	O
5,712,088,	:	O
issued	,	O
Jan.	,	O
27,	FW	O
1998;	,	O
Houghton,	NNP	O
M.,	.	O
et	.	O
al.,	,	O
U.S.	VBD	O
Pat.	NNP	O
No.	,	O
5,683,864,	:	O
issued	,	O
Nov.	,	O
4,	FW	O
1997;	,	O
Weiner,	NNP	O
A.	.	O
J.,	.	O
et	,	O
al.,	VBD	O
U.S.	NNP	O
Pat.	,	O
No.	:	O
5,728,520,	,	O
issued	NNP	O
Mar.	,	O
17,	FW	O
1998;	,	O
Weiner,	NNP	O
A.	.	O
J.,	.	O
et	,	O
al.,	VBN	O
U.S.	.	O
Pat.	,	O
No.	:	O
5,766,845,	,	O
issued	NNP	O
Jun.	,	O
16,	FW	O
1998;	,	O
Weiner,	NNP	O
A.	.	O
J.,	.	O
et	,	O
al.,	VBN	O
U.S.	.	O
Pat.	,	O
No.	:	O
5,670,152,	,	O
issued	NNP	O
Sep.	,	O
23,	FW	O
1997;	,	O
all	NNP	O
herein	.	O
incorporated	.	O
by	,	O
reference),	VBN	O
HIV	NNP	O
antigens	,	O
(e.g.,	:	O
derived	DT	O
from	NN	O
nef,	VBN	O
tat,	IN	O
rev,	,	O
vpu,	NNP	O
vif,	VBZ	O
vpr	,	O
and/or	VBN	O
env);	IN	O
and	,	O
sequences	,	O
encoding	,	O
tumor	,	O
antigens/epitopes.	,	O
Additional	FW	O
sequences	FW	O
are	:	O
described	CC	O
below.	NNS	O
Also,	VBG	O
variations	NN	O
on	.	O
the	JJ	O
orientation	NNS	O
of	VBP	O
the	VBN	O
Gag	.	O
and	,	O
other	NNS	O
coding	IN	O
sequences,	DT	O
relative	NN	O
to	IN	O
each	DT	O
other,	NNP	O
are	CC	O
also	JJ	O
described	NN	O
below.	,	O
Gag,	JJ	O
Gag-protease,	TO	O
Gag-reverse	DT	O
transcriptase	,	O
and/or	VBP	O
Gag-polymerase	RB	O
polypeptide	VBN	O
coding	.	O
sequences	,	O
can	,	O
be	NNP	O
obtained	NN	O
from	VBZ	O
any	NNP	O
HIV	NN	O
isolates	VBG	O
(different	NNS	O
families,	MD	O
subtypes,	VB	O
and	VBN	O
strains)	IN	O
including	DT	O
but	NNP	O
not	NNS	O
limited	JJ	O
to	,	O
the	,	O
isolates	CC	O
HIVIIIb,	)	O
HIVSF2,	VBG	O
HIVSF162,	CC	O
HIVus4,	RB	O
HIVcm235,	JJ	O
HIVLAV,	TO	O
HIVMN)	DT	O
(see,	NNS	O
e.g.,	,	O
Myers	,	O
et	,	O
al.	,	O
Los	,	O
Alamos	,	O
Database,	)	O
Los	,	O
Alamos	,	O
National	NNP	O
Laboratory,	VBP	O
Los	.	O
Alamos,	NNP	O
N.	NNP	O
Mex.	,	O
(1992);	NNP	O
Myers	NNP	O
et	NNP	O
al.,	,	O
Human	NNP	O
Retroviruses	,	O
and	NNP	O
Aids,	.	O
1997,	:	O
Los	NNP	O
Alamos,	FW	O
N.	,	O
Mex.:	NNP	O
Los	NNP	O
Alamos	CC	O
National	,	O
Laboratory).	,	O
Synthetic	NNP	O
expression	,	O
cassettes	.	O
can	:	O
be	NNP	O
generated	NNP	O
using	NNP	O
such	.	O
coding	JJ	O
sequences	NN	O
as	NNS	O
starting	MD	O
material	VB	O
by	VBN	O
following	VBG	O
the	JJ	O
teachings	JJ	O
of	NNS	O
the	IN	O
present	VBG	O
specification	NN	O
(e.g.,	IN	O
see	VBG	O
Example	DT	O
1).	NNS	O
Further,	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	,	O
of	VBP	O
the	JJ	O
present	.	O
invention	,	O
include	DT	O
related	JJ	O
Gag	NN	O
polypeptide	NNS	O
coding	IN	O
sequences	DT	O
having	JJ	O
greater	NN	O
than	VBP	O
75%	VBN	O
,	NNP	O
preferably	IN	O
greater	VBG	O
than	NNS	O
80-85%	VBG	O
,	JJR	O
more	IN	O
preferably	NN	O
greater	,	O
than	RB	O
90-95%	JJR	O
,	IN	O
and	NN	O
most	,	O
preferably	JJR	O
greater	RB	O
than	JJR	O
98%	IN	O
sequence	NN	O
identity	,	O
(or	CC	O
any	JJS	O
integer	RB	O
value	JJR	O
within	IN	O
these	NN	O
ranges)	NN	O
to	NN	O
the	CC	O
synthetic	DT	O
expression	JJ	O
cassette	NN	O
sequences	IN	O
disclosed	DT	O
herein	)	O
(for	TO	O
example,	DT	O
SEQ	JJ	O
ID	NN	O
NO:4;	NN	O
SEQ	NNS	O
ID	VBD	O
NO:5;	NN	O
SEQ	IN	O
ID	,	O
NO:6;	NNP	O
and	NNP	O
SEQ	:	O
ID	NNP	O
NO:20,	NNP	O
the	:	O
Gag	NNP	O
Major	NNP	O
Homology	:	O
Region).	CC	O
2.1.3	NNP	O
Expression	NNP	O
of	,	O
Synthetic	DT	O
Sequences	NNP	O
Encoding	NNP	O
HIV-1	NNP	O
Gag	.	O
and	CD	O
Related	NN	O
Polypeptides	IN	O
Several	JJ	O
synthetic	NNS	O
Gag-encoding	VBG	O
sequences	NNP	O
(expression	NNP	O
cassettes)	CC	O
of	NNP	O
the	NNP	O
present	NNP	O
invention	JJ	O
were	NNP	O
cloned	NNS	O
into	NN	O
a	)	O
number	IN	O
of	DT	O
different	JJ	O
expression	NN	O
vectors	VBD	O
(Example	VBN	O
1)	IN	O
to	DT	O
evaluate	NN	O
levels	IN	O
of	JJ	O
expression	NN	O
and	NNS	O
production	NNP	O
of	)	O
VLPs.	TO	O
Two	VB	O
modified	NNS	O
synthetic	IN	O
coding	NN	O
sequences	CC	O
are	NN	O
presented	IN	O
as	.	O
a	CD	O
synthetic	VBD	O
Gag	JJ	O
expression	NN	O
cassette	NNS	O
(SEQ	VBP	O
ID	VBN	O
NO:4)	IN	O
and	DT	O
a	JJ	O
synthetic	NNP	O
Gag-protease	NN	O
expression	NN	O
cassette	NNP	O
(SEQ	NNP	O
ID	)	O
NOs:78	CC	O
and	DT	O
79).	JJ	O
Other	NNP	O
synthetic	NN	O
Gag-encoding	NN	O
proteins	NNP	O
are	NNP	O
presented,	NNP	O
for	CC	O
example,	.	O
as	JJ	O
SEQ	JJ	O
ID	JJ	O
NOs:80	NNS	O
through	VBP	O
84.	,	O
The	IN	O
synthetic	,	O
DNA	IN	O
fragments	NNP	O
for	NNP	O
Gag-encoding	NNP	O
polypeptides	IN	O
(e.g.,	.	O
Gag,	DT	O
Gag-protease,	JJ	O
Gag-polymerase,	NN	O
Gag-reverse	NNS	O
transcriptase)	IN	O
were	NNP	O
cloned	NNS	O
into	,	O
expression	,	O
vectors	,	O
described	,	O
in	NNP	O
Example	)	O
1,	VBD	O
including,	VBN	O
a	IN	O
transient	NN	O
expression	NNS	O
vector,	VBD	O
CMV-promoter-based	IN	O
mammalian	NNP	O
vectors,	,	O
and	,	O
a	DT	O
shuttle	JJ	O
vector	NN	O
for	,	O
use	JJ	O
in	JJ	O
baculovirus	,	O
expression	CC	O
systems.	DT	O
Corresponding	JJ	O
wild-type	NN	O
sequences	IN	O
were	NN	O
cloned	IN	O
into	JJ	O
the	NN	O
same	.	O
vectors.	VBG	O
These	JJ	O
vectors	NNS	O
were	VBD	O
then	VBN	O
transfected	IN	O
into	DT	O
a	JJ	O
several	.	O
different	DT	O
cell	NNS	O
types,	VBD	O
including	RB	O
a	VBN	O
variety	IN	O
of	DT	O
mammalian	JJ	O
cell	JJ	O
lines,	NN	O
(293,	,	O
RD,	VBG	O
COS-7,	DT	O
and	NN	O
CHO,	IN	O
cell	JJ	O
lines	NN	O
available,	,	O
for	,	O
example,	,	O
from	,	O
the	CC	O
A.T.C.C.).	,	O
The	NN	O
cell	NNS	O
lines	,	O
were	IN	O
cultured	,	O
under	IN	O
appropriate	DT	O
conditions	.	O
and	DT	O
the	NN	O
levels	NNS	O
of	VBD	O
p24	VBN	O
(Gag)	IN	O
expression	JJ	O
in	NNS	O
supernatants	CC	O
were	DT	O
evaluated	NNS	O
(Example	IN	O
2).	NN	O
The	)	O
results	NN	O
of	IN	O
these	NNS	O
assays	VBD	O
demonstrated	VBN	O
that	NNP	O
expression	.	O
of	DT	O
synthetic	NNS	O
Gag-encoding	IN	O
sequences	DT	O
were	NNS	O
significantly	VBD	O
higher	IN	O
than	NN	O
corresponding	IN	O
wild-type	JJ	O
sequences	JJ	O
(Example	NNS	O
2;	VBD	O
Table	RB	O
2).	JJR	O
Further,	IN	O
Western	VBG	O
Blot	JJ	O
analysis	NNS	O
showed	JJ	O
that	:	O
cells	NNP	O
containing	.	O
the	,	O
synthetic	JJ	O
Gag	NNP	O
expression	NN	O
cassette	VBD	O
produced	IN	O
the	NNS	O
expected	VBG	O
55	DT	O
kD	JJ	O
(p55)	NNP	O
protein	NN	O
at	NN	O
higher	VBD	O
per-cell	DT	O
concentrations	JJ	O
than	CD	O
cells	NN	O
containing	)	O
the	NN	O
native	IN	O
expression	JJR	O
cassette.	NN	O
The	NNS	O
Gag	IN	O
p55	NNS	O
protein	VBG	O
was	DT	O
seen	JJ	O
in	NN	O
both	.	O
cell	DT	O
lysates	NNP	O
and	NN	O
supernatants.	NN	O
The	VBD	O
levels	VBN	O
of	IN	O
production	DT	O
were	NN	O
significantly	NNS	O
higher	CC	O
in	.	O
cell	DT	O
supernatants	NNS	O
for	IN	O
cells	NN	O
transfected	VBD	O
with	RB	O
the	JJR	O
synthetic	IN	O
Gag	NN	O
expression	NNS	O
cassette	IN	O
of	NNS	O
the	VBN	O
present	IN	O
invention.	DT	O
Experiments	JJ	O
performed	NNP	O
in	NN	O
support	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	.	O
suggest	NNS	O
that	VBN	O
cells	IN	O
containing	NN	O
the	IN	O
synthetic	DT	O
Gag-prot	JJ	O
expression	NN	O
cassettes	VBP	O
produced	IN	O
the	NNS	O
expected	VBG	O
Gag-prot	DT	O
protein	JJ	O
at	NNP	O
comparably	NN	O
higher	NNS	O
per-cell	VBD	O
concentrations	DT	O
than	VBN	O
cells	NNP	O
containing	NN	O
the	IN	O
wild-type	RB	O
expression	JJR	O
cassette.	NN	O
Fractionation	NNS	O
of	IN	O
the	NNS	O
supernatants	VBG	O
from	DT	O
mammalian	JJ	O
cells	NN	O
transfected	.	O
with	NN	O
the	IN	O
synthetic	DT	O
Gag	NNS	O
expression	IN	O
cassette	JJ	O
showed	NNS	O
that	VBN	O
it	IN	O
provides	DT	O
superior	JJ	O
production	NNP	O
of	NN	O
both	NN	O
p55	VBD	O
protein	IN	O
and	PRP	O
VLPs,	VBZ	O
relative	JJ	O
to	NN	O
the	IN	O
wild-type	DT	O
Gag	JJ	O
sequences	NN	O
(Examples	CC	O
6	,	O
and	JJ	O
7).	TO	O
Efficient	DT	O
expression	JJ	O
of	NNP	O
these	NNS	O
Gag-containing	NNP	O
polypeptides	CD	O
in	CC	O
mammalian	.	O
cell	JJ	O
lines	NN	O
provides	IN	O
the	DT	O
following	NNP	O
benefits:	NNS	O
the	IN	O
Gag	JJ	O
polypeptides	NN	O
are	NNS	O
free	VBZ	O
of	DT	O
baculovirus	JJ	O
contaminants;	:	O
production	DT	O
by	NNP	O
established	NNS	O
methods	VBP	O
approved	JJ	O
by	IN	O
the	NN	O
FDA;	:	O
increased	NN	O
purity;	IN	O
greater	VBN	O
yields	NNS	O
(relative	VBN	O
to	IN	O
native	DT	O
coding	:	O
sequences);	VBD	O
and	:	O
a	JJR	O
novel	NNS	O
method	JJ	O
of	TO	O
producing	JJ	O
the	NN	O
Gag-containing	:	O
polypeptides	CC	O
in	DT	O
CHO	JJ	O
or	NN	O
other	IN	O
mammalian	VBG	O
cells	DT	O
which	NNP	O
is	NNS	O
not	IN	O
feasible	NNP	O
in	CC	O
the	JJ	O
absence	JJ	O
of	NNS	O
the	WDT	O
increased	VBZ	O
expression	RB	O
obtained	JJ	O
using	IN	O
the	DT	O
constructs	NN	O
of	IN	O
the	DT	O
present	VBN	O
invention.	NN	O
Exemplary	VBN	O
Mammalian	VBG	O
cell	DT	O
lines	NNS	O
include,	IN	O
but	DT	O
are	JJ	O
not	.	O
limited	JJ	O
to,	NNP	O
BHK,	NN	O
VERO,	NNS	O
HT1080,	,	O
293,	CC	O
293T,	VBP	O
RD,	RB	O
COS-7,	VBN	O
CHO,	,	O
Jurkat,	,	O
HUT,	,	O
SUPT,	,	O
C8166,	,	O
MOLT4/clone8,	,	O
MT-2,	,	O
MT-4,	,	O
H9,	,	O
PM1,	,	O
CEM,	,	O
myeloma	,	O
cells	,	O
(e.g.,	,	O
SB20	,	O
cells)	,	O
and	,	O
CEMX174,	,	O
such	,	O
cell	NN	O
lines	NNS	O
are	,	O
available,	NNP	O
for	)	O
example,	CC	O
from	,	O
the	JJ	O
A.T.C.C.).	NN	O
A	NNS	O
synthetic	VBP	O
Gag	,	O
expression	IN	O
cassette	,	O
of	IN	O
the	DT	O
present	.	O
invention	DT	O
also	JJ	O
demonstrated	NNP	O
high	NN	O
levels	NN	O
of	IN	O
expression	DT	O
and	JJ	O
VLP	NN	O
production	RB	O
when	VBD	O
transfected	JJ	O
into	NNS	O
insect	IN	O
cells	NN	O
(Example	CC	O
7).	NNP	O
Further,	NN	O
in	WRB	O
addition	VBN	O
to	IN	O
a	JJ	O
higher	NNS	O
total	NNP	O
protein	.	O
yield,	,	O
the	IN	O
final	NN	O
product	TO	O
from	DT	O
the	JJR	O
synthetic	JJ	O
p55-expressed	JJ	O
Gag	,	O
consistently	DT	O
contained	JJ	O
lower	NN	O
amounts	IN	O
of	DT	O
contaminating	JJ	O
baculovirus	JJ	O
proteins	NNP	O
than	RB	O
the	VBD	O
final	JJR	O
purified	NNS	O
product	IN	O
from	VBG	O
the	NN	O
native	NNS	O
p55-expressed	IN	O
Gag.	DT	O
Further,	JJ	O
synthetic	JJ	O
Gag	NN	O
expression	IN	O
cassettes	DT	O
of	JJ	O
the	JJ	O
present	.	O
invention	,	O
have	JJ	O
also	NNP	O
been	NN	O
introduced	NNS	O
into	IN	O
yeast	DT	O
vectors	JJ	O
which	NN	O
were	VBP	O
transformed	RB	O
into	VBN	O
and	VBN	O
efficiently	IN	O
expressed	NN	O
by	NNS	O
yeast	WDT	O
cells	VBD	O
(Saccharomyces	VBN	O
cerevisea;	IN	O
using	CC	O
vectors	RB	O
as	VBN	O
described	IN	O
in	NN	O
Rosenberg,	NNS	O
S.	NNPS	O
and	:	O
Tekamp-Olson,	VBG	O
P.,	NNS	O
U.S.	IN	O
Pat.	VBN	O
No.	IN	O
RE35,749,	,	O
issued,	NNP	O
Mar.	CC	O
17,	,	O
1998,	,	O
herein	NNP	O
incorporated	.	O
by	.	O
reference).	,	O
In	,	O
addition	.	O
to	,	O
the	,	O
mammalian	RB	O
and	VBN	O
insect	IN	O
vectors	.	O
described	IN	O
in	NN	O
the	TO	O
Examples,	DT	O
the	JJ	O
synthetic	CC	O
expression	JJ	O
cassettes	NNS	O
of	VBN	O
the	IN	O
present	DT	O
invention	,	O
can	DT	O
be	JJ	O
incorporated	NN	O
into	NNS	O
a	IN	O
variety	DT	O
of	JJ	O
expression	NN	O
vectors	MD	O
using	VB	O
selected	VBN	O
expression	IN	O
control	DT	O
elements.	NN	O
Appropriate	IN	O
vectors	NN	O
and	NNS	O
control	VBG	O
elements	VBN	O
for	NN	O
any	NN	O
given	.	O
cell	JJ	O
type	NNS	O
can	CC	O
be	NN	O
selected	NNS	O
by	IN	O
one	DT	O
having	VBN	O
ordinary	NN	O
skill	NN	O
in	MD	O
the	VB	O
art	VBN	O
in	IN	O
view	CD	O
of	VBG	O
the	JJ	O
teachings	NN	O
of	IN	O
the	DT	O
present	NN	O
specification	IN	O
and	NN	O
information	IN	O
known	DT	O
in	NNS	O
the	IN	O
art	DT	O
about	JJ	O
expression	NN	O
vectors.	CC	O
For	NN	O
example,	VBN	O
a	IN	O
synthetic	DT	O
Gag	NN	O
expression	IN	O
cassette	NN	O
can	.	O
be	IN	O
inserted	,	O
into	DT	O
a	JJ	O
vector	NNP	O
which	NN	O
includes	NN	O
control	MD	O
elements	VB	O
operably	VBN	O
linked	IN	O
to	DT	O
the	NN	O
desired	WDT	O
coding	VBZ	O
sequence,	NN	O
which	NNS	O
allow	RB	O
for	VBN	O
the	TO	O
expression	DT	O
of	VBN	O
the	NN	O
gene	,	O
in	WDT	O
a	VBP	O
selected	IN	O
cell-type.	DT	O
For	NN	O
example,	IN	O
typical	DT	O
promoters	NN	O
for	IN	O
mammalian	DT	O
cell	VBN	O
expression	.	O
include	IN	O
the	,	O
SV40	JJ	O
early	NNS	O
promoter,	IN	O
a	JJ	O
CMV	NN	O
promoter	NN	O
such	VBP	O
as	DT	O
the	NNP	O
CMV	JJ	O
immediate	,	O
early	DT	O
promoter	NNP	O
(a	NN	O
CMV	JJ	O
promoter	IN	O
can	DT	O
include	NNP	O
intron	VBP	O
A),	JJ	O
RSV,	NN	O
HIV-LTR,	DT	O
the	NNP	O
mouse	NN	O
mammary	MD	O
tumor	VB	O
virus	VB	O
LTR	,	O
promoter	,	O
(MMLV-LTR),	,	O
FIV-LTR,	DT	O
the	NN	O
adenovirus	JJ	O
major	NN	O
late	NN	O
promoter	NNP	O
(Ad	NN	O
MLP),	,	O
and	,	O
the	DT	O
herpes	NN	O
simplex	JJ	O
virus	JJ	O
promoter,	NN	O
among	NNP	O
others.	,	O
Other	CC	O
nonviral	DT	O
promoters,	NNS	O
such	JJ	O
as	NN	O
a	,	O
promoter	IN	O
derived	.	O
from	JJ	O
the	JJ	O
murine	,	O
metallothionein	JJ	O
gene,	IN	O
will	DT	O
also	NN	O
find	VBN	O
use	IN	O
for	DT	O
mammalian	NN	O
expression.	NN	O
Typically,	,	O
transcription	MD	O
termination	RB	O
and	VB	O
polyadenylation	NN	O
sequences	IN	O
will	JJ	O
also	.	O
be	,	O
present,	NN	O
located	NN	O
3′	CC	O
to	NN	O
the	NNS	O
translation	MD	O
stop	RB	O
codon.	VB	O
Preferably,	,	O
a	VBN	O
sequence	CD	O
for	TO	O
optimization	DT	O
of	NN	O
initiation	NN	O
of	.	O
translation,	,	O
located	DT	O
5′	NN	O
to	IN	O
the	NN	O
coding	IN	O
sequence,	NN	O
is	IN	O
also	,	O
present.	VBN	O
Examples	CD	O
of	TO	O
transcription	DT	O
terminator/polyadenylation	VBG	O
signals	,	O
include	VBZ	O
those	RB	O
derived	.	O
from	NNS	O
SV40,	IN	O
as	NN	O
described	NN	O
in	NNS	O
Sambrook,	VBP	O
et	DT	O
al.,	VBN	O
supra,	IN	O
as	,	O
well	IN	O
as	VBN	O
a	IN	O
bovine	,	O
growth	FW	O
hormone	,	O
terminator	,	O
sequence.	RB	O
Introns,	RB	O
containing	IN	O
splice	DT	O
donor	NN	O
and	NN	O
acceptor	NN	O
sites,	NN	O
may	.	O
also	,	O
be	VBG	O
designed	NN	O
into	NN	O
the	CC	O
constructs	NN	O
for	,	O
use	MD	O
with	RB	O
the	VB	O
present	VBN	O
invention	IN	O
Chapman	DT	B
et	NNS	I
al.,	IN	I
Nuc.	NN	I
Acids	IN	I
Res.	DT	I
(1991)	JJ	I
19:3979-3986).(	NN	O
Enhancer	NNP	O
elements	VBZ	O
may	,	O
also	.	O
be	NNP	O
used	.	O
herein	)	O
to	.	O
increase	NNP	O
expression	NNS	O
levels	MD	O
of	RB	O
the	VB	O
mammalian	VBN	O
constructs.	NN	O
Examples	TO	O
include	VB	O
the	NN	O
SV40	NNS	O
early	IN	O
gene	DT	O
enhancer,	JJ	O
as	.	O
described	NNS	O
in	VBP	O
Dijkema	DT	B
et	NNP	I
al.,	JJ	I
EMBO	NN	I
J.	,	I
(1985)	IN	I
4:761,	VBN	I
the	IN	O
enhancer/promoter	NNP	O
derived	CC	O
from	,	O
the	NNP	O
long	.	O
terminal	)	O
repeat	,	O
(LTR)	DT	O
of	NN	O
the	VBN	O
Rous	IN	O
Sarcoma	DT	O
Virus,	JJ	O
as	JJ	O
described	NN	O
in	)	O
Gorman	IN	B
et	DT	I
al.,	NNP	I
Proc.	NNP	I
Natl.	,	I
Acad.	IN	I
Sci.	VBN	I
USA	IN	I
(1982b)	NNP	I
79:6777	CC	I
and	,	O
elements	.	O
derived	.	O
from	.	O
human	.	O
CMV,	NNP	O
as	)	O
described	CD	O
in	CC	O
Boshart	NNS	B
et	VBN	I
al.,	IN	I
Cell	JJ	I
(1985)	,	I
41:521,	IN	I
such	VBN	O
as	IN	O
elements	NNP	O
included	FW	O
in	,	O
the	NNP	O
CMV	)	O
intron	,	O
A	JJ	O
sequence	IN	O
Chapman	NNS	B
at	VBN	I
al.,	IN	I
Nuc.	DT	I
Acids	NNP	I
Res.	NN	I
(1991)	NNP	I
19:3979-3986).(	NN	O
The	NNP	O
desired	IN	O
synthetic	,	O
Gag	.	O
polypeptide	NNP	O
encoding	.	O
sequences	)	O
can	.	O
be	DT	O
cloned	VBN	O
into	JJ	O
any	NNP	O
number	NN	O
of	VBG	O
commercially	NNS	O
available	MD	O
vectors	VB	O
to	VBN	O
generate	IN	O
expression	DT	O
of	NN	O
the	IN	O
polypeptide	RB	O
in	JJ	O
an	NNS	O
appropriate	TO	O
host	VB	O
system.	NN	O
These	IN	O
systems	DT	O
include,	NN	O
but	IN	O
are	DT	O
not	JJ	O
limited	NN	O
to,	.	O
the	DT	O
following:	NNS	O
baculovirus	,	O
expression	CC	O
Reilly,	VBP	B
P.	RB	I
R.,	VBN	I
et	,	I
al.,	DT	I
BACULOVIRUS	:	I
EXPRESSION	JJ	I
VECTORS:	NN	I
A	,	I
LABORATORY	NNP	I
MANUAL	,	I
(1992);	FW	I
Beames,	,	B
et	NNP	I
al.,	NNP	I
Biotechniques	:	I
11:378	DT	I
(1991);	NNP	I
{Pharmingen;	NNP	O
Clontech,	:	O
Palo	,	O
Alto,	FW	O
Calif.)},	,	O
vaccinia	NNP	O
expression	CD	O
Earl,	:	B
P.	:	I
L.,	,	I
et	NNP	I
al.,	,	I
“Expression	,	I
of	JJ	I
proteins	NN	I
in	,	I
mammalian	NNP	I
cells	,	I
using	FW	I
vaccinia”	,	I
In	NN	I
Current	IN	I
Protocols	NNS	I
in	IN	I
Molecular	JJ	I
Biology	NNS	I
(F.	VBG	I
M.	NN	I
Ausubel,	IN	I
et	NNP	I
al.	NNP	I
Eds.),	IN	I
Greene	NNP	I
Publishing	NNP	I
Associates	NNP	I
&	NNP	I
Wiley	,	I
Interscience,	RB	I
New	.	I
York	,	I
(1991);	NNP	I
{Moss,	NNP	O
B.,	NNPS	O
et	CC	O
al.,	NNP	O
U.S.	,	O
Pat.	NNP	O
No.	NNP	O
5,135,855,	:	O
issued	,	O
4	,	O
Aug.	FW	O
1992},	,	O
expression	NNP	O
in	.	O
bacteria	.	O
Ausubel,	,	B
F.	VBD	I
M.,	CD	I
et	NNP	I
al.,	,	I
CURRENT	NN	I
PROTOCOLS	IN	I
IN	NNS	I
MOLECULAR	,	I
BIOLOGY,	NNP	I
John	,	I
Wiley	FW	I
and	,	I
Sons,	NNP	I
Inc.,	NNP	I
Media	NNP	I
PA;	NNP	I
Clontech},{	,	O
expression	NNP	O
in	NNP	O
yeast	CC	O
{Rosenberg,	,	O
S.	,	O
and	NNP	O
Tekamp-Olson,	:	O
P.,	,	O
U.S.	NN	O
Pat.	IN	O
No.	NN	O
RE35,749,	,	O
issued,	NNP	O
Mar.	CC	O
17,	,	O
1998,	,	O
herein	NNP	O
incorporated	.	O
by	.	O
reference;	,	O
Shuster,	,	O
J.	.	O
R.,	,	O
U.S.	,	O
Pat.	RB	O
No.	VBN	O
5,629,203,	IN	O
issued	:	O
May	,	O
13,	NNP	O
1997,	,	O
herein	NNP	O
incorporated	.	O
by	.	O
reference;	,	O
Gellissen,	VBN	B
G.,	NNP	I
et	,	I
al.,	,	I
Antonie	RB	I
Van	VBN	I
Leeuwenhoek,	IN	I
62(1-2):79-93	:	I
(1992);	,	I
Romanos,	,	B
M.	FW	I
A.,	,	I
at	NNP	I
al.,	NNP	I
Yeast	,	I
8(6):423-488	NN	I
(1992);	:	I
Goeddel,	,	B
D.	NNP	I
V.,	,	I
Methods	IN	I
in	,	I
Enzymology	NNP	I
185	NN	I
(1990);	:	I
Guthrie,	,	B
C.,	NNP	I
and	,	I
G.	NNP	I
R.	IN	I
Fink,	NNP	I
Methods	CD	I
in	:	I
Enzymology	,	I
194	,	I
(1991)},expression	CC	O
in	NNP	O
mammalian	NNP	O
cells	,	O
{Clontech;	NNP	O
Gibco-BRL,	IN	O
Ground	NNP	O
Island,	CD	O
N.	,	O
Y.;	NN	O
e.g.,	IN	O
Chinese	JJ	O
hamster	NNS	O
ovary	:	O
(CHO)	,	O
cell	NNP	O
lines	,	O
Haynes,	NNP	B
J.,	:	I
et	,	I
al.,	JJ	I
Nuc.	NN	I
Acid.	JJ	I
Res.	)	I
11:687-706	NN	I
(1983);	NNS	I
(1983,	,	O
Lau,	,	B
Y.	FW	I
F.,	,	I
et	.	I
al.,	.	I
Mol.	.	I
Cell.	CD	I
Biol.	:	I
4:1469-1475	,	I
(1984);	,	I
Kaufman,	NNP	B
R.	,	I
J.,	NN	I
“Selection	,	I
and	.	I
coamplification	.	I
of	.	I
heterologous	CD	I
genes	:	I
in	,	I
mammalian	NNP	I
cells,”	,	I
in	NN	I
Methods	CC	I
in	NN	I
Enzymology,	IN	I
vol.	JJ	I
185,	NNS	I
pp	IN	I
537-566.	JJ	I
Academic	NN	I
Press,	IN	I
Inc.,	NNP	I
San	IN	I
Diego	,	I
Calif.	.	I
(1991)},and	,	O
expression	JJ	O
in	.	O
plant	NNP	O
cells	,	O
{plant	,	O
cloning	NNP	O
vectors,	NNP	O
Clontech	NNP	O
Laboratories,	,	O
Inc.,	CC	O
Palo	NN	O
Alto,	IN	O
Calif.,	NN	O
and	NNS	O
Pharmacia	NN	O
LKB	VBG	O
Biotechnology,	,	O
Inc.,	NNP	O
Pistcataway,	,	O
N.J.;	,	O
Hood,	NNP	B
E.,	,	I
et	,	I
al.,	CC	I
J.	NNP	I
Bacteriol.	NNP	I
168:1291-1301	,	I
(1986);	,	I
Nagel,	,	B
R.,	:	I
et	,	I
al.,	,	I
FEMS	FW	I
Microbiol.	,	I
Lett.	NNP	I
67:325	.	I
(1990);	CD	I
An,	:	B
et	,	I
al.,	,	I
“Binary	FW	I
Vectors”,	,	I
and	NNP	I
others	.	I
in	.	I
Plant	CD	I
Molecular	:	I
Biology	,	I
Manual	NN	I
A3:1-19	,	I
(1988);	JJ	I
Miki,	,	B
B.	CC	I
L.	NNS	I
A.,	IN	I
et	NNP	I
al.,	NNP	I
pp.	NNP	I
249-265,	NNP	I
and	NNP	O
others	:	O
in	,	O
Plant	NNP	O
DNA	NNP	O
Infectious	,	O
Agents	FW	O
(Hohn,	,	B
T.,	.	I
et	,	I
al.,	CC	I
eds.)	NNS	I
Springer-Verlag,	IN	I
Wien,	NNP	I
Austria,	NNP	I
(1987);	NNP	I
Plant	NNP	B
Molecular	,	I
Biology:	,	I
Essential	FW	I
Techniques,	,	I
P.	)	I
G.	,	I
Jones	,	I
and	,	I
J.	:	I
M.	NNP	I
Sutton,	NNP	I
New	:	I
York,	JJ	I
J.	,	I
Wiley,	NNP	I
1997;	NNP	I
Miglani,	NNP	B
Gurbachan	CC	I
Dictionary	NNP	I
of	NNP	I
Plant	,	I
Genetics	NNP	I
and	,	I
Molecular	NNP	I
Biology,	,	I
New	:	I
York,	,	I
Food	NNP	I
Products	NNP	I
Press,	IN	I
1998;	NNP	I
Henry,	NNP	B
R.	CC	I
J.,	NNP	I
Practical	,	I
Applications	NNP	I
of	,	I
Plant	NNP	I
Molecular	NNP	I
Biology,	,	I
New	:	I
York,	,	I
Chapman	NNP	I
&	,	I
Hall,	NNP	I
1997}.Also	NNP	O
included	IN	O
in	NNP	O
the	NNP	O
invention	,	O
is	NNP	O
an	,	O
expression	NNP	O
vector,	CC	O
such	,	O
as	.	O
the	RB	O
CMV	VBN	O
promoter-containing	IN	O
vectors	DT	O
described	NN	O
in	VBZ	O
Example	DT	O
1,	NN	O
containing	,	O
coding	JJ	O
sequences	IN	O
and	DT	O
expression	NNP	O
control	JJ	O
elements	NNS	O
which	VBN	O
allow	IN	O
expression	NNP	O
of	,	O
the	VBG	O
coding	VBG	O
regions	NNS	O
in	CC	O
a	NN	O
suitable	NN	O
host.	VBZ	O
The	WDT	O
control	JJ	O
elements	NN	O
generally	IN	O
include	DT	O
a	NN	O
promoter,	NNS	O
translation	IN	O
initiation	DT	O
codon,	JJ	O
and	.	O
translation	DT	O
and	NN	O
transcription	VBZ	O
termination	RB	O
sequences,	VBP	O
and	DT	O
an	,	O
insertion	NN	O
site	NN	O
for	,	O
introducing	CC	O
the	NN	O
insert	CC	O
into	NN	O
the	NN	O
vector.	,	O
Translational	CC	O
control	DT	O
elements	NN	O
have	NN	O
been	IN	O
reviewed	VBG	O
by	DT	O
M.	NN	O
Kozak	IN	O
(e.g.,	DT	O
Kozak,	.	B
M.,	NNP	I
Mamm.	NN	I
Genome	NNS	I
7(8):563-574,	VBP	I
1996;	VBN	I
Kozak,	VBN	B
M.,	IN	I
Biochimie	NNP	I
76(9):815-821,	NNP	I
1994;	,	I
Kozak,	,	B
M.,	,	I
J	.	I
Cell	NNP	I
Biol	,	I
108(2):229-241,	:	I
1989;	,	I
Kozak,	,	B
M.,	NNP	I
and	,	I
Shatkin,	:	I
A.	,	I
J.,	,	I
Methods	NNP	I
Enzymol	NNP	I
60:360-375,	NNP	I
1979).Expression	,	O
in	:	O
yeast	,	O
systems	,	O
has	CC	O
the	,	O
advantage	NNP	O
of	,	O
commercial	NNP	O
production.	NNP	O
Recombinant	,	O
protein	.	O
production	NN	O
by	IN	O
vaccinia	NN	O
and	NNS	O
CHO	VBZ	O
cell	DT	O
line	NN	O
have	IN	O
the	JJ	O
advantage	.	O
of	JJ	O
being	NN	O
mammalian	NN	O
expression	IN	O
systems.	NN	O
Further,	CC	O
vaccinia	NNP	O
virus	VBP	O
expression	NN	O
has	VBP	O
several	DT	O
advantages	NN	O
including	IN	O
the	VBG	O
following:	JJ	O
(i)	NN	O
its	.	O
wide	,	O
host	FW	O
range;	NN	O
(ii)	NN	O
faithful	VBZ	O
post-transcriptional	JJ	O
modification,	NNS	O
processing,	VBG	O
folding,	DT	O
transport,	:	O
secretion,	)	O
and	PRP$	O
assembly	JJ	O
of	NN	O
recombinant	:	O
proteins;	)	O
(iii)	JJ	O
high	JJ	O
level	,	O
expression	,	O
of	,	O
relatively	,	O
soluble	,	O
recombinant	CC	O
proteins;	RB	O
and	IN	O
(iv)	JJ	O
a	:	O
large	)	O
capacity	JJ	O
to	NN	O
accommodate	NN	O
foreign	IN	O
DNA.	RB	O
The	JJ	O
recombinantly	JJ	O
expressed	:	O
polypeptides	CC	O
from	)	O
synthetic	DT	O
Gag-encoding	JJ	O
expression	NN	O
cassettes	TO	O
are	VB	O
typically	JJ	O
isolated	.	O
from	DT	O
lysed	RB	O
cells	VBN	O
or	NNS	O
culture	IN	O
media.	JJ	O
Purification	NNP	O
can	NN	O
be	NNS	O
carried	VBP	O
out	RB	O
by	VBN	O
methods	IN	O
known	JJ	O
in	NNS	O
the	CC	O
art	NN	O
including	.	O
salt	NN	O
fractionation,	MD	O
ion	VB	O
exchange	VBN	O
chromatography,	RP	O
gel	IN	O
filtration,	NNS	O
size-exclusion	VBN	O
chromatography,	IN	O
size-fractionation,	DT	O
and	NN	O
affinity	VBG	O
chromatography.	NN	O
Immunoaffinity	,	O
chromatography	NN	O
can	NN	O
be	,	O
employed	JJ	O
using	,	O
antibodies	NN	O
generated	,	O
based	,	O
on,	CC	O
for	NN	O
example,	.	O
Gag	NNP	O
antigens.	NN	O
Advantages	MD	O
of	VB	O
expressing	VBN	O
the	VBG	O
Gag-containing	NNS	O
proteins	VBD	O
of	VBN	O
the	,	O
present	IN	O
invention	,	O
using	NNP	O
mammalian	.	O
cells	NNS	O
include,	IN	O
but	VBG	O
are	DT	O
not	JJ	O
limited	NNS	O
to,	IN	O
the	DT	O
following:	JJ	O
well-established	NN	O
protocols	VBG	O
for	JJ	O
scale-up	NNS	O
production;	,	O
the	CC	O
ability	VBP	O
to	RB	O
produce	VBN	O
VLPs;	,	O
cell	DT	O
lines	:	O
are	JJ	O
suitable	NNS	O
to	IN	O
meet	JJ	O
good	:	O
manufacturing	DT	O
process	NN	O
(GMP)	TO	O
standards;	VB	O
culture	:	O
conditions	NN	O
for	NNS	O
mammalian	VBP	O
cells	JJ	O
are	TO	O
known	VB	O
in	JJ	O
the	NN	O
art.	NN	O
2.1.4	)	O
Modification	:	O
of	NN	O
HIV-1	NNS	O
Env	IN	O
Nucleic	JJ	O
Acid	NNS	O
Coding	VBP	O
Sequences	VBN	O
One	IN	O
aspect	DT	O
of	.	O
the	CD	O
present	NN	O
invention	IN	O
is	NNP	O
the	NNP	O
generation	NNP	O
of	NNP	O
HIV-1	NNP	O
Env	NNP	O
protein	NNP	O
coding	NN	O
sequences,	IN	O
and	DT	O
related	JJ	O
sequences,	NN	O
having	VBZ	O
improved	DT	O
expression	NN	O
relative	IN	O
to	NNP	O
the	NNP	O
corresponding	NN	O
wild-type	VBG	O
sequence.	,	O
Exemplary	CC	O
embodiments	JJ	O
of	,	O
the	VBG	O
present	VBN	O
invention	NN	O
are	NN	O
illustrated	TO	O
herein	DT	O
modifying	JJ	O
the	JJ	O
Env	.	O
protein	JJ	O
wild-type	NNS	O
sequences	IN	O
obtained	DT	O
from	JJ	O
the	NN	O
HIV-1	VBP	O
subtype	VBN	O
B	JJ	O
strains	VBG	O
HIV-1US4	DT	O
and	NNP	O
HIV-1SF162	NN	O
(Myers	JJ	O
et	NNS	O
al.,	VBN	O
Los	IN	O
Alamos	DT	O
Database,	NNP	O
Los	NN	O
Alamos	NNP	O
National	VBZ	O
Laboratory,	NNP	O
Los	CC	O
Alamos,	NNP	O
N.	NNP	O
Mex.	VBP	O
(1992);	,	O
Myers	NNP	O
et	NNP	O
al.,	,	O
Human	NNP	O
Retroviruses	NNP	O
and	NNP	O
Aids,	,	O
1997,	NNP	O
Los	,	O
Alamos,	NNP	O
N.	.	O
Mex.:	:	O
Los	NNP	O
Alamos	FW	O
National	,	O
Laboratory).	NNP	O
Env	NNP	O
sequence	CC	O
obtained	,	O
from	,	O
other	NNP	O
HIV	,	O
variants	.	O
may	:	O
be	NNP	O
manipulated	NNP	O
in	NNP	O
similar	.	O
fashion	NNP	O
following	NN	O
the	VBN	O
teachings	IN	O
of	JJ	O
the	NNP	O
present	NNS	O
specification.	MD	O
Such	VB	O
other	VBN	O
variants	IN	O
include	JJ	O
those	NN	O
described	VBG	O
above	DT	O
in	NNS	O
Section	IN	O
2.1.1	DT	O
and	JJ	O
on	.	O
the	JJ	O
World	JJ	O
Wide	NNS	O
Web	VBP	O
(Internet),	DT	O
for	VBN	O
example	IN	O
at	IN	O
http://hiv-web.lan1.gov/cgi-bin/hivDB3/public/wdb/ssampublic	NN	O
and	CD	O
http://hiv-web.lan1.gov.	CC	O
First,	IN	O
the	DT	O
HIV-1	NNP	O
codon	NNP	O
usage	NNP	O
pattern	,	O
was	IN	O
modified	NN	O
so	IN	O
that	JJ	O
the	CC	O
resulting	.	O
nucleic	,	O
acid	DT	O
coding	NNP	O
sequence	NN	O
was	NN	O
comparable	NN	O
to	VBD	O
codon	VBN	O
usage	RB	O
found	IN	O
in	DT	O
highly	VBG	O
expressed	JJ	O
human	NN	O
genes	VBG	O
(Example	NN	O
1).	VBD	O
The	JJ	O
HIV	TO	O
codon	VB	O
usage	NN	O
reflects	VBN	O
a	IN	O
high	RB	O
content	VBN	O
of	JJ	O
the	NNS	O
nucleotides	NNP	O
A	.	O
or	DT	O
T	NNP	O
of	NN	O
the	NN	O
codon-triplet.	VBZ	O
The	DT	O
effect	JJ	O
of	NN	O
the	IN	O
HIV-1	DT	O
codon	NNS	O
usage	NNP	O
is	CC	O
a	NNP	O
high	IN	O
AT	DT	O
content	.	O
in	DT	O
the	NN	O
DNA	IN	O
sequence	DT	O
that	NNP	O
results	NN	O
in	NN	O
a	VBZ	O
decreased	DT	O
translation	JJ	O
ability	NNP	O
and	NN	O
instability	IN	O
of	DT	O
the	NN	O
mRNA.	NN	O
In	WDT	O
comparison,	NNS	O
highly	IN	O
expressed	DT	O
human	JJ	O
codons	NN	O
prefer	NN	O
the	CC	O
nucleotides	NN	O
G	IN	O
or	DT	O
C.	.	O
The	IN	O
Env	,	O
coding	RB	O
sequences	VBN	O
were	JJ	O
modified	NNS	O
to	VBP	O
be	DT	O
comparable	NNS	O
to	NNP	O
codon	CC	O
usage	NNP	O
found	DT	O
in	NNP	O
highly	NN	O
expressed	NNS	O
human	VBD	O
genes.	VBN	O
Experiments	TO	O
performed	VB	O
in	JJ	O
support	TO	O
of	VB	O
the	NN	O
present	VBN	O
invention	IN	O
showed	RB	O
that	VBN	O
the	JJ	O
synthetic	.	O
Env	NNS	O
sequences	VBN	O
were	IN	O
capable	NN	O
of	IN	O
higher	DT	O
level	JJ	O
of	NN	O
protein	VBD	O
production	IN	O
(see	DT	O
the	JJ	O
Examples)	NNP	O
relative	NNS	O
to	VBD	O
the	JJ	O
native	IN	O
Env	JJR	O
sequences.	NN	O
One	IN	O
reason	JJ	O
for	NN	O
this	VB	O
increased	DT	O
production	)	O
may	VBP	O
be	TO	O
increased	DT	O
stability	JJ	O
of	NNP	O
the	.	O
mRNA	CD	O
corresponding	NN	O
to	IN	O
the	DT	O
synthetic	VBN	O
Env	NN	O
coding	MD	O
sequences	VB	O
versus	VBN	O
the	NN	O
mRNA	IN	O
corresponding	DT	O
to	NN	O
the	VBG	O
native	TO	O
Env	DT	O
coding	JJ	O
sequences.	NNP	O
Modification	NN	O
of	NNS	O
the	VBP	O
Env	DT	O
polypeptide	NN	O
coding	VBG	O
sequences	TO	O
resulted	DT	O
in	JJ	O
improved	NNP	O
expression	NN	O
relative	.	O
to	NN	O
the	IN	O
wild-type	DT	O
coding	NNP	O
sequences	NN	O
in	VBG	O
a	NNS	O
number	VBD	O
of	IN	O
mammalian	JJ	O
cell	NN	O
lines.	NN	O
Similar	TO	O
Env	DT	O
polypeptide	JJ	O
coding	NN	O
sequences	NNS	O
can	IN	O
be	DT	O
obtained	NN	O
from	IN	O
a	JJ	O
variety	NN	O
of	.	O
isolates	JJ	O
(families,	NNP	O
sub-types,	NN	O
etc.).	VBG	O
Env	NNS	O
polypeptide	MD	O
encoding	VB	O
sequences	VBN	O
derived	IN	O
from	DT	O
these	NN	O
variants	IN	O
can	NNS	O
be	,	O
optimized	,	O
and	.	O
tested	NNP	O
for	NN	O
improved	VBG	O
expression	NNS	O
in	VBN	O
mammals	IN	O
by	DT	O
following	NNS	O
the	MD	O
teachings	VB	O
of	VBN	O
the	CC	O
present	VBN	O
specification	IN	O
(see	JJ	O
the	NN	O
Examples,	IN	O
in	NNS	O
particular	IN	O
Example	VBG	O
2).	DT	O
2.1.5	NNS	O
Further	IN	O
Modification	DT	O
of	JJ	O
HIV-1	NN	O
Env	VB	O
Nucleic	DT	O
Acid	,	O
Coding	IN	O
Sequences	JJ	O
In	NNP	O
addition	.	O
to	CD	O
proteins	JJ	O
containing	NN	O
HIV-related	IN	O
sequences,	NNP	O
the	NNP	O
Env	NNP	O
encoding	NNP	O
sequences	NNP	O
of	NNPS	O
the	IN	O
present	NN	O
invention	TO	O
can	NNS	O
be	VBG	O
fused	JJ	O
to	,	O
other	DT	O
polypeptides	NNP	O
(creating	VBG	O
chimeric	NNS	O
polypeptides).	IN	O
Also,	DT	O
variations	JJ	O
on	NN	O
the	MD	O
orientation	VB	O
of	VBN	O
the	TO	O
Env	JJ	O
and	NNS	O
other	VBG	O
coding	RB	O
sequences,	.	O
relative	,	O
to	NNS	O
each	IN	O
other,	DT	O
are	NN	O
contemplated.	IN	O
Further,	DT	O
the	NNP	O
HIV	CC	O
protein	JJ	O
encoding	NN	O
cassettes	,	O
of	JJ	O
the	TO	O
present	DT	O
invention	,	O
can	VBP	O
be	.	O
co-expressed	,	O
using	DT	O
one	NNP	O
vector	NN	O
or	VBG	O
multiple	NNS	O
vectors.	IN	O
In	DT	O
addition,	JJ	O
the	NN	O
polyproteins	MD	O
can	VB	O
be	JJ	O
operably	VBG	O
linked	CD	O
to	NN	O
the	CC	O
same	JJ	O
or	.	O
different	IN	O
promoters.	,	O
Env	DT	O
polypeptide	NNS	O
coding	MD	O
sequences	VB	O
can	RB	O
be	VBN	O
obtained	TO	O
from	DT	O
any	JJ	O
HIV	CC	O
isolates	JJ	O
(different	.	O
families,	NNP	O
subtypes,	NN	O
and	VBG	O
strains)	NNS	O
including	MD	O
but	VB	O
not	VBN	O
limited	IN	O
to	DT	O
the	NNP	O
isolates	NNS	O
HIVIIIb,	JJ	O
HIVSF2,	,	O
HIVus4,	,	O
HIVCM235,	CC	O
HIVSF162,	)	O
HIVLAV,	VBG	O
HIVLAI,	CC	O
HIVMN)	RB	O
(see,	JJ	O
e.g.,	TO	O
Myers	DT	O
et	NNS	O
al.,	,	O
Los	,	O
Alamos	,	O
Database,	,	O
Los	,	O
Alamos	,	O
National	,	O
Laboratory,	)	O
Los	,	O
Alamos,	,	O
N.	NNP	O
Mex.	VBP	O
(1992);	,	O
Myers	NNP	O
et	NNP	O
al.,	,	O
Human	NNP	O
Retroviruses	NNP	O
and	NNP	O
Aids,	,	O
1997,	NNP	O
Los	,	O
Alamos,	NNP	O
N.	.	O
Mex.:	:	O
Los	NNP	O
Alamos	FW	O
National	,	O
Laboratory).	NNP	O
Synthetic	NNP	O
expression	CC	O
cassettes	,	O
can	,	O
be	NNP	O
generated	,	O
using	.	O
such	:	O
coding	NNP	O
sequences	NNP	O
as	NNP	O
starting	.	O
material	JJ	O
by	NN	O
following	NNS	O
the	MD	O
teachings	VB	O
of	VBN	O
the	VBG	O
present	JJ	O
specification	JJ	O
(e.g.,	NNS	O
see	IN	O
Example	VBG	O
1).	NN	O
Further,	IN	O
the	VBG	O
synthetic	DT	O
expression	NNS	O
cassettes	IN	O
(and	DT	O
purified	JJ	O
polynucleotides)	NN	O
of	,	O
the	VBP	O
present	JJ	O
invention	.	O
include	,	O
related	DT	O
Env	JJ	O
polypeptide	NN	O
coding	NNS	O
sequences	CC	O
having	VBN	O
greater	)	O
than	IN	O
90%	DT	O
,	JJ	O
preferably	NN	O
greater	VBP	O
than	VBN	O
92%	NNP	O
,	IN	O
more	VBG	O
preferably	NNS	O
greater	VBG	O
than	JJR	O
95%	IN	O
,	NN	O
and	,	O
most	RB	O
preferably	JJR	O
greater	IN	O
than	NN	O
98%	,	O
sequence	JJR	O
identity	RB	O
to	JJR	O
the	IN	O
synthetic	NN	O
expression	,	O
cassette	CC	O
sequences	JJS	O
disclosed	RB	O
herein	JJR	O
(for	IN	O
example,	NN	O
SEQ	NN	O
ID	NN	O
NOs:71-72;	TO	O
and/or	DT	O
the	JJ	O
sequences	NN	O
presented	NN	O
in	NNS	O
Tables	VBD	O
1A	NN	O
and	IN	O
1B)	,	O
when	NNP	O
the	NNP	O
sequences	:	O
of	VBZ	O
the	DT	O
present	NNS	O
invention	VBN	O
are	IN	O
used	NNP	O
as	CD	O
the	CC	O
query	)	O
sequence.	WRB	O
2.1.6	DT	O
Expression	NNS	O
of	IN	O
Synthetic	DT	O
Sequences	JJ	O
Encoding	NN	O
HIV-1	VBP	O
Env	VBN	O
and	IN	O
Related	DT	O
Polypeptides	NN	O
Several	.	O
synthetic	CD	O
Env-encoding	NN	O
sequences	IN	O
(expression	JJ	O
cassettes)	NNS	O
of	VBG	O
the	NNP	O
present	NNP	O
invention	CC	O
were	NNP	O
cloned	NNP	O
into	NNP	O
a	JJ	O
number	JJ	O
of	NNS	O
different	NN	O
expression	)	O
vectors	IN	O
(Example	DT	O
1)	JJ	O
to	NN	O
evaluate	VBD	O
levels	VBN	O
of	IN	O
expression	DT	O
and	NN	O
production	IN	O
of	JJ	O
Env	NN	O
polypeptide.	NNS	O
A	NNP	O
modified	)	O
synthetic	TO	O
coding	VB	O
sequence	NNS	O
is	IN	O
presented	NN	O
as	CC	O
synthetic	NN	O
Env	IN	O
expression	NNP	O
cassettes	.	O
(Example	DT	O
1,	VBN	O
e.g.,	JJ	O
Tables	NN	O
1A	NN	O
and	VBZ	O
1B).	VBN	O
The	IN	O
synthetic	JJ	O
DNA	NNP	O
fragments	NN	O
for	NNS	O
Env	JJ	O
were	,	O
cloned	,	O
into	VBZ	O
eucaryotic	CD	O
expression	CC	O
vectors	.	O
described	DT	O
in	JJ	O
Example	NN	O
1	NNS	O
and	IN	O
in	NNP	O
Section	VBD	O
2.1.3	VBN	O
above,	IN	O
including,	JJ	O
a	NN	O
transient	NNS	O
expression	VBD	O
vector	IN	O
and	NNP	O
CMV-promoter-based	CD	O
mammalian	CC	O
vectors.	IN	O
Corresponding	NNP	O
wild-type	CD	O
sequences	,	O
were	,	O
cloned	DT	O
into	JJ	O
the	NN	O
same	NN	O
vectors.	CC	O
These	JJ	O
vectors	JJ	O
were	.	O
then	VBG	O
transfected	JJ	O
into	NNS	O
a	VBD	O
several	VBN	O
different	IN	O
cell	DT	O
types,	JJ	O
including	.	O
a	DT	O
variety	NNS	O
of	VBD	O
mammalian	RB	O
cell	VBN	O
lines,	IN	O
(293,	DT	O
RD,	JJ	O
COS-7,	JJ	O
and	NN	O
CHO,	,	O
cell	VBG	O
lines	DT	O
available,	NN	O
for	IN	O
example,	JJ	O
from	NN	O
the	,	O
A.T.C.C.).	,	O
The	,	O
cell	,	O
lines	CC	O
were	,	O
cultured	NN	O
under	NNS	O
appropriate	,	O
conditions	IN	O
and	,	O
the	IN	O
levels	DT	O
of	.	O
gp120,	DT	O
gp140	NN	O
and	NNS	O
gp160	VBD	O
Env	VBN	O
expression	IN	O
in	JJ	O
supernatants	NNS	O
were	CC	O
evaluated	DT	O
(Example	NNS	O
2).	IN	O
Env	,	O
polypeptides	NN	O
include,	CC	O
but	NN	O
are	NNP	O
not	NN	O
limited	IN	O
to,	NNS	O
for	VBD	O
example,	VBN	O
native	NNP	O
gp160,	.	O
oligomeric	NNP	O
gp140,	NNS	O
monomeric	,	O
gp120	CC	O
as	VBP	O
well	RB	O
as	VBN	O
modified	,	O
sequences	IN	O
of	,	O
these	JJ	O
polypeptides.	,	O
The	JJ	O
results	,	O
of	JJ	O
these	NN	O
assays	RB	O
demonstrated	RB	O
that	IN	O
expression	JJ	O
of	NNS	O
synthetic	IN	O
Env	DT	O
encoding	.	O
sequences	DT	O
were	NNS	O
significantly	IN	O
higher	DT	O
than	NNS	O
corresponding	VBD	O
wild-type	IN	O
sequences	NN	O
(Example	IN	O
2;	JJ	O
Tables	NNP	O
3	VBG	O
and	NNS	O
4).	VBD	O
Further,	RB	O
Western	JJR	O
Blot	IN	O
analysis	VBG	O
showed	JJ	O
that	NNS	O
cells	JJ	O
containing	:	O
the	NNP	O
synthetic	CD	O
Env	CC	O
expression	.	O
cassette	,	O
produced	JJ	O
the	NNP	O
expected	NN	O
protein	VBD	O
(gp120,	IN	O
gp140	NNS	O
or	VBG	O
gp160)	DT	O
at	JJ	O
higher	NNP	O
per-cell	NN	O
concentrations	NN	O
than	VBD	O
cells	DT	O
containing	VBN	O
the	NN	O
native	,	O
expression	NN	O
cassette.	CC	O
The	)	O
Env	IN	O
proteins	JJR	O
were	NN	O
seen	NNS	O
in	IN	O
both	NNS	O
cell	VBG	O
lysates	DT	O
and	JJ	O
supernatants.	NN	O
The	.	O
levels	DT	O
of	NNP	O
production	NNS	O
were	VBD	O
significantly	VBN	O
higher	IN	O
in	DT	O
cell	NN	O
supernatants	NNS	O
for	CC	O
cells	.	O
transfected	DT	O
with	NNS	O
the	IN	O
synthetic	NN	O
Env	VBD	O
expression	RB	O
cassettes	JJR	O
of	IN	O
the	NN	O
present	NNS	O
invention	IN	O
as	NNS	O
compared	VBN	O
to	IN	O
wild	DT	O
type.	JJ	O
Fractionation	NNP	O
of	NN	O
the	NNS	O
supernatants	IN	O
from	DT	O
mammalian	JJ	O
cells	NN	O
transfected	IN	O
with	VBN	O
the	TO	O
synthetic	VB	O
Env	.	O
expression	NN	O
cassettes	IN	O
showed	DT	O
that	NNS	O
it	IN	O
provides	JJ	O
superior	NNS	O
production	VBN	O
of	IN	O
Env	DT	O
proteins,	JJ	O
relative	NNP	O
to	NN	O
the	NNS	O
wild-type	VBD	O
Env	IN	O
sequences	PRP	O
(Examples	VBZ	O
2	JJ	O
and	NN	O
3).	IN	O
Efficient	NNP	O
expression	,	O
of	JJ	O
these	TO	O
Env-containing	DT	O
polypeptides	JJ	O
in	NNP	O
mammalian	NNS	O
cell	NNP	O
lines	CD	O
provides	CC	O
the	.	O
following	JJ	O
benefits:	NN	O
the	IN	O
Env	DT	O
polypeptides	NNP	O
are	NNS	O
free	IN	O
of	JJ	O
baculovirus	NN	O
or	NNS	O
other	VBZ	O
viral	DT	O
contaminants;	JJ	O
production	:	O
by	DT	O
established	NNP	O
methods	NNS	O
approved	VBP	O
by	JJ	O
the	IN	O
FDA;	NN	O
increased	CC	O
purity;	JJ	O
greater	JJ	O
yields	:	O
(relative	NN	O
to	IN	O
native	VBN	O
coding	NNS	O
sequences);	VBN	O
and	IN	O
a	DT	O
novel	:	O
method	VBD	O
of	:	O
producing	JJR	O
the	NNS	O
Env-containing	JJ	O
polypeptides	TO	O
in	JJ	O
CHO	NN	O
cells	:	O
which	CC	O
is	DT	O
less	JJ	O
feasible	NN	O
in	IN	O
the	VBG	O
absence	DT	O
of	JJ	O
the	NNS	O
increased	IN	O
expression	NNP	O
obtained	NNS	O
using	WDT	O
the	VBZ	O
constructs	RBR	O
of	JJ	O
the	IN	O
present	DT	O
invention.	NN	O
Exemplary	IN	O
cell	DT	O
lines	VBN	O
(e.g.,	NN	O
mammalian,	VBN	O
yeast,	VBG	O
insect,	DT	O
etc.)	NNS	O
include	IN	O
those	DT	O
described	JJ	O
above	.	O
in	NNP	O
Section	NN	O
2.1.3	NNS	O
for	,	O
Gag-containing	,	O
constructs.	,	O
Further,	,	O
appropriate	)	O
vectors	VBP	O
and	DT	O
control	VBN	O
elements	IN	O
(e.g.,	IN	O
promoters,	NN	O
enhancers,	CD	O
polyadenylation	IN	O
sequences,	JJ	O
etc.)	.	O
for	,	O
any	JJ	O
given	NNS	O
cell	CC	O
type	NN	O
can	NNS	O
be	,	O
selected,	,	O
as	,	O
described	NN	O
above	,	O
in	)	O
Section	IN	O
2.1.3,	DT	O
by	VBN	O
one	NN	O
having	NN	O
ordinary	MD	O
skill	VB	O
in	,	O
the	IN	O
art	VBN	O
in	IN	O
view	IN	O
of	NN	O
the	,	O
teachings	IN	O
of	CD	O
the	VBG	O
present	JJ	O
specification	NN	O
and	IN	O
information	DT	O
known	NN	O
in	IN	O
the	NN	O
art	IN	O
about	DT	O
expression	NNS	O
vectors.	IN	O
In	DT	O
addition,	JJ	O
the	NN	O
recombinantly	CC	O
expressed	NN	O
polypeptides	VBN	O
from	IN	O
synthetic	DT	O
Env-encoding	NN	O
expression	IN	O
cassettes	NN	O
are	.	O
typically	IN	O
isolated	,	O
and	DT	O
purified	RB	O
from	VBN	O
lysed	NNS	O
cells	IN	O
or	JJ	O
culture	JJ	O
media,	NN	O
as	NNS	O
described	VBP	O
above	RB	O
for	JJ	O
Gag-encoding	CC	O
expression	VBN	O
cassettes.	IN	O
An	JJ	O
exemplary	NNS	O
purification	CC	O
is	NN	O
described	,	O
in	IN	O
Example	VBN	O
4	IN	O
and	IN	O
shown	NNP	O
in	NN	O
FIG.	.	O
60.	DT	O
2.1.7	JJ	O
Modification	NN	O
of	VBZ	O
HIV-1	VBN	O
Tat	IN	O
Nucleic	NNP	O
Acid	CD	O
Coding	CC	O
Sequences	VBN	O
Another	IN	O
aspect	.	O
of	.	O
the	CD	O
present	NN	O
invention	IN	O
is	NNP	O
the	NNP	O
generation	NNP	O
of	NNP	O
HIV-1	NNP	O
tat	NNP	O
protein	DT	O
coding	NN	O
sequences,	IN	O
and	DT	O
related	JJ	O
sequences,	NN	O
having	VBZ	O
improved	DT	O
expression	NN	O
relative	IN	O
to	NNP	O
the	NN	O
corresponding	NN	O
wild-type	VBG	O
sequence.	,	O
Exemplary	CC	O
embodiments	JJ	O
of	,	O
the	VBG	O
present	VBN	O
invention	NN	O
are	NN	O
illustrated	TO	O
herein	DT	O
modifying	JJ	O
the	JJ	O
tat	.	O
wild-type	JJ	O
nucleotide	NNS	O
sequence	IN	O
(SEQ	DT	O
ID	JJ	O
NO:85,	NN	O
FIG.	VBP	O
76)	VBN	O
obtained	JJ	O
from	VBG	O
SF162	DT	O
as	JJ	O
described	JJ	O
above.	JJ	O
Exemplary	NN	O
synthetic	NNP	O
tat	NNP	O
constructs	,	O
are	.	O
shown	)	O
in	VBN	O
SEQ	IN	O
ID	NNP	O
NO:87,	IN	O
which	VBN	O
depicts	.	O
a	NNP	O
tat	JJ	O
construct	NN	O
encoding	NNS	O
a	VBP	O
full-length	VBN	O
tat	IN	O
polypeptide	NNP	O
from	NNP	O
strain	,	O
SF162;	WDT	O
SEQ	VBZ	O
ID	DT	O
NO:88,	JJ	O
which	NN	O
depicts	VBG	O
a	DT	O
tat	JJ	O
construct	NN	O
encoding	NN	O
a	IN	O
tat	NN	O
polypeptide	:	O
having	NNP	O
the	NNP	O
cystein	,	O
residue	WDT	O
at	VBZ	O
position	DT	O
22	JJ	O
changed;	NN	O
and	VBG	O
SEQ	DT	O
ID	NN	O
NO:89,	NN	O
which	VBG	O
depicts	DT	O
a	NN	O
tat	NN	O
construct	IN	O
encoding	NN	O
the	CD	O
amino	:	O
terminal	CC	O
portion	NNP	O
of	NNP	O
a	,	O
tat	WDT	O
polypeptide	VBZ	O
from	DT	O
strain	JJ	O
SF162.	NN	O
The	VBG	O
amino	DT	O
portion	JJ	O
of	JJ	O
the	NN	O
tat	IN	O
protein	DT	O
appears	JJ	O
to	NN	O
contain	IN	O
many	NN	O
of	.	O
the	DT	O
epitopes	JJ	O
that	NN	O
induce	IN	O
an	DT	O
immune	NN	O
response.	NN	O
In	VBZ	O
addition,	TO	O
further	VB	O
modifications	JJ	O
include	IN	O
replacement	DT	O
or	NNS	O
deletion	WDT	O
of	VBP	O
the	DT	O
cystein	JJ	O
residue	.	O
at	IN	O
position	,	O
22,	JJ	O
for	NNS	O
example	VBP	O
with	NN	O
a	CC	O
valine	NN	O
residue,	IN	O
an	DT	O
alanine	NN	O
residue	NN	O
or	IN	O
a	NN	O
glycine	,	O
residue	IN	O
(SEQ	NN	O
ID	IN	O
Nos:	DT	O
88	NN	O
and	,	O
89,	DT	O
FIGS.	NN	O
79	NN	O
and	CC	O
81),	DT	O
see,	NN	O
e.g.,	NN	O
Caputo	NNP	B
et	NNP	I
al.	:	I
(1996)	CD	I
Gene	CC	I
Ther.	,	I
3:235.	.	I
In	CD	O
FIG.	CC	O
81,	,	O
which	,	O
depicts	,	O
a	NNP	O
tat	CC	O
construct	.	O
encoding	)	O
the	NNP	O
amino	.	O
terminal	.	O
portion	IN	O
of	.	O
a	,	O
tat	WDT	O
polypeptide,	VBZ	O
the	DT	O
nucleotides	JJ	O
(nucleotides	NN	O
64-66)	VBG	O
encoding	DT	O
the	JJ	O
cystein	JJ	O
residues	NN	O
are	IN	O
underlined.	DT	O
The	JJ	O
design	,	O
and	DT	O
construction	NNS	O
of	IN	O
suitable	)	O
construct	VBG	O
can	DT	O
be	NN	O
readily	NNS	O
done	VBP	O
using	.	O
the	DT	O
teachings	NN	O
of	CC	O
the	NN	O
present	IN	O
specification.	JJ	O
As	NN	O
with	MD	O
Gag,	VB	O
pol,	RB	O
prot	VBN	O
and	VBG	O
Env,	DT	O
tat	NNS	O
polypeptide	IN	O
coding	DT	O
sequences	JJ	O
can	.	O
be	IN	O
obtained	IN	O
from	,	O
a	,	O
variety	NN	O
of	CC	O
isolates	,	O
(families,	JJ	O
sub-types,	IN	O
etc.).	VBG	O
Modification	NNS	O
of	MD	O
the	VB	O
tat	VBN	O
polypeptide	IN	O
coding	DT	O
sequences	NN	O
result	IN	O
in	NNS	O
improved	,	O
expression	,	O
relative	.	O
to	NN	O
the	IN	O
wild-type	DT	O
coding	NN	O
sequences	IN	O
in	VBG	O
a	NNS	O
number	NN	O
of	IN	O
cell	JJ	O
lines	NN	O
(e.g.,	NN	O
mammalian,	TO	O
yeast,	DT	O
bacterial	JJ	O
and	NN	O
insect	NNS	O
cells).	IN	O
Tat	DT	O
polypeptide	NN	O
encoding	IN	O
sequences	NN	O
derived	NNS	O
from	,	O
these	,	O
variants	,	O
can	JJ	O
be	CC	O
optimized	JJ	O
and	.	O
tested	NNP	O
for	NN	O
improved	VBG	O
expression	NNS	O
in	VBN	O
mammals	IN	O
by	DT	O
following	NNS	O
the	MD	O
teachings	VB	O
of	VBN	O
the	CC	O
present	VBN	O
specification	IN	O
(see	JJ	O
the	NN	O
Examples,	IN	O
in	NNS	O
particular	IN	O
Example	VBG	O
2).	DT	O
Various	NNS	O
forms	IN	O
of	DT	O
the	JJ	O
different	NN	O
embodiments	VB	O
of	DT	O
the	,	O
invention,	IN	O
described	JJ	O
herein,	NNP	O
may	.	O
be	JJ	O
combined.	NNS	O
For	IN	O
example,	DT	O
polynucleotides	JJ	O
may	NNS	O
be	IN	O
derived	DT	O
from	,	O
the	VBN	O
polynucleotide	,	O
sequences	MD	O
of	VB	O
the	.	O
present	IN	O
invention,	,	O
including,	NNS	O
but	MD	O
not	VB	O
limited	VBN	O
to,	IN	O
coding	DT	O
sequences	JJ	O
for	NNS	O
Gag	IN	O
polypeptides,	DT	O
Env	JJ	O
polypeptides,	,	O
polymerase	,	O
polypeptides,	CC	O
protease	RB	O
polypeptides,	JJ	O
tat	,	O
polypeptides,	VBG	O
and	NNS	O
reverse	IN	O
transcriptase	NNP	O
polypeptides.	,	O
Further,	NNP	O
the	,	O
polynucleotide	NN	O
coding	,	O
sequences	NN	O
of	,	O
the	NN	O
present	,	O
invention	CC	O
may	VB	O
be	NN	O
combined	.	O
into	,	O
multi-cistronic	DT	O
expression	NN	O
cassettes	VBG	O
where	NNS	O
typically	IN	O
each	DT	O
coding	JJ	O
sequence	NN	O
for	MD	O
each	VB	O
polypeptide	VBN	O
is	IN	O
preceded	JJ	O
by	NN	O
IRES	NNS	O
sequences.	WRB	O
2.2	RB	O
Production	DT	O
of	VBG	O
Virus-Like	NN	O
Particles	IN	O
and	DT	O
Use	NN	O
of	VBZ	O
the	VBN	O
Constructs	IN	O
of	NNP	O
the	.	O
Present	CD	O
Invention	NN	O
to	IN	O
Create	NNP	O
Packaging	NNP	O
Cell	CC	O
Lines	NNP	O
The	IN	O
group-specific	DT	O
antigens	NNP	O
(Gag)	IN	O
of	DT	O
human	JJ	O
immunodeficiency	NNP	O
virus	TO	O
type-1	VB	O
(HIV-1)	NNP	O
self-assemble	NNP	O
into	VBZ	O
noninfectious	DT	O
virus-like	JJ	O
particles	NNS	O
(VLP)	)	O
that	IN	O
are	JJ	O
released	NN	O
from	NN	O
various	NN	O
eucaryotic	)	O
cells	JJ	O
by	IN	O
budding	JJ	O
(reviewed	JJ	O
by	NNS	O
Freed,	)	B
E.	WDT	I
O.,	VBP	I
Virology	VBN	I
251:1-15,	IN	I
1998).The	JJ	O
synthetic	JJ	O
expression	NNS	O
cassettes	IN	O
of	VBG	O
the	VBN	O
present	IN	O
invention	,	O
provide	NNP	O
efficient	,	O
means	NNP	O
for	,	O
the	.	O
production	DT	O
of	JJ	O
HIV-Gag	NN	O
virus-like	NNS	O
particles	IN	O
(VLPs)	DT	O
using	JJ	O
a	NN	O
variety	VBP	O
of	NN	O
different	NNS	O
cell	IN	O
types,	DT	O
including,	NN	O
but	IN	O
not	NNP	O
limited	JJ	O
to,	NNS	O
mammalian	)	O
cells.	VBG	O
Viral	DT	O
particles	NN	O
can	IN	O
be	JJ	O
used	NN	O
as	,	O
a	,	O
matrix	CC	O
for	RB	O
the	JJ	O
proper	,	O
presentation	JJ	O
of	.	O
an	JJ	O
antigen	NNS	O
entrapped	MD	O
or	VB	O
associated	VBN	O
therewith	IN	O
to	DT	O
the	NN	O
immune	IN	O
system	DT	O
of	JJ	O
the	NN	O
host.	IN	O
For	DT	O
example,	NN	O
U.S.	VBD	O
Pat.	CC	O
No.	VBN	O
4,722,840	NN	O
describes	TO	O
hybrid	DT	O
particles	JJ	O
comprised	NN	O
of	IN	O
a	DT	O
particle-forming	.	O
fragment	IN	O
of	,	O
a	NNP	O
structural	.	O
protein	.	O
from	CD	O
a	NNS	O
virus,	JJ	O
such	NNS	O
as	VBN	O
a	IN	O
particle-forming	DT	O
fragment	JJ	O
of	NN	O
hepatitis	IN	O
B	DT	O
virus	JJ	O
(HBV)	NN	O
surface	IN	O
antigen	DT	O
(HBsAg),	,	O
fused	JJ	O
to	IN	O
a	DT	O
heterologous	JJ	O
polypeptide.	NN	O
Tindle	IN	B
et	NN	I
al.,	NNP	I
Virology	NN	I
(1994)	)	I
200:547-557,	NN	I
describes	NN	O
the	,	O
production	VBN	O
and	TO	O
use	DT	O
of	JJ	O
chimeric	.	O
HBV	NNP	O
core	CC	O
antigen	,	O
particles	NNP	O
containing	)	O
epitopes	,	O
of	VBZ	O
human	DT	O
papillomavirus	NN	O
(HPV)	CC	O
type	NN	O
16	IN	O
E7	JJ	O
transforming	NNP	O
protein.	NN	O
Adams	NN	B
et	NNS	I
al.,	VBG	I
Nature	NNS	I
(1987)	IN	I
329:68-70,	JJ	I
describes	NN	O
the	)	O
recombinant	VBD	O
production	CD	O
of	NNP	O
hybrid	VBG	O
HIVgp120:Ty	.	O
VLPs	NNP	O
in	CC	O
yeast	,	O
and	NNP	O
Brown	)	O
et	,	O
al.,	VBZ	O
Virology	DT	B
(1994)	JJ	I
198:477-488,	NN	I
the	IN	O
production	JJ	O
of	NNP	O
chimeric	NNP	O
proteins	IN	O
consisting	NN	O
of	CC	O
the	NNP	O
VP2	FW	O
protein	,	O
of	NNP	O
human	)	O
parvovirus	,	O
B19	DT	O
and	NN	O
epitopes	IN	O
from	JJ	O
human	NNS	O
herpes	VBG	O
simplex	IN	O
virus	DT	O
type	NNP	O
1,	NN	O
as	IN	O
well	JJ	O
as	NN	O
mouse	NNP	O
hepatitis	CC	O
virus	NNS	O
A59.	IN	O
Wagner	JJ	B
et	NNS	I
al.,	JJ	I
(Virology	NN	I
(1994)	NN	I
200:162-175,	,	I
Brand	RB	B
et	RB	I
al.,	IN	I
J.	NN	I
Virol.	NN	I
Meth.	NN	I
(1995)	.	I
51:153-168;	NNP	I
Virology	CC	B
(1996)	,	I
220:128-140)	NNP	I
and	)	O
Wolf,	,	O
et	NNP	O
al.,	FW	O
(EP	,	O
0	NNP	O
449	.	O
116	.	O
A1,	)	O
published	:	O
2	NNP	O
Oct.	)	O
1991;	)	O
WO	CC	O
96/30523,	,	O
published	FW	O
3	,	O
Oct.	NNP	O
1996)	CD	O
describe	CD	O
the	CD	O
assembly	,	O
of	VBD	O
chimeric	CD	O
HIV-1	NNP	O
p55Gag	:	O
particles.	NNP	O
U.S.	,	O
Pat.	VBD	O
No.	CD	O
5,503,833	NNP	O
describes	)	O
the	VB	O
use	DT	O
of	NN	O
rotavirus	IN	O
VP6	JJ	O
spheres	NNP	O
for	NN	O
encapsulating	.	O
and	NNP	O
delivering	.	O
therapeutic	.	O
agents.	CD	O
2.2.1	VBZ	O
VLP	DT	O
Production	NN	O
Using	IN	O
the	NN	O
Synthetic	NNP	O
Expression	VBZ	O
Cassettes	IN	O
of	VBG	O
the	CC	O
Present	VBG	O
Invention	JJ	O
Experiments	.	O
performed	CD	O
in	NNP	O
support	NNP	O
of	VBG	O
the	DT	O
present	JJ	O
invention	NNP	O
have	NNP	O
demonstrated	IN	O
that	DT	O
the	JJ	O
synthetic	NNP	O
expression	NNP	O
cassettes	VBD	O
of	IN	O
the	NN	O
present	IN	O
invention	DT	O
provide	JJ	O
superior	NN	O
production	VBP	O
of	VBN	O
both	IN	O
protein	DT	O
and	JJ	O
VLPs,	NN	O
relative	NNS	O
to	IN	O
native	DT	O
coding	JJ	O
sequences	NN	O
(Examples	NN	O
7	JJ	O
and	NN	O
15).	IN	O
Further,	DT	O
electron	NN	O
microscopic	CC	O
evaluation	,	O
of	JJ	O
VLP	TO	O
production	JJ	O
(Examples	NN	O
6	NNS	O
and	NNP	O
15,	CD	O
FIGS.	CC	O
3A-B	.	O
and	,	O
65A-F)	FW	O
showed	FW	O
that	NN	O
free	IN	O
and	NNP	O
budding	NN	O
immature	NNP	O
virus	CD	O
particles	CC	O
of	,	O
the	.	O
expected	JJ	O
size	CC	O
were	)	O
produced	VBD	O
by	IN	O
cells	JJ	O
containing	CC	O
the	JJ	O
synthetic	NN	O
expression	NN	O
cassettes.	NNS	O
Using	IN	O
the	DT	O
synthetic	JJ	O
expression	NN	O
cassettes	VBD	O
of	VBN	O
the	IN	O
present	NNS	O
invention,	VBG	O
rather	DT	O
than	JJ	O
native	NN	O
coding	.	O
sequences,	VBG	O
for	DT	O
the	JJ	O
production	NN	O
of	NNS	O
virus-like	IN	O
particles	DT	O
provide	JJ	O
several	,	O
advantages.	RB	O
First,	IN	O
VLPs	JJ	O
can	NN	O
be	,	O
produced	IN	O
in	DT	O
enhanced	NN	O
quantity	IN	O
making	JJ	O
isolation	NNS	O
and	IN	O
purification	JJ	O
of	.	O
the	,	O
VLPs	NNP	O
easier.	MD	O
Second,	VB	O
VLPs	VBN	O
can	IN	O
be	JJ	O
produced	NN	O
in	VBG	O
a	NN	O
variety	CC	O
of	NN	O
cell	IN	O
types	DT	O
using	NNP	O
the	.	O
synthetic	,	O
expression	NNP	O
cassettes,	MD	O
in	VB	O
particular,	VBN	O
mammalian	IN	O
cell	DT	O
lines	NN	O
can	IN	O
be	NN	O
used	NNS	O
for	VBG	O
VLP	DT	O
production,	JJ	O
for	NN	O
example,	,	O
CHO	IN	O
cells.	,	O
Production	JJ	O
using	NN	O
CHO	NNS	O
cells	MD	O
provides	VB	O
(i)	VBN	O
VLP	IN	O
formation;	NNP	O
(ii)	,	O
correct	IN	O
myristylation	,	O
and	NNP	O
budding;	.	O
(iii)	NN	O
absence	VBG	O
of	NNP	O
non-mammalian	NNS	O
cell	VBZ	O
contaminants	)	O
(e.g.,	NNP	O
insect	:	O
viruses	)	O
and/or	VBP	O
cells);	NN	O
and	CC	O
(iv)	:	O
ease	)	O
of	NN	O
purification.	IN	O
The	JJ	O
synthetic	NN	O
expression	NNS	O
cassettes	,	O
of	JJ	O
the	NNS	O
present	VBP	O
invention	:	O
are	CC	O
also	)	O
useful	NN	O
for	IN	O
enhanced	.	O
expression	DT	O
in	JJ	O
cell-types	NN	O
other	NNS	O
than	IN	O
mammalian	DT	O
cell	JJ	O
lines.	NN	O
For	VBP	O
example,	RB	O
infection	JJ	O
of	IN	O
insect	JJ	O
cells	NN	O
with	IN	O
baculovirus	NNS	O
vectors	JJ	O
encoding	IN	O
the	JJ	O
synthetic	NN	O
expression	.	O
cassettes	IN	O
resulted	,	O
in	NN	O
higher	IN	O
levels	JJ	O
of	NNS	O
total	IN	O
protein	NN	O
yield	NNS	O
and	VBG	O
higher	DT	O
levels	JJ	O
of	NN	O
VLP	NNS	O
production	VBD	O
(relative	IN	O
to	JJR	O
wild-type	NNS	O
coding	IN	O
sequences).	JJ	O
Further,	JJ	O
the	NN	O
final	CC	O
product	JJR	O
from	NNS	O
insect	IN	O
cells	NNP	O
infected	NN	O
with	JJ	O
the	TO	O
baculovirus-Gag	JJ	O
synthetic	NN	O
expression	.	O
cassettes	,	O
consistently	DT	O
contained	JJ	O
lower	NN	O
amounts	IN	O
of	JJ	O
contaminating	NNS	O
insect	VBN	O
proteins	IN	O
than	DT	O
the	JJ	O
final	JJ	O
product	NN	O
when	NNS	O
wild-type	RB	O
coding	VBD	O
sequences	JJR	O
were	NNS	O
used	IN	O
(Examples).	VBG	O
VLPs	JJ	O
can	NNS	O
spontaneously	IN	O
form	DT	O
when	JJ	O
the	NN	O
particle-forming	WRB	O
polypeptide	JJ	O
of	NN	O
interest	NNS	O
is	VBD	O
recombinantly	VBN	O
expressed	.	O
in	NNP	O
an	MD	O
appropriate	RB	O
host	VB	O
cell.	WRB	O
Thus,	DT	O
the	JJ	O
VLPs	NN	O
produced	IN	O
using	NN	O
the	VBZ	O
synthetic	RB	O
expression	VBN	O
cassettes	IN	O
of	DT	O
the	JJ	O
present	NN	O
invention	.	O
are	,	O
conveniently	DT	O
prepared	NNP	O
using	VBD	O
recombinant	VBG	O
techniques.	DT	O
As	JJ	O
discussed	NN	O
below,	NNS	O
the	IN	O
Gag	DT	O
polypeptide	JJ	O
encoding	NN	O
synthetic	VBP	O
expression	RB	O
cassettes	JJ	O
of	VBG	O
the	JJ	O
present	.	O
invention	IN	O
can	VBN	O
include	,	O
other	DT	O
polypeptide	NNP	O
coding	NN	O
sequences	VBG	O
of	JJ	O
interest	NN	O
(for	NNS	O
example,	IN	O
Env,	DT	O
tat,	JJ	O
rev,	NN	O
HIV	MD	O
protease,	VB	O
HIV	JJ	O
polymerase,	JJ	O
HCV	VBG	O
core;	NNS	O
see,	IN	O
Example	NN	O
1).	IN	O
Expression	,	O
of	,	O
such	,	O
synthetic	,	O
expression	NNP	O
cassettes	,	O
yields	NNP	O
VLPs	,	O
comprising	NNP	O
the	:	O
product	,	O
of	NNP	O
the	.	O
synthetic	NN	O
expression	IN	O
cassette,	JJ	O
as	JJ	O
well	NN	O
as,	NNS	O
the	NNS	O
polypeptide	NNP	O
of	VBG	O
interest.	DT	O
Once	NN	O
coding	IN	O
sequences	DT	O
for	JJ	O
the	NN	O
desired	,	O
particle-forming	RB	O
polypeptides	RB	O
have	,	O
been	DT	O
isolated	NN	O
or	IN	O
synthesized,	.	O
they	RB	O
can	VBG	O
be	NNS	O
cloned	IN	O
into	DT	O
any	JJ	O
suitable	NN	O
vector	NNS	O
or	VBP	O
replicon	VBN	O
for	VBN	O
expression.	CC	O
Numerous	,	O
cloning	PRP	O
vectors	MD	O
are	VB	O
known	VBN	O
to	IN	O
those	DT	O
of	JJ	O
skill	NN	O
in	CC	O
the	NN	O
art,	IN	O
and	.	O
the	JJ	O
selection	VBG	O
of	NNS	O
an	VBP	O
appropriate	VBN	O
cloning	TO	O
vector	DT	O
is	IN	O
a	NN	O
matter	IN	O
of	DT	O
choice.	,	O
See,	CC	O
generally,	DT	O
Ausubel	NN	O
et	IN	O
al,	DT	O
supra	JJ	O
or	NN	O
Sambrook	NN	O
et	VBZ	O
al,	DT	O
supra.	NN	O
The	IN	O
vector	.	O
is	,	O
then	,	O
used	NNP	O
to	FW	O
transform	,	O
an	NN	O
appropriate	CC	O
host	NNP	O
cell.	CC	O
Suitable	,	O
recombinant	.	O
expression	DT	O
systems	NN	O
include,	VBZ	O
but	RB	O
are	VBN	O
not	TO	O
limited	VB	O
to,	DT	O
bacterial,	JJ	O
mammalian,	NN	O
baculovirus/insect,	.	O
vaccinia,	JJ	O
Semliki	JJ	O
Forest	NN	O
virus	NNS	O
(SFV),	,	O
Alphaviruses	CC	O
(such	VBP	O
as,	RB	O
Sindbis,	VBN	O
Venezuelan	,	O
Equine	,	O
Encephalitis	,	O
(VEE)),	,	O
mammalian,	,	O
yeast	NNP	O
and	NNP	O
Xenopus	NN	O
expression	,	O
systems,	NNP	O
well	JJ	O
known	,	O
in	,	O
the	NNP	O
art.	NNP	O
Particularly	NNP	O
preferred	,	O
expression	,	O
systems	NN	O
are	CC	O
mammalian	NNP	O
cell	NN	O
lines,	,	O
vaccinia,	RB	O
Sindbis,	VBN	O
insect	IN	O
and	DT	O
yeast	.	O
systems.	RB	O
For	JJ	O
example,	NN	O
a	NNS	O
number	VBP	O
of	JJ	O
mammalian	NN	O
cell	,	O
lines	,	O
are	,	O
known	NN	O
in	CC	O
the	JJ	O
art	.	O
and	IN	O
include	,	O
immortalized	DT	O
cell	NN	O
lines	IN	O
available	JJ	O
from	NN	O
the	NNS	O
American	VBP	O
Type	VBN	O
Culture	IN	O
Collection	DT	O
(A.T.C.C.),	NN	O
such	CC	O
as,	VBP	O
but	VBN	O
not	NN	O
limited	NNS	O
to,	JJ	O
Chinese	IN	O
hamster	DT	O
ovary	JJ	O
(CHO)	NNP	O
cells,	NNP	O
293	NNP	O
cells,	,	O
HeLa	JJ	O
cells,	,	O
baby	CC	O
hamster	RB	O
kidney	JJ	O
(BHK)	,	O
cells,	JJ	O
mouse	NN	O
myeloma	JJ	O
(SB20),	)	O
monkey	,	O
kidney	CD	O
cells	,	O
(COS),	NNP	O
as	,	O
well	NN	O
as	NN	O
others.	NN	O
Similarly,	)	O
bacterial	,	O
hosts	NN	O
such	NN	O
as	,	O
E.	JJ	O
coli,	NN	O
Bacillus	NNS	O
subtilis,	,	O
and	RB	O
Streptococcus	RB	O
spp.,	IN	O
will	.	O
find	,	O
use	JJ	O
with	NNS	O
the	JJ	O
present	IN	O
expression	NNP	O
constructs.	,	O
Yeast	NNP	O
hosts	,	O
useful	CC	O
in	NNP	O
the	,	O
present	MD	O
invention	VB	O
include	NN	O
inter	IN	O
alia,	DT	O
Saccharomyces	JJ	O
cerevisiae,	NN	O
Candida	.	O
albicans,	JJ	O
Candida	NNS	O
maltose,	JJ	O
Hansenula	IN	O
polymorpha,	DT	O
Kluyveromyces	JJ	O
fragilis,	NN	O
Kluyveromyces	VBP	O
lactis,	NN	O
Pichia	,	O
guillerimondii,	NNP	O
Pichia	,	O
pastoris,	NNP	O
Schizosaccharomyces	,	O
pombe	NNP	O
and	,	O
Yarrowia	NNP	O
lipolytica.	,	O
Insect	NNP	O
cells	,	O
for	NNP	O
use	,	O
with	NNP	O
baculovirus	,	O
expression	NNP	O
vectors	,	O
include,	NNP	O
inter	NN	O
alia,	CC	O
Aedes	NNP	O
aegypti,	.	O
Autographa	NNP	O
californica	NNS	O
,	IN	O
Bombyx	NN	O
mori,	IN	O
Drosophila	JJ	O
melanogaster,	NN	O
Spodoptera	NNS	O
frugiperda,	,	O
and	JJ	O
Trichoplusia	,	O
ni.	NNP	O
See,	,	O
e.g.,	NNP	O
Summers	NN	O
and	,	O
Smith,	NNP	O
Texas	,	O
Agricultural	NNP	O
Experiment	,	O
Station	NNP	O
Bulletin	,	O
No.	CC	O
1555	NNP	O
(1987).	.	O
Fungal	,	O
hosts	,	O
include,	NNPS	O
for	CC	O
example,	,	O
Aspergillus.	NNP	O
Viral	NNP	O
vectors	NNP	O
can	NNP	O
be	NNP	O
used	.	O
for	CD	O
the	.	O
production	JJ	O
of	NNS	O
particles	,	O
in	IN	O
eucaryotic	,	O
cells,	.	O
such	JJ	O
as	NNS	O
those	MD	O
derived	VB	O
from	VBN	O
the	IN	O
pox	DT	O
family	NN	O
of	IN	O
viruses,	NNS	O
including	IN	O
vaccinia	JJ	O
virus	,	O
and	JJ	O
avian	IN	O
poxvirus.	DT	O
Additionally,	VBN	O
a	IN	O
vaccinia	DT	O
based	JJ	O
infection/transfection	NN	O
system,	IN	O
as	,	O
described	VBG	O
in	NN	O
Tomei	NN	B
et	CC	I
al.,	JJ	I
J.	.	I
Virol.	,	I
(1993)	DT	I
67:4017-4026	NN	I
and	VBN	O
Selby	NN	B
et	,	I
al.,	IN	I
J.	VBN	I
Gen.	IN	I
Virol.	NNP	I
(1993)	CC	I
74:1103-1113,	,	I
will	NNP	O
also	.	O
find	)	O
use	CD	O
with	CC	O
the	NNP	O
present	VBP	O
invention.	,	O
In	NNP	O
this	NNP	O
system,	.	O
cells	)	O
are	,	O
first	MD	O
infected	RB	O
in	VB	O
vitro	NN	O
with	IN	O
a	DT	O
vaccinia	JJ	O
virus	.	O
recombinant	IN	O
that	DT	O
encodes	,	O
the	NNS	O
bacteriophage	VBP	O
T7	RB	O
RNA	VBN	O
polymerase.	IN	O
This	NN	O
polymerase	IN	O
displays	DT	O
exquisite	NN	O
specificity	NN	O
in	NN	O
that	WDT	O
it	VBZ	O
only	DT	O
transcribes	NN	O
templates	NNP	O
bearing	NNP	O
T7	.	O
promoters.	DT	O
Following	NN	O
infection,	VBZ	O
cells	JJ	O
are	NN	O
transfected	IN	O
with	DT	O
the	PRP	O
DNA	RB	O
of	VBZ	O
interest,	NNS	O
driven	VBG	O
by	NNP	O
a	.	O
T7	VBG	O
promoter.	,	O
The	NNS	O
polymerase	VBP	O
expressed	VBN	O
in	IN	O
the	DT	O
cytoplasm	NN	O
from	IN	O
the	,	O
vaccinia	VBN	O
virus	IN	O
recombinant	DT	O
transcribes	NNP	O
the	.	O
transfected	DT	O
DNA	NN	O
into	VBN	O
RNA	IN	O
which	DT	O
is	NN	O
then	IN	O
translated	DT	O
into	NN	O
protein	NN	O
by	NN	O
the	VBZ	O
host	DT	O
translational	JJ	O
machinery.	NNP	O
Alternately,	IN	O
T7	NNP	O
can	WDT	O
be	VBZ	O
added	RB	O
as	VBN	O
a	IN	O
purified	NN	O
protein	IN	O
or	DT	O
enzyme	NN	O
as	JJ	O
in	.	O
the	,	O
“Progenitor”	NNP	O
system	MD	O
Studier	VB	B
and	VBN	I
Moffatt,	IN	I
J.	DT	I
Mol.	JJ	I
Biol.	NN	I
(1986)	CC	I
189:113-130).(	NN	O
The	IN	O
method	IN	O
provides	DT	O
for	NN	O
high	NN	O
level,	NNP	O
transient,	CC	O
cytoplasmic	,	O
production	NNP	O
of	.	O
large	.	O
quantities	)	O
of	.	O
RNA	DT	O
and	NN	O
its	VBZ	O
translation	IN	O
product(s).	JJ	O
Depending	,	O
on	,	O
the	JJ	O
expression	NN	O
system	IN	O
and	JJ	O
host	NNS	O
selected,	IN	O
the	NNP	O
VLPS	CC	O
are	PRP$	O
produced	NN	O
by	.	O
growing	VBG	O
host	IN	O
cells	DT	O
transformed	NN	O
by	NN	O
an	CC	O
expression	NN	O
vector	,	O
under	DT	O
conditions	NNP	O
whereby	VBP	O
the	VBN	O
particle-forming	IN	O
polypeptide	VBG	O
is	NN	O
expressed	NNS	O
and	VBN	O
VLPs	IN	O
can	DT	O
be	NN	O
formed.	NN	O
The	IN	O
selection	NNS	O
of	VBP	O
the	DT	O
appropriate	JJ	O
growth	NN	O
conditions	VBZ	O
is	VBN	O
within	CC	O
the	NNP	O
skill	MD	O
of	VB	O
the	.	O
art.	DT	O
If	NN	O
the	IN	O
VLPs	DT	O
are	JJ	O
formed	NN	O
intracellularly,	NNS	O
the	VBZ	O
cells	IN	O
are	DT	O
then	NN	O
disrupted,	IN	O
using	DT	O
chemical,	.	O
physical	IN	O
or	DT	O
mechanical	NNP	O
means,	VBP	O
which	VBN	O
lyse	,	O
the	DT	O
cells	NNS	O
yet	VBP	O
keep	RB	O
the	,	O
VLPs	VBG	O
substantially	,	O
intact.	JJ	O
Such	CC	O
methods	JJ	O
are	,	O
known	WDT	O
to	VBZ	O
those	DT	O
of	NNS	O
skill	RB	O
in	VBP	O
the	DT	O
art	NNP	O
and	RB	O
are	.	O
described	JJ	O
in,	NNS	O
e.g.,	VBP	O
Protein	VBN	B
Purification	TO	I
Applications:	DT	I
A	IN	I
Practical	NN	I
Approach,	IN	I
(E.	DT	I
L.	NN	I
V.	CC	I
Harris	VBP	I
and	VBN	I
S.	,	I
Angal,	,	I
Eds.,	NNP	I
1990).
The	NNP	O
particles	:	O
are	DT	O
then	NNP	O
isolated	,	O
(or	NNP	O
substantially	NNP	O
purified)	NNP	O
using	NNP	O
methods	CC	O
that	NNP	O
preserve	,	O
the	,	O
integrity	.	O
thereof,	DT	O
such	NNS	O
as,	VBP	O
by	RB	O
density	VBN	O
gradient	CC	O
centrifugation,	RB	O
e.g.,	)	O
sucrose	VBG	O
gradients,	NNS	O
PEG-precipitation,	WDT	O
pelleting,	VBP	O
and	DT	O
the	NN	O
like	,	O
(see,	JJ	O
e.g.,	,	O
Kirnbauer	IN	B
et	NN	I
al.	NN	I
J.	,	I
Virol.	,	I
(1993)	JJ	I
67:6929-6936),as	,	O
well	,	O
as	,	O
standard	CC	O
purification	DT	O
techniques	JJ	O
including,	,	O
e.g.,	,	O
ion	NNP	O
exchange	CC	O
and	.	O
gel	NNP	O
filtration	.	O
chromatography.	)	O
VLPs	,	O
produced	RB	O
by	RB	O
cells	IN	O
containing	JJ	O
the	NN	O
synthetic	NNS	O
expression	,	O
cassettes	,	O
of	NN	O
the	NN	O
present	CC	O
invention	JJ	O
can	NN	O
be	.	O
used	NNP	O
to	VBN	O
elicit	IN	O
an	NNS	O
immune	VBG	O
response	DT	O
when	JJ	O
administered	NN	O
to	NNS	O
a	IN	O
subject.	DT	O
One	JJ	O
advantage	NN	O
of	MD	O
the	VB	O
present	VBN	O
invention	TO	O
is	VB	O
that	DT	O
VLPs	JJ	O
can	NN	O
be	WRB	O
produced	VBN	O
by	TO	O
mammalian	DT	O
cells	.	O
carrying	CD	O
the	NN	O
synthetic	IN	O
expression	DT	O
cassettes	JJ	O
at	NN	O
levels	VBZ	O
previously	IN	O
not	NNP	O
possible.	MD	O
As	VB	O
discussed	VBN	O
above,	IN	O
the	JJ	O
VLPs	NNS	O
can	VBG	O
comprise	DT	O
a	JJ	O
variety	NN	O
of	NNS	O
antigens	IN	O
in	NNS	O
addition	RB	O
to	RB	O
the	.	O
Gag	IN	O
polypeptides	VBN	O
(e.g.,	,	O
Env,	DT	O
tat,	NNP	O
Gag-protease,	MD	O
Gag-polymerase,	VB	O
Gag-HCV-core).	DT	O
Purified	NN	O
VLPs,	IN	O
produced	NNS	O
using	IN	O
the	NN	O
synthetic	TO	O
expression	DT	O
cassettes	NNP	O
of	NNS	O
the	,	O
present	,	O
invention,	,	O
can	,	O
be	,	O
administered	.	O
to	NNP	O
a	,	O
vertebrate	VBD	O
subject,	VBG	O
usually	DT	O
in	JJ	O
the	NN	O
form	NNS	O
of	IN	O
vaccine	DT	O
compositions.	JJ	O
Combination	,	O
vaccines	MD	O
may	VB	O
also	VBN	O
be	TO	O
used,	DT	O
where	NN	O
such	,	O
vaccines	RB	O
contain,	IN	O
for	DT	O
example,	NN	O
other	IN	O
subunit	JJ	O
proteins	.	O
derived	NNP	O
from	NNS	O
HIV	MD	O
or	RB	O
other	VB	O
organisms	,	O
(e.g.,	WRB	O
env)	JJ	O
or	NNS	O
gene	,	O
delivery	IN	O
vaccines	,	O
encoding	JJ	O
such	NN	O
antigens.	NNS	O
Administration	VBN	O
can	IN	O
take	NNP	O
place	CC	O
using	JJ	O
the	NNS	O
VLPs	,	O
formulated	)	O
alone	CC	O
or	NN	O
formulated	NN	O
with	NNS	O
other	VBG	O
antigens.	JJ	O
Further,	.	O
the	NN	O
VLPs	MD	O
can	VB	O
be	NN	O
administered	VBG	O
prior	DT	O
to,	NNP	O
concurrent	VBD	O
with,	RB	O
or	CC	O
subsequent	VBN	O
to,	IN	O
delivery	JJ	O
of	.	O
the	,	O
synthetic	DT	O
expression	NNP	O
cassettes	MD	O
for	VB	O
DNA	VBN	O
immunization	RB	O
(see	,	O
below)	NN	O
and/or	,	O
delivery	CC	O
of	JJ	O
other	,	O
vaccines.	NN	O
Also,	IN	O
the	DT	O
site	JJ	O
of	NN	O
VLP	NNS	O
administration	IN	O
may	NNP	O
be	NN	O
the	VB	O
same	)	O
or	NN	O
different	NN	O
as	IN	O
other	JJ	O
vaccine	.	O
compositions	,	O
that	DT	O
are	NN	O
being	IN	O
administered.	NNP	O
Gene	NN	O
delivery	MD	O
can	VB	O
be	DT	O
accomplished	JJ	O
by	CC	O
a	JJ	O
number	IN	O
of	JJ	O
methods	NN	O
including,	NNS	O
but	WDT	O
are	VBP	O
not	VBG	O
limited	.	O
to,	NNP	O
immunization	NN	O
with	MD	O
DNA,	VB	O
alphavirus	VBN	O
vectors,	IN	O
pox	DT	O
virus	NN	O
vectors,	IN	O
and	NNS	O
vaccinia	,	O
virus	CC	O
vectors.	VBP	O
VLP	RB	O
immune-stimulating	VBN	O
(or	,	O
vaccine)	NN	O
compositions	IN	O
can	,	O
include	NN	O
various	,	O
excipients,	NN	O
adjuvants,	NN	O
carriers,	,	O
auxiliary	CC	O
substances,	NN	O
modulating	NN	O
agents,	.	O
and	NNP	O
the	NN	O
like.	CC	O
The	)	O
immune	NNS	O
stimulating	MD	O
compositions	VB	O
will	JJ	O
include	,	O
an	,	O
amount	,	O
of	JJ	O
the	,	O
VLP/antigen	VBG	O
sufficient	,	O
to	CC	O
mount	DT	O
an	.	O
immunological	DT	O
response.	JJ	O
An	NN	O
appropriate	NNS	O
effective	MD	O
amount	VB	O
can	DT	O
be	NN	O
determined	IN	O
by	DT	O
one	NNP	O
of	NN	O
skill	TO	O
in	VB	O
the	DT	O
art.	JJ	O
Such	.	O
an	DT	O
amount	JJ	O
will	JJ	O
fall	NN	O
in	MD	O
a	VB	O
relatively	VBN	O
broad	IN	O
range	CD	O
that	IN	O
can	NN	O
be	IN	O
determined	DT	O
through	.	O
routine	JJ	O
trials	DT	O
and	NN	O
will	MD	O
generally	VB	O
be	IN	O
an	DT	O
amount	RB	O
on	JJ	O
the	NN	O
order	WDT	O
of	MD	O
about	VB	O
0.1	VBN	O
μg	IN	O
to	JJ	O
about	NNS	O
1000	CC	O
μg,	MD	O
more	RB	O
preferably	VB	O
about	DT	O
1	NN	O
μg	IN	O
to	DT	O
about	NN	O
300	IN	O
μg,	IN	O
of	CD	O
VLP/antigen.	NNS	O
A	TO	O
carrier	IN	O
is	CD	O
optionally	,	O
present	JJR	O
which	RB	O
is	IN	O
a	CD	O
molecule	NNS	O
that	TO	O
does	IN	O
not	CD	O
itself	,	O
induce	IN	O
the	.	O
production	DT	O
of	NN	O
antibodies	VBZ	O
harmful	RB	O
to	JJ	O
the	WDT	O
individual	VBZ	O
receiving	DT	O
the	NN	O
composition.	WDT	O
Suitable	VBZ	O
carriers	RB	O
are	PRP	O
typically	VBP	O
large,	DT	O
slowly	NN	O
metabolized	IN	O
macromolecules	NNS	O
such	VBP	O
as	TO	O
proteins,	DT	O
polysaccharides,	JJ	O
polylactic	VBG	O
acids,	DT	O
polyglycollic	.	O
acids,	JJ	O
polymeric	NNS	O
amino	VBP	O
acids,	RB	O
amino	,	O
acid	RB	O
copolymers,	VBN	O
lipid	NNS	O
aggregates	JJ	O
(such	IN	O
as	,	O
oil	,	O
droplets	JJ	O
or	,	O
liposomes),	JJ	O
and	,	O
inactive	JJ	O
virus	NN	O
particles.	,	O
Examples	JJ	O
of	NN	O
particulate	,	O
carriers	JJ	O
include	NNS	O
those	JJ	O
derived	IN	O
from	NN	O
polymethyl	NNS	O
methacrylate	CC	O
polymers,	,	O
as	CC	O
well	JJ	O
as	NN	O
microparticles	.	O
derived	NNS	O
from	IN	O
poly(lactides)	NN	O
and	NNS	O
poly(lactide-co-glycolides),	VBP	O
known	DT	O
as	VBN	O
PLG.	IN	O
See,	NN	O
e.g.,	NN	O
Jeffery	,	B
et	RB	I
al.,	RB	I
Pharm.	IN	I
Res.	NNS	I
(1993)	VBN	I
10:362-368;	IN	I
McGee	)	B
J	CC	I
P,	,	I
et	VBN	I
al.,	IN	I
J.	.	I
Microencapsul.	,	I
14(2):197-210,	,	I
1997;	NNP	I
O'Hagan	CC	B
D	,	I
T,	.	I
et	.	I
al.,	)	I
Vaccine	:	I
11(2):149-54,	NNP	I
1993.	NNP	I
Such	,	O
carriers	FW	O
are	,	O
well	NNP	O
known	.	O
to	,	O
those	:	O
of	NNP	O
ordinary	NNP	O
skill	,	O
in	FW	O
the	,	O
art.	NNP	O
Additionally,	,	O
these	.	O
carriers	JJ	O
may	NNS	O
function	VBP	O
as	RB	O
immunostimulating	VBN	O
agents	TO	O
(“adjuvants”).	DT	O
Furthermore,	IN	O
the	JJ	O
antigen	NN	O
may	IN	O
be	DT	O
conjugated	.	O
to	,	O
a	DT	O
bacterial	NNS	O
toxoid,	MD	O
such	VB	O
as	IN	O
toxoid	VBG	O
from	NNS	O
diphtheria,	.	O
tetanus,	,	O
cholera,	DT	O
etc.,	NN	O
as	MD	O
well	VB	O
as	VBN	O
toxins	TO	O
derived	DT	O
from	JJ	O
E.	,	O
coli.	JJ	O
Such	IN	O
adjuvants	NN	O
include,	IN	O
but	,	O
are	,	O
not	,	O
limited	,	O
to:	RB	O
(1)	RB	O
aluminum	IN	O
salts	NNS	O
(alum),	VBN	O
such	IN	O
as	NNP	O
aluminum	.	O
hydroxide,	JJ	O
aluminum	NNS	O
phosphate,	,	O
aluminum	CC	O
sulfate,	VBP	O
etc.;	RB	O
(2)	VBN	O
oil-in-water	:	O
emulsion	)	O
formulations	NN	O
(with	NNS	O
or	,	O
without	JJ	O
other	IN	O
specific	NN	O
immunostimulating	,	O
agents	NN	O
such	,	O
as	NN	O
muramyl	,	O
peptides	:	O
(see	)	O
below)	NN	O
or	NN	O
bacterial	NNS	O
cell	IN	O
wall	CC	O
components),	IN	O
such	JJ	O
as	JJ	O
for	VBG	O
example	NNS	O
(a)	JJ	O
MF59	IN	O
(International	NN	O
Publication	NNS	O
No.	VB	O
WO	)	O
90/14837),	CC	O
containing	JJ	O
5%	NN	O
Squalene,	NN	O
0.5%	,	O
Tween	JJ	O
80,	IN	O
and	IN	O
0.5%	NN	O
Span	)	O
85	NNP	O
(optionally	NNP	O
containing	NNP	O
various	.	O
amounts	NNP	O
of	,	O
MTP-PE	VBG	O
(see	NN	O
below),	,	O
although	NN	O
not	NNP	O
required)	,	O
formulated	CC	O
into	NN	O
submicron	NNP	O
particles	CD	O
using	RB	O
a	VBG	O
microfluidizer	JJ	O
such	NNS	O
as	IN	O
Model	NNP	O
110Y	VB	O
microfluidizer	,	O
(Microfluidics,	IN	O
Newton,	RB	O
Mass.),	)	O
(b)	VBN	O
SAF,	IN	O
containing	NN	O
10%	NNS	O
Squalane,	VBG	O
0.4%	DT	O
Tween	NN	O
80,	JJ	O
5%	IN	O
pluronic-blocked	NNP	O
polymer	CD	O
L121,	NN	O
and	,	O
thr-MDP	,	O
(see	,	O
below)	)	O
either	,	O
microfluidized	VBG	O
into	NN	O
a	,	O
submicron	NN	O
emulsion	NNP	O
or	,	O
vortexed	NN	O
to	JJ	O
generate	NN	O
a	,	O
larger	CC	O
particle	NN	O
size	VB	O
emulsion,	)	O
and	CC	O
(c)	VBN	O
Ribi™	IN	O
adjuvant	DT	O
system	JJ	O
(RAS),	NN	O
(Ribi	CC	O
Immunochem,	NN	O
Hamilton,	TO	O
Mont.)	VB	O
containing	DT	O
2%	JJR	O
Squalene,	NN	O
0.2%	NN	O
Tween	,	O
80,	CC	O
and	)	O
one	NNP	O
or	JJ	O
more	NN	O
bacterial	,	O
cell	NNP	O
wall	,	O
components	,	O
from	)	O
the	VBG	O
group	NN	O
consisting	,	O
of	NN	O
monophosphorylipid	NNP	O
A	,	O
(MPL),	CC	O
trehalose	CD	O
dimycolate	CC	O
(TDM),	JJR	O
and	JJ	O
cell	NN	O
wall	NN	O
skeleton	NNS	O
(CWS),	IN	O
preferably	DT	O
MPL+CWS	NN	O
(Detox™);	VBG	O
(3)	IN	O
saponin	NN	O
adjuvants,	NNP	O
such	,	O
as	JJ	O
Stimulon™	NN	O
(Cambridge	,	O
Bioscience,	CC	O
Worcester,	NN	O
Mass.)	NN	O
may	NN	O
be	,	O
used	RB	O
or	NNP	O
particle	:	O
generated	)	O
therefrom	NN	O
such	,	O
as	JJ	O
ISCOMs	IN	O
(immunostimulating	NNP	O
complexes);	NNP	O
(4)	,	O
Complete	,	O
Freunds	)	O
Adjuvant	MD	O
(CFA)	VB	O
and	VBN	O
Incomplete	CC	O
Freunds	NN	O
Adjuvant	VBN	O
(IFA);	NNS	O
(5)	JJ	O
cytokines,	IN	O
such	NNP	O
as	VBG	O
interleukins	:	O
(IL-1,	)	O
IL-2,	NNP	O
etc.),	NNP	O
macrophage	NNP	O
colony	)	O
stimulating	CC	O
factor	NNP	O
(M-CSF),	NNP	O
tumor	NNP	O
necrosis	:	O
factor	)	O
(TNF),	,	O
beta	JJ	O
chemokines	IN	O
(MIP,	NNS	O
1-alpha,	,	O
1-beta	,	O
Rantes,	,	O
etc.);	NN	O
(6)	NN	O
detoxified	VBG	O
mutants	NN	O
of	,	O
a	JJ	O
bacterial	NN	O
ADP-ribosylating	NN	O
toxin	,	O
such	JJ	O
as	NNS	O
a	,	O
cholera	,	O
toxin	JJ	O
(CT),	,	O
a	:	O
pertussis	)	O
toxin	VBD	O
(PT),	NNS	O
or	IN	O
an	DT	O
E.	JJ	O
coli	JJ	O
heat-labile	NN	O
toxin	JJ	O
(LT),	IN	O
particularly	DT	O
LT-K63	NN	O
(where	NN	O
lysine	,	O
is	DT	O
substituted	NN	O
for	NN	O
the	,	O
wild-type	CC	O
amino	DT	O
acid	NNP	O
at	NNS	O
position	JJ	O
63)	NN	O
LT-R72	,	O
(where	RB	O
arginine	NNP	O
is	WRB	O
substituted	NN	O
for	VBZ	O
the	VBN	O
wild-type	IN	O
amino	DT	O
acid	JJ	O
at	NN	O
position	NN	O
72),	IN	O
CT-S109	NN	O
(where	)	O
serine	NN	O
is	WRB	O
substituted	NN	O
for	VBZ	O
the	VBN	O
wild-type	IN	O
amino	DT	O
acid	JJ	O
at	NN	O
position	NN	O
109),	IN	O
and	NN	O
PT-K9/G129	,	O
(where	NNP	O
lysine	WRB	O
is	NN	O
substituted	VBZ	O
for	VBN	O
the	IN	O
wild-type	DT	O
amino	JJ	O
acid	NN	O
at	NN	O
position	IN	O
9	NN	O
and	,	O
glycine	CC	O
substituted	NNP	O
at	WRB	O
position	NN	O
129)	VBZ	O
(see,	VBN	O
e.g.,	IN	O
International	DT	O
Publication	JJ	O
Nos.	NN	O
WO93/13202	NN	O
and	IN	O
WO92/19265);	NN	O
and	CD	O
(7)	CC	O
other	NN	O
substances	VBN	O
that	IN	O
act	NN	O
as	)	O
immunostimulating	,	O
agents	,	O
to	NNP	O
enhance	NNP	O
the	.	O
effectiveness	NNP	O
of	CC	O
the	:	O
composition.	CC	O
Muramyl	)	O
peptides	JJ	O
include,	NNS	O
but	WDT	O
are	VBP	O
not	IN	O
limited	VBG	O
to,	NNS	O
N-acetyl-muramyl-L-threonyl-D-isoglutamine	TO	O
(thr-MDP),	VB	O
N-acteyl-normuramyl-L-alanyl-D-isogluatme	DT	O
(nor-MDP),	NN	O
N-acetylmuramyl-L-alanyl-D-isogluatminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-huydroxyphosphoryloxy)-ethylamine	IN	O
(MTP-PE),	DT	O
etc.	.	O
Dosage	NNP	O
treatment	NNS	O
with	,	O
the	CC	O
VLP	VBP	O
composition	RB	O
may	VBN	O
be	,	O
a	NNP	O
single	,	O
dose	NNP	O
schedule	,	O
or	NN	O
a	,	O
multiple	.	O
dose	NN	O
schedule.	NN	O
A	IN	O
multiple	DT	O
dose	NNP	O
schedule	NN	O
is	MD	O
one	VB	O
in	DT	O
which	JJ	O
a	NN	O
primary	NN	O
course	CC	O
of	DT	O
vaccination	JJ	O
may	NN	O
be	.	O
with	DT	O
1-10	JJ	O
separate	NN	O
doses,	NN	O
followed	VBZ	O
by	CD	O
other	IN	O
doses	WDT	O
given	DT	O
at	JJ	O
subsequent	NN	O
time	IN	O
intervals,	NN	O
chosen	MD	O
to	VB	O
maintain	IN	O
and/or	JJ	O
reinforce	JJ	O
the	,	O
immune	VBN	O
response,	IN	O
for	JJ	O
example	NNS	O
at	VBN	O
1-4	IN	O
months	JJ	O
for	NN	O
a	,	O
second	VBN	O
dose,	TO	O
and	VB	O
if	JJ	O
needed,	VB	O
a	DT	O
subsequent	JJ	O
dose(s)	,	O
after	IN	O
several	NN	O
months.	IN	O
The	JJ	O
dosage	NNS	O
regimen	IN	O
will	DT	O
also,	JJ	O
at	,	O
least	CC	O
in	IN	O
part,	,	O
be	DT	O
determined	JJ	O
by	)	O
the	IN	O
potency	JJ	O
of	.	O
the	DT	O
modality,	NN	O
the	NNS	O
vaccine	MD	O
delivery	,	O
employed,	IN	O
the	JJS	O
need	IN	O
of	,	O
the	VB	O
subject	VBN	O
and	IN	O
be	DT	O
dependent	NN	O
on	IN	O
the	DT	O
judgment	,	O
of	DT	O
the	NN	O
practitioner.	NN	O
If	,	O
prevention	DT	O
of	NN	O
disease	IN	O
is	DT	O
desired	NN	O
(e.g.,	CC	O
reduction	VB	O
of	VBN	O
symptoms,	IN	O
recurrences	DT	O
or	NN	O
of	IN	O
disease	DT	O
progression),	.	O
the	IN	O
antigen	NN	O
carrying	IN	O
VLPs	NN	O
are	VBZ	O
generally	VBN	O
administered	,	O
prior	NN	O
to	IN	O
primary	,	O
infection	NNS	O
with	CC	O
the	IN	O
pathogen	JJ	O
of	,	O
interest.	DT	O
If	NN	O
treatment	NN	O
is	NNP	O
desired,	VBP	O
e.g.,	RB	O
the	VBN	O
reduction	RB	O
of	TO	O
symptoms	JJ	O
or	NN	O
recurrences,	IN	O
the	DT	O
VLP	NN	O
compositions	IN	O
are	.	O
generally	IN	O
administered	NN	O
subsequent	VBZ	O
to	,	O
primary	,	O
infection.	DT	O
2.2.2	NN	O
Using	IN	O
the	NNS	O
Synthetic	CC	O
Expression	,	O
Cassettes	DT	O
of	NNP	O
the	NNS	O
Present	VBP	O
Invention	RB	O
to	VBN	O
Create	JJ	O
Packaging	TO	O
Cell	JJ	O
Lines	.	O
A	CD	O
number	VBG	O
of	DT	O
viral	JJ	O
based	NNP	O
systems	NNP	O
have	IN	O
been	DT	O
developed	JJ	O
for	NNP	O
use	TO	O
as	VB	O
gene	NNP	O
transfer	NNP	O
vectors	VBZ	O
for	NNP	O
mammalian	NN	O
host	IN	O
cells.	JJ	O
For	VBN	O
example,	NNS	O
retroviruses	VBP	O
(in	VBN	O
particular,	VBN	O
lentiviral	IN	O
vectors)	NN	O
provide	IN	O
a	NN	O
convenient	NN	O
platform	NNS	O
for	IN	O
gene	JJ	O
delivery	NN	O
systems.	.	O
A	IN	O
coding	,	O
sequence	VBZ	O
of	IN	O
interest	,	O
(for	JJ	O
example,	)	O
a	VBP	O
sequence	DT	O
useful	NN	O
for	NN	O
gene	IN	O
therapy	NN	O
applications)	NN	O
can	.	O
be	DT	O
inserted	VBG	O
into	NN	O
a	IN	O
gene	NN	O
delivery	IN	O
vector	,	O
and	DT	O
packaged	NN	O
in	JJ	O
retroviral	IN	O
particles	NN	O
using	NN	O
techniques	)	O
known	MD	O
in	VB	O
the	VBN	O
art.	IN	O
Recombinant	DT	O
virus	NN	O
can	NN	O
then	NN	O
be	CC	O
isolated	VBN	O
and	IN	O
delivered	JJ	O
to	NNS	O
cells	VBG	O
of	NNS	O
the	VBN	O
subject	IN	O
either	DT	O
in	.	O
vivo	JJ	O
or	NN	O
ex	MD	O
vivo.	RB	O
A	VB	O
number	VBN	O
of	CC	O
retroviral	VBN	O
systems	TO	O
have	NNS	O
been	IN	O
described,	DT	O
including,	NN	O
for	CC	O
example,	IN	O
the	NN	O
following:	CC	O
(U.S.	NN	O
Pat.	.	O
No.	DT	O
5,219,740;	NN	O
Miller	IN	B
et	JJ	I
al.	NNS	I
(1989)	VBP	I
Biotechniques	VBN	I
7:980;	,	I
Miller,	,	B
A.	IN	I
D.	,	I
(1990)	DT	I
Human	:	I
Gene	NNP	I
Therapy	.	I
1:5;	.	I
Scarpa	:	B
et	NNP	I
al.	FW	I
(1991)	.	I
Virology	)	I
180:849;	VBZ	I
Burns	:	B
et	,	I
al.	NNP	I
(1993)	NNP	I
Proc.	)	I
Natl.	NNP	I
Acad.	NNP	I
Sci.	NNP	I
USA	:	I
90:8033;	NNP	I
Boris-Lawrie	FW	B
et	.	I
al.	)	I
(1993)	NNP	I
Cur.	:	I
Opin.	NNP	I
Genet.	FW	I
Develop.	.	I
3:102;	)	I
GB	.	O
2200651;	.	O
EP	.	O
0415731;	.	O
EP	NNP	O
0345242;	:	O
WO	NNP	O
89/02468;	FW	O
WO	.	O
89/05349;	)	O
WO	.	O
89/09271;	.	O
WO	.	O
90/02806;	.	O
WO	:	O
90/07936;	NNP	O
WO	:	O
90/07936;	NNP	O
WO	:	O
94/03622;	NNP	O
WO	:	O
93/25698;	NNP	O
WO	:	O
93/25234;	NNP	O
WO	:	O
93/11230;	NNP	O
WO	:	O
93/10218;	NNP	O
WO	:	O
91/02805;	NNP	O
in	:	O
U.S.	NNP	O
Pat.	:	O
No.	NNP	O
5,219,740;	:	O
U.S.	NNP	O
Pat.	:	O
No.	NNP	O
4,405,712;	:	O
U.S.	NNP	O
Pat.	:	O
No.	NNP	O
4,861,719;	:	O
U.S.	NNP	O
Pat.	:	O
No.	IN	O
4,980,289	NNP	O
and	.	O
U.S.	.	O
Pat.	:	O
No.	NNP	O
4,777,127;	.	O
in	.	O
U.S.	:	O
Ser.	NNP	O
No.	.	O
07/800,921;	.	O
and	:	O
in	NNP	O
Vile	.	O
(1993)	.	O
Cancer	CD	O
Res	CC	O
53:3860-3864;	NNP	O
Vile	.	O
(1993)	.	O
Cancer	:	O
Res	IN	O
53:962-967;	NNP	O
Ram	.	O
(1993)	.	O
Cancer	:	O
Res	CC	O
53:83-88;	IN	O
Takamiya	NNP	O
(1992)	)	O
Neurosci	NNP	O
Res	NNP	O
33:493-503;	:	O
Baba	NNP	O
(1993)	)	O
J	NNP	O
Neurosurg	NNP	O
79:729-735;	:	O
Mann	NNP	O
(1983)	)	O
Cell	NNP	O
33:153;	NNP	O
Cane	:	O
(1984)	NNP	O
Proc	)	O
Natl	NNP	O
Acad	NNP	O
Sci	:	O
USA	NNP	O
81;	)	O
6349;	NNP	O
and	NNP	O
Miller	:	O
(1990)	NNP	O
Human	)	O
Gene	NNP	O
Therapy	:	O
1.	NNP	O
Sequences	)	O
useful	NNP	O
for	NNP	O
gene	NNP	O
therapy	NNP	O
applications	NNP	O
include,	:	O
but	:	O
are	CC	O
not	NNP	O
limited	)	O
to,	NNP	O
the	NNP	O
following.	NNP	O
Factor	.	O
VIII	NNS	O
cDNA,	JJ	O
including	IN	O
derivatives	NN	O
and	NN	O
deletions	NNS	O
thereof	,	O
(International	CC	O
Publication	VBP	O
Nos.	RB	O
WO	VBN	O
96/21035,	,	O
WO	DT	O
97/03193,	.	O
WO	NNP	O
97/03194,	NNP	O
WO	,	O
97/03195,	VBG	O
and	NNS	O
WO	CC	O
97/03191,	NNS	O
all	NN	O
of	NNP	O
which	NNP	O
are	.	O
hereby	NNP	O
incorporated	,	O
by	NNP	O
reference).	,	O
Factor	NNP	O
IX	,	O
cDNA	NNP	O
Kurachi	,	B
et	CC	I
al.	NNP	I
(1982)	,	I
Proc.	DT	I
Natl.	IN	I
Acad.	WDT	I
Sci.	VBP	I
USA	RB	I
79:6461-6464).(	VBN	O
Factor	IN	O
V	.	O
cDNA	NNP	O
can	NNP	O
be	NN	O
obtained	NNP	O
from	RB	O
pMT2-V	.	O
Jenny	)	B
(1987)	.	I
Proc.	.	I
Natl.	.	I
Acad.	.	I
Sci.	NNP	I
USA	.	I
84:4846,	NNP	I
A.T.C.C.	NNP	I
Deposit	NN	I
No.	MD	I
40515).(	VB	O
A	VBN	O
full-length	IN	O
factor	NN	O
V	NNP	O
cDNA,	)	O
or	.	O
a	.	O
B	.	O
domain	.	O
deletion	NNP	O
or	,	O
B	.	O
domain	NN	O
substitution	.	O
thereof,	.	O
can	DT	O
be	JJ	O
used.	NN	O
B	NNP	O
domain	,	O
deletions	CC	O
of	DT	O
factor	NNP	O
V,	NN	O
include	NN	O
those	CC	O
reported	NNP	O
by	VBP	O
Marquette	NN	B
(1995)	,	I
Blood	MD	I
86:3026	VB	I
and	.	O
Kane	NNP	B
(1990)	NN	I
Biochemistry	NNS	I
29:6762.	IN	I
Antithrombin	NN	O
III	,	O
cDNA	VBP	O
Prochownik	DT	B
(1983)	VBN	I
J.	IN	I
Biol.	NNP	I
Chem.	)	I
258:8389,	VBD	I
A.T.C.C.	CD	I
Deposit	CC	I
No.	NNP	I
57224/57225).(	)	O
Protein	NNP	O
C	.	O
encoding	NNP	O
cDNA	NNP	O
Foster	NN	B
(1984)	NNP	I
Proc.	)	I
Natl.	NNP	I
Acad.	.	I
Sci.	.	I
USA	,	I
81:4766;	.	I
Beckmann	NN	B
(1985)	.	I
Nucleic	.	I
Acids	NNP	I
Res.	NNP	I
13:5233).(	VBG	O
Prothrombin	NN	O
cDNA	NNP	O
can	)	O
be	.	O
obtained	.	O
by	.	O
restriction	.	O
enzyme	NNP	O
digestion	:	O
of	NNP	O
a	)	O
published	NNP	O
vector	NNP	O
Degen	.	B
(1983)	.	I
Biochemistry	NNP	I
22:2087).(	NN	O
The	MD	O
endothelial	VB	O
cell	VBN	O
surface	IN	O
protein,	NN	O
thrombomodulin,	JJ	O
is	NN	O
a	IN	O
necessary	DT	O
cofactor	VBN	O
for	NN	O
the	NNP	O
normal	)	O
activation	NNP	O
of	.	O
protein	DT	O
C	JJ	O
by	NN	O
thrombin.	NN	O
A	,	O
soluble	,	O
recombinant	VBZ	O
form	DT	O
has	JJ	O
been	NN	O
described	IN	O
Parkinson	DT	B
(1990)	JJ	I
J.	NN	I
Biol.	IN	I
Chem.	NN	I
265:12602;	NNP	I
Jackman	IN	B
(1987)	.	I
Proc.	DT	I
Natl.	JJ	I
Acad.	JJ	I
Sci.	NN	I
USA	VBZ	I
84:6425;	VBN	I
Shirai	VBN	B
(1988)	NNP	I
J.	)	I
Biochem.	NNP	I
103:281;	.	I
Wen	.	B
(1987)	:	I
Biochemistry	NNP	I
26:4350;	)	I
(Suzuki	.	O
(1987)	.	O
EMBO	.	O
J.	.	O
6:1891,	NNP	O
A.T.C.C.	:	O
Deposit	NNP	O
No.	)	O
61348,	NNP	O
61349).	.	O
Many	:	O
genetic	NNP	O
diseases	)	O
caused	NNP	O
by	:	O
inheritance	NNP	O
of	)	O
defective	NNP	O
genes	.	O
result	,	O
in	.	O
the	NN	O
failure	.	O
to	,	O
produce	.	O
normal	JJ	O
gene	JJ	O
products,	NNS	O
for	VBN	O
example,	IN	O
thalassemia,	NN	O
phenylketonuria,	IN	O
Lesch-Nyhan	JJ	O
syndrome,	NNS	O
severe	NN	O
combined	IN	O
immunodeficiency	DT	O
(SCID),	NN	O
hemophilia	TO	O
A	VB	O
and	JJ	O
B,	NN	O
cystic	,	O
fibrosis,	IN	O
Duchenne's	,	O
Muscular	,	O
Dystrophy,	,	O
inherited	NNP	O
emphysema	,	O
and	JJ	O
familial	VBN	O
hypercholesterolemia	NN	O
Mulligan	,	B
et	VBZ	I
al.	NNP	I
(1993)	CC	I
Science	,	I
260:926;	JJ	I
Anderson	,	B
et	POS	I
al.	NNP	I
(1992)	,	I
Science	VBD	I
256:808;	NN	I
Friedman	CC	B
et	JJ	I
al.	NN	I
(1989)	NNP	I
Science	RB	I
244:1275).(	.	O
Although	)	O
genetic	NN	O
diseases	:	O
may	NNP	O
result	FW	O
in	.	O
the	)	O
absence	NN	O
of	:	O
a	NNP	O
gene	VBZ	O
product,	.	O
endocrine	)	O
disorders,	NNP	O
such	.	O
as	IN	O
diabetes	JJ	O
and	NNS	O
hypopituitarism,	MD	O
are	VB	O
caused	IN	O
by	DT	O
the	NN	O
inability	IN	O
of	DT	O
the	NN	O
gene	,	O
to	JJ	O
produce	,	O
adequate	JJ	O
levels	IN	O
of	NNS	O
the	CC	O
appropriate	,	O
hormone	VBP	O
insulin	VBN	O
and	IN	O
human	DT	O
growth	NN	O
hormone	IN	O
respectively.	DT	O
In	NN	O
one	TO	O
aspect,	VB	O
gene	JJ	O
therapy	NNS	O
employing	IN	O
the	DT	O
constructs	JJ	O
and	NN	O
methods	NN	O
of	CC	O
the	JJ	O
present	NN	O
invention	NN	O
involves	.	O
the	IN	O
introduction	CD	O
of	,	O
normal	NN	O
recombinant	NN	O
genes	VBG	O
into	DT	O
T	NNS	O
cells	CC	O
so	NNS	O
that	IN	O
new	DT	O
or	JJ	O
missing	NN	O
proteins	VBZ	O
are	DT	O
produced	NN	O
by	IN	O
the	JJ	O
T	JJ	O
cells	NNS	O
after	IN	O
introduction	NNP	O
or	NNS	O
reintroduction	RB	O
thereof	IN	O
into	JJ	O
a	CC	O
patient.	JJ	O
A	NNS	O
number	VBP	O
of	VBN	O
genetic	IN	O
diseases	DT	O
have	NNP	O
been	NNS	O
selected	IN	O
for	NN	O
treatment	CC	O
with	NN	O
gene	NN	O
therapy,	IN	O
including	DT	O
adenine	.	O
deaminase	DT	O
deficiency,	NN	O
cystic	IN	O
fibrosis,	JJ	O
α1-antitrypsin	NNS	O
deficiency,	VBP	O
Gaucher's	VBN	O
syndrome,	VBN	O
as	IN	O
well	NN	O
as	IN	O
non-genetic	NN	O
diseases.	,	O
In	VBG	O
particular,	JJ	O
Gaucher's	NN	O
syndrome	,	O
is	JJ	O
a	,	O
genetic	JJ	O
disorder	,	O
characterized	POS	O
by	,	O
a	RB	O
deficiency	RB	O
of	IN	O
the	JJ	O
enzyme	.	O
glucocerebrosidase.	IN	O
This	,	O
enzyme	POS	O
deficiency	NN	O
leads	VBZ	O
to	DT	O
the	JJ	O
accumulation	NN	O
of	VBN	O
glucocerebroside	IN	O
in	DT	O
the	NN	O
lysosomes	IN	O
of	DT	O
all	JJ	O
cells	.	O
in	DT	O
the	JJ	O
body.	NN	O
For	VBZ	O
a	TO	O
review	DT	O
see	NN	O
Science	IN	B
256:794	NN	I
(1992)	IN	I
and	DT	O
Scriver	NNS	B
et	IN	I
al.,	DT	I
The	NNS	I
Metabolic	IN	I
Basis	DT	I
of	.	I
Inherited	IN	I
Disease,	DT	I
6th	NN	I
ed.,	NN	I
vol.	NNP	I
2,	CD	I
page	)	I
1677).Thus,	CC	O
gene	NNP	O
transfer	VBP	O
vectors	,	O
that	DT	O
express	NNP	O
glucocerebrosidase	NNP	O
can	IN	O
be	NNP	O
constructed	,	O
for	CD	O
use	,	O
in	.	O
the	,	O
treatment	NN	O
of	.	O
this	,	O
disorder.	NN	O
Likewise,	NN	O
gene	NNS	O
transfer	WDT	O
vectors	VBP	O
encoding	NN	O
lactase	MD	O
can	VB	O
be	VBN	O
used	IN	O
in	NN	O
the	IN	O
treatment	DT	O
of	NN	O
hereditary	IN	O
lactose	DT	O
intolerance,	.	O
those	,	O
expressing	NN	O
AD	NN	O
can	NNS	O
be	VBG	O
used	NN	O
for	MD	O
treatment	VB	O
of	VBN	O
ADA	IN	O
deficiency,	DT	O
and	NN	O
gene	IN	O
transfer	JJ	O
vectors	JJ	O
encoding	,	O
α1-antitrypsin	DT	O
can	VBG	O
be	NNP	O
used	MD	O
to	VB	O
treat	VBN	O
α1-antitrypsin	IN	O
deficiency.	NN	O
See	IN	O
Ledley,	NNP	B
F.	,	I
D.	CC	I
(1987)	NN	I
J.	NN	I
Pediatrics	NNS	I
110:157-174,	VBG	I
Verma,	NN	B
I.	MD	I
(November	VB	I
1987)	VBN	I
Scientific	TO	I
American	VB	I
pp.	JJ	I
68-84,	.	I
and	NNP	O
International	,	O
Publication	NNP	O
No.	NNP	O
WO	)	O
95/27512	NNP	O
entitled	NNP	O
“Gene	,	O
Therapy	,	O
Treatment	.	O
for	NNP	O
a	)	O
Variety	FW	O
of	JJ	O
Diseases	.	O
and	,	O
Disorders,”	CC	O
for	NNP	O
a	NNP	O
description	.	O
of	$	O
gene	CD	O
therapy	VBN	O
treatment	JJ	O
of	NNP	O
genetic	NNP	O
diseases.	IN	O
In	DT	O
still	NNP	O
further	IN	O
embodiments	NNP	O
of	CC	O
the	NNP	O
invention,	IN	O
nucleotide	DT	O
sequences	NN	O
which	IN	O
can	NN	O
be	NN	O
incorporated	NN	O
into	IN	O
a	JJ	O
gene	.	O
transfer	IN	O
vector	RB	O
include,	JJ	O
but	NNS	O
are	IN	O
not	DT	O
limited	,	O
to,	NN	O
proteins	NNS	O
associated	WDT	O
with	MD	O
enzyme-deficiency	VB	O
disorders,	VBN	O
such	IN	O
as	DT	O
the	NN	O
cystic	NN	O
fibrosis	NN	O
transmembrane	,	O
regulator	CC	O
(see,	VBP	O
for	RB	O
example,	VBN	O
U.S.	,	O
Pat.	NNS	O
No.	VBN	O
5,240,846	IN	O
and	NN	O
Larrick	,	O
et	JJ	O
al.	IN	O
(1991)	DT	O
Gene	JJ	O
Therapy	NN	O
Applications	NN	O
of	NN	O
Molecular	,	O
Biology,	IN	O
Elsevier,	,	O
New	NNP	O
York	.	O
and	.	O
adenosine	CD	O
deaminase	CC	O
(ADA)	NNP	O
(see	VBP	O
U.S.	.	O
Pat.	)	O
No.	NNP	O
5,399,346);	NNP	O
growth	NNP	O
factors,	IN	O
or	NNP	O
an	,	O
agonist	,	O
or	NNP	O
antagonist	NNP	O
of	CC	O
a	JJ	O
growth	NN	O
factor	)	O
Bandara	VB	B
et	NNP	I
al.	.	I
(1992)	.	I
DNA	:	I
and	NN	I
Cell	,	I
Biology,	CC	I
11:227);(	DT	O
one	NN	O
or	CC	O
more	NN	O
tumor	IN	O
suppressor	DT	O
genes	NN	O
such	NN	O
as	NNP	O
p53,	RB	O
Rb,	.	O
or	)	O
C-CAMI	NN	O
Kleinerman	CC	B
et	NNP	I
al.	,	I
(1995)	:	I
Cancer	CD	I
Research	CC	I
55:2831);(	JJR	O
a	NN	O
molecule	NN	O
that	NNS	O
modulates	JJ	O
the	IN	O
immune	,	O
system	,	O
of	CC	O
an	NNP	O
organism,	NNP	O
such	VBZ	O
as	.	O
a	)	O
HLA	NNP	O
molecule	NNP	O
Nabel	:	B
et	DT	I
al.	NN	I
(1993)	WDT	I
Proc.	VBZ	I
Natl.	DT	I
Acad.	JJ	I
Sci.	NN	I
USA	IN	I
90:11307);(	DT	O
a	,	O
ribozyme	JJ	O
Larsson	IN	B
et	DT	I
al.	NNP	I
(1996)	NN	I
Virology	NNP	I
219:161);(	RB	O
a	.	O
peptide	)	O
nucleic	.	O
acid	.	O
Hirshman	.	B
et	.	I
al.	NNP	I
(1996)	:	I
J.	DT	I
Invest.	NN	I
Med.	NNP	I
44:347);(	RB	O
an	.	O
antisense	)	O
molecule	NNP	O
Bordier	:	B
et	DT	I
al.	NN	I
(1995)	JJ	I
Proc.	NN	I
Natl.	NNP	I
Acad.	VBZ	I
Sci.	.	I
USA	)	I
92:9383)	.	I
(which	.	O
can	.	O
be	:	O
used	DT	O
to	NN	O
down-regulate	NN	O
the	NNP	O
expression	RB	O
or	.	O
synthesis	)	O
of	.	O
aberrant	.	O
or	.	O
foreign	.	O
proteins,	NNP	O
such	)	O
as	WDT	O
HIV	MD	O
proteins	VB	O
or	VBN	O
a	TO	O
wide	VB	O
variety	DT	O
of	NN	O
oncogenes	CC	O
such	NN	O
as	IN	O
p53	NN	O
(Hesketh,	CC	O
The	JJ	O
Oncogene	,	O
Facts	JJ	O
Book,	IN	O
Academic	NNP	O
Press,	VBZ	O
New	CC	O
York,	DT	O
(1995);	JJ	O
a	NN	O
biopharmaceutical	IN	O
agent	NNS	O
or	JJ	O
antisense	IN	O
molecule	NN	O
used	,	O
to	DT	O
treat	NNP	O
HIV-infection,	NNP	O
such	,	O
as	NNP	O
an	,	O
inhibitor	NNP	O
of	,	O
p24	:	O
Nakashima	DT	B
et	JJ	I
al.	NN	I
(1994)	CC	I
Nucleic	NN	I
Acids	NN	I
Res.	VBN	I
22:5004);(	TO	O
or	VB	O
reverse-transcriptase	,	O
(see,	JJ	O
Bordier,	IN	O
supra).	DT	O
Other	NN	O
proteins	IN	O
of	NN	O
therapeutic	NNP	O
interest	RB	O
can	.	O
be	)	O
expressed	NNP	O
in	NNP	O
vivo	.	O
by	:	O
gene	CC	O
transfer	NN	O
vectors	,	O
using	,	O
the	.	O
methods	JJ	O
of	NNS	O
the	IN	O
invention.	JJ	O
For	NN	O
instance	MD	O
sustained	VB	O
in	VBN	O
vivo	IN	O
expression	NN	O
of	IN	O
tissue	NN	O
factor	NN	O
inhibitory	NNS	O
protein	VBG	O
(TFPI)	DT	O
is	NNS	O
useful	IN	O
for	DT	O
treatment	.	O
of	IN	O
conditions	NN	O
including	VBN	O
sepsis	IN	O
and	JJ	O
DIC	NN	O
and	IN	O
in	NN	O
preventing	NN	O
reperfusion	NN	O
injury.	NN	O
(See	)	O
International	VBZ	O
Publications	JJ	O
Nos.	IN	O
WO	NN	O
93/24143,	IN	O
WO	NNS	O
93/25230	VBG	O
and	NN	O
WO	CC	O
96/06637).	NNP	O
Nucleic	CC	O
acid	IN	O
sequences	VBG	O
encoding	NN	O
various	.	O
forms	VB	O
of	NNP	O
TFPI	NNP	O
can	.	O
be	NNP	O
obtained,	,	O
for	NNP	O
example,	CD	O
as	CC	O
described	NNP	O
in	.	O
U.S.	NNP	O
Pat.	NN	O
Nos.	NNS	O
4,966,852;	VBG	O
5,106,833;	JJ	O
and	NNS	O
5,466,783,	IN	O
and	NNP	O
incorporated	MD	O
into	VB	O
the	,	O
gene	IN	O
transfer	,	O
vectors	IN	O
described	VBN	O
herein.	IN	O
Erythropoietin	NNP	O
(EPO)	.	O
and	.	O
leptin	:	O
can	:	O
also	CC	O
be	,	O
expressed	CC	O
in	VBN	O
vivo	IN	O
from	DT	O
genetically	NN	O
modified	NN	O
T	NNS	O
cells	VBD	O
according	.	O
to	NNP	O
the	)	O
methods	CC	O
of	NN	O
the	MD	O
invention.	RB	O
For	VB	O
instance	VBN	O
EPO	IN	O
is	NN	O
useful	IN	O
in	RB	O
gene	VBN	O
therapy	NNP	O
treatment	NNS	O
of	VBG	O
a	TO	O
variety	DT	O
of	NNS	O
disorders	IN	O
including	DT	O
anemia	.	O
(see	IN	O
International	NN	O
Publication	NNP	O
No.	VBZ	O
WO	JJ	O
95/13376	IN	O
entitled	NN	O
“Gene	NN	O
Therapy	NN	O
for	IN	O
Treatment	DT	O
of	NN	O
Anemia”).	IN	O
Sustained	NNS	O
delivery	VBG	O
of	NN	O
leptin	VB	O
by	NNP	O
the	NNP	O
methods	.	O
of	$	O
the	CD	O
invention	VBN	O
is	NN	O
useful	NNP	O
in	IN	O
treatment	NNP	O
of	IN	O
obesity.	.	O
See	JJ	O
International	NN	O
Publication	IN	O
No.	NN	O
WO	IN	O
96/05309	DT	O
for	NNS	O
a	IN	O
description	DT	O
of	NN	O
the	VBZ	O
leptin	JJ	O
gene	IN	O
and	NN	O
the	IN	O
use	.	O
thereof	NNP	O
in	NNP	O
the	NNP	O
treatment	.	O
of	$	O
obesity.	CD	O
A	IN	O
variety	DT	O
of	NN	O
other	IN	O
disorders	DT	O
can	JJ	O
also	NN	O
be	CC	O
treated	DT	O
by	NN	O
the	NN	O
methods	IN	O
of	DT	O
the	NN	O
invention.	IN	O
For	.	O
example,	DT	O
sustained	NN	O
in	IN	O
vivo	JJ	O
systemic	NNS	O
production	MD	O
of	RB	O
apolipoprotein	VB	O
E	VBN	O
or	IN	O
apolipoprotein	DT	O
A	NNS	O
from	IN	O
genetically	DT	O
modified	.	O
T	IN	O
cells	,	O
can	VBN	O
be	IN	O
used	JJ	O
for	JJ	O
treatment	NN	O
of	IN	O
hyperlipidemia	JJ	O
(see	NNP	O
Breslow	CC	B
et	VB	I
al.	DT	I
(1994)	IN	I
Biotechnology	RB	I
12:365).Sustained	VBN	O
production	NNP	O
of	NNS	O
angiotensin	MD	O
receptor	VB	O
inhibitor	VBN	O
Goodfriend	IN	B
et	NN	I
al.	IN	I
(1996)	NN	I
N.	VB	I
Engl.	NNP	I
J.	FW	I
Med.	.	I
334:1469)	)	I
(can	NNP	O
be	.	O
provided	VBN	O
by	NN	O
the	IN	O
methods	NN	O
described	NN	O
herein.	NN	O
As	NNP	O
yet	VBZ	O
an	.	O
additional	)	O
example,	NNP	O
the	.	O
long	NNP	O
term	.	O
in	)	O
vivo	MD	O
systemic	VB	O
production	VBN	O
of	IN	O
angiostatin	DT	O
is	NNS	O
useful	VBD	O
in	.	O
the	IN	O
treatment	RB	O
of	DT	O
a	JJ	O
variety	,	O
of	DT	O
tumors.	JJ	O
(See	NN	O
O'Reilly	IN	B
et	JJ	I
al.	JJ	I
(1996)	NN	I
Nature	IN	I
Med.	NN	I
2:689).In	VBZ	O
other	JJ	O
embodiments,	IN	O
gene	DT	O
transfer	NN	O
vectors	IN	O
can	DT	O
be	NN	O
constructed	IN	O
to	.	O
encode	VB	O
a	RB	O
cytokine	JJ	O
or	.	O
other	)	O
immunomodulatory	NN	O
molecule.	.	O
For	.	O
example,	IN	O
nucleic	JJ	O
acid	,	O
sequences	NN	O
encoding	NN	O
native	NNS	O
IL-2	MD	O
and	VB	O
gamma-interferon	VBN	O
can	TO	O
be	VB	O
obtained	DT	O
as	NN	O
described	CC	O
in	JJ	O
U.S.	JJ	O
Pat.	.	O
Nos.	IN	O
4,738,927	,	O
and	JJ	O
5,326,859,	NN	O
respectively,	NNS	O
while	VBG	O
useful	JJ	O
muteins	JJ	O
of	CC	O
these	NN	O
proteins	MD	O
can	VB	O
be	VBN	O
obtained	IN	O
as	VBN	O
described	IN	O
in	NNP	O
U.S.	.	O
Pat.	.	O
No.	CD	O
4,853,332.	CC	O
Nucleic	,	O
acid	,	O
sequences	IN	O
encoding	JJ	O
the	NNS	O
short	IN	O
and	DT	O
long	NNS	O
forms	MD	O
of	VB	O
mCSF	VBN	O
can	IN	O
be	VBN	O
obtained	IN	O
as	NNP	O
described	.	O
in	.	O
U.S.	.	O
Pat.	NNP	O
Nos.	NN	O
4,847,201	NNS	O
and	VBG	O
4,879,227,	DT	O
respectively.	JJ	O
In	CC	O
particular	JJ	O
aspects	NNS	O
of	IN	O
the	NN	O
invention,	MD	O
retroviral	VB	O
vectors	VBN	O
expressing	IN	O
cytokine	VBN	O
or	IN	O
immunomodulatory	NNP	O
genes	.	O
can	.	O
be	CD	O
produced	CC	O
as	,	O
described	.	O
herein	IN	O
(for	JJ	O
example,	NNS	O
employing	IN	O
the	DT	O
packaging	,	O
cell	JJ	O
lines	NNS	O
of	VBG	O
the	NN	O
present	CC	O
invention)	JJ	O
and	NNS	O
in	MD	O
International	VB	O
Application	VBN	O
No.	IN	O
PCT	JJ	O
US	NN	O
94/02951,	IN	O
entitled	,	O
“Compositions	VBG	O
and	DT	O
Methods	NN	O
for	NN	O
Cancer	NNS	O
Immunotherapy.”	IN	O
Examples	DT	O
of	JJ	O
suitable	)	O
immunomodulatory	CC	O
molecules	IN	O
for	NNP	O
use	NNP	O
herein	.	O
include	NNP	O
the	NNP	O
following:	,	O
IL-1	VBN	O
and	NNS	O
IL-2	CC	O
Karupiah	NNS	B
et	IN	I
al.	NNP	I
(1990)	NNP	I
J.	NNP	I
Immunology	IN	I
144:290-298,	JJ	I
Weber	NN	B
et	NNS	I
al.	IN	I
(1987).	NN	I
J.	NN	I
Exp.	VBP	I
Med.	DT	I
166:1716-1733,	:	I
Gansbacher	JJ	B
et	CC	I
al.	NNP	I
(1990)	NNP	I
J.	RB	I
Exp.	.	I
Med.	)	I
172:1217-1224,	.	I
(and	NNP	O
U.S.	,	O
Pat.	NNP	O
No.	CC	O
4,738,927);	.	O
IL-3	.	O
and	NNP	O
IL-4	.	O
Tepper	.	B
et	,	I
al.	NNP	I
(1989)	CC	I
Cell	.	I
57:503-512,	)	I
Golumbek	NNP	B
et	.	I
al.	.	I
(1991)	,	I
Science	CC	I
254:713-716,	NNP	I
(and	.	O
U.S.	.	O
Pat.	:	O
No.	JJ	O
5,017,691);	CC	O
IL-5	NNP	O
and	NNP	O
IL-6	VBZ	O
Brakenhof	.	B
et	)	I
al.	NNP	I
(1987)	,	I
J.	NNP	I
Immunol.	CC	I
139:4116-4121,	.	I
(and	)	O
International	NNP	O
Publication	,	O
No.	CC	O
WO	NNP	O
90/06370);	.	O
IL-7	.	O
(U.S.	:	O
Pat.	JJ	O
No.	CC	O
4,965,195);	NNP	O
IL-8,	NNP	O
IL-9,	RB	O
IL-10,	.	O
IL-11,	)	O
IL-12,	NNP	O
and	.	O
IL-13	,	O
(Cytokine	CC	O
Bulletin,	NNP	O
Summer	NNP	O
1994);	.	O
IL-14	NNP	O
and	:	O
IL-15;	NNP	O
alpha	NNP	O
interferon	.	O
Finter	.	B
et	:	I
al.	,	I
(1991)	,	I
Drugs	,	I
42:749-765,	,	I
(U.S.	,	O
Pat.	CC	O
Nos.	NNP	O
4,892,743	NNP	O
and	,	O
4,966,843,	NNP	O
International	:	O
Publication	JJ	O
No.	CC	O
WO	:	O
85/02862,	JJ	O
Nagata	NN	B
et	NNP	I
al.	RB	I
(1980)	.	I
Nature	)	I
284:316-320,	NNP	I
Familletti	,	B
et	NNP	I
al.	.	I
(1981)	.	I
Methods	CD	I
in	CC	I
Enz.	,	I
78:387-394,	NNP	I
Twu	NNP	B
et	.	I
al.	NNP	I
(1989)	,	I
Proc.	NNP	I
Natl.	CC	I
Acad.	.	I
Sci.	)	I
USA	NN	I
86:2046-2050,	,	I
and	NNP	O
Faktor	CC	B
et	.	I
al.	)	I
(1990)	NNS	I
Oncogene	IN	I
5:867-872);	.	I
beta-interferon	,	O
Seif	NNP	B
et	CC	I
al.	.	I
(1991)	)	I
J.	.	I
Virol.	.	I
65:664-671);(	.	O
gamma-interferons	.	O
Radford	NNP	B
et	,	I
al.	CC	I
(1991)	NNP	I
The	VBP	I
American	.	I
Society	)	I
of	NNP	I
Hepatology	:	I
20082015,	NN	I
Watanabe	NNP	B
et	RB	I
al.	.	I
(1989)	)	I
Proc.	NNP	I
Natl.	.	I
Acad.	:	I
Sci.	NNS	I
USA	NNP	I
86:9456-9460,	VBZ	I
Gansbacher	.	B
et	)	I
al.	DT	I
(1990)	JJ	I
Cancer	NNP	I
Research	IN	I
50:7820-7825,	NNP	I
Maio	,	B
et	NNP	I
al.	CC	I
(1989)	.	I
Can.	)	I
Immunol.	.	I
Immunother.	.	I
30:34-42,	.	I
(and	.	O
U.S.	NNP	O
Pat.	,	O
Nos.	NNP	O
4,762,791	CC	O
and	.	O
4,727,138);	)	O
G-CSF	NNP	O
(U.S.	NNP	O
Pat.	,	O
Nos.	NNP	O
4,999,291	CC	O
and	.	O
4,810,643);	)	O
GM-CSF	.	O
(International	.	O
Publication	.	O
No.	,	O
WO	CC	O
85/04188);	NNP	O
tumor	.	O
necrosis	.	O
factors	CD	O
(TNFs)	CC	O
Jayaraman	:	B
et	NNP	I
al.	NNP	I
(1990)	.	I
J.	.	I
Immunology	CD	I
144:942-951);(	CC	O
CD3	:	O
Krissanen	NNP	B
et	NNP	I
al.	NNP	I
(1987)	.	I
Immunogenetics	NNP	I
26:258-266);(	:	O
ICAM-1	CC	O
Altman	NN	B
et	NNS	I
al.	)	I
(1989)	NNP	I
Nature	VBZ	I
338:512-514,	.	I
Simmons	)	B
et	.	I
al.	NNP	I
(1988)	:	I
Nature	NNP	I
331:624-627);(	NNP	O
ICAM-2,	RB	O
LFA-1,	.	O
LFA-3	)	O
Wallner	NNPS	B
et	:	I
al.	NNP	I
(1987)	NNP	I
J.	VBZ	I
Exp.	.	I
Med.	)	I
166:923-932);(	NN	O
MHC	,	O
class	NNP	O
I	CC	O
molecules,	.	O
MHC	)	O
class	NNP	O
II	:	O
molecules,	,	O
B7.1-.3,	,	O
β2-microglobulin	NNP	O
Parnes	NNP	B
et	RB	I
al.	.	I
(1981)	)	I
Proc.	NNP	I
Natl.	.	I
Acad.	.	I
Sci.	:	I
USA	NNP	I
78:2253-2257);(	NN	O
chaperones	PRP	O
such	,	O
as	NNP	O
calnexin;	NN	O
and	NNP	O
MHC-linked	,	O
transporter	,	O
proteins	NNP	O
or	NNP	O
analogs	RB	O
thereof	.	O
Powis	)	B
et	.	I
al.	.	I
(1991)	.	I
Nature	.	I
354:528-531).(	NNP	O
Immunomodulatory	:	O
factors	NNS	O
may	JJ	O
also	IN	O
be	:	O
agonists,	CC	O
antagonists,	JJ	O
or	NN	O
ligands	NNS	O
for	CC	O
these	NNS	O
molecules.	NNS	O
For	NNP	O
example,	RB	O
soluble	.	O
forms	)	O
of	NNP	O
receptors	.	O
can	JJ	O
often	NNS	O
behave	MD	O
as	RB	O
antagonists	VB	O
for	,	O
these	,	O
types	CC	O
of	VBZ	O
factors,	IN	O
as	DT	O
can	.	O
mutated	IN	O
forms	,	O
of	JJ	O
the	NNS	O
factors	IN	O
themselves.	NNS	O
Nucleic	MD	O
acid	RB	O
molecules	VB	O
that	IN	O
encode	NNS	O
the	IN	O
above-described	DT	O
substances,	NNS	O
as	IN	O
well	,	O
as	IN	O
other	MD	O
nucleic	VBD	O
acid	NNS	O
molecules	IN	O
that	DT	O
are	NNS	O
advantageous	.	O
for	NNP	O
use	NN	O
within	NNS	O
the	WDT	O
present	VBP	O
invention,	DT	O
may	JJ	O
be	,	O
readily	RB	O
obtained	RB	O
from	IN	O
a	JJ	O
variety	JJ	O
of	NN	O
sources,	NNS	O
including,	WDT	O
for	VBP	O
example,	JJ	O
depositories	IN	O
such	NN	O
as	IN	O
the	DT	O
American	JJ	O
Type	,	O
Culture	MD	O
Collection,	VB	O
or	RB	O
from	VBN	O
commercial	IN	O
sources	DT	O
such	NN	O
as	IN	O
British	,	O
Bio-Technology	,	O
Limited	IN	O
(Cowley,	,	O
Oxford	NNS	O
England).	JJ	O
Representative	IN	O
examples	DT	O
include	NNP	O
BBG	NNP	O
12	NNP	O
(containing	,	O
the	CC	O
GM-CSF	IN	O
gene	JJ	O
coding	NNS	O
for	JJ	O
the	IN	O
mature	JJ	O
protein	NNP	O
of	NNP	O
127	,	O
amino	NNP	O
acids),	.	O
BBG	JJ	O
6	NNS	O
(which	VBP	O
contains	NNP	O
sequences	CD	O
encoding	VBG	O
gamma	DT	O
interferon),	NNP	O
A.T.C.C.	NN	O
Deposit	VBG	O
No.	IN	O
39656	DT	O
(which	NN	O
contains	NN	O
sequences	IN	O
encoding	CD	O
TNF),	JJ	O
A.T.C.C.	,	O
Deposit	NNP	O
No.	CD	O
20663	WDT	O
(which	VBZ	O
contains	NNS	O
sequences	VBG	O
encoding	NN	O
alpha-interferon),	,	O
A.T.C.C.	.	O
Deposit	NN	O
Nos.	.	O
31902,	CD	O
31902	WDT	O
and	VBZ	O
39517	NNS	O
(which	VBG	O
contain	,	O
sequences	.	O
encoding	NN	O
beta-interferon),	.	O
A.T.C.C.	CD	O
Deposit	WDT	O
No.	VBZ	O
67024	NNS	O
(which	VBG	O
contains	,	O
a	.	O
sequence	NNP	O
which	.	O
encodes	,	O
Interleukin-1b),	CD	O
A.T.C.C.	CC	O
Deposit	CD	O
Nos.	WDT	O
39405,	VBP	O
39452,	NNS	O
39516,	VBG	O
39626	,	O
and	.	O
39673	NN	O
(which	.	O
contain	CD	O
sequences	WDT	O
encoding	VBZ	O
Interleukin-2),	DT	O
A.T.C.C.	NN	O
Deposit	WDT	O
Nos.	VBZ	O
59399,	,	O
59398,	.	O
and	NNP	O
67326	.	O
(which	,	O
contain	,	O
sequences	,	O
encoding	CD	O
Interleukin-3),	CC	O
A.T.C.C.	CD	O
Deposit	WDT	O
No.	VBP	O
57592	NNS	O
(which	VBG	O
contains	,	O
sequences	.	O
encoding	NNP	O
Interleukin-4),	.	O
A.T.C.C.	,	O
Deposit	,	O
Nos.	CC	O
59394	CD	O
and	WDT	O
59395	VBP	O
(which	NNS	O
contain	VBG	O
sequences	,	O
encoding	.	O
Interleukin-5),	NN	O
and	.	O
A.T.C.C.	CD	O
Deposit	WDT	O
No.	VBZ	O
67153	NNS	O
(which	VBG	O
contains	,	O
sequences	.	O
encoding	NNP	O
Interleukin-6).	.	O
Plasmids	CD	O
containing	CC	O
cytokine	CD	O
genes	WDT	O
or	VBP	O
immunomodulatory	NNS	O
genes	VBG	O
(International	,	O
Publication	CC	O
Nos.	.	O
WO	NN	O
94/02951	.	O
and	CD	O
WO	WDT	O
96/21015,	VBZ	O
both	NNS	O
of	VBG	O
which	.	O
are	NNS	O
incorporated	VBG	O
by	NN	O
reference	NNS	O
in	CC	O
their	NN	O
entirety)	NNS	O
can	NNP	O
be	NNP	O
digested	.	O
with	$	O
appropriate	CD	O
restriction	CC	O
enzymes,	NNP	O
and	,	O
DNA	DT	O
fragments	IN	O
containing	WDT	O
the	VBP	O
particular	VBN	O
gene	IN	O
of	NN	O
interest	IN	O
can	PRP$	O
be	)	O
inserted	MD	O
into	VB	O
a	VBN	O
gene	IN	O
transfer	JJ	O
vector	NN	O
using	,	O
standard	CC	O
molecular	NNP	O
biology	NNS	O
techniques.	VBG	O
(See,	DT	O
e.g.,	JJ	O
Sambrook	NN	O
et	IN	O
al.,	NN	O
supra.,	MD	O
or	VB	O
Ausubel	VBN	B
et	IN	I
al.	DT	I
(eds)	NN	I
Current	NN	I
Protocols	NN	I
in	VBG	I
Molecular	JJ	I
Biology,	JJ	I
Greene	NN	I
Publishing	.	I
and	,	I
Wiley-Interscience).Exemplary	,	O
hormones,	NNP	O
growth	FW	O
factors	,	O
and	,	O
other	CC	O
proteins	NNP	O
which	CC	O
are	.	O
useful	)	O
for	NNP	O
long	NNP	O
term	IN	O
expression	NNP	O
are	,	O
described,	NNP	O
for	NNP	O
example,	CC	O
in	.	O
European	JJ	O
Publication	,	O
No.	NN	O
0437478B1,	NNS	O
entitled	CC	O
“Cyclodextrin-Peptide	JJ	O
Complexes.”	NNS	O
Nucleic	WDT	O
acid	VBP	O
sequences	JJ	O
encoding	IN	O
a	JJ	O
variety	NN	O
of	NN	O
hormones	VBP	O
can	,	O
be	IN	O
used,	,	O
including	IN	O
those	JJ	O
encoding	NNP	O
human	.	O
growth	,	O
hormone,	VBN	O
insulin,	JJ	O
calcitonin,	NNP	O
prolactin,	NNP	O
follicle	NN	O
stimulating	NNS	O
hormone	VBG	O
(FSH),	DT	O
luteinizing	NN	O
hormone	IN	O
(LH),	NNS	O
human	MD	O
chorionic	VB	O
gonadotropin	,	O
(HCG),	VBG	O
and	DT	O
thyroid	VBG	O
stimulating	JJ	O
hormone	NN	O
(TSH).	,	O
A	,	O
variety	,	O
of	,	O
different	NN	O
forms	VBG	O
of	NN	O
IGF-1	,	O
and	VBG	O
IGF-2	NN	O
growth	,	O
factor	JJ	O
polypeptides	NN	O
are	NN	O
also	,	O
well	CC	O
known	JJ	O
the	VBG	O
art	NN	O
and	.	O
can	DT	O
be	NN	O
incorporated	IN	O
into	JJ	O
gene	NNS	O
transfer	IN	O
vectors	NNP	O
for	CC	O
long	NNP	O
term	NN	O
expression	NN	O
in	NNS	O
vivo.	VBP	O
See,	RB	O
e.g.,	RB	O
European	VBN	O
Patent	DT	O
No.	NN	O
0123228B1,	CC	O
published	MD	O
for	VB	O
grant	VBN	O
Sep.	IN	O
19,	NN	O
1993,	NN	O
entitled	NNS	O
“Hybrid	IN	O
DNA	JJ	O
Synthesis	NN	O
of	NN	O
Mature	IN	O
Insulin-like	.	O
Growth	,	O
Factors.”	,	O
As	JJ	O
an	NNP	O
additional	.	O
example,	,	O
the	VBN	O
long	IN	O
term	NN	O
in	NNP	O
vivo	,	O
expression	,	O
of	VBD	O
different	JJ	O
forms	NNP	O
of	NNP	O
fibroblast	IN	O
growth	NNP	O
factor	NNP	O
can	NNP	O
also	NNP	O
be	IN	O
effected	DT	O
employing	JJ	O
the	,	O
compositions	DT	O
and	JJ	O
methods	NN	O
of	IN	O
invention.	JJ	O
See,	NN	O
e.g.,	IN	O
U.S.	JJ	O
Pat.	NNS	O
Nos.	IN	O
5,464,774,	JJ	O
5,155,214,	NN	O
and	NN	O
4,994,559	MD	O
for	RB	O
a	VB	O
description	VBN	O
of	VBG	O
different	DT	O
fibroblast	NNS	O
growth	CC	O
factors.	NNS	O
Polynucleotide	IN	O
sequences	.	O
coding	,	O
for	,	O
the	NNP	O
above-described	.	O
molecules	.	O
can	,	O
be	,	O
obtained	CC	O
using	CD	O
recombinant	IN	O
methods,	DT	O
such	NN	O
as	IN	O
by	JJ	O
screening	JJ	O
cDNA	NN	O
and	.	O
genomic	NNP	O
libraries	NNS	O
from	VBG	O
cells	IN	O
expressing	DT	O
the	JJ	O
gene,	NNS	O
or	MD	O
by	VB	O
deriving	VBN	O
the	VBG	O
gene	JJ	O
from	,	O
a	JJ	O
vector	IN	O
known	IN	O
to	VBG	O
include	NN	O
the	CC	O
same.	JJ	O
For	NNS	O
example,	IN	O
plasmids	NNS	O
which	VBG	O
contain	DT	O
sequences	,	O
that	CC	O
encode	IN	O
altered	VBG	O
cellular	DT	O
products	NN	O
may	IN	O
be	DT	O
obtained	NN	O
from	VBN	O
a	TO	O
depository	VB	O
such	DT	O
as	.	O
the	IN	O
A.T.C.C.,	,	O
or	NNS	O
from	WDT	O
commercial	VBP	O
sources.	NNS	O
Plasmids	WDT	O
containing	VBP	O
the	VBN	O
nucleotide	JJ	O
sequences	NNS	O
of	MD	O
interest	VB	O
can	VBN	O
be	IN	O
digested	DT	O
with	NN	O
appropriate	JJ	O
restriction	IN	O
enzymes,	DT	O
and	,	O
DNA	CC	O
fragments	IN	O
containing	JJ	O
the	.	O
nucleotide	NNS	O
sequences	VBG	O
can	DT	O
be	JJ	O
inserted	NNS	O
into	IN	O
a	NN	O
gene	MD	O
transfer	VB	O
vector	VBN	O
using	IN	O
standard	JJ	O
molecular	NN	O
biology	,	O
techniques.	CC	O
Alternatively,	NNP	O
cDNA	NNS	O
sequences	VBG	O
for	DT	O
use	JJ	O
with	NNS	O
the	MD	O
present	VB	O
invention	VBN	O
may	IN	O
be	DT	O
obtained	NN	O
from	NN	O
cells	NN	O
which	VBG	O
express	JJ	O
or	JJ	O
contain	NN	O
the	.	O
sequences,	,	O
using	NN	O
standard	NNS	O
techniques,	IN	O
such	NN	O
as	IN	O
phenol	DT	O
extraction	JJ	O
and	NN	O
PCR	MD	O
of	VB	O
cDNA	VBN	O
or	IN	O
genomic	NNS	O
DNA.	WDT	O
See,	VBP	O
e.g.,	CC	O
Sambrook	VBP	O
et	DT	O
al.,	,	O
supra,	VBG	O
for	JJ	O
a	,	O
description	JJ	O
of	IN	O
techniques	JJ	O
used	NN	O
to	CC	O
obtain	NNP	O
and	IN	O
isolate	NN	O
DNA.	CC	O
Briefly,	JJ	O
mRNA	.	O
from	,	O
a	,	O
cell	NNP	O
which	FW	O
expresses	,	O
the	,	O
gene	IN	O
of	DT	O
interest	NN	O
can	IN	O
be	NNS	O
reverse	VBN	O
transcribed	TO	O
with	VB	O
reverse	CC	O
transcriptase	VB	O
using	.	O
oligo-dT	,	O
or	NN	O
random	IN	O
primers.	DT	O
The	NN	O
single	WDT	O
stranded	VBZ	O
cDNA	DT	O
may	NN	O
then	IN	O
be	NN	O
amplified	MD	O
by	VB	O
PCR	JJ	O
(see	VBN	O
U.S.	IN	O
Pat.	JJ	O
Nos.	NN	O
4,683,202,	VBG	O
4,683,195	JJ	O
and	CC	O
4,800,159,	JJ	O
see	.	O
also	DT	O
PCR	JJ	B
Technology:	VBD	I
Principles	NN	I
and	MD	I
Applications	RB	I
for	VB	I
DNA	VBN	I
Amplification,	IN	I
Erlich	NNP	I
(ed.),	VB	I
Stockton	NNP	I
Press,	.	I
1989))	.	I
using	,	O
oligonucleotide	CD	O
primers	CC	O
complementary	,	O
to	NN	O
sequences	RB	O
on	NNP	O
either	:	O
side	NNS	O
of	CC	O
desired	NNS	O
sequences.	IN	O
The	NNP	O
nucleotide	,	O
sequence	NNP	O
of	,	O
interest	NNP	O
can	,	O
also	)	O
be	VBG	O
produced	JJ	O
synthetically,	NNS	O
rather	VBP	O
than	TO	O
cloned,	NNS	O
using	IN	O
a	DT	O
DNA	NN	O
synthesizer	IN	O
(e.g.,	JJ	O
an	.	O
Applied	DT	O
Biosystems	JJ	O
Model	NN	O
392	IN	O
DNA	NN	O
Synthesizer,	MD	O
available	RB	O
from	VB	O
ABI,	VBN	O
Foster	,	O
City,	RB	O
Calif.).	IN	O
The	,	O
nucleotide	VBG	O
sequence	DT	O
can	NN	O
be	NN	O
designed	,	O
with	DT	O
the	NNP	O
appropriate	NNP	O
codons	NNP	O
for	CD	O
the	NNP	O
expression	,	O
product	JJ	O
desired.	IN	O
The	,	O
complete	NNP	O
sequence	,	O
is	.	O
assembled	DT	O
from	JJ	O
overlapping	NN	O
oligonucleotides	MD	O
prepared	VB	O
by	VBN	O
standard	IN	O
methods	DT	O
and	JJ	O
assembled	NNS	O
into	IN	O
a	DT	O
complete	NN	O
coding	NN	O
sequence.	.	O
See,	DT	O
e.g.,	JJ	O
Edge	NN	B
(1981)	VBZ	I
Nature	VBN	I
292:756;	IN	I
Nambair	VBG	B
et	NNS	I
al.	VBN	I
(1984)	IN	I
Science	JJ	I
223:1299;	NNS	I
Jay	CC	B
et	VBD	I
al.	IN	I
(1984)	DT	I
J.	JJ	I
Biol.	NN	I
Chem.	.	I
259:6311.
The	,	O
synthetic	,	O
expression	NNP	O
cassettes	)	O
of	NN	O
the	:	O
present	NNP	O
invention	FW	O
can	.	O
be	)	O
employed	NN	O
in	:	O
the	NNP	O
construction	FW	O
of	.	O
packaging	)	O
cell	NNP	O
lines	.	O
for	.	O
use	.	O
with	DT	O
retroviral	JJ	O
vectors.	NN	O
One	NNS	O
type	IN	O
of	DT	O
retrovirus,	JJ	O
the	NN	O
murine	MD	O
leukemia	VB	O
virus,	VBN	O
or	IN	O
“MLV”,	DT	O
has	NN	O
been	IN	O
widely	NN	O
utilized	NN	O
for	NNS	O
gene	IN	O
therapy	NN	O
applications	IN	O
(see	JJ	O
generally	.	O
Mann	CD	B
et	NN	I
al.	IN	I
(Cell	,	I
33:153,	DT	I
1993),	NN	I
Cane	NN	B
and	,	I
Mulligan	CC	I
(Proc,	,	I
Nat'l.	VBZ	I
Acad.	VBN	I
Sci.	RB	I
USA	VBN	I
81:6349,	IN	I
1984),	NN	I
and	NN	O
Miller	NNS	B
et	VB	I
al.,	RB	I
Human	NNP	I
Gene	CC	I
2lerapy	.	I
1:5-14,	NNP	I
1990.
Lentiviral	,	O
vectors	,	O
typically,	NNP	O
comprise	CC	O
a	NNP	O
5′	,	O
lentiviral	.	O
LTR,	.	O
a	.	O
tRNA	NNP	O
binding	,	O
site,	,	O
a	CC	O
packaging	NNP	O
signal,	FW	O
a	,	O
promoter	NNP	O
operably	NNP	O
linked	CD	O
to	,	O
one	.	O
or	JJ	O
more	NNS	O
genes	,	O
of	VB	O
interest,	DT	O
an	CD	O
origin	JJ	O
of	,	O
second	DT	O
strand	NN	O
DNA	VBG	O
synthesis	,	O
and	DT	O
a	NN	O
3′	,	O
lentiviral	DT	O
LTR,	NN	O
wherein	RB	O
the	VBD	O
lentiviral	TO	O
vector	CD	O
contains	CC	O
a	JJR	O
nuclear	NNS	O
transport	IN	O
element.	,	O
The	DT	O
nuclear	NN	O
transport	IN	O
element	JJ	O
may	NN	O
be	NNP	O
located	NN	O
either	CC	O
upstream	DT	O
(5′)	CD	O
or	JJ	O
downstream	,	O
(3′)	VBD	O
of	DT	O
a	JJ	O
coding	NN	O
sequence	VBZ	O
of	DT	O
interest.	JJ	O
Within	NN	O
certain	.	O
embodiments,	DT	O
the	JJ	O
nuclear	NN	O
transport	NN	O
element	MD	O
is	VB	O
not	VBN	O
RRE.	DT	O
Within	NN	O
one	)	O
embodiment	CC	O
the	NN	O
packaging	)	O
signal	IN	O
is	DT	O
an	VBG	O
extended	NN	O
packaging	IN	O
signal.	.	O
Within	IN	O
other	JJ	O
embodiments	,	O
the	DT	O
promoter	JJ	O
is	NN	O
a	NN	O
tissue	VBZ	O
specific	RB	O
promoter,	.	O
or,	IN	O
alternatively,	CD	O
a	NN	O
promoter	DT	O
such	NN	O
as	NN	O
CMV.	VBZ	O
Within	DT	O
other	JJ	O
embodiments,	NN	O
the	.	O
lentiviral	IN	O
vector	JJ	O
further	NNS	O
comprises	DT	O
an	NN	O
internal	VBZ	O
ribosome	DT	O
entry	NN	O
site.	JJ	O
A	,	O
wide	,	O
variety	,	O
of	DT	O
lentiviruses	NN	O
may	JJ	O
be	IN	O
utilized	.	O
within	IN	O
the	JJ	O
context	,	O
of	DT	O
the	JJ	O
present	NN	O
invention,	RBR	O
including	VBZ	O
for	DT	O
example,	JJ	O
lentiviruses	NN	O
selected	NN	O
from	.	O
the	DT	O
group	JJ	O
consisting	NN	O
of	IN	O
HIV,	NNS	O
HIV-1,	MD	O
HIV-2,	VB	O
FIV	VBN	O
and	IN	O
SIV.	DT	O
In	NN	O
one	IN	O
embodiment	DT	O
of	JJ	O
the	,	O
present	VBG	O
invention	IN	O
synthetic	,	O
Env	VBZ	O
and/or	VBN	O
Gag-polymerase	IN	O
expression	DT	O
cassettes	NN	O
are	VBG	O
provided	IN	O
comprising	,	O
a	,	O
promoter	,	O
and	NNP	O
a	CC	O
sequence	.	O
encoding	IN	O
synthetic	CD	O
Gag-polymerase	NN	O
(SEQ	IN	O
ID	DT	O
NO:6)	JJ	O
and	NN	O
at	JJ	O
least	NNP	O
one	POS	O
of	NNP	O
vpr,	NN	O
vpu,	NNS	O
nef	VBP	O
or	VBN	O
vif,	VBG	O
wherein	DT	O
the	NN	O
promoter	CC	O
is	DT	O
operably	NN	O
linked	VBG	O
to	JJ	O
Gag-polymerase	NNP	O
and	NNP	O
vpr,	NNP	O
vpu,	)	O
nef	CC	O
or	IN	O
vif.	JJS	O
Within	CD	O
yet	IN	O
another	,	O
aspect	,	O
of	''	O
the	CC	O
invention,	,	O
host	VB	O
cells	DT	O
(e.g.,	NN	O
packaging	VBZ	O
cell	RB	O
lines)	VBN	O
are	TO	O
provided	NNP	O
which	CC	O
contain	,	O
any	,	O
of	''	O
the	CC	O
expression	.	O
cassettes	IN	O
described	RB	O
herein.	DT	O
For	NN	O
example,	IN	O
within	DT	O
one	,	O
aspect	NN	O
packaging	NNS	O
cell	,	O
line	NN	O
are	NN	O
provided	)	O
comprising	VBP	O
an	VBN	O
expression	WDT	O
cassette	VBP	O
that	DT	O
comprises	IN	O
a	DT	O
sequence	NN	O
encoding	VBZ	O
synthetic	VBN	O
Env	.	O
and/or	IN	O
Gag-polymerase,	,	O
and	IN	O
a	CD	O
nuclear	NN	O
transport	NN	O
element,	NN	O
wherein	NN	O
the	VBP	O
promoter	VBN	O
is	VBG	O
operably	DT	O
linked	NN	O
to	NN	O
the	WDT	O
sequence	VBZ	O
encoding	DT	O
Env	NN	O
and/or	VBG	O
Gag-polymerase.	JJ	O
Packaging	NNP	O
cell	NN	O
lines	,	O
may	CC	O
further	DT	O
comprise	JJ	O
a	NN	O
promoter	,	O
and	VBP	O
a	DT	O
sequence	NN	O
encoding	VBZ	O
tat,	RB	O
rev,	VBN	O
or	TO	O
an	DT	O
envelope,	NN	O
wherein	VBG	O
the	NNP	O
promoter	JJ	O
is	.	O
operably	VBG	O
linked	NN	O
to	NNS	O
the	MD	O
sequence	RB	O
encoding	VB	O
tat,	DT	O
rev,	NN	O
or,	CC	O
the	DT	O
envelope.	NN	O
The	VBG	O
packaging	,	O
cell	,	O
line	CC	O
may	DT	O
further	,	O
comprise	VBP	O
a	DT	O
sequence	NN	O
encoding	VBZ	O
any	RB	O
one	VBN	O
or	TO	O
more	DT	O
of	NN	O
nef,	VBG	O
vif,	,	O
vpu	,	O
or	,	O
vpr.	DT	O
In	.	O
one	DT	O
embodiment,	NN	O
the	NN	O
expression	NN	O
cassette	MD	O
(carrying,	RB	O
for	VB	O
example,	DT	O
the	NN	O
synthetic	VBG	O
Env,	DT	O
synthetic	CD	O
tat	CC	O
and/or	JJR	O
synthetic	IN	O
Gag-polymerase)	,	O
is	,	O
stably	NN	O
integrated.	CC	O
The	.	O
packaging	IN	O
cell	CD	O
line,	,	O
upon	DT	O
introduction	NN	O
of	NN	O
a	,	O
lentiviral	IN	O
vector,	,	O
typically	DT	O
produces	JJ	O
viral	,	O
particles.	JJ	O
The	NN	O
promoter	JJ	O
regulating	JJ	O
expression	)	O
of	VBZ	O
the	RB	O
synthetic	.	O
expression	DT	O
cassette	NN	O
may	NN	O
be	,	O
inducible.	IN	O
Typically,	NN	O
the	IN	O
packaging	DT	O
cell	JJ	O
line,	,	O
upon	RB	O
introduction	VBZ	O
of	JJ	O
a	.	O
lentiviral	DT	O
vector,	NN	O
produces	VBG	O
viral	NN	O
particles	IN	O
that	DT	O
are	JJ	O
essentially	NN	O
free	NN	O
of	MD	O
replication	VB	O
competent	.	O
virus.	,	O
Packaging	DT	O
cell	NN	O
lines	NN	O
are	,	O
provided	IN	O
comprising	NN	O
an	IN	O
expression	DT	O
cassette	JJ	O
which	,	O
directs	VBZ	O
the	JJ	O
expression	NNS	O
of	WDT	O
a	VBP	O
synthetic	RB	O
Env	JJ	O
(or	IN	O
Gag-polymerase)	NN	O
gene,	NN	O
an	.	O
expression	VBG	O
cassette	NN	O
which	NNS	O
directs	VBP	O
the	VBN	O
expression	VBG	O
of	DT	O
a	NN	O
Gag	NN	O
(or	WDT	O
Env)	VBZ	O
gene	DT	O
optimized	NN	O
for	IN	O
expression	DT	O
(e.g.,	JJ	O
Andre,	NNP	B
S.,	CC	I
et	)	I
al.,	,	I
Journal	DT	I
of	NN	I
Virology	NN	I
72(2):1497-1503,	WDT	I
1998;	VBZ	I
Haas,	DT	B
J.,	NN	I
et	IN	I
al.,	DT	I
Current	NNP	I
Biology	CC	I
6(3):315-324,	)	I
1996).A	NN	O
lentiviral	VBN	O
vector	IN	O
is	NN	O
introduced	,	O
into	,	O
the	,	O
packaging	FW	O
cell	,	O
line	NNP	O
to	IN	O
produce	NNP	O
a	,	O
vector	:	O
particle	,	O
producing	,	O
cell	FW	O
line.	,	O
As	NNP	O
noted	NNP	O
above,	,	O
lentiviral	.	O
vectors	DT	O
can	JJ	O
be	NN	O
designed	VBZ	O
to	VBN	O
carry	IN	O
or	DT	O
express	NN	O
a	NN	O
selected	NN	O
gene(s)	TO	O
or	VB	O
sequences	DT	O
of	NN	O
interest.	NN	O
Lentiviral	VBG	O
vectors	NN	O
may	.	O
be	IN	O
readily	VBN	O
constructed	,	O
from	JJ	O
a	NNS	O
wide	MD	O
variety	VB	O
of	VBN	O
lentiviruses	TO	O
(see	VB	O
RNA	CC	O
Tumor	VB	O
Viruses,	DT	O
Second	VBN	O
Edition,	)	O
Cold	CC	O
Spring	NNS	O
Harbor	IN	O
Laboratory,	.	O
1985).	JJ	O
Representative	NNS	O
examples	MD	O
of	VB	O
lentiviruses	RB	O
included	VBN	O
HIV,	IN	O
HIV-1,	DT	O
HIV-2,	JJ	O
FIV	NN	O
and	IN	O
SIV.	NNS	O
Such	VB	O
lentiviruses	NNP	O
may	NNP	O
either	,	O
be	NNP	O
obtained	,	O
from	NNP	O
patient	NNP	O
isolates,	NNP	O
or,	,	O
more	.	O
preferably,	JJ	O
from	NNS	O
depositories	IN	O
or	NNS	O
collections	VBN	O
such	,	O
as	,	O
the	,	O
American	NNP	O
Type	CC	O
Culture	.	O
Collection,	JJ	O
or	NNS	O
isolated	MD	O
from	RB	O
known	VB	O
sources	VBN	O
using	IN	O
available	JJ	O
techniques.	,	O
Portions	,	O
of	JJR	O
the	,	O
lentiviral	IN	O
gene	NNS	O
delivery	CC	O
vectors	NNS	O
(or	JJ	O
vehicles)	IN	O
may	DT	O
be	NNP	O
derived	NNP	O
from	NNP	O
different	,	O
viruses.	CC	O
For	VBN	O
example,	IN	O
in	VBN	O
a	NNS	O
given	VBG	O
recombinant	JJ	O
lentiviral	.	O
vector,	NNS	O
LTRs	IN	O
may	DT	O
be	JJ	O
derived	NN	O
from	NN	O
an	NNS	O
HIV,	CC	O
a	)	O
packaging	MD	O
signal	VB	O
from	VBN	O
SIV,	IN	O
and	JJ	O
an	.	O
origin	IN	O
of	,	O
second	IN	O
strand	DT	O
synthesis	VBN	O
from	JJ	O
HrV-2.	JJ	O
Lentiviral	,	O
vector	NNP	O
constructs	MD	O
may	VB	O
comprise	VBN	O
a	IN	O
5′	DT	O
lentiviral	,	O
LTR,	DT	O
a	NN	O
tRNA	NN	O
binding	IN	O
site,	,	O
a	CC	O
packaging	DT	O
signal,	NN	O
one	IN	O
or	JJ	O
more	NN	O
heterologous	NN	O
sequences,	IN	O
an	.	O
origin	JJ	O
of	NN	O
second	NNS	O
strand	MD	O
DNA	VB	O
synthesis	DT	O
and	CD	O
a	JJ	O
3′	,	O
LTR,	DT	O
wherein	NN	O
said	VBG	O
lentiviral	,	O
vector	DT	O
contains	NN	O
a	,	O
nuclear	CD	O
transport	CC	O
element	JJR	O
that	JJ	O
is	,	O
not	DT	O
RRE.	NN	O
Briefly,	IN	O
Long	JJ	O
Terminal	NN	O
Repeats	NNP	O
(“LTRs”)	NN	O
are	CC	O
subdivided	DT	O
into	CD	O
three	,	O
elements,	NN	O
designated	VBD	O
U5,	JJ	O
R	NN	O
and	VBZ	O
U3.	DT	O
These	JJ	O
elements	NN	O
contain	NN	O
a	WDT	O
variety	VBZ	O
of	RB	O
signals	.	O
which	,	O
are	NNP	O
responsible	NNP	O
for	NNP	O
the	)	O
biological	VBP	O
activity	VBN	O
of	IN	O
a	CD	O
retrovirus,	,	O
including	VBN	O
for	,	O
example,	NNP	O
promoter	CC	O
and	.	O
enhancer	DT	O
elements	NNS	O
which	VBP	O
are	DT	O
located	NN	O
within	IN	O
U3.	NNS	O
LTRs	WDT	O
may	VBP	O
be	JJ	O
readily	IN	O
identified	DT	O
in	JJ	O
the	NN	O
provirus	IN	O
(integrated	DT	O
DNA	,	O
form)	VBG	O
due	IN	O
to	,	O
their	NN	O
precise	CC	O
duplication	NN	O
at	NNS	O
either	WDT	O
end	VBP	O
of	VBN	O
the	IN	O
genome.	.	O
As	NNP	O
utilized	MD	O
herein,	VB	O
a	RB	O
5′	VBN	O
LTR	IN	O
should	DT	O
be	NN	O
understood	JJ	O
to	NNP	O
include	)	O
a	RB	O
5′	TO	O
promoter	PRP$	O
element	JJ	O
and	NN	O
sufficient	IN	O
LTR	DT	O
sequence	NN	O
to	IN	O
allow	DT	O
reverse	.	O
transcription	IN	O
and	JJ	O
integration	,	O
of	DT	O
the	CD	O
DNA	NNP	O
form	MD	O
of	VB	O
the	JJ	O
vector.	TO	O
The	VB	O
3′	DT	O
LTR	CD	O
should	NN	O
be	NN	O
understood	CC	O
to	JJ	O
include	NNP	O
a	NN	O
polyadenylation	TO	O
signal,	VB	O
and	JJ	O
sufficient	NN	O
LTR	CC	O
sequence	NN	O
to	IN	O
allow	DT	O
reverse	NNP	O
transcription	NN	O
and	IN	O
integration	DT	O
of	.	O
the	DT	O
DNA	CD	O
form	NNP	O
of	MD	O
the	VB	O
vector.	JJ	O
The	TO	O
tRNA	VB	O
binding	DT	O
site	NN	O
and	,	O
origin	CC	O
of	JJ	O
second	NNP	O
strand	NN	O
DNA	TO	O
synthesis	VB	O
are	JJ	O
also	NN	O
important	CC	O
for	NN	O
a	IN	O
retrovirus	DT	O
to	NNP	O
be	NN	O
biologically	IN	O
active,	DT	O
and	.	O
may	DT	O
be	NN	O
readily	VBG	O
identified	NN	O
by	CC	O
one	NN	O
of	IN	O
skill	JJ	O
in	NN	O
the	NNP	O
art.	NN	O
For	VBP	O
example,	RB	O
retroviral	JJ	O
tRNA	IN	O
binds	DT	O
to	NN	O
a	TO	O
tRNA	VB	O
binding	RB	O
site	,	O
by	CC	O
Watson-Crick	MD	O
base	VB	O
pairing,	RB	O
and	VBN	O
is	IN	O
carried	CD	O
with	IN	O
the	NN	O
retrovirus	IN	O
genome	DT	O
into	.	O
a	IN	O
viral	,	O
particle.	JJ	O
The	NN	O
tRNA	NNS	O
is	TO	O
then	DT	O
utilized	NN	O
as	VBG	O
a	NN	O
primer	IN	O
for	JJ	O
DNA	NN	O
synthesis	,	O
by	CC	O
reverse	VBZ	O
transcriptase.	VBN	O
The	IN	O
tRNA	DT	O
binding	NN	O
site	NN	O
may	IN	O
be	DT	O
readily	JJ	O
identified	.	O
based	DT	O
upon	NN	O
its	VBZ	O
location	RB	O
just	JJ	O
downstream	IN	O
from	DT	O
the	NN	O
5′LTR.	IN	O
Similarly,	NNP	O
the	NN	O
origin	IN	O
of	JJ	O
second	.	O
strand	DT	O
DNA	NN	O
synthesis	VBG	O
is,	NN	O
as	MD	O
its	VB	O
name	RB	O
implies,	VBN	O
important	VBN	O
for	IN	O
the	PRP$	O
second	NN	O
strand	RB	O
DNA	NN	O
synthesis	IN	O
of	DT	O
a	.	O
retrovirus.	,	O
This	DT	O
region,	NN	O
which	IN	O
is	JJ	O
also	NN	O
referred	NNP	O
to	NN	O
as	,	O
the	IN	O
poly-purine	PRP$	O
tract,	NN	O
is	,	O
located	JJ	O
just	IN	O
upstream	DT	O
of	JJ	O
the	NN	O
3′LTR.	NNP	O
In	NN	O
addition	IN	O
to	DT	O
a	.	O
5′	DT	O
and	,	O
3′	WDT	O
LTR,	VBZ	O
tRNA	RB	O
binding	VBN	O
site,	TO	O
and	IN	O
origin	DT	O
of	JJ	O
second	,	O
strand	VBZ	O
DNA	VBN	O
synthesis,	RB	O
recombinant	NN	O
retroviral	IN	O
vector	DT	O
constructs	.	O
may	IN	O
also	NN	O
comprise	TO	O
a	DT	O
packaging	CD	O
signal,	CC	O
as	CD	O
well	,	O
as	NN	O
one	NN	O
or	,	O
more	CC	O
genes	NN	O
or	IN	O
coding	JJ	O
sequences	NN	O
of	NNP	O
interest.	,	O
In	JJ	O
addition,	JJ	O
the	NN	O
lentiviral	NNS	O
vectors	MD	O
have	RB	O
a	VB	O
nuclear	DT	O
transport	NN	O
element	,	O
which,	RB	O
in	RB	O
preferred	IN	O
embodiments	CD	O
is	CC	O
not	JJR	O
RRE.	NNS	O
Representative	CC	O
examples	VBG	O
of	NNS	O
suitable	IN	O
nuclear	.	O
transport	IN	O
elements	,	O
include	DT	O
the	JJ	O
element	NNS	O
in	VBP	O
Rous	DT	O
sarcoma	JJ	O
virus	NN	O
Ogert,	NN	B
et	,	I
al.,	IN	I
J.	JJ	I
Virol.	NNS	I
70,	VBZ	I
3834-3843,	RB	I
1996),(	.	O
the	JJ	O
element	NNS	O
in	IN	O
Rous	JJ	O
sarcoma	JJ	O
virus	NN	O
Liu	NNS	B
&	VBP	I
Mertz,	DT	I
Genes	NN	I
&	IN	I
Dev.,	NNP	I
9,	NN	I
1766-1789,	NN	I
1995)	,	I
(and	FW	O
the	,	O
element	NNP	O
in	.	O
the	,	O
genome	,	O
of	,	O
simian	DT	O
retrovirus	NN	O
type	IN	O
I	NNP	O
Zolotukhin,	NN	B
et	NN	I
al.,	NNP	I
J.	CC	I
Virol.	,	I
68,	NNP	I
7944-7952,	CC	I
1994).(	,	O
Other	,	O
potential	,	O
elements	)	O
include	CC	O
the	DT	O
elements	NN	O
in	IN	O
the	DT	O
histone	NN	O
gene	IN	O
Kedes,	JJ	B
Annu.	NN	I
Rev.	NN	I
Biochem.	PRP	I
48,	,	I
837-870,	FW	I
1970),(	,	O
the	NNP	O
α-interferon	.	O
gene	,	O
Nagata	,	B
et	.	I
al.,	JJ	I
Nature	JJ	I
287,	NNS	I
401-408,	VBP	I
1980),(	DT	O
the	NNS	O
β-adrenergic	IN	O
receptor	DT	O
gene	NN	O
Koilka,	NN	B
et	,	I
al.,	.	I
Nature	.	I
329,	.	I
75-79,	,	I
1987),(	,	O
and	,	O
the	DT	O
c-Jun	JJ	O
gene	NN	O
Hattorie,	NNP	B
et	RB	I
al.,	,	I
Proc.	NNP	I
Natl.	,	I
Acad.	,	I
Sci.	,	I
USA	DT	I
85,	JJ	I
9148-9152,	NN	I
1988).(	NN	O
Recombinant	,	O
lentiviral	FW	O
vector	,	O
constructs	NNP	O
typically	,	O
lack	,	O
both	,	O
Gag-polymerase	CC	O
and	DT	O
env	JJ	O
coding	NN	O
sequences.	,	O
Recombinant	FW	O
lentiviral	,	O
vector	.	O
typically	.	O
contain	.	O
less	.	O
than	NNP	O
20,	,	O
preferably	,	O
15,	.	O
more	JJ	O
preferably	JJ	O
10,	NN	O
and	NNS	O
most	RB	O
preferably	VBP	O
8	DT	O
consecutive	NNP	O
nucleotides	CC	O
found	VB	O
in	VBG	O
Gag-polymerase	.	O
or	JJ	O
env	JJ	O
genes.	NN	O
One	RB	O
advantage	VBZ	O
of	JJR	O
the	IN	O
present	,	O
invention	RB	O
is	,	O
that	JJR	O
the	RB	O
synthetic	,	O
Gag-polymerase	CC	O
expression	JJS	O
cassettes,	RB	O
which	CD	O
can	JJ	O
be	NNS	O
used	VBN	O
to	IN	O
construct	NNP	O
packaging	CC	O
cell	JJ	O
lines	.	O
for	CD	O
the	NN	O
recombinant	IN	O
retroviral	DT	O
vector	JJ	O
constructs,	NN	O
have	VBZ	O
little	IN	O
homology	DT	O
to	JJ	O
wild-type	NNP	O
Gag-polymerase	NN	O
sequences	,	O
and	WDT	O
thus	MD	O
considerably	VB	O
reduce	VBN	O
or	TO	O
eliminate	VB	O
the	NN	O
possibility	NN	O
of	NNS	O
homologous	IN	O
recombination	DT	O
between	JJ	O
the	JJ	O
synthetic	NN	O
and	,	O
wild-type	VBP	O
sequences.	JJ	O
Lentiviral	NN	O
vectors	TO	O
may	JJ	O
also	NNP	O
include	NNS	O
tissue-specific	CC	O
promoters	RB	O
to	RB	O
drive	VB	O
expression	CC	O
of	VB	O
one	DT	O
or	NN	O
more	IN	O
genes	JJ	O
or	NN	O
sequences	IN	O
of	DT	O
interest.	JJ	O
For	CC	O
example,	JJ	O
lentiviral	.	O
vector	JJ	O
particles	NNS	O
of	MD	O
the	RB	O
invention	VB	O
can	JJ	O
contain	NNS	O
a	TO	O
liver	VB	O
specific	NN	O
promoter	IN	O
to	CD	O
maximize	CC	O
the	JJR	O
potential	NNS	O
for	CC	O
liver	NNS	O
specific	IN	O
expression	.	O
of	IN	O
the	,	O
exogenous	JJ	O
DNA	NN	O
sequence	NNS	O
contained	IN	O
in	DT	O
the	NN	O
vectors.	MD	O
Preferred	VB	O
liver	DT	O
specific	NN	O
promoters	JJ	O
include	NN	O
the	TO	O
hepatitis	VB	O
B	DT	O
X-gene	NN	O
promoter	IN	O
and	NN	O
the	JJ	O
hepatitis	NN	O
B	IN	O
core	DT	O
protein	JJ	O
promoter.	NNP	O
These	NN	O
liver	VBD	O
specific	IN	O
promoters	DT	O
are	.	O
preferably	VBN	O
employed	NN	O
with	JJ	O
their	NNS	O
respective	VBP	O
enhancers.	DT	O
The	NN	O
enhancer	NNP	O
element	NNP	O
can	NN	O
be	CC	O
linked	DT	O
at	NN	O
either	NNP	O
the	NN	O
5′	NN	O
or	.	O
the	DT	O
3′	WRB	O
end	JJ	O
of	NNS	O
the	VBP	O
nucleic	RB	O
acid	VBN	O
encoding	IN	O
the	PRP$	O
sequences	JJ	O
of	.	O
interest.	DT	O
The	NN	O
hepatitis	NN	O
B	MD	O
X	VB	O
gene	VBN	O
promoter	IN	O
and	CC	O
its	DT	O
enhancer	CD	O
can	CC	O
be	DT	O
obtained	CD	O
from	NN	O
the	IN	O
viral	DT	O
genome	JJ	O
as	NN	O
a	VBG	O
332	DT	O
base	NNS	O
pair	IN	O
EcoRV-NcoI	.	O
DNA	DT	O
fragment	NN	O
employing	NNP	O
the	NNP	O
methods	NN	O
described	NN	O
in	CC	O
Twu,	PRP$	B
et	NN	I
al.,	MD	I
J.	VB	I
Virol.	VBN	I
61:3448-3453,	IN	I
1987.	DT	I
The	JJ	O
hepatitis	NN	O
B	IN	O
core	DT	O
protein	CD	O
promoter	NN	O
can	NN	O
be	NNP	O
obtained	NNP	O
from	NN	O
the	VBG	O
viral	DT	O
genome	NNS	O
as	VBN	O
a	IN	O
584	,	O
base	FW	O
pair	,	O
BamHI-BglII	NNP	O
DNA	.	O
fragment	,	O
employing	.	O
the	DT	O
methods	NN	O
described	NNP	O
in	NN	O
Gerlach,	NN	B
et	NN	I
al.,	MD	I
Virol	VB	I
189:59-66,	VBN	I
1992.	IN	I
It	DT	O
may	JJ	O
be	NN	O
necessary	IN	O
to	DT	O
remove	CD	O
the	NN	O
negative	NN	O
regulatory	NNP	O
sequence	NNP	O
in	NN	O
the	VBG	O
BamHI-BglII	DT	O
fragment	NNS	O
prior	VBN	O
to	IN	O
inserting	,	O
it.	FW	O
Other	,	O
liver	NNP	O
specific	,	O
promoters	.	O
include	PRP	O
the	MD	O
AFP	VB	O
(alpha	JJ	O
fetal	TO	O
protein)	VB	O
gene	DT	O
promoter	JJ	O
and	JJ	O
the	NN	O
albumin	IN	O
gene	DT	O
promoter,	NNP	O
as	NN	O
disclosed	RB	O
in	TO	O
EP	VBG	O
Patent	.	O
Publication	JJ	O
0	NN	O
415	JJ	O
731,	NNS	O
the	VBP	O
−1	DT	O
antitrypsin	NNP	O
gene	JJ	O
promoter,	JJ	O
as	)	O
disclosed	NN	O
in	NN	O
Rettenger,	CC	B
et	DT	I
al.,	JJ	I
Proc.	NN	I
Natl.	,	I
Acad.	IN	I
Sci.	VBN	I
91:1460-1464,	IN	I
1994,	NNP	I
the	NNP	O
fibrinogen	NNP	O
gene	CD	O
promoter,	CD	O
the	,	O
APO-A1	DT	O
(Apolipoprotein	NNP	O
A1)	NN	O
gene	NN	O
promoter,	,	O
and	IN	O
the	VBN	O
promoter	IN	O
genes	,	O
for	FW	O
liver	,	O
transference	.	O
enzymes	.	O
such	.	O
as,	.	O
for	,	O
example,	,	O
SGOT,	DT	O
SGPT	NN	O
and	NN	O
glutamyle	,	O
transferase.	DT	O
See	NNP	O
also	NNP	O
PCT	)	O
Patent	NN	O
Publications	,	O
WO	CC	O
90/07936	DT	O
and	NN	O
WO	NNS	O
91/02805	IN	O
for	NN	O
a	NN	O
description	NNS	O
of	JJ	O
the	,	O
use	IN	O
of	,	O
liver	,	O
specific	NNP	O
promoters	CC	O
in	JJ	O
lentiviral	.	O
vector	NNP	O
particles.	RB	O
Lentiviral	NNP	O
vector	NNP	O
constructs	NNP	O
may	NNP	O
be	CD	O
generated	CC	O
such	NNP	O
that	CD	O
more	IN	O
than	DT	O
one	NN	O
gene	IN	O
of	DT	O
interest	NN	O
is	IN	O
expressed.	NN	O
This	JJ	O
may	NNS	O
be	IN	O
accomplished	JJ	O
through	NN	O
the	.	O
use	JJ	O
of	NN	O
di-	NNS	O
or	MD	O
oligo-cistronic	VB	O
cassettes	VBN	O
(e.g.,	JJ	O
where	IN	O
the	JJR	O
coding	IN	O
regions	CD	O
are	NN	O
separated	IN	O
by	NN	O
80	VBZ	O
nucleotides	.	O
or	DT	O
less,	MD	O
see	VB	O
generally	VBN	O
Levin	IN	B
et	DT	I
al.,	NN	I
Gene	IN	I
108:167-174,	NN	I
1991),or	CC	O
through	JJ	O
the	NNS	O
use	,	O
of	WRB	O
Internal	DT	O
Ribosome	NN	O
Entry	NNS	O
Sites	VBP	O
(“IRES”).	VBN	O
Packaging	IN	O
cell	CD	O
lines	NNS	O
suitable	CC	O
for	,	O
use	VBP	O
with	RB	O
the	NNP	O
above	CC	O
described	,	O
recombinant	NNP	O
retroviral	,	O
vector	,	O
constructs	CC	O
may	IN	O
be	DT	O
readily	NN	O
prepared	IN	O
given	NNP	O
the	NNP	O
disclosure	NNP	O
provided	NNP	O
herein.	.	O
Briefly,	VBG	O
the	NN	O
parent	NNS	O
cell	JJ	O
line	IN	O
from	NN	O
which	IN	O
the	DT	O
packaging	JJ	O
cell	NN	O
line	JJ	O
is	JJ	O
derived	NN	O
can	NNS	O
be	MD	O
selected	VB	O
from	RB	O
a	JJ	O
variety	VBN	O
of	DT	O
mammalian	NN	O
cell	VBD	O
lines,	.	O
including	,	O
for	DT	O
example,	NN	O
293,	NN	O
RD,	NN	O
COS-7,	IN	O
CHO,	WDT	O
BHK,	DT	O
VERO,	NN	O
HT1080,	NN	O
and	NN	O
myeloma	VBZ	O
cells.	VBN	O
After	MD	O
selection	VB	O
of	VBN	O
a	IN	O
suitable	DT	O
host	NN	O
cell	IN	O
for	JJ	O
the	NN	O
generation	,	O
of	VBG	O
a	IN	O
packaging	,	O
cell	,	O
line,	,	O
one	,	O
or	,	O
more	,	O
expression	,	O
cassettes	,	O
are	CC	O
introduced	NN	O
into	.	O
the	IN	O
cell	NN	O
line	IN	O
in	DT	O
order	JJ	O
to	NN	O
complement	NN	O
or	IN	O
supply	DT	O
in	NN	O
trans	IN	O
components	DT	O
of	NN	O
the	NN	O
vector	,	O
which	CD	O
have	CC	O
been	JJR	O
deleted.	NN	O
Representative	NNS	O
examples	VBP	O
of	VBN	O
suitable	IN	O
expression	DT	O
cassettes	NN	O
have	NN	O
been	IN	O
described	NN	O
herein	TO	O
and	VB	O
include	CC	O
synthetic	VB	O
Env,	IN	O
tat,	JJ	O
Gag,	NNS	O
synthetic	IN	O
Gag-protease,	DT	O
synthetic	NN	O
Gag-reverse	WDT	O
transcriptase	VBP	O
and	VBN	O
synthetic	.	O
Gag-polymerase	JJ	O
expression	NNS	O
cassettes,	IN	O
which	JJ	O
comprise	NN	O
a	NNS	O
promoter	VBP	O
and	VBN	O
a	VBN	O
sequence	JJ	O
encoding,	CC	O
e.g.,	VBP	O
Env,	JJ	O
tat,	,	O
or	,	O
Gag-polymerase	,	O
and	JJ	O
at	,	O
least	JJ	O
one	NNP	O
of	NN	O
vpr,	CC	O
vpu,	JJ	O
nef	NNP	O
or	NN	O
vif,	,	O
wherein	WDT	O
the	VBP	O
promoter	DT	O
is	NN	O
operably	CC	O
linked	DT	O
to	NN	O
Env,	,	O
tat	,	O
or	,	O
Gag-polymerase	,	O
and	CC	O
vpr,	NNP	O
vpu,	CC	O
nef	IN	O
or	JJS	O
vif.	CD	O
As	IN	O
described	,	O
above,	,	O
optimized	''	O
Env,	CC	O
Gag	,	O
and/or	VB	O
tat	DT	O
coding	NN	O
sequences	VBZ	O
may	RB	O
also	VBN	O
be	TO	O
utilized	,	O
in	NN	O
various	CC	O
combinations	NNP	O
in	CC	O
the	,	O
generation	,	O
of	''	O
packaging	CC	O
cell	.	O
lines.	IN	O
Utilizing	VBN	O
the	,	O
above-described	VBD	O
expression	,	O
cassettes,	NNP	O
a	VBZ	O
wide	JJ	O
variety	VBG	O
of	NNS	O
packaging	MD	O
cell	RB	O
lines	VB	O
can	VBN	O
be	IN	O
generated.	JJ	O
For	NNS	O
example,	IN	O
within	DT	O
one	NN	O
aspect	IN	O
packaging	NN	O
cell	NN	O
line	.	O
are	VBG	O
provided	DT	O
comprising	JJ	O
an	NN	O
expression	,	O
cassette	DT	O
that	JJ	O
comprises	NN	O
a	IN	O
sequence	NN	O
encoding	NN	O
synthetic	NNS	O
HIV	MD	O
(e.g.,	VB	O
Gag,	.	O
Env,	IN	O
tat,	,	O
Gag-polymerase,	IN	O
Gag-reverse	CD	O
transcriptase	NN	O
or	NN	O
Gag-protease)	NN	O
polypeptide,	NN	O
and	VBP	O
a	VBN	O
nuclear	VBG	O
transport	DT	O
element,	NN	O
wherein	NN	O
the	WDT	O
promoter	VBZ	O
is	DT	O
operably	NN	O
linked	VBG	O
to	JJ	O
the	NNP	O
sequence	,	O
encoding	,	O
the	,	O
HIV	,	O
polypeptide.	,	O
Within	NNP	O
other	NN	O
aspects,	CC	O
packaging	)	O
cell	,	O
lines	CC	O
are	DT	O
provided	JJ	O
comprising	NN	O
a	,	O
promoter	VBP	O
and	DT	O
a	NN	O
sequence	VBZ	O
encoding	RB	O
Gag,	VBN	O
tat,	TO	O
rev,	DT	O
or	NN	O
an	VBG	O
envelope	DT	O
(e.g.,	NNP	O
HIV	.	O
env),	IN	O
wherein	JJ	O
the	,	O
promoter	NN	O
is	NN	O
operably	NNS	O
linked	VBP	O
to	VBN	O
the	VBG	O
sequence	DT	O
encoding	NN	O
Gag,	CC	O
tat,	DT	O
rev,	NN	O
or,	VBG	O
the	,	O
envelope.	,	O
Within	,	O
further	CC	O
embodiments,	DT	O
the	NN	O
packaging	,	O
cell	NNP	O
line	,	O
may	VBD	O
comprise	DT	O
a	NN	O
sequence	VBZ	O
encoding	RB	O
any	VBN	O
one	TO	O
or	DT	O
more	NN	O
of	VBG	O
nef,	,	O
vif,	,	O
vpu	,	O
or	,	O
vpr.	DT	O
For	.	O
example,	IN	O
the	JJ	O
packaging	,	O
cell	DT	O
line	NN	O
may	NN	O
contain	NN	O
only	MD	O
nef,	VB	O
vif,	DT	O
vpu,	NN	O
or	VBG	O
vpr	DT	O
alone,	CD	O
nef	CC	O
and	JJR	O
vif,	IN	O
nef	,	O
and	,	O
vpu,	NN	O
nef	CC	O
and	.	O
vpr,	IN	O
vif	,	O
and	DT	O
vpu,	NN	O
vif	NN	O
and	NN	O
vpr,	MD	O
vpu	VB	O
and	RB	O
vpr,	,	O
nef	,	O
vif	,	O
and	CC	O
vpu,	VB	O
nef	,	O
vif	JJ	O
and	CC	O
vpr,	,	O
nef	NN	O
vpu	CC	O
and	,	O
vpr,	NN	O
vvir	CC	O
vpu	,	O
and	NN	O
vpr,	CC	O
or,	,	O
all	NN	O
four	CC	O
of	,	O
nef	NN	O
vif	CC	O
vpu	,	O
and	JJ	O
vpr.	NN	O
In	CC	O
one	,	O
embodiment,	JJ	O
the	NN	O
expression	CC	O
cassette	,	O
is	JJ	O
stably	NN	O
integrated.	CC	O
Within	,	O
another	NN	O
embodiment,	NN	O
the	CC	O
packaging	,	O
cell	,	O
line,	DT	O
upon	CD	O
introduction	IN	O
of	NN	O
a	NN	O
lentiviral	NN	O
vector,	CC	O
produces	.	O
particles.	IN	O
Within	CD	O
further	,	O
embodiments	DT	O
the	NN	O
promoter	NN	O
is	VBZ	O
inducible.	RB	O
Within	.	O
certain	IN	O
preferred	DT	O
embodiments	,	O
of	DT	O
the	NN	O
invention,	NN	O
the	,	O
packaging	IN	O
cell	NN	O
line,	IN	O
upon	DT	O
introduction	JJ	O
of	,	O
a	VBZ	O
lentiviral	.	O
vector,	IN	O
produces	JJ	O
particles	NNS	O
that	DT	O
are	NN	O
free	VBZ	O
of	.	O
replication	IN	O
competent	JJ	O
virus.	JJ	O
The	NNS	O
synthetic	IN	O
cassettes	DT	O
containing	,	O
optimized	DT	O
coding	NN	O
sequences	NN	O
are	,	O
transfected	IN	O
into	NN	O
a	IN	O
selected	DT	O
cell	JJ	O
line.	,	O
Transfected	VBZ	O
cells	NNS	O
are	WDT	O
selected	VBP	O
that	JJ	O
(i)	IN	O
carry,	NN	O
typically,	NN	O
integrated,	.	O
stable	DT	O
copies	JJ	O
of	NNS	O
the	VBG	O
Gag,	JJ	O
Pol,	NN	O
and	NNS	O
Env	VBP	O
coding	VBN	O
sequences,	IN	O
and	DT	O
(ii)	VBN	O
are	NN	O
expressing	.	O
acceptable	VBN	O
levels	NNS	O
of	VBP	O
these	VBN	O
polypeptides	IN	O
(expression	)	O
can	,	O
be	,	O
evaluated	,	O
by	JJ	O
methods	NNS	O
known	IN	O
in	DT	O
the	,	O
prior	,	O
art,	CC	O
e.g.,	NNP	O
see	NN	O
Examples	,	O
1-4).	CC	O
The	)	O
ability	VBP	O
of	VBG	O
the	JJ	O
cell	NNS	O
line	IN	O
to	DT	O
produce	NNS	O
VLPs	NN	O
may	MD	O
also	VB	O
be	VBN	O
verified	IN	O
(Examples	NNS	O
6,	VBN	O
7	IN	O
and	DT	O
15).	JJ	O
A	,	O
sequence	,	O
of	VBP	O
interest	NNP	O
is	.	O
constructed	DT	O
into	NN	O
a	IN	O
suitable	DT	O
viral	NN	O
vector	NN	O
as	TO	O
discussed	VB	O
above.	NNP	O
This	MD	O
defective	RB	O
virus	VB	O
is	VBN	O
then	NNP	O
transfected	,	O
into	CD	O
the	CC	O
packaging	.	O
cell	DT	O
line.	NN	O
The	IN	O
packaging	NN	O
cell	VBZ	O
line	VBN	O
provides	IN	O
the	DT	O
viral	JJ	O
functions	JJ	O
necessary	NN	O
for	IN	O
producing	VBN	O
virus-like	.	O
particles	DT	O
into	JJ	O
which	NN	O
the	VBZ	O
defective	RB	O
viral	VBN	O
genome,	IN	O
containing	DT	O
the	NN	O
sequence	NN	O
of	.	O
interest,	DT	O
are	NN	O
packaged.	NN	O
These	NN	O
VLPs	VBZ	O
are	DT	O
then	JJ	O
isolated	NNS	O
and	JJ	O
can	IN	O
be	VBG	O
used,	JJ	O
for	NNS	O
example,	IN	O
in	WDT	O
gene	DT	O
delivery	JJ	O
or	JJ	O
gene	,	O
therapy.	VBG	O
Further,	DT	O
such	NN	O
packaging	IN	O
cell	,	O
lines	VBP	O
can	.	O
also	DT	O
be	NNP	O
used	VBP	O
to	RB	O
produce	JJ	O
VLPs	CC	O
alone,	MD	O
which	VB	O
can,	,	O
for	IN	O
example,	,	O
be	IN	O
used	NN	O
as	NN	O
adjuvants	CC	O
for	NN	O
administration	.	O
with	,	O
other	JJ	O
antigens	NN	O
or	NN	O
in	NNS	O
vaccine	MD	O
compositions.	RB	O
Also,	VB	O
co-expression	VBN	O
of	TO	O
a	VB	O
selected	NNP	O
sequence	,	O
of	WDT	O
interest	,	O
encoding	IN	O
a	,	O
polypeptide	VB	O
(for	VBN	O
example,	IN	O
an	NNS	O
antigen)	IN	O
in	NN	O
the	IN	O
packaging	JJ	O
cell	NNS	O
line	CC	O
can	IN	O
also	JJ	O
result	.	O
in	,	O
the	NN	O
entrapment	IN	O
and/or	DT	O
association	VBN	O
of	NN	O
the	IN	O
selected	NN	O
polypeptide	VBG	O
in/with	DT	O
the	NN	O
VLPs.	IN	O
2.3	,	O
DNA	DT	O
Immunization	)	O
and	IN	O
Gene	DT	O
Delivery	NN	O
A	NN	O
variety	NN	O
of	MD	O
polypeptide	RB	O
antigens	VB	O
can	IN	O
be	DT	O
used	NN	O
in	NN	O
the	NN	O
practice	IN	O
of	DT	O
the	VBN	O
present	NN	O
invention.	VBZ	O
Polypeptide	DT	O
antigens	.	O
can	CD	O
be	NNP	O
included	NNP	O
in	CC	O
DNA	NNP	O
immunization	NNP	O
constructs	NNP	O
containing,	NN	O
for	IN	O
example,	JJ	O
any	NNS	O
of	MD	O
the	VB	O
synthetic	VBN	O
expression	IN	O
cassettes	DT	O
described	NN	O
herein	IN	O
fused	DT	O
in-frame	JJ	O
to	.	O
a	IN	O
coding	NNS	O
sequence	MD	O
for	VB	O
the	VBN	O
polypeptide	IN	O
antigen,	NNP	O
where	NN	O
expression	NNS	O
of	,	O
the	IN	O
construct	,	O
results	DT	O
in	IN	O
VLPs	DT	O
presenting	JJ	O
the	NN	O
antigen	NNS	O
of	VBD	O
interest.	NNS	O
Antigens	VBD	O
can	NN	O
be	TO	O
derived	DT	O
from	NN	O
a	NN	O
wide	IN	O
variety	DT	O
of	NN	O
viruses,	,	O
bacteria,	WRB	O
fungi,	NN	O
plants,	IN	O
protozoans	DT	O
and	NN	O
other	NNS	O
parasites.	IN	O
For	NNP	O
example,	VBG	O
the	DT	O
present	NN	O
invention	IN	O
will	.	O
find	NNS	O
use	MD	O
for	VB	O
stimulating	VBN	O
an	IN	O
immune	DT	O
response	JJ	O
against	NN	O
a	IN	O
wide	,	O
variety	,	O
of	,	O
proteins	,	O
from	NNS	O
the	CC	O
herpesvirus	JJ	O
family,	.	O
including	IN	O
proteins	,	O
derived	DT	O
from	JJ	O
herpes	NN	O
simplex	MD	O
virus	VB	O
(HSV)	NN	O
types	IN	O
1	VBG	O
and	DT	O
2,	JJ	O
such	NN	O
as	IN	O
HSV-1	DT	O
and	JJ	O
HSV-2	NN	O
gB,	IN	O
gD,	NNS	O
gH,	IN	O
VP16	DT	O
and	NN	O
VP22;	,	O
antigens	VBG	O
derived	NNS	O
from	VBN	O
varicella	IN	O
zoster	NNS	O
virus	JJ	O
(VZV),	NN	O
Epstein-Barr	)	O
virus	VBZ	O
(EBV)	CD	O
and	CC	O
cytomegalovirus	,	O
(CMV)	JJ	O
including	IN	O
CMV	NNP	O
gB	CC	O
and	NNP	O
gH;	,	O
and	,	O
antigens	,	O
derived	NNP	O
from	CC	O
other	:	O
human	VBZ	O
herpesviruses	VBN	O
such	IN	O
as	NN	O
HHV6	NN	O
and	NN	O
HHV7.	,	O
(See,	JJ	O
e.g.	NN	O
Chee	)	B
et	CC	I
al.,	NN	I
Cytomegaloviruses	)	I
(J.	VBG	I
K.	NNP	I
McDougall,	NN	I
ed.,	CC	I
Springer-Verlag	:	I
1990)	CC	I
pp.	VBZ	I
125-169,	VBN	I
for	IN	O
a	JJ	O
review	JJ	O
of	NNS	O
the	JJ	O
protein	IN	O
coding	NNP	O
content	CC	O
of	.	O
cytomegalovirus;	,	O
McGeoch	.	B
et	NNP	I
al.,	CC	I
J.	,	I
Gen.	NNP	I
Virol.	NNP	I
(1988)	NNP	I
69:1531-1574,	,	I
for	,	O
a	NNP	O
discussion	)	O
of	.	O
the	,	O
various	IN	O
HSV-1	DT	O
encoded	NN	O
proteins;	IN	O
U.S.	DT	O
Pat.	NN	O
No.	VBG	O
5,171,568	NN	O
for	IN	O
a	:	O
discussion	NNP	O
of	FW	O
HSV-1	,	O
and	NNP	O
HSV-2	NNP	O
gB	.	O
and	)	O
gD	,	O
proteins	IN	O
and	DT	O
the	NN	O
genes	IN	O
encoding	DT	O
therefore;	JJ	O
Baer	NNP	B
et	VBD	I
al.,	:	I
Nature	NNP	I
(1984)	.	I
310:207-211,	.	I
for	CD	O
the	IN	O
identification	DT	O
of	NN	O
protein	IN	O
coding	NNP	O
sequences	CC	O
in	NNP	O
an	NN	O
EBV	CC	O
genome;	NN	O
and	NNS	O
Davison	CC	B
and	DT	I
Scott,	NNS	I
J.	VBG	I
Gen.	:	I
Virol.	NNP	I
(1986)	FW	I
67:1759-1816,	,	I
for	NNP	O
a	)	O
review	,	O
of	IN	O
VZV.)	DT	O
Additionally,	NN	O
immune	IN	O
responses	NN	O
to	VBG	O
antigens	NNS	O
from	IN	O
the	DT	O
hepatitis	NNP	O
family	:	O
of	CC	O
viruses,	NNP	O
including	CC	O
hepatitis	,	O
A	NNP	O
virus	NNP	O
(HAV),	.	O
hepatitis	)	O
B	,	O
virus	IN	O
(HBV),	DT	O
hepatitis	NN	O
C	IN	O
virus	)	O
(HCV),	,	O
the	JJ	O
delta	NNS	O
hepatitis	TO	O
virus	NNS	O
(HDV),	IN	O
hepatitis	DT	O
E	NN	O
virus	NN	O
(HEV),	IN	O
and	,	O
hepatitis	VBG	O
G	NN	O
virus,	DT	O
can	NN	O
also	,	O
be	NN	O
stimulated	NNP	O
using	NN	O
the	,	O
constructs	FW	O
of	NNP	O
the	NN	O
present	,	O
invention.	DT	O
By	NN	O
way	NN	O
of	NN	O
example,	,	O
the	FW	O
HCV	NNP	O
genome	NN	O
encodes	,	O
several	CC	O
viral	NN	O
proteins,	NNP	O
including	,	O
E1	MD	O
(also	RB	O
known	VB	O
as	VBN	O
E)	VBG	O
and	DT	O
E2	NNS	O
(also	IN	O
known	DT	O
as	JJ	O
E2/NSI),	.	O
which	IN	O
will	NN	O
find	IN	O
use	,	O
with	DT	O
the	NNP	O
present	NN	O
invention	NNS	O
(see,	JJ	O
Houghton	JJ	B
et	,	I
al.	VBG	I
Hepatology	NNP	I
(1991)	RB	I
14:381-388,	VBN	I
for	IN	O
a	)	O
discussion	CC	O
of	NNP	O
HCV	RB	O
proteins,	VBN	O
including	IN	O
E1	,	O
and	WDT	O
E2).	MD	O
The	VB	O
δ-antigen	NN	O
from	IN	O
HDV	DT	O
can	JJ	O
also	NN	O
be	,	O
used	NNP	O
(see,	VBZ	O
e.g.,	.	O
U.S.	NNP	O
Pat.	)	O
No.	,	O
5,389,528,	IN	O
for	DT	O
a	NN	O
description	IN	O
of	NNP	O
the	,	O
δ-antigen).	VBG	O
Similarly,	NNP	O
influenza	CC	O
virus	.	O
is	DT	O
another	NN	O
example	IN	O
of	NNP	O
a	MD	O
virus	RB	O
for	VB	O
which	VBN	O
the	,	O
present	,	O
invention	NNP	O
will	.	O
be	.	O
particularly	,	O
useful.	IN	O
Specifically,	DT	O
the	NN	O
envelope	IN	O
glycoproteins	DT	O
HA	.	O
and	,	O
NA	JJ	O
of	NN	O
influenza	VBZ	O
A	DT	O
are	NN	O
of	IN	O
particular	DT	O
interest	NN	O
for	IN	O
generating	WDT	O
an	DT	O
immune	JJ	O
response.	NN	O
Numerous	MD	O
HA	VB	O
subtypes	RB	O
of	.	O
influenza	,	O
A	DT	O
have	NN	O
been	VBZ	O
identified	NNP	O
Kawaoka	CC	B
et	NNP	I
al.,	IN	I
Virology	NN	I
(1990)	DT	I
179:759-767;	VBP	I
Webster	IN	B
et	JJ	I
al.	NN	I
“Antigenic	IN	I
variation	VBG	I
among	DT	I
type	JJ	I
A	.	I
influenza	JJ	I
viruses,”	NNP	I
p.	NNS	I
127-168.	IN	I
In:	NN	I
P.	DT	I
Palese	VBP	I
and	VBN	I
D.	VBN	I
W.	NNP	I
Kingsbury	RB	I
(ed.),	,	I
Genetics	NNP	I
of	)	I
influenza	:	I
viruses.	NNP	I
Springer-Verlag,	FW	I
New	.	I
York).(	JJ	O
Other	NN	O
antigens	IN	O
of	NN	O
particular	NNP	O
interest	NN	O
to	JJ	O
be	NN	O
used	.	O
in	:	O
the	NNP	O
practice	NNP	O
of	CC	O
the	NNP	O
present	NNP	O
invention	NNP	O
include	,	O
antigens	NNP	O
and	IN	O
polypeptides	NN	O
derived	.	O
therefrom	,	O
from	NNP	O
human	.	O
papillomavirus	JJ	O
(HPV),	NNS	O
such	IN	O
as	JJ	O
one	NN	O
or	TO	O
more	VB	O
of	VBN	O
the	IN	O
various	DT	O
early	NN	O
proteins	IN	O
including	DT	O
E6	JJ	O
and	NN	O
E7;	VBP	O
tick-borne	NNS	O
encephalitis	CC	O
viruses;	NNS	O
and	VBN	O
HIV-1	IN	O
(also	IN	O
known	JJ	O
as	NN	O
HTLV-III,	,	O
LAV,	JJ	O
ARV,	IN	O
etc.),	CD	O
including,	CC	O
but	JJR	O
not	IN	O
limited	DT	O
to,	JJ	O
antigens	JJ	O
such	NNS	O
as	VBG	O
gp120,	NNP	O
gp41,	CC	O
gp160,	:	O
Gag	JJ	O
and	NN	O
pol	:	O
from	CC	O
a	NNP	O
variety	RB	O
of	VBN	O
isolates	IN	O
including,	,	O
but	,	O
not	,	O
limited	,	O
to,	,	O
HIVIIIb,	CC	O
HIVSF2,	RB	O
HIV-1SF162,	JJ	O
HIV-1SF170,	,	O
HIVLAV,	NNS	O
HIVLAI,	JJ	O
HIVMN,	IN	O
HIV-1CM235,	,	O
HIV-1US4,	,	O
other	,	O
HIV-1	NNP	O
strains	CC	O
from	NN	O
diverse	IN	O
subtypes(e.g.,	DT	O
subtypes,	NN	O
A	IN	O
through	NNS	O
G,	,	O
and	CC	O
O),	RB	O
HIV-2	JJ	O
strains	,	O
and	,	O
diverse	,	O
subtypes	,	O
(e.g.,	,	O
HIV-2UC1	,	O
and	,	O
HIV-2UC2).	,	O
See,	,	O
e.g.,	,	O
Myers,	JJ	B
et	JJ	I
al.,	NNS	I
Los	IN	I
Alamos	JJ	I
Database,	,	I
Los	,	I
Alamos	NNP	I
National	IN	I
Laboratory,	,	I
Los	CC	I
Alamos,	,	I
N.	NNP	I
Mex.;	NNS	I
Myers,	CC	B
et	JJ	I
al.,	NNS	I
Human	,	I
Retroviruses	NNP	I
and	CC	I
Aids,	.	I
1990,	,	I
Los	,	I
Alamos,	,	I
N.	FW	I
Mex.:	,	I
Los	NNP	I
Alamos	NNP	I
National	,	I
Laboratory.
Proteins	NNP	O
derived	NNP	O
from	NNP	O
other	,	O
viruses	NNP	O
will	,	O
also	.	O
find	:	O
use	,	O
in	FW	O
the	,	O
claimed	NNP	O
methods,	NNP	O
such	CC	O
as	,	O
without	,	O
limitation,	NNP	O
proteins	,	O
from	.	O
members	:	O
of	NNP	O
the	NNP	O
families	NNP	O
Picornaviridae	.	O
(e.g.,	NNS	O
polioviruses,	VBN	O
etc.);	IN	O
Caliciviridae;	JJ	O
Togaviridae	NNS	O
(e.g.,	MD	O
rubella	RB	O
virus,	VB	O
dengue	NN	O
virus,	IN	O
etc.);	DT	O
Flaviviridae;	JJ	O
Coronaviridae;	,	O
Reoviridae;	JJ	O
Birnaviridae;	IN	O
Rhabodoviridae	IN	O
(e.g.,	,	O
rabies	VBZ	O
virus,	IN	O
etc.);	NNS	O
Filoviridae;	IN	O
Paramyxoviridae	DT	O
(e.g.,	NNS	O
mumps	NNP	O
virus,	,	O
measles	,	O
virus,	:	O
respiratory	:	O
syncytial	NNP	O
virus,	,	O
etc.);	NN	O
Orthomyxoviridae	,	O
(e.g.,	NN	O
influenza	,	O
virus	:	O
types	:	O
A,	:	O
B	:	O
and	:	O
C,	NNP	O
etc.);	,	O
Bunyaviridae;	NNS	O
Arenaviridae;	,	O
Retroviradae,	:	O
e.g.,	:	O
HTLV-I;	NNP	O
HTLV-II;	,	O
HIV-1;	NNS	O
HIV-2;	,	O
simian	NNS	O
immunodeficiency	,	O
virus	JJ	O
(SIV)	JJ	O
among	,	O
others.	:	O
See,	NNP	O
e.g.	,	O
Virology,	JJ	B
3rd	NN	I
Edition	VBZ	I
(W.	,	I
K.	NNP	I
Joklik	CC	I
ed.	,	I
1988);	:	I
Fundamental	:	B
Virology,	:	I
2nd	,	I
Edition	,	I
(B.	:	I
N.	:	I
Fields	:	I
and	:	I
D.	JJ	I
M.	NN	I
Knipe,	NN	I
eds.	)	I
1991;	IN	I
Virology,	.	B
3rd	,	I
Edition	.	I
(Fields,	,	I
B	CD	I
N,	NNP	I
D	NNP	I
M	NNP	I
Knipe,	NNP	I
P	.	I
M	:	I
Howley,	NNP	I
Editors,	,	I
1996,	CD	I
Lippincott-Raven,	NNP	I
Philadelphia,	NNP	I
Pa.)	NNP	I
for	NNP	O
a	CC	O
description	NNP	O
of	NNP	O
these	,	O
and	.	O
other	:	O
viruses.	,	O
Particularly	CD	O
preferred	NNP	O
bacterial	,	O
antigens	NNP	O
are	,	O
derived	NNP	O
from	NNP	O
organisms	,	O
that	NNP	O
cause	NNP	O
diphtheria,	,	O
tetanus,	,	O
pertussis,	,	O
meningitis,	,	O
and	,	O
other	)	O
pathogenic	IN	O
states,	DT	O
including,	NN	O
without	IN	O
limitation,	DT	O
antigens	CC	O
derived	JJ	O
from	.	O
Corynebacterium	RB	O
diphtheriae,	VBN	O
Clostridium	JJ	O
tetani,	NNS	O
Bordetella	VBP	O
pertusis,	VBN	O
Neisseria	IN	O
meningitidis,	NNS	O
including	WDT	O
serotypes	VBP	O
Meningococcus	,	O
A,	,	O
B,	,	O
C,	,	O
Y	CC	O
and	JJ	O
WI35	JJ	O
(MenA,	,	O
B,	,	O
C,	IN	O
Y	,	O
and	VBZ	O
WI35),	VBN	O
Haemophilus	IN	O
influenza	NNP	O
type	,	O
B	NNP	O
(Hib),	,	O
and	NNP	O
Helicobacter	,	O
pylori.	NNP	O
Examples	,	O
of	VBG	O
parasitic	NNS	O
antigens	NNP	O
include	,	O
those	,	O
derived	,	O
from	NNP	O
organisms	CC	O
causing	NNP	O
malaria,	,	O
tuberculosis,	,	O
and	,	O
Lyme	NNP	O
disease.	CC	O
Furthermore,	,	O
the	NNP	O
methods	VBP	O
described	NN	O
herein	NNP	O
provide	,	O
means	CC	O
for	NNP	O
treating	.	O
a	NNS	O
variety	IN	O
of	JJ	O
malignant	NNS	O
cancers.	VBP	O
For	DT	O
example,	VBN	O
the	IN	O
system	JJ	O
of	VBG	O
the	,	O
present	,	O
invention	CC	O
can	NNP	O
be	.	O
used	,	O
to	DT	O
enhance	NNS	O
both	VBD	O
humoral	JJ	O
and	NN	O
cell-mediated	VBZ	O
immune	IN	O
responses	VBG	O
to	DT	O
particular	NN	O
proteins	IN	O
specific	JJ	O
to	.	O
a	IN	O
cancer	,	O
in	DT	O
question,	NN	O
such	IN	O
as	DT	O
an	JJ	O
activated	NN	O
oncogene,	MD	O
a	VB	O
fetal	VBN	O
antigen,	TO	O
or	VB	O
an	DT	O
activation	JJ	O
marker.	CC	O
Such	JJ	O
tumor	NN	O
antigens	NNS	O
include	TO	O
any	JJ	O
of	NNS	O
the	JJ	O
various	TO	O
MAGEs	DT	O
(melanoma	NN	O
associated	IN	O
antigen	,	O
E),	JJ	O
including	IN	O
MAGE	DT	O
1,	JJ	O
2,	,	O
3,	DT	O
4,	JJ	O
etc.	,	O
Boon,	CC	B
T.	DT	I
Scientific	NN	I
American	.	I
(March	JJ	I
1993):82-89);(	NN	O
any	NNS	O
of	VBP	O
the	DT	O
various	IN	O
tyrosinases;	DT	O
MART	JJ	O
1	NNP	O
(melanoma	NN	O
antigen	VBN	O
recognized	IN	O
by	,	O
T	VBG	O
cells),	NNP	O
mutant	,	O
ras;	,	O
mutant	,	O
p53;	,	O
p97	.	O
melanoma	,	O
antigen;	NNP	O
CEA	NNP	O
(carcinoembryonic	NNP	O
antigen),	NNP	O
among	:	O
others.	DT	O
DNA	IN	O
immunization	DT	O
using	JJ	O
synthetic	:	O
expression	NNP	O
cassettes	CD	O
of	NN	O
the	NN	O
present	VBN	O
invention	IN	O
has	NNP	O
been	,	O
demonstrated	JJ	O
to	:	O
be	JJ	O
efficacious	:	O
(Examples	CC	O
8	VB	O
and	:	O
10-12).	NNP	O
Animals	JJ	O
were	,	O
immunized	IN	O
with	.	O
both	NN	O
the	NN	O
synthetic	VBG	O
expression	JJ	O
cassette	NN	O
and	NNS	O
the	IN	O
wild	DT	O
type	JJ	O
expression	NN	O
cassette.	VBZ	O
The	VBN	O
results	VBN	O
of	TO	O
the	VB	O
immunizations	JJ	O
with	NNP	O
plasmid-DNAs	CD	O
showed	CC	O
that	.	O
the	NNS	O
synthetic	VBD	O
expression	VBN	O
cassettes	IN	O
provide	DT	O
a	DT	O
clear	JJ	O
improvement	NN	O
of	NN	O
immunogenicity	CC	O
relative	DT	O
to	JJ	O
the	JJ	O
native	NN	O
expression	.	O
cassettes.	DT	O
Also,	NNS	O
the	IN	O
second	DT	O
boost	NNS	O
immunization	IN	O
induced	NN	O
a	VBD	O
secondary	IN	O
immune	DT	O
response,	JJ	O
for	NN	O
example	NNS	O
after	VBP	O
two	DT	O
to	JJ	O
eight	NN	O
weeks.	IN	O
Further,	NN	O
the	NN	O
results	TO	O
of	DT	O
CTL	JJ	O
assays	NN	O
showed	.	O
increased	,	O
potency	DT	O
of	JJ	O
synthetic	NN	O
expression	NN	O
cassettes	VBD	O
for	DT	O
induction	JJ	O
of	NN	O
cytotoxic	,	O
T-lymphocyte	IN	O
(CTL)	NN	O
responses	IN	O
by	CD	O
DNA	TO	O
immunization.	CD	O
It	.	O
is	,	O
readily	DT	O
apparent	NNS	O
that	IN	O
the	NNP	O
subject	NNS	O
invention	VBD	O
can	JJ	O
be	NN	O
used	IN	O
to	JJ	O
mount	NN	O
an	NNS	O
immune	IN	O
response	NN	O
to	IN	O
a	JJ	O
wide	NNP	O
variety	)	O
of	NNS	O
antigens	IN	O
and	NNP	O
hence	.	O
to	PRP	O
treat	VBZ	O
or	RB	O
prevent	JJ	O
a	IN	O
large	DT	O
number	JJ	O
of	NN	O
diseases.	MD	O
2.3.1	VB	O
Delivery	VBN	O
of	TO	O
the	VB	O
Synthetic	DT	O
Expression	JJ	O
Cassettes	NN	O
of	TO	O
the	DT	O
Present	JJ	O
Invention	NN	O
Polynucleotide	IN	O
sequences	NNS	O
coding	CC	O
for	NN	O
the	TO	O
above-described	VB	O
molecules	CC	O
can	VB	O
be	DT	O
obtained	JJ	O
using	NN	O
recombinant	IN	O
methods,	.	O
such	CD	O
as	NNP	O
by	IN	O
screening	DT	O
cDNA	NNP	O
and	NNP	O
genomic	NNP	O
libraries	IN	O
from	DT	O
cells	JJ	O
expressing	NNP	O
the	NNP	O
gene,	VBZ	O
or	VBG	O
by	IN	O
deriving	DT	O
the	JJ	O
gene	NNS	O
from	MD	O
a	VB	O
vector	VBN	O
known	VBG	O
to	JJ	O
include	,	O
the	JJ	O
same.	IN	O
The	IN	O
sequences	VBG	O
can	NN	O
be	CC	O
analyzed	JJ	O
by	NNS	O
conventional	IN	O
sequencing	NNS	O
techniques.	VBG	O
Furthermore,	DT	O
the	,	O
desired	CC	O
gene	IN	O
can	VBG	O
be	DT	O
isolated	NN	O
directly	IN	O
from	DT	O
cells	NN	O
and	VBN	O
tissues	TO	O
containing	VB	O
the	DT	O
same,	.	O
using	DT	O
standard	NNS	O
techniques,	MD	O
such	VB	O
as	VBN	O
phenol	IN	O
extraction	JJ	O
and	VBG	O
PCR	.	O
of	,	O
cDNA	DT	O
or	JJ	O
genomic	NN	O
DNA.	MD	O
See,	VB	O
e.g.,	VBN	O
Sambrook	RB	O
et	IN	O
al.,	NNS	O
supra,	CC	O
for	NNS	O
a	VBG	O
description	DT	O
of	,	O
techniques	VBG	O
used	JJ	O
to	,	O
obtain,	JJ	O
isolate	IN	O
and	JJ	O
sequence	NN	O
DNA.	CC	O
Once	NNP	O
the	IN	O
sequence	NN	O
is	CC	O
known,	JJ	O
the	.	O
gene	,	O
of	,	O
interest	NNP	O
can	FW	O
also	,	O
be	,	O
produced	IN	O
synthetically,	DT	O
rather	NN	O
than	IN	O
cloned.	NNS	O
The	VBN	O
nucleotide	TO	O
sequence	,	O
can	NN	O
be	CC	O
designed	NN	O
with	.	O
the	RB	O
appropriate	DT	O
codons	NN	O
for	VBZ	O
the	,	O
particular	DT	O
amino	NN	O
acid	IN	O
sequence	NN	O
desired.	MD	O
In	RB	O
general,	VB	O
one	VBN	O
will	,	O
select	RB	O
preferred	IN	O
codons	.	O
for	DT	O
the	JJ	O
intended	NN	O
host	MD	O
in	VB	O
which	VBN	O
the	IN	O
sequence	DT	O
will	JJ	O
be	NNS	O
expressed.	IN	O
The	DT	O
complete	JJ	O
sequence	NN	O
is	NN	O
assembled	NN	O
from	.	O
overlapping	IN	O
oligonucleotides	,	O
prepared	CD	O
by	MD	O
standard	VB	O
methods	JJ	O
and	NNS	O
assembled	IN	O
into	DT	O
a	JJ	O
complete	NN	O
coding	IN	O
sequence.	WDT	O
See,	DT	O
e.g.,	NN	O
Edge,	MD	B
Nature	VB	I
(1981)	.	I
292:756;	DT	I
Nambair	JJ	B
et	NN	I
al.,	VBZ	I
Science	VBN	I
(1984)	IN	I
223:1299;	VBG	I
Jay	NNS	B
et	VBN	I
al.,	IN	I
J.	JJ	I
Biol.	NNS	I
Chem.	CC	I
(1984)	VBD	I
259:6311;	IN	I
Stemmer,	DT	B
W.	JJ	I
P.C.,	NN	I
(1995)	.	I
Gene	,	I
164:49-53.
Next,	,	O
the	,	O
gene	NNP	O
sequence	)	O
encoding	:	O
the	NNP	O
desired	FW	O
antigen	,	O
can	NNP	O
be	)	O
inserted	:	O
into	NNP	O
a	FW	O
vector	,	O
containing	NNP	O
a	.	O
synthetic	.	O
expression	)	O
cassette	:	O
of	,	O
the	.	O
present	,	O
invention	)	O
(e.g.,	NNP	O
see	.	O
Example	,	O
1	DT	O
for	NN	O
construction	NN	O
of	VBG	O
various	DT	O
exemplary	JJ	O
synthetic	NN	O
expression	MD	O
cassette).	VB	O
The	VBN	O
antigen	IN	O
is	DT	O
inserted	NN	O
into	VBG	O
the	DT	O
synthetic	JJ	O
coding	NN	O
sequence	NN	O
such	IN	O
that	DT	O
when	JJ	O
the	NN	O
combined	,	O
sequence	VBP	O
is	JJ	O
expressed	CD	O
it	IN	O
results	NN	O
in	IN	O
the	JJ	O
production	JJ	O
of	JJ	O
VLPs	NN	O
comprising	.	O
the	DT	O
polypeptide	NN	O
and/or	VBZ	O
the	VBN	O
antigen	IN	O
of	DT	O
interest.	JJ	O
Insertions	NN	O
can	NN	O
be	JJ	O
made	IN	O
within	WRB	O
the	DT	O
Gag	VBN	O
coding	NN	O
sequence	VBZ	O
or	VBN	O
at	PRP	O
either	NNS	O
end	IN	O
of	DT	O
the	NN	O
coding	IN	O
sequence	NNP	O
(5′,	VBG	O
amino	DT	O
terminus	NN	O
of	IN	O
the	DT	O
expressed	NN	O
polypeptide;	IN	O
or	.	O
3′,	NNS	O
carboxy	MD	O
terminus	VB	O
of	VBN	O
the	IN	O
expressed	DT	O
polypeptide—e.g.,	NNP	O
see	VBG	O
Example	NN	O
Wagner,	CC	B
R.,	IN	I
et	DT	I
al.,	NN	I
Arch	IN	I
Virol.	DT	I
127:117-137,	VBG	I
1992;	NN	I
Wagner,	,	B
R.,	JJ	I
et	NN	I
al.,	IN	I
Virology	DT	I
200:162-175,	JJ	I
1994;	:	I
Wu,	CC	B
X.,	,	I
et	JJ	I
al.,	NN	I
J.	IN	I
Virol.	DT	I
69(6):3389-3398,	JJ	I
1995;	,	I
Wang,	VBP	B
C-T.,	JJ	I
et	,	I
al.,	,	I
Virology	FW	I
200:524-534,	,	I
1994;	NNP	I
Chazal,	.	B
N.,	,	I
et	:	I
al.,	,	I
Virology	,	I
68(1):111-122,	FW	I
1994;	,	I
Griffiths,	NNP	B
J.	,	I
C.,	:	I
et	,	I
al.,	,	I
J.	FW	I
Virol.	,	I
67(6):3191-3198,	NNP	I
1993;	.	I
Reicin,	,	B
A.	:	I
S.,	,	I
et	,	I
al.,	FW	I
J.	,	I
Virol.	NNP	I
69(2):642-650,	,	I
1995).
1)(	:	O
Up	,	O
to	,	O
50%	FW	O
of	,	O
the	NNP	O
coding	,	O
sequences	:	O
of	,	O
p55Gag	NNP	O
can	,	O
be	FW	O
deleted	,	O
without	NNP	O
affecting	.	O
the	,	O
assembly	:	O
to	,	O
virus-like	NNP	O
particles	,	O
and	FW	O
expression	,	O
efficiency	NNP	O
Borsetti,	.	B
A.,	,	I
et	.	I
al,	RB	I
J.	TO	I
Virol.	NN	I
72(11):9313-9317,	IN	I
1998;	DT	I
Garnier,	VBG	B
L.,	NNS	I
et	IN	I
al.,	NN	I
J	MD	I
Virol	VB	I
72(6):4667-4677,	VBN	I
1998;	IN	I
Zhang,	VBG	B
Y.,	DT	I
et	NN	I
al.,	TO	I
J	JJ	I
Virol	NNS	I
72(3):1782-1789,	CC	I
1998;	NN	I
Wang,	NN	B
C.,	,	I
et	,	I
al.,	FW	I
J	,	I
Virol	NNP	I
72(10):	.	I
7950-7959,	,	I
1998).(	:	O
In	,	O
one	,	O
embodiment	FW	O
of	,	O
the	NNP	O
present	NNP	O
invention,	,	O
immunogenicity	:	O
of	,	O
the	,	O
high	FW	O
level	,	O
expressing	NNP	O
synthetic	NNP	O
p55GagMod	,	O
and	:	O
p55GagProtMod	,	O
expression	,	O
cassettes	FW	O
can	,	O
be	NNP	O
increased	NNP	O
by	:	O
the	,	O
insertion	.	O
of	IN	O
different	CD	O
structural	NN	O
or	IN	O
non-structural	DT	O
HIV	JJ	O
antigens,	,	O
multiepitope	NN	O
cassettes,	IN	O
or	DT	O
cytokine	JJ	O
sequences	NN	O
into	VBG	O
deleted,	JJ	O
mutated	NN	O
or	CC	O
truncated	JJ	O
regions	NN	O
of	NNS	O
p55GagMod	MD	O
sequence.	VB	O
In	VBN	O
another	IN	O
embodiment	DT	O
of	NN	O
the	IN	O
present	JJ	O
invention,	JJ	O
immunogenicity	CC	O
of	JJ	O
the	NNP	O
high	,	O
level	NN	O
expressing	,	O
synthetic	CC	O
Env	NN	O
expression	NNS	O
cassettes	IN	O
can	,	O
be	VBD	O
increased	CC	O
by	JJ	O
the	NNS	O
insertion	IN	O
of	JJ	O
different	.	O
structural	IN	O
or	DT	O
non-structural	NN	O
HIV	IN	O
antigens,	DT	O
multiepitope	JJ	O
cassettes,	,	O
or	NN	O
cytokine	IN	O
sequences	DT	O
into	JJ	O
deleted	NN	O
regions	VBG	O
of	JJ	O
gp120Mod,	NNP	O
gp140Mod	NN	O
or	NNS	O
gp160Mod	MD	O
sequences.	VB	O
Such	VBN	O
deletions	IN	O
may	DT	O
be	NN	O
generated	IN	O
following	JJ	O
the	JJ	O
teachings	CC	O
of	JJ	O
the	NNP	O
present	,	O
invention	NN	O
and	,	O
information	CC	O
available	NN	O
to	NNS	O
one	IN	O
of	JJ	O
ordinary	NNS	O
skill	IN	O
in	,	O
the	NN	O
art.	CC	O
One	NN	O
possible	.	O
advantage	JJ	O
of	NNS	O
this	MD	O
approach,	VB	O
relative	VBN	O
to	VBG	O
using	DT	O
full-length	NNS	O
modified	IN	O
Env	DT	O
sequences	JJ	O
fused	NN	O
to	CC	O
heterologous	NN	O
polypeptides,	JJ	O
can	TO	O
be	CD	O
higher	IN	O
expression/secretion	JJ	O
efficiency	NN	O
and/or	IN	O
higher	DT	O
immunogenicity	.	O
of	CD	O
the	JJ	O
expression	NN	O
product.	IN	O
Such	DT	O
deletions	,	O
may	JJ	O
be	TO	O
generated	VBG	O
following	JJ	O
the	VBN	O
teachings	NNP	O
of	NNS	O
the	VBD	O
present	TO	O
invention	JJ	O
and	,	O
information	MD	O
available	VB	O
to	JJR	O
one	NN	O
of	NN	O
ordinary	IN	O
skill	JJR	O
in	NN	O
the	IN	O
art.	DT	O
One	NN	O
possible	.	O
advantage	JJ	O
of	NNS	O
this	MD	O
approach,	VB	O
relative	VBN	O
to	VBG	O
using	DT	O
full-length	NNS	O
Env,	IN	O
Gag	DT	O
or	JJ	O
Tat	NN	O
sequences	CC	O
fused	NN	O
to	JJ	O
heterologous	TO	O
polypeptides,	CD	O
can	IN	O
be	JJ	O
higher	NN	O
expression/secretion	IN	O
efficiency	DT	O
and/or	.	O
immunogenicity	CD	O
of	JJ	O
the	NN	O
expression	IN	O
product.	DT	O
When	,	O
sequences	JJ	O
are	TO	O
added	VBG	O
to	JJ	O
the	,	O
amino	NNP	O
terminal	CC	O
end	NNP	O
of	NNS	O
Gag	VBD	O
(for	TO	O
example,	JJ	O
when	,	O
using	MD	O
the	VB	O
synthetic	JJR	O
p55GagMod	NN	O
expression	NN	O
cassette	JJ	O
of	NN	O
the	IN	O
present	DT	O
invention),	NN	O
the	.	O
polynucleotide	WRB	O
can	NNS	O
contain	VBP	O
coding	VBN	O
sequences	TO	O
at	DT	O
the	NN	O
5′	JJ	O
end	NN	O
that	IN	O
encode	NNP	O
a	IN	O
signal	,	O
for	WRB	O
addition	VBG	O
of	DT	O
a	JJ	O
myristic	NN	O
moiety	NN	O
to	NN	O
the	IN	O
Gag-containing	DT	O
polypeptide	JJ	O
(e.g.,	,	O
sequences	DT	O
that	NN	O
encode	MD	O
Met-Gly).	VB	O
The	JJ	O
ability	NNS	O
of	IN	O
Gag-containing	DT	O
polypeptide	CD	O
constructs	NN	O
to	WDT	O
form	VBZ	O
VLPs	DT	O
can	NN	O
be	IN	O
empirically	NN	O
determined	IN	O
following	DT	O
the	JJ	O
teachings	NN	O
of	TO	O
the	DT	O
present	NNP	O
specification.	NN	O
HIV	,	O
polypeptide/antigen	NNS	O
synthetic	IN	O
expression	VBP	O
cassettes	.	O
include	DT	O
control	NN	O
elements	IN	O
operably	NNP	O
linked	NN	O
to	NNS	O
the	TO	O
coding	VB	O
sequence,	NNP	O
which	MD	O
allow	VB	O
for	RB	O
the	VBN	O
expression	VBG	O
of	DT	O
the	NNS	O
gene	IN	O
in	DT	O
vivo	JJ	O
in	.	O
the	NNP	O
subject	NN	O
species.	JJ	O
For	NN	O
example,	NNS	O
typical	VBP	O
promoters	JJ	O
for	NNS	O
mammalian	RB	O
cell	VBN	O
expression	TO	O
include	DT	O
the	VBG	O
SV40	,	O
early	WDT	O
promoter,	VBP	O
a	IN	O
CMV	DT	O
promoter	NN	O
such	IN	O
as	DT	O
the	NN	O
CMV	IN	O
immediate	NN	O
early	IN	O
promoter,	DT	O
the	NN	O
mouse	.	O
mammary	IN	O
tumor	,	O
virus	JJ	O
LTR	NNS	O
promoter,	IN	O
the	JJ	O
adenovirus	NN	O
major	NN	O
late	VBP	O
promoter	DT	O
(Ad	NNP	O
MLP),	JJ	O
and	,	O
the	DT	O
herpes	NNP	O
simplex	NN	O
virus	JJ	O
promoter,	IN	O
among	DT	O
others.	NNP	O
Other	VBP	O
nonviral	JJ	O
promoters,	,	O
such	DT	O
as	NN	O
a	JJ	O
promoter	NN	O
derived	NN	O
from	NNP	O
the	,	O
murine	DT	O
metallothionein	NN	O
gene,	JJ	O
will	JJ	O
also	NN	O
find	NNP	O
use	,	O
for	CC	O
mammalian	DT	O
expression.	NNS	O
Typically,	JJ	O
transcription	NN	O
termination	,	O
and	IN	O
polyadenylation	.	O
sequences	JJ	O
will	JJ	O
also	,	O
be	JJ	O
present,	IN	O
located	DT	O
3′	NN	O
to	VBN	O
the	IN	O
translation	DT	O
stop	NN	O
codon.	NN	O
Preferably,	,	O
a	MD	O
sequence	RB	O
for	VB	O
optimization	NN	O
of	IN	O
initiation	JJ	O
of	.	O
translation,	,	O
located	NN	O
5′	NN	O
to	CC	O
the	NN	O
coding	NNS	O
sequence,	MD	O
is	RB	O
also	VB	O
present.	,	O
Examples	VBN	O
of	CD	O
transcription	TO	O
terminator/polyadenylation	DT	O
signals	NN	O
include	NN	O
those	.	O
derived	,	O
from	DT	O
SV40,	NN	O
as	IN	O
described	NN	O
in	IN	O
Sambrook	NN	O
et	IN	O
al.,	,	O
supra,	VBN	O
as	CD	O
well	TO	O
as	DT	O
a	VBG	O
bovine	,	O
growth	VBZ	O
hormone	RB	O
terminator	.	O
sequence.	NNS	O
Enhancer	IN	O
elements	NN	O
may	NN	O
also	NNS	O
be	VBP	O
used	DT	O
herein	VBN	O
to	IN	O
increase	,	O
expression	IN	O
levels	VBN	O
of	IN	O
the	NNP	O
mammalian	CC	O
constructs.	,	O
Examples	,	O
include	RB	O
the	RB	O
SV40	IN	O
early	DT	O
gene	NN	O
enhancer,	NN	O
as	NN	O
described	NN	O
in	.	O
Dijkema	NNP	B
et	NNS	I
al.,	MD	I
EMBO	RB	I
J.	VB	I
(1985)	VBN	I
4:761,	NN	I
the	TO	O
enhancer/promoter	VB	O
derived	NN	O
from	NNS	O
the	IN	O
long	DT	O
terminal	JJ	O
repeat	.	O
(LTR)	NNS	O
of	VBP	O
the	DT	O
Rous	NNP	O
Sarcoma	JJ	O
Virus,	NN	O
as	,	O
described	IN	O
in	VBN	O
Gorman	IN	B
et	NNP	I
al.,	CC	I
Proc.	,	I
Natl.	NNP	I
Acad.	.	I
Sci.	)	I
USA	,	I
(1982b)	DT	I
79:6777	NN	I
and	VBN	O
elements	IN	O
derived	DT	O
from	JJ	O
human	JJ	O
CMV,	NN	O
as	)	O
described	IN	O
in	DT	O
Boshart	NNP	B
et	NNP	I
al.,	,	I
Cell	IN	I
(1985)	VBN	I
41:521,	IN	I
such	NNP	O
as	CC	O
elements	,	O
included	.	O
in	.	O
the	.	O
CMV	.	O
intron	NNP	O
A	)	O
sequence.	CD	O
Furthermore,	CC	O
plasmids	NNS	O
can	VBN	O
be	IN	O
constructed	JJ	O
which	,	O
include	IN	O
a	VBN	O
chimeric	IN	O
antigen-coding	NNP	O
gene	FW	O
sequences,	,	O
encoding,	NNP	O
e.g.,	)	O
multiple	,	O
antigens/epitopes	JJ	O
of	IN	O
interest,	NNS	O
for	VBN	O
example	IN	O
derived	DT	O
from	NNP	O
a	NN	O
single	DT	O
or	.	O
from	,	O
more	NNS	O
than	MD	O
one	VB	O
viral	VBN	O
isolate.	WDT	O
Typically	VBP	O
the	DT	O
antigen	JJ	O
coding	JJ	O
sequences	NN	O
precede	,	O
or	,	O
follow	,	O
the	JJ	O
synthetic	NNS	O
coding	IN	O
sequences	,	O
and	IN	O
the	NN	O
chimeric	VBN	O
transcription	IN	O
unit	DT	O
will	JJ	O
have	CC	O
a	IN	O
single	JJR	O
open	IN	O
reading	CD	O
frame	JJ	O
encoding	.	O
both	RB	O
the	DT	O
antigen	NN	O
of	VBG	O
interest	NNS	O
and	VBP	O
the	CC	O
synthetic	VBP	O
Gag	DT	O
coding	JJ	O
sequences.	NN	O
Alternatively,	NNS	O
multi-cistronic	CC	O
cassettes	DT	O
(e.g.,	JJ	O
bi-cistronic	NN	O
cassettes)	NN	O
can	MD	O
be	VB	O
constructed	DT	O
allowing	JJ	O
expression	JJ	O
of	NN	O
multiple	NN	O
antigens	VBG	O
from	CC	O
a	DT	O
single	NN	O
mRNA	IN	O
using	NN	O
the	CC	O
EMCV	DT	O
IRES,	JJ	O
or	NNP	O
the	NN	O
like.	.	O
Lastly,	,	O
antigens	JJ	O
can	NNS	O
be	,	O
encoded	JJ	O
on	)	O
separate	MD	O
transcripts	VB	O
from	VBN	O
independent	VBG	O
promoters	NN	O
on	IN	O
a	JJ	O
single	NNS	O
plasmid	IN	O
or	DT	O
other	JJ	O
vector.	NN	O
Once	VBG	O
complete,	DT	O
the	NNP	O
constructs	,	O
are	CC	O
used	DT	O
for	.	O
nucleic	,	O
acid	NNS	O
immunization	MD	O
or	VB	O
the	VBN	O
like	IN	O
using	JJ	O
standard	NNS	O
gene	IN	O
delivery	JJ	O
protocols.	NNS	O
Methods	IN	O
for	DT	O
gene	JJ	O
delivery	NN	O
are	CC	O
known	JJ	O
in	.	O
the	RB	O
art.	,	O
See,	DT	O
e.g.,	NNS	O
U.S.	VBP	O
Pat.	VBN	O
Nos.	IN	O
5,399,346,	JJ	O
5,580,859,	JJ	O
5,589,466.	NN	O
Genes	CC	O
can	DT	O
be	JJ	O
delivered	VBG	O
either	JJ	O
directly	NN	O
to	NN	O
the	.	O
vertebrate	NNS	O
subject	IN	O
or,	NN	O
alternatively,	NN	O
delivered	VBP	O
ex	VBN	O
vivo,	IN	O
to	DT	O
cells	.	O
derived	,	O
from	,	O
the	NNP	O
subject	.	O
and	.	O
the	,	O
cells	,	O
reimplanted	.	O
in	NNS	O
the	MD	O
subject.	VB	O
A	VBN	O
number	DT	O
of	RB	O
viral	TO	O
based	DT	O
systems	NN	O
have	NN	O
been	,	O
developed	,	O
for	VBD	O
gene	JJ	O
transfer	,	O
into	TO	O
mammalian	NNS	O
cells.	VBN	O
For	IN	O
example,	DT	O
retroviruses	NN	O
provide	CC	O
a	DT	O
convenient	NNS	O
platform	VBN	O
for	IN	O
gene	DT	O
delivery	.	O
systems.	DT	O
Selected	NN	O
sequences	IN	O
can	JJ	O
be	VBN	O
inserted	NNS	O
into	VBP	O
a	VBN	O
vector	VBN	O
and	IN	O
packaged	NN	O
in	NN	O
retroviral	IN	O
particles	JJ	O
using	.	O
techniques	IN	O
known	,	O
in	VBZ	O
the	VBP	O
art.	DT	O
The	NN	O
recombinant	NN	O
virus	IN	O
can	NN	O
then	NN	O
be	.	O
isolated	VBN	O
and	NNS	O
delivered	MD	O
to	VB	O
cells	VBN	O
of	IN	O
the	DT	O
subject	NN	O
either	CC	O
in	VBN	O
vivo	IN	O
or	JJ	O
ex	NNS	O
vivo.	VBG	O
A	NNS	O
number	VBN	O
of	IN	O
retroviral	DT	O
systems	.	O
have	DT	O
been	JJ	O
described	NN	O
(U.S.	MD	O
Pat.	RB	O
No.	VB	O
5,219,740;	VBN	O
Miller	CC	B
and	VBN	I
Rosman,	TO	I
BioTechniques	NNS	I
(1989)	IN	I
7:980-990;	DT	I
Miller,	NN	B
A.	CC	I
D.,	IN	I
Human	NN	I
Gene	CC	I
Therapy	NN	I
(1990)	.	I
1:5-14;	DT	I
Scarpa	NN	B
et	IN	I
al.,	JJ	I
Virology	NNS	I
(1991)	VBP	I
180:849-852;	VBN	I
Burns	VBN	B
et	NNP	I
al.,	.	I
Proc.	.	I
Natl.	:	I
Acad.	NNP	I
Sci.	CC	I
USA	,	I
(1993)	NNP	I
90:8033-8037;	)	I
and	:	O
Boris-Lawrie	,	B
and	NNP	I
Temin,	,	I
Cur.	NNP	I
Opin.	NNP	I
Genet.	NNP	I
Develop.	)	I
(1993)	:	I
3:102-109.
A	NNP	O
number	FW	O
of	,	O
adenovirus	NNP	O
vectors	)	O
have	:	O
also	NNP	O
been	FW	O
described.	,	O
Unlike	.	O
retroviruses	.	O
which	.	O
integrate	.	O
into	NNP	O
the	)	O
host	:	O
genome,	CC	O
adenoviruses	NNP	O
persist	CC	O
extrachromosomally	,	O
thus	.	O
minimizing	.	O
the	.	O
risks	.	O
associated	)	O
with	.	O
insertional	DT	O
mutagenesis	NN	O
Haj-Ahmad	IN	B
and	JJ	I
Graham,	NNS	I
J.	VBP	I
Virol.	RB	I
(1986)	VBN	I
57:267-274;	.	I
Bett	IN	B
et	NNS	I
al.,	WDT	I
J.	VBP	I
Virol.	IN	I
(1993)	DT	I
67:5911-5921;	NN	I
Mittereder	,	B
et	VBZ	I
al.,	VBP	I
Human	RB	I
Gene	RB	I
Therapy	VBG	I
(1994)	DT	I
5:717-729;	NNS	I
Seth	VBN	B
et	IN	I
al.,	JJ	I
J.	NN	I
Virol.	NNP	I
(1994)	CC	I
68:933-940;	,	I
Barr	NNP	B
et	.	I
al.,	)	I
Gene	:	I
Therapy	NNP	I
(1994)	FW	I
1:51-58;	,	I
Berkner,	NNP	B
K.	.	I
L.	)	I
BioTechniques	:	I
(1988)	NNP	I
6:616-629;	FW	I
(and	,	O
Rich	NNP	B
et	NNP	I
al.,	NNP	I
Human	)	I
Gene	:	I
Therapy	NNP	I
(1993)	FW	I
4:461-476).Additionally,	,	O
various	NNP	O
adeno-associated	.	O
virus	)	O
(AAV)	:	O
vector	NNP	O
systems	FW	O
have	,	O
been	NNP	O
developed	NNP	O
for	)	O
gene	:	O
delivery.	,	O
AAV	NNP	O
vectors	NNP	O
can	NNP	O
be	)	O
readily	:	O
constructed	CC	O
using	NNP	O
techniques	VBP	O
well	,	O
known	NNP	O
in	NNP	O
the	NNP	O
art.	)	O
See,	.	O
e.g.,	,	O
U.S.	JJ	O
Pat.	JJ	O
Nos.	NN	O
5,173,414	)	O
and	NN	O
5,139,941;	NNS	O
International	VBP	O
Publication	VBN	O
Nos.	VBN	O
WO	IN	O
92/01070	NN	O
(published	.	O
23	NNP	O
Jan.	NNS	O
1992)	MD	O
and	VB	O
WO	RB	O
93/03769	VBN	O
(published	VBG	O
4	NNS	O
Mar.	RB	O
1993);	VBN	O
Lebkowski	IN	B
et	DT	I
al.,	.	I
Molec.	,	I
Cell.	,	I
Biol.	NNP	I
(1988)	.	I
8:3988-3996;	.	I
Vincent	CD	B
et	CC	I
al.,	:	I
Vaccines	NNP	I
90	NNP	I
(1990)	.	I
(Cold	$	I
Spring	CD	I
Harbor	VBN	I
Laboratory	CD	I
Press);	NNP	I
Carter,	)	B
B.	CC	I
J.	$	I
Current	CD	I
Opinion	VBN	I
in	CD	I
Biotechnology	.	I
(1992)	:	I
3:533-539;	NNP	I
Muzyczka,	FW	B
N.	,	I
Current	.	I
Topics	.	I
in	.	I
Microbiol.	)	I
and	:	I
Immunol.	NNP	I
(1992)	FW	I
158:97-129;	,	I
Kotin,	VBZ	B
R.	CD	I
M.	)	I
Human	JJ	I
Gene	NN	I
Therapy	NNP	I
(1994)	NNP	I
5:793-801;	:	I
Shelling	,	B
and	NNP	I
Smith,	.	I
Gene	JJ	I
Therapy	NN	I
(1994)	IN	I
1:165-169;	NNP	I
and	)	O
Zhou	:	B
et	,	I
al.,	NNP	I
J.	NNP	I
Exp.	NNPS	I
Med.	IN	I
(1994)	.	I
179:1867-1875.
Another	CC	O
vector	.	O
system	)	O
useful	:	O
for	,	O
delivering	NNP	O
the	NNP	O
polynucleotides	NNP	O
of	NNP	O
the	NNP	O
present	)	O
invention	:	O
is	NNP	O
the	CC	O
enterically	,	O
administered	NNP	O
recombinant	NNP	O
poxvirus	)	O
vaccines	:	O
described	CC	O
by	NNP	O
Small,	VBP	O
Jr.,	,	O
P.	NNP	O
A.,	.	O
et	.	O
al.	)	O
(U.S.	.	O
Pat.	DT	O
No.	NN	O
5,676,950,	NN	O
issued	JJ	O
Oct.	IN	O
14,	VBG	O
1997,	DT	O
herein	NNS	O
incorporated	IN	O
by	DT	O
reference).	JJ	O
Additional	NN	O
viral	VBZ	O
vectors	DT	O
which	RB	O
will	VBN	O
find	JJ	O
use	NN	O
for	NNS	O
delivering	VBN	O
the	IN	O
nucleic	,	O
acid	,	O
molecules	NNP	O
encoding	,	O
the	CC	O
antigens	.	O
of	NNP	O
interest	.	O
include	.	O
those	,	O
derived	VBN	O
from	NNP	O
the	,	O
pox	,	O
family	RB	O
of	VBN	O
viruses,	IN	O
including	.	O
vaccinia	JJ	O
virus	NN	O
and	NNS	O
avian	WDT	O
poxvirus.	MD	O
By	VB	O
way	NN	O
of	IN	O
example,	VBG	O
vaccinia	DT	O
virus	JJ	O
recombinants	NN	O
expressing	NNS	O
the	VBG	O
genes	DT	O
can	NNS	O
be	IN	O
constructed	NN	O
as	VBP	O
follows.	DT	O
The	VBN	O
DNA	IN	O
encoding	DT	O
the	JJ	O
particular	NN	O
synthetic	IN	O
Gag/antigen	,	O
coding	VBG	O
sequence	NN	O
is	NN	O
first	CC	O
inserted	JJ	O
into	.	O
an	IN	O
appropriate	NN	O
vector	IN	O
so	,	O
that	FW	O
it	NN	O
is	NNS	O
adjacent	VBG	O
to	DT	O
a	NNS	O
vaccinia	MD	O
promoter	VB	O
and	VBN	O
flanking	IN	O
vaccinia	.	O
DNA	DT	O
sequences,	NN	O
such	VBG	O
as	DT	O
the	JJ	O
sequence	JJ	O
encoding	NNP	O
thymidine	VBG	O
kinase	NN	O
(TK).	VBZ	O
This	RB	O
vector	VBN	O
is	IN	O
then	DT	O
used	JJ	O
to	NN	O
transfect	IN	O
cells	IN	O
which	PRP	O
are	VBZ	O
simultaneously	JJ	O
infected	TO	O
with	DT	O
vaccinia.	NN	O
Homologous	NN	O
recombination	CC	O
serves	VBG	O
to	NN	O
insert	NNP	O
the	,	O
vaccinia	JJ	O
promoter	IN	O
plus	DT	O
the	NN	O
gene	VBG	O
encoding	JJ	O
the	NN	O
coding	.	O
sequences	DT	O
of	NN	O
interest	VBZ	O
into	RB	O
the	VBN	O
viral	TO	O
genome.	VB	O
The	NNS	O
resulting	WDT	O
TK−	VBP	O
recombinant	RB	O
can	VBN	O
be	IN	O
selected	.	O
by	JJ	O
culturing	NN	O
the	NNS	O
cells	TO	O
in	VB	O
the	DT	O
presence	NN	O
of	NN	O
5-bromodeoxyuridine	CC	O
and	DT	O
picking	NN	O
viral	VBG	O
plaques	DT	O
resistant	VBG	O
thereto.	NNS	O
Alternatively,	IN	O
avipoxviruses,	NN	O
such	IN	O
as	DT	O
the	JJ	O
fowlpox	.	O
and	DT	O
canarypox	VBG	O
viruses,	NNP	O
can	NN	O
also	MD	O
be	VB	O
used	VBN	O
to	IN	O
deliver	VBG	O
the	DT	O
genes.	NNS	O
Recombinant	IN	O
avipox	DT	O
viruses,	NN	O
expressing	IN	O
immunogens	JJ	O
from	CC	O
mammalian	JJ	O
pathogens,	JJ	O
are	NNS	O
known	JJ	O
to	.	O
confer	,	O
protective	,	O
immunity	JJ	O
when	IN	O
administered	DT	O
to	NN	O
non-avian	CC	O
species.	NN	O
The	,	O
use	MD	O
of	RB	O
an	VB	O
avipox	VBN	O
vector	TO	O
is	VB	O
particularly	DT	O
desirable	.	O
in	JJ	O
human	NN	O
and	,	O
other	VBG	O
mammalian	NNS	O
species	IN	O
since	JJ	O
members	,	O
of	VBP	O
the	VBN	O
avipox	TO	O
genus	VB	O
can	JJ	O
only	NN	O
productively	WRB	O
replicate	VBN	O
in	TO	O
susceptible	JJ	O
avian	.	O
species	DT	O
and	NN	O
therefore	IN	O
are	DT	O
not	JJ	O
infective	NN	O
in	VBZ	O
mammalian	RB	O
cells.	JJ	O
Methods	IN	O
for	JJ	O
producing	CC	O
recombinant	JJ	O
avipoxviruses	JJ	O
are	NNS	O
known	IN	O
in	NNS	O
the	IN	O
art	DT	O
and	JJ	O
employ	NN	O
genetic	MD	O
recombination,	RB	O
as	RB	O
described	VB	O
above	IN	O
with	JJ	O
respect	JJ	O
to	NNS	O
the	CC	O
production	RB	O
of	VBP	O
vaccinia	RB	O
viruses.	JJ	O
See,	IN	O
e.g.,	JJ	O
WO	.	O
91/12882;	NNS	O
WO	IN	O
89/03429;	VBG	O
and	JJ	O
WO	NNS	O
92/03545.	VBP	O
Molecular	VBN	O
conjugate	IN	O
vectors,	DT	O
such	NN	O
as	CC	O
the	JJ	O
adenovirus	JJ	O
chimeric	,	O
vectors	IN	O
described	VBN	O
in	IN	O
Michael	IN	B
et	NN	I
al.,	TO	I
J.	DT	I
Biol.	NN	I
Chem.	IN	I
(1993)	NN	I
268:6866-6869	.	I
and	,	O
Wagner	,	B
et	NNP	I
al.,	:	I
Proc.	NNP	I
Natl.	:	I
Acad.	CC	I
Sci.	NNP	I
USA	.	I
(1992)	JJ	I
89:6099-6103,	NN	I
can	,	O
also	JJ	O
be	IN	O
used	DT	O
for	NN	O
gene	JJ	O
delivery.	NNS	O
Members	VBD	O
of	IN	O
the	NNP	O
Alphavirus	CC	O
genus,	,	O
such	NNP	O
as,	.	O
but	.	O
not	)	O
limited	CD	O
to,	CC	O
vectors	NNP	O
derived	VBP	O
from	,	O
the	.	O
Sindbis,	.	O
Semliki	.	O
Forest,	.	O
and	NNP	O
Venezuelan	)	O
Equine	,	O
Encephalitis	MD	O
viruses,	RB	O
will	VB	O
also	VBN	O
find	IN	O
use	NN	O
as	.	O
viral	NNS	O
vectors	IN	O
for	DT	O
delivering	NNP	O
the	,	O
polynucleotides	JJ	O
of	,	O
the	CC	O
present	RB	O
invention	JJ	O
(for	,	O
example,	NNS	O
a	VBD	O
synthetic	IN	O
Gag-	DT	O
or	,	O
Env-polypeptide	NNP	O
encoding	,	O
expression	CC	O
cassette	NNP	O
as	NNP	O
described	NNP	O
in	,	O
Example	MD	O
14	RB	O
below).	VB	O
For	NN	O
a	IN	O
description	JJ	O
of	NNS	O
Sindbis-virus	IN	O
derived	VBG	O
vectors	DT	O
useful	NNS	O
for	IN	O
the	DT	O
practice	JJ	O
of	NN	O
the	IN	O
instant	,	O
methods,	DT	O
see,	JJ	O
Dubensky	NNP	B
et	CC	I
al.,	NNP	I
J.	VBG	I
Virol.	NN	I
(1996)	NN	I
70:508-519;	IN	I
and	VBN	O
International	IN	O
Publication	NNP	O
Nos.	CD	O
WO	.	O
95/07995	IN	O
and	DT	O
WO	NN	O
96/17072;	IN	O
as	NNP	O
well	VBD	O
as,	NNS	O
Dubensky,	JJ	O
Jr.,	IN	O
T.	DT	O
W.,	NN	O
et	IN	O
al.,	DT	O
U.S.	JJ	O
Pat.	,	O
No.	,	O
5,843,723,	NNP	O
issued	FW	O
Dec.	,	O
1,	NNP	O
1998,	.	O
and	)	O
Dubensky,	:	O
Jr.,	CC	O
T.	NNP	O
W.,	NNP	O
U.S.	.	O
Pat.	$	O
No.	CD	O
5,789,245,	CC	O
issued	NNP	O
Aug.	:	O
4,	RB	O
1998,	RB	O
both	,	O
herein	,	O
incorporated	,	O
by	NNP	O
reference.	,	O
A	FW	O
vaccinia	,	O
based	NNP	O
infection/transfection	.	O
system	.	O
can	,	O
be	VBN	O
conveniently	NNP	O
used	,	O
to	,	O
provide	CC	O
for	,	O
inducible,	,	O
transient,	NNP	O
expression	,	O
of	NNP	O
the	.	O
coding	.	O
sequences	,	O
of	VBN	O
interest	NNP	O
(for	,	O
example,	,	O
a	DT	O
synthetic	NNS	O
Gag/HCV-core	VBN	O
expression	IN	O
cassette)	.	O
in	DT	O
a	NN	O
host	VBN	O
cell.	NN	O
In	NN	O
this	MD	O
system,	VB	O
cells	RB	O
are	VBN	O
first	TO	O
infected	VB	O
in	IN	O
vitro	,	O
with	,	O
a	NN	O
vaccinia	IN	O
virus	DT	O
recombinant	VBG	O
that	NNS	O
encodes	IN	O
the	NN	O
bacteriophage	IN	O
T7	,	O
RNA	DT	O
polymerase.	JJ	O
This	NNP	O
polymerase	NN	O
displays	)	O
exquisite	IN	O
specificity	DT	O
in	NN	O
that	.	O
it	IN	O
only	DT	O
transcribes	,	O
templates	NNS	O
bearing	VBP	O
T7	RB	O
promoters.	VBN	O
Following	IN	O
infection,	NN	O
cells	IN	O
are	DT	O
transfected	NN	O
with	NN	O
the	NN	O
polynucleotide	WDT	O
of	VBZ	O
interest,	DT	O
driven	NN	O
by	NNP	O
a	NNP	O
T7	.	O
promoter.	DT	O
The	NN	O
polymerase	VBZ	O
expressed	JJ	O
in	NN	O
the	IN	O
cytoplasm	DT	O
from	PRP	O
the	RB	O
vaccinia	VBZ	O
virus	NNS	O
recombinant	VBG	O
transcribes	NNP	O
the	.	O
transfected	VBG	O
DNA	,	O
into	NNS	O
RNA	VBP	O
which	VBN	O
is	IN	O
then	DT	O
translated	NN	O
into	IN	O
protein	,	O
by	VBN	O
the	IN	O
host	DT	O
translational	NNP	O
machinery.	.	O
The	DT	O
method	NN	O
provides	VBN	O
for	IN	O
high	DT	O
level,	NN	O
transient,	IN	O
cytoplasmic	DT	O
production	NN	O
of	NN	O
large	NN	O
quantities	VBZ	O
of	DT	O
RNA	JJ	O
and	NNP	O
its	IN	O
translation	NNP	O
products.	WDT	O
See,	VBZ	O
e.g.,	RB	O
Elroy-Stein	VBN	B
and	IN	I
Moss,	NN	I
Proc.	IN	I
Natl.	DT	I
Acad.	NN	I
Sci.	JJ	I
USA	.	I
(1990)	DT	I
87:6743-6747;	NN	I
Fuerst	VBZ	B
et	IN	I
al.,	JJ	I
Proc.	,	I
Natl.	,	I
Acad.	JJ	I
Sci.	NN	I
USA	IN	I
(1986)	JJ	I
83:8122-8126.
As	NNS	O
an	IN	O
alternative	NNP	O
approach	CC	O
to	PRP$	O
infection	NN	O
with	.	O
vaccinia	,	O
or	,	O
avipox	NNP	O
virus	CC	O
recombinants,	,	O
or	.	O
to	.	O
the	.	O
delivery	.	O
of	NNP	O
genes	)	O
using	:	O
other	NNP	O
viral	FW	O
vectors,	,	O
an	.	O
amplification	.	O
system	.	O
can	.	O
be	NNP	O
used	)	O
that	.	O
will	IN	O
lead	DT	O
to	JJ	O
high	NN	O
level	TO	O
expression	NN	O
following	IN	O
introduction	NN	O
into	CC	O
host	JJ	O
cells.	NN	O
Specifically,	,	O
a	CC	O
T7	TO	O
RNA	DT	O
polymerase	NN	O
promoter	IN	O
preceding	NNS	O
the	VBG	O
coding	JJ	O
region	JJ	O
for	,	O
T7	DT	O
RNA	NN	O
polymerase	NN	O
can	MD	O
be	VB	O
engineered.	VBN	O
Translation	DT	O
of	MD	O
RNA	VB	O
derived	TO	O
from	JJ	O
this	NN	O
template	NN	O
will	VBG	O
generate	NN	O
T7	IN	O
RNA	NN	O
polymerase	.	O
which	,	O
in	DT	O
turn	NNP	O
will	NNP	O
transcribe	NN	O
more	NN	O
template.	VBG	O
Concomitantly,	DT	O
there	NN	O
will	NN	O
be	IN	O
a	NNP	O
cDNA	NNP	O
whose	NN	O
expression	MD	O
is	VB	O
under	.	O
the	NN	O
control	IN	O
of	NNP	O
the	VBD	O
T7	IN	O
promoter.	DT	O
Thus,	NN	O
some	MD	O
of	VB	O
the	NNP	O
T7	NNP	O
RNA	NN	O
polymerase	WDT	O
generated	IN	O
from	NN	O
translation	MD	O
of	VB	O
the	JJR	O
amplification	.	O
template	,	O
RNA	EX	O
will	MD	O
lead	VB	O
to	DT	O
transcription	NN	O
of	WP$	O
the	NN	O
desired	VBZ	O
gene.	IN	O
Because	DT	O
some	NN	O
T7	IN	O
RNA	DT	O
polymerase	NNP	O
is	.	O
required	,	O
to	DT	O
initiate	IN	O
the	DT	O
amplification,	NNP	O
T7	NNP	O
RNA	NN	O
polymerase	VBD	O
can	IN	O
be	NN	O
introduced	IN	O
into	DT	O
cells	NN	O
along	NN	O
with	NNP	O
the	MD	O
template(s)	VB	O
to	TO	O
prime	NN	O
the	IN	O
transcription	DT	O
reaction.	JJ	O
The	.	O
polymerase	IN	O
can	DT	O
be	NNP	O
introduced	NNP	O
as	NN	O
a	VBZ	O
protein	VBN	O
or	TO	O
on	VB	O
a	DT	O
plasmid	,	O
encoding	NNP	O
the	NNP	O
RNA	NN	O
polymerase.	MD	O
For	VB	O
a	VBN	O
further	IN	O
discussion	NNS	O
of	IN	O
T7	IN	O
systems	DT	O
and	)	O
their	TO	O
use	VB	O
for	DT	O
transforming	NN	O
cells,	.	O
see,	DT	O
e.g.,	NN	O
International	MD	B
Publication	VB	I
No.	VBN	I
WO	IN	I
94/26911;	DT	I
Studier	NN	B
and	CC	I
Moffatt,	IN	I
J.	DT	I
Mol.	NN	I
Biol.	VBG	I
(1986)	DT	I
189:113-130;	NNP	I
Deng	.	B
and	IN	I
Wolff,	DT	I
Gene	JJ	I
(1994)	NN	I
143:245-249;	IN	I
Gao	NNP	B
et	NNS	I
al.,	CC	I
Biochem.	PRP$	I
Biophys.	NN	I
Res.	IN	I
Commun.	VBG	I
(1994)	,	I
200:1201-1206;	,	I
Gao	,	B
and	NNP	I
Huang,	NNP	I
Nuc.	.	I
Acids	NNP	I
Res.	:	I
(1993)	NNP	I
21:2867-2872;	CC	I
Chen	,	B
et	NNP	I
al.,	.	I
Nuc.	.	I
Acids	)	I
Res.	:	I
(1994)	NNP	I
22:2114-2120;	CC	I
and	,	O
U.S.	NNP	O
Pat.	)	O
No.	:	O
5,135,855.	NNP	O
The	FW	O
synthetic	,	O
expression	.	O
cassette	.	O
of	.	O
interest	.	O
can	)	O
also	:	O
be	NNP	O
delivered	CC	O
without	,	O
a	.	O
viral	NNP	O
vector.	.	O
For	)	O
example,	:	O
the	NNP	O
synthetic	FW	O
expression	,	O
cassette	.	O
can	NNP	O
be	.	O
packaged	)	O
as	:	O
DNA	CC	O
or	NNP	O
RNA	.	O
in	.	O
liposomes	.	O
prior	DT	O
to	JJ	O
delivery	NN	O
to	NN	O
the	IN	O
subject	NN	O
or	MD	O
to	RB	O
cells	VB	O
derived	VBN	O
therefrom.	IN	O
Lipid	DT	O
encapsulation	JJ	O
is	.	O
generally	IN	O
accomplished	,	O
using	DT	O
liposomes	JJ	O
which	NN	O
are	NN	O
able	MD	O
to	VB	O
stably	VBN	O
bind	IN	O
or	NN	O
entrap	CC	O
and	NNP	O
retain	IN	O
nucleic	RB	O
acid.	JJ	O
The	TO	O
ratio	NN	O
of	TO	O
condensed	DT	O
DNA	NN	O
to	CC	O
lipid	TO	O
preparation	NNS	O
can	VBN	O
vary	.	O
but	JJ	O
will	NN	O
generally	VBZ	O
be	RB	O
around	VBN	O
1:1	VBG	O
(mg	NNS	O
DNA:micromoles	WDT	O
lipid),	VBP	O
or	JJ	O
more	TO	O
of	VB	O
lipid.	NN	O
For	CC	O
a	NN	O
review	CC	O
of	VB	O
the	JJ	O
use	.	O
of	DT	O
liposomes	NN	O
as	IN	O
carriers	JJ	O
for	NN	O
delivery	TO	O
of	JJ	O
nucleic	NN	O
acids,	MD	O
see,	VB	O
Hug	CC	B
and	MD	I
Sleight,	RB	I
Biochim.	VB	I
Biophys.	IN	I
Acta.	CD	I
(1991)	JJ	I
1097:1-17;	NNS	I
Straubinger	,	B
et	CC	I
al.,	JJR	I
in	IN	I
Methods	.	I
of	IN	I
Enzymology	DT	I
(1983),	NN	I
Vol.	IN	I
101,	DT	I
pp.	NN	I
512-527.
Liposomal	IN	O
preparations	NNS	O
for	IN	O
use	NNS	O
in	IN	O
the	NN	O
present	IN	O
invention	JJ	O
include	,	O
cationic	,	O
(positively	NNP	O
charged),	CC	O
anionic	,	O
(negatively	.	O
charged)	.	O
and	.	O
neutral	)	O
preparations,	:	O
with	NNP	O
cationic	FW	O
liposomes	,	O
particularly	IN	O
preferred.	NNP	O
Cationic	IN	O
liposomes	NNP	O
have	,	O
been	.	O
shown	,	O
to	.	O
mediate	.	O
intracellular	JJ	O
delivery	NNS	O
of	IN	O
plasmid	NN	O
DNA	IN	O
Felgner	DT	B
et	JJ	I
al.,	NN	I
Proc.	VBP	I
Natl.	JJ	I
Acad.	RB	I
Sci.	,	I
USA	JJ	I
(1987)	RB	I
84:7413-7416);(	)	O
mRNA	CC	O
(Malone	JJ	O
et	,	O
al.,	IN	O
Proc.	JJ	O
Natl.	NNS	O
Acad.	RB	O
Sci.	.	O
USA	NNP	O
(1989)	NNS	O
86:6077-6081);	VBP	O
and	VBN	O
purified	VBN	O
transcription	TO	O
factors	VB	O
Debs	JJ	B
et	NN	I
al.,	IN	I
J.	NN	I
Biol.	NNP	I
Chem.	NNP	I
(1990)	RB	I
265:10189-10192),(	,	O
in	.	O
functional	.	O
form.	.	O
Cationic	.	O
liposomes	NNP	O
are	)	O
readily	:	O
available.	FW	O
For	NNP	O
example,	RB	O
N[1-2,3-dioleyloxy)propyl]-N,N,N-triethylammonium	,	O
(DOTMA)	.	O
liposomes	.	O
are	.	O
available	.	O
under	NNP	O
the	)	O
trademark	:	O
Lipofectin,	CC	O
from	JJ	O
GIBCO	NN	O
BRL,	NNS	O
Grand	NNP	O
Island,	RB	O
N.	,	O
Y.	NNP	O
(See,	.	O
also,	.	O
Feigner	)	B
et	,	I
al.,	IN	I
Proc.	JJ	I
Natl.	.	I
Acad.	JJ	I
Sci.	NNS	I
USA	VBP	I
(1987)	RB	I
84:7413-7416).Other	.	O
commercially	IN	O
available	,	O
lipids	NNP	O
include	)	O
(DDAB/DOPE)	NNS	O
and	VBP	O
DOTAP/DOPE	JJ	O
(Boerhinger).	IN	O
Other	DT	O
cationic	NN	O
liposomes	,	O
can	IN	O
be	NNP	O
prepared	,	O
from	NNP	O
readily	,	O
available	NNP	O
materials	.	O
using	,	O
techniques	,	O
well	NNP	O
known	CC	O
in	,	O
the	.	O
art.	.	O
See,	.	O
e.g.,	.	O
Szoka	NNP	B
et	)	I
al.,	.	I
Proc.	JJ	I
Natl.	RB	I
Acad.	JJ	I
Sci.	NNS	I
USA	VBP	I
(1978)	)	I
75:4194-4198;	CC	I
PCT	NNP	O
Publication	.	O
No.	JJ	O
WO	JJ	O
90/11092	NNS	O
for	MD	O
a	VB	O
description	VBN	O
of	IN	O
the	RB	O
synthesis	JJ	O
of	NNS	O
DOTAP	VBG	O
(1,2-bis(oleoyloxy)-3-(trimethylammonio)propane)	NNS	O
liposomes.	RB	O
Similarly,	VBN	O
anionic	IN	O
and	DT	O
neutral	.	O
liposomes	,	O
are	,	O
readily	NNP	O
available,	FW	O
such	,	O
as,	.	O
from	.	O
Avanti	.	O
Polar	.	O
Lipids	NNP	O
(Birmingham,	)	O
Ala.),	:	O
or	NNP	O
can	NNP	O
be	.	O
easily	$	O
prepared	CD	O
using	IN	O
readily	DT	O
available	NN	O
materials.	IN	O
Such	DT	O
materials	NN	O
include	IN	O
phosphatidyl	NNP	O
choline,	)	O
cholesterol,	.	O
phosphatidyl	,	O
ethanolamine,	JJ	O
dioleoylphosphatidyl	CC	O
choline	JJ	O
(DOPC),	NNS	O
dioleoylphosphatidyl	VBP	O
glycerol	RB	O
(DOPG),	,	O
dioleoylphoshatidyl	JJ	O
ethanolamine	,	O
(DOPE),	IN	O
among	NNP	O
others.	NNP	O
These	NNP	O
materials	,	O
can	,	O
also	CC	O
be	MD	O
mixed	VB	O
with	RB	O
the	JJ	O
DOTMA	VBG	O
and	RB	O
DOTAP	JJ	O
starting	.	O
materials	JJ	O
in	NNS	O
appropriate	VBP	O
ratios.	JJ	O
Methods	,	O
for	,	O
making	JJ	O
liposomes	,	O
using	JJ	O
these	NN	O
materials	,	O
are	JJ	O
well	NN	O
known	,	O
in	JJ	O
the	NN	O
art.	,	O
The	IN	O
liposomes	.	O
can	DT	O
comprise	NNS	O
multilammelar	MD	O
vesicles	RB	O
(MLVs),	VB	O
small	JJ	O
unilamellar	IN	O
vesicles	DT	O
(SUVs),	NNP	O
or	CC	O
large	NNP	O
unilamellar	VBG	O
vesicles	NNS	O
(LUVs).	IN	O
The	JJ	O
various	.	O
liposome-nucleic	NNS	O
acid	IN	O
complexes	VBG	O
are	NNS	O
prepared	VBG	O
using	DT	O
methods	NNS	O
known	VBP	O
in	RB	O
the	VBN	O
art.	IN	O
See,	DT	O
e.g.,	.	O
Straubinger	DT	B
et	NNS	I
al.,	MD	I
in	VB	I
METHODS	JJ	I
OF	NNS	I
IMMUNOLOGY	,	I
(1983),	JJ	I
Vol.	JJ	I
101,	NNS	I
pp.	,	I
512-527;	CC	I
Szoka	JJ	B
et	JJ	I
al.,	NNS	I
Proc.	.	I
Natl.	DT	I
Acad.	JJ	I
Sci.	JJ	I
USA	NN	I
(1978)	NNS	I
75:4194-4198;	VBP	I
Papahadjopoulos	JJ	B
et	VBG	I
al.,	NNS	I
Biochim.	VBN	I
Biophys.	IN	I
Acta	DT	I
(1975)	.	I
394:483;	,	I
Wilson	,	B
et	NNP	I
al.,	CC	I
Cell	,	I
(1979)	IN	I
17:77);	NNP	I
Deamer	NNP	B
and	NNP	I
Bangham,	,	I
Biochim.	.	I
Biophys.	,	I
Acta	.	I
(1976)	:	I
443:629;	NNP	I
Ostro	FW	B
et	,	I
al.,	.	I
Biochem.	.	I
Biophys.	.	I
Res.	.	I
Commun.	NNP	I
(1977)	)	I
76:836;	:	I
Fraley	NNP	B
et	FW	I
al.,	,	I
Proc.	.	I
Natl.	.	I
Acad.	NNP	I
Sci.	)	I
USA	:	I
(1979)	NNP	I
76:3348);	FW	I
Enoch	,	B
and	NNP	I
Strittmatter,	)	I
Proc.	:	I
Natl.	NNP	I
Acad.	CC	I
Sci.	,	I
USA	.	I
(1979)	.	I
76:145);	NNP	I
Fraley	)	B
et	:	I
al.,	NNP	I
J.	FW	I
Biol.	,	I
Chem.	.	I
(1980)	.	I
255:10431;	.	I
Szoka	.	B
and	)	I
Papahadjopoulos,	:	I
Proc.	NNP	I
Natl.	FW	I
Acad.	,	I
Sci.	.	I
USA	.	I
(1978)	.	I
75:145;	.	I
and	NNP	O
Schaefer-Ridder	)	B
et	:	I
al.,	NNP	I
Science	CC	I
(1982)	,	I
215:166.
The	.	O
DNA	.	O
and/or	.	O
protein	.	O
antigen(s)	NNP	O
can	)	O
also	:	O
be	NNP	O
delivered	FW	O
in	,	O
cochleate	NNP	O
lipid	.	O
compositions	.	O
similar	)	O
to	:	O
those	NNP	O
described	CC	O
by	,	O
Papahadjopoulos	.	B
et	.	I
al.,	.	I
Biochem.	.	I
Biophys.	NNP	I
Acta.	)	I
(1975)	:	I
394:483-491.	CC	I
See,	NNP	O
also,	NNP	O
U.S.	,	O
Pat.	NNP	O
Nos.	)	O
4,663,161	.	O
and	DT	O
4,871,488.	NNP	O
The	NN	O
synthetic	NN	O
expression	)	O
cassette	MD	O
of	RB	O
interest	VB	O
(e.g.,	VBN	O
any	IN	O
of	NN	O
the	JJ	O
synthetic	NNS	O
expression	JJ	O
cassettes	TO	O
described	DT	O
in	VBN	O
Example	IN	O
1)	NNP	O
may	FW	O
also	,	O
be	.	O
encapsulated,	.	O
adsorbed	.	O
to,	)	O
or	.	O
associated	,	O
with,	,	O
particulate	NNP	O
carriers.	.	O
Such	.	O
carriers	CD	O
present	CC	O
multiple	.	O
copies	DT	O
of	JJ	O
a	NN	O
selected	NN	O
antigen	IN	O
to	NN	O
the	,	O
immune	DT	O
system	IN	O
and	DT	O
promote	JJ	O
migration,	NN	O
trapping	NNS	O
and	VBN	O
retention	IN	O
of	NNP	O
antigens	)	O
in	MD	O
local	RB	O
lymph	VB	O
nodes.	,	O
The	VBN	O
particles	,	O
can	CC	O
be	VBN	O
taken	,	O
up	NN	O
by	.	O
profession	JJ	O
antigen	NNS	O
presenting	JJ	O
cells	JJ	O
such	NNS	O
as	IN	O
macrophages	DT	O
and	VBN	O
dendritic	NN	O
cells,	TO	O
and/or	DT	O
can	NN	O
enhance	NN	O
antigen	CC	O
presentation	NN	O
through	,	O
other	VBG	O
mechanisms	CC	O
such	NN	O
as	IN	O
stimulation	NNS	O
of	IN	O
cytokine	JJ	O
release.	NN	O
Examples	.	O
of	DT	O
particulate	NNS	O
carriers	MD	O
include	VB	O
those	VBN	O
derived	RP	O
from	IN	O
polymethyl	NN	O
methacrylate	NN	O
polymers,	VBG	O
as	NNS	O
well	JJ	O
as	IN	O
microparticles	NNS	O
derived	CC	O
from	JJ	O
poly(lactides)	,	O
and	NNS	O
poly(lactide-co-glycolides),	MD	O
known	VB	O
as	JJ	O
PLG.	NN	O
See,	IN	O
e.g.,	JJ	O
Jeffery	NNS	B
et	JJ	I
al.,	IN	I
Pharm.	NN	I
Res.	IN	I
(1993)	NN	I
10:362-368;	.	I
McGee	NNS	B
J	IN	I
P,	NN	I
et	NNS	I
al.,	VBP	I
J.	DT	I
Microencapsul.	VBN	I
14(2):197-210,	IN	I
1997;	NN	I
O'Hagan	NN	B
D	,	I
T,	RB	I
et	RB	I
al.,	IN	I
Vaccine	NNS	I
11(2):149-54,	VBN	I
1993.
Furthermore,	IN	O
other	)	O
particulate	CC	O
systems	,	O
and	VBN	O
polymers	IN	O
can	.	O
be	,	O
used	,	O
for	NNP	O
the	CC	O
in	,	O
vivo	.	O
or	.	O
ex	)	O
vivo	:	O
delivery	NNP	O
of	NNP	O
the	,	O
gene	FW	O
of	,	O
interest.	NNP	O
For	.	O
example,	,	O
polymers	:	O
such	NNP	O
as	NNP	O
polylysine,	,	O
polyarginine,	FW	O
polyornithine,	,	O
spermine,	NNP	O
spermidine,	,	O
as	.	O
well	,	O
as	JJ	O
conjugates	NN	O
of	NNS	O
these	CC	O
molecules,	NNS	O
are	MD	O
useful	VB	O
for	VBN	O
transferring	IN	O
a	DT	O
nucleic	IN	O
acid	NN	O
of	CC	O
interest.	VB	O
Similarly,	JJ	O
DEAE	NN	O
dextran-mediated	IN	O
transfection,	DT	O
calcium	NN	O
phosphate	IN	O
precipitation	.	O
or	IN	O
precipitation	,	O
using	NNS	O
other	JJ	O
insoluble	IN	O
inorganic	,	O
salts,	,	O
such	,	O
as	,	O
strontium	,	O
phosphate,	RB	O
aluminum	RB	O
silicates	IN	O
including	NNS	O
bentonite	IN	O
and	DT	O
kaolin,	,	O
chromic	VBP	O
oxide,	JJ	O
magnesium	IN	O
silicate,	VBG	O
talc,	DT	O
and	JJ	O
the	NN	O
like,	IN	O
will	.	O
find	,	O
use	NNP	O
with	JJ	O
the	,	O
present	NN	O
methods.	NN	O
See,	NN	O
e.g.,	CC	O
Feigner,	NN	B
P.	VBG	I
L.,	JJ	I
Advanced	JJ	I
Drug	JJ	I
Delivery	,	I
Reviews	JJ	I
(1990)	IN	I
5:163-187,	NN	I
for	,	O
a	NN	O
review	NNS	O
of	VBG	O
delivery	NN	O
systems	CC	O
useful	,	O
for	JJ	O
gene	,	O
transfer.	NN	O
Peptoids	,	O
(Zuckerman,	,	O
R.	CC	O
N.,	DT	O
et	,	O
al.,	MD	O
U.S.	VB	O
Pat.	NN	O
No.	IN	O
5,831,005,	DT	O
issued	JJ	O
Nov.	.	O
3,	,	O
1998,	,	O
herein	,	O
incorporated	NNP	O
by	,	O
reference)	NNP	O
may	NNP	O
also	NNP	O
be	NNP	O
used	)	O
for	,	O
delivery	IN	O
of	DT	O
a	NN	O
construct	IN	O
of	NN	O
the	NNS	O
present	JJ	O
invention.	IN	O
Additionally,	NN	O
biolistic	.	O
delivery	NNS	O
systems	,	O
employing	NNP	O
particulate	,	O
carriers	FW	O
such	,	O
as	NNP	O
gold	.	O
and	.	O
tungsten,	,	O
are	VBD	O
especially	NNP	O
useful	,	O
for	,	O
delivering	RB	O
synthetic	VBN	O
expression	IN	O
cassettes	)	O
of	MD	O
the	RB	O
present	VB	O
invention.	VBN	O
The	IN	O
particles	NN	O
are	IN	O
coated	DT	O
with	NN	O
the	IN	O
synthetic	DT	O
expression	JJ	O
cassette(s)	.	O
to	,	O
be	JJ	O
delivered	NN	O
and	NNS	O
accelerated	VBG	O
to	JJ	O
high	NNS	O
velocity,	JJ	O
generally	IN	O
under	NN	O
a	CC	O
reduced	,	O
atmosphere,	VBP	O
using	RB	O
a	JJ	O
gun	IN	O
powder	VBG	O
discharge	JJ	O
from	NN	O
a	NNS	O
“gene	IN	O
gun.”	DT	O
For	JJ	O
a	.	O
description	DT	O
of	NNS	O
such	VBP	O
techniques,	VBN	O
and	IN	O
apparatuses	DT	O
useful	JJ	O
therefore,	NN	O
see,	)	O
e.g.,	TO	O
U.S.	VB	O
Pat.	VBN	O
Nos.	CC	O
4,945,050;	VBN	O
5,036,006;	TO	O
5,100,792;	JJ	O
5,179,022;	,	O
5,371,015;	RB	O
and	IN	O
5,478,744.	DT	O
Also,	VBN	O
needle-less	,	O
injection	VBG	O
systems	DT	O
can	NN	O
be	NN	O
used	NN	O
Davis,	IN	B
H.	DT	I
L.,	NNP	I
et	NN	I
al,	IN	I
Vaccine	DT	I
12:1503-1509,	NN	I
1994;	IN	I
(Bioject,	JJ	O
Inc.,	,	O
Portland,	CC	O
Oreg.).	VBZ	O
Recombinant	JJ	O
vectors	,	O
carrying	,	O
a	,	O
synthetic	NNP	O
expression	.	O
cassette	.	O
of	:	O
the	:	O
present	:	O
invention	:	O
are	:	O
formulated	CC	O
into	.	O
compositions	,	O
for	JJ	O
delivery	NN	O
to	NNS	O
the	MD	O
vertebrate	VB	O
subject.	VBN	O
These	,	O
compositions	NNP	O
may	,	O
either	FW	O
be	,	O
prophylactic	NNP	O
(to	,	O
prevent	:	O
infection)	,	O
or	,	O
therapeutic	,	O
(to	.	O
treat	JJ	O
disease	NNS	O
after	VBG	O
infection).	DT	O
The	JJ	O
compositions	NN	O
will	NN	O
comprise	IN	O
a	DT	O
“therapeutically	JJ	O
effective	NN	O
amount”	VBP	O
of	VBN	O
the	IN	O
gene	NNS	O
of	IN	O
interest	NN	O
such	TO	O
that	DT	O
an	NN	O
amount	.	O
of	DT	O
the	NNS	O
antigen	MD	O
can	RB	O
be	VB	O
produced	JJ	O
in	TO	O
vivo	VB	O
so	)	O
that	CC	O
an	JJ	O
immune	TO	O
response	VB	O
is	NN	O
generated	IN	O
in	.	O
the	DT	O
individual	NNS	O
to	MD	O
which	VB	O
it	DT	O
is	RB	O
administered.	JJ	O
The	NN	O
exact	IN	O
amount	DT	O
necessary	NN	O
will	IN	O
vary	NN	O
depending	JJ	O
on	IN	O
the	DT	O
subject	NN	O
being	IN	O
treated;	DT	O
the	NN	O
age	MD	O
and	VB	O
general	VBN	O
condition	IN	O
of	NN	O
the	RB	O
subject	IN	O
to	DT	O
be	JJ	O
treated;	NN	O
the	VBZ	O
capacity	VBN	O
of	IN	O
the	DT	O
subject's	NN	O
immune	TO	O
system	WDT	O
to	PRP	O
synthesize	VBZ	O
antibodies;	.	O
the	DT	O
degree	JJ	O
of	NN	O
protection	JJ	O
desired;	MD	O
the	VB	O
severity	VBG	O
of	IN	O
the	DT	O
condition	NN	O
being	VBG	O
treated;	:	O
the	DT	O
particular	NN	O
antigen	CC	O
selected	JJ	O
and	NN	O
its	IN	O
mode	DT	O
of	NN	O
administration,	TO	O
among	VB	O
other	:	O
factors.	DT	O
An	NN	O
appropriate	IN	O
effective	DT	O
amount	POS	O
can	NN	O
be	NN	O
readily	TO	O
determined	VB	O
by	:	O
one	DT	O
of	NN	O
skill	IN	O
in	NN	O
the	:	O
art.	DT	O
Thus,	NN	O
a	IN	O
“therapeutically	DT	O
effective	NN	O
amount”	VBG	O
will	:	O
fall	DT	O
in	JJ	O
a	NN	O
relatively	VBN	O
broad	CC	O
range	PRP$	O
that	NN	O
can	IN	O
be	,	O
determined	IN	O
through	JJ	O
routine	.	O
trials.	DT	O
The	JJ	O
compositions	JJ	O
will	NN	O
generally	MD	O
include	VB	O
one	RB	O
or	VBN	O
more	IN	O
“pharmaceutically	CD	O
acceptable	IN	O
excipients	NN	O
or	IN	O
vehicles”	DT	O
such	.	O
as	,	O
water,	DT	O
saline,	RB	O
glycerol,	JJ	O
polyethyleneglycol,	NN	O
hyaluronic	MD	O
acid,	VB	O
ethanol,	IN	O
etc.	DT	O
Additionally,	RB	O
auxiliary	JJ	O
substances,	NN	O
such	WDT	O
as	MD	O
wetting	VB	O
or	VBN	O
emulsifying	IN	O
agents,	JJ	O
pH	.	O
buffering	DT	O
substances,	NNS	O
surfactants	MD	O
and	RB	O
the	VB	O
like,	CD	O
may	CC	O
be	JJR	O
present	RB	O
in	JJ	O
such	NNS	O
vehicles.	CC	O
Certain	NNS	O
facilitators	JJ	O
of	IN	O
immunogenicity	,	O
or	,	O
of	,	O
nucleic	,	O
acid	JJ	O
uptake	,	O
and/or	,	O
expression	.	O
can	,	O
also	JJ	O
be	,	O
included	JJ	O
in	IN	O
the	VBG	O
compositions	CC	O
or	VBG	O
coadministered,	,	O
such	NN	O
as,	NN	O
but	,	O
not	NNS	O
limited	CC	O
to,	DT	O
bupivacaine,	,	O
cardiotoxin	MD	O
and	VB	O
sucrose.	JJ	O
Once	IN	O
formulated,	JJ	O
the	.	O
compositions	NNP	O
of	NNS	O
the	IN	O
invention	NN	O
can	CC	O
be	IN	O
administered	JJ	O
directly	NNS	O
to	VBP	O
the	JJ	O
subject	NN	O
(e.g.,	MD	O
as	RB	O
described	VB	O
above)	VBN	O
or,	IN	O
alternatively,	DT	O
delivered	NNS	O
ex	CC	O
vivo,	,	O
to	JJ	O
cells	,	O
derived	CC	O
from	RB	O
the	JJ	O
subject,	,	O
using	,	O
methods	NN	O
such	CC	O
as	.	O
those	RB	O
described	,	O
above.	DT	O
For	NNS	O
example,	IN	O
methods	DT	O
for	NN	O
the	MD	O
ex	VB	O
vivo	VBN	O
delivery	RB	O
and	TO	O
reimplantation	DT	O
of	NN	O
transformed	,	O
cells	IN	O
into	VBN	O
a	)	O
subject	,	O
are	,	O
known	VBD	O
in	JJ	O
the	,	O
art	TO	O
and	NNS	O
can	VBN	O
include,	IN	O
e.g.,	DT	O
dextran-mediated	,	O
transfection,	VBG	O
calcium	NNS	O
phosphate	JJ	O
precipitation,	IN	O
polybrene	DT	O
mediated	VBN	O
transfection,	.	O
lipofectamine	IN	O
and	,	O
LT-1	NNS	O
mediated	IN	O
transfection,	DT	O
protoplast	NN	O
fusion,	NN	O
electroporation,	NN	O
encapsulation	CC	O
of	NN	O
the	IN	O
polynucleotide(s)	JJ	O
(with	NNS	O
or	IN	O
without	DT	O
the	NN	O
corresponding	VBP	O
antigen)	VBN	O
in	IN	O
liposomes,	DT	O
and	NN	O
direct	CC	O
microinjection	MD	O
of	,	O
the	,	O
DNA	JJ	O
into	,	O
nuclei.	NN	O
Direct	NN	O
delivery	,	O
of	NN	O
synthetic	VBD	O
expression	,	O
cassette	NN	O
compositions	CC	O
in	NNP	O
vivo	VBD	O
will	,	O
generally	JJ	O
be	,	O
accomplished	,	O
with	NN	O
or	IN	O
without	DT	O
viral	)	O
vectors,	IN	O
as	CC	O
described	IN	O
above,	DT	O
by	JJ	O
injection	)	O
using	IN	O
either	,	O
a	CC	O
conventional	JJ	O
syringe,	NN	O
needless	IN	O
devices	DT	O
such	NNP	O
as	IN	O
Bioject®	.	O
or	JJ	O
a	NN	O
gene	IN	O
gun,	JJ	O
such	NN	O
as	NN	O
the	NNS	O
Accell®	IN	O
gene	NN	O
delivery	MD	O
system	RB	O
(PowderJect	VB	O
Technologies,	VBN	O
Inc.,	IN	O
Oxford,	CC	O
England).	IN	O
The	JJ	O
constructs	,	O
can	IN	O
be	VBN	O
delivered	,	O
(e.g.,	IN	O
injected)	NN	O
either	VBG	O
subcutaneously,	CC	O
epidermally,	DT	O
intradermally,	JJ	O
intramuscularly,	,	O
intravenous,	JJ	O
intramucosally	NNS	O
(such	JJ	O
as	IN	O
nasally,	NNP	O
rectally	CC	O
and	DT	O
vaginally),	NN	O
intraperitoneally	,	O
or	JJ	O
orally.	IN	O
Delivery	DT	O
of	NNP	O
DNA	NN	O
into	NN	O
cells	NN	O
of	NNP	O
the	,	O
epidermis	,	O
is	,	O
particularly	.	O
preferred	DT	O
as	NNS	O
this	MD	O
mode	VB	O
of	VBN	O
administration	,	O
provides	)	O
access	DT	O
to	,	O
skin-associated	,	O
lymphoid	,	O
cells	,	O
and	,	O
provides	RB	O
for	JJ	O
a	IN	O
transient	,	O
presence	RB	O
of	CC	O
DNA	,	O
in	RB	O
the	CC	O
recipient.	.	O
Other	NN	O
modes	IN	O
of	NNP	O
administration	IN	O
include	NNS	O
oral	IN	O
ingestion	DT	O
and	NN	O
pulmonary	VBZ	O
administration,	RB	O
suppositories,	VBN	O
needle-less	IN	O
injection,	DT	O
transcutaneous	NN	O
and	IN	O
transdermal	NN	O
applications.	VBZ	O
Dosage	NN	O
treatment	TO	O
may	JJ	O
be	JJ	O
a	NNS	O
single	CC	O
dose	VBZ	O
schedule	IN	O
or	DT	O
a	JJ	O
multiple	NN	O
dose	IN	O
schedule.	NNP	O
2.3.2	IN	O
Ex	DT	O
Vivo	.	O
Delivery	JJ	O
of	NNS	O
the	IN	O
Synthetic	NN	O
Expression	VBP	O
Cassettes	JJ	O
of	NN	O
the	CC	O
Present	JJ	O
Invention	,	O
In	,	O
one	JJ	O
embodiment,	,	O
T	JJ	O
cells,	CC	O
and	JJ	O
related	.	O
cell	NNP	O
types	NN	O
(including	MD	O
but	VB	O
not	DT	O
limited	JJ	O
to	NN	O
antigen	NN	O
presenting	CC	O
cells,	DT	O
such	JJ	O
as,	NN	O
macrophage,	.	O
monocytes,	CD	O
lymphoid	NNP	O
cells,	NNP	O
dendritic	NNP	O
cells,	IN	O
B-cells,	DT	O
T-cells,	NNP	O
stem	NNP	O
cells,	NNP	O
and	IN	O
progenitor	DT	O
cells	JJ	O
thereof),	NNP	O
can	IN	O
be	CD	O
used	,	O
for	NNP	O
ex	,	O
vivo	CC	O
delivery	VBN	O
of	NN	O
the	NNS	O
synthetic	VBG	O
expression	CC	O
cassettes	RB	O
of	JJ	O
the	TO	O
present	VB	O
invention.	VBG	O
T	,	O
cells	JJ	O
can	,	O
be	,	O
isolated	,	O
from	JJ	O
peripheral	,	O
blood	JJ	O
lymphocytes	,	O
(PBLs)	,	O
by	,	O
a	NN	O
variety	,	O
of	CC	O
procedures	NN	O
known	NNS	O
to	,	O
those	MD	O
skilled	VB	O
in	VBN	O
the	IN	O
art.	JJ	O
For	JJ	O
example,	NN	O
T	IN	O
cell	DT	O
populations	JJ	O
can	NN	O
be	NNS	O
“enriched”	IN	O
from	DT	O
a	JJ	O
population	.	O
of	NNP	O
PBLs	NNS	O
through	MD	O
the	VB	O
removal	VBN	O
of	IN	O
accessory	JJ	O
and	NN	O
B	NNS	O
cells.	)	O
In	IN	O
particular,	DT	O
T	NN	O
cell	IN	O
enrichment	NNS	O
can	VBN	O
be	TO	O
accomplished	DT	O
by	VBN	O
the	IN	O
elimination	DT	O
of	.	O
non-T	IN	O
cells	,	O
using	NNP	O
anti-MHC	NN	O
class	NNS	O
II	MD	O
monoclonal	VB	O
antibodies.	VBN	O
Similarly,	IN	O
other	DT	O
antibodies	NN	O
can	IN	O
be	NNP	O
used	IN	O
to	DT	O
deplete	NN	O
specific	IN	O
populations	NN	O
of	CC	O
non-T	NNP	O
cells.	.	O
For	IN	O
example,	,	O
anti-Ig	NNP	O
antibody	NN	O
molecules	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	IN	O
deplete	DT	O
B	NN	O
cells	IN	O
and	JJ	O
anti-MacI	NNS	O
antibody	VBG	O
molecules	JJ	O
can	NN	O
be	NNP	O
used	JJ	O
to	.	O
deplete	,	O
macrophages.	JJ	O
T	NNS	O
cells	MD	O
can	VB	O
be	VBN	O
further	TO	O
fractionated	VB	O
into	JJ	O
a	NNS	O
number	IN	O
of	JJ	O
different	.	O
subpopulations	IN	O
by	,	O
techniques	JJ	O
known	NN	O
to	NNS	O
those	MD	O
skilled	VB	O
in	VBN	O
the	TO	O
art.	VB	O
Two	NNP	O
major	NNS	O
subpopulations	CC	O
can	JJ	O
be	NN	O
isolated	NNS	O
based	MD	O
on	VB	O
their	VBN	O
differential	TO	O
expression	VB	O
of	.	O
the	NNP	O
cell	NNS	O
surface	MD	O
markers	VB	O
CD4	RB	O
and	VBN	O
CD8.	IN	O
For	DT	O
example,	NN	O
following	IN	O
the	JJ	O
enrichment	NNS	O
of	IN	O
T	NNS	O
cells	VBN	O
as	TO	O
described	DT	O
above,	VBN	O
CD4+	IN	O
cells	DT	O
can	.	O
be	CD	O
enriched	JJ	O
using	NNS	O
antibodies	MD	O
specific	VB	O
for	VBN	O
CD4	VBN	O
(see	IN	O
Coligan	PRP$	O
et	JJ	O
al.,	NN	O
supra).	IN	O
The	DT	O
antibodies	NN	O
may	NN	O
be	NNS	O
coupled	NNP	O
to	CC	O
a	.	O
solid	IN	O
support	,	O
such	VBG	O
as	DT	O
magnetic	NN	O
beads.	IN	O
Conversely,	NNP	O
CD8+	NNS	O
cells	IN	O
can	VBN	O
be	,	O
enriched	NNP	O
through	NNS	O
the	MD	O
use	VB	O
of	VBN	O
antibodies	VBG	O
specific	NNS	O
for	JJ	O
CD4	IN	O
(to	NNP	O
remove	VB	O
CD4+	NNP	O
cells),	FW	O
or	,	O
can	.	O
be	DT	O
isolated	NNS	O
by	MD	O
the	VB	O
use	VBN	O
of	TO	O
CD8	DT	O
antibodies	JJ	O
coupled	NN	O
to	JJ	O
a	IN	O
solid	JJ	O
support.	.	O
CD4	,	O
lymphocytes	NNP	O
from	NNS	O
HIV-1	MD	O
infected	VB	O
patients	VBN	O
can	IN	O
be	DT	O
expanded	NN	O
ex	IN	O
vivo,	NNS	O
before	JJ	O
or	IN	O
after	NNP	O
transduction	TO	O
as	VB	O
described	NNP	O
by	,	O
Wilson	CC	B
et.	MD	I
al.	VB	I
(1995)	VBN	I
J.	IN	I
Infect.	DT	I
Dis.	NN	I
172:88.
Following	IN	O
purification	NNP	O
of	NNS	O
T	VBD	O
cells,	TO	O
a	DT	O
variety	JJ	O
of	.	O
methods	NNP	O
of	VBZ	O
genetic	IN	O
modification	NNP	O
known	JJ	O
to	NNS	O
those	MD	O
skilled	VB	O
in	VBN	O
the	JJ	O
art	,	O
can	IN	O
be	CC	O
performed	IN	O
using	NN	O
non-viral	IN	O
or	VBN	O
viral-based	IN	O
gene	NNP	O
transfer	.	O
vectors	.	O
constructed	)	O
as	NNP	O
described	.	O
herein.	.	O
For	.	O
example,	VBG	O
one	NN	O
such	IN	O
approach	NNP	O
involves	,	O
transduction	DT	O
of	NN	O
the	IN	O
purified	NNS	O
T	IN	O
cell	JJ	O
population	NN	O
with	VBN	O
vector-containing	TO	O
supernatant	DT	O
of	VBN	O
cultures	IN	O
derived	DT	O
from	NN	O
vector	MD	O
producing	VB	O
cells.	VBN	O
A	VBG	O
second	JJ	O
approach	CC	O
involves	JJ	O
co-cultivation	NN	O
of	NN	O
an	NNS	O
irradiated	VBD	O
monolayer	IN	O
of	JJ	O
vector-producing	.	O
cells	IN	O
with	,	O
the	CD	O
purified	JJ	O
T	NN	O
cells.	VBZ	O
A	NN	O
third	IN	O
approach	DT	O
involves	JJ	O
a	NNP	O
similar	NN	O
co-cultivation	NN	O
approach;	IN	O
however,	JJ	O
the	NN	O
purified	IN	O
T	NNS	O
cells	VBN	O
are	IN	O
pre-stimulated	NN	O
with	VBG	O
various	.	O
cytokines	DT	O
and	JJ	O
cultured	NN	O
48	VBZ	O
hours	NN	O
prior	IN	O
to	DT	O
the	JJ	O
co-cultivation	NN	O
with	IN	O
the	JJ	O
irradiated	NNS	O
vector	IN	O
producing	DT	O
cells.	JJ	O
Pre-stimulation	NNP	O
prior	.	O
to	DT	O
such	JJ	O
transduction	NN	O
increases	VBZ	O
effective	DT	O
gene	JJ	O
transfer	NN	O
Nolta	:	B
et	,	I
al.	DT	I
(1992)	JJ	I
Exp.	NNP	I
Hematol.	NNS	I
20:1065).(	VBP	O
Stimulation	JJ	O
of	IN	O
these	JJ	O
cultures	NNS	O
to	CC	O
proliferate	VBD	O
also	CD	O
provides	NNS	O
increased	RB	O
cell	TO	O
populations	DT	O
for	NN	O
re-infusion	IN	O
into	DT	O
the	JJ	O
patient.	NN	O
Subsequent	VBG	O
to	.	O
co-cultivation,	NN	O
T	RB	O
cells	TO	O
are	JJ	O
collected	NN	O
from	NNS	O
the	JJ	O
vector	NN	O
producing	NN	O
cell	NNP	O
monolayer,	RB	O
expanded,	.	O
and	)	O
frozen	.	O
in	.	O
liquid	.	O
nitrogen.	NN	O
Gene	IN	O
transfer	DT	O
vectors,	NNS	O
containing	TO	O
one	VB	O
or	RB	O
more	VBZ	O
synthetic	JJ	O
expression	NN	O
cassette	NNS	O
of	IN	O
the	NN	O
present	IN	O
invention	DT	O
(associated	.	O
with	JJ	O
appropriate	TO	O
control	,	O
elements	NNP	O
for	NNS	O
delivery	VBP	O
to	VBN	O
the	IN	O
isolated	DT	O
T	NN	O
cells)	VBG	O
can	NN	O
be	,	O
assembled	,	O
using	CC	O
known	NNS	O
methods.	IN	O
Selectable	JJ	O
markers	.	O
can	NNP	O
also	NN	O
be	,	O
used	VBG	O
in	CD	O
the	CC	O
construction	JJR	O
of	JJ	O
gene	NN	O
transfer	NN	O
vectors.	IN	O
For	DT	O
example,	JJ	O
a	NN	O
marker	VBN	O
can	IN	O
be	JJ	O
used	NN	O
which	NNS	O
imparts	IN	O
to	NN	O
a	TO	O
mammalian	DT	O
cell	JJ	O
transduced	NNP	O
with	)	O
the	MD	O
gene	VB	O
transfer	VBN	O
vector	VBG	O
resistance	VBN	O
to	.	O
a	JJ	O
cytotoxic	NNS	O
agent.	MD	O
The	RB	O
cytotoxic	VB	O
agent	VBN	O
can	IN	O
be,	DT	O
but	NN	O
is	IN	O
not	NN	O
limited	NN	O
to,	.	O
neomycin,	IN	O
aminoglycoside,	,	O
tetracycline,	DT	O
chloramphenicol,	NN	O
sulfonamide,	MD	O
actinomycin,	VB	O
netropsin,	VBN	O
distamycin	WDT	O
A,	VBZ	O
anthracycline,	TO	O
or	DT	O
pyrazinamide.	JJ	O
For	NN	O
example,	VBD	O
neomycin	IN	O
phosphotransferase	DT	O
II	NN	O
imparts	NN	O
resistance	NN	O
to	NN	O
the	TO	O
neomycin	DT	O
analogue	NN	O
geneticin	.	O
(G418).	DT	O
The	NN	O
T	NN	O
cells	MD	O
can	,	O
also	CC	O
be	VBZ	O
maintained	RB	O
in	VBN	O
a	,	O
medium	,	O
containing	,	O
at	,	O
least	,	O
one	,	O
type	,	O
of	,	O
growth	VB	O
factor	,	O
prior	,	O
to	CC	O
being	.	O
selected.	IN	O
A	,	O
variety	JJ	O
of	NN	O
growth	NNP	O
factors	VBZ	O
are	NN	O
known	TO	O
in	DT	O
the	JJ	O
art	NN	O
which	NN	O
sustain	.	O
the	DT	O
growth	NNP	O
of	NNS	O
a	MD	O
particular	RB	O
cell	VB	O
type.	VBN	O
Examples	IN	O
of	DT	O
such	NN	O
growth	VBG	O
factors	IN	O
are	JJS	O
cytokine	CD	O
mitogens	NN	O
such	IN	O
as	NN	O
rIL-2,	NN	O
IL-10,	RB	O
IL-12,	TO	O
and	VBG	O
IL-15,	.	O
which	DT	O
promote	NN	O
growth	IN	O
and	NN	O
activation	NNS	O
of	VBP	O
lymphocytes.	VBN	O
Certain	IN	O
types	DT	O
of	NN	O
cells	WDT	O
are	VBP	O
stimulated	DT	O
by	NN	O
other	IN	O
growth	DT	O
factors	JJ	O
such	NN	O
as	.	O
hormones,	NNS	O
including	IN	O
human	JJ	O
chorionic	NN	O
gonadotropin	NNS	O
(hCG)	VBP	O
and	JJ	O
human	NNS	O
growth	JJ	O
hormone.	IN	O
The	,	O
selection	,	O
of	,	O
an	CC	O
appropriate	,	O
growth	WDT	O
factor	VBP	O
for	NN	O
a	CC	O
particular	NN	O
cell	IN	O
population	.	O
is	NNP	O
readily	NNS	O
accomplished	IN	O
by	NNS	O
one	VBP	O
of	VBN	O
skill	IN	O
in	JJ	O
the	NN	O
art.	NNS	O
For	JJ	O
example,	IN	O
white	,	O
blood	VBG	O
cells	JJ	O
such	JJ	O
as	NN	O
differentiated	)	O
progenitor	CC	O
and	JJ	O
stem	NN	O
cells	.	O
are	DT	O
stimulated	NN	O
by	IN	O
a	DT	O
variety	JJ	O
of	NN	O
growth	NN	O
factors.	IN	O
More	DT	O
particularly,	JJ	O
IL-3,	NN	O
IL-4,	NN	O
IL-5,	VBZ	O
IL-6,	RB	O
IL-9,	VBN	O
GM-CSF,	IN	O
M-CSF,	CD	O
and	IN	O
G-CSF,	NN	O
produced	IN	O
by	DT	O
activated	.	O
TH	IN	O
and	,	O
activated	JJ	O
macrophages,	NN	O
stimulate	NNS	O
myeloid	JJ	O
stem	IN	O
cells,	JJ	O
which	NN	O
then	CC	O
differentiate	NN	O
into	NNS	O
pluripotent	VBP	O
stem	VBN	O
cells,	IN	O
granulocyte-monocyte	DT	O
progenitors,	NN	O
eosinophil	IN	O
progenitors,	NN	O
basophil	.	O
progenitors,	RBR	O
megakaryocytes,	,	O
and	,	O
erythroid	,	O
progenitors.	,	O
Differentiation	,	O
is	,	O
modulated	,	O
by	,	O
growth	CC	O
factors	,	O
such	VBN	O
as	IN	O
GM-CSF,	JJ	O
IL-3,	NNP	O
IL-6,	CC	O
IL-11,	VBD	O
and	,	O
EPO.	VBP	O
Pluripotent	JJ	O
stem	NN	O
cells	,	O
then	WDT	O
differentiate	RB	O
into	VBP	O
lymphoid	IN	O
stem	JJ	O
cells,	NN	O
bone	,	O
marrow	JJ	O
stromal	,	O
cells,	JJ	O
T	,	O
cell	NN	O
progenitors,	,	O
B	,	O
cell	CC	O
progenitors,	JJ	O
thymocytes,	.	O
TH	NN	O
Cells,	VBZ	O
TC	VBN	O
cells,	IN	O
and	NN	O
B	NNS	O
cells.	JJ	O
This	IN	O
differentiation	,	O
is	,	O
modulated	,	O
by	,	O
growth	CC	O
factors	.	O
such	JJ	O
as	NN	O
IL-3,	NNS	O
IL-4,	RB	O
IL-6,	VB	O
IL-7,	IN	O
GM-CSF,	JJ	O
M-CSF,	NN	O
G-CSF,	,	O
IL-2,	NN	O
and	NN	O
IL-5.	JJ	O
Granulocyte-monocyte	,	O
progenitors	NNP	O
differentiate	NN	O
to	,	O
monocytes,	NNP	O
macrophages,	NN	O
and	,	O
neutrophils.	,	O
Such	NNP	O
differentiation	,	O
is	NNP	O
modulated	,	O
by	CC	O
the	NNP	O
growth	.	O
factors	DT	O
GM-CSF,	NN	O
M-CSF,	VBZ	O
and	VBN	O
IL-8.	IN	O
Eosinophil	NN	O
progenitors	NNS	O
differentiate	JJ	O
into	IN	O
eosinophils.	,	O
This	,	O
process	,	O
is	,	O
modulated	,	O
by	,	O
GM-CSF	,	O
and	,	O
IL-5.	CC	O
The	.	O
differentiation	JJ	O
of	NNS	O
basophil	VBP	O
progenitors	TO	O
into	,	O
mast	,	O
cells	CC	O
and	.	O
basophils	JJ	O
is	NN	O
modulated	VBZ	O
by	VBN	O
GM-CSF,	IN	O
IL-4,	DT	O
and	NN	O
IL-9.	NNS	O
Megakaryocytes	,	O
produce	,	O
platelets	CC	O
in	.	O
response	NNP	O
to	NNS	O
GM-CSF,	VBP	O
EPO,	IN	O
and	.	O
IL-6.	DT	O
Erythroid	NN	O
progenitor	VBZ	O
cells	VBN	O
differentiate	IN	O
into	NNP	O
red	CC	O
blood	.	O
cells	DT	O
in	NN	O
response	IN	O
to	NN	O
EPO.	NNS	O
Thus,	IN	O
during	NN	O
activation	NNS	O
by	CC	O
the	NNS	O
CD3-binding	VBZ	O
agent,	VBN	O
T	IN	O
cells	,	O
can	,	O
also	CC	O
be	.	O
contacted	NNS	O
with	VBP	O
a	NNS	O
mitogen,	IN	O
for	NN	O
example	TO	O
a	,	O
cytokine	,	O
such	CC	O
as	.	O
IL-2.	NNP	O
In	NN	O
particularly	NNS	O
preferred	VBP	O
embodiments,	IN	O
the	JJ	O
IL-2	NN	O
is	NNS	O
added	IN	O
to	NN	O
the	TO	O
population	.	O
of	,	O
T	IN	O
cells	NN	O
at	IN	O
a	DT	O
concentration	NNP	O
of	,	O
about	NNP	O
50	NNS	O
to	MD	O
100	RB	O
μg/ml.	VB	O
Activation	VBN	O
with	IN	O
the	DT	O
CD3-binding	,	O
agent	IN	O
can	NN	O
be	DT	O
carried	NN	O
out	JJ	O
for	IN	O
2	.	O
to	IN	O
4	RB	O
days.	JJ	O
Once	,	O
suitably	DT	O
activated,	NNP	O
the	VBZ	O
T	VBN	O
cells	TO	O
are	DT	O
genetically	NN	O
modified	IN	O
by	NNP	O
contacting	NNS	O
the	IN	O
same	DT	O
with	NN	O
a	IN	O
suitable	RB	O
gene	CD	O
transfer	TO	O
vector	CD	O
under	.	O
conditions	NN	O
that	IN	O
allow	DT	O
for	JJ	O
transfection	NN	O
of	MD	O
the	VB	O
vectors	VBN	O
into	IN	O
the	IN	O
T	CD	O
cells.	TO	O
Genetic	CD	O
modification	.	O
is	RB	O
carried	RB	O
out	,	O
when	DT	O
the	NNP	O
cell	NNS	O
density	VBP	O
of	RB	O
the	VBN	O
T	IN	O
cell	VBG	O
population	DT	O
is	JJ	O
between	IN	O
about	DT	O
0.1×106	JJ	O
and	NN	O
5×106,	NN	O
preferably	NN	O
between	IN	O
about	NNS	O
0.5×106	WDT	O
and	VBP	O
2×106.	IN	O
A	NN	O
number	IN	O
of	DT	O
suitable	NNS	O
viral	IN	O
and	DT	O
nonviral-based	NNP	O
gene	.	O
transfer	JJ	O
vectors	NN	O
have	VBZ	O
been	VBN	O
described	RP	O
for	WRB	O
use	DT	O
herein.	NN	O
After	NN	O
transduction,	IN	O
transduced	DT	O
cells	NNP	O
are	NN	O
selected	NN	O
away	VBZ	O
from	IN	O
non-transduced	IN	O
cells	CD	O
using	CC	O
known	,	O
techniques.	RB	O
For	IN	O
example,	IN	O
if	CD	O
the	CC	O
gene	.	O
transfer	DT	O
vector	NN	O
used	IN	O
in	JJ	O
the	JJ	O
transduction	CC	O
includes	JJ	O
a	NN	O
selectable	NN	O
marker	NNS	O
which	VBP	O
confers	VBN	O
resistance	VBN	O
to	IN	O
a	NN	O
cytotoxic	.	O
agent,	IN	O
the	,	O
cells	JJ	O
can	NNS	O
be	VBP	O
contacted	VBN	O
with	RB	O
the	IN	O
appropriate	JJ	O
cytotoxic	NNS	O
agent,	VBG	O
whereby	VBN	O
non-transduced	.	O
cells	IN	O
can	,	O
be	IN	O
negatively	DT	O
selected	NN	O
away	NN	O
from	NN	O
the	VBN	O
transduced	IN	O
cells.	DT	O
If	NN	O
the	VBZ	O
selectable	DT	O
marker	JJ	O
is	NN	O
a	WDT	O
cell	VBZ	O
surface	NN	O
marker,	TO	O
the	DT	O
cells	NN	O
can	,	O
be	DT	O
contacted	NNS	O
with	MD	O
a	VB	O
binding	VBN	O
agent	IN	O
specific	DT	O
for	JJ	O
the	NN	O
particular	,	O
cell	WRB	O
surface	JJ	O
marker,	NNS	O
whereby	MD	O
the	VB	O
transduced	RB	O
cells	VBN	O
can	RB	O
be	IN	O
positively	DT	O
selected	JJ	O
away	.	O
from	IN	O
the	DT	O
population.	JJ	O
The	NN	O
selection	VBZ	O
step	DT	O
can	NN	O
also	NN	O
entail	,	O
fluorescence-activated	DT	O
cell	NNS	O
sorting	MD	O
(FACS)	VB	O
techniques,	VBN	O
such	IN	O
as	DT	O
where	NN	O
FACS	NN	O
is	NN	O
used	IN	O
to	DT	O
select	JJ	O
cells	NN	O
from	NN	O
the	,	O
population	WRB	O
containing	DT	O
a	JJ	O
particular	NNS	O
surface	MD	O
marker,	VB	O
or	RB	O
the	VBN	O
selection	RB	O
step	IN	O
can	DT	O
entail	.	O
the	DT	O
use	JJ	O
of	NN	O
magnetically	MD	O
responsive	RB	O
particles	VB	O
as	JJ	O
retrievable	NN	O
supports	VBG	O
for	)	O
target	,	O
cell	JJ	O
capture	IN	O
and/or	WRB	O
background	NNP	O
removal.	VBZ	O
More	VBN	O
particularly,	TO	O
positive	VB	O
selection	NNS	O
of	IN	O
the	DT	O
transduced	NN	O
cells	VBG	O
can	DT	O
be	JJ	O
performed	NN	O
using	,	O
a	CC	O
FACS	DT	O
cell	JJ	O
sorter	NN	O
(e.g.	MD	O
a	VB	O
FACSVantage™	DT	O
Cell	NN	O
Sorter,	IN	O
Becton	RB	O
Dickinson	JJ	O
Immunocytometry	NNS	O
Systems,	IN	O
San	JJ	O
Jose,	NNS	O
Calif.)	IN	O
to	NN	O
sort	NN	O
and	NN	O
collect	NN	O
transduced	NN	O
cells	.	O
expressing	RBR	O
a	,	O
selectable	JJ	O
cell	NN	O
surface	IN	O
marker.	DT	O
Following	JJ	O
transduction,	NNS	O
the	MD	O
cells	VB	O
are	VBN	O
stained	VBG	O
with	DT	O
fluorescent-labeled	NNP	O
antibody	NN	O
molecules	NN	O
directed	.	O
against	DT	O
the	NNP	O
particular	NNP	O
cell	,	O
surface	NNP	O
marker.	NNP	O
The	NNP	O
amount	,	O
of	NNP	O
bound	,	O
antibody	)	O
on	TO	O
each	VB	O
cell	CC	O
can	VB	O
be	JJ	O
measured	NNS	O
by	VBG	O
passing	DT	O
droplets	JJ	O
containing	NN	O
the	NN	O
cells	.	O
through	VBG	O
the	,	O
cell	DT	O
sorter.	NNS	O
By	VBP	O
imparting	VBN	O
an	IN	O
electromagnetic	JJ	O
charge	NN	O
to	NNS	O
droplets	VBN	O
containing	IN	O
the	DT	O
stained	JJ	O
cells,	NN	O
the	NN	O
transduced	.	O
cells	DT	O
can	NN	O
be	IN	O
separated	NN	O
from	NN	O
other	IN	O
cells.	DT	O
The	NN	O
positively	MD	O
selected	VB	O
cells	VBN	O
are	IN	O
then	VBG	O
harvested	NNS	O
in	VBG	O
sterile	DT	O
collection	NNS	O
vessels.	IN	O
These	DT	O
cell	NN	O
sorting	.	O
procedures	IN	O
are	VBG	O
described	DT	O
in	JJ	O
detail,	NN	O
for	TO	O
example,	NNS	O
in	VBG	O
the	DT	O
FACSVantage™	JJ	O
Training	,	O
Manual,	DT	O
with	JJ	O
particular	NNS	O
reference	MD	O
to	VB	O
sections	VBN	O
3-11	IN	O
to	JJ	O
3-28	.	O
and	DT	O
10-1	RB	O
to	VBN	O
10-17.	NNS	O
Positive	VBP	O
selection	RB	O
of	VBN	O
the	IN	O
transduced	JJ	O
cells	NN	O
can	.	O
also	DT	O
be	NN	O
performed	NN	O
using	NNS	O
magnetic	VBP	O
separation	VBN	O
of	IN	O
cells	,	O
based	IN	O
on	,	O
expression	IN	O
or	DT	O
a	NNP	O
particular	NNP	O
cell	,	O
surface	IN	O
marker.	JJ	O
In	NN	O
such	TO	O
separation	VB	O
techniques,	JJ	O
cells	TO	O
to	JJ	O
be	CC	O
positively	JJ	O
selected	TO	O
are	.	O
first	JJ	O
contacted	NN	O
with	IN	O
specific	DT	O
binding	JJ	O
agent	NNS	O
(e.g.,	MD	O
an	RB	O
antibody	VB	O
or	VBN	O
reagent	VBG	O
the	JJ	O
interacts	NN	O
specifically	IN	O
with	NNS	O
the	VBN	O
cell	IN	O
surface	NN	O
marker).	CC	O
The	DT	O
cells	JJ	O
are	NN	O
then	NN	O
contacted	.	O
with	IN	O
retrievable	JJ	O
particles	NN	O
(e.g.,	,	O
magnetically	NNS	O
responsive	TO	O
particles)	VB	O
which	RB	O
are	VBN	O
coupled	VBP	O
with	JJ	O
a	VBN	O
reagent	IN	O
that	JJ	O
binds	VBG	O
the	NN	O
specific	,	O
binding	DT	O
agent	NN	O
(that	CC	O
has	VB	O
bound	DT	O
to	NNS	O
the	RB	O
positive	IN	O
cells).	DT	O
The	NN	O
cell-binding	NN	O
agent-particle	.	O
complex	DT	O
can	NNS	O
then	VBP	O
be	RB	O
physically	VBN	O
separated	IN	O
from	JJ	O
non-labeled	NNS	O
cells,	,	O
for	RB	O
example	JJ	O
using	)	O
a	WDT	O
magnetic	VBP	O
field.	VBN	O
When	IN	O
using	DT	O
magnetically	NN	O
responsive	WDT	O
particles,	VBZ	O
the	DT	O
labeled	JJ	O
cells	NN	O
can	NN	O
be	WDT	O
retained	VBZ	O
in	VBN	O
a	TO	O
container	DT	O
using	JJ	O
a	.	O
magnetic	DT	O
filed	JJ	O
while	NN	O
the	NN	O
negative	MD	O
cells	RB	O
are	VB	O
removed.	RB	O
These	VBN	O
and	IN	O
similar	JJ	O
separation	,	O
procedures	IN	O
are	NN	O
known	VBG	O
to	DT	O
those	JJ	O
of	.	O
ordinary	WRB	O
skill	VBG	O
in	RB	O
the	JJ	O
art.	,	O
Expression	DT	O
of	JJ	O
the	NNS	O
vector	MD	O
in	VB	O
the	VBN	O
selected	IN	O
transduced	DT	O
cells	NN	O
can	VBG	O
be	DT	O
assessed	JJ	O
by	VBN	O
a	IN	O
number	DT	O
of	JJ	O
assays	NNS	O
known	VBP	O
to	.	O
those	DT	O
skilled	CC	O
in	JJ	O
the	NN	O
art.	NNS	O
For	VBP	O
example,	VBN	O
Western	TO	O
blot	DT	O
or	IN	O
Northern	JJ	O
analysis	NN	O
can	IN	O
be	DT	O
employed	.	O
depending	NN	O
on	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
inserted	VBN	O
nucleotide	JJ	O
sequence	NNS	O
of	MD	O
interest.	VB	O
Once	VBN	O
expression	IN	O
has	DT	O
been	NN	O
established	IN	O
and	NNS	O
the	VBN	O
transformed	TO	O
T	DT	O
cells	VBN	O
have	IN	O
been	DT	O
tested	.	O
for	IN	O
the	,	O
presence	JJ	O
of	NN	O
the	CC	O
selected	NNP	O
synthetic	NN	O
expression	MD	O
cassette,	VB	O
they	VBN	O
are	VBG	O
ready	IN	O
for	DT	O
infusion	NN	O
into	IN	O
a	DT	O
patient	JJ	O
via	JJ	O
the	NN	O
peripheral	IN	O
blood	.	O
stream.	RB	O
The	NN	O
invention	VBZ	O
includes	VBN	O
a	VBN	O
kit	CC	O
for	DT	O
genetic	JJ	O
modification	NNP	O
of	NNS	O
an	VBP	O
ex	VBN	O
vivo	VBN	O
population	IN	O
of	DT	O
primary	NN	O
mammalian	IN	O
cells.	DT	O
The	VBN	O
kit	JJ	O
typically	NN	O
contains	,	O
a	PRP	O
gene	VBP	O
transfer	JJ	O
vector	IN	O
coding	NN	O
for	IN	O
at	DT	O
least	NN	O
one	IN	O
selectable	DT	O
marker	JJ	O
and	NN	O
at	.	O
least	DT	O
one	NN	O
synthetic	VBZ	O
expression	DT	O
cassette	NN	O
contained	IN	O
in	JJ	O
one	NN	O
or	IN	O
more	DT	O
containers,	NN	O
ancillary	JJ	O
reagents	NN	O
or	IN	O
hardware,	JJ	O
and	JJ	O
instructions	.	O
for	DT	O
use	NN	O
of	RB	O
the	VBZ	O
kit.	DT	O
EXPERIMENTAL	NN	O
Below	NN	O
are	NN	O
examples	VBG	O
of	IN	O
specific	IN	O
embodiments	JJS	O
for	CD	O
carrying	JJ	O
out	NN	O
the	CC	O
present	IN	O
invention.	JJS	O
The	CD	O
examples	JJ	O
are	NN	O
offered	NN	O
for	VBN	O
illustrative	IN	O
purposes	CD	O
only,	CC	O
and	JJR	O
are	,	O
not	JJ	O
intended	NNS	O
to	CC	O
limit	,	O
the	CC	O
scope	NNS	O
of	IN	O
the	NN	O
present	IN	O
invention	DT	O
in	.	O
any	NNP	O
way.	NNP	O
Efforts	VBP	O
have	NNS	O
been	IN	O
made	JJ	O
to	NNS	O
ensure	IN	O
accuracy	VBG	O
with	RP	O
respect	DT	O
to	JJ	O
numbers	.	O
used	DT	O
(e.g.,	NNS	O
amounts,	VBP	O
temperatures,	VBN	O
etc.),	IN	O
but	JJ	O
some	NNS	O
experimental	,	O
error	CC	O
and	VBP	O
deviation	RB	O
should,	VBN	O
of	TO	O
course,	VB	O
be	DT	O
allowed	NN	O
for.	IN	O
Example	DT	O
1	JJ	O
Generation	NN	O
of	IN	O
Synthetic	DT	O
Gag	.	O
and	NNS	O
Env	VBP	O
Expression	VBN	O
Cassettes	VBN	O
A.	TO	O
Modification	VB	O
of	NN	O
HIV-1	IN	O
Gag,	NN	O
Gag-Protease,	TO	O
Gag-Reverse	NNS	O
Transcriptase	VBN	O
and	,	O
Gag-Polymerase	,	O
Nucleic	,	O
Acid	,	O
Coding	CC	O
Sequences	DT	O
The	JJ	O
Gag	NN	O
(SEQ	CC	O
ID	NN	O
NO:1),	,	O
Gag-protease	IN	O
(SEQ	,	O
ID	VB	O
NO:2),	VBN	O
Gag-polymerase	.	O
(SEQ	RB	O
ID	CD	O
NO:3),	NNP	O
and	IN	O
Gag-reverse	NNP	O
transcriptase	NNP	O
(SEQ	CC	O
ID	NNP	O
NO:77)	NNP	O
coding	VBZ	O
sequences	.	O
were	NN	O
selected	IN	O
from	NNP	O
the	,	O
HIV-1SF2	,	O
strain	NNP	O
Sanchez-Pescador,	NNP	B
R.,	CC	I
et	NNP	I
al.,	NNP	I
Science	NNP	I
227(4686):	NNP	I
484-492,	VBZ	I
1985;	DT	I
(Luciw,	NNP	O
P.	NNP	O
A.,	NNP	O
et	,	O
al.	NNP	O
U.S.	NNP	O
Pat.	NNP	O
No.	,	O
5,156,949,	NNP	O
issued	NNP	O
Oct.	NNP	O
20,	,	O
1992,	CC	O
herein	JJ	O
incorporated	NN	O
by	NNP	O
reference;	NNP	O
Luciw,	)	O
P.	VBG	O
A.,	NNS	O
et	VBD	O
al.,	VBN	O
U.S.	IN	O
Pat.	DT	O
No.	NNP	O
5,688,688,	NN	O
Nov.	,	O
18,	,	O
1997).	FW	O
These	,	O
sequences	NNP	O
were	:	O
manipulated	,	O
to	:	O
maximize	,	O
expression	NNP	O
of	,	O
their	CC	O
gene	.	O
products.	NNP	O
First,	.	O
the	.	O
HIV-1	,	O
codon	VBN	O
usage	NNP	O
pattern	,	O
was	,	O
modified	RB	O
so	VBN	O
that	IN	O
the	:	O
resulting	,	O
nucleic	NNP	O
acid	,	O
coding	FW	O
sequence	,	O
was	NNP	O
comparable	.	O
to	.	O
codon	,	O
usage	NNP	O
found	,	O
in	.	O
highly	DT	O
expressed	NNS	O
human	VBD	O
genes.	VBN	O
The	TO	O
HIV	VB	O
codon	NN	O
usage	IN	O
reflects	PRP$	O
a	NN	O
high	.	O
content	,	O
of	DT	O
the	NNP	O
nucleotides	NN	O
A	NN	O
or	NN	O
T	VBD	O
of	VBN	O
the	RB	O
codon-triplet.	IN	O
The	DT	O
effect	VBG	O
of	JJ	O
the	NN	O
HIV-1	VBG	O
codon	NN	O
usage	VBD	O
is	JJ	O
a	TO	O
high	VB	O
AT	NN	O
content	VBN	O
in	IN	O
the	RB	O
DNA	VBN	O
sequence	JJ	O
that	.	O
results	DT	O
in	NNP	O
a	NN	O
high	NN	O
AU	VBZ	O
content	DT	O
in	JJ	O
the	NN	O
RNA	IN	O
and	DT	O
in	NNS	O
a	NNP	O
decreased	CC	O
translation	NNP	O
ability	IN	O
and	DT	O
instability	.	O
of	DT	O
the	NN	O
mRNA.	IN	O
In	DT	O
comparison,	NNP	O
highly	NN	O
expressed	NN	O
human	VBZ	O
codons	DT	O
prefer	JJ	O
the	NNP	O
nucleotides	NN	O
G	IN	O
or	DT	O
C.	NN	O
The	NN	O
Gag-encoding	WDT	O
sequences	NNS	O
were	IN	O
modified	DT	O
to	JJ	O
be	NNP	O
comparable	NN	O
to	IN	O
codon	DT	O
usage	NNP	O
found	CC	O
in	IN	O
highly	DT	O
expressed	JJ	O
human	NN	O
genes.	NN	O
FIG.	CC	O
11	NN	O
presents	IN	O
a	DT	O
comparison	.	O
of	IN	O
the	,	O
percent	RB	O
A-T	VBN	O
content	JJ	O
for	NNS	O
the	VBP	O
cDNAs	DT	O
of	NNS	O
stable	NNP	O
versus	CC	O
unstable	NNP	O
RNAs	DT	O
(comparison	NNP	O
window	NNS	O
size=50).	VBD	O
Human	VBN	O
IFNγ	TO	O
mRNA	VB	O
is	JJ	O
known	TO	O
to	VB	O
(i)	NN	O
be	VBN	O
unstable,	IN	O
(ii)	RB	O
have	VBN	O
a	JJ	O
short	.	O
half-life,	.	O
and	CD	O
(iii)	NNS	O
have	DT	O
a	NN	O
high	IN	O
A-U	DT	O
content.	NN	O
Human	NNP	O
GAPDH	NN	O
(glyceraldehyde-3-phosphate	IN	O
dehydrogenase)	DT	O
mRNA	NN	O
is	IN	O
known	JJ	O
to	NN	O
(i)	JJ	O
be	NNP	O
a	NN	O
stable	NN	O
RNA,	.	O
and	NNP	O
(i)	NNP	O
have	NN	O
a	VBZ	O
low	VBN	O
A-U	TO	O
content.	)	O
In	VB	O
FIG.	,	O
11,	)	O
the	VBP	O
percent	DT	O
A-T	JJ	O
content	,	O
of	CC	O
these	)	O
two	VBP	O
sequences	DT	O
are	JJ	O
compared	JJ	O
to	.	O
the	NNP	O
percent	NNP	O
A-T	JJ	O
content	)	O
of	NN	O
native	VBZ	O
HIV-1SF2	VBN	O
Gag	TO	O
cDNA	)	O
and	VB	O
to	DT	O
the	JJ	O
synthetic	,	O
Gag	CC	O
cDNA	)	O
sequence	VBP	O
of	DT	O
the	JJ	O
present	NNP	O
invention.	.	O
The	IN	O
top	.	O
two	,	O
panels	DT	O
of	NN	O
the	NNP	O
figure	NN	O
show	IN	O
the	DT	O
percent	CD	O
A-T	NNS	O
content	VBP	O
over	VBN	O
the	TO	O
length	DT	O
of	NN	O
the	NNP	O
sequences	NN	O
for	IN	O
IFNγ	JJ	O
and	NNP	O
native	NNP	O
Gag.	NN	O
The	CC	O
bottom	TO	O
two	DT	O
panels	JJ	O
of	NNP	O
the	NN	O
figure	NN	O
show	IN	O
the	DT	O
percent	JJ	O
A-T	.	O
content	DT	O
over	JJ	O
the	CD	O
length	NNS	O
of	IN	O
the	DT	O
sequences	NN	O
for	VBP	O
GAPDH	DT	O
and	NN	O
the	NNP	O
synthetic	NN	O
Gag.	IN	O
Experiments	DT	O
performed	NN	O
in	IN	O
support	DT	O
of	NNS	O
the	IN	O
present	NNP	O
invention	CC	O
showed	JJ	O
that	.	O
the	DT	O
synthetic	JJ	O
Gag	CD	O
sequences	NNS	O
were	IN	O
capable	DT	O
of	NN	O
higher	VBP	O
level	DT	O
of	NN	O
protein	NNP	O
production	NN	O
(see	IN	O
the	DT	O
Examples)	NN	O
than	IN	O
the	DT	O
native	NNS	O
Gag	IN	O
sequences.	NNP	O
The	CC	O
data	DT	O
in	JJ	O
FIG.	.	O
11	NNS	O
suggest	VBN	O
that	IN	O
one	NN	O
reason	IN	O
for	DT	O
this	JJ	O
increased	NN	O
production	VBD	O
may	IN	O
be	DT	O
increased	JJ	O
stability	NNP	O
of	NNS	O
the	VBD	O
mRNA	JJ	O
corresponding	IN	O
to	JJR	O
the	NN	O
synthetic	IN	O
Gag	JJ	O
coding	NN	O
sequences	VB	O
versus	DT	O
the	)	O
mRNA	IN	O
corresponding	DT	O
to	JJ	O
the	NNP	O
native	.	O
Gag	DT	O
coding	NN	O
sequences.	IN	O
Second,	.	O
there	CD	O
are	JJS	O
inhibitory	IN	O
(or	CD	O
instability)	NN	O
elements	IN	O
(INS)	DT	O
located	VBN	O
within	NN	O
the	MD	O
coding	VB	O
sequences	VBN	O
of	NN	O
the	IN	O
Gag	DT	O
and	NN	O
Gag-protease	VBG	O
coding	TO	O
sequences	DT	O
Schneider	JJ	B
R,	NNP	I
et	NN	I
al.,	NNS	I
J.	VBP	I
Virol.	DT	I
71(7):4892-4903,	NN	I
1997).(	VBG	O
RRE	TO	O
is	DT	O
a	JJ	O
secondary	NNP	O
RNA	NN	O
structure	.	O
that	,	O
interacts	EX	O
with	VBP	O
the	JJ	O
HIV	CC	O
encoded	)	O
Rev-protein	NNS	O
to	)	O
overcome	VBD	O
the	IN	O
expression	DT	O
down-regulating	VBG	O
effects	NNS	O
of	IN	O
the	DT	O
INS.	NNP	O
To	CC	O
overcome	NNP	O
the	NN	O
requirement	NNS	O
for	NNP	O
post-transcriptional	,	O
activating	FW	O
mechanisms	,	O
of	NNP	O
RRE	.	O
and	,	O
Rev,	.	O
and	NNP	O
to	VBZ	O
enhance	DT	O
independent	JJ	O
expression	NNP	O
of	NN	O
the	WDT	O
Gag	VBZ	O
polypeptide,	IN	O
the	DT	O
INS	NNP	O
were	VBD	O
inactivated	NNP	O
by	TO	O
introducing	VB	O
multiple	DT	O
point	NN	O
mutations	JJ	O
that	NNS	O
did	IN	O
not	DT	O
alter	.	O
the	TO	O
reading	VB	O
frame	DT	O
of	NN	O
the	IN	O
encoded	JJ	O
proteins.	VBG	O
FIG.	NN	O
1	IN	O
shows	NNP	O
the	CC	O
original	,	O
SF2	CC	O
Gag	TO	O
sequence,	VB	O
the	JJ	O
location	NN	O
of	IN	O
the	DT	O
INS	NNP	O
sequences,	,	O
and	DT	O
the	NNP	O
modifications	VBD	O
made	VBN	O
to	IN	O
the	VBG	O
INS	JJ	O
sequences	NN	O
to	NNS	O
reduce	WDT	O
their	VBD	O
effects.	RB	O
For	VB	O
the	DT	O
Gag-protease	NN	O
sequence	NN	O
(wild	IN	O
type,	DT	O
SEQ	JJ	O
ID	.	O
NO:2;	.	O
synthetic,	CD	O
SEQ	VBZ	O
ID	DT	O
NOs:5,	JJ	O
78	NNP	O
and	NNP	O
79),	,	O
the	DT	O
changes	NN	O
in	IN	O
codon	DT	O
usage	NNP	O
were	,	O
restricted	CC	O
to	DT	O
the	NNS	O
regions	VBN	O
up	TO	O
to	DT	O
the	NNP	O
−1	NNS	O
frameshift	TO	O
and	VB	O
starting	PRP$	O
again	.	O
at	IN	O
the	DT	O
end	NNP	O
of	NN	O
the	JJ	O
Gag	,	O
reading	NNP	O
frame	NNP	O
(FIG.	:	O
2;	,	O
the	NNP	O
region	NNP	O
indicated	,	O
in	CD	O
lower	CC	O
case	,	O
letters	DT	O
in	NNS	O
FIG.	IN	O
2	NN	O
is	NN	O
the	VBD	O
unmodified	VBN	O
region).	TO	O
Further,	DT	O
inhibitory	NNS	O
(or	IN	O
instability)	TO	O
elements	DT	O
(INS)	NNP	O
located	NN	O
within	CC	O
the	VBG	O
coding	RB	O
sequences	IN	O
of	DT	O
the	NN	O
Gag-protease	IN	O
polypeptide	DT	O
coding	NNP	O
sequence	NN	O
were	NN	O
altered	.	O
as	:	O
well	DT	O
(indicated	NN	O
in	VBD	O
FIG.	IN	O
2).	JJR	O
The	NN	O
synthetic	NNS	O
coding	IN	O
sequences	.	O
were	CD	O
assembled	VBZ	O
by	DT	O
the	JJ	O
Midland	.	O
Certified	,	O
Reagent	NN	O
Company	CC	O
(Midland,	)	O
Tex.).	NNS	O
Modification	)	O
of	VBD	O
the	IN	O
Gag-polymerase	DT	O
sequences	VBG	O
(wild	NNS	O
type,	IN	O
SEQ	DT	O
ID	NNP	O
NO:3;	NN	O
synthetic,	VBG	O
SEQ	NN	O
ID	VBD	O
NO:6)	VBN	O
and	RB	O
Gag-reverse	RB	O
transcriptase	VBN	O
sequences	IN	O
(SEQ	.	O
ID	.	O
NOs:80	DT	O
through	JJ	O
84)	NN	O
include	NNS	O
similar	VBD	O
modifications	VBN	O
as	IN	O
described	DT	O
for	NNP	O
Gag-protease	NNP	O
in	NNP	O
order	NNP	O
to	,	O
preserve	.	O
the	NN	O
frameshift	IN	O
region.	DT	O
Locations	NNP	O
of	NNS	O
the	JJ	O
inactivation	,	O
sites	NNP	O
and	NNP	O
changes	:	O
to	,	O
the	NNP	O
sequence	NNP	O
to	)	O
alter	CC	O
the	JJ	O
inactivation	NN	O
sites	NNS	O
are	NNP	O
presented	NNP	O
in	NNP	O
FIG.	IN	O
12	)	O
for	VBP	O
the	JJ	O
native	NNS	O
HIV-1SF2	IN	O
Gag-polymerase	VBN	O
sequence.	IN	O
In	NNP	O
one	IN	O
embodiment	NN	O
of	TO	O
the	VB	O
invention,	DT	O
the	JJ	O
full	.	O
length	NNS	O
polymerase	IN	O
coding	DT	O
region	NN	O
of	VBZ	O
the	CC	O
Gag-polymerase	NNS	O
sequence	TO	O
is	DT	O
included	NN	O
with	TO	O
the	VB	O
synthetic	DT	O
Gag	NN	O
sequences	NNS	O
in	VBP	O
order	VBN	O
to	IN	O
increase	.	O
the	CD	O
number	IN	O
of	DT	O
epitopes	JJ	O
for	NNP	O
virus-like	NNP	O
particles	.	O
expressed	IN	O
by	CD	O
the	NN	O
synthetic,	IN	O
optimized	DT	O
Gag	,	O
expression	DT	O
cassette.	JJ	O
Because	NN	O
synthetic	NN	O
HIV-1	VBG	O
Gag-polymerase	NN	O
expresses	IN	O
the	DT	O
potentially	NNP	O
deleterious	NN	O
functional	VBZ	O
enzymes	VBN	O
reverse	IN	O
transcriptase	DT	O
(RT)	JJ	O
and	NNP	O
integrase	NNS	O
(INT)	IN	O
(in	NN	O
addition	TO	O
to	VB	O
the	DT	O
structural	NN	O
proteins	IN	O
and	NNS	O
protease),	IN	O
it	JJ	O
is	NNS	O
important	VBN	O
to	IN	O
inactivate	DT	O
RT	,	O
and	JJ	O
INT	NNP	O
functions.	NN	O
Several	.	O
in-frame	IN	O
deletions	JJ	O
in	NNP	O
the	NNP	O
RT	VBZ	O
and	DT	O
INT	RB	O
reading	JJ	O
frame	JJ	O
can	NNS	O
be	JJ	O
made	NN	O
to	)	O
achieve	CC	O
catalytic	NN	O
nonfunctional	)	O
enzymes	IN	O
with	NN	O
respect	TO	O
to	DT	O
their	JJ	O
RT	NNS	O
and	CC	O
INT	,	O
activity.	PRP	O
{Jay.	VBZ	O
A.	JJ	O
Levy	TO	B
(Editor)	VB	I
(1995)	NNP	I
The	CC	I
Retroviridae,	NNP	I
Plenum	.	I
Press,	JJ	I
New	JJ	I
York.	NNS	I
ISBN	IN	I
0-306-45033X.	DT	I
Pages	NNP	I
215-20;	CC	I
Grimison,	NNP	B
B.	NN	I
and	NN	I
Laurence,	MD	I
J.	VB	I
(1995),	VBN	I
Journal	TO	I
Of	VB	I
Acquired	JJ	I
Immune	JJ	I
Deficiency	NNS	I
Syndromes	IN	I
and	NN	I
Human	TO	I
Retrovirology	PRP$	I
9(1):58-68;	NNP	I
Wakefield,	CC	B
J.	NNP	I
K.,	.	I
et	.	I
al.,	.	I
(1992)	NNP	I
Journal	)	I
Of	)	I
Virology	DT	I
66(11):6806-6812;	,	I
Esnouf,	NNP	B
R.,	,	I
et	NNP	I
al.,	.	I
(1995)	NNP	I
Nature	.	I
Structural	NNS	I
Biology	:	I
2(4):303-308;	,	I
Maignan,	NNP	B
S.,	CC	I
et	,	I
al.,	.	I
(1998)	,	I
Journal	NNP	I
Of	IN	I
Molecular	NNP	I
Biology	NNP	I
282(2):359-368;	NNP	I
Katz,	NNP	B
R.	CC	I
A.	NNP	I
and	NNP	I
Skalka,	:	I
A.	,	I
M.	NNP	I
(1994)	,	I
Annual	FW	I
Review	,	I
Of	)	I
Biochemistry	NNP	I
73	IN	I
(1994);	NNP	I
Jacobo-Molina,	:	B
A.,	,	I
et	,	I
al.,	FW	I
(1993)	,	I
Proceedings	)	I
Of	NNP	I
the	NNP	I
National	NNP	I
Academy	:	I
Of	,	I
Sciences	,	I
Of	FW	I
the	,	I
United	)	I
States	NNP	I
Of	IN	I
America	NNP	I
90(13):6320-6324;	NNP	I
Hickman,	:	B
A.	,	I
B.,	NNP	I
et	NN	I
al.,	CC	I
(1994)	,	I
Journal	NNP	I
Of	NNP	I
Biological	)	I
Chemistry	NNP	I
269(46):29279-29287;	NNP	I
Goldgur,	IN	B
Y.,	NNP	I
et	CD	I
al.,	:	I
(1998)	,	I
Proceedings	,	I
Of	FW	I
the	,	I
National	)	I
Academy	NNS	I
Of	IN	I
Sciences	DT	I
Of	NNP	I
the	NNP	I
United	IN	I
States	NNPS	I
Of	IN	I
America	DT	I
95(16):9150-9154;	NNP	I
Goette,	NNPS	B
M.,	IN	I
et	NNP	I
al.,	:	I
(1998)	,	I
Journal	.	I
Of	,	I
Biological	FW	I
Chemistry	,	I
273(17):10139-10146;	)	I
Gorton,	NNP	B
J.	IN	I
L.,	NNP	I
et	NNP	I
al.,	:	I
(1998)	,	I
Journal	,	I
of	FW	I
Virology	,	I
72(6):5046-5055;	)	I
Engelman,	NNS	B
A.,	IN	I
et	DT	I
al.,	NNP	I
(1997)	NNP	I
Journal	IN	I
Of	NNPS	I
Virology	IN	I
71(5):3507-3514;	DT	I
Dyda,	NNP	B
F.,	NNPS	I
et	IN	I
al.,	NNP	I
Science	:	I
266(5193):1981-1986;	,	I
Davies,	,	B
J.	FW	I
F.,	,	I
et	)	I
al.,	NNP	I
(1991)	IN	I
Science	NNP	I
252(5002):88-95;	NNP	I
Bujacz,	:	B
G.,	,	I
et	NNP	I
al.,	,	I
(1996)	FW	I
Febs	,	I
Letters	)	I
398(2-3):175-178;	NNP	I
Beard,	IN	B
W.	NNP	I
A.,	:	I
et	,	I
al.,	,	I
(1996)	FW	I
Journal	,	I
Of	)	I
Biological	NNP	I
Chemistry	IN	I
271(21):12213-12220;	NNP	I
Kohlstaedt,	:	B
L.	,	I
A.,	,	I
et	NN	I
al.,	,	I
(1992)	NNP	I
Science	:	I
256(5065):1783-1790;	,	I
Krug,	NNP	B
M.	,	I
S,	NN	I
and	,	I
Berger,	)	I
S.	NN	I
L.	:	I
(1991)	,	I
Biochemistry	,	I
30(44):10614-10623;	FW	I
Mazumder,	,	B
A.,	)	I
et	NNP	I
al.,	NNP	I
(1996)	:	I
Molecular	,	I
Pharmacology	NNP	I
49(4):621-628;	,	I
Palaniappan,	FW	B
C.,	,	I
et	)	I
al.,	NNP	I
(1997)	IN	I
Journal	NNP	I
Of	NNP	I
Biological	:	I
Chemistry	,	I
272(17):11157-11164;	NNP	I
Rodgers,	,	B
D.	FW	I
W.,	,	I
et	)	I
al.,	NN	I
(1995)	:	I
Proceedings	,	I
Of	NNP	I
the	,	I
National	CC	I
Academy	,	I
Of	NNP	I
Sciences	NNP	I
Of	)	I
the	NN	I
United	:	I
States	,	I
Of	,	I
America	FW	I
92(4):1222-1226;	,	I
Sheng,	)	B
N.	NNP	I
and	NNP	I
Dennis,	:	I
D.	,	I
(1993)	,	I
Biochemistry	FW	I
32(18):4938-4942;	,	I
Spence,	)	B
R.	NNP	I
A.,	IN	I
et	NNP	I
al.,	NNP	I
(1995)	:	I
Science	,	I
267(5200):988-993.}Furthermore	NNP	O
selected	,	O
B-	FW	O
and/or	,	O
T-cell	)	O
epitopes	NNS	O
can	IN	O
be	DT	O
added	NNP	O
to	NNP	O
the	IN	O
Gag-polymerase	NNPS	O
constructs	IN	O
within	DT	O
the	NNP	O
deletions	NNPS	O
of	IN	O
the	NNP	O
RT-	:	O
and	,	O
INT-coding	NNP	O
sequence	CC	O
to	,	O
replace	NNP	O
and	)	O
augment	NN	O
any	:	O
epitopes	,	O
deleted	NNP	O
by	,	O
the	FW	O
functional	,	O
modifications	)	O
of	NN	O
RT	)	O
and	RB	O
INT.	VBN	O
Alternately,	NNP	O
selected	JJ	O
B-	NNP	O
and	NNS	O
T-cell	MD	O
epitopes	VB	O
(including	VBN	O
CTL	TO	O
epitopes)	DT	O
from	NNP	O
RT	NNS	O
and	IN	O
INT	DT	O
can	NNS	O
be	IN	O
included	DT	O
in	NNP	O
a	CC	O
minimal	NNP	O
VLP	NN	O
formed	TO	O
by	VB	O
expression	CC	O
of	VB	O
the	DT	O
synthetic	NNS	O
Gag	VBN	O
or	IN	O
synthetic	DT	O
GagProt	JJ	O
cassette,	NNS	O
described	IN	O
above.	NNP	O
(For	CC	O
descriptions	.	O
of	,	O
known	VBN	O
HIV	NNP	O
B-	CC	O
and	NNP	O
T-cell	NNS	O
epitopes	VBG	O
see,	NNP	O
HIV	)	O
Molecular	IN	O
Immunology	NNP	O
Database	CC	O
CTL	NNP	O
Search	MD	O
Interface;	VB	O
Los	VBN	O
Alamos	IN	O
Sequence	DT	O
Compendia,	JJ	O
1987-1997;Internet	NNP	O
address:	VBN	O
http://hiv-web.lan1.gov/immunology/index.html.)	IN	O
The	NN	O
resulting	IN	O
modified	DT	O
coding	JJ	O
sequences	NNP	O
are	CC	O
presented	JJ	O
as	NNP	O
a	,	O
synthetic	VBN	O
Gag	.	O
expression	IN	O
cassette	NNS	O
(SEQ	IN	O
ID	VBN	O
NO:4),	NNP	O
a	NNP	O
synthetic	CC	O
Gag-protease	NNP	O
expression	NNS	O
cassette	,	O
(SEQ	NNP	O
ID	NNP	O
NOs:5,	NNP	O
78	NNP	O
and	NNP	O
79),	NNP	O
and	:	O
a	NNP	O
synthetic	NNP	O
Gag-polymerase	NNP	O
expression	,	O
cassette	NNP	O
(SEQ	:	O
ID	)	O
NO:6).	DT	O
Synthetic	VBG	O
expression	JJ	O
cassettes	NN	O
containing	NNS	O
codon	VBP	O
modifications	VBN	O
in	IN	O
the	DT	O
reverse	JJ	O
transcriptase	NNP	O
region	NN	O
are	NN	O
shown	NNP	O
in	NNP	O
SEQ	,	O
ID	DT	O
NOs:80	JJ	O
through	NNP	O
84.	NN	O
An	NN	O
alignment	NNP	O
of	NNP	O
selected	,	O
sequences	CD	O
is	CC	O
presented	,	O
in	CC	O
FIG.	DT	O
7.	JJ	O
A	NNP	O
common	NN	O
region	NN	O
(Gag-common;	NNP	O
SEQ	NNP	O
ID	.	O
NO:9)	JJ	O
extends	NN	O
from	NNS	O
position	VBG	O
1	NN	O
to	NNS	O
position	IN	O
1262.	DT	O
The	NN	O
synthetic	NN	O
DNA	NN	O
fragments	VBP	O
for	VBN	O
Gag	IN	O
and	NNP	O
Gag-protease	NNP	O
were	NNP	O
cloned	IN	O
into	.	O
the	DT	O
following	NN	O
expression	IN	O
vectors:	VBN	O
pCMVKm2,	NNS	O
for	VBZ	O
transient	VBN	O
expression	IN	O
assays	.	O
and	.	O
DNA	DT	O
immunization	JJ	O
studies,	NN	O
the	:	O
pCMVKm2	NNP	O
vector	NNP	O
was	)	O
derived	VBZ	O
from	IN	O
pCMV6a	NN	O
Chapman	CD	B
et	TO	I
al.,	NN	I
Nuc.	.	I
Acids	DT	I
Res.	JJ	I
(1991)	NN	I
19:3979-3986)	NNS	I
(and	IN	O
comprises	NNP	O
a	CC	O
kanamycin	NNP	O
selectable	VBD	O
marker,	VBN	O
a	IN	O
ColE1	DT	O
origin	JJ	O
of	NN	O
replication,	:	O
a	,	O
CMV	IN	O
promoter	JJ	O
enhancer	NN	O
and	NNS	O
Intron	CC	O
A,	NNP	O
followed	NN	O
by	,	O
an	DT	O
insertion	NN	O
site	NN	O
for	VBD	O
the	VBN	O
synthetic	IN	O
sequences	NN	O
described	NNP	O
below	VBZ	O
followed	,	O
by	.	O
a	NNP	O
polyadenylation	.	O
signal	)	O
derived	)	O
from	CC	O
bovine	VBZ	O
growth	DT	O
hormone—the	NN	O
pCMVKm2	JJ	O
vector	,	O
differs	DT	O
from	NNP	O
the	NN	O
pCMV-link	IN	O
vector	,	O
only	DT	O
in	NNP	O
that	NN	O
a	NN	O
polylinker	CC	O
site	NNP	O
was	,	O
inserted	VBN	O
into	IN	O
pCMVKm2	DT	O
to	NN	O
generate	NN	O
pCMV-link	IN	O
(FIG.	DT	O
14,	JJ	O
polylinker	NNS	O
at	VBN	O
positions	IN	O
1646	VBN	O
to	IN	O
1697);	DT	O
pESN2dhfr	NN	O
(FIG.	NN	O
13A)	VBN	O
and	IN	O
pCMVPLEdhfr	NN	O
(also	NN	O
known	VBP	O
as	NN	O
pCMVIII	NN	O
as	NNS	O
shown	IN	O
in	DT	O
FIG.	NN	O
13B),	NN	O
for	RB	O
expression	IN	O
in	DT	O
Chinese	DT	O
Hamster	NN	O
Ovary	NN	O
(CHO)	VBD	O
cells;	VBN	O
and,	IN	O
pAcC13,	NN	O
a	TO	O
shuttle	VB	O
vector	NN	O
for	.	O
use	,	O
in	NN	O
the	IN	O
Baculovirus	NNS	O
expression	CD	O
system	TO	O
(pAcC13,	:	O
was	NN	O
derived	.	O
from	)	O
pAcC12	CC	O
which	NN	O
was	RB	O
described	VBN	O
by	RB	O
Munemitsu	NN	B
S.,	IN	I
et	VBN	I
al.,	IN	I
Mol	.	I
Cell	,	I
Biol.	IN	I
10(11):5977-5982,	NN	I
1990).A	IN	O
restriction	JJ	O
map	NNP	O
for	NNP	O
vector	)	O
pCMV-link	:	O
is	,	O
presented	,	O
in	DT	O
FIG.	JJ	O
14.	NN	O
In	IN	O
the	NN	O
figure,	IN	O
the	DT	O
CMV	NNP	O
promoter	NN	O
(CMV	NN	O
IE	,	O
ENH/PRO),	VBD	O
bovine	VBN	O
growth	IN	O
hormone	NN	O
terminator	WDT	O
(BGH	VBD	O
pA),	VBN	O
kanamycin	IN	O
selectable	NNP	O
marker	,	O
(kan),	FW	O
and	,	O
a	NNP	O
ColE1	NNP	O
origin	.	O
of	,	O
replication	.	O
(ColE1	DT	O
ori)	NN	O
are	NN	O
indicated.	IN	O
A	NN	O
polycloning	NN	O
site	VBZ	O
is	VBN	O
also	IN	O
indicated	.	O
in	.	O
the	IN	O
figure	DT	O
following	,	O
the	DT	O
CMV	NNP	O
promoter	NN	O
sequences.	NNP	O
A	NNP	O
restriction	,	O
map	JJ	O
for	NN	O
vector	NN	O
pESN2dhfr	NN	O
is	NNP	O
presented	,	O
in	FW	O
FIG.	JJ	O
13A.	NN	O
In	,	O
the	CC	O
figure,	DT	O
the	NNP	O
CMV	NN	O
promoter	IN	O
(pCMV,	NN	O
hCMVIE),	NNP	O
bovine	)	O
growth	VBP	O
hormone	.	O
terminator	DT	O
(BGHpA),	NN	O
SV40	NN	O
origin	VBZ	O
of	RB	O
replication	VBN	O
(SV40ori),	IN	O
neomycin	DT	O
selectable	NN	O
marker	VBG	O
(Neo),	DT	O
SV40	NNP	O
polyA	NN	O
(SV40pA),	.	O
Adenovirus	DT	O
2	NN	O
late	NN	O
promoter	IN	O
(Ad2VLP),	NN	O
and	NN	O
the	VBZ	O
murine	VBN	O
dhfr	IN	O
gene	.	O
(mu	.	O
dhfr)	IN	O
are	DT	O
indicated.	,	O
A	DT	O
polycloning	NNP	O
site	NN	O
is	,	O
also	,	O
indicated	JJ	O
in	NN	O
the	NN	O
figure	NN	O
following	,	O
the	NNP	O
CMV	NN	O
promoter	IN	O
sequences.	NN	O
Briefly,	,	O
construction	RB	O
of	JJ	O
pCMVPLEdhfr	NN	O
(pCMVIII)	,	O
was	NNP	O
as	NN	O
follows.	,	O
To	NNP	O
construct	CD	O
a	JJ	O
DHFR	NN	O
cassette,	,	O
the	CC	O
EMCV	DT	O
IRES	NN	O
(internal	NN	O
ribosome	NN	O
entry	JJ	O
site)	)	O
leader	VBP	O
was	.	O
PCR-amplified	DT	O
from	NN	O
pCite-4-a+	NN	O
(Novagen,	VBZ	O
Inc.,	RB	O
Milwaukee,	VBN	O
Wis.)	IN	O
and	DT	O
inserted	NN	O
into	VBG	O
pET-23d	DT	O
(Novagen,	NNP	O
Inc.,	NN	O
Milwaukee,	.	O
Wis.)	,	O
as	NN	O
an	IN	O
Xba-Nco	NN	O
fragment	)	O
to	VBD	O
give	IN	O
pET-EMCV.	.	O
The	TO	O
dhfr	VB	O
gene	DT	O
was	NNP	O
PCR-amplified	,	O
from	DT	O
pESN2dhfr	NNP	O
to	NNP	O
give	JJ	O
a	NN	O
product	NN	O
with	)	O
a	NN	O
Gly-Gly-Gly-Ser	VBD	O
spacer	JJ	O
in	IN	O
place	NN	O
of	,	O
the	,	O
translation	,	O
stop	)	O
codon	CC	O
and	VBN	O
inserted	IN	O
as	NN	O
an	,	O
Nco-BamH1	,	O
fragment	,	O
to	)	O
give	IN	O
pET-E-DHFR.	DT	O
Next,	JJ	O
the	NN	O
attenuated	TO	O
neo	VB	O
gene	.	O
was	DT	O
PCR	NN	O
amplified	NN	O
from	VBD	O
a	VBN	O
pSV2Neo	IN	O
(Clontech,	NN	O
Palo	TO	O
Alto,	VB	O
Calif.)	DT	O
derivative	NN	O
and	IN	O
inserted	DT	O
into	JJ	O
the	NN	O
unique	IN	O
BamH1	NN	O
site	IN	O
of	DT	O
pET-E-DHFR	NN	O
to	NN	O
give	NN	O
pET-E-DHFR/Neo(m2).	CC	O
Then,	VBN	O
the	IN	O
bovine	DT	O
growth	JJ	O
hormone	NN	O
terminator	TO	O
from	VB	O
pcDNA3	.	O
(Invitrogen,	,	O
Inc.,	DT	O
Carlsbad,	VBN	O
Calif.)	JJ	O
was	NN	O
inserted	VBD	O
downstream	NNP	O
of	VBD	O
the	IN	O
neo	DT	O
gene	NN	O
to	,	O
give	NNP	O
pET-E-DHFR/Neo(m2)BGHt.	,	O
The	)	O
EMCV-dhfr/neo	NN	O
selectable	CC	O
marker	VBN	O
cassette	IN	O
fragment	DT	O
was	JJ	O
prepared	NNP	O
by	NN	O
cleavage	IN	O
of	JJ	O
pET-E-DHFR/Neo(m2)BGHt.	TO	O
The	VB	O
CMV	.	O
enhancer/promoter	,	O
plus	DT	O
Intron	NN	O
A	NN	O
was	NN	O
transferred	NN	O
from	IN	O
pCMV6a	NN	O
Chapman	,	B
et	,	I
al.,	,	I
Nuc.	)	I
Acids	VBD	I
Res.	VBN	I
(1991)	NN	I
19:3979-3986)	IN	I
(as	DT	O
a	JJ	O
HindIII-SalI	NN	O
fragment	TO	O
into	VB	O
pUC19	.	O
(New	DT	O
England	NNP	O
Biolabs,	JJ	O
Inc.,	NN	O
Beverly,	NN	O
Mass.).	NN	O
The	VBD	O
vector	VBN	O
backbone	IN	O
of	NN	O
pUC19	IN	O
was	.	O
deleted	DT	O
from	NNP	O
the	NN	O
Nde1	CC	O
to	NNP	O
the	NNP	O
Sap1	VBD	O
sites.	VBN	O
The	IN	O
above	NN	O
described	NNP	O
DHFR	VBZ	O
cassette	,	O
was	.	O
added	NNP	O
to	.	O
the	)	O
construct	)	O
such	IN	O
that	DT	O
the	JJ	O
EMCV	NN	O
IRES	IN	O
followed	NN	O
the	NNP	O
CMV	NNP	O
promoter	,	O
to	,	O
produce	,	O
the	.	O
final	DT	O
construct.	NN	O
The	NN	O
vector	IN	O
also	NN	O
contained	VBD	O
an	VBN	O
ampr	IN	O
gene	DT	O
and	NNP	O
an	TO	O
SV40	DT	O
origin	NNP	O
of	.	O
replication.	DT	O
Selected	JJ	O
pCMVKm2	NN	O
vectors	NNP	O
containing	NN	O
the	VBD	O
synthetic	VBN	O
expression	TO	O
cassettes	DT	O
have	NN	O
been	JJ	O
designated	IN	O
as	DT	O
follows:	NNP	O
pCMVKm2.GagMod.SF2,	NNP	O
pCMVKm2.GagprotMod.SF2,	VBD	O
and	DT	O
pCMVKm2.GagpolMod.SF2,	NNP	O
pCMVKm2.GagprotMod.SF2.GP1	NN	O
(SEQ	TO	O
ID	VB	O
NO:78)	DT	O
and	JJ	O
pCMVKm2.GagprotMod.SF2.GP2	.	O
(SEQ	DT	O
ID	NN	O
NO:79).	RB	O
Other	VBD	O
exemplary	DT	O
Gag-encoding	JJ	O
expressing	NN	O
cassettes	CC	O
are	DT	O
shown	NNP	O
in	NN	O
the	IN	O
Figures	.	O
and	VBN	O
as	JJ	O
Sequence	NNS	O
Listings.	VBG	O
B.	DT	O
Modification	JJ	O
of	NN	O
HIV-1	NNS	O
Gag/Hepatitis	VBP	O
C	VBN	O
Core	VBN	O
Chimeric	IN	O
Protein	:	O
Nucleic	,	O
Acid	,	O
Coding	CC	O
Sequences	,	O
Generation	NN	O
of	NNP	O
Synthetic	NNP	O
Expression	)	O
Cassettes	CC	O
To	NN	O
facilitate	NNP	O
the	NNP	O
ligation	.	O
of	JJ	O
the	JJ	O
Gag	JJ	O
and	NN	O
HCV	NNS	O
core	VBP	O
coding	VBN	O
sequences,	IN	O
PCR	DT	O
amplification	NNS	O
was	CC	O
employed.	IN	O
The	NNP	O
synthetic	.	O
p55Gag	.	O
expression	NN	O
cassette	IN	O
was	NNP	O
used	NNP	O
as	NNP	O
a	NNP	O
PCR	NNP	O
template	NNP	O
with	NNP	O
the	NNP	O
following	NNP	O
primers:	NNPS	O
GAG5(SEQ	NNP	O
ID	IN	O
NO:11)	NNP	O
and	NNP	O
P55-SAL3	NNP	O
(SEQ	TO	O
ID	VB	O
NO:12).	DT	O
The	NN	O
PCR	IN	O
amplification	DT	O
was	NNP	O
conducted	CC	O
at	NNP	O
55°	NN	O
C.	NN	O
for	,	O
25	NNP	O
cycles	NN	O
using	VBD	O
Stratagene's	.	O
Pfu	DT	O
polymerase.	JJ	O
The	NN	O
resulting	NN	O
PCR	NN	O
product	VBD	O
was	VBN	O
rendered	IN	O
free	DT	O
of	NNP	O
nucleotides	NN	O
and	IN	O
primers	DT	O
using	VBG	O
the	:	O
Promega	NNP	O
PCR	NNP	O
clean-up	)	O
kit	CC	O
and	NNP	O
then	NNP	O
subjected	NNP	O
to	.	O
EcoRI	DT	O
and	NNP	O
SalI	NN	O
digestions.	VBD	O
For	VBN	O
HCV	IN	O
core	CD	O
coding	NNP	O
sequences,	IN	O
the	CD	O
following	NNS	O
primers	VBG	O
were	POS	O
used	NNP	O
with	.	O
an	DT	O
HCV	VBG	O
template	NNP	O
(Houghton,	NN	O
M.,	VBD	O
et	VBN	O
al.,	JJ	O
U.S.	IN	O
Pat.	NNS	O
No.	CC	O
5,714,596,	NNS	O
issued	VBG	O
Feb.	DT	O
3,	NNP	O
1998;	NNP	O
Houghton,	JJ	O
M.,	NN	O
et	CC	O
al.,	RB	O
U.S.	VBD	O
Pat.	TO	O
No.	NNP	O
5,712,088,	CC	O
issued	NNP	O
Jan.	.	O
27,	IN	O
1998;	NNP	O
Houghton,	NN	O
M.,	NN	O
et	,	O
al.,	DT	O
U.S.	JJ	O
Pat.	NNS	O
No.	VBD	O
5,683,864,	VBN	O
issued	IN	O
Nov.	DT	O
4,	NNP	O
1997;	NN	O
Weiner,	,	O
A.	,	O
J.,	FW	O
et	,	O
al.,	NNP	O
U.S.	.	O
Pat.	.	O
No.	,	O
5,728,520,	VBN	O
issued	NNP	O
Mar.	,	O
17,	:	O
1998;	,	O
Weiner,	,	O
A.	FW	O
J.,	,	O
et	NNP	O
al.,	.	O
U.S.	.	O
Pat.	,	O
No.	VBD	O
5,766,845,	NNP	O
issued	,	O
Jun.	:	O
16,	,	O
1998;	,	O
Weiner,	FW	O
A.	,	O
J.,	NNP	O
et	.	O
al.,	.	O
U.S.	,	O
Pat.	VBD	O
No.	NNP	O
5,670,152,	,	O
issued	:	O
Sep.	,	O
23,	NNP	O
1997;	,	O
all	FW	O
herein	,	O
incorporated	NNP	O
by	.	O
reference):	.	O
CORESAL	,	O
5	VBN	O
(SEQ	.	O
ID	,	O
NO:13)	:	O
and	,	O
173CORE(SEQ	NNP	O
ID	,	O
NO:14)	FW	O
using	,	O
the	NNP	O
conditions	.	O
outlined	.	O
above.	,	O
The	VBN	O
purified	.	O
product	,	O
was	:	O
digested	,	O
with	NNP	O
SalI	,	O
and	FW	O
BamHI	,	O
restriction	NNP	O
enzymes.	.	O
The	.	O
digested	,	O
Gag	VBN	O
and	NNP	O
HCV	,	O
core	:	O
PCR	DT	O
products	NN	O
were	VBN	O
ligated	IN	O
into	:	O
the	$	O
pCMVKm2	CD	O
vector	NNP	O
digested	NNP	O
with	)	O
EcoRI	CC	O
and	NNP	O
BamHI.	NNP	O
Ligation	)	O
of	VBG	O
the	DT	O
PCR	NNS	O
products	VBN	O
at	.	O
the	DT	O
SalI	JJ	O
site	NN	O
resulted	VBD	O
in	VBN	O
a	IN	O
direct	NNP	O
fusion	CC	O
of	NNP	O
the	NN	O
final	.	O
amino	DT	O
acid	JJ	O
of	NNP	O
p55Gag	CC	O
to	NNP	O
the	VBP	O
second	NNP	O
amino	NNS	O
acid	VBD	O
of	VBN	O
HCV	IN	O
core,	DT	O
serine.	NN	O
Amino	NN	O
acid	VBD	O
173	IN	O
of	NNP	O
core	CC	O
is	.	O
a	NN	O
serine	IN	O
and	DT	O
is	NNP	O
followed	NNS	O
immediately	IN	O
by	DT	O
a	NNP	O
TAG	NN	O
termination	VBD	O
codon.	IN	O
The	DT	O
sequence	JJ	O
of	NN	O
the	IN	O
fusion	DT	O
clone	JJ	O
was	NN	O
confirmed.	NN	O
The	IN	O
pCMVKm2	NN	O
vector	TO	O
containing	DT	O
the	JJ	O
synthetic	NN	O
expression	NN	O
cassette	IN	O
was	NNP	O
designated	,	O
as	.	O
pCMVKm2.GagModHCVcore.	NNP	O
The	VBD	O
EcoRI-BamHI	CD	O
fragment	IN	O
of	NN	O
p55Gag-core	VBZ	O
173	DT	O
was	NN	O
also	CC	O
cloned	VBZ	O
into	VBN	O
EcoRI-BamHI-digested	RB	O
pAcC13	IN	O
for	DT	O
baculovirus	NNP	O
expression.	NN	O
Western	.	O
blots	DT	O
confirmed	NN	O
expression	IN	O
and	DT	O
sucrose	NN	O
gradient	NN	O
sedimentation	VBD	O
along	.	O
with	DT	O
electron	NN	O
microscopy	NN	O
confirmed	VBG	O
particle	DT	O
formation.	JJ	O
To	NN	O
generate	NN	O
the	VBD	O
above	VBN	O
clone	IN	O
but	.	O
containing	DT	O
the	NNP	O
synthetic	NN	O
Gag	IN	O
sequences	NN	O
(instead	CD	O
of	VBD	O
wild-type),	RB	O
the	VBN	O
following	IN	O
steps	JJ	O
were	NN	O
performed:	IN	O
pCMVKm2-modified	NN	O
p55Gag	.	O
was	JJ	O
used	NNS	O
as	VBN	O
template	NN	O
for	CC	O
PCR	JJ	O
amplification	JJ	O
with	NN	O
MS65	IN	O
(SEQ	IN	O
ID	NN	O
NO:15)	NN	O
and	VBD	O
MS66(SEQ	NN	O
ID	.	O
NO:16)	TO	O
primers.	VB	O
The	DT	O
region	JJ	O
amplified	NN	O
corresponds	CC	O
to	VBG	O
the	DT	O
BspHI	JJ	O
and	NNP	O
SalI	NNS	O
sites	RB	O
at	IN	O
the	,	O
C-terminus	DT	O
of	JJ	O
synthetic	NNS	O
Gag	VBD	O
sequence.	:	O
The	JJ	O
amplification	NN	O
product	VBD	O
was	VBN	O
digested	IN	O
with	NN	O
BspHI	IN	O
and	NNP	O
SalI	NN	O
and	IN	O
ligated	NNP	O
to	NNP	O
SalI/BamHI	NNP	O
digested	)	O
pCMV-link	CC	O
along	NNP	O
with	NNP	O
the	)	O
Sal/BspHI	.	O
fragment	DT	O
from	NN	O
pCMV-Km-p55modGag,	VBD	O
representing	NNS	O
the	TO	O
amino	DT	O
terminal	NNP	O
end	CC	O
of	NNP	O
modified	NNS	O
Gag,	IN	O
and	DT	O
the	NNP	O
SalI/BamHI	IN	O
fragment	JJ	O
from	NNP	O
pCMV-p55Gag-core173.	.	O
Thereafter,	DT	O
a	NN	O
T4-blunted-SalI	NN	O
partial/BamHI	VBD	O
fragment	VBN	O
was	IN	O
ligated	NNP	O
into	CC	O
pAcC4-SmaI/BamHI	NNP	O
to	CC	O
generate	VBN	O
pAcC4-p55GagMod-core173	TO	O
(containing	NNP	O
the	VBD	O
synthetic	NN	O
sequence	IN	O
presented	IN	O
as	DT	O
SEQ	NNP	O
ID	NN	O
NO:7).	IN	O
C.	,	O
Defining	VBG	O
of	DT	O
the	NN	O
Major	JJ	O
Homology	NN	O
Region	IN	O
(MHR)	JJ	O
of	,	O
HIV-1	CC	O
p55Gag	DT	O
The	NNP	O
Major	NN	O
Homology	IN	O
Region	.	O
(MHR)	,	O
of	DT	O
HIV-1	JJ	O
p55	NN	O
(Gag)	NN	O
is	VBD	O
located	VBN	O
in	IN	O
the	JJ	O
p24-CA	TO	O
sequence	VB	O
of	NN	O
Gag.	VBG	O
It	DT	O
is	JJ	O
a	NN	O
conserved	VBD	O
stretch	IN	O
of	NNP	O
20	NNP	O
amino	.	O
acids	NNP	O
(SEQ	NNP	O
ID	IN	O
NO:19).	DT	O
The	NNP	O
position	NNP	O
in	NNP	O
the	)	O
wild	IN	O
type	NNP	O
HIV-1SF2	IN	O
Gag	DT	O
protein	NNP	O
is	NNP	O
from	NNP	O
aa	)	O
286-305	IN	O
and	NNP	O
spans	NN	O
a	)	O
region	VBZ	O
from	VBN	O
nucleotides	IN	O
856-915	DT	O
in	JJ	O
the	NN	O
native	IN	O
HIV-1SF2	.	O
Gag	PRP	O
DNA-sequence.	VBZ	O
The	DT	O
position	JJ	O
in	NN	O
the	IN	O
synthetic	CD	O
Gag	JJ	O
protein	NNS	O
is	NNP	O
from	NNP	O
aa	.	O
288-307	DT	O
and	NN	O
spans	IN	O
a	DT	O
region	JJ	O
from	JJ	O
nucleotides	NNP	O
862-921	NNP	O
for	NN	O
the	VBZ	O
synthetic	IN	O
Gag	JJ	O
DNA-sequence.	JJ	O
The	CC	O
nucleotide	VBZ	O
sequence	DT	O
for	NN	O
the	IN	O
MHR	JJ	O
in	CD	O
the	IN	O
synthetic	DT	O
GagMod.SF2	JJ	O
is	NNP	O
presented	NNP	O
as	.	O
SEQ	DT	O
ID	NN	O
NO:20.	IN	O
Mutations	DT	O
or	JJ	O
deletions	NNP	O
in	NN	O
the	VBZ	O
amino	IN	O
acid	JJ	O
sequence	JJ	O
of	CC	O
the	VBZ	O
MHR	DT	O
can	NN	O
severely	IN	O
impair	NNS	O
particle	CD	O
production	IN	O
Borsetti,	DT	B
A.,	JJ	I
et	NNP	I
al.,	.	I
J.	DT	I
Virol.	JJ	I
72(11):9313-9317,	NN	I
1998;	IN	I
Mammano,	DT	B
F.,	NNP	I
et	IN	I
al.,	DT	I
J	JJ	I
Virol	NNP	I
68(8):4927-4936,	VBZ	I
1994).(	VBN	O
Percent	IN	O
identity	NNP	O
to	NNP	O
the	.	O
MHR	NNS	O
nucleotide	CC	O
sequence	NNS	O
can	IN	O
be	DT	O
determined,	NN	O
for	JJ	O
example,	NN	O
using	IN	O
the	DT	O
MacDNAsis	NNP	O
program	MD	O
(Hitachi	RB	O
Software	VB	O
Engineering	NN	O
America	NN	O
Limited,	,	O
South	,	O
San	FW	O
Francisco,	,	O
Calif.),	NNP	O
Higgins	.	O
algorithm,	,	O
with	:	O
the	,	O
following	,	O
exemplary	NN	O
parameters:	,	O
gap	NNP	O
penalty=5,	NNP	O
no.	,	O
of	.	O
top	NN	O
diagonals=5,	NN	O
fixed	TO	O
gap	DT	O
penalty=5,	NNP	O
K-tuple=2,	JJ	O
window	NN	O
size=5,	MD	O
and	VB	O
floating	,	O
gap	IN	O
penalty=10.	,	O
D.	VBG	O
Generation	DT	O
of	NNP	O
Synthetic	NN	O
Env	NNP	O
Expression	NNP	O
Cassettes	NNP	O
Env	NNP	O
coding	,	O
sequences	NNP	O
of	NNP	O
the	,	O
present	,	O
invention	NNP	O
include,	,	O
but	IN	O
are	DT	O
not	JJ	O
limited	JJ	O
to,	:	O
polynucleotide	NN	O
sequences	,	O
encoding	.	O
the	IN	O
following	JJ	O
HIV-encoded	,	O
polypeptides:	VBN	O
gp160,	NN	O
gp140,	,	O
and	,	O
gp120	NN	O
(see,	,	O
e.g.,	CC	O
U.S.	VBG	O
Pat.	NN	O
No.	.	O
5,792,459	NNP	O
for	NNP	O
a	IN	O
description	NNP	O
of	NNP	O
the	NNP	O
HIV-1SF2	NNP	O
(“SF2”)	NNP	O
Env	VBG	O
polypeptide).	NNS	O
The	IN	O
relationships	DT	O
between	JJ	O
these	NN	O
polypeptides	,	O
is	CC	O
shown	VBP	O
schematically	RB	O
in	VBN	O
FIG.	,	O
15	VB	O
(in	NNS	O
the	VBG	O
figure:	DT	O
the	JJ	O
polypeptides	JJ	O
are	:	O
indicated	,	O
as	,	O
lines,	CC	O
the	NN	O
amino	,	O
and	,	O
carboxy	NNP	O
termini	.	O
are	.	O
indicated	CD	O
on	IN	O
the	DT	O
gp160	NN	O
line;	IN	O
the	DT	O
open	NNP	O
circle	)	O
represents	NNP	O
the	.	O
oligomerization	DT	O
domain;	NNS	O
the	IN	O
open	DT	O
square	NNS	O
represents	VBZ	O
a	VBN	O
transmembrane	RB	O
spanning	IN	O
domain	.	O
(TM);	CD	O
and	IN	O
“c”	DT	O
represents	:	O
the	DT	O
location	NNS	O
of	VBP	O
a	VBN	O
cleavage	IN	O
site,	,	O
in	DT	O
gp140.mut	NN	O
the	CC	O
“X”	NN	O
indicates	NN	O
that	VBP	O
the	VBN	O
cleavage	IN	O
site	DT	O
has	JJ	O
been	:	O
mutated	DT	O
such	JJ	O
that	NN	O
it	VBZ	O
no	DT	O
longer	NN	O
functions	:	O
as	DT	O
a	JJ	O
cleavage	NN	O
site).	VBZ	O
The	DT	O
polypeptide	NN	O
gp160	VBG	O
includes	NN	O
the	:	O
coding	CC	O
sequences	VB	O
for	VBZ	O
gp120	DT	O
and	NN	O
gp41.	IN	O
The	DT	O
polypeptide	NN	O
gp41	,	O
is	IN	O
comprised	NN	O
of	DT	O
several	NN	O
domains	VBZ	O
including	IN	O
an	DT	O
oligomerization	NN	O
domain	NN	O
(OD)	VBZ	O
and	VBN	O
a	VBN	O
transmembrane	JJ	O
spanning	IN	O
domain	PRP	O
(TM).	RB	O
In	RBR	O
the	NNS	O
native	IN	O
envelope,	DT	O
the	NN	O
oligomerization	.	O
domain	DT	O
is	NN	O
required	NN	O
for	VBZ	O
the	DT	O
non-covalent	NN	O
association	NNS	O
of	IN	O
three	NN	O
gp41	CC	O
polypeptides	.	O
to	DT	O
form	NN	O
a	NN	O
trimeric	VBZ	O
structure:	VBN	O
through	IN	O
non-covalent	JJ	O
interactions	NNS	O
with	VBG	O
the	DT	O
gp41	NN	O
trimer	NN	O
(and	)	O
itself),	CC	O
the	DT	O
gp120	NN	O
polypeptides	VBG	O
are	NN	O
also	.	O
organized	IN	O
in	DT	O
a	JJ	O
trimeric	,	O
structure.	DT	O
A	NN	O
cleavage	NN	O
site	VBZ	O
(or	VBN	O
cleavage	IN	O
sites)	DT	O
exists	JJ	O
approximately	NN	O
between	IN	O
the	CD	O
polypeptide	NNS	O
sequences	NNS	O
for	TO	O
gp120	VB	O
and	DT	O
the	JJ	O
polypeptide	:	O
sequences	IN	O
corresponding	JJ	O
to	NNS	O
gp41.	IN	O
This	DT	O
cleavage	NN	O
site(s)	NN	O
can	CC	O
be	,	O
mutated	DT	O
to	NN	O
prevent	NNS	O
cleavage	VBP	O
at	RB	O
the	VBN	O
site.	IN	O
The	DT	O
resulting	JJ	O
gp140	.	O
polypeptide	DT	O
corresponds	NN	O
to	NN	O
a	CC	O
truncated	VB	O
form	)	O
of	VBZ	O
gp160	RB	O
where	IN	O
the	DT	O
transmembrane	NN	O
spanning	NNS	O
domain	IN	O
of	NN	O
gp41	CC	O
has	DT	O
been	NN	O
deleted.	VBZ	O
This	VBG	O
gp140	TO	O
polypeptide	.	O
can	DT	O
exist	NN	O
in	)	O
both	MD	O
monomeric	VB	O
and	VBN	O
oligomeric	TO	O
(i.e.	VB	O
trimeric)	NN	O
forms	IN	O
by	DT	O
virtue	.	O
of	DT	O
the	VBG	O
presence	JJ	O
of	NN	O
the	VBZ	O
oligomerization	TO	O
domain	DT	O
in	JJ	O
the	NN	O
gp41	IN	O
moiety.	NN	O
In	WRB	O
the	DT	O
situation	NN	O
where	VBG	O
the	NN	O
cleavage	IN	O
site	NN	O
has	VBZ	O
been	VBN	O
mutated	.	O
to	DT	O
prevent	JJ	O
cleavage	NN	O
and	MD	O
the	VB	O
transmembrane	IN	O
portion	DT	O
of	JJ	O
gp41	CC	O
has	JJ	O
been	.	O
deleted	)	O
the	NNS	O
resulting	IN	O
polypeptide	NN	O
product	IN	O
is	DT	O
designated	NN	O
“mutated”	IN	O
gp140	DT	O
(e.g.,	NN	O
gp140.mut).	NN	O
As	IN	O
will	DT	O
be	NN	O
apparent	.	O
to	IN	O
those	DT	O
in	NN	O
the	WRB	O
field,	DT	O
the	NN	O
cleavage	NN	O
site	VBZ	O
can	VBN	O
be	VBN	O
mutated	TO	O
in	VB	O
a	NN	O
variety	CC	O
of	DT	O
ways.	JJ	O
The	NN	O
native	IN	O
amino	NN	O
acid	VBZ	O
sequence	VBN	O
in	VBN	O
the	DT	O
SF162	VBG	O
cleavage	JJ	O
sites	NN	O
is:	VBZ	O
APTKAKRRVVQREKR	VBN	O
(SEQ	JJ	O
ID	NN	O
NO:21),	,	O
where	.	O
KAKRR	IN	O
(SEQ	MD	O
ID	VB	O
NO:22)	JJ	O
is	TO	O
termed	DT	O
the	IN	O
“second”	DT	O
site	,	O
and	DT	O
REKR	NN	O
(SEQ	NN	O
ID	MD	O
NO:23)	VB	O
is	VBN	O
the	IN	O
“first	DT	O
site”.	NN	O
Exemplary	IN	O
mutations	.	O
include	DT	O
the	JJ	O
following	NN	O
constructs:	NN	O
gp140.mut7.modSF162	NN	O
which	IN	O
encodes	DT	O
the	NNP	O
amino	NN	O
acid	NNS	O
sequence	:	O
APTKAISSVVQSEKS	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:24)	,	O
in	WRB	O
the	NNP	O
cleavage	NNP	O
site	NNP	O
region;	)	O
gp140.mut8.modSF162	VBZ	O
which	VBN	O
encodes	DT	O
the	NNP	O
amino	NN	O
acid	CC	O
sequence	NNP	O
APTIAISSVVQSEKS	NNP	O
(SEQ	NNP	O
ID	)	O
NO:25)	VBZ	O
in	DT	O
the	JJ	O
cleavage	.	O
site	JJ	O
region	NNS	O
and	VBP	O
gp140mut.modSF162	DT	O
which	JJ	O
encodes	:	O
the	NN	O
amino	WDT	O
acid	VBZ	O
sequence	DT	O
APTKAKRRVVQREKS	NN	O
(SEQ	JJ	O
ID	NN	O
NO:26).	NNP	O
Mutations	NNP	O
are	NNP	O
denoted	)	O
in	IN	O
bold.	DT	O
The	NN	O
native	NN	O
amino	:	O
acid	CC	O
sequence	WDT	O
in	VBZ	O
the	DT	O
US4	NN	O
cleavage	JJ	O
sites	NN	O
is:	NNP	O
APTQAKRRVVQREKR	NNP	O
(SEQ	NNP	O
ID	)	O
NO:27),	IN	O
where	DT	O
QAKRR	NN	O
(SEQ	NN	O
ID	NN	O
NO:28)	CC	O
is	NN	O
termed	WDT	O
the	VBZ	O
“second”	DT	O
site	NN	O
and	JJ	O
REKR	NN	O
(SEQ	NNP	O
ID	NNP	O
NO:23)	NNP	O
is	.	O
the	NNS	O
“first	VBP	O
site”.	VBN	O
Exemplary	IN	O
mutations	.	O
include	DT	O
the	JJ	O
following	NN	O
construct:	NN	O
gp140.mut.modUS4	NN	O
which	IN	O
encodes	DT	O
the	NNP	O
amino	NN	O
acid	NNS	O
sequence	:	O
APTQAKRRVVQREKS	NNP	O
(SEQ	NNP	O
ID	NNP	O
NO:29)	,	O
in	WRB	O
the	NNP	O
cleavage	NNP	O
site	NNP	O
region.	)	O
Mutations	VBZ	O
are	VBN	O
denoted	DT	O
in	NNP	O
bold.	NN	O
E.	CC	O
Modification	NNP	O
of	NNP	O
HIV-1	NNP	O
Env	)	O
(Envelope)	VBZ	O
Nucleic	DT	O
Acid	JJ	O
Coding	.	O
Sequences	JJ	O
In	NNS	O
one	VBP	O
embodiment	DT	O
of	JJ	O
the	:	O
present	NN	O
invention,	WDT	O
wild-type	VBZ	O
Env	DT	O
coding	NN	O
sequences	JJ	O
were	NN	O
selected	NNP	O
from	NNP	O
the	NNP	O
HIV-1SF162	)	O
(“SF162”)	IN	O
strain	DT	O
(Cheng-Mayer	NN	O
(1989)	NN	O
PNAS	.	O
USA	NNS	O
86:8575-8579).	VBP	O
These	VBN	O
SF162	IN	O
sequences	.	O
were	NNP	O
as	NNP	O
follows:	IN	O
gp120,	NNP	O
SEQ	NNP	O
ID	)	O
NO:30	NNP	O
(FIG.	NNP	O
16);	NNP	O
gp140,	NNPS	O
SEQ	IN	O
ID	CD	O
NO:31	NN	O
(FIG.	IN	O
17);	DT	O
and	JJ	O
gp160,	,	O
SEQ	JJ	O
ID	NNP	O
NO:32	NN	O
(FIG.	NNS	O
18).	VBD	O
In	VBN	O
another	IN	O
embodiment	DT	O
of	NNP	O
the	)	O
present	NN	O
invention,	NNP	O
wild-type	)	O
Env	NNP	O
coding	NNP	O
sequences	.	O
were	DT	O
selected	NNP	O
from	NNS	O
the	VBD	O
HIV-US4	IN	O
strain	:	O
Mascola,	,	B
et	NNP	I
al.	NNP	I
(1994)	NNP	I
J.	.	I
Infect.	:	I
Dis.	,	I
169:48-54).(	NNP	O
These	NNP	O
US4	NNP	O
sequences	.	O
were	:	O
as	CC	O
follows:	,	O
gp120,	NNP	O
SEQ	NNP	O
ID	NNP	O
NO:51	.	O
(FIG.	.	O
38);	IN	O
gp140,	DT	O
SEQ	NN	O
ID	IN	O
NO:52	DT	O
(FIG.	JJ	O
39);	,	O
and	JJ	O
gp160,	NNP	O
SEQ	NN	O
ID	NNS	O
NO:53	VBD	O
(FIG.	VBN	O
40).	IN	O
These	DT	O
Env	NNP	O
coding	NN	O
sequences	,	O
were	RB	O
manipulated	.	O
to	)	O
maximize	NNP	O
expression	.	O
of	.	O
their	.	O
gene	DT	O
products.	NNP	O
First,	NNS	O
the	VBD	O
wild-type	IN	O
coding	:	O
region	,	O
was	NNP	O
modified	NNP	O
in	NNP	O
one	.	O
or	:	O
more	,	O
of	NNP	O
the	NNP	O
following	NNP	O
ways.	.	O
In	:	O
one	CC	O
embodiment,	,	O
sequences	NNP	O
encoding	NNP	O
hypervariable	NNP	O
regions	.	O
of	.	O
Env,	DT	O
particularly	NNP	O
V1	NN	O
and/or	NNS	O
V2	VBD	O
were	VBN	O
deleted.	TO	O
In	VB	O
other	NN	O
embodiments,	IN	O
mutations	PRP$	O
were	NN	O
introduced	.	O
into	,	O
sequences	DT	O
encoding	JJ	O
the	NN	O
cleavage	NN	O
site	VBD	O
in	VBN	O
Env	IN	O
to	CD	O
abrogate	CC	O
the	JJR	O
enzymatic	IN	O
cleavage	DT	O
of	JJ	O
oligomeric	.	O
gp140	IN	O
into	CD	O
gp120	,	O
monomers.	NNS	O
(See,	VBG	O
e.g.,	JJ	O
Earl	NNS	O
et	IN	O
al.	,	O
(1990)	RB	O
PNAS	NNP	O
USA	NN	O
87:648-652;	NNP	O
Earl	VBD	B
et	.	I
al.	IN	I
(1991)	JJ	I
J.	,	I
Virol.	NNS	I
65:31-41).In	VBD	O
yet	VBN	O
other	IN	O
embodiments,	NNS	O
hypervariable	VBG	O
region(s)	DT	O
were	NN	O
deleted,	NN	O
N-glycosylation	IN	O
sites	NNP	O
were	TO	O
removed	VB	O
and/or	DT	O
cleavage	JJ	O
sites	NN	O
mutated.	IN	O
Second,	JJ	O
the	NN	O
HIV-1	IN	O
codon	JJ	O
usage	.	O
pattern	,	O
was	,	O
modified	NNP	O
so	CC	O
that	.	O
the	)	O
resulting	NNP	O
nucleic	NNP	O
acid	:	O
coding	NNP	O
sequence	FW	O
was	.	O
comparable	)	O
to	NNP	O
codon	.	O
usage	.	O
found	IN	O
in	RB	O
highly	JJ	O
expressed	,	O
human	JJ	O
genes.	)	O
The	VBD	O
HIV	,	O
codon	NNP	O
usage	NNS	O
reflects	VBD	O
a	VBN	O
high	JJ	O
content	NN	O
of	NNS	O
the	.	O
nucleotides	,	O
A	DT	O
or	NNP	O
T	NN	O
in	NN	O
the	NN	O
codon-triplet.	VBD	O
The	VBN	O
effect	RB	O
of	IN	O
the	DT	O
HIV-1	VBG	O
codon	JJ	O
usage	NN	O
is	VBG	O
a	NN	O
high	VBD	O
AT	JJ	O
content	TO	O
in	VB	O
the	NN	O
DNA	VBN	O
sequence	IN	O
that	RB	O
results	VBN	O
in	JJ	O
a	.	O
decreased	DT	O
translation	NNP	O
ability	NN	O
and	NN	O
instability	VBZ	O
of	DT	O
the	JJ	O
mRNA.	NN	O
In	IN	O
comparison,	DT	O
highly	NNS	O
expressed	NNP	O
human	CC	O
codons	NNP	O
prefer	IN	O
the	DT	O
nucleotides	.	O
G	DT	O
or	NN	O
C.	IN	O
The	DT	O
Env	NNP	O
coding	NN	O
sequences	NN	O
were	VBZ	O
modified	DT	O
to	JJ	O
be	NNP	O
comparable	NN	O
to	IN	O
codon	DT	O
usage	NN	O
found	NN	O
in	WDT	O
highly	NNS	O
expressed	IN	O
human	DT	O
genes.	JJ	O
FIGS.	NN	O
22A-22H	NN	O
present	CC	O
comparisons	NN	O
of	IN	O
the	DT	O
percent	.	O
A-T	IN	O
content	,	O
for	RB	O
the	VBN	O
cDNAs	JJ	O
of	NNS	O
stable	VBP	O
versus	DT	O
unstable	NNS	O
RNAs	NNP	O
(comparison	CC	O
window	NNP	O
size=50).	DT	O
Human	NNP	O
IFNγ	NN	O
mRNA	NNS	O
is	VBD	O
known	VBN	O
to	TO	O
(i)	VB	O
be	JJ	O
unstable,	TO	O
(ii)	VB	O
have	NN	O
a	VBN	O
short	IN	O
half-life,	RB	O
and	VBN	O
(iii)	JJ	O
have	.	O
a	.	O
high	JJ	O
A-U	JJ	O
content.	NNS	O
Human	IN	O
GAPDH	DT	O
(glyceraldehyde-3-phosphate	NN	O
dehydrogenase)	NNP	O
mRNA	NN	O
is	IN	O
known	DT	O
to	NN	O
(i)	IN	O
be	JJ	O
a	NN	O
stable	JJ	O
RNA,	NNP	O
and	NN	O
(i)	NN	O
have	.	O
a	NNP	O
low	NNP	O
A-U	NN	O
content.	VBZ	O
In	VBN	O
FIGS.	TO	O
22A-H,	)	O
the	VB	O
percent	,	O
A-T	)	O
content	VBP	O
of	DT	O
these	JJ	O
two	,	O
sequences	CC	O
are	)	O
compared	VBP	O
to	DT	O
the	JJ	O
percent	JJ	O
A-T	.	O
content	NNP	O
of	NNP	O
(1)	JJ	O
native	)	O
HIV-1	NN	O
US4	VBZ	O
Env	VBN	O
gp160	TO	O
cDNA,	)	O
a	VB	O
synthetic	DT	O
US4	JJ	O
Env	,	O
gp160	CC	O
cDNA	)	O
sequence	VBP	O
(i.e.,	DT	O
having	JJ	O
modified	NNP	O
codons)	.	O
of	IN	O
the	.	O
present	,	O
invention;	DT	O
and	NN	O
(2)	NNP	O
native	NN	O
HIV-1	IN	O
SF162	DT	O
Env	CD	O
gp160	NNS	O
cDNA,	VBP	O
a	VBN	O
synthetic	TO	O
SF162	DT	O
Env	NN	O
gp160	NNP	O
cDNA	NN	O
sequence	IN	O
(i.e.,	)	O
having	JJ	O
modified	NNP	O
codons)	NNP	O
of	NNP	O
the	NN	O
present	,	O
invention.	DT	O
FIGS.	JJ	O
22A-H	NNP	O
show	NNP	O
the	NN	O
percent	NN	O
A-T	NN	O
content	,	O
over	VBG	O
the	VBN	O
length	)	O
of	IN	O
the	DT	O
sequences	JJ	O
for	:	O
IFNγ	CC	O
(FIGS.	)	O
22C	JJ	O
and	NNP	O
22G);	NNP	O
native	NNP	O
gp160	NN	O
Env	,	O
US4	DT	O
and	JJ	O
SF162	NNP	O
(FIGS.	NNP	O
22A	NN	O
and	NN	O
22E,	NN	O
respectively);	,	O
GAPDH	VBG	O
(FIGS.	VBN	O
22D	)	O
and	IN	O
22H);	DT	O
and	JJ	O
the	.	O
synthetic	.	O
gp160	JJ	O
Env	NN	O
for	DT	O
US4	NN	O
and	NNP	O
SF162	NN	O
(FIGS.	IN	O
22B	DT	O
and	NN	O
22F).	IN	O
Experiments	DT	O
performed	NNS	O
in	IN	O
support	NNP	O
of	.	O
the	CD	O
present	CC	O
invention	:	O
showed	JJ	O
that	NN	O
the	NNP	O
synthetic	NNP	O
Env	CC	O
sequences	NNP	O
were	.	O
capable	CD	O
of	CC	O
higher	,	O
level	:	O
of	NNP	O
protein	.	O
production	CD	O
(see	CC	O
the	:	O
Examples)	CC	O
than	DT	O
the	JJ	O
native	NN	O
Env	NNP	O
sequences.	IN	O
The	NNP	O
data	CC	O
in	NNP	O
FIGS.	.	O
22A-H	CD	O
suggest	CC	O
that	.	O
one	NNS	O
reason	VBN	O
for	IN	O
this	NN	O
increased	IN	O
production	DT	O
is	JJ	O
increased	NN	O
stability	VBD	O
of	IN	O
the	DT	O
mRNA	JJ	O
corresponding	NNP	O
to	NNS	O
the	VBD	O
synthetic	JJ	O
Env	IN	O
coding	JJR	O
sequences	NN	O
versus	IN	O
the	JJ	O
mRNA	NN	O
corresponding	VB	O
to	DT	O
the	)	O
native	IN	O
Env	DT	O
coding	JJ	O
sequences.	NNP	O
To	.	O
create	DT	O
the	NN	O
synthetic	IN	O
coding	.	O
sequences	JJ	O
of	NN	O
the	IN	O
present	CD	O
invention	NN	O
the	IN	O
gene	DT	O
cassettes	VBN	O
were	NN	O
designed	VBZ	O
to	VBN	O
comprise	NN	O
the	IN	O
entire	DT	O
coding	NN	O
sequence	VBG	O
of	TO	O
interest.	DT	O
Synthetic	JJ	O
gene	NNP	O
cassettes	NN	O
were	NNS	O
constructed	VBP	O
by	DT	O
oligonucleotide	NN	O
synthesis	VBG	O
and	TO	O
PCR	DT	O
amplification	JJ	O
to	NNP	O
generate	NN	O
gene	.	O
fragments.	TO	O
Primers	VB	O
were	DT	O
chosen	JJ	O
to	NN	O
provide	NNS	O
convenient	IN	O
restriction	DT	O
sites	JJ	O
for	NN	O
subcloning.	DT	O
The	NN	O
resulting	NNS	O
fragments	VBD	O
were	VBN	O
then	TO	O
ligated	VB	O
to	DT	O
create	JJ	O
the	NN	O
entire	NN	O
desired	IN	O
sequence	.	O
which	JJ	O
was	NN	O
then	NNS	O
cloned	VBD	O
into	VBN	O
an	IN	O
appropriate	JJ	O
vector.	NN	O
The	CC	O
final	NNP	O
synthetic	NN	O
sequences	TO	O
were	VB	O
(i)	NN	O
screened	.	O
by	NNS	O
restriction	VBD	O
endonuclease	VBN	O
digestion	TO	O
and	VB	O
analysis,	JJ	O
(ii)	NN	O
subjected	NNS	O
to	IN	O
DNA	.	O
sequencing	DT	O
in	VBG	O
order	NNS	O
to	VBD	O
confirm	RB	O
that	VBN	O
the	TO	O
desired	VB	O
sequence	DT	O
had	JJ	O
been	VBD	O
obtained	NN	O
and	WDT	O
(iii)	VBD	O
the	RB	O
identity	VBN	O
and	IN	O
integrity	DT	O
of	JJ	O
the	.	O
expressed	DT	O
protein	JJ	O
confirmed	JJ	O
by	NNS	O
SDS-PAGE	VBD	O
and	)	O
Western	VBN	O
blotting	IN	O
(See,	NN	O
Examples.	NN	O
The	NN	O
synthetic	CC	O
coding	,	O
sequences	)	O
were	VBD	O
assembled	TO	O
at	NNP	O
Chiron	VBG	O
Corp.	IN	O
or	NN	O
by	TO	O
the	VB	O
Midland	IN	O
Certified	DT	O
Reagent	JJ	O
Company	NN	O
(Midland,	VBD	O
Tex.).	VBN	O
Exemplary	VBN	O
modified	CC	O
coding	)	O
sequences	DT	O
are	NN	O
presented	CC	O
as	NN	O
synthetic	IN	O
Env	DT	O
expression	JJ	O
cassettes	NN	O
in	VBN	O
Table	IN	O
1A	NNP	O
and	CC	O
1B.	NNP	O
The	NN	O
following	,	O
expression	.	O
cassettes	DT	O
(i)	JJ	O
have	NN	O
unique,	NNS	O
terminal	VBD	O
EcoRI	VBN	O
and	IN	O
XbaI	NNP	O
cloning	NNP	O
sites;	CC	O
(ii)	IN	O
include	DT	O
Kozak	NNP	O
sequences	NNP	O
to	NNP	O
promote	NNP	O
optimal	,	O
translation;	.	O
(iii)	NNP	O
tPA	VBD	O
signal	VBG	O
sequences	NNS	O
(to	VBP	O
direct	VBN	O
the	IN	O
ENV	JJ	O
polypeptide	NNP	O
to	NN	O
the	NNS	O
cell	IN	O
membrane,	JJ	O
see,	CD	O
e.g.,	CC	O
Chapman	.	O
et	DT	O
al.,	JJ	O
infra);	NN	O
(iv)	NNS	O
open	)	O
reading	VBP	O
frames	,	O
optimized	JJ	O
for	NNP	O
expression	CC	O
in	NNP	O
mammalian	VBG	O
cells;	:	O
and	)	O
(v)	VBP	O
a	NNP	O
translational	NNS	O
stop	TO	O
signal	VB	O
codon.	JJ	O
Alignments	:	O
of	)	O
the	VBZ	O
sequences	JJ	O
presented	NNS	O
in	TO	O
the	VB	O
above	DT	O
tables	NNP	O
are	NN	O
presented	TO	O
in	DT	O
FIGS.	NN	O
66A	,	O
and	,	O
66B.	,	O
A	NNP	O
common	VBZ	O
region	,	O
(Env-common)	:	O
extends	)	O
from	JJ	O
nucleotide	VBG	O
position	NNS	O
1186	VBN	O
to	IN	O
nucleotide	NN	O
position	IN	O
1329	JJ	O
(SEQ	:	O
ID	CC	O
NO:69,	)	O
FIG.	DT	O
56)	JJ	O
relative	JJ	O
to	NN	O
the	.	O
wild-type	NNS	O
US4	IN	O
sequence	DT	O
and	NNS	O
from	VBN	O
nucleotide	IN	O
position	DT	O
1117	JJ	O
to	NNS	O
position	VBP	O
1260	VBN	O
(SEQ	IN	O
ID	.	O
NO:79,	CD	O
FIG.	CC	O
57)	.	O
relative	DT	O
to	JJ	O
the	NN	O
wild-type	)	O
SF162	VBZ	O
sequence.	IN	O
The	JJ	O
synthetic	NN	O
sequences	CD	O
of	TO	O
the	VB	O
present	NN	O
invention	CD	O
corresponding	NNP	O
to	NNP	O
these	,	O
regions	.	O
are	)	O
presented,	NN	O
as	TO	O
SEQ	DT	O
ID	JJ	O
NO:71	NNP	O
(FIG.	NN	O
58)	CC	O
for	IN	O
the	JJ	O
synthetic	NN	O
Env	CD	O
US4	TO	O
common	NN	O
region	CD	O
and	NNP	O
as	NNP	O
SEQ	,	O
ID	.	O
NO:72	)	O
(FIG.	NN	O
59)	TO	O
for	DT	O
the	JJ	O
synthetic	NNP	O
Env	.	O
SF162	DT	O
common	JJ	O
region.	NNS	O
Percent	IN	O
identity	DT	O
to	JJ	O
this	NN	O
sequence	VBG	O
can	TO	O
be	DT	O
determined,	NNS	O
for	VBP	O
example,	,	O
using	IN	O
the	NNP	O
Smith-Waterman	NNP	O
search	NNP	O
algorithm	.	O
(Time	)	O
Logic,	IN	O
Incline	DT	O
Village,	JJ	O
Nev.),	NNP	O
with	NNP	O
the	JJ	O
following	NN	O
exemplary	CC	O
parameters:	IN	O
weight	NNP	O
matrix=nuc4×4hb;	NNP	O
gap	NNP	O
opening	.	O
penalty=20,	)	O
gap	IN	O
extension	DT	O
penalty=5,	JJ	O
reporting	NNP	O
threshold=1;	NNP	O
alignment	JJ	O
threshold=20.	.	O
Various	NN	O
forms	NN	O
of	TO	O
the	DT	O
different	NN	O
embodiments	MD	O
of	VB	O
the	,	O
present	IN	O
invention	,	O
(e.g.,	VBG	O
constructs)	DT	O
may	JJ	O
be	NN	O
combined.	NN	O
F.	NNP	O
Cloning	,	O
Synthetic	NNP	O
Env	,	O
Expression	,	O
Cassettes	IN	O
of	DT	O
the	JJ	O
Present	JJ	O
Invention.	:	O
The	NN	O
synthetic	:	O
DNA	CC	O
fragments	VBG	O
encoding	,	O
the	NN	O
Env	NN	O
polypeptides	,	O
were	VBG	O
typically	:	O
cloned	JJ	O
into	.	O
the	JJ	O
eucaryotic	NNS	O
expression	IN	O
vectors	DT	O
described	JJ	O
above	NNS	O
for	IN	O
Gag,	DT	O
for	JJ	O
example,	NN	O
pCMVKm2/pCMVlink	,	O
(FIG.	)	O
4),	MD	O
pCMV6a,	VB	O
pESN2dhfr	.	O
(FIG.	NNP	O
13A),	NNP	O
pCMVIII	NNP	O
(FIG.	NNP	O
13B;	NNP	O
alternately	NNP	O
designated	IN	O
as	DT	O
the	JJ	O
pCMV-PL-E-dhfr/neo	.	O
vector).	DT	O
Exemplary	JJ	O
designations	NN	O
for	NNS	O
pCMVlink	VBG	O
vectors	DT	O
containing	NNP	O
synthetic	NNS	O
expression	VBD	O
cassettes	RB	O
of	VBN	O
the	IN	O
present	DT	O
invention	JJ	O
are	NN	O
as	NNS	O
follows:	VBD	O
pCMVlink.gp140.modSF162;	IN	O
pCMVlink.gp140.-modSF162.delV2;	IN	O
pCMVlink.gp140.mut.modSF162;	,	O
pCMVlink.gp140.mut.modSF162.delV2;	IN	O
pCMVKm2.gp140modUS4;	,	O
pCMVKm2.9p140.modUS4.delV2;	NN	O
pCMVKm2.gp140.mut.modUS4;	.	O
and,	,	O
pCMVKm2.gp140.mut.modUS4.delV1/V2.	,	O
G.	NN	O
Generation	.	O
of	,	O
Synthetic	FW	O
Tat	.	O
Expression	:	O
Cassettes	RB	O
Tat	VBN	O
coding	IN	O
sequences	DT	O
have	JJ	O
also	.	O
been	JJ	O
modified	NNS	O
according	IN	O
to	NN	O
the	NNS	O
teachings	VBG	O
of	JJ	O
the	NN	O
present	NNS	O
specification.	IN	O
The	DT	O
wild	JJ	O
type	NN	O
nucleotide	VBP	O
sequence	IN	O
encoding	:	O
tat	:	O
from	:	O
variant	:	O
SF162	:	O
is	:	O
presented	:	O
in	:	O
FIG.	,	O
76	.	O
(SEQ	NNP	O
ID	NNP	O
NO:85).	IN	O
The	NNP	O
corresponding	NNP	O
wild-type	NNP	O
amino	NNP	O
acid	NNP	O
sequence	VBG	O
is	NNS	O
presented	VBP	O
in	RB	O
FIG.	VBN	O
77	VBN	O
(SEQ	VBG	O
ID	TO	O
NO:86).	DT	O
FIG.	NNS	O
81	IN	O
(SEQ	DT	O
ID	JJ	O
NO:89)	.	O
shows	DT	O
the	JJ	O
nucleotide	NN	O
sequence	NN	O
encoding	NN	O
the	VBG	O
amino	NN	O
terminal	IN	O
of	JJ	O
the	NNP	O
tat	VBZ	O
protein	VBN	O
and	IN	O
the	.	O
codon	CD	O
encoding	NNP	O
cystein-22	NNP	O
is	.	O
underlined.	DT	O
Other	JJ	O
exemplary	JJ	O
constructs	NN	O
encoding	NN	O
synthetic	NN	O
tat	VBZ	O
polypeptides	VBN	O
are	IN	O
shown	.	O
in	CD	O
FIGS.	NNP	O
78	NNP	O
and	.	O
79	.	O
(SEQ	CD	O
ID	NNP	O
NOs:87	NNP	O
and	)	O
88).	VBZ	O
In	DT	O
one	JJ	O
embodiment	NN	O
(SEQ	VBG	O
ID	DT	O
NO:88),	JJ	O
the	NN	O
cystein	IN	O
residue	DT	O
at	NN	O
position	NN	O
22	CC	O
is	DT	O
replaced	NN	O
by	VBG	O
a	NN	O
glycine.	VBZ	O
Caputo	.	B
et	JJ	I
al.	JJ	I
(1996)	NNS	I
Gene	VBG	I
Therapy	JJ	I
3:235	NN	I
have	NNS	O
shown	VBP	O
that	VBN	O
this	IN	O
mutation	.	O
affects	CD	O
the	CC	O
trans	CD	O
activation	NNP	O
domain	NNP	O
of	NNP	O
Tat.	CC	O
Various	.	O
forms	IN	O
of	CD	O
the	NN	O
different	NNP	O
embodiments	NNP	O
of	,	O
the	DT	O
invention,	NN	O
described	NN	O
herein,	IN	O
may	NN	O
be	CD	O
combined.	VBZ	O
H.	VBN	O
Deposit	IN	O
of	DT	O
Vectors	.	O
Selected	NNP	O
exemplary	CC	O
constructs	.	O
shown	)	O
below	NNP	O
and	NNP	O
described	CD	O
herein	VBP	O
are	VBN	O
deposited	IN	O
at	DT	O
Chiron	NN	O
Corporation,	VBZ	O
Emeryville,	DT	O
Calif.,	NNS	O
94662-8097,	VBP	O
and	NN	O
were	IN	O
sent	.	O
to	JJ	O
the	NNS	O
American	IN	O
Type	DT	O
Culture	JJ	O
Collection,	NNS	O
10801	IN	O
University	DT	O
Boulevard,	,	O
Manassas,	VBN	O
Va.	,	O
20110-2209	MD	O
on	VB	O
Dec.	.	O
27,	NNP	O
1999.	NNP	O
Example	IN	O
2	NNP	O
Expression	NNP	O
Assays	JJ	O
for	NNS	O
the	VBN	O
Synthetic	IN	O
Gag,	CC	O
Env	VBD	O
and	NNS	O
Tat	VBP	O
Coding	VBN	O
Sequences	IN	O
A.	NNP	O
Gag	,	O
and	,	O
Gag-Protease	,	O
Coding	,	O
Sequences	CC	O
The	VBD	O
HIV-1SF2	VBN	O
wild-type	TO	O
Gag	DT	O
(SEQ	JJ	O
ID	NNP	O
NO:1)	NNP	O
and	,	O
Gag-protease	CD	O
(SEQ	NNP	O
ID	,	O
NO:2)	,	O
sequences	NNP	O
were	CD	O
cloned	IN	O
into	NNP	O
expression	,	O
vectors	.	O
having	RB	O
the	CD	O
same	NNP	O
features	NNP	O
as	IN	O
the	DT	O
vectors	NNP	O
into	,	O
which	NNP	O
the	CC	O
synthetic	NNP	O
Gag	NNP	O
(SEQ	NNP	O
ID	NN	O
NO:4)	NNP	O
and	CC	O
Gag-protease	NNP	O
(SEQ	NNP	O
ID	VBZ	O
NOs:5,	DT	O
78	JJ	O
or	JJ	O
79))	NNP	O
sequences	NNP	O
were	NNP	O
cloned.	)	O
Expression	CC	O
efficiencies	NNP	O
for	NNP	O
various	NNP	O
vectors	)	O
carrying	NNS	O
the	VBD	O
HIV-15F2	VBN	O
wild-type	IN	O
and	NN	O
synthetic	NNS	O
Gag	VBG	O
sequences	DT	O
were	JJ	O
evaluated	NNS	O
as	IN	O
follows.	DT	O
Cells	NNS	O
from	IN	O
several	WDT	O
mammalian	DT	O
cell	JJ	O
lines	NNP	O
(293,	NNP	O
RD,	NNP	O
COS-7,	)	O
and	CC	O
CHO;	NNP	O
all	NNP	O
obtained	NNP	O
from	,	O
the	CD	O
American	CC	O
Type	)	O
Culture	NNS	O
Collection,	VBD	O
10801	.	O
University	NN	O
Boulevard,	NNS	O
Manassas,	IN	O
Va.	JJ	O
20110-2209)	NNS	O
were	VBG	O
transfected	DT	O
with	NNP	O
2	NN	O
μg	CC	O
of	JJ	O
DNA	NNP	O
in	NNS	O
transfection	VBD	O
reagent	VBN	O
LT1	IN	O
(PanVera	.	O
Corporation,	NNS	O
545	IN	O
Science	JJ	O
Dr.,	JJ	O
Madison,	NN	O
Wis.).	NNS	O
The	,	O
cells	,	O
were	,	O
incubated	CC	O
for	:	O
5	DT	O
hours	VBN	O
in	IN	O
reduced	DT	O
serum	JJ	O
medium	NNP	O
(Opti-MEM,	NNP	O
Gibco-BRL,	,	O
Gaithersburg,	CD	O
Md.).	NNP	O
The	,	O
medium	,	O
was	NNP	O
then	)	O
replaced	VBD	O
with	VBN	O
normal	IN	O
medium	CD	O
as	NNS	O
follows:	IN	O
293	NN	O
cells,	IN	O
IMDM,	NN	O
10%	NN	O
fetal	NNP	O
calf	NNP	O
serum,	,	O
2%	CD	O
glutamine	NNP	O
(BioWhittaker,	,	O
Walkersville,	,	O
Md.);	.	O
RD	DT	O
and	NNS	O
COS-7	VBD	O
cells,	VBN	O
D-MEM,	IN	O
10%	CD	O
fetal	NNS	O
calf	IN	O
serum,	JJ	O
2%	NN	O
glutamine	NN	O
(Opti-MEM,	,	O
Gibco-BRL,	,	O
Gaithersburg,	,	O
Md.);	.	O
and	DT	O
CHO	NN	O
cells,	VBD	O
Ham's	RB	O
F-12,	VBN	O
10%	IN	O
fetal	JJ	O
calf	NN	O
serum,	IN	O
2%	:	O
glutamine	CD	O
(Opti-MEM,	,	O
Gibco-BRL,	,	O
Gaithersburg,	NN	O
Md.).	JJ	O
The	NN	O
cells	,	O
were	NN	O
incubated	NN	O
for	,	O
either	,	O
48	:	O
or	NNP	O
60	CC	O
hours.	NNP	O
Supernatants	,	O
were	,	O
harvested	NN	O
and	JJ	O
filtered	NN	O
through	,	O
0.45	NN	O
μm	NN	O
syringe	,	O
filters	,	O
and,	,	O
optionally,	:	O
stored	CC	O
at	NNP	O
−20°	,	O
C.	POS	O
Supernatants	,	O
were	NN	O
evaluated	JJ	O
using	NN	O
the	,	O
Coulter	NN	O
p24-assay	NN	O
(Coulter	,	O
Corporation,	,	O
Hialeah,	,	O
Fla.,	.	O
US),	DT	O
using	NNS	O
96-well	VBD	O
plates	VBN	O
coated	IN	O
with	DT	O
a	CD	O
murine	CC	O
monoclonal	CD	O
antibody	.	O
directed	NNS	O
against	VBD	O
HIV	VBN	O
core	CC	O
antigen.	VBN	O
The	IN	O
HIV-1	CD	O
p24	JJ	O
antigen	NN	O
binds	NNS	O
to	,	O
the	,	O
coated	VBD	O
wells.	IN	O
Biotinylated	NNP	O
antibodies	NNP	O
against	NNP	O
HIV	VBD	O
recognize	VBN	O
the	VBG	O
bound	DT	O
p24	NNP	O
antigen.	NN	O
Conjugated	NNP	O
strepavidin-horseradish	,	O
peroxidase	,	O
reacts	,	O
with	,	O
the	VBG	O
biotin.	CD	O
Color	NNS	O
develops	VBN	O
from	IN	O
the	DT	O
reaction	JJ	O
of	JJ	O
peroxidase	NN	O
with	VBN	O
TMB	IN	O
substrate.	NNP	O
The	NN	O
reaction	.	O
is	DT	O
terminated	NNP	O
by	NN	O
addition	NN	O
of	VBZ	O
4NH2SO4.	TO	O
The	DT	O
intensity	VBN	O
of	.	O
the	JJ	O
color	NNS	O
is	IN	O
directly	NNP	O
proportional	VBP	O
to	DT	O
the	NN	O
amount	NN	O
of	.	O
HIV	VBN	O
p24	JJ	O
antigen	NN	O
in	NNS	O
a	IN	O
sample.	DT	O
The	.	O
results	NNP	O
of	VBZ	O
these	IN	O
expression	DT	O
assays	NN	O
are	IN	O
presented	NN	O
in	IN	O
Tables	NNP	O
2A	.	O
and	DT	O
2B.	NN	O
Tables	VBZ	O
2A	VBN	O
and	IN	O
2B	NN	O
shows	IN	O
data	.	O
obtained	DT	O
using	NN	O
the	IN	O
synthetic	DT	O
Gag-protease	NN	O
expression	VBZ	O
cassette	RB	O
of	JJ	O
SEQ	TO	O
ID	DT	O
NO:5.	NN	O
Similar	IN	O
results	NNP	O
were	NN	O
obtained	NN	O
using	IN	O
the	DT	O
Gag-protease	.	O
expression	DT	O
cassettes	NNS	O
of	IN	O
SEQ	DT	O
ID	NN	O
NOs:78	NNS	O
and	VBP	O
79.	VBN	O
Table	IN	O
2:	NNP	O
In	CD	O
Vitro	CC	O
Gag	.	O
and	NNS	O
Gagprot	CD	O
p24	CC	O
Expression	CD	O
The	NNS	O
data	NNS	O
showed	VBD	O
that	VBG	O
the	DT	O
synthetic	JJ	O
Gag	NNP	O
and	NN	O
Gag-protease	NN	O
expression	IN	O
cassettes	NNP	O
provided	NNP	O
dramatic	.	O
increases	JJ	O
in	NNS	O
production	VBD	O
of	VBN	O
their	VBG	O
protein	DT	O
products,	NNP	O
relative	NN	O
to	NNS	O
the	IN	O
native	NNP	O
(HIV-1SF2	NNP	O
wild-type)	NNP	O
sequences,	CC	O
when	.	O
expressed	JJ	O
in	:	O
a	IN	O
variety	NNP	O
of	NNP	O
cell	CC	O
lines.	NNP	O
B.	VBP	O
Env	NNP	O
Coding	DT	O
Sequences	NN	O
The	VBD	O
HIV-SF162	IN	O
(“SF162”)	DT	O
wild-type	JJ	O
Env	NNP	O
(SEQ	CC	O
ID	NNP	O
NO:1-3)	NN	O
and	NNS	O
HIV-US4	VBD	O
(“US4”)	JJ	O
wild-type	NNS	O
Env	IN	O
(SEQ	NN	O
ID	IN	O
NO:22-24)	PRP$	O
sequences	NN	O
were	,	O
cloned	JJ	O
into	TO	O
expression	DT	O
vectors	JJ	O
having	NNP	O
the	)	O
same	,	O
features	WRB	O
as	VBN	O
the	IN	O
vectors	DT	O
into	NN	O
which	IN	O
the	NN	O
synthetic	.	O
Env	NNP	O
sequences	NNP	O
were	NNP	O
cloned.	VBZ	O
Expression	DT	O
efficiencies	NNP	O
for	)	O
various	NN	O
vectors	NNP	O
carrying	NNP	O
the	NNP	O
SF162	)	O
and	CC	O
US4	NNP	O
wild-type	)	O
and	NN	O
synthetic	NNP	O
Env	NNP	O
sequences	NNP	O
were	)	O
evaluated	NNS	O
essentially	VBD	O
as	VBN	O
described	IN	O
above	NN	O
for	NNS	O
Gag	VBG	O
except	DT	O
that	JJ	O
cell	NNS	O
lysates	IN	O
were	DT	O
prepared	NNS	O
in	IN	O
40	WDT	O
μl	DT	O
lysis	JJ	O
buffer	NNP	O
(1.0%	NNS	O
NP40,	VBD	O
0.1	.	O
M	NN	O
Tris	NNS	O
pH	IN	O
7.5)	JJ	O
and	NNS	O
frozen	VBG	O
at	DT	O
−20°	NNP	O
C.	CC	O
and	NNP	O
capture	NN	O
ELISAs	CC	O
were	JJ	O
performed	NNP	O
as	NNS	O
follows.	VBD	O
For	VBN	O
Capture	RB	O
ELISAs,	IN	O
250	VBN	O
ng	IN	O
of	IN	O
an	NNP	O
ammonium	IN	O
sulfate	DT	O
IgG	NN	O
cut	VBZ	O
of	VBD	O
goat	VBN	O
polyclonal	IN	O
antibody	CD	O
to	JJ	O
gp120SF2/env2-3	NN	O
was	NN	O
used	NN	O
to	,	O
coat	CD	O
each	NNP	O
well	NNP	O
of	VBZ	O
a	)	O
96-well	CC	O
plate	JJ	O
(Corning,	IN	O
Corning,	NNP	O
N.	NNP	O
Y.).	CC	O
Serial	NN	O
dilutions	NNP	O
of	VBD	O
gp120/SF2	VBN	O
protein	IN	O
(MID	.	O
167)	IN	O
were	NNP	O
used	,	O
to	CD	O
set	NN	O
the	IN	O
quantitation	DT	O
curve	NN	O
from	NN	O
which	NNP	O
expression	NN	O
of	IN	O
US4	NN	O
or	JJ	O
SF162	NN	O
gp120	TO	O
proteins	NN	O
from	VBD	O
transfection	VBN	O
supernatant	TO	O
and	VB	O
lysates	DT	O
were	NN	O
calculated.	IN	O
Samples	DT	O
were	JJ	O
screened	NN	O
undiluted	,	O
and,	,	O
optionally,	.	O
by	.	O
serial	JJ	O
2-fold	NNS	O
dilutions.	IN	O
A	NN	O
human	NN	O
polyclonal	NNP	O
antibody	)	O
to	VBD	O
HIV-1	VBN	O
gp120/SF2	TO	O
was	VB	O
used	DT	O
to	NN	O
detect	NN	O
bound	IN	O
gp120	WDT	O
envelope	NN	O
protein,	IN	O
followed	NNP	O
by	CC	O
horse-radish	NNP	O
peroxidase	VBP	O
(HRP)-labeled	NNS	O
goat	IN	O
anti-human	NN	O
IgG	NN	O
conjugates.	CC	O
TME	NNS	O
(Pierce,	VBD	O
Rockford,	.	O
Ill.)	NNS	O
was	VBD	O
used	VBN	O
as	JJ	O
the	,	O
substrate	,	O
and	IN	O
the	JJ	O
reaction	JJ	O
is	.	O
terminated	DT	O
by	JJ	O
addition	JJ	O
of	NN	O
4N	TO	O
H2SO4.	NNP	O
The	NN	O
reaction	VBD	O
was	VBN	O
quantified	TO	O
by	VB	O
measuring	NN	O
the	FW	O
optical	NN	O
density	,	O
(OD)	VBN	O
at	IN	O
450	JJ	O
nm.	NN	O
The	VBD	O
intensity	JJ	O
of	JJ	O
the	NNP	O
color	.	O
is	NNP	O
directly	,	O
proportional	,	O
to	)	O
the	VBD	O
amount	VBN	O
of	IN	O
HIV	DT	O
gp120	NN	O
antigen	CC	O
in	DT	O
a	NN	O
sample.	VBZ	O
Purified	VBN	O
SF2	IN	O
gp120	NN	O
protein	IN	O
was	CD	O
diluted	.	O
and	DT	O
used	NN	O
as	VBD	O
a	VBN	O
standard.	IN	O
The	VBG	O
results	DT	O
of	JJ	O
the	NN	O
transient	)	O
expression	IN	O
assays	CD	O
are	.	O
presented	DT	O
in	NN	O
Tables	IN	O
3	DT	O
and	NN	O
4.	VBZ	O
Table	RB	O
3	JJ	O
depicts	TO	O
transient	DT	O
expression	NN	O
in	IN	O
293	NNP	O
cells	NN	O
transfected	NN	O
with	IN	O
a	DT	O
pCMVKm2	.	O
vector	NNP	O
carrying	NNP	O
the	NN	O
Env	NN	O
cassette	VBD	O
of	VBN	O
interest.	CC	O
Table	VBN	O
4	IN	O
depicts	DT	O
transient	.	O
expression	DT	O
in	NNS	O
RD	IN	O
cells	DT	O
transfected	JJ	O
with	NN	O
a	NNS	O
pCMVKm2	VBP	O
vector	VBN	O
carrying	IN	O
the	NNP	O
Env	CD	O
cassette	CC	O
of	.	O
interest.	JJ	O
The	CD	O
data	NNS	O
showed	JJ	O
that	NN	O
the	IN	O
synthetic	CD	O
Env	NNS	O
and	VBN	O
expression	IN	O
cassettes	DT	O
provided	NN	O
a	NN	O
significant	VBG	O
increase	DT	O
in	NNP	O
production	NN	O
of	IN	O
their	.	O
protein	JJ	O
products,	CD	O
relative	NNS	O
to	JJ	O
the	NN	O
native	IN	O
(HIV-1SF162	NNP	O
or	NNS	O
US4	VBN	O
wild-type)	IN	O
sequences,	DT	O
when	NN	O
expressed	NN	O
in	VBG	O
a	DT	O
variety	NNP	O
of	NN	O
cell	IN	O
lines.	.	O
C.	DT	O
CHO	NN	O
Cell	VBD	O
Line	IN	O
Env	DT	O
Expression	JJ	O
Data	NNP	O
Chinese	CC	O
hamster	NN	O
ovary	NNS	O
(CHO)	VBD	O
cells	DT	O
were	JJ	O
transfected	NN	O
with	IN	O
plasmid	NN	O
DNA	IN	O
encoding	PRP$	O
the	NN	O
synthetic	,	O
HIV-1	JJ	O
gp120	TO	O
or	DT	O
gp140	JJ	O
proteins	NNP	O
(e.g.,	CC	O
pESN2dhfr	NNP	O
or	)	O
pCMVIII	,	O
vector	WRB	O
backbone)	VBN	O
using	IN	O
Mirus	DT	O
TransIT-LT1	NN	O
polyamine	IN	O
transfection	NN	O
reagent	.	O
(Pan	NNP	O
Vera)	NNP	O
according	NNP	O
to	NNP	O
the	NNP	O
manufacturers	NNP	O
instructions	NNP	O
and	NNP	O
incubated	NN	O
for	NN	O
96	)	O
hours.	NNS	O
After	VBD	O
96	VBN	O
hours,	IN	O
media	JJ	O
was	NNP	O
changed	VBG	O
to	DT	O
selective	JJ	O
media	NNP	O
(F12	NN	O
special	CC	O
with	NN	O
250	NNS	O
μg/ml	,	O
G418)	NN	O
and	CC	O
cells	NN	O
were	NN	O
split	)	O
1:5	VBG	O
and	NNP	O
incubated	NNP	O
for	NN	O
an	NN	O
additional	NN	O
48	NNP	O
hours.	)	O
Media	VBG	O
was	TO	O
changed	DT	O
every	NNS	O
5-7	NNS	O
days	CC	O
until	VBN	O
colonies	IN	O
started	CD	O
forming	.	O
at	IN	O
which	CD	O
time	,	O
the	NNS	O
colonies	VBD	O
were	VBN	O
picked,	TO	O
plated	JJ	O
into	NNS	O
96	NNP	O
well	JJ	O
plates	IN	O
and	CD	O
screened	NNS	O
by	)	O
gp120	CC	O
Capture	NNS	O
ELISA.	VBD	O
Positive	JJ	O
clones	CD	O
were	CC	O
expanded	VBD	O
in	IN	O
24	DT	O
well	JJ	O
plates	CD	O
and	.	O
screened	NNP	O
several	VBD	O
times	VBN	O
for	DT	O
Env	JJ	O
protein	NNS	O
production	IN	O
by	NNS	O
Capture	VBD	O
ELISA,	VBG	O
as	IN	O
described	WDT	O
above.	NN	O
After	DT	O
reaching	NNS	O
confluency	VBD	O
in	,	O
24	VBN	O
well	IN	O
plates,	CD	O
positive	RB	O
clones	NNS	O
were	CC	O
expanded	VBN	O
to	IN	O
T25	JJ	O
flasks	NNP	O
(Corning,	.	O
Corning,	JJ	O
N.	NNS	O
Y.).	VBD	O
These	VBN	O
were	IN	O
screened	CD	O
several	RB	O
times	NNS	O
after	CC	O
confluency	VBD	O
and	JJ	O
positive	NNS	O
clones	IN	O
were	NNP	O
expanded	NN	O
to	NN	O
T75	IN	O
flasks.	NNP	O
Positive	,	O
T75	IN	O
clones	VBN	O
were	.	O
frozen	IN	O
in	VBG	O
LN2	NN	O
and	IN	O
the	CD	O
highest	RB	O
expressing	,	O
clones	JJ	O
amplified	NNS	O
with	VBD	O
0-5	VBN	O
μM	TO	O
methotrexate	NNP	O
(MTX)	NNS	O
at	,	O
several	,	O
concentrations	.	O
and	.	O
plated	DT	O
in	VBD	O
100	VBN	O
mm	JJ	O
culture	NNS	O
dishes.	IN	O
Plates	NN	O
were	CC	O
screened	JJ	O
for	NNS	O
colony	VBD	O
formation	VBN	O
and	TO	O
all	NNP	O
positive	.	O
closed	JJ	O
were	NNP	O
again	NNS	O
expanded	VBD	O
as	VBN	O
described	IN	O
above.	NNP	O
Clones	CC	O
were	DT	O
expanded	JJS	O
an	NN	O
amplified	NNS	O
and	VBN	O
screened	IN	O
at	JJ	O
each	NN	O
step	NN	O
by	)	O
gp120	IN	O
capture	JJ	O
ELISA.	NNS	O
Positive	CC	O
clones	VBN	O
were	IN	O
frozen	CD	O
at	JJ	O
each	NN	O
methotrexate	.	O
level.	NNS	O
Highest	VBD	O
producing	VBN	O
clones	IN	O
were	NN	O
grown	NN	O
in	CC	O
perfusion	DT	O
bioreactors	JJ	O
(3L,	VBN	O
100L)	VBD	O
for	RB	O
expansion	VBN	O
and	IN	O
adaptation	VBN	O
to	.	O
low	NNS	O
serum	VBD	O
suspension	VBN	O
culture	DT	O
conditions	JJ	O
for	CC	O
scale-up	VBN	O
to	IN	O
larger	DT	O
bioreactors.	NN	O
Tables	IN	O
5	JJ	O
and	NN	O
6	.	O
show	JJ	O
Capture	NNS	O
ELISA	VBD	O
data	VBN	O
from	IN	O
CHO	DT	O
cells	NN	O
transfected	.	O
with	NNP	O
pCMVIII	VBG	O
vector	NNS	O
carrying	VBD	O
a	VBN	O
cassette	IN	O
encoding	NN	O
synthetic	NNS	O
HIV-US4	,	O
and	)	O
SF162	IN	O
Env	NN	O
polypeptides	CC	O
(e.g.,	NN	O
mutated	TO	O
cleavage	JJ	O
sites,	NN	O
modified	NN	O
codon	NN	O
usage	NNS	O
and/or	IN	O
deleted	NN	O
hypervariable	TO	O
regions).	JJR	O
Thus,	.	O
stably	NNS	O
transfected	CD	O
CHO	CC	O
cell	CD	O
lines	NN	O
which	NNP	O
express	NNP	O
Env	NNS	O
polypeptides	IN	O
(e.g.,	NNP	O
gp120,	NNS	O
gp140-monomeric,	VBD	O
and	IN	O
gp140-oligomeric)	JJ	O
have	NN	O
been	VBG	O
produced.	DT	O
The	NN	O
results	VBG	O
presented	JJ	O
above	NNP	O
demonstrate	CC	O
the	NNP	O
ability	NNP	O
of	NNS	O
the	,	O
constructs	VBN	O
of	NN	O
the	,	O
present	VBD	O
invention	JJ	O
to	JJ	O
provide	NN	O
expression	VBD	O
of	JJ	O
Env	.	O
polypeptides	,	O
in	RB	O
CHO	VBD	O
cells.	NNP	O
Production	NN	O
of	NNS	O
polypeptides	WDT	O
using	VBP	O
CHO	NNP	O
cells	NNS	O
provides	,	O
(i)	,	O
correct	,	O
glycosylation	CC	O
patterns	)	O
and	VBP	O
protein	VBN	O
conformation	.	O
(as	DT	O
determined	NNS	O
by	VBN	O
binding	IN	O
to	NN	O
panel	DT	O
of	NN	O
MAbs);	IN	O
(ii)	DT	O
correct	NNS	O
binding	IN	O
to	DT	O
CD4	JJ	O
receptor	NN	O
molecules;	TO	O
(iii)	VB	O
absence	NN	O
of	IN	O
non-mammalian	NNP	O
cell	NNS	O
contaminants	IN	O
(e.g.,	NNP	O
insect	.	O
viruses	NN	O
and/or	IN	O
cells);	NNS	O
and	VBG	O
(iv)	NNP	O
ease	NNS	O
of	VBZ	O
purification.	)	O
D.	VBP	O
Tat	NN	O
Coding	NNS	O
Sequences	CC	O
The	JJ	O
HIV-SF162	NN	O
(“SF162”)	IN	O
wild-type	VBN	O
Tat	IN	O
(SEQ	VBG	O
ID	TO	O
NO:85)	NN	O
sequences	IN	O
were	:	O
cloned	)	O
into	VBP	O
expression	VBG	O
vectors	TO	O
having	NNP	O
the	NN	O
same	:	O
features	)	O
as	NN	O
the	IN	O
vectors	JJ	O
into	NN	O
which	NNS	O
the	,	O
synthetic	JJ	O
Tat	NNS	O
sequences	VBP	O
were	:	O
cloned	CC	O
(SEQ	)	O
ID	NN	O
NOs:87,	IN	O
88	.	O
and	NNP	O
89).	NNP	O
Expression	NNP	O
efficiencies	VBZ	O
for	DT	O
various	NNP	O
vectors	)	O
carrying	NN	O
the	NNP	O
SF162	NNP	O
wild-type	NNP	O
and	)	O
synthetic	NNS	O
Tat	VBD	O
sequences	VBN	O
are	IN	O
evaluated	NN	O
essentially	NNS	O
as	VBG	O
described	DT	O
above	JJ	O
for	NNS	O
Gag	IN	O
and	DT	O
Env	NNS	O
using	IN	O
capture	WDT	O
ELISAs	DT	O
with	JJ	O
the	NNP	O
appropriate	NNS	O
anti-tat	VBD	O
antibodies	VBN	O
and/or	NNP	O
CHO	NNP	O
cell	,	O
assays.	CD	O
Expression	CC	O
of	.	O
the	NN	O
polypeptides	NNS	O
encoded	IN	O
by	JJ	O
the	NNS	O
synthetic	VBG	O
cassettes	DT	O
is	NNP	O
improved	NN	O
relative	CC	O
to	JJ	O
wild	NNP	O
type.	NNS	O
Example	VBP	O
3	VBN	O
Western	RB	O
Blot	IN	O
Analysis	VBN	O
of	IN	O
Expression	IN	O
A.	NNP	O
Gag	CC	O
and	NNP	O
Gag-Protease	VBG	O
Coding	NN	O
Sequences	NNP	O
Human	IN	O
293	DT	O
cells	JJ	O
were	JJ	O
transfected	NNS	O
as	VBP	O
described	NNP	O
in	NN	O
Example	.	O
2	NN	O
with	IN	O
pCMV6a-based	DT	O
vectors	NNS	O
containing	VBN	O
native	IN	O
or	DT	O
synthetic	JJ	O
Gag	NNS	O
expression	VBZ	O
cassettes.	JJ	O
Cells	JJ	O
were	TO	O
cultivated	VB	O
for	.	O
60	RB	O
hours	CD	O
post-transfection.	JJ	O
Supernatants	NNP	O
were	NNP	O
prepared	IN	O
as	NNP	O
described.	NNP	O
Cell	NNP	O
lysates	CC	O
were	NNP	O
prepared	NNP	O
as	NNP	O
follows.	NNP	O
The	CD	O
cells	NNS	O
were	VBD	O
washed	VBN	O
once	IN	O
with	VBN	O
phosphate-buffered	IN	O
saline,	NNP	O
lysed	CD	O
with	IN	O
detergent	JJ	O
[1%	NNS	O
NP40	VBG	O
(Sigma	JJ	O
Chemical	CC	O
Co.,	JJ	O
St.	NNP	O
Louis,	NN	O
Mo.)	.	O
in	NNS	O
0.1	VBD	O
M	VBN	O
Tris-HCl,	IN	O
pH	CD	O
7.5],	NNS	O
and	.	O
the	NNS	O
lysate	VBD	O
transferred	VBN	O
into	IN	O
fresh	.	O
tubes.	NNP	O
SDS-polyacrylamide	NNS	O
gels	VBD	O
(pre-cast	VBN	O
8-16%;	IN	O
Novex,	.	O
San	DT	O
Diego,	NNS	O
Calif.)	VBD	O
were	VBN	O
loaded	RB	O
with	IN	O
20	JJ	O
μl	,	O
of	VBN	O
supernatant	IN	O
or	NN	O
12.5	NN	O
μl	NNP	O
of	NNP	O
cell	NNP	O
lysate.	,	O
A	NNP	O
protein	,	O
standard	)	O
was	IN	O
also	CD	O
loaded	NNP	O
(5	,	O
μl,	VBZ	O
broad	,	O
size	CC	O
range	DT	O
standard;	NN	O
BioRad	VBD	O
Laboratories,	IN	O
Hercules,	JJ	O
Calif.).	.	O
Electrophoresis	JJ	O
was	NNS	O
carried	JJ	O
out	:	O
and	,	O
the	NNP	O
proteins	,	O
were	)	O
transferred	VBD	O
using	VBN	O
a	IN	O
BioRad	CD	O
Transfer	NNS	O
Chamber	IN	O
(BioRad	NN	O
Laboratories,	CC	O
Hercules,	CD	O
Calif.)	NN	O
to	IN	O
Immobilon	NN	O
P	.	O
membranes	DT	O
(Millipore	JJ	O
Corp.,	NN	O
Bedford,	VBD	O
Mass.)	RB	O
using	VBN	O
the	CD	O
transfer	,	O
buffer	JJ	O
recommended	NN	O
by	NN	O
the	:	O
manufacturer	NNP	O
(Millipore),	,	O
where	,	O
the	.	O
transfer	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
100	CC	O
volts	DT	O
for	NNS	O
90	VBD	O
minutes.	VBN	O
The	VBG	O
membranes	DT	O
were	NNP	O
exposed	NNP	O
to	NNP	O
HIV-1-positive	NNP	O
human	,	O
patient	,	O
serum	)	O
and	TO	O
immunostained	NNP	O
using	NNP	O
o-phenylenediamine	NNS	O
dihydrochloride	NNP	O
(OPD;	,	O
Sigma).	,	O
The	)	O
results	VBG	O
of	DT	O
the	NN	O
immunoblotting	NN	O
analysis	VBN	O
showed	IN	O
that	DT	O
cells	NN	O
containing	,	O
the	WRB	O
synthetic	DT	O
Gag	NN	O
expression	VBD	O
cassette	VBN	O
produced	IN	O
the	CD	O
expected	NNS	O
p55	IN	O
protein	CD	O
at	.	O
higher	DT	O
per-cell	NNS	O
concentrations	VBD	O
than	VBN	O
cells	TO	O
containing	JJ	O
the	JJ	O
native	NN	O
expression	NN	O
cassette.	CC	O
The	VBD	O
Gag	VBG	O
p55	JJ	O
protein	NN	O
was	:	O
seen	.	O
in	DT	O
both	NNS	O
cell	IN	O
lysates	DT	O
and	NN	O
supernatants.	NN	O
The	VBD	O
levels	IN	O
of	NNS	O
production	VBG	O
were	DT	O
significantly	JJ	O
higher	NNP	O
in	NN	O
cell	NN	O
supernatants	VBD	O
for	DT	O
cells	VBN	O
transfected	NN	O
with	NN	O
the	IN	O
synthetic	JJR	O
Gag	NN	O
expression	NNS	O
cassette	IN	O
of	NNS	O
the	VBG	O
present	DT	O
invention.	JJ	O
Experiments	NN	O
performed	.	O
in	DT	O
support	NNP	O
of	NN	O
the	NN	O
present	VBD	O
invention	VBN	O
suggest	IN	O
that	DT	O
cells	NN	O
containing	NNS	O
the	CC	O
synthetic	.	O
Gag-prot	DT	O
expression	NNS	O
cassette	IN	O
produced	NN	O
the	VBD	O
expected	RB	O
Gag-prot	JJR	O
protein	IN	O
at	NN	O
comparably	NNS	O
higher	IN	O
per-cell	NNS	O
concentrations	VBN	O
than	IN	O
cells	DT	O
containing	JJ	O
the	NNP	O
native	NN	O
expression	NN	O
cassette.	IN	O
In	DT	O
addition,	JJ	O
supernatants	.	O
from	NNS	O
the	VBN	O
transfected	IN	O
293	NN	O
cells	IN	O
were	DT	O
fractionated	JJ	O
on	NN	O
sucrose	VBP	O
gradients.	IN	O
Aliquots	NNS	O
of	VBG	O
the	DT	O
supernatant	JJ	O
were	NNP	O
transferred	NN	O
to	NN	O
Polyclear™	VBD	O
ultra-centrifuge	DT	O
tubes	VBN	O
(Beckman	NNP	O
Instruments,	NN	O
Columbia,	IN	O
Md.),	RB	O
under-laid	JJR	O
with	NN	O
a	NNS	O
solution	IN	O
of	NNS	O
20%	VBG	O
(wt/wt)	DT	O
sucrose,	JJ	O
and	NN	O
subjected	.	O
to	IN	O
2	,	O
hours	NNS	O
centrifugation	IN	O
at	DT	O
28,000	JJ	O
rpm	CD	O
in	NNS	O
a	VBD	O
Beckman	VBN	O
SW28	IN	O
rotor.	JJ	O
The	.	O
resulting	NNS	O
pellet	IN	O
was	DT	O
suspended	NN	O
in	VBD	O
PBS	VBN	O
and	TO	O
layered	VB	O
onto	JJ	O
a	NNS	O
20-60%	NNP	O
(wt/wt)	,	O
sucrose	,	O
gradient	,	O
and	JJ	O
subjected	IN	O
to	DT	O
2	NN	O
hours	IN	O
centrifugation	NN	O
at	)	O
40,000	,	O
rpm	CC	O
in	VBD	O
a	TO	O
Beckman	CD	O
SW41ti	NNS	O
rotor.	NN	O
The	IN	O
gradient	CD	O
was	NN	O
then	IN	O
fractionated	DT	O
into	NNP	O
approximately	NNP	O
10×1	.	O
ml	DT	O
aliquots	VBG	O
(starting	NN	O
at	VBD	O
the	VBN	O
top,	IN	O
20%-end,	NNP	O
of	CC	O
the	VBD	O
gradient).	IN	O
Samples	DT	O
were	NN	O
taken	)	O
from	VB	O
fractions	NN	O
1-9	CC	O
and	VBN	O
were	TO	O
electrophoresed	CD	O
on	NNS	O
8-16%	NN	O
SDS	IN	O
polyacrylamide	CD	O
gels.	NN	O
Fraction	IN	O
number	DT	O
4	NNP	O
(the	NNP	O
peak	.	O
fraction)	DT	O
corresponds	NN	O
to	VBD	O
the	RB	O
expected	VBN	O
density	IN	O
of	RB	O
Gag	CD	O
protein	JJ	O
VLPs.	NNS	O
The	VBG	O
supernatants	IN	O
from	DT	O
293/synthetic	,	O
Gag	,	O
cells	IN	O
gave	DT	O
much	.	O
stronger	NNS	O
p55	VBD	O
bands	VBN	O
than	IN	O
supernatants	NNS	O
from	CD	O
293/native	CC	O
Gag	VBD	O
cells,	VBN	O
and,	IN	O
as	NN	O
expected,	NNP	O
the	NN	O
highest	.	O
concentration	NNP	O
of	NN	O
p55	CD	O
in	DT	O
either	NN	O
supernatant	)	O
was	VBZ	O
found	TO	O
in	DT	O
fraction	VBN	O
4.	NN	O
These	IN	O
results	NNP	O
demonstrate	NN	O
that	.	O
the	DT	O
synthetic	NNS	O
Gag	IN	O
expression	CD	O
cassette	NNP	O
provides	NNS	O
superior	VBD	O
production	RB	O
of	JJR	O
both	NN	O
p55	NNS	O
protein	IN	O
and	NNS	O
VLPs,	IN	O
relative	CD	O
to	NNP	O
the	,	O
native	,	O
Gag	IN	O
coding	,	O
sequences.	DT	O
B.	JJS	O
Env	NN	O
Coding	IN	O
Sequences	NN	O
Human	IN	O
293	DT	O
cells	NN	O
were	VBD	O
transfected	VBN	O
as	IN	O
described	NN	O
in	.	O
Example	DT	O
2	NNS	O
with	VBP	O
pCMVKm2-based;	IN	O
pCMVlink-based;	DT	O
p-CMVII-based	JJ	O
or	NNP	O
pESN2-based	NN	O
vectors	NN	O
containing	VBZ	O
native	JJ	O
or	NN	O
synthetic	IN	O
Env	DT	O
expression	JJ	O
cassettes.	NN	O
Cells	CC	O
were	,	O
cultivated	JJ	O
for	TO	O
48	DT	O
or	JJ	O
60	NNP	O
hours	NN	O
post-transfection.	.	O
Cell	NNP	O
lysates	NNP	O
and	NNP	O
supernatants	NNP	O
were	NNP	O
prepared	CD	O
as	NNS	O
described	VBD	O
(Example	VBN	O
2).	IN	O
Briefly,	VBN	O
the	IN	O
cells	NNP	O
were	CD	O
washed	IN	O
once	:	O
with	:	O
phosphate-buffered	JJ	O
saline,	CC	O
lysed	JJ	O
with	NNS	O
detergent	VBG	O
[1%	JJ	O
NP40	CC	O
(Sigma	JJ	O
Chemical	NNP	O
Co.,	NN	O
St.	.	O
Louis,	NNS	O
Mo.)]	VBD	O
in	VBN	O
0.1	IN	O
M	CD	O
Tris-HCl,	CC	O
pH	CD	O
7.5],	NNS	O
and	.	O
the	NNP	O
lysate	NNS	O
transferred	CC	O
into	NNS	O
fresh	VBD	O
tubes.	VBN	O
SDS-polyacrylamide	IN	O
gels	NN	O
(pre-cast	NNP	O
8-16%;	.	O
Novex,	,	O
San	DT	O
Diego,	NNS	O
Calif.)	VBD	O
were	VBN	O
loaded	RB	O
with	IN	O
20	JJ	O
μl	,	O
of	VBN	O
supernatant	IN	O
or	NN	O
12.5	NN	O
μl	NNP	O
of	NNP	O
cell	NNP	O
lysate.	,	O
A	NNP	O
protein	,	O
molecular	NN	O
weight	IN	O
standard	CD	O
and	NNP	O
an	,	O
HIV	VBZ	O
SF2	,	O
gp120	CC	O
positive	DT	O
control	NN	O
protein	VBD	O
(5	IN	O
μl,	JJ	O
broad	.	O
size	JJ	O
range	NNS	O
standard;	JJ	O
BioRad	:	O
Laboratories,	,	O
Hercules,	NNP	O
Calif.)	,	O
were	)	O
also	VBD	O
loaded.	VBN	O
Electrophoresis	IN	O
was	CD	O
carried	NNS	O
out	IN	O
and	NN	O
the	CC	O
proteins	CD	O
were	NN	O
transferred	IN	O
using	NN	O
a	.	O
BioRad	DT	O
Transfer	NN	O
Chamber	JJ	O
(BioRad	JJ	O
Laboratories,	NN	O
Hercules,	CC	O
Calif.)	DT	O
to	NNP	O
Immobilon	NNP	O
P	FW	O
membranes	JJ	O
(Millipore	NN	O
Corp.,	NN	O
Bedford,	CD	O
Mass.)	,	O
using	JJ	O
the	NN	O
transfer	NN	O
buffer	:	O
recommended	NNP	O
by	,	O
the	,	O
manufacturer	)	O
(Millipore),	VBD	O
where	RB	O
the	.	O
transfer	NN	O
was	VBD	O
performed	VBN	O
at	IN	O
100	CC	O
volts	DT	O
for	NNS	O
90	VBD	O
minutes.	VBN	O
The	VBG	O
membranes	DT	O
were	NNP	O
then	NNP	O
reacted	NNP	O
against	NNP	O
polyclonal	,	O
goat	,	O
anti-gp120SF2/env2-3	)	O
anti-sera,	TO	O
followed	NNP	O
by	NNP	O
incubation	NNS	O
with	NNP	O
swine	,	O
anti-goat	,	O
IgG-peroxidase	)	O
(POD)	VBG	O
(Sigma,	DT	O
St.	NN	O
Louis,	NN	O
Mo.).	VBN	O
Bands	IN	O
indicative	DT	O
of	NN	O
binding	,	O
were	WRB	O
visualized	DT	O
by	NN	O
adding	VBD	O
DAB	VBN	O
with	IN	O
hydrogen	CD	O
peroxide	NNS	O
which	IN	O
deposits	CD	O
a	.	O
brown	DT	O
precipitate	NNS	O
on	VBD	O
the	RB	O
membranes.	VBN	O
The	IN	O
results	JJ	O
of	NN	O
the	JJ	O
immunoblotting	,	O
analysis	VBN	O
showed	IN	O
that	NN	O
cells	IN	O
containing	JJ	O
the	JJ	O
synthetic	NNP	O
Env	)	O
expression	,	O
cassette	NNP	O
produced	,	O
the	.	O
expected	NNP	O
Env	NN	O
gp	IN	O
proteins	VBG	O
of	VBD	O
the	VBN	O
predicted	IN	O
molecular	VBG	O
weights	NNP	O
as	IN	O
determined	NN	O
by	NN	O
mobilities	WDT	O
in	VBZ	O
SDS-polyacrylamide	DT	O
gels	JJ	O
at	NN	O
higher	IN	O
per-cell	DT	O
concentrations	.	O
than	DT	O
cells	NNS	O
containing	IN	O
the	DT	O
native	NN	O
expression	NN	O
cassette.	VBD	O
The	IN	O
Env	NNS	O
proteins	VBG	O
were	DT	O
seen	JJ	O
in	NNP	O
both	NN	O
cell	NN	O
lysates	VBD	O
and	DT	O
supernatants.	VBN	O
The	NNP	O
levels	JJ	O
of	NNS	O
production	IN	O
were	DT	O
significantly	JJ	O
higher	JJ	O
in	NNS	O
cell	IN	O
supernatants	VBN	O
for	IN	O
cells	NNS	O
transfected	IN	O
with	JJ	O
the	NNS	O
synthetic	IN	O
Env	JJR	O
expression	NN	O
cassette	NNS	O
of	IN	O
the	NNS	O
present	VBG	O
invention.	DT	O
C.	JJ	O
Tat	NN	O
Coding	.	O
Sequences	DT	O
Human	NNP	O
293	NNS	O
cells	VBD	O
are	VBN	O
transfected	IN	O
as	DT	O
described	NN	O
in	NNS	O
Example	CC	O
2	.	O
with	DT	O
various	NNS	O
vectors	IN	O
containing	NN	O
native	VBD	O
or	RB	O
synthetic	JJR	O
Tat	IN	O
expression	NN	O
cassettes.	NNS	O
Cells	IN	O
are	NNS	O
cultivated	VBN	O
and	IN	O
isolated	DT	O
proteins	JJ	O
analyzed	NNP	O
as	NN	O
described	NN	O
above.	IN	O
Immunoblotting	DT	O
analysis	JJ	O
shows	.	O
that	NNP	O
cells	NNP	O
containing	NNP	O
the	NNP	O
synthetic	NNP	O
Tat	CD	O
expression	NNS	O
cassette	VBP	O
produced	VBN	O
the	IN	O
expected	VBN	O
Tat	IN	O
proteins	NNP	O
of	CD	O
the	IN	O
predicted	JJ	O
molecular	NNS	O
weights	VBG	O
as	JJ	O
determined	CC	O
by	JJ	O
mobilities	NNP	O
in	NN	O
SDS-polyacrylamide	.	O
gels	NNS	O
at	VBP	O
higher	VBN	O
per-cell	CC	O
concentrations	JJ	O
than	NNS	O
cells	VBN	O
containing	IN	O
the	VBN	O
native	.	O
expression	VBG	O
cassette.	NN	O
Example	NNS	O
4	WDT	O
Purification	NNS	O
of	VBG	O
Env	DT	O
Polypeptides	JJ	O
A.	NNP	O
Purification	NN	O
of	NN	O
Oligomeric	VBD	O
gp140	DT	O
Purification	VBN	O
of	NNP	O
oligomeric	NNS	O
gp140	IN	O
(o-gp140	DT	O
US4)	JJ	O
was	JJ	O
conducted	NNS	O
essentially	IN	O
as	VBN	O
shown	IN	O
in	NNS	O
FIG.	IN	O
60.	JJ	O
For	NNS	O
the	IN	O
experiments	JJR	O
described	NN	O
herein,	NNS	O
o-gp140	IN	O
refers	NNS	O
to	VBG	O
oligomeric	DT	O
gp140	JJ	O
in	NN	O
either	.	O
native	RB	O
or	CD	O
modified	NN	O
(e.g.,	IN	O
optimized	NNP	O
expression	NNP	O
sequences,	NNP	O
deleted,	NNP	O
mutated,	IN	O
truncated,	NNP	O
etc.)	JJ	O
form.	NNP	O
Briefly,	IN	O
concentrated	JJ	O
(30-50×)	NN	O
supernatants	JJ	O
obtained	)	O
from	VBD	O
CHO	VBN	O
cell	RB	O
cultures	IN	O
were	VBN	O
loaded	IN	O
onto	.	O
an	.	O
anion	IN	O
exchange	DT	O
(DEAE)	NNS	O
column	VBD	O
which	,	O
removed	JJ	O
DNA	NNS	O
and	TO	O
other	VB	O
serum	NN	O
proteins.	IN	O
The	CC	O
eluted	JJ	O
material	CC	O
was	VBN	O
loaded	,	O
onto	VBN	O
a	NN	O
ceramic	,	O
hydroxyapatite	,	O
column	,	O
(CHAP)	,	O
which	)	O
bound	.	O
serum	,	O
proteins	VBD	O
but	)	O
not	NNS	O
HIV	VBN	O
Env	IN	O
proteins.	NNP	O
The	NN	O
flow-through	NNS	O
from	VBD	O
the	VBN	O
DEAE	IN	O
and	DT	O
CHAP	NN	O
columns	NN	O
was	)	O
loaded	NN	O
onto	WDT	O
a	VBD	O
Protein	NNP	O
A	CC	O
column	JJ	O
as	NN	O
a	.	O
precautionary	DT	O
step	JJ	O
to	NN	O
remove	VBD	O
any	VBN	O
remaining	IN	O
serum	DT	O
immunoglobulins.	JJ	O
The	NN	O
Env	NN	O
proteins	)	O
in	WDT	O
the	VBP	O
flow-through	NN	O
were	NNS	O
then	CC	O
captured	RB	O
using	NNP	O
the	NNP	O
lectin	.	O
gluvanthus	DT	O
navalis	NN	O
(GNA,	IN	O
Vector	DT	O
Labs,	NNP	O
Burlingame,	CC	O
Calif.).	NNP	O
GNA	NN	O
has	VBD	O
high	VBN	O
affinity	IN	O
for	DT	O
mannose	NNP	O
rich	NNP	O
carbohydrates	NN	O
such	IN	O
as	DT	O
Env.	JJ	O
The	NN	O
Env	TO	O
proteins	VB	O
were	DT	O
then	VBG	O
eluted	NN	O
with	.	O
GNA	DT	O
substrate.	NNP	O
To	NNS	O
remove	IN	O
other	DT	O
highly	JJ	O
glycosylated	VBD	O
proteins,	RB	O
a	VBN	O
cation	VBG	O
exchange	DT	O
column	NN	O
(SP)	NN	O
was	NN	O
used	,	O
to	NNP	O
purify	,	O
gp140/gp120.	,	O
In	.	O
a	NNP	O
final	VBZ	O
step,	JJ	O
which	NN	O
separates	IN	O
gp120	JJ	O
from	JJ	O
o-gp140,	NNS	O
a	JJ	O
gel	IN	O
filtration	.	O
column	DT	O
was	NNP	O
used	NNS	O
to	VBD	O
separate	RB	O
oligomers	VBN	O
from	IN	O
monomers.	NNP	O
Sizing	.	O
and	TO	O
chromatography	VB	O
analysis	JJ	O
of	RB	O
the	JJ	O
final	,	O
product	DT	O
revealed	NN	O
that	NN	O
this	NN	O
strategy	)	O
lead	VBD	O
to	VBN	O
the	TO	O
successful	VB	O
isolation	.	O
of	IN	O
oligomeric	DT	O
gp140.	JJ	O
B.	,	O
Purification	WDT	O
of	VBZ	O
gp120	NN	O
Purification	IN	O
of	,	O
gp120	DT	O
was	JJ	O
conducted	NN	O
essentially	NN	O
as	VBD	O
previously	VBN	O
described	TO	O
for	JJ	O
other	NNS	O
Env	IN	O
proteins.	.	O
Briefly,	VBG	O
concentrated	CC	O
supernatants	JJ	O
obtained	NN	O
from	IN	O
CHO	DT	O
cell	JJ	O
cultures	NN	O
were	VBD	O
loaded	IN	O
onto	DT	O
an	NN	O
anion	NN	O
exchange	TO	O
(DEAF)	DT	O
column	JJ	O
which	NN	O
removed	IN	O
DNA	JJ	O
and	.	O
other	NNP	O
serum	NNP	O
proteins.	IN	O
The	JJ	O
eluted	NNP	O
material	IN	O
was	NN	O
loaded	VBD	O
onto	VBN	O
a	RB	O
ceramic	IN	O
hydroxyapatite	RB	O
column	VBN	O
(CHAP)	IN	O
which	JJ	O
bound	NNP	O
serum	.	O
proteins	,	O
but	VBD	O
not	NNS	O
HIV	VBN	O
Env	IN	O
proteins.	NNP	O
The	NN	O
flow-through	NNS	O
from	VBD	O
the	VBN	O
CHAP	IN	O
column	DT	O
was	NN	O
loaded	NN	O
a	)	O
cation	NN	O
exchange	WDT	O
column	VBD	O
(SP)	NNP	O
where	CC	O
the	JJ	O
flow-through	NN	O
was	.	O
discarded	DT	O
and	JJ	O
the	NN	O
bound	VBD	O
fraction	VBN	O
eluted	IN	O
with	DT	O
salt.	JJ	O
The	NN	O
eluted	NN	O
fraction(s)	)	O
were	WDT	O
loaded	VBP	O
onto	NN	O
a	NNS	O
Suprose	CC	O
12/Superdex	RB	O
200	NNP	O
Tandem	NNP	O
column	.	O
(Pharmacia-Upjohn,	DT	O
Uppsala,	NN	O
Sweden)	IN	O
from	DT	O
which	NNP	O
purified	NN	O
gp120	VBD	O
was	VBN	O
obtained.	DT	O
Sizing	NN	O
and	NN	O
chromatography	NN	O
analysis	)	O
of	WRB	O
the	DT	O
final	NN	O
product	VBD	O
revealed	VBN	O
that	CC	O
this	DT	O
strategy	NN	O
successfully	NN	O
purified	VBN	O
gp120	IN	O
proteins.	.	O
Example	DT	O
5	JJ	O
Analysis	)	O
of	VBD	O
Purified	VBN	O
Env	IN	O
Polypeptides	DT	O
A.	NNP	O
Analysis	CD	O
of	CD	O
o-gp140	NNP	O
It	NN	O
is	,	O
well	,	O
documented	)	O
that	IN	O
HIV	WDT	O
Env	VBD	O
protein	NN	O
binds	VBD	O
to	.	O
CD4	VBG	O
only	CC	O
in	JJ	O
its	NN	O
correct	IN	O
conformation.	DT	O
Accordingly,	JJ	O
the	NN	O
ability	VBD	O
of	IN	O
o-gp140	DT	O
US4	NN	O
polypeptides,	RB	O
produced	VBN	O
and	NN	O
purified	.	O
as	RB	O
described	CD	O
above,	NN	O
to	IN	O
bind	NNP	O
CD4	NNP	O
cells	NNP	O
was	.	O
tested.	NN	O
O-gp140	IN	O
US4	JJ	O
was	PRP	O
incubated	VBZ	O
for	RB	O
15	VBN	O
minutes	IN	O
with	NNP	O
FITC-labeled	NNP	O
CD4	NN	O
at	VBZ	O
room	TO	O
temperature	NNP	O
and	RB	O
loaded	IN	O
onto	PRP$	O
a	JJ	O
Biosil	.	O
250	,	O
(BioRad)	DT	O
size	NN	O
exclusion	IN	O
column	JJ	O
using	NNP	O
Waters	,	O
HPLC.	VBN	O
CD4-FITC	CC	O
has	VBN	O
the	IN	O
longest	VBN	O
retention	,	O
time	TO	O
(2.67	VB	O
minutes),	NNP	O
followed	NNS	O
by	VBD	O
CD4-FITC-gp120	.	O
(2.167	JJ	O
min).	NNP	O
The	VBD	O
shortest	VBN	O
retention	IN	O
time	CD	O
(1.9	NNS	O
min)	IN	O
was	JJ	O
observed	NNP	O
for	IN	O
CD4-FITC-o-gp140	NN	O
US4	NN	O
indicating	CC	O
that,	VBD	O
as	IN	O
expected,	DT	O
o-gp140	NNP	O
US4	CD	O
binds	)	O
to	NN	O
CD4	NN	O
forming	NN	O
a	VBG	O
large	NNP	O
complex	.	O
which	NNP	O
reduces	VBZ	O
retention	DT	O
time	JJS	O
on	NN	O
the	NN	O
column.	CD	O
Thus,	,	O
the	VBN	O
o-gp140	IN	O
US4	NNP	O
produced	CD	O
and	.	O
purified	DT	O
as	JJS	O
described	NN	O
above	NN	O
is	CD	O
of	)	O
the	VBD	O
correct	VBN	O
size	IN	O
and	NNP	O
conformation.	NNP	O
In	NN	O
addition,	,	O
the	IN	O
US4	,	O
o-gp140,	JJ	O
purified	NNP	O
as	VBZ	O
described	TO	O
above,	NNP	O
was	VBG	O
also	DT	O
tested	JJ	O
for	NN	O
its	WDT	O
ability	VBZ	O
to	NN	O
bind	NN	O
to	IN	O
a	DT	O
variety	.	O
of	,	O
monoclonal	DT	O
antibodies	JJ	O
with	NNP	O
known	VBD	O
epitope	CC	O
specificities	VBD	O
for	IN	O
the	VBN	O
CD4	IN	O
binding	VBZ	O
site,	IN	O
the	DT	O
CD4	JJ	O
inducible	NN	O
site,	CC	O
the	.	O
V3	IN	O
loop	,	O
and	DT	O
oligomer-specific	NNP	O
gp41	,	O
epitope.	VBN	O
O-gp140	IN	O
bound	VBN	O
strongly	,	O
to	VBD	O
these	RB	O
antibodies,	VBN	O
indicating	IN	O
that	PRP$	O
the	NN	O
purified	TO	O
protein	VB	O
retains	TO	O
its	DT	O
structural	NN	O
integrity.	IN	O
B.	JJ	O
Analysis	NNS	O
of	IN	O
gp120	VBN	O
As	NN	O
described	NNS	O
above,	IN	O
CD4-FITC	DT	O
binds	NNP	O
gp120,	NN	O
as	,	O
demonstrated	DT	O
by	NNP	O
the	JJ	O
decreased	,	O
retention	DT	O
time	NNP	O
on	NN	O
the	CC	O
HPLC	JJ	O
column.	NN	O
Thus,	.	O
US4	NNP	O
gp120	NN	O
purified	RB	O
by	TO	O
the	DT	O
above	,	O
method	VBG	O
retains	IN	O
its	DT	O
conformational	JJ	O
integrity.	NN	O
In	VBZ	O
addition,	PRP$	O
the	JJ	O
properties	.	O
of	.	O
purified	NN	O
gp120	IN	O
can	NN	O
be	IN	O
tested	VBN	O
by	,	O
examining	NNP	O
its	VBZ	O
integrity	,	O
and	IN	O
identity	VBN	O
on	IN	O
western	DT	O
blots,	JJ	O
as	NN	O
well	NN	O
as,	IN	O
by	DT	O
examining	NNP	O
protein	.	O
concentration,	,	O
pH,	NNP	O
conductivity,	NN	O
endotoxin	VBN	O
levels,	IN	O
bioburden	DT	O
and	JJ	O
the	NN	O
like.	VBZ	O
US4	PRP$	O
gp120,	JJ	O
purified	.	O
as	IN	O
described	,	O
above,	DT	O
was	NNS	O
also	IN	O
tested	JJ	O
for	NN	O
its	MD	O
ability	VB	O
to	VBN	O
bind	IN	O
to	VBG	O
a	PRP$	O
variety	NN	O
of	CC	O
monoclonal	NN	O
antibodies	IN	O
with	JJ	O
known	,	O
epitope	RB	O
specificities	RB	O
for	,	O
the	IN	O
CD4	VBG	O
binding	JJ	O
site,	,	O
the	,	O
CD4	,	O
inducible	NN	O
site,	,	O
the	NN	O
V3	CC	O
loop	DT	O
and	.	O
oligomer-specific	NNP	O
gp41	,	O
epitope.	VBD	O
The	IN	O
pattern	VBN	O
of	,	O
mAb	VBD	O
binding	RB	O
to	VBN	O
gp120	IN	O
indicated	PRP$	O
that	NN	O
the	TO	O
purified	VB	O
protein	TO	O
retained	DT	O
its	NN	O
structural	IN	O
integrity,	JJ	O
for	NNS	O
example,	IN	O
the	VBN	O
purified	NN	O
gp120	NNS	O
did	IN	O
not	DT	O
bind	NNP	O
the	NN	O
mAb	,	O
having	DT	O
the	NNP	O
oligomer-specific	JJ	O
gp41	,	O
epitope	DT	O
(as	NNP	O
expected).	NN	O
Example	CC	O
6	JJ	O
Electron	NN	O
Microscopic	.	O
Evaluation	DT	O
of	NN	O
VLP	IN	O
Production	NN	O
The	NN	O
cells	TO	O
for	VB	O
electron	JJ	O
microscopy	IN	O
were	DT	O
plated	JJ	O
at	NN	O
a	VBD	O
density	PRP$	O
of	JJ	O
50-70%	,	O
confluence,	IN	O
one	,	O
day	DT	O
before	JJ	O
transfection.	NN	O
The	VBD	O
cells	RB	O
were	VB	O
transfected	DT	O
with	NN	O
10	VBG	O
μg	DT	O
of	JJ	O
DNA	NN	O
using	NN	O
transfection	IN	O
reagent	.	O
LT1	RB	O
(Panvera)	CD	O
and	NNP	O
incubated	NNP	O
for	NNP	O
5	IN	O
hours	NNP	O
in	NNP	O
serum-reduced	DT	O
medium	NNS	O
(see	IN	O
Example	NN	O
2).	NN	O
The	VBD	O
medium	VBN	O
was	IN	O
then	DT	O
replaced	NN	O
with	IN	O
normal	NN	O
medium	,	O
(see	CD	O
Example	NN	O
2)	IN	O
and	.	O
the	DT	O
cells	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
14	CD	O
hours	NNS	O
(COS-7)	IN	O
or	NNP	O
40	VBG	O
hours	NN	O
(CHO).	NN	O
After	NNP	O
incubation	)	O
the	CC	O
cells	VBN	O
were	IN	O
washed	CD	O
twice	NNS	O
with	IN	O
PBS	JJ	O
and	NN	O
fixed	VB	O
with	NNP	O
2%	.	O
glutaraldehyde.	DT	O
Electron	NN	O
microscopy	VBD	O
was	RB	O
performed	VBN	O
by	IN	O
Prof.	JJ	O
T.	NN	O
S.	VB	O
Benedict	NNP	O
Yen,	)	O
Veterans	CC	O
Affairs,	DT	O
Medical	NNS	O
Center,	VBD	O
San	VBN	O
Francisco,	IN	O
Calif.).	CD	O
Electron	NNS	O
microscopy	)	O
was	CC	O
carried	CD	O
out	NNS	O
using	.	O
a	IN	O
transmission	NN	O
electron	DT	O
microscope	NNS	O
(Zeiss	VBD	O
10c).	VBN	O
The	RB	O
cells	IN	O
were	NNP	O
pre-stained	CC	O
with	VBN	O
osmium	IN	O
and	NN	O
stained	.	O
with	NNP	O
uranium	NN	O
acetate	VBD	O
and	VBN	O
lead	IN	O
citrate.	NNP	O
The	NNP	O
magnification	NNP	O
was	NNP	O
100,000×.	,	O
FIGS.	NNP	O
3A	,	O
and	NNP	O
3B	,	O
show	NNP	O
micrographs	,	O
of	.	O
CHO	NNP	O
cells	NN	O
transfected	VBD	O
with	VBN	O
pCMVKM2	RP	O
carrying	VBG	O
the	DT	O
synthetic	NN	O
Gag	NN	O
expression	NN	O
cassette	NNP	O
(SEQ	.	O
ID	DT	O
NO:5)	NNS	O
or	VBD	O
carrying	JJ	O
the	IN	O
Gag-prot	NN	O
expression	CC	O
cassette	VBN	O
(SEQ	IN	O
ID	JJ	O
NO:79).	NN	O
In	CC	O
the	JJ	O
figure,	.	O
free	DT	O
and	NN	O
budding	VBD	O
immature	.	O
virus-like-particles	.	O
(VLP)	CD	O
of	CC	O
the	CD	O
expected	NN	O
size	NN	O
(100	IN	O
nm)	NNP	O
are	NNS	O
seen	VBD	O
for	IN	O
the	NN	O
Gag	VBG	O
expression	DT	O
cassette	JJ	O
(FIG.	NNP	O
3A)	NN	O
and	NN	O
both	NNP	O
immature	NNP	O
and	)	O
mature	CC	O
VLPs	VBG	O
are	DT	O
seen	NNP	O
for	NN	O
the	NN	O
Gag-prot	NNP	O
expression	NNP	O
cassette	.	O
(FIG.	IN	O
38).	DT	O
COS-7	,	O
cells	JJ	O
transfected	CC	O
with	JJ	O
the	NN	O
same	NNS	O
vector	)	O
have	IN	O
the	DT	O
same	VBN	O
expression	NN	O
pattern.	CD	O
VLP	)	O
can	VBP	O
also	VBN	O
be	IN	O
found	DT	O
intracellularly	NNP	O
in	NN	O
CHO	NN	O
and	.	O
COS-7	)	O
cells.	CC	O
Native	DT	O
and	NN	O
synthetic	CC	O
Gag	NN	O
expression	NNP	O
cassettes	VBP	O
were	VBN	O
compared	IN	O
for	DT	O
their	NNP	O
associated	NN	O
levels	NN	O
of	.	O
VLP	.	O
production	NNP	O
when	NNS	O
used	VBN	O
to	IN	O
transfect	DT	O
human	JJ	O
293	NN	O
cells.	VBP	O
The	DT	O
comparison	JJ	O
was	NN	O
performed	.	O
by	NNP	O
density	MD	O
gradient	RB	O
ultracentrifugation	VB	O
of	VBN	O
cell	RB	O
supernatants	IN	O
and	NNP	O
Western-blot	CC	O
analysis	NNP	O
of	.	O
the	JJ	O
gradient	CC	O
fractions.	JJ	O
There	NNP	O
was	NN	O
a	NNS	O
clear	VBD	O
improvement	VBN	O
in	IN	O
production	PRP$	O
of	JJ	O
VLPs	NNS	O
when	IN	O
using	NNP	O
the	NN	O
synthetic	WRB	O
Gag	VBN	O
construct.	TO	O
Example	VB	O
7	JJ	O
Expression	CD	O
of	.	O
Virus-Like	DT	O
Particles	NN	O
in	VBD	O
the	VBN	O
Baculovirus	IN	O
System	NN	O
A.	JJ	O
Expression	NN	O
of	IN	O
Native	NN	O
HIV	NNS	O
p55	CC	O
Gag	JJ	O
To	NN	O
construct	IN	O
the	DT	O
native	JJ	O
HIV	.	O
p55	EX	O
Gag	VBD	O
baculovirus	DT	O
shuttle	JJ	O
vector,	NN	O
the	IN	O
prototype	NN	O
SF2	IN	O
HIV	NNP	O
p55	WRB	O
plasmid,	VBG	O
pTM1-Gag	DT	O
Selby	JJ	B
M.	NNP	I
J.,	.	I
et	RB	I
al.,	CD	I
J.	NN	I
Virol.	IN	I
71(10):7827-7831,	NNP	I
1997),(	NNP	O
was	IN	O
digested	DT	O
with	NNP	O
restriction	NNP	O
endonucleases	.	O
NcoI	NN	O
and	IN	O
BamHI	NNP	O
to	NNP	O
extract	NN	O
a	NNP	O
1.5	TO	O
Kb	VB	O
fragment	DT	O
that	JJ	O
was	NNP	O
subsequently	NN	O
subcloned	NNP	O
into	NN	O
pAcC4	NN	O
(Bio/Technology	,	O
6:47-55,	DT	O
1988),	NN	O
a	NNP	O
derivative	NNP	O
of	NN	O
pAc436.	,	O
Generation	NN	O
of	NNP	O
the	NNP	O
recombinant	,	O
baculovirus	FW	O
was	,	O
achieved	NNP	O
by	.	O
co-transfecting	,	O
2	,	O
μg	VBD	O
of	VBN	O
the	IN	O
HIV	NN	O
p55	NNS	O
Gag	NNP	O
pAcC4	CC	O
shuttle	NNP	O
vector	TO	O
with	VB	O
0.5	DT	O
μg	CD	O
of	NNP	O
linearized,	NN	O
Autographa	WDT	O
californica	VBD	O
baculovirus	RB	O
(AcNPV)	VBN	O
wild-type	IN	O
viral	NN	O
DNA	NNP	O
into	,	O
Spodoptera	,	O
frugiperda	DT	O
(Sf9)	NN	O
cells	IN	O
Kitts,	.	B
P.	NN	I
A.,	IN	I
Ayres	DT	I
M.	JJ	I
D.,	NN	I
and	VBD	I
Possee	VBN	I
R.	IN	I
D.,	JJ	I
Nucleic	CD	I
Acids	NN	I
Res.	IN	I
18:5667-5672,	DT	I
1990).(	NNP	O
The	NN	O
isolation	NNP	O
of	NN	O
recombinant	NN	O
virus	NN	O
expressing	IN	O
HIV	CD	O
p55	NNS	O
Gag	IN	O
was	,	O
performed	NNP	O
according	NN	O
to	NN	O
standard	)	O
techniques	JJ	O
(O'Reilly,	JJ	O
D.	NNP	O
R.,	IN	O
L.	NNP	O
K.	NN	O
Miller,	)	O
and	NNS	O
V.	,	O
A.	NNP	O
Luckow,	,	O
Baculovirus	NNP	O
Expression	NNP	O
Vector:	,	O
A	CC	O
Laboratory	NNP	O
Manual,	NNP	O
W.H.	,	O
Freeman	NNP	O
and	NNP	O
Company,	.	O
New	,	O
York,	.	O
1992).	DT	O
Expression	NN	O
of	IN	O
the	JJ	O
HIV	NN	O
p55	VBG	O
Gag	NNP	O
was	NN	O
achieved	NNP	O
using	VBD	O
a	VBN	O
500	VBG	O
ml	TO	O
suspension	NN	O
culture	NNS	O
of,	,	O
Sf9	NNP	O
cells	,	O
grown	NNP	O
in	NNP	O
serum-free	,	O
medium	CC	O
Miaorella,	NNP	B
B.,	NNP	I
D.	,	I
Inlow,	NNP	I
A.	NNP	I
Shauger,	:	I
and	DT	I
D.	NNP	I
Harano,	,	I
Bio/Technology	.	I
6:1506-1510,	NNP	I
1988)	CC	I
(that	,	O
had	NNP	O
been	,	O
infected	.	O
with	NN	O
the	IN	O
HIV	DT	O
p55	NNP	O
Gag	NN	O
recombinant	NNP	O
baculovirus	VBD	O
at	VBN	O
a	VBG	O
multiplicity	DT	O
of	CD	O
infection	NN	O
(MOI)	NN	O
of	NN	O
10.	,	O
Forty-eight	NNP	O
hours	NNS	O
post-infection,	VBN	O
the	IN	O
supernatant	JJ	O
was	NN	O
separated	,	O
by	,	O
centrifugation	NNP	O
and	,	O
filtered	NNP	O
through	,	O
a	CC	O
0.2	NNP	O
μm	,	O
filter.	NNP	O
Aliquots	,	O
of	)	O
the	WDT	O
supernatant	VBD	O
were	VBN	O
then	VBN	O
transferred	IN	O
to	DT	O
Polyclear™	NNP	O
(Beckman	NN	O
Instruments,	NNP	O
Palo	NN	O
Alto,	NN	O
Calif.)	IN	O
ultracentrifuge	DT	O
tubes,	NN	O
underlaid	IN	O
with	NN	O
20%	)	O
(wt/wt)	IN	O
sucrose,	.	O
and	JJ	O
subjected	NNS	O
to	,	O
2	DT	O
hours	NN	O
centrifugation	VBD	O
at	VBN	O
24,00	IN	O
rpm	NN	O
using	CC	O
a	VBD	O
Beckman	IN	O
SW28	DT	O
rotor.	CD	O
The	NN	O
resulting	.	O
pellet	NNS	O
was	IN	O
suspended	DT	O
in	NN	O
Tris	VBD	O
buffer	RB	O
(20	VBN	O
mM	TO	O
Tris	NNP	O
HCl,	NNP	O
pH	,	O
7.5,	NNP	O
250	,	O
mM	)	O
NaCl,	NN	O
and	,	O
2.5	JJ	O
mM	IN	O
ethylenediaminetetraacetic	NN	O
acid	)	O
[EDTA]),	,	O
layered	CC	O
onto	VBD	O
a	TO	O
20-60%	CD	O
(wt/wt)	NNS	O
sucrose	NN	O
gradient,	IN	O
and	CD	O
subjected	NN	O
to	VBG	O
2	DT	O
hours	NNP	O
centrifugation	NNP	O
at	.	O
40,000	DT	O
rpm	VBG	O
using	NN	O
a	VBD	O
Beckman	VBN	O
SW41ti	IN	O
rotor.	NNP	O
The	NN	O
gradient	CD	O
was	NN	O
then	NNP	O
fractionated	,	O
starting	NN	O
at	,	O
the	CD	O
top	NN	O
(20%	,	O
sucrose)	CC	O
of	CD	O
the	NNS	O
gradient	JJ	O
into	NN	O
approximately	,	O
twelve	VBD	O
0.75	IN	O
ml	DT	O
aliquots.	NN	O
A	)	O
sample	NN	O
of	,	O
each	CC	O
fraction	VBD	O
was	TO	O
electrophoresed	CD	O
on	NNS	O
8-16%	NN	O
SDS	IN	O
polyacrylamide	CD	O
gels	NN	O
and	VBG	O
the	DT	O
resulting	NNP	O
bands	NNP	O
were	.	O
visualized	DT	O
after	NN	O
commassie	VBD	O
staining	RB	O
(FIG.	VBN	O
4).	VBG	O
Additional	IN	O
aliquots	DT	O
were	NN	O
subjected	NN	O
to	)	O
refractive	IN	O
index	DT	O
analysis.	NN	O
The	IN	O
results	RB	O
shown	JJ	O
in	CD	O
FIG.	JJ	O
4	.	O
indicated	DT	O
that	NN	O
the	IN	O
p55	DT	O
Gag	NN	O
virus-like	VBD	O
particles	VBN	O
banded	IN	O
at	NN	O
a	NNP	O
sucrose	NN	O
density	NNS	O
of	CC	O
range	DT	O
of	VBG	O
1.15-1.19	NNS	O
g/ml	VBD	O
with	VBN	O
the	IN	O
peak	NN	O
at	NN	O
approximately	.	O
1.17	.	O
g/ml.	JJ	O
The	NNS	O
peak	VBD	O
fractions	VBN	O
were	TO	O
pooled	VB	O
and	NN	O
concentrated	.	O
by	DT	O
a	NNS	O
second	VBN	O
20%	IN	O
sucrose	.	O
pelleting.	CD	O
The	VBD	O
resulting	IN	O
pellet	DT	O
was	NN	O
suspended	NNP	O
in	JJ	O
1	NNS	O
ml	VBN	O
of	IN	O
Tris	DT	O
buffer	JJ	O
(described	NN	O
above).	IN	O
The	NN	O
total	IN	O
protein	JJ	O
yield	NN	O
as	IN	O
estimated	DT	O
by	NN	O
Bicimchrominic	IN	O
Acid	RB	O
(BCA)	CD	O
(Pierce	.	O
Chemical,	DT	O
Rockford,	JJ	O
Ill.)	NNS	O
was	VBD	O
1.6	VBN	O
mg.	CC	O
B.	VBN	O
Expression	IN	O
of	DT	O
Synthetic	JJ	O
HIV	NN	O
p55	JJ	O
Gag	.	O
A	DT	O
baculovirus	VBG	O
shuttle	NN	O
vector	VBD	O
containing	VBN	O
the	IN	O
synthetic	CD	O
p55	NN	O
Gag	IN	O
sequence	NNP	O
was	NN	O
constructed	VBN	O
as	.	O
follows.	DT	O
The	JJ	O
synthetic	JJ	O
HIV	NN	O
p55	IN	O
expression	VBN	O
cassette	IN	O
(Example	NNP	O
1)	NNP	O
was	)	O
digested	NNP	O
with	,	O
restriction	,	O
enzyme	)	O
Sail	VBD	O
followed	CD	O
by	NN	O
incubation	.	O
with	NN	O
T4-DNA	IN	O
polymerase.	NNP	O
The	NNP	O
resulting	NN	O
fragment	NNP	O
was	NNP	O
isolated	NN	O
(PCR	NN	O
Clean-Up™,	NN	O
Promega,	VBG	O
Madison,	DT	O
Wis.)	JJ	O
and	NN	O
then	NNP	O
digested	NN	O
with	VBD	O
BamHI	VBN	O
endonuclease.	IN	O
The	.	O
shuttle	DT	O
vector	JJ	O
pAcC13	NNP	O
Munemitsu	NN	B
S.,	NN	I
et	NN	I
al.,	NNP	I
Mol	)	I
Cell	VBD	I
Biol.	VBN	I
10(11):5977-5982,	IN	I
1990)	NN	I
(was	NN	O
linearized	NNP	O
by	VBN	O
digestion	IN	O
with	NN	O
EcoI,	IN	O
followed	NNP	O
by	.	O
incubation	DT	O
with	VBG	O
T4-DNA	NN	O
polymerase,	VBD	O
and	VBN	O
then	NNP	O
isolated	,	O
(PCR	,	O
Clean-Up™).	,	O
The	)	O
linearized	CC	O
vector	RB	O
was	VBD	O
digested	IN	O
with	NNP	O
BamHI,	.	O
treated	DT	O
with	JJ	O
alkaline	NN	O
phosphatase,	NN	O
and	NNP	O
isolated	,	O
by	FW	O
size	,	O
fragmentation	NNP	O
in	NNP	O
an	.	O
agarose	,	O
gel.	)	O
The	VBD	O
isolated	VBN	O
1.5	IN	O
kb	NN	O
fragment	IN	O
was	,	O
ligated	VBN	O
with	IN	O
the	NN	O
prepared	IN	O
pAcC13	NNP	O
vector.	,	O
The	CC	O
resulting	RB	O
clone	VBD	O
was	NNP	O
designated	.	O
pAcC13-Modif.p55Gag.	DT	O
The	JJ	O
expression	NN	O
conditions	VBD	O
for	VBN	O
the	IN	O
synthetic	,	O
HIV	VBD	O
p55	IN	O
VLPs	JJ	O
differed	,	O
from	CC	O
those	VBN	O
of	IN	O
the	NN	O
native	NN	O
p55	IN	O
Gag	DT	O
as	JJ	O
follows:	.	O
a	DT	O
culture	JJ	O
volume	CD	O
of	JJ	O
1	NN	O
liter	VBD	O
used	VBN	O
instead	IN	O
of	DT	O
500	JJ	O
ml;	NN	O
Trichoplusia	.	O
ni	DT	O
(Tn5)	VBG	O
Wickham,	NN	B
T.	VBD	I
J.,	VBN	I
and	.	I
Nermerow,	DT	I
G.	NN	I
R.,	NNS	I
BioTechnology	IN	I
Progress,	DT	I
9:25-30,	JJ	I
1993)	NNP	I
(insect	NN	O
cells	NNP	O
were	VBD	O
used	IN	O
instead	DT	O
of	IN	O
Sf9	DT	O
insect	JJ	O
cells;	NN	O
and,	NNP	O
an	IN	O
MOI	:	O
of	DT	O
3	NN	O
was	NN	O
instead	IN	O
of	CD	O
an	NN	O
MOI	VBN	O
of	RB	O
10.	IN	O
Experiments	CD	O
performed	:	O
in	NNP	O
support	FW	O
of	)	O
the	,	O
present	NNP	O
invention	,	O
showed	CC	O
that	,	O
there	NNP	O
was	,	O
no	NNP	O
appreciable	,	O
difference	,	O
in	)	O
expression	VBP	O
level	NNS	O
between	VBD	O
the	VBN	O
Sf9	RB	O
and	IN	O
Tn5	NNP	O
insect	JJ	O
cells	:	O
with	,	O
the	DT	O
native	NNP	O
p55	IN	O
clone.	CD	O
In	VBD	O
terms	RB	O
of	IN	O
MOI,	DT	O
experience	NNP	O
with	IN	O
the	.	O
native	NNS	O
p55	VBN	O
clone	IN	O
suggested	NN	O
that	IN	O
an	DT	O
MOI	JJ	O
of	NN	O
10	VBD	O
resulted	IN	O
in	EX	O
higher	VBD	O
expression	DT	O
(approximately	JJ	O
2-fold)	NN	O
of	IN	O
VLPs	NN	O
than	NN	O
a	IN	O
lower	DT	O
MOI.	NNP	O
The	CC	O
sucrose	NNP	O
pelleting	VBP	O
and	NNS	O
banding	IN	O
methods	DT	O
used	JJ	O
for	NN	O
the	.	O
synthetic	IN	O
p55	NNS	O
VLPs	IN	O
were	,	O
similar	NN	O
to	IN	O
those	DT	O
employed	JJ	O
for	NN	O
the	NN	O
native	VBD	O
p55	IN	O
VLPs	DT	O
(described	NNP	O
above),	IN	O
with	CD	O
the	VBD	O
following	IN	O
exceptions:	JJR	O
pelleted	NN	O
VLPs	RB	O
were	)	O
suspended	IN	O
in	NNP	O
4	IN	O
ml	DT	O
of	JJR	O
phosphate	.	O
buffered	DT	O
saline	JJ	O
(PBS)	NN	O
instead	CC	O
of	NN	O
1.0	NNS	O
ml	VBN	O
of	IN	O
the	DT	O
Tris	JJ	O
buffer;	NN	O
and	NNP	O
four,	VBD	O
20-60%	JJ	O
sucrose	TO	O
gradients	DT	O
were	VBN	O
used	IN	O
instead	DT	O
of	JJ	O
a	NN	O
single	NNP	O
gradient.	VBN	O
Also,	,	O
due	IN	O
to	DT	O
the	JJ	O
high	:	O
concentration	VBN	O
of	NNP	O
banded	VBD	O
VLPs,	VBN	O
further	IN	O
concentration	CD	O
by	NN	O
pelleting	IN	O
was	NN	O
not	VBN	O
required.	NN	O
The	)	O
peak	RB	O
fractions	IN	O
from	CD	O
all	NN	O
4	IN	O
gradients	DT	O
were	NNP	O
simply	:	O
dialyzed	CC	O
against	,	O
PBS.	NN	O
The	JJ	O
approximate	NNS	O
density	VBD	O
of	VBN	O
the	RB	O
banded	IN	O
VLPs	DT	O
ranged	JJ	O
from	.	O
1.23-1.28	,	O
g/ml.	JJ	O
A	TO	O
total	DT	O
protein	JJ	O
yield	NN	O
as	IN	O
estimated	JJ	O
by	,	O
BCA	JJ	O
was	NN	O
46	IN	O
mg.	VBG	O
Results	VBD	O
from	RB	O
the	.	O
sucrose	DT	O
gradient	JJ	O
banding	NNS	O
of	IN	O
the	DT	O
synthetic	CD	O
p55	NNS	O
are	VBD	O
shown	RB	O
in	VBN	O
FIG.	IN	O
5.	.	O
A	DT	O
comparison	JJ	O
of	NN	O
the	IN	O
total	DT	O
amount	JJ	O
of	NNP	O
purified	VBD	O
HIV	IN	O
p55	JJ	O
Gag	.	O
from	DT	O
several	JJ	O
preparations	JJ	O
obtained	NN	O
from	IN	O
the	VBN	O
two	IN	O
baculovirus	NNP	O
expression	VBD	O
cassettes	CD	O
has	.	O
been	NNS	O
summarized	IN	O
in	DT	O
FIG.	JJ	O
6.	NN	O
The	NN	O
average	IN	O
yield	DT	O
from	JJ	O
the	NN	O
native	VBP	O
p55	VBN	O
was	IN	O
3.16	.	O
mg/liter	.	O
of	DT	O
culture	NN	O
(n=5,	IN	O
standard	DT	O
deviation	JJ	O
(sd)	NN	O
±1.07,	IN	O
range=1.8-4.8	JJ	O
mg/L)	NNP	O
whereas	NN	O
the	NNP	O
average	IN	O
yield	JJ	O
from	NNS	O
the	VBN	O
synthetic	IN	O
p55	DT	O
was	CD	O
more	NN	O
than	NN	O
ten-fold	VBZ	O
higher	VBZ	O
at	VBN	O
44.5	VBN	O
mg/liter	IN	O
of	.	O
culture	.	O
(n=2,	DT	O
sd=±6.4).	JJ	O
In	NN	O
addition	IN	O
to	DT	O
a	JJ	O
higher	NN	O
total	VBD	O
protein	CD	O
yield,	NN	O
the	IN	O
final	NN	O
product	,	O
from	JJ	O
the	NN	O
synthetic	)	O
p55-expressed	,	O
Gag	JJ	O
consistently	)	O
contained	IN	O
lower	DT	O
amounts	JJ	O
of	NN	O
contaminating	IN	O
baculovirus	DT	O
proteins	JJ	O
than	NN	O
the	VBD	O
final	JJR	O
product	IN	O
from	JJ	O
the	JJR	O
native	IN	O
p55-expressed	CD	O
Gag.	NN	O
This	IN	O
difference	NN	O
can	,	O
be	.	O
seen	IN	O
in	NN	O
the	TO	O
two	DT	O
commassie-stained	JJR	O
gels	JJ	O
FIGS.	JJ	O
4	,	O
and	DT	O
5.	JJ	O
C.	NN	O
Expression	IN	O
of	DT	O
Native	JJ	O
and	JJ	O
Synthetic	NNP	O
Gag-Core	RB	O
Expression	VBD	O
of	JJR	O
the	NNS	O
HIV	IN	O
p55	VBG	O
Gag/HCV	NN	O
Core	NNS	O
173	IN	O
(SEQ	DT	O
ID	JJ	O
NO:8)	NN	O
was	IN	O
achieved	DT	O
using	JJ	O
a	JJ	O
2.5	.	O
liter	DT	O
suspension	NN	O
culture	MD	O
of	VB	O
Sf9	VBN	O
cells	IN	O
grown	DT	O
in	CD	O
serum-free	JJ	O
medium	NNS	O
Miaorella,	.	B
B.,	CD	I
D.	CC	I
Inlow,	.	I
A.	NNP	I
Shauger,	NNP	I
and	IN	I
D.	NNP	I
Harano.	CC	I
1988	NNP	I
Bio/Technology	NNP	I
6:1506-1510).(	NNP	O
The	IN	O
cells	DT	O
were	NNP	O
infected	NN	O
with	NNP	O
an	NNP	O
HIV	CD	O
p55	NNP	O
Gag/HCV	NNP	O
Core	)	O
173	VBD	O
recombinant	VBN	O
baculovirus.	VBG	O
Forty-eight	DT	O
hours	CD	O
post-infection,	NN	O
the	NN	O
supernatant	NN	O
was	IN	O
separated	NNP	O
from	NNS	O
the	VBN	O
cells	IN	O
by	JJ	O
centrifugation	NN	O
and	,	O
filtered	,	O
through	NNP	O
a	,	O
0.2	NNP	O
μm	,	O
filter.	CC	O
Aliquots	NNP	O
of	.	O
the	CD	O
supernatant	NNP	O
were	.	O
then	DT	O
transferred	NNS	O
to	VBD	O
a	VBN	O
Polyclear™	IN	O
(Beckman	DT	O
Instruments,	NNP	O
Palo	NN	O
Alto,	NNP	O
Calif.)	NNP	O
ultracentrifuge	CD	O
tubes	NN	O
containing	.	O
30%	JJ	O
(wt/wt)	NNS	O
sucrose,	,	O
and	DT	O
subjected	NN	O
to	VBD	O
2	VBN	O
hours	IN	O
of	DT	O
centrifugation	NNS	O
at	IN	O
24,000	NN	O
rpm	CC	O
in	VBD	O
a	IN	O
Beckman	DT	O
SW28	CD	O
rotor	NN	O
and	.	O
ultracentrifuge.	NNS	O
The	IN	O
resulting	DT	O
pellet	NN	O
was	VBD	O
suspended	RB	O
in	VBN	O
Tris	TO	O
buffer	DT	O
(50	NNP	O
mM	NNP	O
Tris-HCl,	,	O
pH	NNP	O
7.5,	,	O
500	)	O
mM	NN	O
NaCl)	NNS	O
and	VBG	O
layered	NN	O
onto	)	O
a	,	O
30-60%	CC	O
(wt/wt)	VBD	O
sucrose	TO	O
gradient	CD	O
and	NNS	O
subjected	IN	O
to	NN	O
2	IN	O
hours	CD	O
centrifugation	NN	O
at	IN	O
40,000	DT	O
rpm	NNP	O
in	NNP	O
a	NN	O
Beckman	CC	O
SW41ti	.	O
rotor	DT	O
and	VBG	O
ultracentrifuge.	NN	O
The	VBD	O
gradient	VBN	O
was	IN	O
then	NNP	O
fractionated	NN	O
starting	CD	O
at	RB	O
the	,	O
top	NN	O
(30%)	,	O
of	CD	O
the	NN	O
gradient	)	O
into	CC	O
approximately	VBN	O
11×1.0	IN	O
ml	DT	O
aliquots.	NN	O
A	)	O
sample	VB	O
of	NN	O
each	CC	O
fraction	VBN	O
was	TO	O
electrophoresed	CD	O
on	NNS	O
8-16%	NN	O
SDS	IN	O
polyacrylamide	CD	O
gels	NN	O
and	IN	O
the	DT	O
resulting	NNP	O
bands	NNP	O
were	NN	O
visualized	CC	O
after	.	O
commassie	DT	O
staining.	NN	O
A	VBD	O
subset	RB	O
of	VBN	O
aliquots	VBG	O
were	IN	O
also	DT	O
subjected	NN	O
to	)	O
Western	IN	O
blot	DT	O
analysis	NN	O
using	IN	O
monoclonal	RB	O
antibody	CD	O
76C.5EG	JJ	O
Steimer,	.	B
K.	DT	I
S.,	NN	I
et	IN	I
al.,	DT	I
Virology	NN	I
150:283-290,	VBD	I
1986)	VBN	I
(which	IN	O
is	NN	O
specific	NNP	O
for	NN	O
HIV	NNS	O
p24	CC	O
(a	DT	O
subunit	VBG	O
of	NNS	O
HIV	VBD	O
p55).	VBN	O
The	IN	O
peak	NN	O
fractions	.	O
from	DT	O
the	NN	O
sucrose	IN	O
gradient	NNS	O
were	VBD	O
pooled	RB	O
and	VBN	O
concentrated	TO	O
by	NNP	O
a	NN	O
second	NN	O
20%	VBG	O
sucrose	JJ	O
pelleting.	NN	O
The	CD	O
resulting	,	O
pellet	NNP	O
was	,	O
suspended	FW	O
in	,	O
1	NNP	O
ml	,	O
of	)	O
buffer	WDT	O
Tris	VBZ	O
buffer	JJ	O
and	IN	O
the	NNP	O
total	NN	O
protein	DT	O
yield	NN	O
as	IN	O
estimated	NNP	O
by	.	O
BCA	DT	O
(Pierce	JJ	O
Chemical,	NNS	O
Rockford,	IN	O
Ill.)	DT	O
was	JJ	O
˜1.0	NN	O
mg.	VBD	O
The	VBN	O
results	CC	O
from	VBN	O
the	IN	O
SDS	DT	O
PAGE	JJ	O
are	NN	O
shown	JJ	O
in	.	O
FIG.	DT	O
8	VBG	O
and	NN	O
the	VBD	O
anti-p24	VBN	O
Western	IN	O
blot	CD	O
results	NN	O
are	IN	O
shown	NN	O
in	NNP	O
FIG.	NN	O
9.	CC	O
Taken	DT	O
together,	JJ	O
these	JJ	O
results	NN	O
indicate	IN	O
that	VBN	O
the	IN	O
HIV	NNP	O
p55	NNP	O
Gag/HCV	,	O
Core	,	O
173	)	O
chimeric	VBD	O
VLPs	JJ	O
banded	.	O
at	DT	O
a	NNS	O
sucrose	IN	O
density	DT	O
similar	NNP	O
to	NNP	O
that	VBP	O
of	VBN	O
the	IN	O
HIV	.	O
p55	CD	O
Gag	CC	O
VLPs	DT	O
and	JJ	O
the	JJ	O
visible	NN	O
protein	NNS	O
band	VBP	O
that	VBN	O
migrated	IN	O
at	.	O
a	.	O
molecular	VBN	O
weight	,	O
of	DT	O
˜72,000	NNS	O
kd	VBP	O
was	IN	O
reactive	DT	O
with	NNP	O
the	NN	O
HIV	NNP	O
p24-specific	NNP	O
monoclonal	CD	O
antibody.	NN	O
An	NNP	O
additional	VBD	O
immunoreactive	IN	O
band	DT	O
at	JJ	O
approximately	NN	O
55,000	JJ	O
kd	TO	O
also	DT	O
appeared	IN	O
to	DT	O
be	NNP	O
reactive	NN	O
with	NNP	O
the	NNP	O
anti-p24	CC	O
antibody	DT	O
and	JJ	O
may	NN	O
be	NN	O
a	WDT	O
degradation	VBD	O
product.	IN	O
Although	DT	O
aliquots	JJ	O
from	NN	O
the	IN	O
above	NNP	O
preparation	NN	O
were	VBD	O
not	JJ	O
tested	IN	O
for	DT	O
reactivity	NNP	O
with	JJ	O
an	JJ	O
HCV	.	O
Core-specific	DT	O
antibody	JJ	O
(an	NN	O
anti-CD22	NN	O
rabbit	IN	O
serum),	RB	O
results	CD	O
from	NNS	O
a	RB	O
similar	VBD	O
preparation	TO	O
are	VB	O
shown	JJ	O
in	IN	O
FIG.	DT	O
10	JJ	O
and	NN	O
indicate	CC	O
that	MD	O
the	VB	O
main	DT	O
HCV	NN	O
Core-specific	.	O
reactivity	IN	O
migrates	NNS	O
at	IN	O
an	DT	O
approximate	JJ	O
molecular	NN	O
weight	VBD	O
of	RB	O
72,000	VBN	O
kd	IN	O
which	NN	O
is	IN	O
in	DT	O
accordance	NNP	O
with	NNP	O
the	NN	O
predicted	DT	O
molecular	JJ	O
weight	NN	O
of	,	O
the	NNS	O
chimeric	IN	O
protein.	DT	O
The	JJ	O
expression	NN	O
conditions	VBP	O
for	VBN	O
the	IN	O
synthetic	.	O
HIV	CD	O
p55	CC	O
Gag/HCV	VB	O
Core	IN	O
173	DT	O
(SEQ	JJ	O
ID	NNP	O
NO:8)	NNP	O
VLPs	NN	O
differed	NNS	O
from	IN	O
those	DT	O
of	JJ	O
the	JJ	O
native	NN	O
p55	IN	O
Gag	CD	O
and	NN	O
are	WDT	O
as	VBZ	O
follows:	IN	O
a	NN	O
culture	IN	O
volume	DT	O
of	JJ	O
1	JJ	O
liter	NN	O
used	IN	O
instead	DT	O
of	JJ	O
2.5	.	O
liters,	DT	O
Trichoplusia	NN	O
ni	NNS	O
(Tn5)	IN	O
Wickham,	DT	B
T.	JJ	I
J.,	NNP	I
and	NN	I
Nemerow,	NNP	I
G.	NNP	I
R.	CD	I
1993	NNP	I
BioTechnology	NNP	I
Progress,	)	I
9:25-30)	NNP	I
(insect	VBN	O
cells	IN	O
were	DT	O
used	IN	O
instead	DT	O
of	JJ	O
Sf9	NN	O
insect	NNP	O
cells	CC	O
and	VBP	O
an	IN	O
MOI	:	O
of	DT	O
3	NN	O
was	NN	O
instead	IN	O
of	CD	O
an	NN	O
MOI	VBN	O
of	RB	O
10.	IN	O
The	CD	O
sucrose	,	O
pelleting	NNP	O
and	FW	O
banding	)	O
methods	,	O
used	NNP	O
for	,	O
the	CC	O
synthetic	,	O
HIV	NNP	O
p55	NNP	O
Gag/HCV	CD	O
Core	NNP	O
173	,	O
VLPs	)	O
were	NN	O
similar	NNS	O
to	VBD	O
those	VBN	O
employed	RB	O
for	IN	O
the	NNP	O
native	JJ	O
HIV	NNS	O
p55	CC	O
Gag/HCV	DT	O
Core	NNP	O
173	IN	O
VLPs.	CD	O
However,	VBD	O
differences	RB	O
included:	IN	O
pelleted	DT	O
VLPs	NNP	O
were	IN	O
suspended	.	O
in	DT	O
1	JJ	O
ml	NN	O
of	CC	O
phosphate	NN	O
buffered	NNS	O
saline	VBN	O
(PBS)	IN	O
instead	DT	O
of	JJ	O
1.0	NNP	O
ml	NN	O
of	NNP	O
the	NNP	O
Tris	CD	O
buffer,	NNP	O
and	VBD	O
a	JJ	O
single	TO	O
20-60%	DT	O
sucrose	VBN	O
gradients	IN	O
was	DT	O
used.	JJ	O
A	NNP	O
comparison	NN	O
of	NNP	O
the	NNP	O
total	CD	O
amount	.	O
of	,	O
purified	NNS	O
HIV	:	O
p55	VBN	O
Gag/HCV	NNP	O
Core	VBD	O
173	VBN	O
from	IN	O
multiple	CD	O
preparations	NN	O
obtained	IN	O
from	NN	O
the	VBN	O
two	NN	O
baculovirus	)	O
expression	RB	O
cassettes	IN	O
showed	CD	O
that	NN	O
there	IN	O
was	DT	O
an	NNP	O
increase	,	O
in	CC	O
expression	DT	O
using	JJ	O
the	NN	O
synthetic	JJ	O
HIV	NNS	O
p55	VBD	O
Gag/HCV	.	O
Core	DT	O
173	NN	O
cassette.	IN	O
D.	DT	O
Alternative	JJ	O
Method	NN	O
for	IN	O
the	JJ	O
Enrichment	NNP	O
of	NN	O
HIV	NNP	O
p55	NNP	O
Gag	CD	O
VLPs	IN	O
In	JJ	O
addition	NNS	O
to	VBN	O
purification	IN	O
from	DT	O
the	CD	O
media,	NN	O
p55	NN	O
(Gag	VBZ	O
protein)	VBD	O
expressed	IN	O
in	EX	O
baculovirus	VBD	O
(e.g.,	DT	O
using	NN	O
a	IN	O
synthetic	NN	O
expression	VBG	O
cassette	DT	O
of	JJ	O
the	NNP	O
present	NN	O
invention)	NNP	O
can	NNP	O
also	CD	O
be	.	O
purified	NNP	O
as	NNP	O
virus-like	NNP	O
particles	IN	O
from	DT	O
the	NNP	O
infected	IN	O
insect	NNP	O
cells.	NN	O
For	NNP	O
example,	NNP	O
forty-eight	IN	O
hours	NN	O
post	TO	O
infection,	NN	O
the	IN	O
media	DT	O
and	,	O
cell	NN	O
pellet	NNP	O
are	)	O
separated	VBN	O
by	IN	O
centrifugation	NN	O
and	,	O
the	VBG	O
cell	DT	O
pellet	JJ	O
is	NN	O
stored	NN	O
at	IN	O
−70°	DT	O
C.	JJ	O
until	)	O
future	MD	O
use.	RB	O
At	VB	O
the	VBN	O
time	IN	O
of	JJ	O
processing,	NNS	O
the	IN	O
cell	DT	O
pellet	JJ	O
is	NN	O
suspended	.	O
in	IN	O
5	,	O
volumes	JJ	O
of	NNS	O
hypotonic	NN	O
lysis	,	O
buffer	DT	O
(20	NNS	O
mM	CC	O
Tris-HCl,	NN	O
pH	NN	O
8.2,	VBP	O
1	VBN	O
mM	IN	O
EGTA;	NN	O
1	CC	O
mM	DT	O
MgCl,	NN	O
and	NN	O
Complete	VBZ	O
Protease	VBN	O
Inhibitor®	IN	O
(Boehringer	NNP	O
Mannheim	NNP	O
Corp.,	IN	O
Indianapolis,	JJ	O
Ind.]).	.	O
If	IN	O
needed,	DT	O
the	NN	O
cells	IN	O
are	,	O
then	DT	O
dounced	NN	O
8-10	NN	O
times	VBZ	O
to	VBN	O
complete	IN	O
cell	CD	O
lysis.	NNS	O
The	IN	O
lysate	JJ	O
is	NN	O
then	NN	O
centrifuged	CD	O
at	RB	O
approximately	,	O
1000-1500×g	NN	O
for	,	O
20	CD	O
minutes.	NN	O
The	:	O
supernatant	CD	O
is	NN	O
decanted	,	O
into	CC	O
UltraClear™	NNP	O
tubes,	NNP	O
underlayed	NNP	O
with	NNP	O
20%	NNP	O
sucrose	,	O
(w/w)	,	O
and	.	O
centrifuged	IN	O
at	,	O
24,000	DT	O
rpm	NNS	O
in	VBP	O
SW28	RB	O
buckets	VBN	O
for	JJ	O
2	NNS	O
hours.	TO	O
The	VB	O
resulting	NN	O
pellet	.	O
is	DT	O
suspended	NN	O
in	VBZ	O
Tris	RB	O
buffer	VBN	O
(20	IN	O
mM	RB	O
Tris	JJ	O
HCl,	IN	O
pH	CD	O
7.5,	.	O
250	DT	O
mM	NN	O
NaCl,	VBZ	O
and	VBN	O
2.5	IN	O
mM	NNP	O
ethylene-diamine-tetraacetic	,	O
acid	JJ	O
(EDTA)	IN	O
with	NN	O
0.1%	NN	O
IGEPAL	)	O
detergent	CC	O
(Sigma	VBN	O
Chemical,	IN	O
St.	CD	O
Louis,	NN	O
Mo.)	IN	O
and	NNP	O
250	NNS	O
units/ml	IN	O
of	CD	O
benzonase	.	O
(American	DT	O
International	JJ	O
Chemical,	NN	O
Inc.,	VBZ	O
Natick,	VBN	O
Mass.)	IN	O
and	NNP	O
incubated	NN	O
at	CD	O
4°	NN	O
C.	NNP	O
for	,	O
at	NN	O
least	,	O
30	CD	O
minutes.	NN	O
The	,	O
suspension	CC	O
is	CD	O
subsequently	JJ	O
layered	JJ	O
onto	NN	O
a	)	O
20-60%	IN	O
sucrose	NN	O
gradient	NNP	O
and	NN	O
spun	NNP	O
at	,	O
40,000	NNP	O
rpm	,	O
using	)	O
an	CC	O
SW41ti	CD	O
rotor	NN	O
for	IN	O
20-24	NN	O
hours.	JJ	O
After	NNP	O
ultracentrifugation,	,	O
the	,	O
sucrose	,	O
gradient	)	O
is	CC	O
fractionated	VBN	O
and	IN	O
aliquots	CD	O
run	NNP	O
on	IN	O
SDS	IN	O
PAGE	JJS	O
to	CD	O
identify	.	O
peak	DT	O
fractions.	NN	O
The	VBZ	O
peak	RB	O
fractions	VBN	O
are	IN	O
dialyzed	DT	O
against	NN	O
PBS	JJ	O
and	NN	O
measured	CC	O
for	NN	O
protein	IN	O
content.	CD	O
Negatively	NN	O
stained	VBG	O
electron	DT	O
mircographs	NNP	O
typically	NN	O
show	IN	O
non-enveloped	JJ	O
VLPs	.	O
somewhat	IN	O
smaller	,	O
in	DT	O
diameter	JJ	O
(80-120	NN	O
nm)	VBZ	O
than	VBN	O
the	CC	O
budded	NNS	O
VLPs.	VBP	O
HIV	IN	O
Gag	NNP	O
VLPs	NNP	O
prepared	TO	O
in	VB	O
this	JJ	O
manner	.	O
are	DT	O
also	JJ	O
capable	NNS	O
of	VBP	O
generating	VBN	O
Gag-specific	IN	O
CTL	NNP	O
responses	CC	O
in	VBN	O
mice.	IN	O
Example	NN	O
8	.	O
In	RB	O
Vivo	VBN	O
Immunogenicity	NN	O
of	NN	O
Synthetic	RB	O
Gag	VBP	O
Expression	JJ	O
Cassettes	NNP	O
A.	RB	O
Immunization	JJR	O
To	IN	O
evaluate	NN	O
the	JJ	O
possibly	)	O
improved	IN	O
immunogenicity	DT	O
of	JJ	O
the	.	O
synthetic	NNP	O
Gag	NNP	O
expression	NNP	O
cassettes,	VBD	O
a	IN	O
mouse	DT	O
study	NN	O
was	VBP	O
performed.	RB	O
The	JJ	O
plasmid	IN	O
DNA,	VBG	O
pCMVKM2	NNP	O
carrying	NNP	O
the	NNS	O
synthetic	IN	O
Gag	.	O
expression	JJ	O
cassette,	CD	O
was	IN	O
diluted	NNP	O
to	NNP	O
the	IN	O
following	NNP	O
final	NNP	O
concentrations	NNP	O
in	NNP	O
a	NNP	O
total	NNP	O
injection	TO	O
volume	VB	O
of	DT	O
100	RB	O
μl:	VBN	O
20	NN	O
μg,	IN	O
2	DT	O
μg,	JJ	O
0.2	NNP	O
μg,	NN	O
and	,	O
0.02	DT	O
μg.	NN	O
To	NN	O
overcome	VBD	O
possible	.	O
negative	DT	O
dilution	NN	O
effects	,	O
of	NN	O
the	VBG	O
diluted	DT	O
DNA,	JJ	O
the	NNP	O
total	NN	O
DNA	,	O
concentration	VBD	O
in	VBN	O
each	TO	O
sample	DT	O
was	JJ	O
brought	JJ	O
up	NNS	O
to	IN	O
20	DT	O
μg	JJ	O
using	NN	O
the	NN	O
vector	IN	O
(pCMVKM2)	CD	O
alone.	:	O
As	CD	O
a	,	O
control,	CD	O
plasmid	,	O
DNA	CD	O
of	,	O
the	CC	O
native	CD	O
Gag	.	O
expression	TO	O
cassette	VB	O
was	JJ	O
handled	JJ	O
in	NN	O
the	NNS	O
same	IN	O
manner.	DT	O
Twelve	JJ	O
groups	,	O
of	DT	O
four	JJ	O
Balb/c	NNP	O
mice	NN	O
(Charles	IN	O
River,	DT	O
Boston,	NN	O
Mass.)	VBD	O
were	VBN	O
intramuscularly	RP	O
immunized	TO	O
(50	CD	O
μl	NNS	O
per	VBG	O
leg,	DT	O
intramuscular	NN	O
injection	)	O
into	.	O
the	IN	O
tibialis	DT	O
anterior)	,	O
according	JJ	O
to	NN	O
the	IN	O
schedule	DT	O
in	JJ	O
Table	NNP	O
7.	NN	O
B.	NN	O
Humoral	VBD	O
Immune	VBN	O
Response	IN	O
The	DT	O
humoral	JJ	O
immune	.	O
response	NNP	O
was	NNS	O
checked	IN	O
with	CD	O
an	NNP	O
anti-HIV	NN	O
Gag	NNP	O
antibody	,	O
ELISAs	,	O
(enzyme-linked	)	O
immunosorbent	VBD	O
assays)	RB	O
of	VBN	O
the	CD	O
mice	NN	O
sera	IN	O
0	,	O
and	JJ	O
4	NN	O
weeks	IN	O
post	DT	O
immunization	JJ	O
(groups	)	O
5-12)	VBG	O
and,	TO	O
in	DT	O
addition,	NN	O
6	IN	O
and	JJ	O
8	.	O
weeks	NNP	O
post	NNP	O
immunization,	NNP	O
respectively,	NNP	O
2	DT	O
and	JJ	O
4	NN	O
weeks	NN	O
post	VBD	O
second	VBN	O
immunization	IN	O
(groups	DT	O
1-4).	JJ	O
The	NNP	O
antibody	NN	O
titers	NNP	O
of	JJ	O
the	NN	O
sera	)	O
were	IN	O
determined	DT	O
by	NN	O
anti-Gag	NN	O
antibody	CD	O
ELISA.	CC	O
Briefly,	CD	O
sera	NNS	O
from	NN	O
immunized	NN	O
mice	NNS	O
were	)	O
screened	,	O
for	IN	O
antibodies	,	O
directed	CD	O
against	CC	O
the	CD	O
HIV	NNS	O
p55	NN	O
Gag	,	O
protein.	,	O
ELISA	CD	O
microtiter	CC	O
plates	CD	O
were	NNS	O
coated	RB	O
with	JJ	O
0.2	NN	O
μg	NNS	O
of	.	O
HIV-1SF2	DT	O
p24-Gag	NN	O
protein	NNS	O
per	IN	O
well	DT	O
overnight	NN	O
and	VBD	O
washed	VBN	O
four	IN	O
times;	JJ	O
subsequently,	NN	O
blocking	.	O
was	,	O
done	NN	O
with	IN	O
PBS-0.2%	JJ	O
Tween	NNS	O
(Sigma)	VBD	O
for	VBN	O
2	IN	O
hours.	NNS	O
After	VBN	O
removal	IN	O
of	DT	O
the	NNP	O
blocking	NN	O
solution,	NNP	O
100	.	O
μl	NNP	O
of	NN	O
diluted	NNS	O
mouse	VBD	O
serum	VBN	O
was	IN	O
added.	CD	O
Sera	NNS	O
were	IN	O
tested	NNP	O
at	JJ	O
1/25	NN	O
dilutions	IN	O
and	RB	O
by	JJ	O
serial	CC	O
3-fold	VBD	O
dilutions,	CD	O
thereafter.	:	O
Microtiter	,	O
plates	VBG	O
were	VBD	O
washed	VBN	O
four	IN	O
times	NN	O
and	NNP	O
incubated	)	O
with	IN	O
a	CD	O
secondary,	.	O
peroxidase-coupled	IN	O
anti-mouse	NN	O
IgG	IN	O
antibody	DT	O
(Pierce,	VBG	O
Rockford,	,	O
Ill.).	CD	O
ELISA	NN	O
plates	IN	O
were	VBN	O
washed	NN	O
and	NN	O
100	VBD	O
μl	.	O
of	NN	O
3,3′,5,5′-tetramethyl	VBD	O
benzidine	VBN	O
(TMB;	IN	O
Pierce)	CD	O
was	NNS	O
added	CC	O
per	IN	O
well.	JJ	O
The	JJ	O
optical	,	O
density	.	O
of	NN	O
each	NNS	O
well	VBD	O
was	VBN	O
measured	CD	O
after	NNS	O
15	CC	O
minutes.	VBN	O
The	IN	O
titers	DT	O
reported	,	O
are	JJ	O
the	NN	O
reciprocal	NNP	O
of	NN	O
the	,	O
dilution	,	O
of	.	O
serum	NNP	O
that	NNS	O
gave	VBD	O
a	VBN	O
half-maximum	CC	O
optical	CD	O
density	NN	O
(O.	IN	O
D.).	JJ	O
The	NN	O
ELISA	:	O
results	)	O
are	VBD	O
presented	VBN	O
in	IN	O
Table	.	O
8.	DT	O
The	JJ	O
results	NN	O
of	IN	O
the	DT	O
mouse	NN	O
immunizations	VBD	O
with	VBN	O
plasmid-DNAs	IN	O
show	CD	O
that	.	O
the	DT	O
synthetic	NNS	O
expression	VBN	O
cassettes	VBP	O
provide	DT	O
a	NN	O
clear	IN	O
improvement	DT	O
of	NN	O
immunogenicity	IN	O
relative	NN	O
to	WDT	O
the	VBD	O
native	DT	O
expression	JJ	O
cassettes.	JJ	O
Also,	NN	O
the	NNP	O
second	.	O
boost	DT	O
immunization	NNP	O
induced	NNS	O
a	VBP	O
secondary	VBN	O
immune	IN	O
response	JJ	O
after	.	O
two	DT	O
weeks	NNS	O
(groups	IN	O
1-3).	DT	O
C.	NN	O
Cellular	NNS	O
Immune	IN	O
Response	JJ	O
The	NN	O
frequency	IN	O
of	DT	O
specific	JJ	O
cytotoxic	NN	O
T-lymphocytes	NNS	O
(CTL)	VBP	O
was	DT	O
evaluated	JJ	O
by	NN	O
a	IN	O
standard	NN	O
chromium	NN	O
release	TO	O
assay	DT	O
of	JJ	O
peptide	NN	O
pulsed	.	O
Balb/c	,	O
mouse	DT	O
CD4	JJ	O
cells.	NN	O
Gag	NN	O
expressing	VBD	O
vaccinia	DT	O
virus	JJ	O
infected	NN	O
CD-8	NN	O
cells	IN	O
were	CD	O
used	NNS	O
as	NNS	O
a	.	O
positive	NNP	O
control	NNP	O
(vvGag).	NNP	O
Briefly,	NNP	O
spleen	DT	O
cells	NN	O
(Effector	IN	O
cells,	JJ	O
E)	JJ	O
were	NNS	O
obtained	)	O
from	VBD	O
the	VBN	O
BALB/c	IN	O
mice	DT	O
immunized,	JJ	O
as	NN	O
described	NN	O
above	NN	O
(Table	IN	O
8)	NN	O
were	VBN	O
cultured,	NNP	O
restimulated,	NN	O
and	NNP	O
assayed	.	O
for	NNP	O
CTL	VBG	O
activity	NN	O
against	NN	O
Gag	VBD	O
peptide-pulsed	NNP	O
target	NNS	O
cells	VBD	O
as	VBN	O
described	IN	O
Doe,	DT	B
B.,	JJ	I
and	NN	I
Walker,	.	I
C.	,	I
M.,	JJ	I
AIDS	NNS	I
10(7):793-794,	NNP	I
1996).(	,	O
The	)	O
HIV-1SF2	VBD	O
Gag	VBN	O
peptide	IN	O
used	DT	O
was	NNP	O
p7g	NN	O
SEQ	,	O
ID	IN	O
NO:10.	VBN	O
Cytotoxic	IN	O
activity	JJ	O
was	)	O
measured	VBD	O
in	,	O
a	,	O
standard	CC	O
51Cr	VBD	O
release	IN	O
assay.	NNP	O
Target	NN	O
(T)	IN	O
cells	NNP	O
were	JJ	O
cultured	NN	O
with	NNS	O
effector	IN	O
(E)	NN	O
cells	,	O
at	,	O
various	CC	O
E:T	,	O
ratios	NNP	O
for	,	O
4	NNP	O
hours	,	O
and	.	O
the	DT	O
average	NNP	O
cpm	NNP	O
from	NN	O
duplicate	VBN	O
wells	VBD	O
was	JJ	O
used	NNP	O
to	NNP	O
calculate	.	O
percent	NNP	O
specific	NN	O
51Cr	VBD	O
release.	VBN	O
The	IN	O
results	DT	O
are	JJ	O
presented	CD	O
in	NN	O
Table	.	O
9.	NN	O
Cytotoxic	)	O
T-cell	NNS	O
(CTL)	VBD	O
activity	VBN	O
was	IN	O
measured	NN	O
in	)	O
splenocytes	NNS	O
recovered	IN	O
from	JJ	O
the	NNP	O
mice	NNS	O
immunized	IN	O
with	CD	O
HIV	NNS	O
Gag	CC	O
DNA	DT	O
(compare	JJ	O
Effector	NN	O
column,	IN	O
Table	NN	O
9,	NNS	O
to	VBD	O
immunization	VBN	O
schedule,	TO	O
Table	VB	O
8).	NN	O
Effector	JJ	O
cells	CD	O
from	.	O
the	DT	O
Gag	NNS	O
DNA-immunized	VBP	O
animals	VBN	O
exhibited	IN	O
specific	JJ	O
lysis	.	O
of	NNP	O
Gag	NNP	O
p7g	)	O
peptide-pulsed	NN	O
SV-BALB	VBD	O
(MHC	VBN	O
matched)	IN	O
targets	NNS	O
cells	VBN	O
indicative	IN	O
of	DT	O
a	NNS	O
CTL	VBN	O
response.	IN	O
Target	NNP	O
cells	NNP	O
that	NNP	O
were	JJ	O
peptide-pulsed	NNP	O
and	,	O
derived	NNP	O
from	,	O
an	TO	O
MHC-unmatched	NN	O
mouse	,	O
strain	NNP	O
(MC57)	.	O
were	NNP	O
not	NNS	O
lysed	IN	O
(Table	DT	O
9;	NNP	O
MC/p7g).	NNP	O
The	NNS	O
results	VBD	O
of	JJ	O
the	NN	O
CTL	IN	O
assays	NNP	O
show	JJ	O
increased	JJ	O
potency	NNP	O
of	NNP	O
synthetic	)	O
Gag	NNS	O
expression	NNS	O
cassettes	JJ	O
for	IN	O
induction	DT	O
of	NNP	O
cytotoxic	.	O
T-lymphocyte	NN	O
(CTL)	NNS	O
responses	WDT	O
by	VBD	O
DNA	JJ	O
immunization.	CC	O
Example	VBN	O
9	IN	O
In	DT	O
Vivo	JJ	O
Immunization	NN	O
with	NN	O
Env	)	O
Polypeptides	VBD	O
A.	RB	O
Immunogenicity	VBN	O
Study	JJ	O
of	:	O
US4	.	O
o-gp140	DT	O
in	NNS	O
Ras-3c	IN	O
Adjuvant	DT	O
System	NNP	O
Studies	VBZ	O
have	NN	O
been	VBD	O
conducted	NN	O
using	IN	O
rabbits	JJ	O
immunized	NNP	O
with	NN	O
US4	NNS	O
o-gp140	IN	O
purified	NN	O
as	IN	O
described	JJ	O
above.	NNP	O
Studies	)	O
are	NNS	O
also	IN	O
underway	NNP	O
in	.	O
animals	JJ	O
to	CD	O
determine	IN	O
immunogenicity	NNP	O
of	NNP	O
US4	IN	O
gp120,	NNP	O
SF162	NNP	O
o-gp140	NNP	O
and	NNP	O
SF162	NNP	O
gp120.	IN	O
Two	NNP	O
rabbits	JJ	O
(#1	IN	O
and	NNP	O
#2)	NNP	O
were	NNP	O
immunized	NNPS	O
intramuscularly	VBP	O
at	VBN	O
0,	VBN	O
4,	VBG	O
12	NNS	O
and	VBN	O
24	IN	O
weeks	NNP	O
with	JJ	O
50	VBD	O
μg	IN	O
of	VBN	O
US4	.	O
o-gp140	NNS	O
in	VBP	O
the	RB	O
Ribi™	RB	O
adjuvant	IN	O
system	NNS	O
(RAS-3c),	TO	O
(Ribi	VB	O
Immunochem,	NN	O
Hamilton,	IN	O
Mont.)	NNP	O
containing	,	O
2%	NNP	O
Squalene,	NN	O
0.2%	CC	O
Tween	NNP	O
80,	.	O
and	CD	O
one	NNS	O
or	CD	O
more	CC	O
bacterial	)	O
cell	VBD	O
wall	VBN	O
components	RB	O
from	IN	O
the	,	O
group	,	O
consisting	CD	O
of	CC	O
monophosphorylipid	CD	O
A	NNS	O
(MPL,	IN	O
Ribi	CD	O
Immunochem,	NNS	O
Hamilton,	IN	O
Mont.).	NNP	O
In	NN	O
each	IN	O
experiment	DT	O
described	NNP	O
herein,	NN	O
o-gp140	NN	O
can	,	O
be	NNP	O
native,	,	O
mutated	,	O
and/or	)	O
modified.	VBG	O
Antibody	NN	O
responses	,	O
directed	NN	O
against	NNP	O
the	,	O
US4	CC	O
o-gp140	CD	O
protein	CC	O
were	JJR	O
measured	JJ	O
by	NN	O
ELISA.	NN	O
Results	NNS	O
are	IN	O
shown	DT	O
in	NN	O
Table	VBG	O
10.	IN	O
The	NN	O
avidities	NNP	O
of	,	O
antibodies	NNP	O
directed	,	O
against	,	O
the	.	O
US4	IN	O
o-gp140	DT	O
protein	NN	O
were	VBD	O
measured	,	O
in	JJ	O
a	MD	O
similar	VB	O
ELISA	,	O
format	VBD	O
employing	RB	O
successive	.	O
washes	NN	O
with	NNS	O
increasing	VBN	O
concentrations	IN	O
of	DT	O
ammonium	NNP	O
isothiocynate.	JJ	O
Results	NN	O
are	VBD	O
shown	VBN	O
in	IN	O
Table	.	O
11.	NNS	O
These	VBP	O
results	VBN	O
show	IN	O
that	JJ	O
US4	.	O
o-gp140	DT	O
is	NNS	O
highly	IN	O
immunogenic	NNS	O
and	VBN	O
able	IN	O
to	DT	O
induce	NNP	O
substantial	JJ	O
antibody	NN	O
responses	VBD	O
after	VBN	O
only	IN	O
one	DT	O
or	JJ	O
two	NNP	O
immunizations.	NN	O
B.	VBG	O
Immunogenicity	JJ	O
of	NNS	O
US4	IN	O
o-gp140	VBG	O
in	NNS	O
MF59-Based	IN	O
Adjuvants	NN	O
Groups	.	O
of	NNS	O
4	VBP	O
rabbits	VBN	O
were	IN	O
immunized	JJ	O
intramuscularly	.	O
at	DT	O
0,	NNS	O
4,	VBP	O
12	IN	O
and	NNP	O
24	NN	O
weeks	VBZ	O
with	RB	O
various	JJ	O
doses	CC	O
of	JJ	O
US4	TO	O
o-gp140	VB	O
protein	JJ	O
in	NN	O
three	NNS	O
different	IN	O
MF59-based	RB	O
adjuvants	CD	O
(MF59	CC	O
is	CD	O
described	.	O
in	NNP	O
International	NNP	O
Publication	IN	O
No.	NNP	O
WO	JJ	O
90/14837	IN	O
and	JJ	O
typically	NNS	O
contains	NNP	O
5%	IN	O
Squalene,	CD	O
0.5%	NNS	O
Tween	VBD	O
80,	VBN	O
and	RB	O
0.5%	IN	O
Span	,	O
85).	,	O
Antibody	CD	O
titers	CC	O
were	CD	O
measured	NNS	O
post-third	IN	O
by	JJ	O
ELISA	NNS	O
using	IN	O
SF2	NNP	O
gp120	JJ	O
to	NN	O
coat	IN	O
the	CD	O
plates.	JJ	O
QHC	JJ	O
is	NNS	O
a	NNP	O
quill-based	VBZ	O
adjuvant	VBN	O
(Iscotek,	IN	O
Uppsala,	NNP	O
Sweden).	NNP	O
Results	.	O
are	$	O
shown	CD	O
in	CC	O
Table	RB	O
12.	VBZ	O
Thus,	NN	O
adjuvanted	,	O
o-gp140	NN	O
generated	NNP	O
antigen-specific	,	O
antibodies.	CC	O
Further,	NN	O
the	NNP	O
antibodies	.	O
were	NN	O
shown	NNS	O
to	VBD	O
increased	VBN	O
in	JJ	O
avidity	IN	O
over	NNP	O
time.	VBG	O
C.	NNP	O
Neutralizing	NN	O
Antibodies	TO	O
Neutralizing	VB	O
antibodies	DT	O
post-third	.	O
immunization	NNP	O
were	VBZ	O
measured	DT	O
against	JJ	O
HIV-1	NN	O
SF2	,	O
in	,	O
a	.	O
T-cell	NNS	O
line	VBP	O
adapted	VBN	O
virus	IN	O
(TCLA)	JJ	O
assay	.	O
and	,	O
against	VBD	O
PBMC-grown	JJ	O
HIV-1	JJ	O
variants	JJ	O
SF2,	.	O
SF162	,	O
and	DT	O
119	NNS	O
using	VBD	O
the	VBN	O
CCR5+	TO	O
CEMx174	VBN	O
LTR-GFP	IN	O
reporter	NN	O
cell	IN	O
line,	.	O
5.25	NNP	O
(provided	NNP	O
by	NNP	O
N.	NNP	O
Landau,	VBZ	O
Salk	JJ	O
Institute,	NN	O
San	VBD	O
Diego,	VBN	O
Calif.)	IN	O
as	NNP	O
target	NNP	O
cells.	IN	O
Results	DT	O
are	NNP	O
shown	NN	O
in	VBN	O
Table	NN	O
13.	)	O
The	VBP	O
above	CC	O
studies	IN	O
in	NNP	O
rabbits	NNP	O
indicate	NNS	O
that	,	O
the	NNP	O
US4	CC	O
o-gp140	CD	O
protein	VBG	O
is	DT	O
highly	NNP	O
immunogenic.	NNP	O
When	NNP	O
administered	NN	O
with	NN	O
adjuvant,	,	O
this	CD	O
protein	VBN	O
was	IN	O
able	NNP	O
to	,	O
induce	NNP	O
substantial	,	O
antibody	NNP	O
responses	,	O
after	)	O
only	IN	O
one	NN	O
or	.	O
two	NNS	O
immunizations.	VBP	O
Moreover,	VBN	O
the	IN	O
adjuvanted	JJ	O
o-gp140	.	O
protein	DT	O
was	JJ	O
able	NNS	O
to	IN	O
generate	NNS	O
antigen-specific	VBP	O
antibodies	IN	O
which	DT	O
increased	NNP	O
in	JJ	O
avidity	NN	O
after	VBZ	O
successive	RB	O
immunizations,	.	O
and	WRB	O
substantial	VBN	O
neutralizing	IN	O
activity	,	O
against	DT	O
T-cell	NN	O
line	VBD	O
adapted	JJ	O
HIV-1.Neutralizing	TO	O
activity	VB	O
was	JJ	O
also	NN	O
observed	NNS	O
against	IN	O
PBMC-grown	RB	O
primary	CD	O
HIV	CC	O
strains,	CD	O
including	.	O
the	,	O
difficult	DT	O
to	JJ	O
neutralize	JJ	O
CCR5	NN	O
co-receptor	VBD	O
(R5)-utilizing	JJ	O
isolates,	TO	O
SF162	VB	O
and	JJ	O
119.	NNS	O
Example	WDT	O
10	VBD	O
In	IN	O
Vivo	NN	O
Immunogenicity	IN	O
of	JJ	O
Synthetic	,	O
Env	CC	O
Expression	JJ	O
Cassettes	NN	O
A.	NN	O
General	IN	O
Immunization	NNP	O
Methods	NN	O
To	VBD	O
evaluate	NNP	O
the	NN	O
immunogenicity	VBD	O
of	RB	O
the	VBN	O
synthetic	IN	O
Env	NNP	O
expression	JJ	O
cassettes,	NNP	O
studies	,	O
using	VBG	O
guinea	DT	O
pigs,	JJ	O
rabbits,	TO	O
mice,	VB	O
rhesus	NNP	O
macaques	NN	O
and	VBG	O
baboons	,	O
were	NNP	O
performed.	CC	O
The	.	O
studies	JJ	O
were	CD	O
structured	IN	O
as	NNP	O
follows:	NNP	O
DNA	IN	O
immunization	NNP	O
alone	NNP	O
(single	NNP	O
or	VBZ	O
multiple);	.	O
DNA	NNP	O
immunization	NNP	O
followed	NNP	O
by	TO	O
protein	VB	O
immunization	DT	O
(boost);	NN	O
DNA	IN	O
immunization	DT	O
followed	JJ	O
by	NNP	O
Sindbis	NN	O
particle	,	O
immunization;	NNS	O
immunization	VBG	O
by	NN	O
Sindbis	,	O
particles	,	O
alone.	,	O
B.	NN	O
Humoral	NNS	O
Immune	CC	O
Response	NNS	O
The	VBD	O
humoral	.	O
immune	DT	O
response	NNS	O
was	VBD	O
checked	VBN	O
in	IN	O
serum	:	O
specimens	NN	O
from	NN	O
immunized	RB	O
animals	JJ	O
with	CC	O
an	:	O
anti-HIV	NNP	O
Env	NN	O
antibody	VBN	O
ELISAs	IN	O
(enzyme-linked	NN	O
immunosorbent	NN	O
assays)	:	O
at	NNP	O
various	NN	O
times	VBN	O
post-immunization.	IN	O
The	NNP	O
antibody	NN	O
titers	:	O
of	NN	O
the	IN	O
sera	NNP	O
were	NNS	O
determined	.	O
by	NNP	O
anti-Env	NNP	O
antibody	NNP	O
ELISA	NNP	O
as	DT	O
described	JJ	O
above.	NN	O
Briefly,	NN	O
sera	VBD	O
from	VBN	O
immunized	IN	O
animals	NN	O
were	NNS	O
screened	IN	O
for	JJ	O
antibodies	NNS	O
directed	IN	O
against	DT	O
the	JJ	O
HIV	NNP	O
gp120	NN	O
or	NNP	O
gp140	JJ	O
Env	NN	O
protein.	)	O
Wells	IN	O
of	JJ	O
ELISA	NNS	O
microtiter	.	O
plates	DT	O
were	NN	O
coated	NNS	O
overnight	IN	O
with	DT	O
the	NN	O
selected	VBD	O
Env	VBN	O
protein	IN	O
and	JJ	O
washed	NN	O
four	NNP	O
times;	IN	O
subsequently,	VBN	O
blocking	.	O
was	,	O
done	NN	O
with	IN	O
PBS-0.2%	VBN	O
Tween	NNS	O
(Sigma)	VBD	O
for	VBN	O
2	IN	O
hours.	NNS	O
After	VBN	O
removal	IN	O
of	DT	O
the	NNP	O
blocking	NN	O
solution,	CC	O
100	NN	O
μl	NNP	O
of	.	O
diluted	NNP	O
mouse	IN	O
serum	NNP	O
was	NN	O
added.	NNS	O
Sera	VBD	O
were	VBN	O
tested	JJ	O
at	IN	O
1/25	DT	O
dilutions	VBN	O
and	NNP	O
by	NN	O
serial	CC	O
3-fold	VBD	O
dilutions,	CD	O
thereafter.	:	O
Microtiter	,	O
plates	VBG	O
were	VBD	O
washed	VBN	O
four	IN	O
times	NN	O
and	NNP	O
incubated	)	O
with	IN	O
a	CD	O
secondary,	.	O
peroxidase-coupled	IN	O
anti-mouse	NN	O
IgG	IN	O
antibody	DT	O
(Pierce,	VBG	O
Rockford,	,	O
Ill.).	CD	O
ELISA	NN	O
plates	IN	O
were	VBN	O
washed	NN	O
and	NN	O
100	VBD	O
μl	.	O
of	NN	O
3,3′,	VBD	O
5,5′-tetramethyl	VBN	O
benzidine	IN	O
(TMB;	CD	O
Pierce)	NNS	O
was	CC	O
added	IN	O
per	JJ	O
well.	JJ	O
The	,	O
optical	.	O
density	NN	O
of	NNS	O
each	VBD	O
well	VBN	O
was	CD	O
measured	NNS	O
after	CC	O
15	VBN	O
minutes.	IN	O
Titers	DT	O
are	,	O
typically	JJ	O
reported	NN	O
as	NNP	O
the	NN	O
reciprocal	,	O
of	,	O
the	.	O
dilution	NNP	O
of	NNS	O
serum	VBD	O
that	VBN	O
gave	CC	O
a	CD	O
half-maximum	NN	O
optical	IN	O
density	,	O
(O.D.).	JJ	O
Example	NN	O
11	:	O
DNA-immunization	)	O
of	VBD	O
Baboons	VBN	O
Using	IN	O
Synthetic	.	O
Gag	DT	O
Expression	JJ	O
Cassettes	NN	O
A.	IN	O
Baboons	DT	O
Four	NN	O
baboons	VBD	O
were	VBN	O
immunized	IN	O
3	CD	O
times	.	O
(weeks	NNS	O
0,	VBP	O
4	RB	O
and	VBN	O
8)	IN	O
bilaterally,	DT	O
intramuscular	NN	O
into	IN	O
the	DT	O
quadriceps	NN	O
using	IN	O
1	NN	O
mg	WDT	O
pCMVKM2.GagMod.SF2	VBD	O
plasmid-DNA	DT	O
(Example	JJ	O
1).	JJ	O
The	NN	O
animals	.	O
were	JJ	O
bled	CD	O
two	NN	O
weeks	IN	O
after	NNP	O
each	NNP	O
immunization	NNP	O
and	NNP	O
a	NNP	O
p24	NNP	O
antibody	NNP	O
ELISA	NNP	O
was	NNP	O
performed	NNS	O
with	VBD	O
isolated	VBN	O
plasma.	CD	O
The	NNS	O
ELISA	NNS	O
was	,	O
performed	CD	O
essentially	CC	O
as	)	O
described	,	O
in	JJ	O
Example	IN	O
5	DT	O
except	NNS	O
the	VBG	O
second	CD	O
antibody-conjugate	JJ	O
was	NN	O
an	NN	O
anti-human	NNP	O
IgG,	.	O
g-chain	DT	O
specific,	NNS	O
peroxidase	VBD	O
conjugate	VBN	O
(Sigma	CD	O
Chemical	NNS	O
Co.,	IN	O
St.	DT	O
Louis,	NN	O
Md.	CC	O
63178)	DT	O
used	NN	O
at	NN	O
a	NNP	O
dilution	VBD	O
of	VBN	O
1:500.	IN	O
Fifty	JJ	O
μg/ml	.	O
yeast	DT	O
extract	NNP	O
was	VBD	O
added	VBN	O
to	RB	O
the	IN	O
dilutions	VBN	O
of	IN	O
plasma	NNP	O
samples	CD	O
and	IN	O
antibody	DT	O
conjugate	JJ	O
to	NN	O
reduce	VBD	O
non-specific	DT	O
background	JJ	O
due	,	O
to	NN	O
preexisting	,	O
yeast	NN	O
antibodies	NN	O
in	NNP	O
the	NNP	O
baboons.	,	O
The	NNP	O
antibody	,	O
titer	.	O
results	)	O
are	VBN	O
presented	IN	O
in	DT	O
Table	NN	O
14.	IN	O
In	.	O
Table	NNP	O
14,	NNP	O
pre-bleed	NNP	O
data	NN	O
are	VBD	O
given	VBN	O
as	TO	O
Immunization	DT	O
No.	NNS	O
0;	IN	O
data	NN	O
for	NNS	O
bleeds	CC	O
taken	NN	O
2	NN	O
weeks	TO	O
post-first	VB	O
immunization	JJ	O
are	NN	O
given	JJ	O
as	TO	O
Immunization	VBG	O
No.	JJ	O
1;	NNS	O
data	IN	O
for	DT	O
bleeds	.	O
taken	DT	O
2	NN	O
weeks	NN	O
post-second	NNS	O
immunization	VBP	O
are	VBN	O
given	IN	O
as	JJ	O
Immunization	.	O
No.	IN	O
2;	NNP	O
and,	,	O
data	JJ	O
for	NNS	O
bleeds	VBP	O
taken	VBN	O
2	IN	O
weeks	NNP	O
post-third	.	O
immunization	:	O
are	NNS	O
given	IN	O
as	NNS	O
Immunization	VBN	O
No.	CD	O
3.	NNS	O
Further,	JJ	O
lymphoproliferative	NN	O
responses	VBP	O
to	VBN	O
p24	IN	O
antigen	NNP	O
were	.	O
also	:	O
observed	NNS	O
in	IN	O
baboons	NNS	O
221	VBN	O
and	CD	O
222	NNS	O
two	JJ	O
weeks	NN	O
post-fourth	VBP	O
immunization	VBN	O
(at	IN	O
week	NNP	O
14),	.	O
and	:	O
enhanced	,	O
substantially	NNS	O
post-boosting	IN	O
with	NNS	O
VLP	VBN	O
(at	CD	O
week	NNS	O
44	JJ	O
and	NN	O
76).	VBP	O
Such	VBN	O
proliferation	IN	O
results	NNP	O
are	.	O
indicative	.	O
of	,	O
induction	JJ	O
of	NNS	O
T-helper	TO	O
cell	VB	O
functions.	NN	O
B.	VBD	O
Rhesus	RB	O
Macaques	VBN	O
The	IN	O
improved	NNS	O
potency	CD	O
of	CC	O
the	CD	O
codon-modified	CD	O
gag	NNS	O
expression	JJ	O
plasmid	NN	O
observed	IN	O
in	NN	O
mouse	,	O
and	CC	O
baboon	VBD	O
studies	RB	O
was	VBG	O
confirmed	IN	O
in	NNP	O
rhesus	IN	O
macaques.	NN	O
Four	CD	O
of	CC	O
four	.	O
macaques	JJ	O
had	NN	O
detectable	NNS	O
Gag-specific	VBP	O
CTL	JJ	O
after	IN	O
two	NN	O
or	IN	O
three	NNP	O
1	NN	O
mg	.	O
doses	NNP	O
of	NNP	O
modified	NNP	O
gag	DT	O
plasmid.	JJ	O
In	NN	O
contrast,	IN	O
in	DT	O
a	JJ	O
previous	NN	O
study,	NN	O
only	NN	O
one	VBN	O
of	IN	O
four	NN	O
macaques	CC	O
given	NN	O
1	NNS	O
mg	VBD	O
doses	VBN	O
of	IN	O
plasmid-DNA	NN	O
encoding	.	O
the	CD	O
wild-type	IN	O
HIV-1SF2	CD	O
Gag	NNS	O
showed	VBD	O
strong	JJ	O
CTL	NNP	O
activity	NNP	O
that	IN	O
was	CD	O
not	CC	O
apparent	CD	O
until	CD	O
after	NN	O
the	NNS	O
seventh	IN	O
immunization.	JJ	O
Further	NN	O
evidence	.	O
of	IN	O
the	,	O
potency	IN	O
of	DT	O
the	JJ	O
modified	,	O
gag	RB	O
plasmid	CD	O
was	IN	O
the	CD	O
observation	NNS	O
that	VBN	O
CTL	CD	O
from	JJ	O
two	NNS	O
of	IN	O
the	NN	O
four	VBG	O
rhesus	DT	O
macaques	JJ	O
reacted	NNP	O
with	NNP	O
three	VBD	O
nonoverlapping	JJ	O
Gag	NNP	O
peptide	NN	O
pools,	WDT	O
suggesting	VBD	O
that	RB	O
as	JJ	O
many	IN	O
as	IN	O
three	DT	O
different	JJ	O
Gag	.	O
peptides	JJ	O
are	NN	O
recognized	IN	O
and	DT	O
indicating	NN	O
that	IN	O
the	DT	O
CTL	JJ	O
response	NN	O
is	NN	O
polyclonal.	VBD	O
Additional	DT	O
quantification	NN	O
and	WDT	O
specificity	NNP	O
studies	IN	O
are	CD	O
in	IN	O
progress	DT	O
to	CD	O
further	NN	O
characterize	NNS	O
the	VBD	O
T	IN	O
cell	CD	O
responses	VBG	O
to	NNP	O
Gag	NN	O
in	,	O
the	VBG	O
plasmid-immunized	IN	O
rhesus	RB	O
macaques.	JJ	O
DNA	IN	O
immunization	CD	O
of	JJ	O
macaques	NNP	O
with	NNS	O
the	VBP	O
modified	VBN	O
gag	CC	O
plasmid	VBG	O
did	IN	O
not	DT	O
result	NNP	O
in	NN	O
significant	VBZ	O
antibody	.	O
responses,	JJ	O
with	NN	O
only	CC	O
two	NN	O
of	NNS	O
four	VBP	O
animals	IN	O
seroconverting	NN	O
at	TO	O
low	RBR	O
titers.	VB	O
In	DT	O
contrast,	NNP	O
in	NN	O
the	NNS	O
same	TO	O
study	NNP	O
the	IN	O
majority	DT	O
of	JJ	O
macaques	NN	O
in	.	O
groups	NNP	O
immunized	NN	O
with	IN	O
p55Gag	NNS	O
protein	IN	O
seroconverted	DT	O
and	VBN	O
had	NN	O
strong	NN	O
Gag-specific	VBD	O
antibody	RB	O
titers.	VB	O
These	IN	O
data	JJ	O
suggest	NN	O
that	,	O
a	IN	O
prime-boost	RB	O
strategy	CD	O
(DNA-prime	IN	O
and	CD	O
protein-boost)	NNS	O
could	VBG	O
be	IN	O
very	JJ	O
promising	.	O
for	IN	O
the	,	O
induction	IN	O
of	DT	O
a	JJ	O
strong	NN	O
CTL	DT	O
and	NN	O
antibody	IN	O
response.	NNS	O
In	IN	O
sum,	NNS	O
these	VBN	O
results	IN	O
demonstrate	JJ	O
that	NN	O
the	VBD	O
synthetic	CC	O
Gag	VBD	O
plasmid	JJ	O
DNA	NNP	O
is	NN	O
immunogenic	.	O
in	DT	O
non-human	NNS	O
primates.	VBP	O
When	IN	O
similar	DT	O
experiments	JJ	O
were	NN	O
carried	JJ	O
out	CC	O
using	)	O
wild-type	MD	O
Gag	VB	O
plasmid	RB	O
DNA	VBG	O
no	IN	O
such	DT	O
induction	NN	O
of	IN	O
anti-p24	DT	O
antibodies	JJ	O
was	NNP	O
observed	CC	O
after	NN	O
four	.	O
immunizations.	IN	O
Example	,	O
12	DT	O
DNA-	NNS	O
and	VBP	O
Protein	IN	O
Immunizations	DT	O
of	JJ	O
Animals	NNP	O
Using	NN	O
Env	NNP	O
Expression	VBZ	O
Cassettes	JJ	O
and	IN	O
Polypeptides	JJ	O
A.	.	O
Guinea	WRB	O
Pigs	JJ	O
Groups	NNS	O
comprising	VBD	O
six	VBN	O
guinea	RP	O
pigs	VBG	O
each	JJ	O
were	NNP	O
immunized	NN	O
intramuscularly	NNP	O
at	DT	O
0,	JJ	O
4,	NN	O
and	IN	O
12	JJ	O
weeks	NNS	O
with	VBD	O
plasmid	VBN	O
DNAs	IN	O
encoding	CD	O
the	.	O
gp120.modUS4,	JJ	O
gp140.modUS4,	CD	O
gp140.modUS4.delV1,	JJ	O
gp140.modUS4.delV2,	CC	O
gp140.modUS4.delV1/V2,	NNP	O
or	NNP	O
gp160.modUS4	IN	O
coding	NNP	O
sequences	NNP	O
of	NNP	O
the	NNP	O
US4-derived	NNP	O
Env.	CC	O
The	NNP	O
animals	.	O
were	NNP	O
subsequently	NNP	O
boosted	NNP	O
at	VBG	O
18	CD	O
weeks	NN	O
with	NNS	O
a	DT	O
single	VBD	O
intramuscular	VBN	O
dose	RB	O
of	IN	O
US4	,	O
o-gp140.mut.modUS4	,	O
protein	CC	O
in	CD	O
MF59	NNS	O
adjuvant.	IN	O
Anti-gp120	JJ	O
SF2	NNP	O
antibody	VBG	O
titers	DT	O
(geometric	,	O
mean	,	O
titers)	,	O
were	,	O
measured	,	O
at	CC	O
two	NN	O
weeks	VBG	O
following	NNS	O
the	IN	O
third	DT	O
DNA	JJ	O
immunization	.	O
and	DT	O
at	NNS	O
two	VBD	O
weeks	RB	O
after	VBN	O
the	IN	O
protein	CD	O
boost.	NNS	O
Results	IN	O
are	DT	O
shown	JJ	O
in	NN	O
Table	NN	O
15.	IN	O
These	NNP	O
results	JJ	O
demonstrate	NN	O
the	IN	O
usefulness	NNP	O
of	.	O
the	JJ	O
synthetic	NNP	O
constructs	NN	O
to	NNS	O
generate	JJ	O
immune	NN	O
responses,	)	O
as	VBD	O
well	VBN	O
as,	IN	O
the	CD	O
advantage	NNS	O
of	VBG	O
providing	DT	O
a	JJ	O
protein	NNP	O
boost	NN	O
to	CC	O
enhance	IN	O
the	CD	O
immune	NNS	O
response	IN	O
following	DT	O
DNA	NN	O
immunization.	.	O
B.	NNS	O
Rabbits	VBP	O
Rabbits	VBN	O
were	IN	O
immunized	JJ	O
intramuscularly	.	O
and	DT	O
intradermally	NNS	O
using	VBP	O
a	DT	O
Bioject	NN	O
needless	IN	O
syringe	DT	O
with	JJ	O
plasmid	NNS	O
DNAs	TO	O
encoding	VB	O
the	JJ	O
following	,	O
synthetic	RB	O
SF162	RB	O
Env	,	O
polypeptides:	DT	O
gp120.modSF162,	NN	O
gp120.modSF162.delV2,	IN	O
gp140.modSF162,	VBG	O
gp140.modSF162.delV2,	DT	O
gp140.mut.modSF162,	NN	O
gp140.mut.modSF162.delV2,	NN	O
gp160.modSF162,	TO	O
and	VB	O
gp160.modSF162.delV2.	DT	O
Approximately	JJ	O
1	NN	O
mg	VBG	O
of	NNP	O
plasmid	.	O
DNA	NNP	O
(pCMVlink)	NNP	O
carrying	NNP	O
the	VBD	O
synthetic	VBN	O
Env	RB	O
expression	CC	O
cassette	RB	O
was	VBG	O
used	DT	O
to	NNP	O
immunize	JJ	O
the	NN	O
rabbits.	IN	O
Rabbits	JJ	O
were	NNP	O
immunized	VBG	O
with	DT	O
plasmid	JJ	O
DNA	JJ	O
at	NNP	O
0,	NNP	O
4,	:	O
and	,	O
12	,	O
weeks.	,	O
At	,	O
two	,	O
weeks	,	O
after	,	O
the	CC	O
third	.	O
immunization	RB	O
all	CD	O
of	NNS	O
the	IN	O
constructs	NN	O
were	NNP	O
shown	)	O
to	VBG	O
have	DT	O
generated	JJ	O
significant	NNP	O
antibody	NN	O
titers	NN	O
in	VBD	O
the	VBN	O
test	TO	O
animals.	VB	O
Further,	DT	O
rabbits	.	O
immunized	NNS	O
with	VBD	O
constructs	VBN	O
containing	IN	O
deletions	JJ	O
of	NN	O
the	IN	O
V2	,	O
region	,	O
generally	CC	O
generated	CD	O
similar	.	O
antibody	IN	O
titers	CD	O
relative	NNS	O
to	IN	O
rabbits	DT	O
immunized	JJ	O
with	NN	O
the	DT	O
companion	IN	O
construct	DT	O
still	NNS	O
containing	VBD	O
the	VBN	O
V2	TO	O
region.	VB	O
The	VBN	O
nucleic	JJ	O
acid	NN	O
immunizations	NNS	O
are	IN	O
followed	DT	O
by	NN	O
protein	.	O
boosting	,	O
with	NNS	O
o-gp140.modSF162.delV2	VBN	O
(0.1	IN	O
mg	NNS	O
of	VBG	O
purified	NNS	O
protein)	IN	O
at	DT	O
24	NNP	O
weeks	NN	O
after	RB	O
the	VBD	O
initial	JJ	O
immunization.	NN	O
Results	NNS	O
are	VBP	O
shown	TO	O
in	NNS	O
Table	VBN	O
16.	IN	O
All	DT	O
constructs	NN	O
are	NN	O
highly	RB	O
immunogenic	VBG	O
and	DT	O
generate	NNP	O
substantial	.	O
antigen	DT	O
binding	JJ	O
antibody	NN	O
responses	NNS	O
after	VBP	O
only	VBN	O
2	IN	O
immunizations	NN	O
in	VBG	O
rabbits.	IN	O
C.	JJ	O
Baboons	CD	O
Groups	NN	O
of	IN	O
four	JJ	O
baboons	)	O
were	IN	O
immunized	CD	O
intramuscularly	NNS	O
with	IN	O
1	DT	O
mg	JJ	O
doses	.	O
of	NNS	O
DNA	VBP	O
encoding	VBN	O
different	IN	O
forms	JJ	O
of	.	O
synthetic	DT	O
US4	NNS	O
gp140	VBP	O
(see	RB	O
the	JJ	O
following	CC	O
table)	JJ	O
at	JJ	O
0,	NN	O
4,	VBG	O
8,	NN	O
12,	NNS	O
28,	IN	O
and	RB	O
44	CD	O
weeks.	NNS	O
The	IN	O
animals	.	O
were	NNP	O
also	NNP	O
boosted	NNP	O
twice	IN	O
with	CD	O
US4	NNS	O
o-gp140	VBD	O
protein	VBN	O
(gp140.mut.modUS4)	RB	O
at	IN	O
44	CD	O
and	JJ	O
76	NNS	O
weeks	IN	O
using	NNP	O
MF59	VBG	O
as	JJ	O
adjuvant.	NNS	O
Results	IN	O
are	JJ	O
shown	NNP	O
in	NN	O
Table	VB	O
17.	DT	O
The	VBG	O
results	)	O
in	IN	O
Table	,	O
17	,	O
demonstrate	,	O
the	,	O
usefulness	,	O
of	CC	O
the	CD	O
synthetic	.	O
constructs	DT	O
to	NNS	O
generate	VBD	O
immune	RB	O
responses	VBN	O
in	RB	O
primates	IN	O
such	NNP	O
as	JJ	O
baboons.	NN	O
In	)	O
addition,	IN	O
all	CD	O
animals	CC	O
showed	CD	O
evidence	NNS	O
of	VBG	O
antigen-specific	NNP	O
(Env	IN	O
antigen)	.	O
lymphopro-liferative	NNS	O
responses.	VBP	O
D.	VBN	O
Rhesus	IN	O
Macaques	JJ	O
Two	.	O
rhesus	DT	O
macaques	NNS	O
(designated	IN	O
H445	JJ	O
and	CD	O
J408)	NN	O
were	DT	O
immunized	NN	O
with	IN	O
1	DT	O
mg	JJ	O
of	NNS	O
DNA	TO	O
encoding	VB	O
SF162	JJ	O
gp140	NNS	O
with	IN	O
a	NNS	O
deleted	JJ	O
V2	IN	O
region	.	O
(SF162.9p140.delV2)	IN	O
by	,	O
intramuscular	DT	O
(IM)	NNS	O
and	VBD	O
intradermal	NN	O
(ID)	IN	O
routes	JJ	O
at	NNP	O
0,	)	O
4,	JJ	O
8,	.	O
and	NNP	O
28	NNP	O
weeks.	NNP	O
Approximately	CD	O
100	NN	O
μg	NNS	O
of	VBN	O
the	NNP	O
protein	CC	O
encoded	)	O
by	VBD	O
the	VBN	O
SF162.	IN	O
gp140mut.delV2	CD	O
construct	NN	O
was	IN	O
also	NNP	O
administered	VBG	O
in	NNP	O
MF59	NN	O
by	IN	O
IM	DT	O
delivery	JJ	O
at	NNP	O
28	NN	O
weeks.	)	O
ELISA	IN	O
titers	NN	O
are	)	O
shown	CC	O
in	JJ	O
FIG.	)	O
61.	VBZ	O
Neutralizing	IN	O
antibody	,	O
activity	,	O
is	,	O
shown	CC	O
Tables	CD	O
18	.	O
and	RB	O
19.	CD	O
Neutralizing	NNS	O
antibody	IN	O
activity	DT	O
was	NN	O
determined	VBN	O
against	IN	O
a	DT	O
variety	.	O
of	NN	O
primary	NN	O
HIV-1	VBD	O
isolates	RB	O
in	VBN	O
a	IN	O
primary	NNP	O
lymphocyte	IN	O
or	NNP	O
“PBMC-based”	NN	O
assay	IN	O
(see	CD	O
the	.	O
following	NN	O
tables).	NNS	O
Further,	VBP	O
the	VBN	O
phenotypic	IN	O
co-receptor	.	O
usage	.	O
for	VBG	O
each	NN	O
of	NN	O
the	VBZ	O
primary	VBN	O
isolates	NNP	O
is	CD	O
indicated.	CC	O
As	.	O
can	VBG	O
be	NN	O
seen	NN	O
in	VBD	O
the	VBN	O
tables	IN	O
neutralizing	DT	O
antibodies	NN	O
were	IN	O
detected	JJ	O
against	NNP	O
every	NNS	O
isolate	IN	O
tested,	DT	O
including	JJ	O
the	NN	O
HIV-1	CC	O
primary	JJ	O
isolates	NN	O
(i.e.,	VB	O
SF128A,	DT	O
92US660,	JJ	O
92HT593,	.	O
92US657,	,	O
92US714,	DT	O
91US056,	NN	O
and	NN	O
91US054).	NN	O
Lymphoproliferative	IN	O
activity	DT	O
(LPA)	IN	O
was	DT	O
also	JJ	O
determined	NNS	O
by	VBZ	O
antigenic	.	O
stimulation	IN	O
followed	MD	O
by	VB	O
uptake	VBN	O
of	IN	O
3H-thymidine	DT	O
in	NNS	O
these	VBG	O
animals	NNS	O
and	VBD	O
is	VBN	O
shown	IN	O
in	DT	O
Table	NN	O
20.	,	O
Experiment	VBG	O
1	DT	O
was	NNP	O
performed	JJ	O
at	NNS	O
14	,	O
weeks	,	O
post	,	O
third	,	O
DNA	,	O
immunization	,	O
and	,	O
Experiment	CC	O
2	.	O
was	JJ	O
performed	NN	O
at	)	O
2	VBD	O
weeks	RB	O
post	VBN	O
fourth	IN	O
DNA	JJ	O
immunization	NN	O
using	VBN	O
DNA	IN	O
and	NN	O
protein.	IN	O
For	JJ	O
gp120ThaiE,	IN	O
gp120SF2	DT	O
and	NNS	O
US4	CC	O
o-gp140,	VBZ	O
appropriate	VBN	O
background	IN	O
values	JJ	O
were	.	O
used	JJ	O
to	CD	O
calculate	VBD	O
Stimulation	VBN	O
Indices	IN	O
(S.	CD	O
I.;	NNS	O
Antigenic	RB	O
stimulation	JJ	O
CPM/Background	NNP	O
CPM).	NN	O
As	CC	O
can	NNP	O
be	CD	O
seen	VBD	O
by	VBN	O
the	IN	O
results	CD	O
presented	NNS	O
in	RB	O
Table	JJ	O
20	NNP	O
lymphoproliferative	NN	O
responses	VBG	O
to	NNP	O
o-gp140.US4	CC	O
antigen	.	O
were	IN	O
also	,	O
in	NN	O
all	CC	O
four	NNP	O
animals	,	O
at	JJ	O
both	NN	O
experimental	NNS	O
time	VBD	O
points.	VBN	O
Such	TO	O
proliferation	VB	O
results	NNP	O
are	NNP	O
indicative	NNP	O
of	:	O
induction	NNP	O
of	NN	O
T-helper	NNP	O
cell	.	O
functions.	IN	O
The	MD	O
results	VB	O
presented	VBN	O
above	IN	O
demonstrate	DT	O
that	NNS	O
the	VBD	O
synthetic	IN	O
gp140.modSF162.delV2	JJ	O
DNA	CD	O
and	JJ	O
protein	NNS	O
are	TO	O
immunogenic	JJ	O
in	NN	O
non-human	VBD	O
primates.	RB	O
Example	IN	O
13	DT	O
In	CD	O
Vitro	NNS	O
Expression	IN	O
of	DT	O
Recombinant	JJ	O
Sindbis	NN	O
RNA	.	O
and	JJ	O
DNA	NN	O
Containing	NNS	O
the	VBP	O
Synthetic	JJ	O
Gag	IN	O
or	NN	O
Env	IN	O
Expression	NNP	O
Cassettes	NN	O
A.	.	O
Synthetic	DT	O
Gag	NNS	O
Expression	VBN	O
Cassettes	JJ	O
To	NN	O
evaluate	IN	O
the	DT	O
expression	JJ	O
efficiency	NN	O
of	NNP	O
the	CC	O
synthetic	NN	O
Gag	VBP	O
expression	JJ	O
cassette	IN	O
in	JJ	O
Alphavirus	.	O
vectors,	JJ	O
the	CD	O
synthetic	IN	O
Gag	NNP	O
expression	NNP	O
cassette	IN	O
was	NNP	O
subcloned	NNP	O
into	NNP	O
both	CC	O
plasmid	NNP	O
DNA-based	NNP	O
and	DT	O
recombinant	NNP	O
vector	NNP	O
particle-based	CC	O
Sindbis	NNP	O
virus	NNP	O
vectors.	VBZ	O
Specifically,	.	O
a	JJ	O
cDNA	NNP	O
vector	NNP	O
construct	NNP	O
for	TO	O
in	VB	O
vitro	DT	O
transcription	NN	O
of	NN	O
Sindbis	IN	O
virus	DT	O
RNA	JJ	O
vector	NNP	O
replicons	NN	O
(pRSIN-luc;	NN	O
Dubensky,	IN	B
et	NNP	I
al.,	,	I
J	DT	I
Virol.	JJ	I
70:508-519,	NNP	I
1996)	NN	I
was	NN	O
modified	VBD	O
to	VBN	O
contain	IN	O
a	DT	O
PmeI	JJ	O
site	JJ	O
for	CC	O
plasmid	JJ	O
linearization	NN	O
and	JJ	O
a	NNP	O
polylinker	NN	O
for	.	O
insertion	,	O
of	DT	O
heterologous	NN	O
genes.	NN	O
A	NN	O
polylinker	IN	O
was	IN	O
generated	JJ	O
using	NN	O
two	IN	O
oligonucleotides	NNP	O
that	NN	O
contain	NNP	O
the	NN	O
sites	NNS	O
XhoI,	:	O
PmlI,	,	O
ApaI,	FW	O
NarI,	,	O
XbaI,	NNP	O
and	.	O
NotI	,	O
(XPANXNF,	)	O
SEQ	VBD	O
ID	VBN	O
NO:17,	TO	O
and	VB	O
XPANXNR,	DT	O
SEQ	NNP	O
ID	NN	O
NO:18).	IN	O
The	JJ	O
plasmid	NN	O
pRSIN-luc	CC	O
(Dubensky	DT	O
et	NN	O
al.,	IN	O
supra)	NN	O
was	IN	O
digested	JJ	O
with	.	O
XhoI	DT	O
and	NN	O
NotI	VBD	O
to	VBN	O
remove	VBG	O
the	CD	O
luciferase	NNS	O
gene	WDT	O
insert,	VBP	O
blunt-ended	DT	O
using	NNS	O
Klenow	,	O
and	,	O
dNTPs,	,	O
and	,	O
purified	,	O
from	CC	O
an	NNP	O
agarose	,	O
get	NNP	O
using	NNP	O
GeneCleanII	,	O
(Biol0l,	CC	O
Vista,	,	O
Calif.).	NNP	O
The	NNP	O
oligonucleotides	.	O
were	DT	O
annealed	JJ	O
to	NN	O
each	NNP	O
other	FW	O
and	,	O
ligated	)	O
into	VBD	O
the	VBN	O
plasmid.	IN	O
The	NNP	O
resulting	CC	O
construct	NNP	O
was	TO	O
digested	VB	O
with	DT	O
NotI	NN	O
and	NN	O
SacI	,	O
to	JJ	O
remove	VBG	O
the	NNP	O
minimal	CC	O
Sindbis	,	O
3′-end	CC	O
sequence	VBD	O
and	IN	O
A40	DT	O
tract,	JJ	O
and	NN	O
ligated	VBG	O
with	NNP	O
an	,	O
approximately	,	O
0.4	.	O
kbp	DT	O
fragment	NNS	O
from	VBD	O
PKSSIN-BV	VBN	O
(WO	TO	O
97/38087).	DT	O
This	JJ	O
0.4	CC	O
kbp	VBN	O
fragment	IN	O
was	DT	O
obtained	.	O
by	DT	O
digestion	VBG	O
of	NN	O
pKSSIN-BV	VBD	O
with	VBN	O
NotI	IN	O
and	NNP	O
SacI,	CC	O
and	NNP	O
purification	TO	O
after	VB	O
size	DT	O
fractionation	JJ	O
from	NNP	O
an	JJ	O
agarose	NN	O
gel.	CC	O
The	NNP	O
fragment	,	O
contained	CC	O
the	VBD	O
complete	IN	O
Sindbis	DT	O
virus	RB	O
3′-end,	CD	O
an	JJ	O
A40	NN	O
tract	IN	O
and	NNP	O
a	NNP	O
PmeI	.	O
site	DT	O
for	CD	O
linearization.	FW	O
This	NN	O
new	VBD	O
vector	VBN	O
construct	IN	O
was	NN	O
designated	IN	O
SINBVE.	NN	O
The	IN	O
synthetic	NNP	O
HIV	CC	O
Gag	,	O
coding	CC	O
sequence	NN	O
was	IN	O
obtained	NN	O
from	NN	O
the	IN	O
parental	DT	O
plasmid	JJ	O
by	.	O
digestion	DT	O
with	NN	O
EcoRI,	VBD	O
blunt-ending	DT	O
with	JJ	O
Klenow	NNP	O
and	NN	O
dNTPs,	,	O
purification	DT	O
with	NNP	O
GeneCleanII,	NN	O
digestion	CC	O
with	DT	O
Sail,	NNP	O
size	NN	O
fractionation	IN	O
on	.	O
an	DT	O
agarose	JJ	O
gel,	NN	O
and	NN	O
purification	VBD	O
from	VBN	O
the	.	O
agarose	DT	O
gel	JJ	O
using	NNP	O
GeneCleanII.	NNP	O
The	VBG	O
synthetic	NN	O
Gag	VBD	O
coding	VBN	O
fragment	IN	O
was	DT	O
ligated	JJ	O
into	NN	O
the	IN	O
SINBVE	NN	O
vector	IN	O
that	,	O
had	NN	O
been	IN	O
digested	NNP	O
with	CC	O
XhoI	,	O
and	NN	O
PmlI.	IN	O
The	,	O
resulting	NN	O
vector	IN	O
was	,	O
purified	NN	O
using	NN	O
GeneCleanII	IN	O
and	DT	O
designated	JJ	O
SINBVGag.	,	O
Vector	CC	O
RNA	NN	O
replicons	IN	O
may	DT	O
be	JJ	O
transcribed	NN	O
in	VBG	O
vitro	.	O
(Dubensky	DT	O
et	JJ	O
al.,	NNP	O
supra)	VBG	O
from	NN	O
SINBVGag	VBD	O
and	VBN	O
used	IN	O
directly	DT	O
for	NNP	O
transfection	NN	O
of	WDT	O
cells.	VBD	O
Alternatively,	VBN	O
the	VBN	O
replicons	IN	O
may	NNP	O
be	CC	O
packaged	.	O
into	DT	O
recombinant	VBG	O
vector	NN	O
particles	VBD	O
by	VBN	O
co-transfection	VBG	O
with	NNP	O
defective	CC	O
helper	VBN	O
RNAs	.	O
or	NNP	O
using	NNP	O
an	NNS	O
alphavirus	MD	O
packaging	VB	O
cell	VBN	O
line	IN	O
as	NN	O
described,	NNP	O
for	FW	O
example,	,	O
in	)	O
U.S.	IN	O
Pat.	NNP	O
Nos.	CC	O
5,843,723	VBN	O
and	RB	O
5,789,245,	IN	O
and	NN	O
then	IN	O
administered	.	O
in	,	O
vivo	DT	O
as	NNS	O
described.	MD	O
The	VB	O
DNA-based	VBN	O
Sindbis	IN	O
virus	JJ	O
vector	NN	O
pDCMVSIN-beta-gal	NNS	O
Dubensky,	IN	B
et	NN	I
al.,	IN	I
J.	JJ	I
Virol.	NN	I
70:508-519,	NNP	I
1996)	CC	I
(was	VBG	O
digested	DT	O
with	NN	O
Sail	NN	O
and	NN	O
XbaI,	NN	O
to	IN	O
remove	,	O
the	IN	O
beta-galactosidase	,	O
gene	IN	O
insert,	NNP	O
and	.	O
purified	.	O
using	CD	O
GeneCleanII	CC	O
after	,	O
agarose	CC	O
gel	RB	O
size	VBN	O
fractionation.	IN	O
The	NN	O
HIV	IN	O
Gag	.	O
gene	DT	O
was	JJ	O
inserted	NNP	O
into	NN	O
the	NN	O
pDCMVSIN-beta-gal	JJ	O
by	,	O
digestion	FW	O
of	,	O
SINBVGag	NNP	O
with	.	O
SalI	,	O
and	)	O
XhoI,	VBD	O
purification	VBN	O
using	IN	O
GeneCleanII	NNP	O
of	CC	O
the	,	O
Gag-containing	TO	O
fragment	VB	O
after	DT	O
agarose	JJ	O
gel	NN	O
size	,	O
fractionation,	CC	O
and	VBD	O
ligation.	VBG	O
The	NNP	O
resulting	IN	O
construct	JJ	O
was	JJ	O
designated	NN	O
pDSIN-Gag,	.	O
and	DT	O
may	NNP	O
be	NNP	O
used	NN	O
directly	VBD	O
for	VBN	O
in	IN	O
vivo	DT	O
administration	JJ	O
or	IN	O
formulated	NN	O
using	IN	O
any	NNP	O
of	IN	O
the	NNP	O
methods	CC	O
described	,	O
herein.	NN	O
BHK	VBG	O
and	NNP	O
293	IN	O
cells	DT	O
were	NNP	O
transfected	NN	O
with	IN	O
recombinant	JJ	O
Sindbis	JJ	O
vector	NN	O
RNA	,	O
and	CC	O
DNA,	.	O
respectively.	DT	O
The	VBG	O
supernatants	NN	O
and	VBD	O
cell	VBN	O
lysates	,	O
were	CC	O
tested	MD	O
with	VB	O
the	VBN	O
Coulter	RB	O
p24	IN	O
capture	IN	O
ELISA	JJ	O
(Example	NN	O
2).	CC	O
BHK	VBN	O
cells	VBG	O
were	DT	O
transfected	IN	O
by	DT	O
electroporation	NNS	O
with	VBD	O
recombinant	.	O
Sindbis	NNP	O
RNA.	CC	O
The	CD	O
expression	NNS	O
of	VBD	O
p24	VBN	O
(in	IN	O
ng/ml)	JJ	O
is	NNP	O
presented	NN	O
in	NNP	O
Table	CC	O
21.	,	O
In	.	O
the	DT	O
table,	NNS	O
SINGag#1	CC	O
and	NN	O
2	NNS	O
represent	VBD	O
duplicate	VBN	O
measurements,	IN	O
and	DT	O
SINβgal	NNP	O
represents	NN	O
a	NN	O
negative	NNP	O
control.	NNP	O
Supernatants	.	O
and	NNP	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
24	IN	O
h	NN	O
post	IN	O
transfection.	JJ	O
293	NNP	O
cells	.	O
were	DT	O
transfected	NN	O
using	IN	O
LT-1	NN	O
(Example	IN	O
2)	)	O
with	VBZ	O
recombinant	VBN	O
Sindbis	IN	O
DNA.	JJ	O
Synthetic	.	O
pCMVKM2GagMod.SF2	IN	O
was	DT	O
used	,	O
as	CD	O
a	CC	O
positive	CD	O
control.	NN	O
Supernatants	NN	O
and	,	O
lysates	CC	O
were	NNP	O
collected	VBZ	O
48	DT	O
h	JJ	O
post	.	O
transfection.	NNS	O
The	CC	O
expression	NNS	O
of	VBD	O
p24	VBN	O
(in	CD	O
ng/ml)	JJ	O
is	NN	O
presented	.	O
in	CD	O
Table	NNS	O
22.	VBD	O
The	VBN	O
results	VBG	O
presented	NNP	O
in	NNP	O
Tables	)	O
21	IN	O
and	JJ	O
22	NNP	O
demonstrate	.	O
that	JJ	O
Gag	NN	O
proteins	VBD	O
can	VBN	O
be	IN	O
efficiently	DT	O
expressed	JJ	O
from	.	O
both	NNS	O
DNA	CC	O
and	NNS	O
RNA-based	VBD	O
Sindbis	VBN	O
vector	CD	O
systems	JJ	O
using	NN	O
the	.	O
synthetic	DT	O
Gag	NN	O
expression	IN	O
cassette	NN	O
(p55Gag.mod).	IN	O
B.	)	O
Synthetic	VBZ	O
Env	VBN	O
Expression	IN	O
Cassettes	JJ	O
To	.	O
evaluate	DT	O
the	NNS	O
expression	VBD	O
efficiency	IN	O
of	NNP	O
the	CD	O
synthetic	CC	O
Env	CD	O
expression	NN	O
cassette	WDT	O
in	NNP	O
Alphavirus	VBZ	O
vectors,	MD	O
synthetic	VB	O
Env	RB	O
expression	VBN	O
cassettes	IN	O
were	DT	O
subcloned	NNP	O
into	CC	O
both	JJ	O
plasmid	NNP	O
DNA-based	NN	O
and	NNS	O
recombinant	VBG	O
vector	DT	O
particle-based	JJ	O
Sindbis	NNP	O
virus	NN	O
vectors	NN	O
as	.	O
described	.	O
above	JJ	O
for	NNP	O
Gag.	NNP	O
The	NNP	O
synthetic	TO	O
HIV	VB	O
Env	DT	O
coding	NN	O
sequence	NN	O
was	IN	O
obtained	DT	O
from	JJ	O
the	NNP	O
parental	NN	O
plasmid	NN	O
by	IN	O
digestion	NNP	O
with	,	O
SalI	JJ	O
and	NNP	O
XbaI,	NN	O
size	NNS	O
fractionation	VBD	O
on	VBN	O
an	IN	O
agarose	DT	O
gel,	JJ	O
and	JJ	O
purification	CC	O
from	JJ	O
the	NN	O
agarose	JJ	O
gel	NNP	O
using	NN	O
GeneCleanII.	NNS	O
The	IN	O
synthetic	VBN	O
Env	IN	O
coding	IN	O
fragment	.	O
was	DT	O
ligated	JJ	O
into	NNP	O
the	NNP	O
SINBVE	VBG	O
vector	NN	O
that	VBD	O
had	VBN	O
been	IN	O
digested	DT	O
with	JJ	O
XhoI	NN	O
and	IN	O
XbaI.	NN	O
The	IN	O
resulting	NNP	O
vector	CC	O
was	,	O
purified	NN	O
using	NN	O
GeneCleanII	IN	O
and	DT	O
designated	JJ	O
SINBVEnv.	,	O
Vector	CC	O
RNA	NN	O
replicons	IN	O
may	DT	O
be	JJ	O
transcribed	NN	O
in	VBG	O
vitro	.	O
(Dubensky	DT	O
et	JJ	O
al.,	NNP	O
supra)	VBG	O
from	NN	O
SINBVEnv	VBD	O
and	VBN	O
used	IN	O
directly	DT	O
for	NNP	O
transfection	NN	O
of	WDT	O
cells.	VBD	O
Alternatively,	VBN	O
the	VBN	O
replicons	IN	O
may	NNP	O
be	CC	O
packaged	.	O
into	DT	O
recombinant	VBG	O
vector	NN	O
particles	VBD	O
by	VBN	O
co-transfection	VBG	O
with	NNP	O
defective	CC	O
helper	VBN	O
RNAs	.	O
or	NNP	O
using	NNP	O
an	NNS	O
alphavirus	MD	O
packaging	VB	O
cell	VBN	O
line	IN	O
and	NN	O
administered	NNP	O
as	FW	O
described	,	O
above	)	O
for	IN	O
Gag.	NNP	O
The	CC	O
DNA-based	VBN	O
Sindbis	RB	O
virus	IN	O
vector	NN	O
pDCMVSIN-beta-gal	IN	O
Dubensky,	.	B
et	,	I
al.,	DT	I
J.	NNS	I
Virol.	MD	I
70:508-519,	VB	I
1996)	VBN	I
(was	IN	O
digested	JJ	O
with	NN	O
Sail	NNS	O
and	IN	O
XbaI,	NN	O
to	IN	O
remove	JJ	O
the	NN	O
beta-galactosidase	NNP	O
gene	CC	O
insert,	VBG	O
and	DT	O
purified	NN	O
using	NN	O
GeneCleanII	NN	O
after	NN	O
agarose	CC	O
gel	VBD	O
size	IN	O
fractionation.	VBN	O
The	IN	O
HIV	IN	O
Env	.	O
gene	DT	O
was	JJ	O
inserted	NNP	O
into	NN	O
the	NN	O
pDCMVSIN-beta-gal	JJ	O
by	,	O
digestion	FW	O
of	,	O
SINBVEnv	NNP	O
with	.	O
XbaI	,	O
and	)	O
XhoI,	VBD	O
purification	VBN	O
using	IN	O
GeneCleanII	NNP	O
of	CC	O
the	,	O
Env-containing	TO	O
fragment	VB	O
after	DT	O
agarose	JJ	O
gel	NN	O
size	,	O
fractionation,	CC	O
and	VBD	O
ligation.	VBG	O
The	NNP	O
resulting	IN	O
construct	JJ	O
was	JJ	O
designated	NN	O
pDSIN-Env,	.	O
and	DT	O
may	NNP	O
be	NNP	O
used	NN	O
directly	VBD	O
for	VBN	O
in	IN	O
vivo	DT	O
administration	JJ	O
or	IN	O
formulated	NN	O
using	IN	O
any	NNP	O
of	IN	O
the	NNP	O
methods	CC	O
described	,	O
herein.	NN	O
BHK	VBG	O
and	NNP	O
293	IN	O
cells	DT	O
were	NNP	O
transfected	NN	O
with	IN	O
recombinant	JJ	O
Sindbis	JJ	O
vector	NN	O
RNA	,	O
and	CC	O
DNA,	.	O
respectively.	DT	O
The	VBG	O
supernatants	NN	O
and	VBD	O
cell	VBN	O
lysates	,	O
were	CC	O
tested	MD	O
by	VB	O
capture	VBN	O
ELISA.	RB	O
BHK	IN	O
cells	IN	O
were	JJ	O
transfected	NN	O
by	CC	O
electroporation	VBN	O
with	VBG	O
recombinant	DT	O
Sindbis	IN	O
RNA.	DT	O
The	NNS	O
expression	VBD	O
of	.	O
Env	NNP	O
(in	CC	O
ng/ml)	CD	O
is	NNS	O
presented	VBD	O
in	VBN	O
Table	IN	O
23.	JJ	O
In	NNP	O
the	NN	O
table,	NNP	O
the	CC	O
Sindbis	,	O
RNA	.	O
containing	DT	O
synthetic	NNS	O
Env	CC	O
expression	NN	O
cassettes	NNS	O
are	VBD	O
indicated	VBN	O
and	IN	O
βgal	NN	O
represents	.	O
a	NNP	O
negative	NNS	O
control.	VBD	O
Supernatants	VBN	O
and	IN	O
lysates	NN	O
were	IN	O
collected	JJ	O
24	NNP	O
h	.	O
post	DT	O
transfection.	NN	O
293	IN	O
cells	NNP	O
were	IN	O
transfected	)	O
using	VBZ	O
LT-1	VBN	O
mediated	IN	O
transfection	JJ	O
(PanVera)	.	O
with	IN	O
recombinant	DT	O
Sindbis	,	O
DNA	DT	O
containing	NNP	O
synthetic	NNP	O
expression	VBG	O
cassettes	JJ	O
of	NNP	O
the	NN	O
present	NNS	O
invention	VBP	O
and	VBN	O
βgal	CC	O
sequences	JJ	O
as	VBZ	O
a	DT	O
negative	JJ	O
control.	.	O
Supernatants	NNS	O
and	CC	O
lysates	NNS	O
were	VBD	O
collected	VBN	O
48	CD	O
h	JJ	O
post	NN	O
transfection.	.	O
The	CD	O
expression	NNS	O
of	VBD	O
Env	VBN	O
(in	VBG	O
ng/ml)	NNP	O
is	JJ	O
presented	NN	O
in	)	O
Table	IN	O
24.	JJ	O
The	NNP	O
results	NNP	O
presented	VBG	O
in	JJ	O
Tables	NN	O
23	NNS	O
and	IN	O
24	DT	O
demonstrated	JJ	O
that	NN	O
Env	CC	O
proteins	JJ	O
can	NNS	O
be	IN	O
efficiently	DT	O
expressed	JJ	O
from	.	O
both	NNS	O
DNA	CC	O
and	NNS	O
RNA-based	VBD	O
Sindbis	VBN	O
vector	CD	O
systems	JJ	O
using	NN	O
the	.	O
synthetic	DT	O
Env	NN	O
expression	IN	O
cassettes	NNP	O
of	IN	O
the	)	O
present	VBZ	O
invention.	VBN	O
Example	IN	O
14	JJ	O
A.	.	O
In	DT	O
vivo	NNS	O
Immunization	VBD	O
with	IN	O
Gag-containing	NNP	O
DNA	CD	O
and/or	CC	O
Sindbis	CD	O
Particles	VBD	O
CB6F1	IN	O
mice	NNP	O
were	NNS	O
immunized	MD	O
intramuscularly	VB	O
at	RB	O
0	VBN	O
and	IN	O
4	DT	O
weeks	NNP	O
with	CC	O
plasmid	JJ	O
DNA	NNP	O
and/or	NN	O
Sindbis	NNS	O
vector	VBG	O
RNA-containing	DT	O
particles	JJ	O
each	NNP	O
containing	NN	O
GagMod.SF2	NNS	O
sequences	IN	O
as	DT	O
indicated	JJ	O
in	.	O
Table	RB	O
25.	CD	O
Animals	.	O
were	IN	O
challenged	JJ	O
with	NN	O
recombinant	IN	O
vaccinia	NNP	O
expressing	NNP	O
SF2	VBZ	O
Gag	NNP	O
at	NNP	O
3	NNP	O
weeks	NN	O
post	VBD	O
second	VBN	O
immunization	RB	O
(at	IN	O
week	CD	O
7).	CC	O
Spleens	CD	O
were	NNS	O
removed	IN	O
from	JJ	O
the	NNP	O
immunized	NN	O
and	NNP	O
challenged	NN	O
animals	JJ	O
5	NNS	O
days	DT	O
later	VBG	O
for	NNP	O
a	NNS	O
standard	IN	O
51C	VBN	O
release	IN	O
assay	JJ	O
for	.	O
CTL	NNS	O
activity.	VBD	O
Values	VBN	O
shown	IN	O
in	JJ	O
Table	NN	O
25	VBG	O
indicate	NNP	O
the	NNP	O
results	IN	O
from	CD	O
the	NNS	O
spleens	RB	O
of	JJ	O
three	NN	O
mice	IN	O
from	NN	O
each	.	O
group.	NNS	O
The	VBD	O
boxed	VBN	O
values	IN	O
in	DT	O
Table	JJ	O
25	CC	O
indicate	VBD	O
that	NNS	O
all	CD	O
groups	NNS	O
of	RB	O
mice	IN	O
receiving	DT	O
immunizations	JJ	O
with	CD	O
pCMVKm2.GagMod.SF2	NN	O
DNA	NN	O
and/or	IN	O
SindbisGagMod.SF2	NNP	O
virus	.	O
particles	NNS	O
either	VBN	O
alone	IN	O
or	JJ	O
in	CD	O
combinations	VBP	O
showed	DT	O
antigen-specific	NNS	O
CTL	IN	O
activity.	DT	O
B.	NNS	O
In	IN	O
Vivo	CD	O
Immunization	NNS	O
with	IN	O
Env-Containing	DT	O
DNA	.	O
and/or	DT	O
Sindbis	JJ	O
Particles	NNS	O
Balb/C	IN	O
mice	JJ	O
were	CD	O
immunized	NN	O
intramuscularly	IN	O
at	DT	O
0	NNS	O
and	IN	O
4	NNS	O
weeks(as	VBG	O
shown	NNS	O
in	IN	O
the	JJ	O
following	NNP	O
table)	NN	O
with	NNP	O
plasmid	NN	O
DNA	NNS	O
and/or	CC	O
Sindbis-virus	RB	O
RNA-containing	CC	O
particles	IN	O
each	NNS	O
containing	VBD	O
gp120.modUS4	JJ	O
sequences.	NNP	O
Treatment	.	O
regimes	.	O
and	IN	O
antibody	NNP	O
titers	NNP	O
are	IN	O
shown	NNP	O
in	NNP	O
Table	VBZ	O
26.	NNP	O
Antibody	NNP	O
titers	NNP	O
were	NN	O
determined	VBD	O
by	VBN	O
ELISA	RB	O
using	IN	O
gp120	CD	O
SF2	CC	O
protein	CD	O
to	IN	O
coat	VBN	O
the	IN	O
plates.	DT	O
As	JJ	O
can	)	O
be	IN	O
seen	NN	O
from	NNP	O
the	VBZ	O
data	NNP	O
presented	NNP	O
above,	VBZ	O
all	DT	O
of	VBG	O
the	NN	O
mice	.	O
generally	NNP	O
demonstrated	NNS	O
substantial	CC	O
immunological	NN	O
responses	NNS	O
by	VBP	O
bleed	VBN	O
number	IN	O
2.	JJ	O
For	.	O
Env,	NN	O
the	NNS	O
best	VBD	O
results	VBN	O
were	IN	O
obtained	NNP	O
using	VBG	O
either	JJ	O
(i)	NNP	O
50	NN	O
μg	TO	O
of	VB	O
gp120.modUS4	DT	O
DNA	.	O
for	IN	O
the	MD	O
first	VB	O
immunization	VBN	O
followed	IN	O
by	DT	O
a	NNS	O
second	VBN	O
immunization	,	O
using	DT	O
50	IN	O
μg	DT	O
of	NN	O
gp120.modUS4	RB	O
DNA,	VBN	O
or	JJ	O
(ii)	JJ	O
25	NNS	O
μg	IN	O
of	NN	O
gp120.modUS4	NN	O
DNA	.	O
for	IN	O
the	,	O
first	DT	O
immunization	JJS	O
followed	NNS	O
by	VBD	O
a	VBN	O
second	VBG	O
immunization	CC	O
using	)	O
107	CD	O
pfus	NN	O
of	IN	O
Sindbis.	NN	O
The	NN	O
results	IN	O
presented	DT	O
above	JJ	O
demonstrate	NN	O
that	VBN	O
the	IN	O
Env	DT	O
and	JJ	O
Gag	NN	O
proteins	VBG	O
of	CD	O
the	NN	O
present	IN	O
invention	NN	O
are	,	O
effective	CC	O
to	)	O
induce	CD	O
an	NN	O
immune	IN	O
response	NN	O
using	NN	O
Sindbis	IN	O
vector	DT	O
systems	JJ	O
which	NN	O
include	VBN	O
the	IN	O
synthetic	DT	O
Env	JJ	O
(e.g.,	NN	O
gp120.modUS4)	VBG	O
or	CD	O
Gag	NN	O
expression	IN	O
cassettes.	.	O
Example	DT	O
15	NNS	O
Co-Transfection	VBN	O
of	JJ	O
Env	NN	O
and	IN	O
Gag	DT	O
as	NNP	O
Monocistronic	CC	O
and	NNP	O
Bicistronic	NNS	O
Constructs	IN	O
DNA	DT	O
constructs	JJ	O
encoding	NN	O
(i)	VBP	O
wild-type	JJ	O
US4	TO	O
and	VB	O
SF162	DT	O
Env	JJ	O
polypeptides,	NN	O
(ii)	VBG	O
synthetic	NNP	O
US4	NN	O
and	NNS	O
SF162	WDT	O
Env	VBP	O
polypeptides	DT	O
(gp160.modUS4,	JJ	O
gp160.modUS4.delV1/V2,	NNP	O
gp160.modSF162,	,	O
and	)	O
gp120.modSF162.delV2),	CC	O
and	NNP	O
(iii)	NN	O
SF2-gag	.	O
polypeptide	JJ	O
(i.e.,	CD	O
the	NN	O
Gag	IN	O
coding	NNP	O
sequences	CC	O
obtained	NNP	O
from	IN	O
the	NNP	O
SF2	CC	O
variant	NNP	O
or	NNP	O
optimized	NNP	O
sequences	VBZ	O
corresponding	VBG	O
to	)	O
the	NN	O
gagSF2-gag.modSF2)	NNP	O
were	CC	O
prepared.	NNP	O
These	NNP	O
monocistronic	,	O
constructs	)	O
were	JJ	O
co-transfected	NNP	O
into	CC	O
293T	NNP	O
cells	NNP	O
in	NNS	O
a	,	O
transient	,	O
transfection	,	O
protocol	CC	O
using	,	O
the	CC	O
following	)	O
combinations:	NNP	O
gp160.modUS4;	NN	O
gp160.modUS4	,	O
and	DT	O
gag.modSF2;	NNP	O
gp160.modUS4.delV1/V2;	NN	O
gp160.modUS4.delV1/V2	NNS	O
and	VBN	O
gag.modSF2;	IN	O
gp160.modSF162	DT	O
and	NNP	O
gag.modSF2;	NN	O
gp120.modSF162.delV2	CC	O
and	VBN	O
gag.modSF2;	NNS	O
and	VBG	O
gag.modSF2	TO	O
alone.	DT	O
Further	)	O
several	VBD	O
bicistronic	.	O
constructs	DT	O
were	JJ	O
made	NNS	O
where	VBD	O
the	JJ	O
coding	IN	O
sequences	CD	O
for	NNS	O
Env	IN	O
and	DT	O
Gag	JJ	O
were	NN	O
under	NN	O
the	VBG	O
control	DT	O
of	JJ	O
a	:	O
single	:	O
CMV	NN	O
promoter	CC	O
and,	:	O
between	:	O
the	NN	O
two	CC	O
coding	:	O
sequences,	NN	O
an	CC	O
IRES	:	O
(internal	NN	O
ribosome	CC	O
entry	:	O
site	CC	O
(EMCV	VB	O
TRES);	.	O
Kozak,	RB	B
M.,	JJ	I
Critical	JJ	I
Reviews	NNS	I
dn	VBD	I
Biochemistry	VBN	I
and	WRB	I
Molecular	DT	I
Biology	NN	I
27(45):385-402,	NNS	I
1992;	IN	I
Witherell,	NNP	B
G.	CC	I
W.,	NNP	I
et	VBD	I
al.,	IN	I
Virology	DT	I
214:660-663,	NN	I
1995)	IN	I
